data_2kqa_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kqa _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.555 0.693 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 79.9 p -111.33 139.9 46.35 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.456 0.646 . . . . 0.0 109.49 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 39.6 pt -118.13 149.98 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.837 -0.54 . . . . 0.0 111.273 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.15 -169.55 3.28 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -141.58 148.07 38.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.417 -0.802 . . . . 0.0 110.178 178.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.49 143.48 43.32 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.406 -0.809 . . . . 0.0 109.777 179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.73 -9.86 17.05 Favored 'Trans proline' 0 C--N 1.318 -1.078 0 O-C-N 123.324 1.171 . . . . 0.0 112.331 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.453 HG13 ' N ' ' A' ' 9' ' ' TYR . 44.5 pt -70.01 -39.95 77.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 120.968 -1.082 . . . . 0.0 111.434 -179.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.453 ' N ' HG13 ' A' ' 8' ' ' ILE . 51.5 m-85 -72.14 67.5 0.67 Allowed 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 122.752 1.263 . . . . 0.0 111.72 -178.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.55 170.04 8.12 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.054 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.41 -34.38 68.85 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -175.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -90.92 12.12 20.56 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 118.431 -1.308 . . . . 0.0 112.265 -177.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.4 tp -72.53 123.71 23.73 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.246 -0.908 . . . . 0.0 110.2 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -70.54 137.35 50.06 Favored 'General case' 0 N--CA 1.49 1.573 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.035 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 34.6 mtt -70.08 -15.39 62.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.802 -0.561 . . . . 0.0 111.915 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.63 -15.37 68.53 Favored Glycine 0 N--CA 1.494 2.559 0 O-C-N 120.793 -1.192 . . . . 0.0 110.878 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 91.0 p -87.98 -4.45 58.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.192 -1.181 . . . . 0.0 112.157 -178.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.8 p -103.5 168.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.001 -1.062 . . . . 0.0 110.801 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 52' ' ' TRP . . . -60.04 -39.29 85.4 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.471 -0.768 . . . . 0.0 110.644 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.76 67.72 3.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.291 -0.881 . . . . 0.0 110.088 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.6 m -108.71 110.13 21.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.155 -0.966 . . . . 0.0 110.565 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 m120 51.66 -140.98 0.84 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.714 -0.616 . . . . 0.0 111.11 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.43 -155.95 49.02 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -78.07 -41.82 34.2 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.428 -1.042 . . . . 0.0 111.066 179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 87.5 m-70 -89.94 2.14 55.42 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.181 -0.949 . . . . 0.0 111.748 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.55 131.81 49.36 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.002 -1.061 . . . . 0.0 111.15 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt -96.28 -11.57 25.76 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 122.091 -0.652 . . . . 0.0 110.005 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -60.05 -34.42 73.38 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.267 -0.896 . . . . 0.0 110.836 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -74.41 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.558 -0.714 . . . . 0.0 111.691 -178.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -70.04 -39.97 75.43 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.347 -0.846 . . . . 0.0 109.938 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.43 ' CD2' HG21 ' A' ' 37' ' ' VAL . 70.1 m-85 -120.67 89.69 45.19 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.82 -4.97 15.83 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.317 1.167 . . . . 0.0 112.298 -178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.7 m -135.13 149.1 49.94 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.019 -1.051 . . . . 0.0 110.406 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.9 tp -72.45 117.59 14.31 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.758 -0.589 . . . . 0.0 110.528 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.89 32.36 0.04 OUTLIER Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.992 -1.099 . . . . 0.0 110.924 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -158.81 -46.28 0.06 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.195 -1.18 . . . . 0.0 110.21 179.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.43 HG21 ' CD2' ' A' ' 31' ' ' TYR . 3.0 t -61.05 -59.92 12.29 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 52.5 Cg_endo -76.63 -28.35 6.68 Favored 'Trans proline' 0 N--CA 1.487 1.146 0 O-C-N 123.182 1.096 . . . . 0.0 109.371 177.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.3 -62.35 0.63 Allowed Glycine 0 N--CA 1.488 2.146 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 -178.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.632 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 165.27 -58.73 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.467 0 C-N-CA 123.248 0.619 . . . . 0.0 109.804 177.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.632 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.23 18.19 0.33 Allowed 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 121.076 1.184 . . . . 0.0 110.937 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -126.94 42.48 3.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.315 -0.866 . . . . 0.0 109.499 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.3 p -123.58 140.77 46.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-O 121.563 0.697 . . . . 0.0 109.73 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -166.59 169.09 40.46 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.08 157.53 41.19 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.624 -1.79 . . . . 0.0 108.624 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 1.2 pp -146.23 145.21 23.39 Favored Pre-proline 0 N--CA 1.486 1.361 0 O-C-N 121.48 -1.012 . . . . 0.0 109.221 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.435 ' HD2' ' CE1' ' A' ' 83' ' ' PHE . 38.0 Cg_endo -61.73 -7.19 8.71 Favored 'Trans proline' 0 N--CA 1.506 2.249 0 C-N-CA 122.197 1.931 . . . . 0.0 115.075 -177.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -97.46 23.0 8.09 Favored 'General case' 0 N--CA 1.504 2.252 0 O-C-N 120.5 -1.375 . . . . 0.0 112.446 -178.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.448 HD11 HG23 ' A' ' 49' ' ' ILE . 49.4 mm -110.13 130.1 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.17 -48.1 9.48 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.423 -0.798 . . . . 0.0 112.613 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 179.67 -131.48 1.67 Allowed Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.609 -1.758 . . . . 0.0 111.926 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.416 ' CE3' ' OD2' ' A' ' 53' ' ' ASP . 11.8 t90 -54.79 -22.9 15.77 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 -178.006 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.416 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 42.1 m-20 -147.94 62.51 1.12 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.008 -1.057 . . . . 0.0 110.754 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 p -58.6 141.97 83.57 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.476 -0.765 . . . . 0.0 110.967 -178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -77.45 -21.4 11.64 Favored 'Trans proline' 0 C--N 1.319 -0.991 0 O-C-N 123.39 1.205 . . . . 0.0 110.752 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.8 m -97.89 13.81 29.34 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.507 -0.746 . . . . 0.0 111.073 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -68.05 141.34 56.2 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.152 -0.967 . . . . 0.0 109.628 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.8 42.38 11.32 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.2 m -120.03 130.05 54.53 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.395 -1.062 . . . . 0.0 110.198 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 49.1 t -80.14 139.94 36.6 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.097 -177.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.422 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 64.3 m95 -145.27 150.88 37.44 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.543 -0.723 . . . . 0.0 110.376 178.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -109.63 133.02 53.59 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -110.03 128.89 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.443 -0.786 . . . . 0.0 109.727 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 29.5 m -119.98 142.67 48.57 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.831 -0.543 . . . . 0.0 111.662 -177.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.422 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 23.4 pt -119.67 163.55 26.84 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.709 -0.619 . . . . 0.0 110.279 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.422 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.54 -23.56 74.88 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 121.3 1.334 . . . . 0.0 112.672 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -66.38 -40.01 89.42 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.274 -0.891 . . . . 0.0 109.83 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.89 60.42 0.29 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -160.02 150.6 18.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.629 -0.924 . . . . 0.0 109.088 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.1 m -151.06 156.91 42.06 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.037 0.923 . . . . 0.0 112.03 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.6 pt -138.0 165.71 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -106.92 127.5 53.49 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 118.964 -1.094 . . . . 0.0 110.145 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.428 HG23 HD13 ' A' ' 73' ' ' ILE . 48.6 mm -115.78 129.96 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.748 -0.595 . . . . 0.0 110.094 -179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.9 ttt180 -99.81 135.03 41.84 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.14 148.29 24.94 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.8 p -159.9 -37.98 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.767 -0.843 . . . . 0.0 110.057 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -133.18 169.96 16.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.002 -1.061 . . . . 0.0 109.495 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.43 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 86.9 p -97.26 160.05 14.56 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.409 -0.807 . . . . 0.0 110.899 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.94 141.74 12.94 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -60.73 -39.93 90.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.808 -0.819 . . . . 0.0 110.663 178.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.35 71.73 0.09 OUTLIER Glycine 0 N--CA 1.494 2.535 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.63 168.91 15.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.435 ' CE1' ' HD2' ' A' ' 47' ' ' PRO . 96.3 m-85 -98.49 128.57 44.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.755 -0.85 . . . . 0.0 109.948 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -120.63 131.02 54.4 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.378 -0.826 . . . . 0.0 109.531 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.09 174.06 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.064 -1.023 . . . . 0.0 111.387 -178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.1 m-20 -55.78 153.14 17.16 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.355 -0.841 . . . . 0.0 109.996 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.76 -26.23 53.0 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 123.381 1.2 . . . . 0.0 110.019 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.9 m -70.72 -39.98 73.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.092 -1.005 . . . . 0.0 108.982 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.73 79.04 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -60.08 -50.02 75.37 Favored 'General case' 0 N--CA 1.499 2.018 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.689 179.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.8 m -60.04 -38.61 83.28 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.482 -0.761 . . . . 0.0 110.463 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.07 -39.75 75.46 Favored 'General case' 0 N--CA 1.493 1.694 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.937 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 47.9 tp -70.07 -43.58 70.86 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.555 -0.715 . . . . 0.0 111.668 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -95.01 -37.63 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.134 0 O-C-N 121.251 -0.906 . . . . 0.0 110.967 -178.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.26 5.5 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.0 p -156.7 168.76 26.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -1.013 . . . . 0.0 110.121 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 55.1 p -96.77 8.41 44.35 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 110.801 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.04 -29.59 66.66 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.374 -0.829 . . . . 0.0 110.409 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.1 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.565 -0.709 . . . . 0.0 110.54 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 79.02 -83.67 1.28 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 29.2 ttt180 -130.03 133.13 46.53 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.627 -0.926 . . . . 0.0 110.133 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.68 120.13 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.489 -0.757 . . . . 0.0 110.304 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 43.7 p-10 -83.23 174.81 10.43 Favored 'General case' 0 N--CA 1.494 1.746 0 CA-C-O 121.718 0.77 . . . . 0.0 111.544 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 57.7 t30 59.99 40.66 18.56 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.704 -0.622 . . . . 0.0 112.013 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 59.3 t -88.91 127.34 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.937 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -85.14 138.32 32.46 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 119.328 -0.949 . . . . 0.0 109.871 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -134.57 140.48 46.15 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.351 0.596 . . . . 0.0 110.746 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 m -142.67 145.25 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.668 -0.645 . . . . 0.0 109.916 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.422 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 55.4 tt0 -85.03 141.62 30.16 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -136.18 176.96 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.718 -0.614 . . . . 0.0 110.088 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -62.03 149.57 40.59 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.443 -0.786 . . . . 0.0 110.575 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -39.93 87.77 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.488 -0.757 . . . . 0.0 110.992 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 t -51.39 -38.94 55.99 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.424 -0.798 . . . . 0.0 110.822 -178.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -60.91 -39.99 91.45 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.49 -0.756 . . . . 0.0 111.274 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -61.53 -48.22 82.01 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.323 -0.861 . . . . 0.0 110.109 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -67.84 -39.92 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.663 -0.648 . . . . 0.0 110.557 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -65.59 -40.0 92.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.463 -0.773 . . . . 0.0 110.571 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.96 -49.37 35.23 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.54 89.46 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.576 -0.955 . . . . 0.0 110.605 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.7 m120 . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 117.93 -1.034 . . . . 0.0 110.273 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 N--CA 1.499 1.994 0 CA-C-O 120.975 0.416 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 50.5 m -113.3 143.01 45.15 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.537 -0.727 . . . . 0.0 110.795 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.9 pt -114.36 149.93 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.81 -0.556 . . . . 0.0 110.861 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.5 p -147.07 -173.46 4.25 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -142.11 153.33 44.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.355 -0.841 . . . . 0.0 110.246 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.414 ' HB3' ' CD1' ' A' ' 8' ' ' ILE . 0.9 OUTLIER -132.78 145.94 59.24 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.404 -0.81 . . . . 0.0 110.359 -179.592 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -88.43 49.75 1.56 Allowed 'Trans proline' 0 N--CA 1.486 1.077 0 O-C-N 123.219 1.115 . . . . 0.0 113.192 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.448 HG21 HD11 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -134.05 5.88 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.562 0 O-C-N 120.751 -1.218 . . . . 0.0 110.936 178.196 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.422 ' HA ' HD21 ' A' ' 13' ' ' LEU . 31.5 m-85 -114.15 67.2 0.68 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 122.873 1.321 . . . . 0.0 109.442 178.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.31 170.83 7.83 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.858 177.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.98 -32.87 71.24 Favored 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -88.9 11.5 17.85 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.464 -1.397 . . . . 0.0 112.176 -177.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.422 HD21 ' HA ' ' A' ' 9' ' ' TYR . 43.5 tp -72.27 125.1 26.51 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.301 -0.874 . . . . 0.0 109.987 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.4 m -70.38 136.19 49.42 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.276 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.6 mmm -65.26 -16.72 63.85 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.85 -0.531 . . . . 0.0 111.683 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.66 -11.49 80.54 Favored Glycine 0 N--CA 1.496 2.687 0 O-C-N 121.003 -1.061 . . . . 0.0 111.284 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.4 m -89.96 -4.85 57.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.034 -1.274 . . . . 0.0 112.055 -178.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -100.7 169.02 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.966 -1.084 . . . . 0.0 110.434 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 52' ' ' TRP . . . -59.92 -40.06 87.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.15 69.0 4.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.499 -0.751 . . . . 0.0 109.884 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.3 m -108.58 110.81 22.36 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.181 -0.949 . . . . 0.0 110.783 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 50.09 -141.47 0.71 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.747 -0.596 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 64.64 -150.63 51.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.55 -46.26 16.06 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.977 . . . . 0.0 111.494 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 54' ' ' SER . 73.8 m-70 -89.99 1.99 55.65 Favored 'General case' 0 N--CA 1.504 2.262 0 O-C-N 121.209 -0.932 . . . . 0.0 111.84 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -54.9 134.24 47.72 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 121.004 -1.06 . . . . 0.0 111.126 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -100.03 -6.86 25.79 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 122.003 -0.704 . . . . 0.0 110.066 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.4 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.5 ttm -60.3 -35.47 75.67 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.258 -0.901 . . . . 0.0 110.088 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.75 -73.74 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.706 -0.622 . . . . 0.0 111.733 -177.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -69.93 -40.04 75.76 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.345 -0.847 . . . . 0.0 110.241 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.416 ' CD2' HG21 ' A' ' 37' ' ' VAL . 75.5 m-85 -119.81 91.25 44.93 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.53 -11.79 31.91 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.298 1.157 . . . . 0.0 111.579 -178.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.6 m -130.02 143.42 50.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.229 -0.92 . . . . 0.0 110.489 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.4 tp -67.91 119.99 13.46 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.781 -0.574 . . . . 0.0 110.117 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.8 32.53 0.05 OUTLIER Glycine 0 N--CA 1.495 2.623 0 C-N-CA 120.008 -1.092 . . . . 0.0 110.56 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 15.1 mt-10 -155.34 -46.42 0.08 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.312 -1.11 . . . . 0.0 110.14 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.416 HG21 ' CD2' ' A' ' 31' ' ' TYR . 2.9 t -61.84 -59.61 12.74 Favored Pre-proline 0 N--CA 1.496 1.844 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.408 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -76.23 -29.27 6.51 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 N-CA-C 109.184 -1.121 . . . . 0.0 109.184 177.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.5 -60.73 0.66 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 107.433 -2.267 . . . . 0.0 107.433 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.587 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 4.5 t80 162.41 -52.5 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.705 0 C-N-CA 123.595 0.758 . . . . 0.0 109.95 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.07 19.04 0.23 Allowed 'Trans proline' 0 C--N 1.322 -0.819 0 C-N-CA 121.392 1.395 . . . . 0.0 111.347 -178.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.8 m-20 -131.81 49.87 2.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.292 -0.88 . . . . 0.0 110.236 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.4 p -125.97 139.57 51.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-O 121.598 0.713 . . . . 0.0 109.961 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 84' ' ' ASN . . . -169.4 174.28 43.77 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.28 159.28 32.22 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.422 HG21 ' CE1' ' A' ' 83' ' ' PHE . 1.4 pt -149.98 158.09 37.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.662 -0.905 . . . . 0.0 110.634 179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.22 -13.22 35.65 Favored 'Trans proline' 0 N--CA 1.499 1.811 0 C-N-CA 121.419 1.413 . . . . 0.0 114.328 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -94.9 22.23 6.72 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 120.563 -1.336 . . . . 0.0 112.819 -177.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.434 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 49.5 mm -113.12 129.59 68.55 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.073 -1.017 . . . . 0.0 108.52 178.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.73 12.34 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.395 -0.816 . . . . 0.0 112.229 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 170.64 -129.56 1.83 Allowed Glycine 0 N--CA 1.489 2.227 0 C-N-CA 118.813 -1.66 . . . . 0.0 111.139 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.406 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 44.7 t90 -52.1 -22.35 4.09 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.962 -0.728 . . . . 0.0 112.601 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -149.44 65.75 1.01 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.042 -1.036 . . . . 0.0 110.933 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.411 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.0 p -63.47 135.01 96.07 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.548 -0.72 . . . . 0.0 110.855 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.58 -20.76 23.03 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.333 1.175 . . . . 0.0 110.692 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.7 m -98.1 11.53 37.39 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.489 -0.757 . . . . 0.0 111.116 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -65.98 145.29 56.07 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.176 -0.953 . . . . 0.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.24 29.21 34.26 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 16.8 p -101.6 147.69 26.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.532 -0.981 . . . . 0.0 110.548 179.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 53.6 t -97.73 126.96 43.35 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.655 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.483 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 97.5 m95 -131.04 147.67 52.65 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.344 -0.848 . . . . 0.0 110.709 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.7 tttp -109.06 130.7 55.48 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.5 t -110.78 122.56 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.561 -0.712 . . . . 0.0 110.298 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.4 m -121.47 138.73 54.16 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.662 -0.649 . . . . 0.0 110.842 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 11.1 pt -113.59 165.54 13.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.631 -0.668 . . . . 0.0 110.777 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.43 -24.88 75.8 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 121.361 1.374 . . . . 0.0 112.825 -178.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -65.32 -39.87 93.01 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.223 -0.923 . . . . 0.0 109.99 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.19 60.07 0.28 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -160.33 152.18 20.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.669 -0.901 . . . . 0.0 108.887 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.0 p -153.75 158.9 41.65 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.047 -1.061 . . . . 0.0 112.373 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.0 pt -139.92 163.38 24.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -104.2 129.15 51.97 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.958 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.0 130.01 71.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.733 -0.604 . . . . 0.0 109.55 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -100.39 136.28 40.52 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.296 -0.878 . . . . 0.0 109.299 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -56.75 146.73 34.38 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -178.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.406 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 5.4 p -158.26 -42.51 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.816 -0.814 . . . . 0.0 109.461 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.406 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 16.9 t70 -130.43 168.94 16.17 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.225 -0.922 . . . . 0.0 109.522 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.434 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 58.6 p -97.44 160.66 14.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.515 -0.74 . . . . 0.0 111.637 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.03 149.37 19.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 65.0 mtt180 -61.88 -33.09 73.59 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.66 -0.906 . . . . 0.0 110.928 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.43 81.57 0.05 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.3 149.99 5.39 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.897 -1.144 . . . . 0.0 110.351 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.422 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -65.78 136.37 56.12 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.968 -0.725 . . . . 0.0 110.388 179.503 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 56.9 t-20 -134.93 124.23 24.63 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.143 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.9 m -133.81 176.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.133 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.9 m-20 -57.65 154.49 25.34 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.675 -0.64 . . . . 0.0 110.253 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.53 -26.86 46.66 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.468 1.246 . . . . 0.0 110.604 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.0 -40.54 75.23 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.919 -1.113 . . . . 0.0 108.632 178.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.88 -39.92 87.65 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -60.01 -50.06 75.21 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.85 -0.531 . . . . 0.0 110.474 179.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.5 m -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.424 -0.798 . . . . 0.0 110.538 -178.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -69.4 -40.08 77.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.79 -0.764 . . . . 0.0 111.493 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 40.6 tp -71.49 -43.02 67.32 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.525 -0.734 . . . . 0.0 111.504 -178.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.5 t -96.26 -39.63 9.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.309 -0.87 . . . . 0.0 111.492 -177.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.79 7.42 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.3 p -144.78 157.95 43.98 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.453 -1.027 . . . . 0.0 110.117 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.53 15.77 28.14 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.422 -0.799 . . . . 0.0 110.574 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -93.35 -15.0 26.2 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.452 -0.78 . . . . 0.0 110.761 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.93 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.231 -0.918 . . . . 0.0 110.405 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 86.82 -77.01 2.03 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -137.82 135.62 36.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.595 -0.944 . . . . 0.0 110.376 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 56.3 t -120.05 119.24 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.421 -0.799 . . . . 0.0 109.477 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.0 p-10 -85.18 177.05 8.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.792 0.806 . . . . 0.0 112.078 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 60.06 40.0 19.09 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.919 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 86.3 t -95.41 123.27 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.231 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -84.5 146.72 27.44 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.762 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -142.14 148.74 38.79 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.923 -0.486 . . . . 0.0 110.907 -178.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.4 m -149.93 144.91 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 O-C-N 121.348 -0.845 . . . . 0.0 111.782 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.483 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 55.1 tt0 -70.01 140.99 52.98 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.707 -0.62 . . . . 0.0 109.886 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.95 172.78 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.992 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -59.86 145.51 45.36 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.382 -0.824 . . . . 0.0 110.862 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -59.99 -40.09 87.94 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.378 -0.826 . . . . 0.0 110.201 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 70.6 m -54.92 -37.9 66.96 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.627 -0.671 . . . . 0.0 109.847 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -59.98 -39.99 87.56 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.56 -0.712 . . . . 0.0 110.059 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.8 m -64.04 -45.35 89.27 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.489 -0.757 . . . . 0.0 109.225 178.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.2 mm -62.89 -45.72 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.259 0.552 . . . . 0.0 110.137 -178.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -66.53 -40.01 88.9 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.796 -0.565 . . . . 0.0 110.553 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.78 -42.93 99.81 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.56 -40.0 94.77 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.574 -0.957 . . . . 0.0 110.535 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 33.6 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.306 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 120.982 0.42 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.4 t -112.96 139.94 48.18 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.695 . . . . 0.0 110.44 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.9 pt -107.71 145.68 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.688 -0.632 . . . . 0.0 110.693 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.9 m -144.33 -174.25 4.25 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.412 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 45.8 p90 -141.29 147.36 38.06 Favored 'General case' 0 N--CA 1.492 1.671 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.043 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -124.81 145.18 48.96 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.504 -0.747 . . . . 0.0 109.169 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -82.51 -10.08 11.03 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.274 1.144 . . . . 0.0 112.733 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.448 HG13 ' N ' ' A' ' 9' ' ' TYR . 48.9 pt -70.03 -40.04 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 120.947 -1.096 . . . . 0.0 111.37 -179.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.448 ' N ' HG13 ' A' ' 8' ' ' ILE . 42.6 m-85 -73.11 67.34 0.9 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 122.874 1.321 . . . . 0.0 111.698 -178.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.91 173.86 6.12 Favored 'General case' 0 N--CA 1.489 1.505 0 CA-C-N 114.401 -1.272 . . . . 0.0 108.107 176.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.71 -30.35 63.4 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -175.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -89.99 11.55 20.23 Favored 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 118.237 -1.385 . . . . 0.0 112.262 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -67.51 119.78 12.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.295 -0.878 . . . . 0.0 109.878 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.5 m -70.11 137.01 50.78 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.759 0.79 . . . . 0.0 110.007 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 95.4 mmm -64.24 -21.87 66.74 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.885 -0.51 . . . . 0.0 111.634 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.32 -16.07 77.13 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 121.065 -1.022 . . . . 0.0 111.514 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.4 m -90.0 -4.71 57.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.121 -1.223 . . . . 0.0 111.923 -178.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.9 p -101.04 168.64 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.959 -1.088 . . . . 0.0 110.618 -179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.73 94.87 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.476 -0.765 . . . . 0.0 110.005 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.5 m -80.47 71.98 7.33 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.85 -76.96 0.51 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.507 -0.746 . . . . 0.0 109.952 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -127.84 168.55 15.02 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.648 -0.658 . . . . 0.0 109.584 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.21 -154.95 16.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 -178.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -70.72 -42.77 70.15 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -1.109 . . . . 0.0 110.186 179.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.417 ' CD2' ' O ' ' A' ' 54' ' ' SER . 54.7 m-70 -92.61 3.35 55.73 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.412 -0.805 . . . . 0.0 110.836 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.05 129.74 48.07 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.8 mt -99.71 -3.12 33.64 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 122.039 -0.683 . . . . 0.0 110.21 179.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.8 tpp -60.01 -38.59 83.11 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.336 -0.853 . . . . 0.0 110.365 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.77 -75.05 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.68 -0.637 . . . . 0.0 112.195 -177.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -70.05 -41.17 74.56 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.325 -0.86 . . . . 0.0 111.446 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.433 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 97.6 m-85 -122.84 86.4 50.21 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.648 -0.657 . . . . 0.0 110.474 -178.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.06 -7.42 21.36 Favored 'Trans proline' 0 C--N 1.317 -1.099 0 O-C-N 123.387 1.203 . . . . 0.0 111.475 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.3 m -130.02 142.98 50.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.05 -1.031 . . . . 0.0 110.189 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 39.6 tp -75.4 117.83 17.62 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.78 -0.575 . . . . 0.0 110.644 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.05 30.29 0.05 OUTLIER Glycine 0 N--CA 1.496 2.676 0 C-N-CA 120.092 -1.052 . . . . 0.0 110.812 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.416 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 8.9 mt-10 -153.66 -52.79 0.1 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.218 -1.166 . . . . 0.0 110.336 179.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.433 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 2.6 t -60.65 -59.63 13.24 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.419 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 45.7 Cg_endo -73.36 -32.45 8.09 Favored 'Trans proline' 0 N--CA 1.486 1.068 0 N-CA-C 109.114 -1.148 . . . . 0.0 109.114 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.81 -64.35 0.61 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 107.739 -2.144 . . . . 0.0 107.739 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.59 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 162.75 -55.8 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.787 0 C-N-CA 123.477 0.711 . . . . 0.0 110.627 177.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.59 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -101.07 13.09 0.44 Allowed 'Trans proline' 0 N--CA 1.48 0.715 0 C-N-CA 121.348 1.365 . . . . 0.0 111.522 -178.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -122.21 45.76 2.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.223 -179.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -126.78 141.06 47.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.832 0.825 . . . . 0.0 110.19 -179.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.84 173.3 43.4 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 159.23 30.85 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.468 ' CG2' ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -153.38 160.18 31.25 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.581 -0.952 . . . . 0.0 109.493 179.564 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.14 -37.67 31.26 Favored 'Trans proline' 0 N--CA 1.505 2.184 0 C-N-CA 121.831 1.687 . . . . 0.0 116.125 -175.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -69.7 -9.95 56.4 Favored 'General case' 0 N--CA 1.509 2.493 0 O-C-N 120.561 -1.337 . . . . 0.0 112.974 -176.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.431 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 44.4 mm -77.04 125.04 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 O-C-N 120.713 -1.242 . . . . 0.0 108.527 178.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.18 -46.78 12.31 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.261 -0.899 . . . . 0.0 112.568 -178.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 171.94 -137.5 4.33 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.716 -1.707 . . . . 0.0 111.54 -179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 58.2 t90 -42.88 -29.62 0.34 Allowed 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -144.98 62.27 1.31 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 110.508 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.417 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 12.5 p -61.82 139.31 95.55 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.651 -0.656 . . . . 0.0 110.651 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -76.17 -21.36 13.81 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 O-C-N 123.373 1.196 . . . . 0.0 111.113 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.7 m -94.05 14.49 19.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.491 -0.755 . . . . 0.0 111.296 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.3 t -73.85 147.89 42.86 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.16 35.31 53.51 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 89.2 m -119.68 131.55 55.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.595 -0.944 . . . . 0.0 109.882 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.04 145.66 33.73 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.871 -177.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.438 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -149.83 149.34 30.35 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.684 -0.635 . . . . 0.0 110.124 178.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -112.16 135.55 52.67 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.6 t -108.77 126.77 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.8 m -119.22 140.39 50.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.964 -0.46 . . . . 0.0 110.834 -178.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.431 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 39.3 pt -119.16 164.2 22.58 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.616 -0.677 . . . . 0.0 110.531 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.431 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.1 -24.41 79.28 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 121.273 1.315 . . . . 0.0 112.338 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -63.89 -40.02 95.54 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.272 -0.892 . . . . 0.0 109.58 179.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.95 62.57 0.41 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 48.6 t-20 -162.01 153.45 18.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.708 -0.878 . . . . 0.0 108.975 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.4 p -154.64 160.96 41.75 Favored 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 119.261 -0.975 . . . . 0.0 112.329 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.0 pt -136.35 164.44 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -108.65 126.75 53.31 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.16 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 88.0 mt -129.99 140.0 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.254 -0.904 . . . . 0.0 111.454 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . 0.406 ' CD ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -100.87 144.35 29.94 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.868 -0.52 . . . . 0.0 109.654 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.408 ' HA2' HD12 ' A' ' 46' ' ' ILE . . . -62.54 151.06 46.93 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -179.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.409 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 2.7 p -155.73 -44.1 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 178.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.409 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 14.9 t70 -130.3 170.0 14.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 178.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.431 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.7 t -101.48 159.94 14.86 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.775 . . . . 0.0 111.318 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -130.13 154.32 20.5 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.1 mtt180 -59.97 -31.56 70.01 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.555 -0.967 . . . . 0.0 110.403 179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.17 81.73 0.05 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 119.979 -1.105 . . . . 0.0 110.571 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.06 163.9 11.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.161 -1.176 . . . . 0.0 110.161 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.468 ' CD2' ' CG2' ' A' ' 46' ' ' ILE . 28.0 m-85 -88.36 118.63 28.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.512 -0.993 . . . . 0.0 109.746 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 54.6 t-20 -113.04 128.71 56.57 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.418 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.5 m -130.02 172.56 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 120.862 -1.149 . . . . 0.0 112.008 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 -56.52 156.22 12.26 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.504 -0.748 . . . . 0.0 109.594 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.44 -28.49 54.11 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.276 1.145 . . . . 0.0 110.663 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -70.28 -40.63 74.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.99 -1.069 . . . . 0.0 109.382 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.65 89.2 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -60.02 -49.84 76.08 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.826 -0.546 . . . . 0.0 110.311 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.9 m -60.11 -39.98 88.11 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.586 -0.696 . . . . 0.0 110.754 -178.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -68.67 -39.98 80.35 Favored 'General case' 0 N--CA 1.495 1.813 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.172 -178.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 63.1 tp -70.27 -42.9 71.52 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.627 -0.67 . . . . 0.0 111.749 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 92.7 t -97.05 -39.93 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.312 -0.868 . . . . 0.0 111.829 -177.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.07 -25.75 7.36 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 80.9 p -149.93 161.03 43.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.351 -1.088 . . . . 0.0 110.317 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 77.4 p -99.1 1.87 45.54 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.477 -0.765 . . . . 0.0 111.298 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -69.96 -28.65 65.73 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.388 -0.82 . . . . 0.0 111.466 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.82 -40.63 89.06 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.396 -0.815 . . . . 0.0 111.272 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 89.42 -66.26 2.98 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -151.23 155.99 39.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.486 -1.008 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.97 117.65 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.551 -0.718 . . . . 0.0 109.785 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -80.62 169.51 17.55 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.474 -0.766 . . . . 0.0 110.427 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 60.0 51.81 5.62 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.628 -0.67 . . . . 0.0 111.347 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 65.8 t -98.66 129.99 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.434 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -89.04 138.68 31.19 Favored 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.804 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -133.3 140.98 47.75 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.907 -0.496 . . . . 0.0 110.557 -179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.03 143.0 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.589 -0.694 . . . . 0.0 111.242 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.438 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.2 tt0 -70.88 139.78 50.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.681 -0.637 . . . . 0.0 110.444 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.07 163.27 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.098 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -59.62 141.38 55.12 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.543 -0.723 . . . . 0.0 110.478 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.0 -40.0 87.7 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.598 -0.689 . . . . 0.0 111.391 -179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 78.6 p -55.72 -34.23 64.95 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.503 -0.748 . . . . 0.0 110.935 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -69.92 -28.08 65.31 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.348 -0.845 . . . . 0.0 111.339 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 97.3 m -69.96 -46.45 65.22 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.23 -0.919 . . . . 0.0 109.179 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 89.2 mt -69.96 -40.01 78.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.143 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -64.56 -40.0 94.78 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.459 -0.776 . . . . 0.0 110.618 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -83.81 -60.01 2.02 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.454 -0.879 . . . . 0.0 110.93 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.04 -42.52 94.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.611 -0.934 . . . . 0.0 111.202 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.502 2.172 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.727 -179.711 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.694 0.759 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.9 p -111.81 138.94 47.73 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.9 pt -108.78 145.36 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.801 -0.562 . . . . 0.0 110.481 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.4 p -144.22 -173.32 3.98 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.426 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 39.4 p90 -140.02 141.24 36.32 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.456 -0.777 . . . . 0.0 110.696 179.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.14 150.07 50.55 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.483 -0.761 . . . . 0.0 109.284 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -82.83 -10.53 10.51 Favored 'Trans proline' 0 C--N 1.318 -1.067 0 O-C-N 123.105 1.055 . . . . 0.0 112.551 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.465 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.9 pt -70.06 -39.96 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.002 -1.061 . . . . 0.0 111.62 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.465 ' N ' HG13 ' A' ' 8' ' ' ILE . 53.7 m-85 -73.2 67.51 0.95 Allowed 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 122.875 1.321 . . . . 0.0 111.907 -178.32 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.8 169.65 8.36 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.854 176.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.87 -35.09 70.48 Favored 'General case' 0 N--CA 1.497 1.912 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -90.23 10.39 24.86 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 120.497 -1.377 . . . . 0.0 112.295 -177.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.8 tp -68.49 123.45 20.85 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -0.865 . . . . 0.0 109.829 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.3 m -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.806 -0.758 . . . . 0.0 109.775 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 86.6 mtp -69.96 -15.28 63.02 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.91 -0.494 . . . . 0.0 111.864 -178.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.58 -15.95 73.59 Favored Glycine 0 N--CA 1.496 2.654 0 O-C-N 121.021 -1.049 . . . . 0.0 110.816 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.5 m -90.05 -4.99 57.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.175 -1.191 . . . . 0.0 111.716 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 14.8 p -102.26 168.96 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.026 -1.046 . . . . 0.0 110.877 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -59.92 -40.7 89.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.575 -0.703 . . . . 0.0 110.368 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 54.1 m -83.45 74.84 10.05 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.2 m -100.41 -77.04 0.54 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.385 -0.822 . . . . 0.0 110.388 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -129.68 169.98 14.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 0.0 110.485 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.46 -154.4 16.45 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -70.2 -40.94 74.3 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -1.073 . . . . 0.0 109.791 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.406 ' CD2' ' O ' ' A' ' 54' ' ' SER . 44.0 m-70 -91.82 0.59 57.48 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.519 -0.738 . . . . 0.0 110.982 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -52.42 126.07 30.33 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.2 mt -96.53 -9.42 29.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 122.032 -0.687 . . . . 0.0 110.128 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.5 tpp -59.95 -37.03 78.39 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.35 -0.844 . . . . 0.0 110.006 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -74.37 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.513 -0.742 . . . . 0.0 111.983 -178.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -69.98 -39.99 75.6 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.237 -0.915 . . . . 0.0 110.455 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.433 ' CD2' HG22 ' A' ' 37' ' ' VAL . 87.3 m-85 -117.39 100.95 52.99 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.04 -20.92 16.31 Favored 'Trans proline' 0 C--N 1.318 -1.046 0 O-C-N 123.307 1.161 . . . . 0.0 111.367 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 30.2 m -127.84 148.32 50.46 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.371 -0.831 . . . . 0.0 111.017 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.7 tp -67.13 120.44 13.72 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.784 -0.573 . . . . 0.0 110.374 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 150.46 30.02 0.05 OUTLIER Glycine 0 N--CA 1.495 2.603 0 C-N-CA 119.891 -1.147 . . . . 0.0 110.963 179.49 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.415 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 31.7 mt-10 -153.18 -48.67 0.1 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.226 -1.161 . . . . 0.0 110.325 179.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.433 HG22 ' CD2' ' A' ' 31' ' ' TYR . 3.2 t -60.55 -60.48 10.5 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.411 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -75.67 -27.57 8.86 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.113 1.059 . . . . 0.0 109.466 177.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.406 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.27 -58.93 0.67 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.414 -2.274 . . . . 0.0 107.414 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.49 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 165.89 -73.57 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.615 0 C-N-CA 123.666 0.786 . . . . 0.0 109.356 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.49 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -86.21 19.19 1.43 Allowed 'Trans proline' 0 N--CA 1.493 1.465 0 CA-C-N 119.306 0.788 . . . . 0.0 111.16 178.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -118.37 37.03 4.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.059 -1.026 . . . . 0.0 110.18 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.4 p -120.71 141.23 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-O 121.757 0.789 . . . . 0.0 110.716 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.99 171.38 42.92 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.08 152.24 32.63 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.452 HG23 ' CE1' ' A' ' 83' ' ' PHE . 13.7 pt -141.88 156.81 65.41 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.665 -0.903 . . . . 0.0 109.742 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.3 -20.5 36.93 Favored 'Trans proline' 0 N--CA 1.499 1.841 0 C-N-CA 121.399 1.4 . . . . 0.0 113.966 -177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -88.92 20.68 3.44 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.805 -1.184 . . . . 0.0 112.541 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.423 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 40.7 mt -120.02 120.0 61.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.074 -1.016 . . . . 0.0 108.398 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.48 -41.82 21.19 Favored 'General case' 0 N--CA 1.499 2.015 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -176.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 174.83 -138.96 4.6 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 118.323 -1.894 . . . . 0.0 112.171 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 26.3 t90 -39.95 -30.06 0.08 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -146.72 68.52 1.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.998 -1.064 . . . . 0.0 111.24 -178.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.406 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 2.1 t -64.51 136.87 96.94 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.622 -0.674 . . . . 0.0 110.586 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.29 -20.55 21.06 Favored 'Trans proline' 0 C--N 1.32 -0.968 0 O-C-N 123.303 1.159 . . . . 0.0 110.605 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.9 m -99.84 14.82 29.03 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.499 -0.751 . . . . 0.0 110.806 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 23.4 t -72.75 151.12 42.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.238 -0.913 . . . . 0.0 110.061 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.18 21.75 78.62 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 80.4 m -106.58 140.01 40.13 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.515 -0.991 . . . . 0.0 110.277 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 42.3 t -78.59 136.21 37.46 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.687 -178.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.436 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -137.21 146.24 44.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.647 -0.658 . . . . 0.0 110.016 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -116.28 136.46 52.98 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.222 -0.924 . . . . 0.0 110.099 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -114.25 129.99 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.543 -0.723 . . . . 0.0 110.887 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 51.1 m -119.92 144.96 47.16 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.723 -0.611 . . . . 0.0 110.501 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.433 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.6 pt -123.44 164.33 28.85 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.307 -0.871 . . . . 0.0 111.11 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.433 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.28 -26.88 82.53 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.428 1.419 . . . . 0.0 112.574 -178.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -63.45 -39.71 95.2 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.317 -0.864 . . . . 0.0 109.741 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 115.26 61.65 0.37 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -160.6 153.29 20.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.832 -0.805 . . . . 0.0 109.077 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 84.0 p -150.65 158.49 44.21 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 122.18 0.99 . . . . 0.0 112.021 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 27.6 pt -138.7 162.77 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.27 123.83 48.89 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 118.859 -1.136 . . . . 0.0 109.794 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.422 HD11 HG22 ' A' ' 73' ' ' ILE . 48.5 mm -117.13 131.99 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -98.65 132.38 44.1 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.152 -0.968 . . . . 0.0 108.783 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.89 148.35 10.44 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.6 p -159.96 -35.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.792 -0.828 . . . . 0.0 110.406 179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -128.94 165.28 21.38 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.885 -1.134 . . . . 0.0 110.449 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.423 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 79.4 p -82.54 159.78 22.73 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.656 -0.653 . . . . 0.0 110.521 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -127.49 135.4 8.73 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -65.44 -39.95 92.67 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.923 -0.751 . . . . 0.0 109.608 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 176.29 70.28 0.05 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.46 -163.18 33.35 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.59 -1.29 . . . . 0.0 110.766 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.452 ' CE1' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -123.34 136.61 54.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 122.025 -0.691 . . . . 0.0 109.415 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -137.97 126.89 24.02 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.389 -0.925 . . . . 0.0 108.808 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.8 m -133.63 176.8 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.08 -1.012 . . . . 0.0 111.128 -178.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.3 m-20 -56.47 150.25 35.17 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.91 -25.68 67.11 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 O-C-N 123.367 1.193 . . . . 0.0 110.763 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.8 m -70.8 -40.03 72.77 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.976 -1.078 . . . . 0.0 109.308 178.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.03 91.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.04 -49.93 75.74 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.868 -0.52 . . . . 0.0 110.586 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.1 m -60.11 -39.94 87.98 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.439 -0.788 . . . . 0.0 110.606 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.8 mtmt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.273 -179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 45.9 tp -71.6 -46.12 60.16 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 120.047 -0.661 . . . . 0.0 111.357 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.1 t -89.46 -41.39 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.4 -0.812 . . . . 0.0 111.334 -177.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 125.2 -27.25 5.37 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.7 p -158.85 162.32 36.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.551 -0.97 . . . . 0.0 110.024 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.9 p -91.97 1.57 57.1 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.478 -0.764 . . . . 0.0 111.372 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.66 -34.08 77.05 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.36 -41.5 80.25 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.45 -0.781 . . . . 0.0 111.456 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.41 -80.47 1.82 Allowed Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.3 ttm180 -129.0 136.82 50.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.575 -0.956 . . . . 0.0 109.918 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.6 t -119.02 117.29 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.243 -0.91 . . . . 0.0 110.299 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -83.84 171.57 12.98 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.525 0.679 . . . . 0.0 110.65 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.52 52.0 1.87 Allowed 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.623 -0.673 . . . . 0.0 111.06 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.4 t -103.24 129.81 54.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 C-N-CA 119.279 -0.968 . . . . 0.0 110.607 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -90.64 137.92 31.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.309 -0.87 . . . . 0.0 109.6 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 53.8 p90 -140.04 145.83 38.24 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.902 -0.499 . . . . 0.0 110.835 -178.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 29.6 m -151.1 151.58 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.216 -0.928 . . . . 0.0 111.273 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.436 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.0 tt0 -72.37 141.05 48.75 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.682 -0.636 . . . . 0.0 110.47 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 15.7 m -137.03 170.03 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -64.21 148.85 49.14 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.175 -0.953 . . . . 0.0 110.645 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -60.08 -39.77 87.21 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.495 -0.753 . . . . 0.0 110.84 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 89.3 p -52.24 -37.41 55.13 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.413 -0.805 . . . . 0.0 110.614 -178.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.31 -39.27 93.57 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.583 -0.698 . . . . 0.0 111.089 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -59.97 -50.02 75.4 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.394 -0.816 . . . . 0.0 110.064 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 86.9 mt -69.84 -39.98 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.715 -0.616 . . . . 0.0 110.773 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -39.98 96.24 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.39 -0.819 . . . . 0.0 110.521 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -72.66 -47.32 27.41 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.174 -1.171 . . . . 0.0 110.174 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.99 -40.78 90.33 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.502 -0.999 . . . . 0.0 110.707 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.5 t30 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.276 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.013 0.435 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.2 t -113.68 139.19 49.27 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.672 0.749 . . . . 0.0 111.045 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 36.3 pt -111.02 147.65 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.83 -0.544 . . . . 0.0 109.797 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.1 m -146.09 -171.52 3.73 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -140.12 150.01 43.75 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.119 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -126.67 148.07 63.33 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.521 -0.737 . . . . 0.0 110.216 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -86.57 14.14 2.53 Favored 'Trans proline' 0 C--N 1.317 -1.09 0 O-C-N 123.399 1.21 . . . . 0.0 111.636 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.405 HD12 ' CZ ' ' A' ' 9' ' ' TYR . 1.4 pt -100.1 10.06 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.029 -1.044 . . . . 0.0 111.666 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.405 ' CZ ' HD12 ' A' ' 8' ' ' ILE . 21.9 m-85 -123.46 66.64 1.0 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.701 1.239 . . . . 0.0 110.259 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.07 172.76 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.459 -1.246 . . . . 0.0 108.447 176.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.03 -31.97 67.51 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -175.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -89.76 11.98 18.44 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.332 -1.347 . . . . 0.0 111.9 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.3 119.56 13.77 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.281 -0.887 . . . . 0.0 110.043 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 52.6 m -69.18 135.85 51.24 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.757 -0.777 . . . . 0.0 108.958 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 57.1 mtp -70.21 -14.59 62.69 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 120.211 -0.596 . . . . 0.0 111.926 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.65 -18.61 74.08 Favored Glycine 0 N--CA 1.495 2.6 0 O-C-N 120.848 -1.157 . . . . 0.0 110.654 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 70.4 m -88.06 -9.64 52.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.289 -1.124 . . . . 0.0 111.615 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 p -101.74 169.66 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.029 -1.044 . . . . 0.0 110.495 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -59.14 -39.76 83.39 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.568 -0.708 . . . . 0.0 110.594 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.31 82.84 3.08 Favored 'General case' 0 N--CA 1.5 2.025 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 -84.26 0.42 Allowed 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.794 -1.191 . . . . 0.0 113.395 -177.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -143.8 12.56 1.67 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.564 -1.335 . . . . 0.0 112.752 -177.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.89 -149.19 0.11 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -67.22 -39.89 86.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.891 -0.77 . . . . 0.0 110.456 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.563 ' NE2' ' N ' ' A' ' 54' ' ' SER . 11.8 p80 -97.86 6.2 48.08 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.31 138.79 35.53 Favored Glycine 0 N--CA 1.5 2.91 0 O-C-N 121.055 -1.028 . . . . 0.0 110.659 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -102.31 -5.68 23.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.885 -0.774 . . . . 0.0 110.724 179.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.8 ttm -60.44 -33.1 72.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.23 -0.919 . . . . 0.0 110.486 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.79 -72.15 0.06 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.566 -0.709 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -70.0 -40.16 75.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.185 -0.947 . . . . 0.0 110.079 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.414 ' CD2' HG23 ' A' ' 37' ' ' VAL . 60.8 m-85 -122.86 95.16 46.66 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.875 -0.516 . . . . 0.0 109.769 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.63 -19.32 32.13 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 O-C-N 123.398 1.209 . . . . 0.0 111.556 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.7 m -122.61 140.9 52.3 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.296 -0.878 . . . . 0.0 110.736 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.7 tp -61.65 119.91 9.59 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.912 -0.492 . . . . 0.0 110.317 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.77 33.36 0.04 OUTLIER Glycine 0 N--CA 1.496 2.679 0 C-N-CA 119.948 -1.12 . . . . 0.0 110.797 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.66 -45.98 0.06 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.195 -1.179 . . . . 0.0 110.013 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.419 ' CB ' ' CD ' ' A' ' 38' ' ' PRO . 3.2 t -62.69 -60.78 8.93 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 178.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.419 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 50.2 Cg_endo -75.97 -28.15 7.88 Favored 'Trans proline' 0 N--CA 1.485 1.028 0 N-CA-C 109.236 -1.102 . . . . 0.0 109.236 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.402 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.98 -60.93 0.65 Allowed Glycine 0 N--CA 1.486 2.019 0 N-CA-C 107.284 -2.326 . . . . 0.0 107.284 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.59 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.2 t80 164.04 -52.9 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.573 0 C-N-CA 123.381 0.672 . . . . 0.0 109.705 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.59 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.4 Cg_endo -101.78 13.94 0.37 Allowed 'Trans proline' 0 C--N 1.324 -0.742 0 C-N-CA 121.457 1.438 . . . . 0.0 111.486 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -123.46 40.73 3.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -0.928 . . . . 0.0 110.112 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.2 p -115.44 135.74 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 CA-C-O 121.602 0.715 . . . . 0.0 110.681 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -163.94 170.0 39.06 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.37 164.82 30.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.421 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.2 pt -150.92 163.47 23.64 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.74 -0.859 . . . . 0.0 110.12 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 55.6 Cg_endo -73.69 -15.05 24.41 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 121.43 1.42 . . . . 0.0 113.337 -177.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -90.37 12.7 17.58 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.852 -1.155 . . . . 0.0 112.829 -177.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.405 ' CD1' ' CG1' ' A' ' 46' ' ' ILE . 71.9 mt -110.8 129.92 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.068 -1.02 . . . . 0.0 110.18 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.41 -46.45 12.52 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.537 -0.727 . . . . 0.0 112.159 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 164.76 -138.91 5.52 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.895 -1.621 . . . . 0.0 111.371 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.426 ' CE3' ' HB2' ' A' ' 53' ' ' ASP . 71.0 t90 -39.81 -28.78 0.05 Allowed 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -179.005 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.522 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 24.6 t70 -141.09 63.96 1.43 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.281 -0.887 . . . . 0.0 110.576 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.563 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 4.8 t -79.86 139.35 53.83 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.696 -0.627 . . . . 0.0 110.414 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -78.4 -16.63 13.45 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.331 1.174 . . . . 0.0 111.45 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.0 p -98.05 4.84 49.21 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.208 -0.932 . . . . 0.0 112.607 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.59 140.36 58.14 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.738 -1.226 . . . . 0.0 109.73 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.97 -7.93 80.75 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 120.332 -0.937 . . . . 0.0 110.871 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.4 m -69.42 149.84 47.91 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.117 -1.225 . . . . 0.0 109.514 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.6 130.58 45.14 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.987 -0.446 . . . . 0.0 111.341 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -128.15 140.27 52.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.483 -0.761 . . . . 0.0 109.2 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -103.16 132.68 49.24 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.9 t -110.02 124.56 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.621 -0.674 . . . . 0.0 110.499 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.5 m -118.66 135.79 54.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.913 -0.492 . . . . 0.0 110.633 -178.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.428 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.9 pt -115.66 163.58 20.31 Favored Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.461 -0.775 . . . . 0.0 110.723 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.428 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.65 -27.29 76.0 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 121.411 1.407 . . . . 0.0 113.15 -178.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -62.62 -40.0 95.59 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.132 -0.98 . . . . 0.0 109.582 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.9 60.06 0.29 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -155.05 151.11 27.99 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 89.6 p -149.83 153.34 36.6 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.029 0.919 . . . . 0.0 111.747 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.6 pt -139.14 163.09 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -105.51 129.42 53.8 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.871 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 73' ' ' ILE . 48.9 mm -116.09 128.18 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.662 -0.649 . . . . 0.0 109.614 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -100.05 137.96 37.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.28 -0.888 . . . . 0.0 108.888 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -53.43 148.21 16.11 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.423 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.2 p -159.92 -43.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.837 -0.802 . . . . 0.0 109.164 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.423 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 22.8 t70 -132.39 165.48 24.17 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.475 -0.766 . . . . 0.0 109.844 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.4 p -107.62 161.59 14.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 110.158 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -145.01 173.57 25.41 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.1 mtm180 -60.28 -40.03 88.99 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.8 -0.824 . . . . 0.0 112.05 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.06 95.39 0.1 OUTLIER Glycine 0 N--CA 1.504 3.182 0 C-N-CA 119.373 -1.394 . . . . 0.0 111.816 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.64 -164.82 29.96 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -123.31 120.24 32.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.625 -0.927 . . . . 0.0 109.241 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -119.09 130.06 55.4 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.5 m -130.02 174.68 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.036 0 O-C-N 121.088 -1.007 . . . . 0.0 111.725 -178.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -57.9 156.8 17.52 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.554 -0.716 . . . . 0.0 109.935 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.36 -27.73 47.3 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.471 1.248 . . . . 0.0 110.705 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.03 -40.08 75.38 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.012 -1.055 . . . . 0.0 109.485 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.84 -40.13 87.85 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.03 -49.96 75.6 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.783 -0.573 . . . . 0.0 110.678 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 66.6 m -59.97 -38.7 83.29 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.532 -0.73 . . . . 0.0 110.601 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -68.25 -39.81 82.12 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.883 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 54.6 tp -70.0 -42.73 72.68 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.597 -0.689 . . . . 0.0 111.886 -179.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -98.66 -36.91 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 O-C-N 121.221 -0.925 . . . . 0.0 111.709 -177.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.47 -28.83 6.11 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -151.59 162.68 40.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.993 . . . . 0.0 110.394 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.3 p -100.97 14.05 33.18 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.913 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -70.03 -36.68 75.23 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.421 -0.799 . . . . 0.0 111.012 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.87 -40.04 87.3 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.514 -0.742 . . . . 0.0 110.894 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.13 -65.75 2.52 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 -143.19 151.65 40.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.579 -0.954 . . . . 0.0 110.313 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -121.86 121.41 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.548 -0.72 . . . . 0.0 109.979 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -90.13 172.19 8.99 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.342 -0.849 . . . . 0.0 110.635 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 64.5 t30 60.05 47.93 9.1 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.546 -0.722 . . . . 0.0 110.441 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.6 t -96.68 124.49 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 119.832 -0.747 . . . . 0.0 110.38 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -82.68 139.92 33.41 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 119.253 -0.979 . . . . 0.0 108.741 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -135.96 141.86 44.49 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.361 0.601 . . . . 0.0 111.505 -178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.9 m -147.52 145.8 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.769 -0.582 . . . . 0.0 110.847 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -72.08 138.2 47.64 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.635 -0.666 . . . . 0.0 110.069 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.1 m -129.91 162.06 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.738 -0.601 . . . . 0.0 110.3 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -59.65 144.85 46.7 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.483 -0.761 . . . . 0.0 110.301 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.5 tt -60.02 -38.26 82.15 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.658 -0.651 . . . . 0.0 111.108 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.6 m -56.28 -39.11 72.14 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.531 -0.731 . . . . 0.0 110.384 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -59.98 -39.98 87.55 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.429 -0.794 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 76.6 m -61.86 -48.63 79.68 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.364 -0.835 . . . . 0.0 110.718 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 86.3 mt -70.05 -39.99 77.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.653 -0.654 . . . . 0.0 110.668 -178.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.12 -40.03 95.3 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.465 -0.772 . . . . 0.0 110.29 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.88 -47.08 49.44 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -40.26 88.64 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.999 . . . . 0.0 110.5 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.7 t30 . . . . . 0 N--CA 1.502 2.163 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.848 179.791 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.3 m . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 120.876 0.37 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -111.23 141.35 44.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.621 -0.674 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.401 ' O ' ' HA ' ' A' ' 101' ' ' ARG . 42.7 pt -116.1 149.24 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.822 -0.549 . . . . 0.0 110.803 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 m -147.3 -172.1 3.94 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -142.83 147.28 35.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.158 -0.964 . . . . 0.0 110.852 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -135.73 152.96 76.98 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 110.079 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -88.15 37.13 0.43 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.318 1.167 . . . . 0.0 111.031 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.434 HG21 ' CD2' ' A' ' 9' ' ' TYR . 6.0 tp -106.7 -3.46 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.438 -0.789 . . . . 0.0 111.077 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.434 ' CD2' HG21 ' A' ' 8' ' ' ILE . 42.9 m-85 -122.08 76.91 1.34 Allowed 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 122.769 1.271 . . . . 0.0 111.257 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -108.61 169.97 8.32 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.671 177.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.93 -32.69 71.02 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 -176.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -87.99 11.5 15.78 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 120.503 -1.373 . . . . 0.0 112.336 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.1 tp -74.61 121.5 21.7 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.2 -0.937 . . . . 0.0 110.227 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.4 m -67.4 138.99 57.12 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.696 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.2 mmm -68.29 -13.7 62.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.73 -0.606 . . . . 0.0 111.797 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -72.32 -14.49 76.95 Favored Glycine 0 N--CA 1.497 2.703 0 O-C-N 120.98 -1.075 . . . . 0.0 111.312 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.3 t -92.84 -14.88 27.14 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.125 -1.22 . . . . 0.0 111.405 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.431 HG23 ' N ' ' A' ' 19' ' ' ALA . 11.9 p -90.05 165.2 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.246 -0.909 . . . . 0.0 111.0 -178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.431 ' N ' HG23 ' A' ' 18' ' ' VAL . . . -56.96 -45.38 82.9 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.573 -0.705 . . . . 0.0 110.347 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.8 m -80.89 80.08 7.44 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.32 -80.42 0.43 Allowed 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.116 -0.99 . . . . 0.0 113.216 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -138.86 10.08 2.62 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.102 -0.999 . . . . 0.0 112.605 -177.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.61 -150.46 0.45 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -65.65 -40.04 92.05 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.67 -0.9 . . . . 0.0 109.867 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 22.5 m-70 -99.94 8.95 43.69 Favored 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.464 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.19 137.54 49.16 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.5 mt -98.65 -4.05 34.68 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.812 -0.817 . . . . 0.0 110.262 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 54.6 ttm -60.1 -39.55 86.56 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.324 -0.86 . . . . 0.0 110.763 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.83 -75.55 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.443 -0.785 . . . . 0.0 111.723 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -70.06 -40.01 75.32 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.425 -0.797 . . . . 0.0 110.387 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.417 ' CD2' HG21 ' A' ' 37' ' ' VAL . 94.4 m-85 -119.18 89.43 39.54 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.869 -0.519 . . . . 0.0 110.896 -178.081 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.07 -4.71 15.79 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 O-C-N 123.251 1.132 . . . . 0.0 111.073 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 17.5 p -131.41 155.35 47.47 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.147 -0.971 . . . . 0.0 110.219 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 58.2 tp -85.1 113.11 21.25 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.326 -0.55 . . . . 0.0 109.769 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 155.24 33.4 0.03 OUTLIER Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.609 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.401 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 2.6 mt-10 -157.8 -47.77 0.06 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.248 -1.148 . . . . 0.0 109.954 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.425 ' HB ' ' HD3' ' A' ' 38' ' ' PRO . 2.4 t -62.25 -58.0 19.98 Favored Pre-proline 0 N--CA 1.497 1.877 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.425 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.3 Cg_endo -78.66 -31.62 2.46 Favored 'Trans proline' 0 C--N 1.319 -0.995 0 O-C-N 123.282 1.148 . . . . 0.0 109.29 177.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.26 -61.73 0.66 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.568 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 5.3 t80 161.21 -50.85 0.0 OUTLIER Pre-proline 0 N--CA 1.514 2.752 0 C-N-CA 123.664 0.785 . . . . 0.0 110.19 177.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.568 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 50.5 Cg_endo -101.87 18.41 0.25 Allowed 'Trans proline' 0 C--N 1.326 -0.652 0 C-N-CA 121.744 1.629 . . . . 0.0 111.62 -177.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -135.95 55.85 1.85 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.253 -0.904 . . . . 0.0 110.277 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -130.32 141.8 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 CA-C-O 121.681 0.753 . . . . 0.0 110.524 -179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -172.27 179.18 44.03 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.78 154.61 27.02 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.319 -1.912 . . . . 0.0 108.319 178.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 49' ' ' ILE . 5.7 pt -143.44 160.05 52.74 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.512 -0.993 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -69.07 -17.83 40.51 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.142 1.228 . . . . 0.0 114.033 -177.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -93.65 25.41 3.54 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.71 -1.244 . . . . 0.0 112.387 -178.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.454 HG12 HG13 ' A' ' 46' ' ' ILE . 37.1 mm -119.94 120.1 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.024 -1.047 . . . . 0.0 109.012 178.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.55 -44.12 29.62 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.195 -0.941 . . . . 0.0 111.977 -178.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.26 -141.55 6.87 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.078 -1.534 . . . . 0.0 111.424 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 49.3 t90 -41.49 -29.43 0.16 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -178.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -141.44 57.21 1.52 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.021 -1.049 . . . . 0.0 111.206 -178.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 18.2 m -69.05 144.34 95.39 Favored Pre-proline 0 N--CA 1.493 1.713 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.673 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.428 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.6 Cg_endo -74.15 -14.41 23.3 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.328 1.173 . . . . 0.0 111.619 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 70.3 m -103.43 18.4 21.9 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.385 -0.822 . . . . 0.0 111.735 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.401 ' HB2' ' HB3' ' A' ' 25' ' ' HIS . 3.5 m -69.97 139.94 52.89 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.987 -1.071 . . . . 0.0 109.112 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.33 27.66 57.22 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 97.7 m -106.52 138.15 43.22 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.507 -0.996 . . . . 0.0 110.164 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.405 ' HB2' ' HA ' ' A' ' 112' ' ' LEU . 53.2 t -80.04 131.59 35.81 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.389 0.614 . . . . 0.0 110.889 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.439 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.5 m95 -133.99 152.15 51.74 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.541 -0.724 . . . . 0.0 109.379 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.2 tttm -121.69 138.15 54.46 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 120.933 -1.105 . . . . 0.0 110.583 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.7 126.79 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.615 -0.678 . . . . 0.0 111.344 -178.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.9 m -119.54 141.14 49.49 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.742 -0.599 . . . . 0.0 110.48 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.447 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 10.9 pt -119.95 163.93 25.16 Favored Pre-proline 0 N--CA 1.503 2.183 0 O-C-N 121.186 -0.947 . . . . 0.0 110.906 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.9 Cg_endo -62.1 -27.56 79.12 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.564 1.509 . . . . 0.0 113.201 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -62.51 -39.95 95.17 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.244 -0.91 . . . . 0.0 110.045 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.09 60.31 0.31 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -159.92 151.11 19.48 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 86.1 p -151.64 157.77 42.58 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.007 0.908 . . . . 0.0 111.664 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 41.8 pt -137.83 161.65 32.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -102.12 121.29 41.93 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 118.581 -1.248 . . . . 0.0 109.187 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.78 130.6 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -99.33 132.82 44.39 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.112 -0.993 . . . . 0.0 109.251 -179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.9 146.67 13.25 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.404 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 7.5 p -169.76 -33.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.863 -0.787 . . . . 0.0 110.323 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.434 ' OD2' ' CZ ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.0 171.89 12.3 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 120.925 -1.11 . . . . 0.0 108.711 179.737 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -98.09 142.43 29.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.669 -0.644 . . . . 0.0 109.791 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -114.5 144.79 18.45 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -89.22 103.4 16.02 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.578 -0.954 . . . . 0.0 110.526 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 50.12 56.98 10.73 Favored Glycine 0 N--CA 1.497 2.765 0 O-C-N 121.681 -0.637 . . . . 0.0 111.724 178.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.6 -163.5 33.59 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.045 -1.55 . . . . 0.0 111.915 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.454 ' CE1' HG23 ' A' ' 46' ' ' ILE 0.263 0.1 OUTLIER -123.25 122.5 38.52 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -178.908 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -124.12 129.91 51.65 Favored 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 118.892 -1.123 . . . . 0.0 109.83 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.3 m -132.31 172.88 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.376 -178.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -54.15 156.79 5.12 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.551 -0.718 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.64 -18.72 32.7 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.477 1.251 . . . . 0.0 110.051 179.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -80.02 -40.97 26.71 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.088 -1.008 . . . . 0.0 108.991 178.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.59 89.24 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -59.99 -50.05 75.26 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.808 -0.557 . . . . 0.0 110.573 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.3 m -59.92 -40.05 87.57 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.929 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -69.0 -40.13 78.89 Favored 'General case' 0 N--CA 1.495 1.803 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.29 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 49.7 tp -71.97 -43.36 65.27 Favored 'General case' 0 N--CA 1.496 1.871 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.478 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -92.34 -40.51 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.462 -0.774 . . . . 0.0 111.54 -177.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 126.63 -34.96 3.03 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 95.2 p -152.69 164.63 37.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.664 -0.903 . . . . 0.0 110.262 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 69.8 p -90.18 2.61 55.17 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.42 -0.8 . . . . 0.0 111.194 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -69.94 -27.75 65.01 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.327 -0.858 . . . . 0.0 110.738 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.01 -41.72 83.7 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.57 -0.706 . . . . 0.0 110.619 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.56 -80.7 1.63 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 59.9 ttp180 -130.86 138.88 50.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.565 -0.962 . . . . 0.0 111.042 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.54 114.65 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.608 -0.682 . . . . 0.0 110.428 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -82.46 171.02 14.6 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.665 -0.647 . . . . 0.0 110.588 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.7 t30 60.13 48.35 8.48 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.743 -0.598 . . . . 0.0 111.828 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.7 t -98.1 124.56 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.325 179.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t-20 -82.57 134.24 35.19 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.931 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -135.75 140.85 44.67 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.8 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.01 154.67 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.237 -0.914 . . . . 0.0 111.001 -179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.439 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.4 tt0 -74.64 141.53 44.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.713 -0.617 . . . . 0.0 109.834 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.0 m -139.06 168.89 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 120.047 -0.661 . . . . 0.0 109.553 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -59.92 144.34 49.19 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.356 -0.84 . . . . 0.0 110.964 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.405 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 9.4 tt -59.9 -36.18 76.43 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.562 -0.711 . . . . 0.0 111.035 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.4 m -56.48 -39.16 72.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.502 -0.749 . . . . 0.0 109.836 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -61.52 -38.57 87.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.562 -0.711 . . . . 0.0 110.859 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.22 -49.61 76.94 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.301 -0.874 . . . . 0.0 109.846 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.417 HD11 HG21 ' A' ' 116' ' ' ILE . 83.7 mt -69.83 -39.92 78.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.632 -0.668 . . . . 0.0 110.662 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -65.02 -40.49 94.95 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.463 -0.773 . . . . 0.0 110.643 -179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.12 -43.75 70.29 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.99 94.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.765 -0.844 . . . . 0.0 110.264 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.389 -179.86 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.1 m . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 p -112.47 141.95 45.6 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 122.15 0.976 . . . . 0.0 111.575 -178.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.2 pt -119.97 150.02 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.965 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 7.6 m -144.87 -173.0 3.95 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -140.44 147.5 39.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.477 -0.764 . . . . 0.0 109.489 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -138.55 147.68 55.89 Favored Pre-proline 0 N--CA 1.491 1.593 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -74.39 -6.08 17.83 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 O-C-N 123.455 1.239 . . . . 0.0 110.532 178.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.406 HG23 ' CE2' ' A' ' 9' ' ' TYR . 7.3 tp -64.43 -15.86 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.36 -0.837 . . . . 0.0 111.095 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.406 ' CE2' HG23 ' A' ' 8' ' ' ILE . 43.2 m-85 -112.5 69.31 0.69 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 122.72 1.248 . . . . 0.0 110.786 178.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.28 170.03 8.16 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.523 -1.217 . . . . 0.0 108.309 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.9 -32.44 70.75 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -175.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -89.64 11.49 19.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 120.344 -1.473 . . . . 0.0 112.182 -177.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.404 HD22 ' HA ' ' A' ' 9' ' ' TYR . 28.5 tp -71.6 126.32 29.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.317 -0.864 . . . . 0.0 109.974 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.5 p -70.7 136.9 49.33 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.247 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 94.6 mmm -64.66 -15.1 60.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.802 -0.561 . . . . 0.0 111.823 -178.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.66 -12.49 84.43 Favored Glycine 0 N--CA 1.494 2.537 0 O-C-N 121.066 -1.021 . . . . 0.0 111.297 -179.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -85.88 -7.21 58.85 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.113 -1.228 . . . . 0.0 111.935 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.0 p -101.4 168.89 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.03 -1.044 . . . . 0.0 110.672 -179.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.03 -42.38 94.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.605 -0.685 . . . . 0.0 109.881 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 70.42 8.47 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.2 p -92.86 -74.89 0.51 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.782 -0.573 . . . . 0.0 109.691 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -130.01 169.93 14.63 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 121.17 -149.0 17.41 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -179.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -73.48 -44.16 58.58 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.641 -0.917 . . . . 0.0 111.05 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.427 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 44.8 m-70 -98.28 8.9 44.18 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.297 -0.877 . . . . 0.0 110.711 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.2 129.94 46.7 Favored Glycine 0 N--CA 1.496 2.657 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.8 mt -100.03 -4.21 30.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 122.041 -0.682 . . . . 0.0 110.245 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 57.2 ttm -61.67 -37.88 85.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.241 -0.912 . . . . 0.0 109.876 179.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.5 -74.11 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.671 -0.643 . . . . 0.0 112.059 -177.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -69.96 -40.38 75.44 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.273 -0.892 . . . . 0.0 110.659 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.457 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 53.9 m-85 -120.25 86.3 37.91 Favored Pre-proline 0 N--CA 1.492 1.664 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -178.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.37 -11.18 30.75 Favored 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.383 1.202 . . . . 0.0 111.145 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -130.04 141.19 50.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.177 -0.952 . . . . 0.0 110.105 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -69.68 117.46 11.32 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.684 -0.635 . . . . 0.0 110.491 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.43 33.59 0.03 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.079 179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -159.8 -46.07 0.05 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.176 -1.19 . . . . 0.0 110.64 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.457 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 2.6 t -63.0 -59.33 12.75 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.359 -0.838 . . . . 0.0 108.83 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.41 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 47.2 Cg_endo -74.35 -31.77 7.08 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 123.222 1.117 . . . . 0.0 109.408 178.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.437 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 134.57 -63.39 0.61 Allowed Glycine 0 N--CA 1.486 1.979 0 N-CA-C 107.116 -2.393 . . . . 0.0 107.116 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.587 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 161.19 -55.12 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.7 0 C-N-CA 123.457 0.703 . . . . 0.0 110.484 177.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.68 3.52 0.7 Allowed 'Trans proline' 0 C--N 1.322 -0.828 0 C-N-CA 121.068 1.178 . . . . 0.0 112.09 -178.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 72' ' ' PHE . 19.3 m120 -120.19 42.13 3.03 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 0.0 109.415 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.6 p -109.89 142.64 21.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.742 0.782 . . . . 0.0 109.145 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -167.36 172.99 42.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.91 161.54 29.43 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.0 pt -144.49 159.44 51.51 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.705 -0.879 . . . . 0.0 110.684 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -71.25 -14.91 31.68 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.511 1.474 . . . . 0.0 113.115 -178.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -91.55 19.45 6.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.016 -1.053 . . . . 0.0 111.948 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.474 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 62.4 mt -119.97 120.22 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.89 . . . . 0.0 108.938 177.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.69 -41.32 21.51 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -177.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 177.29 -126.32 1.09 Allowed Glycine 0 N--CA 1.492 2.38 0 C-N-CA 118.144 -1.979 . . . . 0.0 112.741 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -40.01 -34.6 0.3 Allowed 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -177.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 39.9 p-10 -172.08 82.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.719 -1.238 . . . . 0.0 109.713 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 t -68.25 150.65 97.64 Favored Pre-proline 0 N--CA 1.495 1.793 0 O-C-N 121.69 -0.631 . . . . 0.0 110.678 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.427 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 41.1 Cg_endo -66.96 -15.86 48.1 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 123.513 1.27 . . . . 0.0 111.194 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -106.84 9.73 30.86 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.327 -0.858 . . . . 0.0 111.446 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -60.84 141.86 56.7 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.846 -1.159 . . . . 0.0 109.947 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.8 17.13 58.69 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 16.8 p -91.49 167.31 12.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.282 -1.128 . . . . 0.0 110.055 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -110.13 136.09 49.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.943 -0.473 . . . . 0.0 110.64 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -132.02 137.63 47.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.497 -0.752 . . . . 0.0 109.096 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 77.4 tttt -100.88 133.31 45.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.298 -0.876 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.9 t -109.98 120.49 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.616 -0.678 . . . . 0.0 109.71 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 44.7 m -116.98 141.89 47.65 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.742 -0.599 . . . . 0.0 111.312 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.424 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 36.8 pt -119.61 163.4 27.57 Favored Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.539 -0.726 . . . . 0.0 110.508 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.424 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -61.95 -24.69 77.2 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.744 1.391 . . . . 0.0 112.675 -178.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -63.84 -40.08 95.73 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.226 -0.921 . . . . 0.0 109.723 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.67 62.02 0.3 Allowed Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 35.8 t-20 -160.06 153.16 21.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.661 -0.905 . . . . 0.0 109.214 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.2 p -150.04 160.1 43.9 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.18 0.991 . . . . 0.0 112.246 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.446 HG23 HD12 ' A' ' 71' ' ' ILE . 12.6 tt -138.96 159.38 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.416 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 93.1 m-85 -104.36 122.35 45.29 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.474 HD12 HG21 ' A' ' 73' ' ' ILE . 47.1 mm -114.85 130.01 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.469 -0.77 . . . . 0.0 110.314 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . 0.406 ' CD ' HG11 ' A' ' 37' ' ' VAL . 5.2 ttp-105 -97.65 139.43 33.55 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.01 146.69 50.51 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -153.1 -43.55 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 122.072 -0.664 . . . . 0.0 109.369 179.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.419 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 18.1 t70 -115.37 162.46 17.1 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.237 -0.915 . . . . 0.0 110.352 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.474 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 26.4 t -79.64 156.8 27.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.818 -0.551 . . . . 0.0 109.608 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -140.62 126.42 3.14 Favored Glycine 0 N--CA 1.482 1.721 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.401 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -59.92 -40.0 87.38 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -167.77 169.13 41.1 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 107.875 -2.09 . . . . 0.0 107.875 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 64.52 -166.84 29.81 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.186 -1.185 . . . . 0.0 112.571 177.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -139.17 139.78 37.66 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 122.225 -0.573 . . . . 0.0 110.754 -178.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.41 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 0.9 OUTLIER -123.58 130.24 52.38 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.019 -1.051 . . . . 0.0 110.14 178.495 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.4 m -129.02 166.53 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.873 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.8 m-20 -54.61 153.65 10.29 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.53 -0.731 . . . . 0.0 110.19 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.24 -30.03 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.498 1.262 . . . . 0.0 110.241 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -69.92 -40.09 75.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.094 -1.004 . . . . 0.0 108.603 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.02 -38.28 85.66 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.11 -49.48 77.47 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.311 0.577 . . . . 0.0 110.099 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.8 m -59.96 -39.73 86.6 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.707 -0.621 . . . . 0.0 110.947 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -68.65 -39.99 80.44 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.707 -178.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 52.7 tp -69.94 -40.62 75.37 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.475 -0.765 . . . . 0.0 112.047 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -96.65 -35.98 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.218 0 O-C-N 121.246 -0.909 . . . . 0.0 111.363 -177.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.77 -38.73 2.27 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.291 -1.924 . . . . 0.0 108.291 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 23.1 t -150.0 133.58 16.65 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.836 -0.802 . . . . 0.0 109.271 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.5 t -90.67 66.69 6.22 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.366 -0.834 . . . . 0.0 110.628 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -114.83 -27.18 7.51 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.624 -0.673 . . . . 0.0 110.637 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.08 -39.93 87.8 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -0.76 . . . . 0.0 110.567 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 103.15 -50.94 0.87 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -157.84 160.02 37.29 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.709 -0.877 . . . . 0.0 110.237 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.52 129.97 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 109.83 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -98.14 169.9 9.28 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.206 -179.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 61.6 t30 59.91 41.34 17.93 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.564 -0.71 . . . . 0.0 110.219 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 61.3 t -89.26 122.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.23 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 -80.52 136.13 36.23 Favored 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.12 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 39.6 p90 -134.87 140.98 46.22 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-O 121.278 0.561 . . . . 0.0 111.532 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.36 144.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.714 -0.616 . . . . 0.0 110.61 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -73.21 144.43 46.79 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.612 -0.68 . . . . 0.0 110.318 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.92 168.89 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.618 -0.676 . . . . 0.0 110.509 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -59.96 144.15 49.86 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.547 -0.721 . . . . 0.0 110.448 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -60.79 -40.03 91.07 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.567 -0.708 . . . . 0.0 110.998 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.9 m -54.61 -35.57 63.53 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.612 -0.68 . . . . 0.0 111.592 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -69.99 -22.13 63.16 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.169 -0.957 . . . . 0.0 111.457 -178.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 96.5 m -75.65 -48.64 21.23 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.2 -0.938 . . . . 0.0 109.35 178.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 94.8 mt -69.96 -40.03 78.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 CA-C-O 121.32 0.581 . . . . 0.0 109.773 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -67.18 -40.03 86.5 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.66 -0.65 . . . . 0.0 110.129 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.7 -49.96 39.64 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.68 -39.92 90.26 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.551 -0.97 . . . . 0.0 110.39 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.316 -179.774 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.431 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.5 m . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.438 0.637 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' SER . . . . . 0.41 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 54.5 m -113.14 145.19 41.37 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.034 0.921 . . . . 0.0 111.035 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.6 pt -115.19 146.36 19.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.25 -172.45 3.87 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.9 p90 -143.87 149.95 37.7 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.075 178.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.72 149.18 72.71 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.547 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -85.12 9.26 4.21 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.39 1.205 . . . . 0.0 111.276 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.439 HD11 ' CE2' ' A' ' 9' ' ' TYR . 1.3 pt -90.05 -0.21 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.113 -0.992 . . . . 0.0 111.068 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.439 ' CE2' HD11 ' A' ' 8' ' ' ILE . 21.7 m-85 -117.35 66.8 0.73 Allowed 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.543 1.164 . . . . 0.0 109.569 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.7 170.64 8.04 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 114.834 -1.076 . . . . 0.0 108.231 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.68 -31.42 64.43 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -89.02 12.93 14.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 120.513 -1.367 . . . . 0.0 112.033 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.418 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 0.4 OUTLIER -71.04 118.42 13.8 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.253 -0.904 . . . . 0.0 110.091 -179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.6 m -68.22 137.63 54.94 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 121.702 0.763 . . . . 0.0 110.43 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 5.3 mmt -62.26 -20.02 63.83 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -73.85 -13.68 80.53 Favored Glycine 0 N--CA 1.498 2.79 0 O-C-N 121.037 -1.04 . . . . 0.0 112.079 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.5 -7.77 46.44 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.944 -1.327 . . . . 0.0 112.183 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.03 169.97 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.93 -1.106 . . . . 0.0 110.19 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' TRP . . . -57.05 -43.5 82.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.279 -0.888 . . . . 0.0 109.711 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.18 83.41 6.06 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.4 m -94.12 -80.0 0.41 Allowed 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.254 -0.904 . . . . 0.0 112.557 -177.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -140.93 11.83 2.23 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.201 -0.937 . . . . 0.0 112.553 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.32 -146.12 0.31 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -69.29 -39.99 77.99 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.812 -0.817 . . . . 0.0 109.268 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 80.7 m-70 -91.48 0.92 57.45 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.689 -0.632 . . . . 0.0 110.696 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.85 132.35 44.37 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.9 mt -98.82 -5.46 31.05 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 122.125 -0.633 . . . . 0.0 110.149 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' N ' ' A' ' 16' ' ' GLY . 55.6 ttm -63.24 -37.77 88.54 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.277 -0.889 . . . . 0.0 111.262 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -74.05 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.522 -0.736 . . . . 0.0 111.667 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -70.04 -39.9 75.44 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 109.687 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.438 ' CD1' ' HB3' ' A' ' 36' ' ' GLU . 44.2 m-85 -120.15 85.39 35.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.53 -12.14 34.55 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 O-C-N 123.258 1.136 . . . . 0.0 111.228 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.9 m -129.18 146.98 50.99 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.228 -0.92 . . . . 0.0 110.349 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 45.1 tp -72.61 119.73 17.24 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.714 -0.616 . . . . 0.0 110.779 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.34 34.19 0.04 OUTLIER Glycine 0 N--CA 1.496 2.642 0 C-N-CA 120.067 -1.063 . . . . 0.0 110.485 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.438 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 21.7 tp10 -158.09 -49.18 0.06 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.298 -1.119 . . . . 0.0 110.485 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.425 HG22 ' CD2' ' A' ' 31' ' ' TYR . 2.7 t -60.63 -59.43 13.88 Favored Pre-proline 0 N--CA 1.499 2.001 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 51.2 Cg_endo -76.02 -29.78 6.36 Favored 'Trans proline' 0 N--CA 1.487 1.129 0 O-C-N 123.258 1.136 . . . . 0.0 109.335 177.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.85 -63.0 0.63 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 -178.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.454 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.9 t80 165.18 -72.22 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.571 0 C-N-CA 123.42 0.688 . . . . 0.0 110.017 177.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.454 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 57.4 Cg_endo -79.09 -18.99 10.99 Favored 'Trans proline' 0 N--CA 1.492 1.424 0 O-C-N 122.409 0.689 . . . . 0.0 111.579 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.0 m-20 -93.93 55.74 2.16 Favored 'General case' 0 N--CA 1.489 1.491 0 CA-C-O 121.8 0.809 . . . . 0.0 109.71 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.7 p -118.92 129.33 75.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-O 121.385 0.612 . . . . 0.0 109.655 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -161.68 167.59 36.51 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 119.991 -1.099 . . . . 0.0 111.279 -179.216 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.68 164.92 29.33 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.415 ' CG1' ' CD1' ' A' ' 49' ' ' ILE . 10.8 pt -143.55 165.87 22.78 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.824 -0.81 . . . . 0.0 109.762 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 82' ' ' GLY . 56.9 Cg_endo -77.12 -10.57 17.86 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 120.972 1.115 . . . . 0.0 113.125 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -95.41 16.65 16.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.071 -1.018 . . . . 0.0 111.916 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.434 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 63.7 mt -109.34 121.31 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.048 -1.032 . . . . 0.0 109.256 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.52 -42.34 43.56 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.426 -0.796 . . . . 0.0 113.13 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.97 -132.59 2.69 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.576 -1.773 . . . . 0.0 112.013 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.429 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 39.3 t90 -44.59 -30.68 0.95 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -178.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -143.62 63.2 1.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.358 -0.839 . . . . 0.0 110.134 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.426 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.8 p -66.24 136.32 95.21 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.804 -0.56 . . . . 0.0 111.118 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -73.54 -21.34 19.54 Favored 'Trans proline' 0 C--N 1.32 -0.974 0 O-C-N 123.338 1.178 . . . . 0.0 111.104 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.4 m -96.48 12.01 32.96 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.388 -0.82 . . . . 0.0 111.089 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.56 143.75 56.85 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.124 -0.985 . . . . 0.0 109.713 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.04 25.27 58.08 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 m -106.28 137.35 44.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.487 -1.007 . . . . 0.0 109.857 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.67 131.13 35.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.911 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.41 ' CD1' HD11 ' A' ' 46' ' ' ILE . 80.2 m95 -130.31 138.56 50.51 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.3 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -107.32 135.65 48.47 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.272 -0.893 . . . . 0.0 109.518 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.7 t -111.6 127.82 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.188 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 95.4 m -120.03 139.15 52.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.967 -0.458 . . . . 0.0 110.637 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.434 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 34.3 pt -117.74 163.73 22.88 Favored Pre-proline 0 N--CA 1.5 2.051 0 O-C-N 121.363 -0.836 . . . . 0.0 110.557 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.434 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -61.54 -23.04 75.94 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.371 1.381 . . . . 0.0 112.689 -178.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -66.52 -40.02 88.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.375 -0.828 . . . . 0.0 109.697 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.29 57.4 0.32 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -150.78 148.62 28.73 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.3 p -151.09 156.23 40.61 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-O 121.93 0.871 . . . . 0.0 111.372 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.6 pt -139.46 164.23 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -109.09 126.59 53.35 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.097 -1.041 . . . . 0.0 108.785 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.421 ' CD1' ' CG1' ' A' ' 85' ' ' VAL . 87.6 mt -129.38 140.0 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.688 -178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -98.04 139.5 33.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.547 -0.72 . . . . 0.0 109.872 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.71 150.28 39.06 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.9 p -149.45 -39.56 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.751 -0.852 . . . . 0.0 109.901 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -129.32 168.02 16.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.224 -0.922 . . . . 0.0 110.5 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.434 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 40.6 t -75.28 155.89 36.21 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.618 0.723 . . . . 0.0 111.739 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -137.66 132.26 5.84 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -60.02 -33.05 71.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 109.871 178.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.31 82.37 0.05 OUTLIER Glycine 0 N--CA 1.498 2.788 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.599 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 151.97 -151.66 23.52 Favored Glycine 0 N--CA 1.499 2.866 0 C-N-CA 119.893 -1.146 . . . . 0.0 110.516 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -136.02 130.77 34.06 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.295 -1.121 . . . . 0.0 111.381 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.458 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 4.4 t-20 -115.61 127.52 55.28 Favored 'General case' 0 N--CA 1.502 2.152 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 178.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.2 m -129.95 164.62 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.363 -177.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-20 -54.54 157.1 5.41 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.328 -0.857 . . . . 0.0 109.897 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.37 -14.35 43.79 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.268 1.141 . . . . 0.0 110.657 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.7 m -82.71 -39.14 22.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.975 -1.078 . . . . 0.0 109.314 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.77 -39.82 84.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.448 -0.783 . . . . 0.0 109.037 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -59.99 -50.02 75.4 Favored 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 120.081 -0.648 . . . . 0.0 110.762 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 73.2 m -60.14 -39.97 88.21 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.368 -0.832 . . . . 0.0 111.071 -178.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -69.68 -40.0 76.66 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.871 -0.732 . . . . 0.0 111.062 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 60.2 tp -70.62 -43.7 68.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.602 -0.686 . . . . 0.0 111.557 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.0 -42.61 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.402 -0.811 . . . . 0.0 111.579 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -20.22 7.93 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.3 t -156.21 159.52 39.02 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.213 -1.169 . . . . 0.0 110.944 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 65.7 p -98.42 6.89 46.86 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.543 -0.723 . . . . 0.0 110.812 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -69.17 -36.76 77.7 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.362 -0.836 . . . . 0.0 111.708 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.52 -40.12 86.09 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.379 -0.826 . . . . 0.0 110.696 -178.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 82.89 -75.03 2.44 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -127.78 133.17 49.46 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.631 -0.923 . . . . 0.0 109.857 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.14 120.14 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.467 -0.771 . . . . 0.0 110.116 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 28.1 p-10 -86.16 178.43 7.2 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.359 0.599 . . . . 0.0 110.707 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.0 t-20 58.88 49.62 9.56 Favored 'General case' 0 N--CA 1.499 2.013 0 CA-C-O 121.28 0.562 . . . . 0.0 111.235 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.431 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 62.5 t -105.77 129.03 59.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.577 -179.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -86.61 137.07 32.78 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 118.936 -1.105 . . . . 0.0 109.477 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -135.45 141.52 45.41 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.93 -0.481 . . . . 0.0 110.536 -178.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 m -148.09 148.17 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.527 -0.733 . . . . 0.0 111.037 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -76.18 143.52 41.05 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.595 -0.691 . . . . 0.0 110.236 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -137.79 167.83 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.578 -0.701 . . . . 0.0 110.561 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -61.52 148.26 42.66 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.403 -0.81 . . . . 0.0 110.749 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.11 -40.07 94.63 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.517 -0.739 . . . . 0.0 112.075 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 82.1 p -53.12 -37.34 61.68 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.263 -0.898 . . . . 0.0 111.023 -178.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -61.12 -37.93 84.54 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.518 -0.739 . . . . 0.0 112.005 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 82.5 m -67.37 -46.29 73.77 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.119 -0.988 . . . . 0.0 110.415 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.2 mt -70.04 -39.94 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 120.109 -0.636 . . . . 0.0 110.518 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.69 -39.98 88.34 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.13 -46.19 44.92 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.03 -44.15 94.83 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.625 -0.926 . . . . 0.0 110.473 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 13.5 m120 . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.186 179.823 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.291 0.567 . . . . 0.0 111.401 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 80.2 p -111.78 139.85 46.91 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.738 -0.601 . . . . 0.0 109.764 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.9 pt -110.86 144.77 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.734 -0.604 . . . . 0.0 110.854 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.35 -176.02 4.57 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.118 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -140.09 141.62 36.15 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.453 179.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -135.71 151.66 74.67 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.441 -0.787 . . . . 0.0 110.433 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -77.12 0.07 10.09 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.421 1.221 . . . . 0.0 111.506 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.417 HG21 ' CD2' ' A' ' 9' ' ' TYR . 7.4 tp -69.54 -14.03 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.276 -0.89 . . . . 0.0 111.274 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.417 ' CD2' HG21 ' A' ' 8' ' ' ILE . 36.7 m-85 -116.72 69.01 0.74 Allowed 'General case' 0 N--CA 1.493 1.683 0 CA-C-O 122.507 1.146 . . . . 0.0 111.335 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.35 168.67 8.92 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.02 70.47 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -88.13 12.08 14.57 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.44 -1.412 . . . . 0.0 112.199 -177.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.6 tp -73.75 122.36 22.26 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.419 -0.801 . . . . 0.0 109.714 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.6 m -66.29 137.39 56.91 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.8 mmm -64.32 -18.99 65.14 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.902 -0.499 . . . . 0.0 111.247 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.423 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -72.2 -14.38 76.64 Favored Glycine 0 N--CA 1.493 2.499 0 O-C-N 121.073 -1.017 . . . . 0.0 110.752 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.7 p -91.63 -15.65 28.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -1.194 . . . . 0.0 111.146 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.05 162.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.931 . . . . 0.0 109.63 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -54.93 -44.35 74.2 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.556 -0.715 . . . . 0.0 110.332 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 83.89 5.83 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.52 -79.98 0.48 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.295 -0.878 . . . . 0.0 113.152 -177.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -136.72 10.11 3.12 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.108 -0.995 . . . . 0.0 113.098 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.43 -152.77 0.89 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -64.25 -39.95 95.01 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.571 -0.958 . . . . 0.0 108.586 177.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 72.8 m-70 -90.15 0.46 57.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.748 -0.595 . . . . 0.0 110.207 179.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.05 133.96 52.48 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 66.0 mt -102.47 1.13 34.78 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 122.06 -0.67 . . . . 0.0 110.226 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.423 ' CE ' ' N ' ' A' ' 16' ' ' GLY . 60.3 tpp -59.99 -38.48 82.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.315 -0.866 . . . . 0.0 111.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -66.41 0.46 Allowed 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.469 -0.769 . . . . 0.0 112.203 -176.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -75.13 -41.4 58.48 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.05 87.46 39.06 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.845 -0.534 . . . . 0.0 109.665 -178.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.3 -8.08 22.66 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.4 1.211 . . . . 0.0 111.543 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -133.51 146.47 51.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.26 -0.9 . . . . 0.0 110.5 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 29.1 tp -71.04 119.17 14.79 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.695 -0.628 . . . . 0.0 110.664 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.19 32.89 0.04 OUTLIER Glycine 0 N--CA 1.498 2.774 0 C-N-CA 120.007 -1.092 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -157.39 -48.63 0.07 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -1.122 . . . . 0.0 110.159 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.407 ' CB ' ' CD ' ' A' ' 38' ' ' PRO . 2.5 t -60.39 -58.61 18.06 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.407 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 54.2 Cg_endo -77.63 -30.8 3.67 Favored 'Trans proline' 0 C--N 1.318 -1.04 0 O-C-N 123.217 1.114 . . . . 0.0 109.537 177.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.97 -63.86 0.62 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 107.272 -2.331 . . . . 0.0 107.272 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.625 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.1 t80 164.53 -56.72 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.581 0 C-N-CA 123.37 0.668 . . . . 0.0 110.231 177.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.625 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 51.2 Cg_endo -101.03 15.55 0.37 Allowed 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 121.313 1.342 . . . . 0.0 111.246 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -125.32 47.52 2.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.296 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.407 ' CG2' HG13 ' A' ' 76' ' ' VAL . 14.6 p -125.47 140.04 49.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.914 0.864 . . . . 0.0 110.435 -179.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.87 175.35 42.76 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.62 159.47 29.43 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.445 ' CD1' HG12 ' A' ' 49' ' ' ILE . 1.1 pt -148.78 159.67 37.43 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.584 -0.95 . . . . 0.0 109.94 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -68.18 -15.9 43.49 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 121.245 1.297 . . . . 0.0 113.829 -177.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -91.7 21.26 4.87 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 120.706 -1.246 . . . . 0.0 113.129 -177.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.461 HD11 HG23 ' A' ' 49' ' ' ILE . 47.8 mm -112.28 122.59 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 177.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.63 -44.38 34.39 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.302 -0.874 . . . . 0.0 111.199 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 164.83 -134.93 3.5 Favored Glycine 0 N--CA 1.484 1.886 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.425 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 64.4 t90 -43.83 -26.78 0.28 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -145.4 72.81 1.33 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.921 . . . . 0.0 110.578 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.414 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 3.4 t -70.35 134.3 86.97 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.773 -0.58 . . . . 0.0 111.528 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.8 -23.98 16.01 Favored 'Trans proline' 0 C--N 1.32 -0.941 0 O-C-N 123.413 1.218 . . . . 0.0 110.545 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.42 12.44 33.23 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.445 -0.784 . . . . 0.0 111.058 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.7 t -72.21 148.8 45.2 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.335 -0.853 . . . . 0.0 110.584 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.86 43.15 9.14 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 8.5 m -130.62 168.74 16.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.707 -0.878 . . . . 0.0 108.684 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 16.8 t -113.38 148.6 35.49 Favored 'General case' 0 N--CA 1.511 2.596 0 O-C-N 121.118 -0.989 . . . . 0.0 113.143 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.481 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 31.5 m95 -139.82 145.35 38.03 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.027 -1.046 . . . . 0.0 110.36 177.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -105.53 129.84 53.72 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 177.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.1 t -110.63 129.95 64.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.316 -0.865 . . . . 0.0 109.95 -178.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 47.1 m -121.63 138.79 54.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.849 -0.532 . . . . 0.0 111.61 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.479 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.6 pt -114.35 166.09 12.32 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.534 -0.729 . . . . 0.0 109.809 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.479 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.44 -25.9 76.26 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 O-C-N 123.217 1.114 . . . . 0.0 112.928 -178.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -64.81 -37.83 88.95 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.052 -1.03 . . . . 0.0 109.751 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.93 65.32 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -162.02 153.15 18.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.769 -0.842 . . . . 0.0 108.867 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 71.5 p -152.8 162.38 41.35 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 122.197 0.999 . . . . 0.0 112.456 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.9 pt -139.39 162.3 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.128 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -107.48 127.15 53.35 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.246 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 90.2 mt -125.9 134.93 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 110.493 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 65.9 ttt180 -95.49 133.92 38.93 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -63.59 144.17 48.8 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 120.296 -0.954 . . . . 0.0 110.76 -178.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.407 HG13 ' CG2' ' A' ' 43' ' ' VAL . 10.1 p -142.67 -41.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 122.104 -0.645 . . . . 0.0 109.906 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.403 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 6.3 t0 -133.67 171.57 13.95 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.114 -0.991 . . . . 0.0 109.496 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.402 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 43.9 t -83.75 146.66 28.05 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.443 -0.785 . . . . 0.0 110.635 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -108.12 148.71 16.73 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -89.07 101.67 14.32 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.487 -1.008 . . . . 0.0 110.601 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 52.79 53.46 32.99 Favored Glycine 0 N--CA 1.498 2.791 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.24 170.08 14.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.929 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.427 ' CD2' HG22 ' A' ' 46' ' ' ILE . 36.3 m-85 -93.13 128.94 39.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.749 -0.853 . . . . 0.0 109.996 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.7 t-20 -120.24 130.84 54.7 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 174.35 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.694 -178.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -55.51 156.8 7.99 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.658 -0.651 . . . . 0.0 109.966 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.7 -27.43 38.26 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.387 1.204 . . . . 0.0 109.706 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -71.28 -40.19 71.07 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.24 -39.56 86.21 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.3 t80 -59.99 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.737 -0.602 . . . . 0.0 110.514 179.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 58.0 m -59.82 -36.92 77.78 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.534 -0.729 . . . . 0.0 110.631 -178.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -69.72 -40.02 76.5 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.805 -0.758 . . . . 0.0 111.258 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 52.6 tp -69.95 -41.81 74.06 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.472 -0.768 . . . . 0.0 111.688 -178.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 94.9 t -100.2 -36.12 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.117 0 O-C-N 121.164 -0.96 . . . . 0.0 111.413 -178.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 117.84 -30.62 6.05 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.0 m -143.03 155.12 44.57 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.48 -1.012 . . . . 0.0 110.897 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.0 p -90.23 1.53 56.39 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.521 -0.737 . . . . 0.0 110.989 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.95 -22.18 63.2 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.381 -0.824 . . . . 0.0 110.702 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.29 -45.27 88.25 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.382 -0.824 . . . . 0.0 110.717 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.68 -77.45 2.11 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -135.44 132.1 37.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.641 -0.917 . . . . 0.0 110.682 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 57.5 t -116.19 115.97 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.523 -0.736 . . . . 0.0 109.739 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 2.8 t0 -84.37 172.53 11.69 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.766 0.794 . . . . 0.0 111.375 -178.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.6 t30 60.07 40.02 19.03 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.807 -0.558 . . . . 0.0 111.591 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 62.8 t -81.65 127.43 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.126 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -91.88 139.98 30.13 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.064 -1.054 . . . . 0.0 108.989 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -140.81 147.22 38.69 Favored 'General case' 0 N--CA 1.493 1.684 0 CA-C-O 121.502 0.668 . . . . 0.0 112.129 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.9 142.57 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.747 -0.595 . . . . 0.0 109.813 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.481 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 62.3 tt0 -84.93 140.44 31.1 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.459 -0.775 . . . . 0.0 110.843 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 27.1 m -129.93 175.32 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -62.62 150.75 39.9 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.391 -0.818 . . . . 0.0 111.004 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.06 -39.94 87.76 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.74 -0.6 . . . . 0.0 110.795 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 61.9 m -52.55 -35.66 54.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.59 -0.694 . . . . 0.0 111.186 -178.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.1 -40.01 93.95 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.426 -0.796 . . . . 0.0 110.967 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.06 -49.34 77.77 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.293 -0.879 . . . . 0.0 110.14 179.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.7 mt -70.03 -39.94 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.611 -0.681 . . . . 0.0 110.834 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -66.19 -40.07 90.14 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.453 -0.78 . . . . 0.0 110.829 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.99 -57.48 3.02 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 -178.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.83 -43.2 94.68 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.518 -0.989 . . . . 0.0 110.469 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.0 t30 . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 117.796 -1.097 . . . . 0.0 110.916 179.83 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 121.187 0.517 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 p -112.67 147.01 37.66 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.707 -0.62 . . . . 0.0 111.019 -179.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 24.7 pt -113.8 147.9 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.796 -0.565 . . . . 0.0 110.161 179.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.84 -172.34 3.89 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -142.22 149.34 39.52 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.519 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -139.09 152.99 71.08 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.377 -0.827 . . . . 0.0 110.078 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -83.55 2.36 8.38 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 O-C-N 123.407 1.214 . . . . 0.0 111.39 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.425 ' O ' ' HG ' ' A' ' 13' ' ' LEU . 26.2 mm -76.5 -2.79 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.16 -0.962 . . . . 0.0 111.165 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -127.34 64.64 1.33 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 122.347 1.07 . . . . 0.0 110.765 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.15 173.97 6.21 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.17 70.66 Favored 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -175.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -89.41 12.28 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 120.446 1.475 . . . . 0.0 112.084 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 8' ' ' ILE . 0.1 OUTLIER -69.71 114.55 8.02 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.303 -0.873 . . . . 0.0 109.301 179.426 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m -62.76 139.4 58.68 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.801 0.81 . . . . 0.0 110.631 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.1 mmm -62.56 -26.38 68.55 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.985 -179.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -19.44 76.44 Favored Glycine 0 N--CA 1.494 2.507 0 O-C-N 121.126 -0.984 . . . . 0.0 110.896 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 75.4 m -86.46 -17.77 33.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.228 -1.16 . . . . 0.0 111.375 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.98 160.02 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.328 -0.858 . . . . 0.0 109.676 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.17 -41.82 65.57 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.58 -0.7 . . . . 0.0 111.164 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 82.92 4.83 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.294 -0.879 . . . . 0.0 108.835 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 m -91.42 -79.34 0.37 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.26 -0.9 . . . . 0.0 113.014 -177.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 t30 -144.09 14.82 1.69 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.772 -1.205 . . . . 0.0 112.474 -178.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.49 -147.19 0.37 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 108.671 -1.772 . . . . 0.0 108.671 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -69.58 -39.97 76.99 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.622 -0.928 . . . . 0.0 108.85 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.431 ' CD2' ' O ' ' A' ' 54' ' ' SER . 56.0 m-70 -89.93 0.04 57.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.698 -0.626 . . . . 0.0 110.208 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.74 133.05 52.3 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 65.0 mt -103.73 -0.07 29.86 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 122.139 -0.624 . . . . 0.0 110.47 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -64.0 -35.46 80.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.274 -0.891 . . . . 0.0 111.068 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.69 -66.16 0.47 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.41 -0.806 . . . . 0.0 111.883 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.418 ' HG3' ' CD2' ' A' ' 31' ' ' TYR . 28.1 pt20 -72.71 -40.5 66.13 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.126 -0.984 . . . . 0.0 110.775 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.418 ' CD2' ' HG3' ' A' ' 30' ' ' GLN . 53.9 m-85 -126.73 91.04 48.22 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.429 -0.794 . . . . 0.0 109.428 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.54 -9.89 27.41 Favored 'Trans proline' 0 N--CA 1.488 1.161 0 O-C-N 123.554 1.292 . . . . 0.0 112.04 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.9 m -129.03 143.95 51.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.098 -1.001 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 21.2 tp -69.93 120.02 15.02 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.878 -0.514 . . . . 0.0 110.546 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 147.36 30.32 0.07 OUTLIER Glycine 0 N--CA 1.496 2.697 0 C-N-CA 119.927 -1.13 . . . . 0.0 110.822 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -154.13 -50.9 0.09 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.26 -1.141 . . . . 0.0 110.286 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.429 HG12 ' CD ' ' A' ' 74' ' ' ARG . 2.7 t -61.66 -59.47 13.29 Favored Pre-proline 0 N--CA 1.497 1.904 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 46.0 Cg_endo -74.08 -32.08 7.25 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 O-C-N 123.258 1.136 . . . . 0.0 109.24 177.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.429 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 131.21 -65.05 0.6 Allowed Glycine 0 N--CA 1.484 1.856 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.476 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.7 t80 163.94 -69.66 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.793 0 C-N-CA 123.522 0.729 . . . . 0.0 110.393 177.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.476 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.9 Cg_endo -80.61 -0.22 10.47 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 120.387 0.725 . . . . 0.0 112.714 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -111.24 53.66 0.7 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.872 -1.143 . . . . 0.0 110.425 -178.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 p -132.44 141.09 46.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 121.859 0.838 . . . . 0.0 110.054 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.69 175.39 43.24 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . 0.401 ' O ' ' CG2' ' A' ' 46' ' ' ILE . . . -87.51 157.67 29.13 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 179.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.409 HG13 HG12 ' A' ' 49' ' ' ILE . 1.7 pt -156.01 160.06 31.07 Favored Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.592 -0.946 . . . . 0.0 109.771 179.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -67.02 -23.49 46.45 Favored 'Trans proline' 0 N--CA 1.502 1.983 0 C-N-CA 121.643 1.562 . . . . 0.0 115.291 -176.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -77.03 -5.02 47.13 Favored 'General case' 0 N--CA 1.506 2.374 0 O-C-N 120.381 -1.45 . . . . 0.0 112.497 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.481 HG21 HD13 ' A' ' 49' ' ' ILE . 43.1 mm -89.71 121.34 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.992 -1.067 . . . . 0.0 108.45 178.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.65 -43.55 47.07 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.243 -0.91 . . . . 0.0 111.537 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.98 -131.73 2.43 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.004 -1.569 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 61.9 t90 -48.71 -26.02 2.11 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.886 -0.773 . . . . 0.0 112.749 -178.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.8 64.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.184 -0.948 . . . . 0.0 110.713 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.431 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 7.9 p -63.5 133.64 95.57 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.648 -0.658 . . . . 0.0 110.986 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.64 -19.47 27.9 Favored 'Trans proline' 0 N--CA 1.485 1.011 0 O-C-N 123.212 1.112 . . . . 0.0 110.911 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 54.0 p -99.04 10.8 40.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.378 -0.827 . . . . 0.0 111.025 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.13 143.1 58.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.135 -0.978 . . . . 0.0 110.056 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.41 26.01 48.92 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.1 p -100.01 134.99 42.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.453 -1.027 . . . . 0.0 110.615 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 42.0 t -81.49 131.11 35.27 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.795 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.468 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 85.6 m95 -133.6 143.58 48.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.387 -0.82 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 tttm -110.67 130.98 55.43 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -111.02 129.73 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.349 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 69.0 m -120.04 135.55 54.89 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.868 -0.52 . . . . 0.0 110.604 -178.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.447 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 8.7 pt -113.8 164.83 14.92 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.425 -0.797 . . . . 0.0 110.849 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -62.96 -27.93 74.79 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.241 1.294 . . . . 0.0 112.937 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -64.58 -40.0 94.76 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.239 -0.913 . . . . 0.0 109.701 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.18 60.01 0.28 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 179.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -153.7 148.7 26.71 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.699 -0.883 . . . . 0.0 108.745 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 47.1 m -149.37 155.49 40.56 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 119.3 -0.96 . . . . 0.0 112.233 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.3 pt -140.76 166.9 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.71 125.45 53.51 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.404 179.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 96.9 mt -124.1 138.63 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.466 -0.771 . . . . 0.0 110.518 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . 0.429 ' CD ' HG12 ' A' ' 37' ' ' VAL . 1.9 ttp-105 -100.85 146.47 27.27 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.586 -0.696 . . . . 0.0 109.745 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.407 ' HA2' ' CD1' ' A' ' 46' ' ' ILE . . . -68.11 151.33 51.81 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.406 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 9.6 p -154.81 -44.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.826 -0.808 . . . . 0.0 109.522 179.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.406 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 5.2 t0 -129.62 169.82 14.56 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.059 -1.025 . . . . 0.0 109.622 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.411 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 92.6 p -101.57 160.07 14.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.577 -0.702 . . . . 0.0 111.055 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.96 155.06 21.62 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 75.4 mtp85 -59.97 -31.41 69.87 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.484 -1.01 . . . . 0.0 109.679 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -176.69 -179.8 47.3 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 50.83 -178.88 0.04 OUTLIER Glycine 0 N--CA 1.496 2.675 0 O-C-N 121.434 -1.039 . . . . 0.0 111.87 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 42.7 m-85 -107.74 127.46 53.71 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.891 -0.77 . . . . 0.0 109.008 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -117.83 127.73 54.16 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.511 -0.875 . . . . 0.0 108.64 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.438 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.4 m -130.79 172.37 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.697 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -55.58 152.79 16.96 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.534 -0.729 . . . . 0.0 109.528 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.21 -26.33 57.0 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.35 1.184 . . . . 0.0 110.186 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.08 -40.24 75.13 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.076 -1.015 . . . . 0.0 109.346 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.03 -40.57 87.24 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -60.71 -50.08 74.9 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.719 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.1 m -61.14 -39.96 92.01 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.403 -0.811 . . . . 0.0 111.273 -178.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.3 mtmt -69.99 -40.05 75.55 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.999 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 tp -69.91 -42.93 72.69 Favored 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.365 -179.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.22 -41.6 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 O-C-N 121.45 -0.781 . . . . 0.0 111.83 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.72 -34.5 4.05 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.3 m -142.44 153.67 43.91 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.524 -0.986 . . . . 0.0 110.14 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.6 p -90.28 3.49 53.46 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.477 -0.765 . . . . 0.0 110.976 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.98 -26.22 63.99 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.423 -0.798 . . . . 0.0 111.158 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.94 -39.92 87.19 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.413 -0.804 . . . . 0.0 110.513 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.75 -79.49 1.84 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -131.8 138.87 48.71 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.694 -0.886 . . . . 0.0 110.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.0 t -120.32 116.97 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.804 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -80.55 170.14 16.74 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.656 0.741 . . . . 0.0 111.346 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 60.0 39.93 19.37 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.007 0.432 . . . . 0.0 111.816 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 78.5 t -85.48 127.52 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.134 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -87.36 140.05 29.93 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.14 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -139.22 144.5 38.5 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.579 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -144.69 141.68 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.498 -0.751 . . . . 0.0 111.231 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.468 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.2 tt0 -73.45 135.01 44.09 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.561 -0.712 . . . . 0.0 109.755 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.27 173.09 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.437 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -60.34 149.71 32.88 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.357 -0.839 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -59.93 -39.08 84.29 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.505 -0.747 . . . . 0.0 110.58 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.9 m -53.5 -38.01 63.28 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.557 -0.714 . . . . 0.0 110.57 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -60.22 -39.93 88.35 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.496 -0.753 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.07 -49.83 76.11 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.257 -0.902 . . . . 0.0 110.246 179.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 90.4 mt -69.25 -39.99 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.704 -0.622 . . . . 0.0 110.253 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.63 -39.93 95.37 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.401 -0.812 . . . . 0.0 110.281 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.81 -41.82 81.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.35 -39.97 94.86 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.75 -0.853 . . . . 0.0 110.305 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.9 p30 . . . . . 0 N--CA 1.495 1.815 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.551 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.51 0.671 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.9 p -114.61 153.99 29.15 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.874 -0.516 . . . . 0.0 110.545 -179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.41 HG23 HD13 ' A' ' 3' ' ' ILE . 39.5 pt -119.99 150.05 22.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.476 -0.765 . . . . 0.0 110.534 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 p -147.84 -171.76 3.89 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -141.5 142.47 33.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.465 178.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -133.78 150.01 73.47 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.476 -0.765 . . . . 0.0 110.208 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -78.87 -0.93 11.18 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 O-C-N 123.377 1.199 . . . . 0.0 111.114 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.437 HG22 ' CE2' ' A' ' 9' ' ' TYR . 6.4 tp -71.67 -15.22 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.244 -0.91 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.437 ' CE2' HG22 ' A' ' 8' ' ' ILE . 34.3 m-85 -114.88 68.53 0.7 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 122.613 1.197 . . . . 0.0 110.553 178.466 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.24 170.06 8.09 Favored 'General case' 0 N--CA 1.492 1.67 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.599 177.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.91 -34.42 73.19 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 -175.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -88.22 13.53 11.27 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.417 -1.427 . . . . 0.0 112.422 -176.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 43.9 tp -75.56 122.82 24.47 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.355 -0.841 . . . . 0.0 110.091 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.8 m -65.73 137.62 57.4 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.801 -0.76 . . . . 0.0 109.627 179.533 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 96.4 mmm -64.22 -19.08 65.11 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.823 -0.548 . . . . 0.0 111.313 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.5 -16.55 78.93 Favored Glycine 0 N--CA 1.495 2.59 0 O-C-N 120.95 -1.094 . . . . 0.0 110.986 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.1 m -88.18 -13.78 40.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.165 -1.197 . . . . 0.0 111.599 -179.148 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.04 159.54 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.149 -0.97 . . . . 0.0 108.869 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -49.07 -41.36 35.04 Favored 'General case' 0 N--CA 1.507 2.418 0 O-C-N 121.266 -0.896 . . . . 0.0 110.562 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -78.23 87.14 4.31 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.8 m -99.4 -82.31 0.44 Allowed 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.117 -0.989 . . . . 0.0 112.954 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -137.91 9.58 2.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.087 -1.008 . . . . 0.0 112.922 -178.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.08 -148.0 0.5 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.801 -1.72 . . . . 0.0 108.801 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -63.03 -40.01 96.47 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.625 -0.927 . . . . 0.0 109.526 178.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 89.6 m-70 -94.6 8.56 41.89 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.567 -0.708 . . . . 0.0 111.151 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.15 127.42 35.89 Favored Glycine 0 N--CA 1.502 3.064 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.491 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 91.2 mt -102.47 -11.46 18.55 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 122.03 -0.688 . . . . 0.0 111.532 -178.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 ttp -60.03 -27.32 66.81 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.261 -0.899 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.52 -61.75 2.27 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.425 -0.797 . . . . 0.0 112.898 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -69.96 -40.01 75.69 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 120.88 -1.137 . . . . 0.0 111.36 -178.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.519 ' CE1' ' CG2' ' A' ' 37' ' ' VAL . 3.8 p90 -136.21 104.76 9.49 Favored Pre-proline 0 C--N 1.302 -1.491 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.42 -11.15 29.01 Favored 'Trans proline' 0 N--CA 1.485 0.98 0 O-C-N 123.482 1.254 . . . . 0.0 111.647 -178.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -126.85 135.76 51.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.245 -0.91 . . . . 0.0 109.761 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 39.4 tp -61.46 126.05 25.95 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.522 -0.736 . . . . 0.0 109.858 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 148.79 27.77 0.06 OUTLIER Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.538 -1.315 . . . . 0.0 111.787 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -144.99 -47.91 0.24 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.074 -1.25 . . . . 0.0 110.917 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.519 ' CG2' ' CE1' ' A' ' 31' ' ' TYR . 1.7 t -67.42 -55.45 15.02 Favored Pre-proline 0 N--CA 1.496 1.844 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.389 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.406 ' HD2' ' N ' ' A' ' 37' ' ' VAL . 42.5 Cg_endo -76.19 -31.44 4.77 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.396 1.208 . . . . 0.0 108.988 178.079 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.424 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 129.77 -64.6 0.6 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.6 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.1 t80 164.38 -56.74 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.595 0 C-N-CA 123.33 0.652 . . . . 0.0 110.844 177.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.6 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.7 Cg_endo -97.42 16.84 0.61 Allowed 'Trans proline' 0 N--CA 1.481 0.773 0 C-N-CA 120.982 1.121 . . . . 0.0 112.044 -177.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -126.12 47.49 2.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.2 -0.937 . . . . 0.0 109.758 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.2 p -128.09 142.43 43.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.596 0.712 . . . . 0.0 109.78 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -166.56 170.43 41.09 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 -179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.79 158.58 35.36 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 178.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.447 HG13 HG12 ' A' ' 49' ' ' ILE . 1.5 pt -147.81 156.2 44.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.439 -1.036 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.66 -12.22 34.79 Favored 'Trans proline' 0 N--CA 1.504 2.119 0 C-N-CA 121.934 1.756 . . . . 0.0 114.668 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -96.72 21.31 9.61 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 120.491 -1.381 . . . . 0.0 112.796 -177.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.447 HG12 HG13 ' A' ' 46' ' ' ILE . 48.9 mm -110.7 129.98 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.37 -0.831 . . . . 0.0 108.807 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.15 -48.26 11.54 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.786 . . . . 0.0 112.256 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.53 -129.04 1.8 Allowed Glycine 0 N--CA 1.488 2.119 0 C-N-CA 118.806 -1.664 . . . . 0.0 111.384 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -50.2 -24.99 3.18 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.89 -0.771 . . . . 0.0 112.881 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.93 71.3 1.22 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.402 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.414 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.2 t -70.04 130.37 89.87 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.865 -0.522 . . . . 0.0 111.075 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.36 -21.47 30.65 Favored 'Trans proline' 0 N--CA 1.486 1.053 0 O-C-N 123.246 1.13 . . . . 0.0 110.566 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -98.52 13.48 31.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.445 -0.785 . . . . 0.0 110.983 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -70.98 147.18 48.91 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.182 -0.949 . . . . 0.0 110.271 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.1 35.37 44.02 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 95.6 m -119.59 135.17 54.91 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.503 -0.998 . . . . 0.0 110.484 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -78.96 145.64 33.88 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.053 -178.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.451 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 96.0 m95 -148.38 143.98 27.19 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.801 -0.562 . . . . 0.0 109.537 178.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -107.36 134.89 49.76 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.305 -0.872 . . . . 0.0 109.134 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 123.34 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.496 -0.752 . . . . 0.0 110.216 -179.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.2 m -118.42 139.71 50.98 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.893 -0.505 . . . . 0.0 110.378 -179.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.451 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 21.0 pt -119.58 164.29 22.62 Favored Pre-proline 0 N--CA 1.5 2.044 0 O-C-N 121.471 -0.768 . . . . 0.0 110.881 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.451 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 36.6 Cg_endo -60.58 -24.11 77.42 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 121.445 1.43 . . . . 0.0 112.794 -178.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -65.55 -36.61 84.28 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.217 -0.927 . . . . 0.0 109.712 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.11 63.41 0.47 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -163.82 153.99 15.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.755 -0.85 . . . . 0.0 108.988 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 95.6 p -155.43 158.38 38.51 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.583 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.6 pt -140.02 166.72 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -104.96 125.78 51.32 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.612 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.472 HD11 HG21 ' A' ' 73' ' ' ILE . 48.4 mm -117.98 130.06 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.75 -0.594 . . . . 0.0 109.621 -179.582 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . 0.439 ' CD ' HG11 ' A' ' 37' ' ' VAL . 1.3 ttp-105 -99.23 139.52 34.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.524 -0.735 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.59 148.04 42.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 3.8 p -155.66 -41.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.807 -0.819 . . . . 0.0 109.798 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -134.58 175.18 9.77 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.145 -0.972 . . . . 0.0 109.767 179.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.409 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 28.8 t -103.81 154.81 19.17 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.471 -0.768 . . . . 0.0 111.521 -179.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.77 147.75 16.66 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.9 mtt180 -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.648 -0.913 . . . . 0.0 110.742 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -177.39 73.65 0.07 OUTLIER Glycine 0 N--CA 1.495 2.585 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.638 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.65 147.33 4.54 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.467 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.445 ' CD2' HG23 ' A' ' 46' ' ' ILE . 32.5 m-85 -73.02 135.16 44.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 122.031 -0.688 . . . . 0.0 110.506 179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.3 131.01 46.87 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 178.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.72 173.73 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.636 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -55.17 152.16 15.77 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 109.927 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.27 -27.55 55.89 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.422 1.222 . . . . 0.0 110.11 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.02 -40.02 75.46 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.952 -1.092 . . . . 0.0 109.048 178.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.92 -40.16 87.59 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.432 -0.793 . . . . 0.0 108.977 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.47 -49.95 75.51 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.799 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 38.9 m -60.02 -39.56 86.25 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.657 -0.652 . . . . 0.0 111.28 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.9 mttm -68.89 -40.02 79.41 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.499 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 41.4 tp -70.78 -42.74 69.95 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.8 -0.76 . . . . 0.0 111.627 -178.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.1 t -97.74 -40.39 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.201 -0.937 . . . . 0.0 111.733 -177.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 118.17 -37.7 3.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.9 m -134.69 149.62 50.52 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.608 -0.937 . . . . 0.0 110.199 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 70.8 p -94.02 3.98 54.56 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.421 -0.799 . . . . 0.0 111.053 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -69.93 -27.64 64.93 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.43 -0.794 . . . . 0.0 111.164 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.97 87.75 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.495 -0.753 . . . . 0.0 110.67 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.28 -60.45 3.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.2 ptt180 -153.61 156.91 38.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.616 -0.932 . . . . 0.0 110.546 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -125.44 117.24 49.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.45 -0.781 . . . . 0.0 109.672 179.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -81.09 169.99 16.74 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.49 -0.756 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 56.4 t30 61.64 47.92 6.05 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.573 -0.704 . . . . 0.0 111.646 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 81.1 t -96.17 124.75 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.031 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -84.92 145.76 27.61 Favored 'General case' 0 N--CA 1.493 1.675 0 C-N-CA 119.779 -0.768 . . . . 0.0 109.281 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.02 147.2 40.04 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.833 -0.542 . . . . 0.0 111.598 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.8 m -147.27 148.66 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.653 -0.654 . . . . 0.0 110.829 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.451 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 16.9 tt0 -82.98 140.93 32.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.656 -0.652 . . . . 0.0 110.314 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.4 m -132.54 168.8 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 120.211 -0.595 . . . . 0.0 109.742 179.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -59.97 149.05 33.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.296 -0.878 . . . . 0.0 109.925 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -40.0 88.03 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.408 -0.807 . . . . 0.0 110.94 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 54.0 p -55.45 -35.54 65.57 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.556 -0.715 . . . . 0.0 110.665 -178.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -60.0 -38.39 82.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.435 -0.79 . . . . 0.0 110.075 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 85.8 m -69.63 -39.93 76.86 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.8 mm -64.09 -43.94 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 120.274 -0.571 . . . . 0.0 109.845 -178.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -70.0 -40.02 75.53 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.76 -0.588 . . . . 0.0 110.547 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.44 -51.63 46.86 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.57 -40.04 94.83 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.588 -0.948 . . . . 0.0 110.249 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.087 -179.87 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.428 HG21 ' CD1' ' A' ' 107' ' ' TYR . 29.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.351 0.596 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.9 m -111.36 137.26 49.36 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 37.8 pt -109.75 146.69 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.6 -0.688 . . . . 0.0 110.354 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.9 m -143.29 -174.59 4.25 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -142.73 150.0 39.51 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.985 179.067 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.55 152.7 77.03 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.504 -0.748 . . . . 0.0 109.755 179.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -84.52 -12.0 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 O-C-N 123.348 1.183 . . . . 0.0 112.659 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.449 HG13 ' N ' ' A' ' 9' ' ' TYR . 35.9 pt -70.05 -39.91 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 120.871 -1.143 . . . . 0.0 111.333 -178.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.449 ' N ' HG13 ' A' ' 8' ' ' ILE . 46.3 m-85 -72.94 65.22 0.73 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 122.652 1.215 . . . . 0.0 111.712 -178.653 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.89 170.46 7.86 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.55 -34.84 73.18 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -87.83 8.99 23.35 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.016 -1.474 . . . . 0.0 111.542 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 45.3 tp -70.01 122.13 18.76 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.303 -0.873 . . . . 0.0 109.424 179.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.1 m -68.31 135.59 52.12 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.413 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 87.0 mtp -70.07 -15.23 62.96 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.16 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -15.87 72.74 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 120.805 -1.184 . . . . 0.0 110.168 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -88.55 -6.67 57.42 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -1.142 . . . . 0.0 111.735 -179.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.409 HG23 ' HB2' ' A' ' 77' ' ' ASP . 10.8 p -96.74 165.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.997 -1.064 . . . . 0.0 110.603 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.33 94.07 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.783 -0.573 . . . . 0.0 110.907 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.1 m -76.98 71.72 3.5 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.383 -0.823 . . . . 0.0 110.186 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 4.2 p -108.36 111.9 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.467 -0.771 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 51.99 -139.71 0.96 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.592 -0.692 . . . . 0.0 110.561 -179.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.458 ' CA ' ' CH2' ' A' ' 52' ' ' TRP . . . 66.02 -156.12 50.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -74.25 -41.03 61.94 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.684 -0.892 . . . . 0.0 112.025 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.403 ' CD2' ' O ' ' A' ' 54' ' ' SER . 79.5 m-70 -99.69 10.04 42.04 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.074 -1.016 . . . . 0.0 111.51 -178.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.78 130.85 51.17 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 120.073 -1.06 . . . . 0.0 110.523 -179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.0 mt -100.6 -5.93 26.02 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.071 -0.664 . . . . 0.0 110.12 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 34.3 tpp -59.95 -36.08 76.31 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.281 -0.887 . . . . 0.0 109.599 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.24 -72.46 0.05 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.723 -0.611 . . . . 0.0 111.784 -178.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -69.95 -39.99 75.72 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.349 -0.845 . . . . 0.0 110.223 -179.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.427 ' CD2' HG22 ' A' ' 37' ' ' VAL . 75.8 m-85 -120.38 102.31 45.65 Favored Pre-proline 0 N--CA 1.491 1.596 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 -178.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.97 -22.39 19.75 Favored 'Trans proline' 0 C--N 1.316 -1.154 0 O-C-N 123.322 1.17 . . . . 0.0 111.381 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.1 m -122.69 144.23 49.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.327 -0.858 . . . . 0.0 110.711 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.9 tp -64.94 120.82 13.29 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.855 -0.528 . . . . 0.0 110.088 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.29 32.17 0.04 OUTLIER Glycine 0 N--CA 1.496 2.698 0 C-N-CA 119.906 -1.14 . . . . 0.0 110.993 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.424 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 19.1 mt-10 -156.09 -48.17 0.08 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.335 -1.097 . . . . 0.0 109.979 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.427 HG22 ' CD2' ' A' ' 31' ' ' TYR . 2.6 t -62.95 -59.48 12.38 Favored Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 46.9 Cg_endo -73.73 -32.29 7.65 Favored 'Trans proline' 0 C--N 1.318 -1.066 0 N-CA-C 108.733 -1.295 . . . . 0.0 108.733 177.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 130.1 -63.46 0.63 Allowed Glycine 0 N--CA 1.487 2.049 0 N-CA-C 107.197 -2.361 . . . . 0.0 107.197 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.613 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.5 t80 163.32 -53.58 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.556 0 C-N-CA 123.601 0.76 . . . . 0.0 109.91 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.613 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.2 Cg_endo -100.55 12.95 0.49 Allowed 'Trans proline' 0 C--N 1.324 -0.728 0 C-N-CA 121.29 1.327 . . . . 0.0 111.198 -179.029 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 46.6 m-20 -125.15 52.19 1.61 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.216 -0.928 . . . . 0.0 109.765 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.4 p -126.21 136.71 60.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 CA-C-O 121.538 0.685 . . . . 0.0 110.283 -179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.414 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -165.8 171.26 40.91 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.81 160.14 29.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.899 -1.681 . . . . 0.0 108.899 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.466 HG23 ' CE1' ' A' ' 83' ' ' PHE . 8.8 pt -146.65 158.63 45.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.806 -0.82 . . . . 0.0 110.414 179.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.14 -16.41 35.94 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.713 1.609 . . . . 0.0 113.63 -178.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -89.94 18.69 5.47 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.816 -1.177 . . . . 0.0 112.577 -177.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 56.0 mt -119.99 123.17 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.146 -0.971 . . . . 0.0 109.05 177.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.58 -43.64 16.8 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 113.388 0.885 . . . . 0.0 113.388 -177.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 179.54 -125.33 0.96 Allowed Glycine 0 N--CA 1.493 2.452 0 C-N-CA 118.119 -1.991 . . . . 0.0 112.909 -178.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.458 ' CH2' ' CA ' ' A' ' 23' ' ' GLY . 6.8 t90 -40.32 -32.8 0.2 Allowed 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 114.56 1.319 . . . . 0.0 114.56 -176.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 40.9 p-10 -174.15 76.83 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.493 -1.38 . . . . 0.0 109.975 178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.403 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 25.4 p -62.74 155.11 72.01 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.636 -0.665 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 -14.36 40.05 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.566 1.298 . . . . 0.0 110.813 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 6.2 m -102.36 7.79 40.4 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.315 -0.865 . . . . 0.0 111.841 -179.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 41.5 t -65.4 143.65 57.59 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 120.755 -1.216 . . . . 0.0 110.109 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.26 6.45 81.35 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 20.9 p -77.67 158.12 29.85 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.149 -1.207 . . . . 0.0 110.998 179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.41 120.02 40.01 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.19 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.425 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -121.36 139.97 52.73 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.39 -0.819 . . . . 0.0 110.934 179.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -105.92 134.14 49.52 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.436 ' CG2' ' CE2' ' A' ' 83' ' ' PHE . 62.8 t -111.69 125.62 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.587 -0.696 . . . . 0.0 110.47 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 58.8 m -116.41 134.8 54.46 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.692 -0.63 . . . . 0.0 110.552 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.446 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 12.8 pt -116.29 164.04 19.56 Favored Pre-proline 0 N--CA 1.503 2.179 0 O-C-N 121.407 -0.808 . . . . 0.0 111.331 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -63.38 -27.36 71.12 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 121.679 1.586 . . . . 0.0 113.296 -178.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -64.67 -40.03 94.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.064 -1.023 . . . . 0.0 109.917 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 119.92 58.53 0.25 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -154.7 148.43 25.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.72 -0.871 . . . . 0.0 108.666 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 74.9 m -146.44 143.74 29.22 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.738 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.9 pt -134.3 164.35 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -107.13 127.92 53.93 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 118.948 -1.101 . . . . 0.0 109.829 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.431 HD11 HG22 ' A' ' 73' ' ' ILE . 48.5 mm -112.79 130.01 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 ttt180 -98.6 134.89 40.91 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.179 -0.95 . . . . 0.0 109.244 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.96 147.04 30.76 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.416 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -155.4 -44.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.416 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 14.4 t70 -128.73 166.38 19.08 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.2 -0.937 . . . . 0.0 109.563 178.75 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 83.5 p -88.88 161.16 16.84 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.579 -0.701 . . . . 0.0 110.338 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.56 142.97 14.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 88.4 mtt-85 -60.08 -34.01 72.86 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.941 . . . . 0.0 110.009 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.24 75.65 0.04 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.62 149.93 5.1 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.99 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.466 ' CE1' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -66.53 140.07 57.97 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.855 -0.791 . . . . 0.0 110.491 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . 0.414 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 52.3 t-20 -136.77 119.0 15.56 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.361 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.3 m -130.24 176.11 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 C-N-CA 119.102 -1.039 . . . . 0.0 112.449 -177.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.2 m-20 -56.18 157.58 8.67 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.578 -0.701 . . . . 0.0 109.937 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -70.35 -28.17 22.76 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.407 1.214 . . . . 0.0 110.166 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -70.36 -41.41 73.18 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.033 -1.042 . . . . 0.0 109.549 178.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.09 90.86 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -60.05 -49.93 75.74 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.401 -0.52 . . . . 0.0 110.708 178.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.7 m -60.01 -39.71 86.73 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.44 -0.788 . . . . 0.0 111.416 -178.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -69.61 -39.99 76.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.563 -0.711 . . . . 0.0 111.274 -178.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 61.0 tp -71.31 -43.46 67.04 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.587 -0.696 . . . . 0.0 111.296 -179.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.6 t -93.32 -40.55 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.473 -0.767 . . . . 0.0 111.293 -178.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.29 -38.78 2.47 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 74.5 m -142.28 156.93 45.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.674 -0.897 . . . . 0.0 110.416 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 67.2 p -89.95 4.17 50.87 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.776 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.98 -26.65 64.19 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.452 -0.78 . . . . 0.0 110.445 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.01 93.21 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.57 -0.706 . . . . 0.0 110.385 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.33 -75.35 2.39 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -133.42 136.63 45.34 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.558 -0.966 . . . . 0.0 110.572 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.8 t -116.8 113.76 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.438 -0.788 . . . . 0.0 109.76 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -86.84 170.58 11.56 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-O 121.848 0.832 . . . . 0.0 111.608 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.2 t30 60.07 40.01 19.04 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.505 0.669 . . . . 0.0 110.333 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.404 ' CG1' HG13 ' A' ' 63' ' ' VAL . 93.8 t -90.73 122.01 41.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -80.0 140.4 36.59 Favored 'General case' 0 N--CA 1.493 1.707 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.651 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . 0.428 ' CD1' HG21 ' A' ' 1' ' ' VAL . 42.2 p90 -139.27 143.88 38.14 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.882 -0.512 . . . . 0.0 111.231 -178.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.5 m -145.54 139.99 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 111.17 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.425 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 57.3 tt0 -72.66 140.01 47.66 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.364 178.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.8 m -138.48 177.7 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.836 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 47.4 t0 -59.89 146.19 43.07 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.665 -0.647 . . . . 0.0 109.976 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.3 tt -60.0 -37.95 81.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.456 -0.777 . . . . 0.0 110.514 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.7 p -52.71 -35.14 55.22 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.517 -0.739 . . . . 0.0 110.595 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -66.45 -36.3 82.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.511 -0.743 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -62.96 -50.18 71.79 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.264 -0.898 . . . . 0.0 110.038 179.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 90.0 mt -69.3 -40.03 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.748 -0.595 . . . . 0.0 110.457 -179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -65.44 -40.02 92.75 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.44 -0.787 . . . . 0.0 110.158 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.58 -42.18 97.51 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.05 91.1 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.675 -0.897 . . . . 0.0 109.945 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 66.5 t30 . . . . . 0 N--CA 1.5 2.058 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.645 179.898 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.375 0.607 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.0 m -111.77 140.7 46.19 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.661 0.744 . . . . 0.0 110.241 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.6 pt -112.18 147.36 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.755 -0.591 . . . . 0.0 110.487 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.0 p -145.78 -173.24 4.09 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.417 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.1 p90 -142.5 148.88 38.4 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.656 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -124.95 150.38 66.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.468 -0.77 . . . . 0.0 109.608 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -84.55 -7.77 9.64 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 O-C-N 123.303 1.159 . . . . 0.0 112.854 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.457 HG21 HD12 ' A' ' 8' ' ' ILE . 41.0 pt -70.02 -40.09 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.201 0 O-C-N 120.887 -1.133 . . . . 0.0 111.102 -179.356 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.455 ' N ' HG13 ' A' ' 8' ' ' ILE . 38.0 m-85 -72.13 66.86 0.64 Allowed 'General case' 0 N--CA 1.496 1.827 0 CA-C-O 122.684 1.23 . . . . 0.0 111.756 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.69 172.2 6.95 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.126 176.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.17 71.57 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -90.3 11.33 21.62 Favored 'General case' 0 N--CA 1.501 2.09 0 C-N-CA 118.078 -1.449 . . . . 0.0 112.424 -177.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.2 tp -72.63 123.87 24.11 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.214 -0.928 . . . . 0.0 109.956 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 48.4 t -69.54 136.31 51.2 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.027 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.1 mmm -69.98 -15.95 63.11 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.856 -0.527 . . . . 0.0 111.717 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.93 -11.18 66.12 Favored Glycine 0 N--CA 1.495 2.632 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.8 m -93.15 -11.97 31.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.254 -1.144 . . . . 0.0 111.708 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.402 HG22 ' O ' ' A' ' 76' ' ' VAL . 7.1 p -92.45 165.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.17 -0.956 . . . . 0.0 110.46 -179.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -57.98 -45.3 86.98 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.642 -0.661 . . . . 0.0 110.093 -179.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.23 80.32 6.68 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.97 -80.02 0.4 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.485 -0.76 . . . . 0.0 112.903 -177.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -139.91 9.43 2.36 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.217 -0.927 . . . . 0.0 112.917 -178.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.47 -143.97 0.24 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -69.97 -40.02 75.64 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.647 -0.914 . . . . 0.0 109.71 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -90.38 2.37 55.65 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.457 -0.777 . . . . 0.0 110.815 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.03 126.42 33.21 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.423 -1.071 . . . . 0.0 110.423 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 96.1 mt -100.09 0.93 41.71 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 122.132 -0.628 . . . . 0.0 110.21 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 56.6 ttm -68.13 -30.65 69.84 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.364 -0.835 . . . . 0.0 110.339 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.0 -71.8 0.06 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.553 -0.717 . . . . 0.0 111.53 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 37.2 mt-30 -69.97 -40.1 75.6 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.285 -0.884 . . . . 0.0 109.99 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.431 ' CD1' ' HB3' ' A' ' 36' ' ' GLU . 66.5 m-85 -123.16 95.07 46.29 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.843 -0.536 . . . . 0.0 110.049 -179.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.02 -18.75 27.32 Favored 'Trans proline' 0 C--N 1.318 -1.054 0 O-C-N 123.411 1.216 . . . . 0.0 111.483 -179.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.5 m -121.39 149.32 43.16 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.257 -0.902 . . . . 0.0 110.435 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.1 tp -70.64 119.89 15.46 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.793 -0.567 . . . . 0.0 110.422 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.29 33.46 0.05 OUTLIER Glycine 0 N--CA 1.495 2.609 0 C-N-CA 120.104 -1.046 . . . . 0.0 110.593 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.431 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 1.6 mt-10 -157.71 -49.91 0.07 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.206 -1.173 . . . . 0.0 110.422 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.414 ' HB ' ' HD3' ' A' ' 38' ' ' PRO . 2.6 t -60.1 -58.61 18.11 Favored Pre-proline 0 N--CA 1.502 2.125 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.414 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -78.54 -29.23 3.84 Favored 'Trans proline' 0 N--CA 1.486 1.079 0 N-CA-C 109.008 -1.189 . . . . 0.0 109.008 176.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 125.4 -64.88 0.56 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 106.676 -2.57 . . . . 0.0 106.676 -178.151 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.545 ' CB ' ' HD3' ' A' ' 41' ' ' PRO . 0.1 OUTLIER 167.98 -58.88 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.377 0 O-C-N 122.277 -0.543 . . . . 0.0 109.962 177.091 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.545 ' HD3' ' CB ' ' A' ' 40' ' ' PHE . 53.4 Cg_endo -95.57 16.87 0.83 Allowed 'Trans proline' 0 C--N 1.325 -0.68 0 O-C-N 123.071 1.037 . . . . 0.0 109.806 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -123.32 38.8 4.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.469 -0.769 . . . . 0.0 109.526 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.8 p -127.89 140.87 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.527 0.679 . . . . 0.0 110.915 -178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.68 175.18 42.69 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.46 161.76 30.13 Favored Glycine 0 N--CA 1.498 2.807 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 179.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.451 ' CG2' ' CD2' ' A' ' 83' ' ' PHE . 0.5 OUTLIER -161.26 164.79 18.01 Favored Pre-proline 0 N--CA 1.503 2.21 0 CA-C-N 118.457 1.128 . . . . 0.0 111.422 -179.097 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.24 -22.27 25.79 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 121.439 1.426 . . . . 0.0 114.593 -177.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -83.94 3.25 34.95 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.382 -1.449 . . . . 0.0 112.762 -177.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.452 HG22 HD12 ' A' ' 49' ' ' ILE . 45.6 mm -97.38 128.94 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.37 -51.01 7.29 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.409 -0.807 . . . . 0.0 111.961 -178.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 174.68 -135.94 3.3 Favored Glycine 0 N--CA 1.487 2.098 0 C-N-CA 118.882 -1.628 . . . . 0.0 111.241 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.411 ' CE3' ' OD2' ' A' ' 53' ' ' ASP . 9.4 t90 -42.74 -27.22 0.16 Allowed 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.411 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 47.2 m-20 -147.0 62.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.208 -0.932 . . . . 0.0 110.901 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 p -56.96 132.9 79.91 Favored Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.436 -0.79 . . . . 0.0 110.461 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.63 -21.16 22.38 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 O-C-N 123.252 1.133 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 38.8 m -96.15 9.47 40.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.456 -0.777 . . . . 0.0 111.043 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -64.0 141.65 58.69 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.327 -0.858 . . . . 0.0 110.265 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 95.33 -24.97 26.64 Favored Glycine 0 N--CA 1.5 2.933 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 178.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.1 m -56.93 161.32 3.02 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.257 -1.143 . . . . 0.0 110.622 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 42.5 t -113.46 152.32 30.28 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.969 -0.457 . . . . 0.0 111.307 -179.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -142.53 149.04 38.58 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.241 -0.912 . . . . 0.0 110.75 178.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.3 tttp -110.71 129.56 55.8 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.2 t -110.9 129.75 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.316 -0.865 . . . . 0.0 110.383 -178.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.5 m -121.12 140.18 52.33 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.842 -0.536 . . . . 0.0 111.381 -178.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.447 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.2 pt -119.27 164.65 20.3 Favored Pre-proline 0 N--CA 1.5 2.057 0 O-C-N 121.499 -0.751 . . . . 0.0 110.311 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.1 Cg_endo -63.5 -24.07 70.61 Favored 'Trans proline' 0 N--CA 1.495 1.613 0 O-C-N 123.404 1.213 . . . . 0.0 112.593 -178.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.3 t-20 -64.47 -39.99 94.86 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.237 -0.915 . . . . 0.0 109.61 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.65 60.56 0.32 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -159.99 150.78 19.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.704 -0.88 . . . . 0.0 109.145 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.411 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.8 m -149.4 157.38 43.26 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 121.992 0.901 . . . . 0.0 112.029 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 71' ' ' ILE . 36.8 pt -140.06 165.84 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -107.61 130.25 54.91 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.128 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.11 130.04 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.691 -0.631 . . . . 0.0 110.726 -178.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -101.24 135.33 42.88 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -62.24 149.34 47.92 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.124 -1.036 . . . . 0.0 111.386 -177.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.427 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 2.6 p -152.63 -45.75 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.427 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 10.3 t70 -129.49 169.04 15.46 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.34 -0.85 . . . . 0.0 109.517 179.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 82.9 p -103.9 159.94 15.23 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.604 -0.685 . . . . 0.0 110.111 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.52 156.64 21.96 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -60.03 -35.78 75.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.674 -0.898 . . . . 0.0 109.109 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -171.32 177.55 44.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 51.54 -168.32 0.56 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 121.355 -1.085 . . . . 0.0 111.567 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.451 ' CD2' ' CG2' ' A' ' 46' ' ' ILE . 32.4 m-85 -120.0 139.06 53.06 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.965 -0.727 . . . . 0.0 109.15 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 33.4 t-20 -129.29 128.48 43.28 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.3 m -130.72 172.07 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.088 -1.008 . . . . 0.0 112.025 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -55.84 152.77 18.8 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.29 -0.881 . . . . 0.0 109.663 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.36 -21.35 61.22 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 O-C-N 123.386 1.203 . . . . 0.0 110.732 -179.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.2 m -78.76 -40.04 34.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.928 -1.107 . . . . 0.0 109.33 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.68 -40.03 88.38 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -60.01 -49.87 75.99 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.794 -0.566 . . . . 0.0 110.447 179.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -59.99 -38.74 83.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.583 -0.698 . . . . 0.0 110.661 -178.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -69.87 -39.87 76.06 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.141 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 61.2 tp -70.14 -43.97 69.82 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.507 -0.746 . . . . 0.0 111.283 -179.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.51 -39.88 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.298 -0.876 . . . . 0.0 111.461 -178.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 119.89 -35.19 3.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 64.2 m -140.03 150.83 44.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.525 -0.985 . . . . 0.0 110.889 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.8 p -89.57 3.74 51.56 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.516 -0.74 . . . . 0.0 110.627 179.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -70.08 -28.32 65.33 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.441 -0.787 . . . . 0.0 110.951 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.17 -40.03 84.37 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.456 -0.777 . . . . 0.0 110.417 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.57 -79.6 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.0 ttm180 -129.85 132.69 46.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.659 -0.906 . . . . 0.0 110.219 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.5 t -119.34 120.06 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.396 -0.815 . . . . 0.0 110.276 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.401 ' O ' ' HB2' ' A' ' 104' ' ' ASN . 9.3 t70 -85.05 173.11 10.75 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.42 0.629 . . . . 0.0 110.876 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 94.9 m-20 60.04 39.97 19.19 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-O 121.091 0.472 . . . . 0.0 111.569 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 63.0 t -86.95 122.58 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -82.25 134.58 35.29 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.173 -1.011 . . . . 0.0 109.425 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -136.28 142.72 43.97 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.325 0.583 . . . . 0.0 111.323 -178.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -144.07 140.05 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.731 -0.606 . . . . 0.0 110.184 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -71.43 140.75 50.2 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.698 . . . . 0.0 110.422 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -136.57 173.26 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.829 178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -61.12 149.67 36.54 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.386 -0.822 . . . . 0.0 110.833 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.5 tt -59.98 -39.3 85.21 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.456 -0.778 . . . . 0.0 110.794 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 62.8 m -53.85 -39.44 65.63 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 110.226 -178.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -60.25 -39.3 86.24 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.606 -0.684 . . . . 0.0 110.988 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -59.97 -49.37 77.94 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.238 -0.914 . . . . 0.0 110.059 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 85.7 mt -69.84 -40.03 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.704 -0.622 . . . . 0.0 110.57 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.18 -40.0 95.18 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.342 -0.849 . . . . 0.0 110.316 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.45 -39.97 79.65 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.26 -39.96 88.62 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.604 -0.939 . . . . 0.0 110.276 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.194 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.863 0.363 . . . . 0.0 110.66 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.3 m -110.95 141.73 44.0 Favored 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.832 0.825 . . . . 0.0 111.332 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.427 HG12 HG21 ' A' ' 105' ' ' VAL . 45.8 pt -119.93 149.94 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.89 -0.507 . . . . 0.0 110.407 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 67.6 m -143.97 -174.08 4.17 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -141.5 150.0 41.63 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.362 -0.836 . . . . 0.0 110.538 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -132.88 144.73 54.07 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.609 -0.682 . . . . 0.0 109.543 179.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.6 -4.46 14.13 Favored 'Trans proline' 0 C--N 1.317 -1.11 0 O-C-N 123.381 1.201 . . . . 0.0 112.405 -178.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.9 pt -69.99 -40.03 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 120.899 -1.126 . . . . 0.0 110.439 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.464 ' N ' HG13 ' A' ' 8' ' ' ILE . 30.8 m-85 -74.52 66.66 1.42 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 122.815 1.293 . . . . 0.0 110.611 -178.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.72 171.62 7.26 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 114.307 -1.315 . . . . 0.0 108.458 177.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.83 -34.47 73.13 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -175.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -89.1 10.1 23.03 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.45 -1.406 . . . . 0.0 111.966 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.7 tp -71.16 122.87 20.93 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.359 -0.838 . . . . 0.0 109.431 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.3 m -68.89 136.84 53.25 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.705 0.764 . . . . 0.0 110.199 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 89.4 mmm -65.58 -16.98 64.23 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.471 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.57 -16.59 77.65 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.012 -1.055 . . . . 0.0 111.069 -179.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 79.6 p -90.33 -17.65 26.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.138 -1.213 . . . . 0.0 111.256 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.6 p -89.97 155.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.333 -0.854 . . . . 0.0 109.598 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -48.41 -40.02 24.53 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.513 -0.742 . . . . 0.0 110.406 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.29 82.59 4.58 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -92.51 -83.41 0.3 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.895 -1.128 . . . . 0.0 112.596 -177.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -154.5 18.02 0.47 Allowed 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.802 -1.186 . . . . 0.0 112.339 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.06 -141.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -70.13 -42.56 72.45 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.692 -0.887 . . . . 0.0 109.634 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.601 ' NE2' ' N ' ' A' ' 54' ' ' SER . 8.2 p80 -97.31 4.48 50.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.477 -0.765 . . . . 0.0 110.861 -179.715 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.56 144.43 37.42 Favored Glycine 0 N--CA 1.494 2.541 0 O-C-N 121.14 -0.975 . . . . 0.0 110.734 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 94.5 mt -99.58 -3.05 34.16 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.825 -0.809 . . . . 0.0 110.539 179.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 55.3 tpp -60.12 -36.39 77.38 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.562 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.89 -77.79 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.423 -0.798 . . . . 0.0 111.977 -177.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -69.98 -39.99 75.63 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.38 -0.825 . . . . 0.0 111.053 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -119.99 88.44 40.65 Favored Pre-proline 0 N--CA 1.493 1.698 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.59 -16.51 42.65 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.353 1.186 . . . . 0.0 111.51 -178.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.5 m -125.6 140.21 52.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.214 -0.929 . . . . 0.0 110.308 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 51.2 tp -68.55 119.74 13.47 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.68 -0.637 . . . . 0.0 110.65 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.31 32.78 0.04 OUTLIER Glycine 0 N--CA 1.497 2.713 0 C-N-CA 119.96 -1.114 . . . . 0.0 110.782 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 -156.14 -49.55 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.161 -1.199 . . . . 0.0 110.603 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.423 ' CB ' ' CD ' ' A' ' 38' ' ' PRO . 2.4 t -61.18 -59.64 13.1 Favored Pre-proline 0 N--CA 1.499 2.008 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 48.5 Cg_endo -75.38 -31.76 5.5 Favored 'Trans proline' 0 C--N 1.318 -1.075 0 N-CA-C 108.872 -1.241 . . . . 0.0 108.872 177.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.438 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.69 -64.22 0.62 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 107.316 -2.314 . . . . 0.0 107.316 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.467 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 163.54 -68.32 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.645 0 C-N-CA 123.533 0.733 . . . . 0.0 109.555 177.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.467 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.4 Cg_endo -80.41 -0.54 10.71 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 O-C-N 122.734 0.86 . . . . 0.0 111.423 179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -109.95 57.18 0.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.195 -0.94 . . . . 0.0 109.449 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.4 p -129.62 135.66 60.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-O 121.551 0.691 . . . . 0.0 110.557 -179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -165.12 173.01 40.91 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.94 163.79 28.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.404 HG13 ' CG1' ' A' ' 49' ' ' ILE . 1.0 OUTLIER -143.73 157.02 59.2 Favored Pre-proline 0 N--CA 1.495 1.81 0 O-C-N 121.698 -0.884 . . . . 0.0 110.19 179.336 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.48 -9.26 25.48 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.567 1.511 . . . . 0.0 113.044 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -99.01 28.16 4.58 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.918 -1.114 . . . . 0.0 112.239 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.436 HG22 HD12 ' A' ' 49' ' ' ILE . 48.6 mm -119.58 121.57 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.085 -1.01 . . . . 0.0 109.36 179.185 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.5 -43.01 57.94 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.323 -0.86 . . . . 0.0 111.487 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 163.96 -133.33 2.99 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 119.296 -1.43 . . . . 0.0 111.141 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 71.4 t90 -51.11 -23.69 3.39 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.562 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 21.5 t70 -143.99 64.4 1.32 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.362 -0.836 . . . . 0.0 110.427 -178.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.601 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 44.0 m -79.37 142.36 58.34 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.431 -0.793 . . . . 0.0 111.03 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.47 -19.27 15.02 Favored 'Trans proline' 0 C--N 1.317 -1.119 0 O-C-N 123.421 1.222 . . . . 0.0 111.031 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.44 9.86 42.17 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.228 -0.92 . . . . 0.0 112.109 -178.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.431 ' HB3' ' ND1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -72.06 154.09 41.33 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.912 -1.117 . . . . 0.0 108.776 178.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.405 ' HA2' ' CZ ' ' A' ' 74' ' ' ARG . . . 78.61 10.02 86.55 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 96.3 m -99.88 139.96 34.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.306 -1.114 . . . . 0.0 109.706 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.4 m -80.12 143.59 33.78 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.299 0.571 . . . . 0.0 111.063 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.41 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 70.1 m95 -145.39 133.64 21.68 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.443 -0.785 . . . . 0.0 109.871 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -108.53 141.55 40.26 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.181 -0.949 . . . . 0.0 110.571 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.4 t -112.95 127.89 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 CA-C-O 121.385 0.612 . . . . 0.0 110.977 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 m -120.03 143.5 48.05 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.702 -0.624 . . . . 0.0 110.254 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.455 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 9.5 pt -120.74 164.15 24.97 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.171 -0.955 . . . . 0.0 111.218 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.2 Cg_endo -61.49 -26.24 80.71 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 121.682 1.588 . . . . 0.0 113.067 -178.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -63.42 -35.67 81.18 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.227 -0.921 . . . . 0.0 109.761 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.59 63.17 0.46 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -164.42 157.23 17.15 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.774 -0.839 . . . . 0.0 109.209 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 73.9 p -154.74 159.74 40.88 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 122.025 0.917 . . . . 0.0 111.515 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 21.7 pt -133.61 164.27 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -103.61 125.0 49.86 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 118.319 -1.353 . . . . 0.0 109.895 -178.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -119.78 123.54 71.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.621 -0.674 . . . . 0.0 109.911 -178.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . 0.405 ' CZ ' ' HA2' ' A' ' 58' ' ' GLY . 0.0 OUTLIER -93.69 133.66 36.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.406 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -54.8 144.77 30.28 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.462 HG11 ' N ' ' A' ' 77' ' ' ASP . 13.4 p -168.35 -28.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.802 -0.822 . . . . 0.0 111.138 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.462 ' N ' HG11 ' A' ' 76' ' ' VAL . 5.4 m-20 -126.07 170.0 12.2 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.721 -1.237 . . . . 0.0 110.258 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.426 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.5 t -101.4 151.92 21.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.7 -0.625 . . . . 0.0 110.686 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.73 144.32 16.24 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.084 -1.207 . . . . 0.0 110.084 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -60.66 -31.45 70.68 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.78 -0.835 . . . . 0.0 109.978 178.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.65 80.81 0.05 OUTLIER Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.72 -176.94 29.07 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.447 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 57.7 m-85 -113.17 130.96 56.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.438 -1.036 . . . . 0.0 109.58 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 36.8 t-20 -120.88 130.96 54.13 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.7 m -130.22 171.8 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.175 -0.953 . . . . 0.0 112.258 -177.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.2 m-20 -54.07 155.83 6.04 Favored Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.588 -0.695 . . . . 0.0 110.321 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.86 -18.12 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.409 1.215 . . . . 0.0 110.761 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.6 m -80.82 -39.76 26.09 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.965 -1.085 . . . . 0.0 109.208 178.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.37 -39.08 85.65 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . 0.451 ' CE1' ' HA ' ' A' ' 97' ' ' THR . 25.3 t80 -59.99 -50.0 75.44 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.634 -0.666 . . . . 0.0 110.762 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -59.98 -38.95 84.02 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.58 -0.7 . . . . 0.0 111.103 -178.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -64.63 -40.02 94.74 Favored 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.962 -0.695 . . . . 0.0 111.562 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 59.8 tp -69.03 -42.54 76.22 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.637 -0.665 . . . . 0.0 111.9 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 49.0 t -100.25 -9.98 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.302 0 O-C-N 121.228 -0.92 . . . . 0.0 111.927 -178.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 99.5 -29.27 12.3 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 -178.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 97.1 p -155.62 159.84 39.96 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.451 ' HA ' ' CE1' ' A' ' 90' ' ' PHE . 2.8 t -109.06 24.69 12.76 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.113 -0.992 . . . . 0.0 111.086 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -73.82 -22.83 59.66 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.555 -0.715 . . . . 0.0 111.067 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.95 -44.8 94.18 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.365 -0.834 . . . . 0.0 110.971 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.15 -68.07 0.53 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -140.25 135.52 32.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.946 . . . . 0.0 110.383 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 68.6 t -119.57 119.7 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -0.824 . . . . 0.0 110.155 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.9 p-10 -87.95 175.07 7.95 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-O 121.563 0.697 . . . . 0.0 111.181 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.3 t30 59.98 40.86 18.34 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.705 -0.622 . . . . 0.0 110.943 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.427 HG21 HG12 ' A' ' 3' ' ' ILE . 91.3 t -93.86 121.38 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.992 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -79.91 139.77 36.97 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 119.353 -0.939 . . . . 0.0 109.299 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -136.67 142.22 43.17 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.864 -0.523 . . . . 0.0 110.517 -179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -148.33 150.35 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.616 -0.678 . . . . 0.0 110.581 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.41 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 61.2 tt0 -90.19 138.81 31.22 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.542 -0.724 . . . . 0.0 110.516 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.49 177.46 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.591 -0.693 . . . . 0.0 110.257 179.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.91 142.96 52.7 Favored 'General case' 0 N--CA 1.496 1.84 0 CA-C-O 121.582 0.706 . . . . 0.0 110.952 -178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.5 tt -60.11 -38.42 82.96 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.814 -0.554 . . . . 0.0 110.769 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 83.3 p -54.31 -37.01 64.33 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.561 -0.712 . . . . 0.0 111.359 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -70.07 -19.94 63.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.432 -0.793 . . . . 0.0 110.506 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 28.2 m -73.63 -52.17 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 86.5 mt -70.0 -39.99 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.523 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -69.67 -40.0 76.69 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 120.025 -0.67 . . . . 0.0 110.108 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.27 -53.02 19.58 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -44.52 94.52 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.523 -0.987 . . . . 0.0 110.582 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.216 -179.901 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.089 0.471 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -113.28 140.48 47.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.742 -0.599 . . . . 0.0 109.958 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 38.5 pt -104.61 145.41 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.649 -0.657 . . . . 0.0 110.055 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m -145.72 -171.6 3.72 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 51.7 p90 -146.16 150.0 35.04 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.41 179.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -129.01 146.17 59.62 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -81.07 -8.05 13.09 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.264 1.139 . . . . 0.0 112.449 -178.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.476 HG13 ' N ' ' A' ' 9' ' ' TYR . 37.5 pt -67.92 -40.09 82.83 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 120.889 -1.132 . . . . 0.0 110.789 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.476 ' N ' HG13 ' A' ' 8' ' ' ILE . 52.3 m-85 -72.77 67.71 0.82 Allowed 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 122.9 1.333 . . . . 0.0 111.443 -178.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.1 171.1 7.49 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.065 176.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.94 -33.92 71.15 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -175.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -91.09 11.56 22.74 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.599 -1.313 . . . . 0.0 112.354 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.3 tp -70.02 123.37 21.38 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.289 -0.882 . . . . 0.0 109.844 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.26 136.12 49.59 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.642 0.734 . . . . 0.0 110.078 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.8 mmm -68.81 -16.68 63.85 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.979 -0.451 . . . . 0.0 111.869 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.77 -14.67 70.44 Favored Glycine 0 N--CA 1.495 2.586 0 O-C-N 120.917 -1.115 . . . . 0.0 111.309 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.2 t -91.05 -8.01 50.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.129 -1.218 . . . . 0.0 112.051 -178.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.426 HG21 ' N ' ' A' ' 19' ' ' ALA . 8.6 p -96.01 167.82 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.107 -0.996 . . . . 0.0 110.26 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.426 ' N ' HG21 ' A' ' 18' ' ' VAL . . . -59.39 -44.49 92.76 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.51 -0.744 . . . . 0.0 109.988 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.4 m -81.76 81.75 7.68 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.522 -0.736 . . . . 0.0 109.112 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -101.29 -79.57 0.51 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.619 -0.676 . . . . 0.0 112.594 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -131.6 10.18 4.73 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.282 -0.886 . . . . 0.0 112.723 -178.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.429 ' HA2' ' CH2' ' A' ' 52' ' ' TRP . . . -73.61 -148.27 1.17 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -64.7 -39.92 94.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 110.865 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.422 ' CG ' ' O ' ' A' ' 54' ' ' SER . 69.1 m-70 -101.16 15.87 27.31 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.331 -0.856 . . . . 0.0 111.231 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.69 131.32 51.99 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.2 mt -97.46 -4.83 37.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.903 -0.763 . . . . 0.0 110.466 179.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 38.3 tpp -60.87 -34.7 75.02 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.331 -0.855 . . . . 0.0 110.635 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.69 -76.75 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.48 -0.762 . . . . 0.0 111.96 -177.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . 0.415 ' NE2' ' CE2' ' A' ' 31' ' ' TYR . 12.7 tt0 -69.91 -39.99 75.86 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.433 -0.792 . . . . 0.0 110.367 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.444 ' CD2' HG21 ' A' ' 37' ' ' VAL . 58.0 m-85 -120.99 93.3 48.84 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.648 -0.658 . . . . 0.0 109.981 -179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.07 -10.65 27.86 Favored 'Trans proline' 0 C--N 1.318 -1.069 0 O-C-N 123.413 1.217 . . . . 0.0 111.132 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.3 p -126.83 154.04 44.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.326 -0.859 . . . . 0.0 110.269 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.1 tp -78.09 116.03 18.25 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.51 34.0 0.03 OUTLIER Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.76 -48.04 0.07 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 110.613 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.444 HG21 ' CD2' ' A' ' 31' ' ' TYR . 2.2 t -61.33 -57.78 23.21 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 108.591 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.402 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.7 Cg_endo -78.8 -28.4 4.13 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 O-C-N 123.307 1.161 . . . . 0.0 109.485 178.179 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.83 -61.13 0.65 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 107.503 -2.239 . . . . 0.0 107.503 -178.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.593 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 163.24 -54.78 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.605 0 C-N-CA 123.414 0.685 . . . . 0.0 110.042 177.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.593 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.38 15.28 0.3 Allowed 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 121.563 1.509 . . . . 0.0 111.448 -178.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -125.37 39.9 3.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.358 -0.839 . . . . 0.0 109.244 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.4 p -123.66 147.52 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 CA-C-O 121.674 0.749 . . . . 0.0 110.264 -178.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -174.48 175.97 46.79 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.94 149.41 37.82 Favored Glycine 0 N--CA 1.484 1.839 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.42 HG13 HG12 ' A' ' 49' ' ' ILE . 1.1 pp -142.37 139.19 17.29 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.545 -0.974 . . . . 0.0 108.847 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -58.89 -10.51 9.91 Favored 'Trans proline' 0 N--CA 1.505 2.202 0 C-N-CA 122.046 1.831 . . . . 0.0 115.261 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -96.19 30.63 2.41 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 120.529 -1.357 . . . . 0.0 111.899 -178.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.469 HD13 HG23 ' A' ' 49' ' ' ILE . 50.8 mm -119.99 125.99 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.142 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.82 -44.62 15.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.551 -0.718 . . . . 0.0 111.78 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.11 -130.6 1.96 Allowed Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.406 -179.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.429 ' CH2' ' HA2' ' A' ' 23' ' ' GLY . 5.5 t90 -40.21 -30.04 0.09 Allowed 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 -177.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -158.97 72.98 0.59 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.689 -1.257 . . . . 0.0 110.83 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.422 ' O ' ' CG ' ' A' ' 25' ' ' HIS . 4.0 t -54.53 140.32 57.19 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.671 -0.643 . . . . 0.0 111.317 -178.887 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.41 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -72.81 -20.42 22.61 Favored 'Trans proline' 0 C--N 1.319 -1.006 0 O-C-N 123.412 1.217 . . . . 0.0 110.558 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 18.9 m -103.93 14.85 29.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.347 -0.846 . . . . 0.0 111.294 -179.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.0 t -67.74 144.68 55.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.117 -0.99 . . . . 0.0 110.383 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.13 8.31 82.06 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 p -80.6 159.71 25.33 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 41.9 t -110.79 137.54 48.32 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.789 -178.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.447 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 81.9 m95 -142.96 155.88 44.77 Favored 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.12 -0.988 . . . . 0.0 111.394 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 68.7 tttt -112.18 132.25 55.0 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 177.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.05 129.9 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.557 -0.715 . . . . 0.0 109.723 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.3 m -120.68 142.18 49.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.749 -0.595 . . . . 0.0 111.362 -178.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.432 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 48.0 pt -119.74 164.37 22.4 Favored Pre-proline 0 N--CA 1.499 2.022 0 O-C-N 121.496 -0.753 . . . . 0.0 110.209 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.432 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.35 -26.02 76.72 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.174 1.25 . . . . 0.0 112.891 -178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -64.76 -39.96 94.48 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.218 -0.926 . . . . 0.0 109.907 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.1 60.75 0.29 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -160.45 153.51 21.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.603 -0.939 . . . . 0.0 109.339 178.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.0 p -151.71 159.68 43.89 Favored 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 122.12 0.962 . . . . 0.0 112.149 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.8 pt -139.91 164.13 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -105.27 127.18 52.81 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 118.86 -1.136 . . . . 0.0 109.784 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -115.89 130.03 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.627 -0.671 . . . . 0.0 110.134 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 51.4 ttt180 -100.67 136.91 39.79 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.64 149.71 39.8 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.947 -178.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 7.0 p -167.47 -35.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.809 -0.818 . . . . 0.0 110.635 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.89 174.48 9.7 Favored 'General case' 0 N--CA 1.508 2.435 0 O-C-N 120.748 -1.22 . . . . 0.0 108.948 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.421 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 36.9 t -98.59 143.14 29.31 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.357 -0.84 . . . . 0.0 110.535 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -107.89 140.29 15.38 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 -81.96 58.2 3.8 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.724 -0.868 . . . . 0.0 111.589 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.99 58.17 1.62 Allowed Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 151.15 5.42 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.791 -1.195 . . . . 0.0 110.386 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -73.68 145.18 45.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.866 -0.785 . . . . 0.0 110.963 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -139.55 130.69 26.55 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.457 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.1 m -132.28 172.5 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.057 -1.027 . . . . 0.0 112.202 -178.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.7 m-20 -54.69 150.8 16.81 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.275 -0.891 . . . . 0.0 109.823 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.43 -18.3 63.96 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.321 1.169 . . . . 0.0 110.656 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 86.1 m -78.73 -40.01 34.7 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.934 -1.104 . . . . 0.0 109.376 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.34 -39.11 82.0 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.509 -0.744 . . . . 0.0 109.107 179.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -59.99 -49.93 75.75 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.767 -0.583 . . . . 0.0 110.704 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.8 m -60.05 -37.37 79.63 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.406 -0.809 . . . . 0.0 110.623 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -70.0 -39.96 75.58 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.043 -179.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 52.7 tp -70.01 -44.25 69.73 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.569 -0.707 . . . . 0.0 111.428 -179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 63.0 t -96.37 -39.92 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.304 -0.873 . . . . 0.0 111.561 -177.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.53 -29.43 4.99 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.7 p -152.66 160.65 43.16 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.461 -1.023 . . . . 0.0 110.457 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 72.7 p -94.62 8.17 43.25 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.532 -0.73 . . . . 0.0 110.857 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -69.15 -36.07 77.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.42 -0.8 . . . . 0.0 110.677 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.75 87.0 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.525 -0.735 . . . . 0.0 110.284 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.38 -63.54 3.64 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 21.3 ptt180 -150.8 157.59 43.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.673 -0.898 . . . . 0.0 110.745 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.2 t -128.09 122.26 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.553 -0.717 . . . . 0.0 110.223 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -82.87 169.12 16.43 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.603 -0.686 . . . . 0.0 110.961 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t30 60.01 43.22 14.84 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.62 -0.675 . . . . 0.0 111.306 179.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 63.7 t -87.21 130.02 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 C-N-CA 120.06 -0.656 . . . . 0.0 109.966 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -87.19 139.43 30.57 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.804 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -139.9 144.32 37.1 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.914 -0.491 . . . . 0.0 111.173 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.95 143.2 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.529 -0.732 . . . . 0.0 110.734 179.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.447 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 66.1 tt0 -75.72 134.33 40.54 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.603 -0.685 . . . . 0.0 110.009 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.34 172.7 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.554 -0.716 . . . . 0.0 110.237 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -60.11 146.07 44.47 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.513 -0.742 . . . . 0.0 110.986 -179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.1 tt -60.96 -37.22 81.64 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.621 -0.674 . . . . 0.0 110.796 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.8 m -55.23 -40.07 70.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.51 -0.744 . . . . 0.0 110.221 -178.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -59.98 -37.41 79.55 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.731 -0.606 . . . . 0.0 110.317 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -63.32 -46.65 85.67 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.369 -0.832 . . . . 0.0 110.116 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.451 HD13 HG23 ' A' ' 116' ' ' ILE . 88.0 mt -70.02 -40.01 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.554 -0.717 . . . . 0.0 110.738 -178.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -66.88 -40.06 87.67 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.468 -0.77 . . . . 0.0 110.498 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.85 -48.08 51.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.97 94.34 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.598 -0.942 . . . . 0.0 110.603 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 118.047 -0.977 . . . . 0.0 110.265 -179.894 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.205 0.526 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t -111.18 137.72 48.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.628 -0.67 . . . . 0.0 109.3 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 42.1 pt -113.98 147.7 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.729 -0.607 . . . . 0.0 111.018 -179.096 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.06 -170.09 3.34 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -141.82 148.1 38.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.41 -0.806 . . . . 0.0 110.337 178.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -127.05 148.61 66.52 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.46 -0.775 . . . . 0.0 109.825 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -82.57 -7.43 11.63 Favored 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.391 1.206 . . . . 0.0 112.367 -179.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 9' ' ' TYR . 27.4 pt -72.93 -42.29 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.139 0 O-C-N 120.933 -1.104 . . . . 0.0 110.885 -179.025 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.459 ' N ' HG13 ' A' ' 8' ' ' ILE . 31.9 m-85 -72.29 67.18 0.68 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 122.651 1.215 . . . . 0.0 111.049 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.55 171.05 7.58 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.327 176.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.04 -34.16 73.02 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -175.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -90.05 10.62 23.51 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.416 -1.314 . . . . 0.0 112.136 -177.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.4 tp -71.02 126.05 28.53 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 178.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.1 t -69.95 136.02 50.07 Favored 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.791 0.805 . . . . 0.0 110.454 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.2 mmm -66.43 -19.07 65.7 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.436 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.27 -14.06 63.48 Favored Glycine 0 N--CA 1.493 2.456 0 O-C-N 121.044 -1.035 . . . . 0.0 110.776 -179.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.9 m -93.16 -14.59 26.97 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -1.161 . . . . 0.0 111.796 -178.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.04 160.04 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 120.996 -1.065 . . . . 0.0 110.708 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -57.59 -42.63 83.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.699 -0.626 . . . . 0.0 110.565 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.0 m -81.64 72.89 8.7 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -101.78 -76.59 0.57 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.705 -0.622 . . . . 0.0 110.628 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -127.27 168.87 14.16 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.108 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.35 -154.81 16.49 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.52 -2.232 . . . . 0.0 107.52 -177.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -70.2 -39.92 74.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.292 -1.122 . . . . 0.0 110.271 179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 58.8 m-70 -94.09 0.71 56.04 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.454 -0.779 . . . . 0.0 111.194 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.59 127.65 37.64 Favored Glycine 0 N--CA 1.495 2.611 0 O-C-N 120.964 -1.085 . . . . 0.0 110.423 -179.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.5 mt -100.04 -5.19 28.44 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 122.012 -0.699 . . . . 0.0 110.072 178.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.2 ttm -63.04 -37.72 88.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.28 -0.887 . . . . 0.0 109.764 179.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.92 -73.45 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.611 -0.681 . . . . 0.0 111.506 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -69.94 -40.05 75.72 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.157 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.423 ' CG ' HG22 ' A' ' 37' ' ' VAL . 35.6 m-85 -120.36 89.89 44.44 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.864 -0.523 . . . . 0.0 109.801 -178.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.07 -10.01 25.38 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 O-C-N 123.196 1.103 . . . . 0.0 111.049 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 31.0 m -130.01 142.13 50.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.231 -0.918 . . . . 0.0 110.366 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.94 119.25 13.87 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.642 -0.661 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.76 32.6 0.04 OUTLIER Glycine 0 N--CA 1.497 2.746 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.985 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -156.95 -44.95 0.07 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -1.16 . . . . 0.0 110.096 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.423 HG22 ' CG ' ' A' ' 31' ' ' TYR . 2.7 t -63.62 -59.03 12.75 Favored Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.552 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 53.5 Cg_endo -76.82 -29.22 5.63 Favored 'Trans proline' 0 N--CA 1.487 1.109 0 O-C-N 123.271 1.143 . . . . 0.0 109.55 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 127.63 -61.92 0.64 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.603 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 164.69 -54.74 0.0 OUTLIER Pre-proline 0 N--CA 1.509 2.503 0 C-N-CA 123.368 0.667 . . . . 0.0 109.885 177.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.603 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.2 Cg_endo -102.21 11.81 0.39 Allowed 'Trans proline' 0 C--N 1.325 -0.702 0 C-N-CA 121.473 1.448 . . . . 0.0 111.419 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -117.61 31.16 6.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.244 -0.91 . . . . 0.0 110.059 -178.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.401 ' CG2' ' CG1' ' A' ' 76' ' ' VAL . 15.0 p -110.46 139.92 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.561 0.696 . . . . 0.0 110.943 -179.306 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.5 173.79 42.59 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.32 163.72 25.38 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.457 ' CD1' HG12 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -154.27 162.53 26.7 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.806 -0.82 . . . . 0.0 109.888 179.015 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -67.33 -16.94 49.23 Favored 'Trans proline' 0 N--CA 1.5 1.902 0 C-N-CA 121.502 1.468 . . . . 0.0 113.95 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.401 ' HB2' ' CD1' ' A' ' 46' ' ' ILE . 94.4 m-20 -89.39 15.83 8.53 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.541 -1.349 . . . . 0.0 113.025 -177.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 46' ' ' ILE . 43.0 mm -108.02 122.63 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.72 -45.47 29.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.305 -0.872 . . . . 0.0 111.664 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.3 -127.81 1.66 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 118.983 -1.58 . . . . 0.0 110.95 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 49.1 t90 -48.92 -26.03 2.25 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.897 -0.767 . . . . 0.0 112.841 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -147.27 63.13 1.16 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.169 -0.957 . . . . 0.0 111.379 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.414 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 4.5 p -63.68 141.72 97.96 Favored Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.359 -0.838 . . . . 0.0 110.87 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.411 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -80.69 -21.74 6.98 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 O-C-N 123.41 1.216 . . . . 0.0 111.599 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.6 m -95.11 11.63 31.5 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.357 -0.84 . . . . 0.0 111.183 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -72.14 146.29 47.54 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.209 -0.932 . . . . 0.0 110.304 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.78 22.83 52.13 Favored Glycine 0 N--CA 1.495 2.568 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.098 178.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.1 m -109.29 170.65 7.92 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -1.11 . . . . 0.0 109.009 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 2.1 m -118.96 148.2 43.22 Favored 'General case' 0 N--CA 1.51 2.556 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -177.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.459 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 67.9 m95 -144.34 149.67 36.55 Favored 'General case' 0 N--CA 1.51 2.565 0 O-C-N 121.116 -0.99 . . . . 0.0 110.219 175.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.3 ttpt -101.46 131.2 47.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 176.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.8 t -108.61 124.47 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.64 -178.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 94.3 m -120.03 130.03 54.52 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-O 121.189 0.519 . . . . 0.0 111.42 -178.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.467 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.4 pt -106.85 166.15 11.63 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.789 -0.569 . . . . 0.0 110.492 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.467 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.7 Cg_endo -63.92 -27.56 66.77 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 O-C-N 123.347 1.183 . . . . 0.0 112.605 -178.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -64.3 -39.92 94.89 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.169 -0.957 . . . . 0.0 109.734 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.46 58.3 0.32 Allowed Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -150.72 147.32 27.19 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 178.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 49.1 m -147.25 152.36 38.19 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.859 -1.136 . . . . 0.0 112.652 -179.467 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 37.7 pt -140.13 161.66 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.31 129.76 47.34 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.093 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.0 mm -116.58 129.97 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 109.782 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 58.6 ttt180 -101.32 133.31 46.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.965 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -52.52 149.59 10.06 Favored Glycine 0 N--CA 1.498 2.795 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 77' ' ' ASP . 14.9 p -174.48 -28.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.652 -0.91 . . . . 0.0 111.121 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.41 ' OD2' ' CE1' ' A' ' 9' ' ' TYR . 5.2 m-20 -129.75 167.47 18.02 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.717 -1.239 . . . . 0.0 109.422 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 77.7 p -97.84 155.89 16.84 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -0.835 . . . . 0.0 110.771 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.94 139.52 11.01 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -61.04 -39.9 91.56 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.837 -0.802 . . . . 0.0 110.209 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.61 73.53 0.08 OUTLIER Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 155.22 -163.34 31.45 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.89 -1.148 . . . . 0.0 110.298 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.477 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 39.8 m-85 -125.63 121.56 33.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.919 -0.753 . . . . 0.0 109.113 179.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -116.08 130.24 56.71 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 26.9 m -129.18 173.47 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.9 m-20 -56.53 158.2 8.55 Favored Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.544 -0.722 . . . . 0.0 110.021 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.83 -28.66 36.13 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.453 1.238 . . . . 0.0 111.06 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -70.03 -39.96 75.44 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.993 -1.067 . . . . 0.0 109.26 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.87 -41.31 87.47 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.64 -50.0 75.27 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.804 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -60.18 -40.04 88.58 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.515 -0.741 . . . . 0.0 110.839 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.27 -39.56 86.06 Favored 'General case' 0 N--CA 1.495 1.797 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.207 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 65.5 tp -69.95 -41.66 74.25 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.835 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -98.89 -36.65 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.255 -0.903 . . . . 0.0 111.722 -177.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.04 -27.43 6.75 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.8 p -153.07 160.46 42.95 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.552 -0.97 . . . . 0.0 109.81 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 60.9 p -90.87 6.82 42.92 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.366 -0.834 . . . . 0.0 110.793 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -69.98 -25.91 63.84 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.31 -0.868 . . . . 0.0 110.87 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.17 77.03 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.466 -0.771 . . . . 0.0 110.949 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.94 -80.46 1.76 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 19.1 ttm180 -137.07 139.94 41.66 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.677 -0.896 . . . . 0.0 110.119 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.24 119.93 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.523 -0.736 . . . . 0.0 110.231 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -90.43 169.7 10.84 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.754 0.787 . . . . 0.0 111.176 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 28.8 t30 59.95 40.05 19.4 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.695 -0.628 . . . . 0.0 111.497 179.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 81.5 t -84.41 126.98 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -92.58 152.26 19.7 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.13 -1.028 . . . . 0.0 108.87 179.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -146.82 150.0 34.43 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.631 -0.668 . . . . 0.0 112.074 -177.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -141.32 134.73 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.745 -0.597 . . . . 0.0 110.097 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.459 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 55.6 tt0 -72.46 141.61 48.6 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.524 0.678 . . . . 0.0 110.979 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.0 m -132.27 172.07 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -60.0 143.98 50.42 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.453 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.03 -39.97 87.74 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.385 -0.822 . . . . 0.0 110.226 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.3 t -51.29 -33.98 31.08 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.615 -0.678 . . . . 0.0 111.28 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -65.38 -39.99 92.94 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.482 -0.761 . . . . 0.0 110.935 -179.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 86.8 m -60.42 -47.76 84.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.393 -0.817 . . . . 0.0 110.243 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.431 HD12 HG22 ' A' ' 116' ' ' ILE . 88.1 mt -69.96 -40.02 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.955 -0.466 . . . . 0.0 110.772 -179.118 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -66.48 -39.99 89.08 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.498 -0.751 . . . . 0.0 110.866 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -78.68 -60.06 2.7 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.159 -178.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.13 93.59 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.418 -1.048 . . . . 0.0 110.738 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.402 -179.784 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.992 0.425 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.5 p -112.95 145.86 40.04 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.686 -0.634 . . . . 0.0 110.085 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 45.1 pt -120.01 149.96 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.626 -0.671 . . . . 0.0 110.743 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.62 -172.37 3.88 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -140.96 145.44 36.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.325 -0.859 . . . . 0.0 110.199 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.73 149.48 64.83 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.409 -0.807 . . . . 0.0 110.005 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.94 48.25 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.074 0 O-C-N 123.432 1.227 . . . . 0.0 110.602 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.44 HG22 ' CD2' ' A' ' 9' ' ' TYR . 7.6 tp -118.79 -6.79 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.527 -0.733 . . . . 0.0 111.052 -179.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' CD2' HG22 ' A' ' 8' ' ' ILE . 29.2 m-85 -122.69 70.94 1.01 Allowed 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 122.62 1.2 . . . . 0.0 110.182 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.54 171.45 7.56 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 114.597 -1.183 . . . . 0.0 107.921 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.56 -28.71 60.8 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.37 12.26 21.07 Favored 'General case' 0 N--CA 1.498 1.966 0 C-N-CA 118.323 -1.351 . . . . 0.0 112.236 -177.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.55 116.62 10.17 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.205 -0.934 . . . . 0.0 109.817 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -65.88 137.74 57.39 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.837 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.9 mmm -67.77 -16.37 64.08 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.87 -0.519 . . . . 0.0 111.715 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.14 -13.82 82.4 Favored Glycine 0 N--CA 1.495 2.607 0 O-C-N 120.849 -1.157 . . . . 0.0 110.626 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -94.98 -17.68 21.74 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.19 -1.183 . . . . 0.0 111.708 -178.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.21 159.16 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.186 -179.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.44 -40.0 64.85 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.198 -0.939 . . . . 0.0 110.301 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 62.8 m -78.88 82.61 5.06 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -90.45 -80.73 0.32 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.048 -1.032 . . . . 0.0 112.875 -177.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -154.88 20.55 0.45 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.734 -1.229 . . . . 0.0 112.535 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.22 -144.91 0.04 OUTLIER Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -69.63 -39.93 76.84 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.821 -0.811 . . . . 0.0 109.808 178.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.47 ' NE2' ' N ' ' A' ' 54' ' ' SER . 2.3 p80 -95.57 4.57 53.02 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.468 -0.77 . . . . 0.0 110.098 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.76 140.75 43.55 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.183 -0.948 . . . . 0.0 111.174 -178.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 91.2 mt -104.34 -0.04 28.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 122.049 -0.677 . . . . 0.0 110.389 178.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.7 ttm -60.05 -35.06 74.32 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 110.521 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.51 -73.22 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.458 -0.776 . . . . 0.0 111.398 -177.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -70.36 -39.99 74.29 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.372 -0.83 . . . . 0.0 110.121 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.425 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 54.1 m-85 -116.97 86.47 19.8 Favored Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -178.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.31 -26.93 24.45 Favored 'Trans proline' 0 C--N 1.317 -1.101 0 O-C-N 123.39 1.205 . . . . 0.0 110.955 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 15.1 m -116.89 161.26 19.61 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.359 -0.838 . . . . 0.0 110.41 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -86.59 114.92 23.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.769 -0.582 . . . . 0.0 111.292 -178.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 156.49 37.09 0.02 OUTLIER Glycine 0 N--CA 1.497 2.734 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -162.2 -48.26 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.376 -1.073 . . . . 0.0 110.578 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.425 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 2.8 t -59.96 -59.36 14.11 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.407 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.3 Cg_endo -76.76 -31.98 3.77 Favored 'Trans proline' 0 C--N 1.317 -1.131 0 N-CA-C 109.007 -1.189 . . . . 0.0 109.007 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 133.68 -60.95 0.65 Allowed Glycine 0 N--CA 1.486 1.977 0 N-CA-C 107.498 -2.241 . . . . 0.0 107.498 -178.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.568 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.1 t80 157.9 -51.06 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.665 0 C-N-CA 123.877 0.871 . . . . 0.0 109.936 177.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.568 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 52.9 Cg_endo -101.0 5.61 0.62 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.595 1.53 . . . . 0.0 112.039 -177.612 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -122.36 47.57 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.975 . . . . 0.0 109.961 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.3 p -117.66 141.11 37.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.869 0.843 . . . . 0.0 110.181 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -169.79 176.19 43.7 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -92.22 165.06 28.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.466 ' CG2' ' CD2' ' A' ' 83' ' ' PHE . 0.9 OUTLIER -154.8 161.0 30.39 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.631 -0.923 . . . . 0.0 109.801 178.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -66.7 -35.01 29.95 Favored 'Trans proline' 0 N--CA 1.502 2.015 0 C-N-CA 121.777 1.651 . . . . 0.0 115.2 -175.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -68.95 -10.0 55.02 Favored 'General case' 0 N--CA 1.507 2.398 0 O-C-N 120.736 -1.227 . . . . 0.0 113.24 -177.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.419 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 35.1 mm -81.23 129.23 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 O-C-N 120.717 -1.24 . . . . 0.0 109.417 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.12 -49.64 7.17 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.325 -0.859 . . . . 0.0 112.108 -178.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 174.55 -139.35 4.85 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.995 -1.574 . . . . 0.0 111.608 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -49.01 -24.58 1.58 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.765 -0.844 . . . . 0.0 112.914 -178.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . 0.453 ' HA ' ' CD2' ' A' ' 25' ' ' HIS . 14.7 t70 -142.27 71.93 1.36 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.191 -0.943 . . . . 0.0 109.583 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.47 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 9.8 p -82.65 136.91 44.72 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.937 -0.477 . . . . 0.0 110.318 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -78.6 -16.81 13.03 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 O-C-N 123.318 1.167 . . . . 0.0 111.167 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.3 m -97.39 4.19 50.74 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.316 -0.865 . . . . 0.0 112.543 -178.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.1 t -66.58 142.53 57.46 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.905 -1.122 . . . . 0.0 110.421 -179.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 94.13 -7.71 72.76 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.574 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 22.4 p -70.44 157.77 37.22 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 118.9 1.35 . . . . 0.0 110.743 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -107.21 130.8 54.68 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.939 -0.476 . . . . 0.0 110.553 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.439 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 92.9 m95 -135.17 147.62 49.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.279 -0.888 . . . . 0.0 110.561 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -106.42 135.55 47.73 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 70' ' ' SER . 72.0 t -108.2 123.88 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.65 -0.656 . . . . 0.0 109.382 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 41.3 m -119.59 137.31 53.93 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.111 0.481 . . . . 0.0 111.075 -178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.436 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 35.1 pt -115.72 164.26 18.08 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.676 -0.64 . . . . 0.0 110.401 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.436 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.09 -25.18 80.77 Favored 'Trans proline' 0 N--CA 1.497 1.683 0 C-N-CA 121.268 1.312 . . . . 0.0 112.514 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -63.23 -40.0 96.21 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.256 -0.903 . . . . 0.0 109.706 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 114.61 60.72 0.38 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -159.95 151.99 20.49 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.717 -0.873 . . . . 0.0 108.854 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.3 p -155.48 161.07 41.02 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.115 -1.034 . . . . 0.0 112.428 -179.316 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 37.8 pt -137.36 166.48 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -105.52 127.04 52.79 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.665 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.434 HG22 HD12 ' A' ' 73' ' ' ILE . 46.3 mm -120.04 129.95 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 121.463 -0.773 . . . . 0.0 110.547 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -100.42 140.04 35.24 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.443 -0.786 . . . . 0.0 109.016 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.02 149.45 41.5 Favored Glycine 0 N--CA 1.494 2.538 0 CA-C-O 122.019 0.788 . . . . 0.0 111.575 -178.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.0 p -159.0 -39.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 122.017 -0.696 . . . . 0.0 109.653 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -135.86 170.2 16.36 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 120.963 -1.086 . . . . 0.0 109.517 179.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.419 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 5.6 t -95.52 160.4 14.53 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.296 -0.877 . . . . 0.0 111.828 -178.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.85 149.14 18.71 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 63.6 mtt180 -60.07 -33.98 72.81 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.655 -0.909 . . . . 0.0 110.586 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.4 79.48 0.05 OUTLIER Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.44 169.0 13.4 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.466 ' CD2' ' CG2' ' A' ' 46' ' ' ILE . 19.1 m-85 -91.24 120.13 31.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.953 . . . . 0.0 109.817 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -114.27 130.46 56.65 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 178.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.9 m -134.86 176.59 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.029 -1.044 . . . . 0.0 111.869 -178.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -57.42 152.7 31.68 Favored Pre-proline 0 N--CA 1.496 1.855 0 C-N-CA 120.133 -0.627 . . . . 0.0 110.051 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.64 -22.69 64.34 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.353 1.186 . . . . 0.0 110.408 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -73.13 -41.03 64.41 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.015 -1.053 . . . . 0.0 108.745 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.85 -39.76 87.68 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -59.98 -49.98 75.55 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.127 179.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 12.1 p -60.01 -35.53 75.25 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.44 -0.787 . . . . 0.0 110.77 -179.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 55.9 mttm -69.95 -40.03 75.71 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.342 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 67.1 tp -70.49 -46.08 64.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 0.0 111.41 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -101.76 -38.13 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.172 0 O-C-N 121.288 -0.883 . . . . 0.0 111.655 -177.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 -18.88 16.46 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 41.8 p -158.8 151.96 22.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.249 -1.148 . . . . 0.0 110.519 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.1 p -93.89 8.51 41.0 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.632 -0.667 . . . . 0.0 110.917 179.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.44 -0.788 . . . . 0.0 110.552 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.0 85.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.608 -0.683 . . . . 0.0 110.92 -178.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -59.4 3.19 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 108.538 -1.825 . . . . 0.0 108.538 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 53.9 ptt85 -150.1 157.14 42.81 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.792 -0.828 . . . . 0.0 109.946 179.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.7 t -128.35 126.23 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.468 -0.77 . . . . 0.0 109.719 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -90.19 169.0 11.51 Favored 'General case' 0 N--CA 1.496 1.867 0 CA-C-O 121.771 0.796 . . . . 0.0 111.75 -178.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 53.2 t30 60.07 40.02 19.05 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 121.402 0.62 . . . . 0.0 111.002 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 79.9 t -85.17 129.68 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.506 179.259 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -88.27 138.83 31.09 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.234 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.1 p90 -132.99 140.85 47.98 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.34 0.59 . . . . 0.0 110.824 -178.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 18.8 m -143.83 139.94 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.755 -0.59 . . . . 0.0 110.987 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.439 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 54.9 tt0 -77.32 139.08 39.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.702 -0.624 . . . . 0.0 110.292 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 34.6 m -130.02 165.35 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.61 -0.681 . . . . 0.0 110.649 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -55.42 139.97 41.55 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.585 -0.697 . . . . 0.0 110.753 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.2 tt -60.83 -39.98 91.06 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.646 -0.659 . . . . 0.0 110.825 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.0 m -54.45 -37.87 65.69 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.577 -0.702 . . . . 0.0 111.112 -177.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -65.73 -36.9 84.91 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.558 -0.714 . . . . 0.0 111.12 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 81.0 m -63.05 -44.43 95.86 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.177 -0.952 . . . . 0.0 109.913 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 80.3 mt -69.64 -39.96 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.099 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -66.4 -40.05 89.39 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.469 -0.769 . . . . 0.0 110.467 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -74.31 -56.52 5.12 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.26 93.94 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.445 -1.032 . . . . 0.0 110.256 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.7 t30 . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 117.832 -1.08 . . . . 0.0 111.054 179.611 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.2 m . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.438 0.637 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 33.9 t -114.09 142.35 46.31 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.381 0.61 . . . . 0.0 110.668 -178.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 42.9 pt -114.25 149.96 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.353 0.596 . . . . 0.0 110.887 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 23.0 m -146.35 -172.82 4.03 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.166 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . 0.416 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -140.06 149.32 42.98 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.82 179.106 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.38 148.9 71.75 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.457 -0.777 . . . . 0.0 109.435 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -84.0 -9.05 9.86 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.275 1.145 . . . . 0.0 112.636 -178.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.454 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.2 pt -70.01 -40.06 78.09 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.227 0 O-C-N 120.953 -1.092 . . . . 0.0 110.984 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.454 ' N ' HG13 ' A' ' 8' ' ' ILE . 50.9 m-85 -73.3 67.3 0.97 Allowed 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 122.877 1.322 . . . . 0.0 111.324 -178.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.93 171.55 7.28 Favored 'General case' 0 N--CA 1.49 1.55 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.203 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.97 -34.45 71.81 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -175.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -89.95 10.94 22.03 Favored 'General case' 0 N--CA 1.501 2.11 0 C-N-CA 118.285 -1.366 . . . . 0.0 112.507 -177.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 tp -70.61 124.45 24.28 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.245 -0.909 . . . . 0.0 109.666 179.343 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 61.5 p -70.76 137.66 49.81 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.672 0.748 . . . . 0.0 110.092 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.9 mmm -66.41 -19.1 65.71 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.938 -0.476 . . . . 0.0 112.025 -178.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.78 -15.39 75.85 Favored Glycine 0 N--CA 1.495 2.626 0 O-C-N 120.95 -1.094 . . . . 0.0 111.296 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.9 p -89.04 -7.52 55.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.208 -1.172 . . . . 0.0 111.9 -178.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 19' ' ' ALA . 9.8 p -99.86 169.47 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.098 -1.001 . . . . 0.0 110.638 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.407 ' N ' HG23 ' A' ' 18' ' ' VAL . . . -58.89 -44.49 91.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.525 -0.734 . . . . 0.0 109.796 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.1 m -80.04 80.71 6.42 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -101.19 -81.56 0.48 Allowed 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.262 -0.899 . . . . 0.0 113.247 -177.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -131.12 11.14 5.02 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.139 -0.976 . . . . 0.0 113.025 -177.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.68 -153.49 3.43 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 179.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -65.93 -40.06 91.05 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.517 -0.99 . . . . 0.0 109.691 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 83.7 m-70 -91.0 6.31 45.3 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -0.797 . . . . 0.0 110.734 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -59.43 134.62 51.71 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.6 mt -101.16 -4.47 27.19 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 122.024 -0.692 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 59.4 ttm -62.22 -37.03 83.79 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.273 -0.892 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.11 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.608 -0.683 . . . . 0.0 111.896 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -69.09 -39.99 78.67 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.367 -0.833 . . . . 0.0 109.743 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.433 ' CD2' HG22 ' A' ' 37' ' ' VAL . 48.7 m-85 -119.94 91.69 45.8 Favored Pre-proline 0 N--CA 1.491 1.608 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.92 -18.67 40.95 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.293 1.154 . . . . 0.0 111.241 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 90.6 m -123.75 141.27 52.18 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.229 -0.919 . . . . 0.0 110.026 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 41.7 tp -65.9 120.75 13.62 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.77 -0.581 . . . . 0.0 111.036 -179.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.29 32.41 0.04 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.862 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.419 ' CB ' ' CD1' ' A' ' 31' ' ' TYR . 25.0 mt-10 -155.29 -49.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -1.128 . . . . 0.0 110.448 178.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.433 HG22 ' CD2' ' A' ' 31' ' ' TYR . 3.1 t -60.27 -60.81 9.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 50.6 Cg_endo -74.79 -28.6 9.43 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 N-CA-C 108.979 -1.2 . . . . 0.0 108.979 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.43 -61.32 0.65 Allowed Glycine 0 N--CA 1.484 1.872 0 N-CA-C 107.017 -2.433 . . . . 0.0 107.017 -178.587 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.469 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.8 t80 165.48 -72.7 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.578 0 C-N-CA 123.377 0.671 . . . . 0.0 110.083 177.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.469 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -83.01 -8.58 10.94 Favored 'Trans proline' 0 N--CA 1.493 1.497 0 CA-C-N 118.995 0.677 . . . . 0.0 112.174 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -97.91 34.29 1.93 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.134 -0.979 . . . . 0.0 110.51 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.95 137.3 42.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.665 0.745 . . . . 0.0 109.498 179.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.62 172.89 43.22 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.044 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.54 156.34 29.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.456 HG21 ' CE2' ' A' ' 83' ' ' PHE . 81.3 mt -139.97 150.46 62.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.426 ' HD2' ' CG2' ' A' ' 46' ' ' ILE . 37.3 Cg_endo -59.36 -10.15 10.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.349 1.184 . . . . 0.0 113.626 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -94.58 -12.54 27.3 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.693 -1.254 . . . . 0.0 112.329 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.493 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 51.3 mm -75.08 119.67 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 C-N-CA 118.601 -1.24 . . . . 0.0 108.397 178.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.74 -45.3 21.47 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.26 -0.9 . . . . 0.0 112.529 -178.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 169.9 -138.91 5.28 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.918 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 36.8 t90 -42.79 -28.81 0.27 Allowed 'General case' 0 N--CA 1.502 2.175 0 O-C-N 121.956 -0.731 . . . . 0.0 112.769 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -142.62 65.34 1.35 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.339 -0.851 . . . . 0.0 110.112 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.426 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 3.0 p -66.39 134.51 94.58 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.643 -0.661 . . . . 0.0 110.899 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -74.93 -23.48 13.9 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 O-C-N 123.45 1.237 . . . . 0.0 111.05 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.62 15.19 14.89 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 111.385 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t -78.28 151.62 32.91 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 110.054 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 71.08 29.89 68.31 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.7 m -117.16 132.97 56.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.59 -0.947 . . . . 0.0 109.963 179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -81.07 145.5 31.07 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -177.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.456 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -149.34 150.09 31.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 110.471 178.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -108.45 132.03 54.2 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.3 t -108.9 127.36 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.49 -0.756 . . . . 0.0 109.597 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 88.0 m -120.06 136.66 54.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.942 -0.474 . . . . 0.0 110.939 -178.135 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.441 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 38.0 pt -115.95 164.82 16.36 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.541 -0.724 . . . . 0.0 110.568 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.8 -25.1 74.61 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 C-N-CA 121.236 1.29 . . . . 0.0 112.66 -178.569 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -64.89 -40.0 94.41 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.23 -0.919 . . . . 0.0 109.794 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.75 61.09 0.32 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.271 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -160.01 150.64 18.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.758 -0.848 . . . . 0.0 108.831 179.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 67.0 p -151.56 157.41 42.19 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.247 -0.981 . . . . 0.0 112.248 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.3 pt -139.34 165.05 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -103.36 125.76 50.15 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.274 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.5 mm -119.8 131.01 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.707 -0.621 . . . . 0.0 110.246 -178.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 -99.38 137.06 38.42 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.439 -0.788 . . . . 0.0 109.079 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.18 150.74 28.62 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.45 HG11 ' N ' ' A' ' 77' ' ' ASP . 11.9 p -169.54 -28.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.679 -0.895 . . . . 0.0 111.307 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.45 ' N ' HG11 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -130.0 166.98 18.99 Favored 'General case' 0 N--CA 1.505 2.306 0 O-C-N 120.585 -1.322 . . . . 0.0 109.712 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.493 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 48.2 t -94.68 144.51 25.55 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.482 -0.761 . . . . 0.0 111.024 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -126.29 141.67 13.0 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -60.68 -28.38 68.57 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.759 -0.847 . . . . 0.0 109.814 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.04 79.92 0.05 OUTLIER Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.27 163.79 11.21 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.827 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.456 ' CE2' HG21 ' A' ' 46' ' ' ILE . 16.1 m-85 -92.16 115.33 27.99 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.666 -0.902 . . . . 0.0 109.915 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 57.7 t-20 -109.04 131.99 54.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.343 -0.848 . . . . 0.0 109.028 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.3 m -132.44 175.52 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.185 0 O-C-N 120.961 -1.087 . . . . 0.0 111.833 -178.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -55.73 156.69 8.83 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.41 -0.806 . . . . 0.0 109.953 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.07 -22.37 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.295 1.155 . . . . 0.0 110.65 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -76.28 -40.03 52.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.021 -1.049 . . . . 0.0 108.953 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.26 -39.87 89.76 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -60.04 -50.03 75.31 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.202 -0.599 . . . . 0.0 110.486 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 56.9 m -59.96 -39.5 85.82 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.546 -0.721 . . . . 0.0 110.709 -178.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.1 mtmt -70.03 -40.05 75.41 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.789 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 65.4 tp -70.02 -43.4 71.42 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.65 -0.656 . . . . 0.0 111.492 -179.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.2 t -96.2 -39.82 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 O-C-N 121.262 -0.899 . . . . 0.0 111.258 -178.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.63 -38.96 2.55 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.8 m -139.98 152.2 46.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.686 -0.891 . . . . 0.0 110.182 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.6 p -90.71 6.33 44.51 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.403 -0.81 . . . . 0.0 111.169 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -70.04 -29.22 66.2 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.478 -0.764 . . . . 0.0 110.736 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.05 -40.09 84.02 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.538 -0.726 . . . . 0.0 110.625 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -74.48 1.68 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 12.1 ptt-85 -144.74 149.54 35.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.681 -0.894 . . . . 0.0 110.271 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.94 119.36 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.487 -0.758 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.404 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 5.0 t0 -83.84 173.49 11.21 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.723 -0.611 . . . . 0.0 110.604 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 60.01 45.75 11.72 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.636 -0.665 . . . . 0.0 110.998 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.405 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 73.7 t -95.53 128.06 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.493 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -85.4 136.1 33.6 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.092 -1.005 . . . . 0.0 109.639 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.8 p90 -132.87 140.98 48.18 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.134 0.492 . . . . 0.0 110.738 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.2 m -144.62 141.21 23.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.609 -0.682 . . . . 0.0 110.979 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.456 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 58.6 tt0 -70.93 140.73 51.05 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.536 -0.727 . . . . 0.0 110.334 178.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.23 167.44 26.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.105 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -61.28 148.26 41.76 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.414 -0.804 . . . . 0.0 110.325 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.73 -40.05 96.0 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.433 -0.792 . . . . 0.0 111.133 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 53.4 m -56.29 -38.18 70.88 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.583 -0.698 . . . . 0.0 110.587 -178.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.09 -35.71 75.81 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.432 -0.792 . . . . 0.0 110.287 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 80.5 m -70.04 -39.99 75.41 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.522 -0.736 . . . . 0.0 109.383 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 50.6 mm -66.77 -40.04 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 CA-C-O 121.473 0.654 . . . . 0.0 109.395 -178.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -69.98 -39.96 75.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.818 -0.551 . . . . 0.0 110.299 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.88 -57.73 5.67 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.96 -41.64 92.37 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.507 -0.996 . . . . 0.0 110.704 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.301 -179.889 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.8 m . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.464 0.65 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.1 t -113.57 140.19 48.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.746 -0.596 . . . . 0.0 109.744 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 37.4 pt -109.16 148.14 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 111.042 -179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.72 -170.82 3.61 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -144.71 150.01 36.58 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.967 179.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -130.29 148.58 70.39 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.566 -0.709 . . . . 0.0 109.554 178.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.79 -6.58 12.43 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 O-C-N 123.247 1.13 . . . . 0.0 112.46 -179.117 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.452 HG13 ' N ' ' A' ' 9' ' ' TYR . 30.1 pt -69.98 -40.0 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 120.865 -1.147 . . . . 0.0 110.925 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.452 ' N ' HG13 ' A' ' 8' ' ' ILE . 40.5 m-85 -74.17 67.24 1.33 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-O 122.774 1.273 . . . . 0.0 111.132 -178.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.19 171.86 7.12 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 114.299 -1.319 . . . . 0.0 108.146 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.05 -33.93 72.72 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.98 10.22 24.84 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.428 -1.42 . . . . 0.0 112.316 -177.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.0 tp -70.33 123.33 21.46 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.263 -0.898 . . . . 0.0 109.703 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.1 m -69.14 136.63 52.46 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.783 -0.767 . . . . 0.0 109.961 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 96.6 mmm -67.21 -17.72 64.94 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 122.03 -0.419 . . . . 0.0 111.65 -178.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -70.75 -14.7 73.01 Favored Glycine 0 N--CA 1.495 2.612 0 O-C-N 120.955 -1.091 . . . . 0.0 111.095 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -88.43 -9.44 52.55 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.203 -1.175 . . . . 0.0 111.787 -179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.54 168.49 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.072 -1.017 . . . . 0.0 110.092 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -57.8 -44.8 86.57 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.542 -0.724 . . . . 0.0 109.939 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.5 m -81.28 84.05 6.71 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.4 m -99.95 -79.95 0.48 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.56 -0.712 . . . . 0.0 112.88 -178.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -131.09 9.93 4.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.24 -0.912 . . . . 0.0 112.77 -178.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.41 -153.2 1.83 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.755 -1.738 . . . . 0.0 108.755 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -70.01 -39.95 75.53 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.789 -0.83 . . . . 0.0 109.648 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.425 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 75.5 m-70 -90.03 0.21 57.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.625 -0.672 . . . . 0.0 110.866 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.71 137.89 49.06 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.0 mt -99.02 -5.22 30.8 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.916 -0.755 . . . . 0.0 110.251 178.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.401 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.1 ttm -60.01 -37.2 79.01 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.307 -0.871 . . . . 0.0 110.97 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.94 -74.84 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.497 -0.752 . . . . 0.0 111.798 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -70.0 -39.97 75.57 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.433 -0.792 . . . . 0.0 110.359 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.453 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 27.6 m-85 -120.02 93.27 47.73 Favored Pre-proline 0 N--CA 1.496 1.83 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -178.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -69.82 -21.87 32.62 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.423 1.223 . . . . 0.0 111.347 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.4 m -123.21 145.9 48.27 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 109.939 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.6 tp -68.68 121.15 15.86 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -0.756 . . . . 0.0 110.753 -179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.88 33.78 0.03 OUTLIER Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.774 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -160.31 -44.12 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.159 -1.201 . . . . 0.0 110.142 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.453 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 3.5 t -60.54 -61.28 8.28 Favored Pre-proline 0 N--CA 1.498 1.967 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.426 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -77.59 -26.11 7.4 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.108 1.057 . . . . 0.0 109.598 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.58 -62.0 0.63 Allowed Glycine 0 N--CA 1.486 1.988 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.496 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.0 t80 166.74 -72.45 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.449 0 C-N-CA 123.267 0.627 . . . . 0.0 109.632 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.496 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 60.2 Cg_endo -84.65 10.7 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 CA-C-N 118.912 0.647 . . . . 0.0 111.647 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -114.54 35.7 4.11 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.011 -1.056 . . . . 0.0 110.015 -178.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.1 p -117.54 143.36 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-O 121.455 0.645 . . . . 0.0 110.11 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.04 166.67 39.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.38 151.37 44.97 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 177.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.428 ' CD1' HG13 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -144.22 142.9 20.61 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.431 -1.04 . . . . 0.0 109.351 179.698 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -61.38 -13.02 26.55 Favored 'Trans proline' 0 N--CA 1.507 2.271 0 C-N-CA 122.193 1.929 . . . . 0.0 115.188 -177.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -92.9 20.1 6.99 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.45 -1.406 . . . . 0.0 112.139 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.428 HG13 ' CD1' ' A' ' 46' ' ' ILE . 57.8 mt -118.57 127.67 75.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.301 -0.875 . . . . 0.0 109.038 177.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.0 -45.35 13.2 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 175.18 -141.17 5.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.403 -1.856 . . . . 0.0 112.194 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 25.3 t90 -39.97 -29.87 0.08 Allowed 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 -178.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -146.15 64.14 1.22 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.985 -1.072 . . . . 0.0 111.325 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.417 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 6.5 t -66.27 139.39 96.34 Favored Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.45 -0.781 . . . . 0.0 110.866 -179.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.425 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -78.05 -20.66 11.37 Favored 'Trans proline' 0 C--N 1.32 -0.959 0 O-C-N 123.4 1.211 . . . . 0.0 110.65 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 17.8 m -92.97 11.54 27.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.484 -0.76 . . . . 0.0 111.231 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.6 t -69.66 145.16 52.61 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.093 -1.004 . . . . 0.0 109.766 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.45 41.9 12.6 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.1 m -120.01 129.95 54.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.397 -1.06 . . . . 0.0 110.477 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 50.1 t -81.29 143.03 32.55 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.513 -178.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -146.4 155.62 42.72 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.526 178.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -114.11 130.19 56.59 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.6 129.59 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.405 -0.809 . . . . 0.0 109.706 -178.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.3 m -121.12 141.07 51.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.803 -0.561 . . . . 0.0 111.459 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.42 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.0 pt -117.62 163.58 23.35 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.521 -0.737 . . . . 0.0 110.036 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.42 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -62.32 -25.35 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 121.184 1.256 . . . . 0.0 112.507 -178.461 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -64.84 -39.01 92.88 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.384 -0.822 . . . . 0.0 109.715 179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.47 61.6 0.33 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -160.58 153.07 20.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.709 -0.877 . . . . 0.0 109.007 178.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.401 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -151.26 158.72 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.207 1.003 . . . . 0.0 112.352 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 pt -139.89 164.73 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.162 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.58 127.0 52.98 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 118.879 -1.128 . . . . 0.0 109.928 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.37 131.89 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.622 -0.674 . . . . 0.0 110.582 -179.123 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -102.21 136.49 41.96 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.27 149.54 42.17 Favored Glycine 0 N--CA 1.494 2.557 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.318 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 5.7 p -156.91 -42.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.743 -0.857 . . . . 0.0 110.118 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.411 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 12.3 t70 -128.34 169.99 13.6 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.109 -0.995 . . . . 0.0 110.06 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 41.8 t -87.67 156.85 19.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.426 -0.796 . . . . 0.0 111.081 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.43 137.34 10.92 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -63.08 -39.87 96.0 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.734 -0.862 . . . . 0.0 110.162 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -178.15 69.96 0.08 OUTLIER Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.74 172.09 18.19 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -98.63 122.53 41.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.652 -0.911 . . . . 0.0 110.334 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -115.05 130.31 56.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.391 -0.818 . . . . 0.0 109.048 179.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.42 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 35.6 m -132.97 174.47 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 120.933 -1.104 . . . . 0.0 111.741 -178.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -54.74 150.9 16.6 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.53 -0.731 . . . . 0.0 109.92 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.6 -21.01 59.97 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.404 1.213 . . . . 0.0 110.76 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 67.7 m -75.79 -39.95 56.02 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.065 -1.022 . . . . 0.0 109.23 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.77 -40.03 88.08 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.422 -0.798 . . . . 0.0 109.116 178.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -60.03 -49.68 76.72 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.807 -0.558 . . . . 0.0 110.632 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.6 m -60.04 -36.99 78.5 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.824 . . . . 0.0 110.787 -178.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -69.95 -40.07 75.67 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.412 -179.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.401 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 56.1 tp -70.39 -44.16 68.58 Favored 'General case' 0 N--CA 1.496 1.851 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.554 -178.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 91.1 t -95.39 -38.61 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.311 -0.868 . . . . 0.0 111.394 -177.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -27.35 6.07 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 43.7 t -156.04 161.19 40.46 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.466 -1.02 . . . . 0.0 110.292 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 68.3 p -97.81 13.24 31.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 111.151 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.99 -36.54 75.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.481 -0.762 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.02 -41.16 91.59 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.444 -0.785 . . . . 0.0 111.05 -178.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.28 -63.48 2.02 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 -179.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -149.37 153.45 37.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.59 -0.947 . . . . 0.0 110.57 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.1 118.94 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.456 -0.777 . . . . 0.0 110.149 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -81.87 169.44 16.84 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.577 -0.702 . . . . 0.0 111.181 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 63.7 t30 59.85 50.06 7.29 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.548 -0.72 . . . . 0.0 110.731 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 66.9 t -94.05 128.73 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.902 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -86.9 140.61 29.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.417 -0.913 . . . . 0.0 109.491 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -139.11 141.87 38.11 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.167 0.508 . . . . 0.0 110.736 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 m -141.14 139.89 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.695 -0.628 . . . . 0.0 110.161 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -77.4 136.86 38.44 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.964 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -134.22 -179.13 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.257 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.41 150.94 47.55 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.406 -0.809 . . . . 0.0 111.075 -179.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.7 tt -62.06 -40.0 94.29 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.559 -0.713 . . . . 0.0 111.389 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 55.8 m -54.28 -39.37 66.84 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.443 -0.785 . . . . 0.0 110.222 -178.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -59.99 -37.65 80.29 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.632 -0.668 . . . . 0.0 110.223 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -68.15 -42.43 80.09 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.49 -0.756 . . . . 0.0 109.481 178.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.0 mm -64.88 -40.52 89.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.023 -0.671 . . . . 0.0 109.853 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -70.05 -39.92 75.41 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.697 -0.627 . . . . 0.0 110.483 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.6 -53.14 37.07 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.05 -43.94 97.24 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.512 -0.993 . . . . 0.0 110.548 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 48.6 t30 . . . . . 0 N--CA 1.501 2.082 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.006 -179.824 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.411 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 35.4 m . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.25 0.548 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' SER . . . . . 0.415 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 24.8 t -114.63 141.18 48.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.536 -0.728 . . . . 0.0 110.39 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 39.3 pt -107.8 147.72 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.679 -0.638 . . . . 0.0 110.6 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.42 -171.89 3.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.8 p90 -142.87 147.32 35.18 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.35 -0.844 . . . . 0.0 110.802 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -137.7 155.22 75.17 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.488 178.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -88.28 48.06 1.37 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.275 1.145 . . . . 0.0 110.659 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 tp -123.01 -8.65 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.48 -0.763 . . . . 0.0 111.276 -179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.408 ' HA ' HD23 ' A' ' 13' ' ' LEU . 35.3 m-85 -118.54 67.65 0.77 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 122.525 1.155 . . . . 0.0 110.947 178.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.02 170.37 7.9 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.679 177.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.424 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . . . -59.6 -32.71 70.64 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 114.115 1.154 . . . . 0.0 114.115 -175.497 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -89.63 13.91 12.94 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 120.424 1.466 . . . . 0.0 112.5 -177.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 9' ' ' TYR . 64.0 tp -73.1 125.94 28.85 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.413 -0.804 . . . . 0.0 110.792 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.18 135.54 49.18 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.6 mmm -66.36 -15.86 63.61 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.777 -0.577 . . . . 0.0 112.048 -178.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.62 -13.86 80.05 Favored Glycine 0 N--CA 1.497 2.701 0 O-C-N 120.977 -1.077 . . . . 0.0 111.337 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 -11.05 47.2 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.054 -1.262 . . . . 0.0 112.063 -178.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -93.72 168.25 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.068 -1.02 . . . . 0.0 110.041 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.09 85.58 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.472 -0.768 . . . . 0.0 109.816 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.03 82.94 2.89 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.586 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.9 m -90.29 -79.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.989 -1.069 . . . . 0.0 112.894 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.401 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 17.9 p30 -143.56 14.21 1.77 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 120.631 -1.293 . . . . 0.0 112.428 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.64 -146.95 0.38 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -66.58 -40.51 88.97 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . 0.407 ' CD2' ' O ' ' A' ' 54' ' ' SER . 64.1 m-70 -90.02 0.56 57.05 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.798 -0.564 . . . . 0.0 110.265 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -55.05 130.4 47.08 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.492 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 84.3 mt -104.87 -5.98 20.62 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 122.146 -0.62 . . . . 0.0 111.203 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' MET . . . . . 0.404 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 44.4 ttm -59.96 -35.63 75.39 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.292 -0.88 . . . . 0.0 110.825 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.43 -63.1 1.26 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -67.26 -40.04 86.18 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.213 -0.93 . . . . 0.0 111.288 -177.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.494 ' CE1' ' CG2' ' A' ' 37' ' ' VAL . 5.5 p90 -143.64 113.72 5.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.879 . . . . 0.0 109.128 179.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.65 -1.62 10.1 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.443 1.233 . . . . 0.0 112.582 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.64 -172.1 2.21 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.995 -1.066 . . . . 0.0 109.71 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -116.51 129.96 56.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.605 -0.685 . . . . 0.0 110.852 -178.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.86 -40.82 1.27 Allowed Glycine 0 N--CA 1.489 2.172 0 C-N-CA 120.077 -1.059 . . . . 0.0 111.044 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -62.42 -39.94 94.93 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.182 -1.187 . . . . 0.0 111.483 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.494 ' CG2' ' CE1' ' A' ' 31' ' ' TYR . 3.2 t -87.62 -61.36 0.24 Allowed Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.336 -0.852 . . . . 0.0 112.699 -178.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 37.4 Cg_endo -64.54 -48.49 4.29 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 O-C-N 123.009 1.005 . . . . 0.0 113.063 -177.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . 0.427 ' O ' ' HD2' ' A' ' 41' ' ' PRO . . . 122.77 67.87 0.23 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 106.541 -2.624 . . . . 0.0 106.541 -177.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' HD3' ' A' ' 41' ' ' PRO . 8.8 t80 19.65 -78.99 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.343 0 N-CA-C 115.101 1.519 . . . . 0.0 115.101 -178.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.497 ' HD3' ' CD2' ' A' ' 40' ' ' PHE . 58.7 Cg_endo -81.91 17.8 1.48 Allowed 'Trans proline' 0 N--CA 1.499 1.804 0 CA-C-N 120.07 1.061 . . . . 0.0 112.588 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -123.79 47.33 2.06 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.836 -1.165 . . . . 0.0 110.201 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.0 p -129.39 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 122.064 0.935 . . . . 0.0 110.334 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.08 175.31 42.3 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.32 161.75 31.6 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 1.1 pt -147.46 152.1 41.35 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.64 -0.917 . . . . 0.0 110.063 179.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.69 -14.7 46.15 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.954 1.77 . . . . 0.0 113.763 -178.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -90.6 23.25 3.11 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 120.591 -1.318 . . . . 0.0 112.259 -178.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.474 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 49.8 mm -113.77 126.91 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.17 13.0 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.311 -0.868 . . . . 0.0 112.077 -178.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -134.34 2.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 118.715 -1.707 . . . . 0.0 111.719 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 53.5 t90 -46.06 -28.48 1.2 Allowed 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -178.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -146.65 61.19 1.21 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.024 -1.048 . . . . 0.0 110.986 -179.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.407 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 35.1 p -61.95 140.07 95.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.49 -0.756 . . . . 0.0 110.444 -179.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.18 -21.8 19.89 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 123.328 1.172 . . . . 0.0 111.151 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.9 m -93.85 13.62 21.98 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.449 -0.782 . . . . 0.0 111.158 -179.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 2.2 t -73.17 145.43 46.32 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.259 -0.9 . . . . 0.0 110.561 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.58 22.79 71.81 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 86.8 m -104.22 139.11 39.71 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.358 -1.084 . . . . 0.0 110.751 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 46.5 t -80.12 132.96 36.03 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.545 -179.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' TRP . . . . . 0.403 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.7 m95 -134.36 147.32 50.51 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -0.76 . . . . 0.0 110.074 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -107.86 131.55 54.38 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.366 -0.834 . . . . 0.0 109.725 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.95 121.03 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.557 0.694 . . . . 0.0 110.252 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 97.8 m -119.99 146.03 46.23 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.859 -0.525 . . . . 0.0 110.575 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.453 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 17.2 pt -122.12 164.51 25.25 Favored Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.473 -0.767 . . . . 0.0 110.98 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -61.31 -25.94 81.09 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.561 1.507 . . . . 0.0 112.837 -178.611 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -66.08 -40.0 90.48 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.248 -0.907 . . . . 0.0 110.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.45 61.11 0.3 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -160.07 151.6 19.81 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.652 -0.911 . . . . 0.0 108.829 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.9 p -155.6 164.99 37.9 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 122.287 1.041 . . . . 0.0 112.193 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 40.0 pt -144.52 165.63 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -106.29 122.64 46.64 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.265 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 66.2 mt -120.02 131.41 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.857 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.8 ttt180 -95.25 136.5 35.53 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.663 -0.648 . . . . 0.0 109.407 -179.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.39 149.72 31.43 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 110.336 -1.106 . . . . 0.0 110.336 -178.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.41 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 4.1 p -154.7 -44.08 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.723 -0.869 . . . . 0.0 109.513 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 11.9 t70 -131.87 169.02 16.84 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 178.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' SER . . . . . 0.474 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 95.5 p -91.91 157.78 16.65 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.4 -0.813 . . . . 0.0 111.618 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -124.2 146.16 16.16 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -60.66 -31.04 70.29 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.649 -0.912 . . . . 0.0 110.174 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.09 76.45 0.04 OUTLIER Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.562 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.82 154.93 6.26 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.115 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.41 114.59 6.22 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.931 -0.746 . . . . 0.0 110.376 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -111.15 119.07 37.74 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 26.8 m -131.1 176.95 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 120.89 -1.131 . . . . 0.0 112.474 -177.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.5 m-20 -55.7 150.9 24.41 Favored Pre-proline 0 N--CA 1.493 1.713 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.214 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.43 -17.27 57.26 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.395 1.208 . . . . 0.0 110.142 178.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 98.1 m -81.28 -40.66 23.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.916 -1.115 . . . . 0.0 109.182 178.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -39.84 91.12 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -60.06 -49.94 75.68 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.754 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.5 m -60.68 -40.0 90.53 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.429 -0.794 . . . . 0.0 111.108 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -68.48 -39.99 81.15 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.35 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 57.8 tp -73.31 -43.24 61.25 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.576 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 51.2 t -91.57 -42.36 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 121.344 -0.848 . . . . 0.0 111.52 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.27 -31.74 3.56 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 90.1 p -154.39 165.88 34.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.502 -0.999 . . . . 0.0 110.457 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.7 p -94.23 -0.05 55.37 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.451 -0.781 . . . . 0.0 111.756 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -70.95 -26.3 63.11 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.336 -0.853 . . . . 0.0 111.675 -179.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -39.98 87.86 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.322 -0.861 . . . . 0.0 110.898 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.68 -67.46 2.17 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -152.1 160.01 43.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.553 -0.969 . . . . 0.0 110.998 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.11 112.73 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.952 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . 0.415 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.1 p-10 -80.06 170.01 17.05 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.464 0.65 . . . . 0.0 111.113 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 59.98 40.02 19.36 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.627 -0.67 . . . . 0.0 111.597 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.411 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 94.5 t -85.15 129.94 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.417 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -86.72 139.49 30.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.002 -1.061 . . . . 0.0 109.545 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -138.02 143.3 40.52 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 122.0 -0.438 . . . . 0.0 110.763 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -149.07 149.02 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.545 -0.722 . . . . 0.0 110.706 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' GLN . . . . . 0.403 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 58.9 tt0 -76.75 139.98 40.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.599 -0.688 . . . . 0.0 110.269 179.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.6 168.26 24.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -57.6 144.83 35.93 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.378 -0.826 . . . . 0.0 110.563 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.6 tt -59.91 -36.75 77.64 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.224 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 91.0 p -54.07 -36.14 62.82 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.491 -0.756 . . . . 0.0 110.502 -179.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -66.67 -39.58 88.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 111.179 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -59.97 -49.16 78.78 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.306 -0.871 . . . . 0.0 109.797 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ILE . . . . . 0.426 HD13 HG23 ' A' ' 116' ' ' ILE . 93.4 mt -69.81 -39.98 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.687 -0.633 . . . . 0.0 110.687 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -64.0 -39.94 95.25 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.35 -0.844 . . . . 0.0 111.052 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.14 -50.83 20.73 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.94 91.62 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.574 -0.957 . . . . 0.0 110.524 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.063 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.555 0.693 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 79.9 p -111.33 139.9 46.35 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.456 0.646 . . . . 0.0 109.49 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 39.6 pt -118.13 149.98 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.837 -0.54 . . . . 0.0 111.273 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -146.15 -169.55 3.28 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -141.58 148.07 38.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.417 -0.802 . . . . 0.0 110.178 178.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.49 143.48 43.32 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.406 -0.809 . . . . 0.0 109.777 179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.73 -9.86 17.05 Favored 'Trans proline' 0 C--N 1.318 -1.078 0 O-C-N 123.324 1.171 . . . . 0.0 112.331 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.453 HG13 ' N ' ' A' ' 9' ' ' TYR . 44.5 pt -70.01 -39.95 77.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 120.968 -1.082 . . . . 0.0 111.434 -179.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.453 ' N ' HG13 ' A' ' 8' ' ' ILE . 51.5 m-85 -72.14 67.5 0.67 Allowed 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 122.752 1.263 . . . . 0.0 111.72 -178.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.55 170.04 8.12 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.054 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.41 -34.38 68.85 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -175.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -90.92 12.12 20.56 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 118.431 -1.308 . . . . 0.0 112.265 -177.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 36.4 tp -72.53 123.71 23.73 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.246 -0.908 . . . . 0.0 110.2 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -70.54 137.35 50.06 Favored 'General case' 0 N--CA 1.49 1.573 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.035 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 34.6 mtt -70.08 -15.39 62.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.802 -0.561 . . . . 0.0 111.915 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.63 -15.37 68.53 Favored Glycine 0 N--CA 1.494 2.559 0 O-C-N 120.793 -1.192 . . . . 0.0 110.878 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 91.0 p -87.98 -4.45 58.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.192 -1.181 . . . . 0.0 112.157 -178.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.8 p -103.5 168.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.001 -1.062 . . . . 0.0 110.801 -179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 52' ' ' TRP . . . -60.04 -39.29 85.4 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.471 -0.768 . . . . 0.0 110.644 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.76 67.72 3.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.291 -0.881 . . . . 0.0 110.088 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.6 m -108.71 110.13 21.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.155 -0.966 . . . . 0.0 110.565 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 m120 51.66 -140.98 0.84 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.714 -0.616 . . . . 0.0 111.11 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.43 -155.95 49.02 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -78.07 -41.82 34.2 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.428 -1.042 . . . . 0.0 111.066 179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 87.5 m-70 -89.94 2.14 55.42 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.181 -0.949 . . . . 0.0 111.748 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.55 131.81 49.36 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.002 -1.061 . . . . 0.0 111.15 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.7 mt -96.28 -11.57 25.76 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 122.091 -0.652 . . . . 0.0 110.005 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -60.05 -34.42 73.38 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.267 -0.896 . . . . 0.0 110.836 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -74.41 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.558 -0.714 . . . . 0.0 111.691 -178.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -70.04 -39.97 75.43 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.347 -0.846 . . . . 0.0 109.938 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.43 ' CD2' HG21 ' A' ' 37' ' ' VAL . 70.1 m-85 -120.67 89.69 45.19 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.82 -4.97 15.83 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.317 1.167 . . . . 0.0 112.298 -178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.7 m -135.13 149.1 49.94 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.019 -1.051 . . . . 0.0 110.406 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.9 tp -72.45 117.59 14.31 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.758 -0.589 . . . . 0.0 110.528 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.89 32.36 0.04 OUTLIER Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.992 -1.099 . . . . 0.0 110.924 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -158.81 -46.28 0.06 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.195 -1.18 . . . . 0.0 110.21 179.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.43 HG21 ' CD2' ' A' ' 31' ' ' TYR . 3.0 t -61.05 -59.92 12.29 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 52.5 Cg_endo -76.63 -28.35 6.68 Favored 'Trans proline' 0 N--CA 1.487 1.146 0 O-C-N 123.182 1.096 . . . . 0.0 109.371 177.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.3 -62.35 0.63 Allowed Glycine 0 N--CA 1.488 2.146 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 -178.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.632 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 165.27 -58.73 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.467 0 C-N-CA 123.248 0.619 . . . . 0.0 109.804 177.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.632 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.23 18.19 0.33 Allowed 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 121.076 1.184 . . . . 0.0 110.937 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -126.94 42.48 3.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.315 -0.866 . . . . 0.0 109.499 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.3 p -123.58 140.77 46.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-O 121.563 0.697 . . . . 0.0 109.73 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -166.59 169.09 40.46 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -80.08 157.53 41.19 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.624 -1.79 . . . . 0.0 108.624 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 1.2 pp -146.23 145.21 23.39 Favored Pre-proline 0 N--CA 1.486 1.361 0 O-C-N 121.48 -1.012 . . . . 0.0 109.221 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.435 ' HD2' ' CE1' ' A' ' 83' ' ' PHE . 38.0 Cg_endo -61.73 -7.19 8.71 Favored 'Trans proline' 0 N--CA 1.506 2.249 0 C-N-CA 122.197 1.931 . . . . 0.0 115.075 -177.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -97.46 23.0 8.09 Favored 'General case' 0 N--CA 1.504 2.252 0 O-C-N 120.5 -1.375 . . . . 0.0 112.446 -178.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.448 HD11 HG23 ' A' ' 49' ' ' ILE . 49.4 mm -110.13 130.1 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.17 -48.1 9.48 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.423 -0.798 . . . . 0.0 112.613 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 179.67 -131.48 1.67 Allowed Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.609 -1.758 . . . . 0.0 111.926 -179.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.416 ' CE3' ' OD2' ' A' ' 53' ' ' ASP . 11.8 t90 -54.79 -22.9 15.77 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 -178.006 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.416 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 42.1 m-20 -147.94 62.51 1.12 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.008 -1.057 . . . . 0.0 110.754 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 p -58.6 141.97 83.57 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.476 -0.765 . . . . 0.0 110.967 -178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -77.45 -21.4 11.64 Favored 'Trans proline' 0 C--N 1.319 -0.991 0 O-C-N 123.39 1.205 . . . . 0.0 110.752 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.8 m -97.89 13.81 29.34 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.507 -0.746 . . . . 0.0 111.073 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -68.05 141.34 56.2 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.152 -0.967 . . . . 0.0 109.628 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.8 42.38 11.32 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.2 m -120.03 130.05 54.53 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.395 -1.062 . . . . 0.0 110.198 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 49.1 t -80.14 139.94 36.6 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.097 -177.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.422 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 64.3 m95 -145.27 150.88 37.44 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.543 -0.723 . . . . 0.0 110.376 178.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -109.63 133.02 53.59 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -110.03 128.89 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.443 -0.786 . . . . 0.0 109.727 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 29.5 m -119.98 142.67 48.57 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.831 -0.543 . . . . 0.0 111.662 -177.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.422 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 23.4 pt -119.67 163.55 26.84 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.709 -0.619 . . . . 0.0 110.279 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.422 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.54 -23.56 74.88 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 121.3 1.334 . . . . 0.0 112.672 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -66.38 -40.01 89.42 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.274 -0.891 . . . . 0.0 109.83 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.89 60.42 0.29 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -160.02 150.6 18.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.629 -0.924 . . . . 0.0 109.088 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.1 m -151.06 156.91 42.06 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.037 0.923 . . . . 0.0 112.03 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.6 pt -138.0 165.71 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -106.92 127.5 53.49 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 118.964 -1.094 . . . . 0.0 110.145 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.428 HG23 HD13 ' A' ' 73' ' ' ILE . 48.6 mm -115.78 129.96 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.748 -0.595 . . . . 0.0 110.094 -179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.9 ttt180 -99.81 135.03 41.84 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.14 148.29 24.94 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.8 p -159.9 -37.98 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.767 -0.843 . . . . 0.0 110.057 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -133.18 169.96 16.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.002 -1.061 . . . . 0.0 109.495 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.43 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 86.9 p -97.26 160.05 14.56 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.409 -0.807 . . . . 0.0 110.899 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.94 141.74 12.94 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -60.73 -39.93 90.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.808 -0.819 . . . . 0.0 110.663 178.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.35 71.73 0.09 OUTLIER Glycine 0 N--CA 1.494 2.535 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.63 168.91 15.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.435 ' CE1' ' HD2' ' A' ' 47' ' ' PRO . 96.3 m-85 -98.49 128.57 44.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.755 -0.85 . . . . 0.0 109.948 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -120.63 131.02 54.4 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.378 -0.826 . . . . 0.0 109.531 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.2 m -131.09 174.06 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.064 -1.023 . . . . 0.0 111.387 -178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.1 m-20 -55.78 153.14 17.16 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.355 -0.841 . . . . 0.0 109.996 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.76 -26.23 53.0 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 123.381 1.2 . . . . 0.0 110.019 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.9 m -70.72 -39.98 73.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.092 -1.005 . . . . 0.0 108.982 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.73 79.04 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -60.08 -50.02 75.37 Favored 'General case' 0 N--CA 1.499 2.018 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.689 179.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.8 m -60.04 -38.61 83.28 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.482 -0.761 . . . . 0.0 110.463 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.07 -39.75 75.46 Favored 'General case' 0 N--CA 1.493 1.694 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.937 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 47.9 tp -70.07 -43.58 70.86 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.555 -0.715 . . . . 0.0 111.668 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -95.01 -37.63 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.134 0 O-C-N 121.251 -0.906 . . . . 0.0 110.967 -178.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.26 5.5 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.0 p -156.7 168.76 26.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -1.013 . . . . 0.0 110.121 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 55.1 p -96.77 8.41 44.35 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 110.801 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.04 -29.59 66.66 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.374 -0.829 . . . . 0.0 110.409 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.1 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.565 -0.709 . . . . 0.0 110.54 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 79.02 -83.67 1.28 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 29.2 ttt180 -130.03 133.13 46.53 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.627 -0.926 . . . . 0.0 110.133 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.68 120.13 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.489 -0.757 . . . . 0.0 110.304 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 43.7 p-10 -83.23 174.81 10.43 Favored 'General case' 0 N--CA 1.494 1.746 0 CA-C-O 121.718 0.77 . . . . 0.0 111.544 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 57.7 t30 59.99 40.66 18.56 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.704 -0.622 . . . . 0.0 112.013 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 59.3 t -88.91 127.34 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.937 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -85.14 138.32 32.46 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 119.328 -0.949 . . . . 0.0 109.871 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -134.57 140.48 46.15 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.351 0.596 . . . . 0.0 110.746 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 m -142.67 145.25 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.668 -0.645 . . . . 0.0 109.916 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.422 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 55.4 tt0 -85.03 141.62 30.16 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -136.18 176.96 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.718 -0.614 . . . . 0.0 110.088 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -62.03 149.57 40.59 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.443 -0.786 . . . . 0.0 110.575 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -39.93 87.77 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.488 -0.757 . . . . 0.0 110.992 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 t -51.39 -38.94 55.99 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.424 -0.798 . . . . 0.0 110.822 -178.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -60.91 -39.99 91.45 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.49 -0.756 . . . . 0.0 111.274 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -61.53 -48.22 82.01 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.323 -0.861 . . . . 0.0 110.109 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -67.84 -39.92 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.663 -0.648 . . . . 0.0 110.557 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -65.59 -40.0 92.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.463 -0.773 . . . . 0.0 110.571 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.96 -49.37 35.23 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.54 89.46 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.576 -0.955 . . . . 0.0 110.605 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.7 m120 . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 117.93 -1.034 . . . . 0.0 110.273 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 N--CA 1.499 1.994 0 CA-C-O 120.975 0.416 . . . . 0.0 110.415 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 50.5 m -113.3 143.01 45.15 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.537 -0.727 . . . . 0.0 110.795 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.9 pt -114.36 149.93 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.81 -0.556 . . . . 0.0 110.861 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.5 p -147.07 -173.46 4.25 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -142.11 153.33 44.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.355 -0.841 . . . . 0.0 110.246 178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.414 ' HB3' ' CD1' ' A' ' 8' ' ' ILE . 0.9 OUTLIER -132.78 145.94 59.24 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.404 -0.81 . . . . 0.0 110.359 -179.592 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -88.43 49.75 1.56 Allowed 'Trans proline' 0 N--CA 1.486 1.077 0 O-C-N 123.219 1.115 . . . . 0.0 113.192 -178.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.448 HG21 HD11 ' A' ' 8' ' ' ILE . 0.1 OUTLIER -134.05 5.88 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.562 0 O-C-N 120.751 -1.218 . . . . 0.0 110.936 178.196 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.422 ' HA ' HD21 ' A' ' 13' ' ' LEU . 31.5 m-85 -114.15 67.2 0.68 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 122.873 1.321 . . . . 0.0 109.442 178.386 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.31 170.83 7.83 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.858 177.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.98 -32.87 71.24 Favored 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -88.9 11.5 17.85 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.464 -1.397 . . . . 0.0 112.176 -177.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.422 HD21 ' HA ' ' A' ' 9' ' ' TYR . 43.5 tp -72.27 125.1 26.51 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.301 -0.874 . . . . 0.0 109.987 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.4 m -70.38 136.19 49.42 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.276 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.6 mmm -65.26 -16.72 63.85 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.85 -0.531 . . . . 0.0 111.683 -178.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.66 -11.49 80.54 Favored Glycine 0 N--CA 1.496 2.687 0 O-C-N 121.003 -1.061 . . . . 0.0 111.284 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.4 m -89.96 -4.85 57.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.034 -1.274 . . . . 0.0 112.055 -178.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.4 p -100.7 169.02 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.966 -1.084 . . . . 0.0 110.434 -179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 52' ' ' TRP . . . -59.92 -40.06 87.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.15 69.0 4.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.499 -0.751 . . . . 0.0 109.884 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.3 m -108.58 110.81 22.36 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.181 -0.949 . . . . 0.0 110.783 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 50.09 -141.47 0.71 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.747 -0.596 . . . . 0.0 111.406 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 64.64 -150.63 51.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.55 -46.26 16.06 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.977 . . . . 0.0 111.494 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 54' ' ' SER . 73.8 m-70 -89.99 1.99 55.65 Favored 'General case' 0 N--CA 1.504 2.262 0 O-C-N 121.209 -0.932 . . . . 0.0 111.84 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -54.9 134.24 47.72 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 121.004 -1.06 . . . . 0.0 111.126 -179.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -100.03 -6.86 25.79 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 122.003 -0.704 . . . . 0.0 110.066 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.4 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.5 ttm -60.3 -35.47 75.67 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.258 -0.901 . . . . 0.0 110.088 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.75 -73.74 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.706 -0.622 . . . . 0.0 111.733 -177.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -69.93 -40.04 75.76 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.345 -0.847 . . . . 0.0 110.241 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.416 ' CD2' HG21 ' A' ' 37' ' ' VAL . 75.5 m-85 -119.81 91.25 44.93 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.53 -11.79 31.91 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.298 1.157 . . . . 0.0 111.579 -178.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.6 m -130.02 143.42 50.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.229 -0.92 . . . . 0.0 110.489 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.4 tp -67.91 119.99 13.46 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.781 -0.574 . . . . 0.0 110.117 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.8 32.53 0.05 OUTLIER Glycine 0 N--CA 1.495 2.623 0 C-N-CA 120.008 -1.092 . . . . 0.0 110.56 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 15.1 mt-10 -155.34 -46.42 0.08 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.312 -1.11 . . . . 0.0 110.14 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.416 HG21 ' CD2' ' A' ' 31' ' ' TYR . 2.9 t -61.84 -59.61 12.74 Favored Pre-proline 0 N--CA 1.496 1.844 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.408 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -76.23 -29.27 6.51 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 N-CA-C 109.184 -1.121 . . . . 0.0 109.184 177.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.5 -60.73 0.66 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 107.433 -2.267 . . . . 0.0 107.433 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.587 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 4.5 t80 162.41 -52.5 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.705 0 C-N-CA 123.595 0.758 . . . . 0.0 109.95 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.07 19.04 0.23 Allowed 'Trans proline' 0 C--N 1.322 -0.819 0 C-N-CA 121.392 1.395 . . . . 0.0 111.347 -178.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.8 m-20 -131.81 49.87 2.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.292 -0.88 . . . . 0.0 110.236 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.4 p -125.97 139.57 51.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-O 121.598 0.713 . . . . 0.0 109.961 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 84' ' ' ASN . . . -169.4 174.28 43.77 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.28 159.28 32.22 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.422 HG21 ' CE1' ' A' ' 83' ' ' PHE . 1.4 pt -149.98 158.09 37.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.662 -0.905 . . . . 0.0 110.634 179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.22 -13.22 35.65 Favored 'Trans proline' 0 N--CA 1.499 1.811 0 C-N-CA 121.419 1.413 . . . . 0.0 114.328 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -94.9 22.23 6.72 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 120.563 -1.336 . . . . 0.0 112.819 -177.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.434 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 49.5 mm -113.12 129.59 68.55 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.073 -1.017 . . . . 0.0 108.52 178.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.73 12.34 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.395 -0.816 . . . . 0.0 112.229 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 170.64 -129.56 1.83 Allowed Glycine 0 N--CA 1.489 2.227 0 C-N-CA 118.813 -1.66 . . . . 0.0 111.139 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.406 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 44.7 t90 -52.1 -22.35 4.09 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.962 -0.728 . . . . 0.0 112.601 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -149.44 65.75 1.01 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.042 -1.036 . . . . 0.0 110.933 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.411 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.0 p -63.47 135.01 96.07 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.548 -0.72 . . . . 0.0 110.855 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.58 -20.76 23.03 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.333 1.175 . . . . 0.0 110.692 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 13.7 m -98.1 11.53 37.39 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.489 -0.757 . . . . 0.0 111.116 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -65.98 145.29 56.07 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.176 -0.953 . . . . 0.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.24 29.21 34.26 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 16.8 p -101.6 147.69 26.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.532 -0.981 . . . . 0.0 110.548 179.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 53.6 t -97.73 126.96 43.35 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.655 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.483 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 97.5 m95 -131.04 147.67 52.65 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.344 -0.848 . . . . 0.0 110.709 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.7 tttp -109.06 130.7 55.48 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.5 t -110.78 122.56 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.561 -0.712 . . . . 0.0 110.298 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.4 m -121.47 138.73 54.16 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.662 -0.649 . . . . 0.0 110.842 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 11.1 pt -113.59 165.54 13.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.631 -0.668 . . . . 0.0 110.777 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.43 -24.88 75.8 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 121.361 1.374 . . . . 0.0 112.825 -178.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -65.32 -39.87 93.01 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.223 -0.923 . . . . 0.0 109.99 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.19 60.07 0.28 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -160.33 152.18 20.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.669 -0.901 . . . . 0.0 108.887 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.0 p -153.75 158.9 41.65 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.047 -1.061 . . . . 0.0 112.373 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.0 pt -139.92 163.38 24.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -104.2 129.15 51.97 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.958 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.0 130.01 71.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.733 -0.604 . . . . 0.0 109.55 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 67.2 ttt180 -100.39 136.28 40.52 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.296 -0.878 . . . . 0.0 109.299 -179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -56.75 146.73 34.38 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -178.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.406 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 5.4 p -158.26 -42.51 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.816 -0.814 . . . . 0.0 109.461 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.406 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 16.9 t70 -130.43 168.94 16.17 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.225 -0.922 . . . . 0.0 109.522 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.434 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 58.6 p -97.44 160.66 14.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.515 -0.74 . . . . 0.0 111.637 -179.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.03 149.37 19.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 65.0 mtt180 -61.88 -33.09 73.59 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.66 -0.906 . . . . 0.0 110.928 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.43 81.57 0.05 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.3 149.99 5.39 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.897 -1.144 . . . . 0.0 110.351 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.422 ' CE1' HG21 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -65.78 136.37 56.12 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.968 -0.725 . . . . 0.0 110.388 179.503 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 56.9 t-20 -134.93 124.23 24.63 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.143 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.9 m -133.81 176.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.133 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.9 m-20 -57.65 154.49 25.34 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.675 -0.64 . . . . 0.0 110.253 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.53 -26.86 46.66 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.468 1.246 . . . . 0.0 110.604 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.0 -40.54 75.23 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.919 -1.113 . . . . 0.0 108.632 178.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.88 -39.92 87.65 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -60.01 -50.06 75.21 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.85 -0.531 . . . . 0.0 110.474 179.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.5 m -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.424 -0.798 . . . . 0.0 110.538 -178.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -69.4 -40.08 77.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.79 -0.764 . . . . 0.0 111.493 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 40.6 tp -71.49 -43.02 67.32 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.525 -0.734 . . . . 0.0 111.504 -178.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.5 t -96.26 -39.63 9.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.309 -0.87 . . . . 0.0 111.492 -177.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.79 7.42 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.3 p -144.78 157.95 43.98 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.453 -1.027 . . . . 0.0 110.117 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.53 15.77 28.14 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.422 -0.799 . . . . 0.0 110.574 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -93.35 -15.0 26.2 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.452 -0.78 . . . . 0.0 110.761 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.93 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.231 -0.918 . . . . 0.0 110.405 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 86.82 -77.01 2.03 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 61.6 ttt180 -137.82 135.62 36.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.595 -0.944 . . . . 0.0 110.376 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 56.3 t -120.05 119.24 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.421 -0.799 . . . . 0.0 109.477 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.0 p-10 -85.18 177.05 8.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.792 0.806 . . . . 0.0 112.078 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 60.06 40.0 19.09 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.919 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 86.3 t -95.41 123.27 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.231 179.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -84.5 146.72 27.44 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.762 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 52.2 p90 -142.14 148.74 38.79 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.923 -0.486 . . . . 0.0 110.907 -178.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.4 m -149.93 144.91 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 O-C-N 121.348 -0.845 . . . . 0.0 111.782 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.483 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 55.1 tt0 -70.01 140.99 52.98 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.707 -0.62 . . . . 0.0 109.886 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.95 172.78 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.992 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -59.86 145.51 45.36 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.382 -0.824 . . . . 0.0 110.862 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -59.99 -40.09 87.94 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.378 -0.826 . . . . 0.0 110.201 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 70.6 m -54.92 -37.9 66.96 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.627 -0.671 . . . . 0.0 109.847 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -59.98 -39.99 87.56 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.56 -0.712 . . . . 0.0 110.059 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.8 m -64.04 -45.35 89.27 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.489 -0.757 . . . . 0.0 109.225 178.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.2 mm -62.89 -45.72 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.259 0.552 . . . . 0.0 110.137 -178.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -66.53 -40.01 88.9 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.796 -0.565 . . . . 0.0 110.553 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.78 -42.93 99.81 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.56 -40.0 94.77 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.574 -0.957 . . . . 0.0 110.535 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 33.6 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.306 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 120.982 0.42 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.4 t -112.96 139.94 48.18 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.695 . . . . 0.0 110.44 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.9 pt -107.71 145.68 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.688 -0.632 . . . . 0.0 110.693 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.9 m -144.33 -174.25 4.25 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.412 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 45.8 p90 -141.29 147.36 38.06 Favored 'General case' 0 N--CA 1.492 1.671 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.043 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -124.81 145.18 48.96 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.504 -0.747 . . . . 0.0 109.169 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -82.51 -10.08 11.03 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.274 1.144 . . . . 0.0 112.733 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.448 HG13 ' N ' ' A' ' 9' ' ' TYR . 48.9 pt -70.03 -40.04 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 120.947 -1.096 . . . . 0.0 111.37 -179.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.448 ' N ' HG13 ' A' ' 8' ' ' ILE . 42.6 m-85 -73.11 67.34 0.9 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 122.874 1.321 . . . . 0.0 111.698 -178.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.91 173.86 6.12 Favored 'General case' 0 N--CA 1.489 1.505 0 CA-C-N 114.401 -1.272 . . . . 0.0 108.107 176.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.71 -30.35 63.4 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -175.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -89.99 11.55 20.23 Favored 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 118.237 -1.385 . . . . 0.0 112.262 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -67.51 119.78 12.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.295 -0.878 . . . . 0.0 109.878 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.5 m -70.11 137.01 50.78 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.759 0.79 . . . . 0.0 110.007 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 95.4 mmm -64.24 -21.87 66.74 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.885 -0.51 . . . . 0.0 111.634 -179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.32 -16.07 77.13 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 121.065 -1.022 . . . . 0.0 111.514 -178.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.4 m -90.0 -4.71 57.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.121 -1.223 . . . . 0.0 111.923 -178.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.9 p -101.04 168.64 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.959 -1.088 . . . . 0.0 110.618 -179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.73 94.87 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.476 -0.765 . . . . 0.0 110.005 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.5 m -80.47 71.98 7.33 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.85 -76.96 0.51 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.507 -0.746 . . . . 0.0 109.952 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -127.84 168.55 15.02 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.648 -0.658 . . . . 0.0 109.584 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.21 -154.95 16.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 -178.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -70.72 -42.77 70.15 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -1.109 . . . . 0.0 110.186 179.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.417 ' CD2' ' O ' ' A' ' 54' ' ' SER . 54.7 m-70 -92.61 3.35 55.73 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.412 -0.805 . . . . 0.0 110.836 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.05 129.74 48.07 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.8 mt -99.71 -3.12 33.64 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 122.039 -0.683 . . . . 0.0 110.21 179.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.8 tpp -60.01 -38.59 83.11 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.336 -0.853 . . . . 0.0 110.365 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.77 -75.05 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.68 -0.637 . . . . 0.0 112.195 -177.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -70.05 -41.17 74.56 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.325 -0.86 . . . . 0.0 111.446 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.433 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 97.6 m-85 -122.84 86.4 50.21 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.648 -0.657 . . . . 0.0 110.474 -178.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.06 -7.42 21.36 Favored 'Trans proline' 0 C--N 1.317 -1.099 0 O-C-N 123.387 1.203 . . . . 0.0 111.475 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.3 m -130.02 142.98 50.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.05 -1.031 . . . . 0.0 110.189 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 39.6 tp -75.4 117.83 17.62 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.78 -0.575 . . . . 0.0 110.644 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.05 30.29 0.05 OUTLIER Glycine 0 N--CA 1.496 2.676 0 C-N-CA 120.092 -1.052 . . . . 0.0 110.812 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.416 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 8.9 mt-10 -153.66 -52.79 0.1 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.218 -1.166 . . . . 0.0 110.336 179.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.433 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 2.6 t -60.65 -59.63 13.24 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.419 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 45.7 Cg_endo -73.36 -32.45 8.09 Favored 'Trans proline' 0 N--CA 1.486 1.068 0 N-CA-C 109.114 -1.148 . . . . 0.0 109.114 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.81 -64.35 0.61 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 107.739 -2.144 . . . . 0.0 107.739 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.59 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 162.75 -55.8 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.787 0 C-N-CA 123.477 0.711 . . . . 0.0 110.627 177.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.59 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -101.07 13.09 0.44 Allowed 'Trans proline' 0 N--CA 1.48 0.715 0 C-N-CA 121.348 1.365 . . . . 0.0 111.522 -178.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -122.21 45.76 2.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.223 -179.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -126.78 141.06 47.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.832 0.825 . . . . 0.0 110.19 -179.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.84 173.3 43.4 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.26 159.23 30.85 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.468 ' CG2' ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -153.38 160.18 31.25 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.581 -0.952 . . . . 0.0 109.493 179.564 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.14 -37.67 31.26 Favored 'Trans proline' 0 N--CA 1.505 2.184 0 C-N-CA 121.831 1.687 . . . . 0.0 116.125 -175.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -69.7 -9.95 56.4 Favored 'General case' 0 N--CA 1.509 2.493 0 O-C-N 120.561 -1.337 . . . . 0.0 112.974 -176.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.431 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 44.4 mm -77.04 125.04 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 O-C-N 120.713 -1.242 . . . . 0.0 108.527 178.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.18 -46.78 12.31 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.261 -0.899 . . . . 0.0 112.568 -178.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 171.94 -137.5 4.33 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.716 -1.707 . . . . 0.0 111.54 -179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 58.2 t90 -42.88 -29.62 0.34 Allowed 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -144.98 62.27 1.31 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 110.508 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.417 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 12.5 p -61.82 139.31 95.55 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.651 -0.656 . . . . 0.0 110.651 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -76.17 -21.36 13.81 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 O-C-N 123.373 1.196 . . . . 0.0 111.113 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.7 m -94.05 14.49 19.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.491 -0.755 . . . . 0.0 111.296 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.3 t -73.85 147.89 42.86 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.16 35.31 53.51 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 89.2 m -119.68 131.55 55.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.595 -0.944 . . . . 0.0 109.882 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.04 145.66 33.73 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.871 -177.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.438 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -149.83 149.34 30.35 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.684 -0.635 . . . . 0.0 110.124 178.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -112.16 135.55 52.67 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.6 t -108.77 126.77 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.8 m -119.22 140.39 50.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.964 -0.46 . . . . 0.0 110.834 -178.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.431 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 39.3 pt -119.16 164.2 22.58 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.616 -0.677 . . . . 0.0 110.531 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.431 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.1 -24.41 79.28 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 121.273 1.315 . . . . 0.0 112.338 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -63.89 -40.02 95.54 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.272 -0.892 . . . . 0.0 109.58 179.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.95 62.57 0.41 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 48.6 t-20 -162.01 153.45 18.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.708 -0.878 . . . . 0.0 108.975 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.4 p -154.64 160.96 41.75 Favored 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 119.261 -0.975 . . . . 0.0 112.329 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.0 pt -136.35 164.44 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -108.65 126.75 53.31 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.16 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 88.0 mt -129.99 140.0 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.254 -0.904 . . . . 0.0 111.454 -178.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . 0.406 ' CD ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -100.87 144.35 29.94 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.868 -0.52 . . . . 0.0 109.654 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.408 ' HA2' HD12 ' A' ' 46' ' ' ILE . . . -62.54 151.06 46.93 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -179.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.409 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 2.7 p -155.73 -44.1 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 178.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.409 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 14.9 t70 -130.3 170.0 14.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 178.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.431 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.7 t -101.48 159.94 14.86 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.775 . . . . 0.0 111.318 -179.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -130.13 154.32 20.5 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.1 mtt180 -59.97 -31.56 70.01 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.555 -0.967 . . . . 0.0 110.403 179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.17 81.73 0.05 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 119.979 -1.105 . . . . 0.0 110.571 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.06 163.9 11.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.161 -1.176 . . . . 0.0 110.161 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.468 ' CD2' ' CG2' ' A' ' 46' ' ' ILE . 28.0 m-85 -88.36 118.63 28.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.512 -0.993 . . . . 0.0 109.746 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 54.6 t-20 -113.04 128.71 56.57 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.418 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.5 m -130.02 172.56 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 120.862 -1.149 . . . . 0.0 112.008 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 -56.52 156.22 12.26 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.504 -0.748 . . . . 0.0 109.594 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.44 -28.49 54.11 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.276 1.145 . . . . 0.0 110.663 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -70.28 -40.63 74.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.99 -1.069 . . . . 0.0 109.382 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.65 89.2 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -60.02 -49.84 76.08 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.826 -0.546 . . . . 0.0 110.311 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.9 m -60.11 -39.98 88.11 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.586 -0.696 . . . . 0.0 110.754 -178.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -68.67 -39.98 80.35 Favored 'General case' 0 N--CA 1.495 1.813 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.172 -178.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 63.1 tp -70.27 -42.9 71.52 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.627 -0.67 . . . . 0.0 111.749 -178.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 92.7 t -97.05 -39.93 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.312 -0.868 . . . . 0.0 111.829 -177.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.07 -25.75 7.36 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 80.9 p -149.93 161.03 43.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.351 -1.088 . . . . 0.0 110.317 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 77.4 p -99.1 1.87 45.54 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.477 -0.765 . . . . 0.0 111.298 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -69.96 -28.65 65.73 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.388 -0.82 . . . . 0.0 111.466 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.82 -40.63 89.06 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.396 -0.815 . . . . 0.0 111.272 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 89.42 -66.26 2.98 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -151.23 155.99 39.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.486 -1.008 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.97 117.65 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.551 -0.718 . . . . 0.0 109.785 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -80.62 169.51 17.55 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.474 -0.766 . . . . 0.0 110.427 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 60.0 51.81 5.62 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.628 -0.67 . . . . 0.0 111.347 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 65.8 t -98.66 129.99 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.434 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -89.04 138.68 31.19 Favored 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.804 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -133.3 140.98 47.75 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.907 -0.496 . . . . 0.0 110.557 -179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.03 143.0 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.589 -0.694 . . . . 0.0 111.242 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.438 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.2 tt0 -70.88 139.78 50.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.681 -0.637 . . . . 0.0 110.444 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.07 163.27 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.098 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -59.62 141.38 55.12 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.543 -0.723 . . . . 0.0 110.478 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.0 -40.0 87.7 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.598 -0.689 . . . . 0.0 111.391 -179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 78.6 p -55.72 -34.23 64.95 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.503 -0.748 . . . . 0.0 110.935 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -69.92 -28.08 65.31 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.348 -0.845 . . . . 0.0 111.339 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 97.3 m -69.96 -46.45 65.22 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.23 -0.919 . . . . 0.0 109.179 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 89.2 mt -69.96 -40.01 78.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.143 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -64.56 -40.0 94.78 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.459 -0.776 . . . . 0.0 110.618 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -83.81 -60.01 2.02 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.454 -0.879 . . . . 0.0 110.93 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.04 -42.52 94.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.611 -0.934 . . . . 0.0 111.202 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.502 2.172 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.727 -179.711 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.694 0.759 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.9 p -111.81 138.94 47.73 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.9 pt -108.78 145.36 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.801 -0.562 . . . . 0.0 110.481 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.4 p -144.22 -173.32 3.98 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.426 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 39.4 p90 -140.02 141.24 36.32 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.456 -0.777 . . . . 0.0 110.696 179.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.14 150.07 50.55 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.483 -0.761 . . . . 0.0 109.284 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -82.83 -10.53 10.51 Favored 'Trans proline' 0 C--N 1.318 -1.067 0 O-C-N 123.105 1.055 . . . . 0.0 112.551 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.465 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.9 pt -70.06 -39.96 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.002 -1.061 . . . . 0.0 111.62 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.465 ' N ' HG13 ' A' ' 8' ' ' ILE . 53.7 m-85 -73.2 67.51 0.95 Allowed 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 122.875 1.321 . . . . 0.0 111.907 -178.32 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.8 169.65 8.36 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.854 176.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.87 -35.09 70.48 Favored 'General case' 0 N--CA 1.497 1.912 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -90.23 10.39 24.86 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 120.497 -1.377 . . . . 0.0 112.295 -177.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.8 tp -68.49 123.45 20.85 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -0.865 . . . . 0.0 109.829 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.3 m -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.806 -0.758 . . . . 0.0 109.775 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 86.6 mtp -69.96 -15.28 63.02 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.91 -0.494 . . . . 0.0 111.864 -178.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.58 -15.95 73.59 Favored Glycine 0 N--CA 1.496 2.654 0 O-C-N 121.021 -1.049 . . . . 0.0 110.816 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.5 m -90.05 -4.99 57.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.175 -1.191 . . . . 0.0 111.716 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 14.8 p -102.26 168.96 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.026 -1.046 . . . . 0.0 110.877 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -59.92 -40.7 89.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.575 -0.703 . . . . 0.0 110.368 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 54.1 m -83.45 74.84 10.05 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.2 m -100.41 -77.04 0.54 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.385 -0.822 . . . . 0.0 110.388 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -129.68 169.98 14.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 0.0 110.485 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.46 -154.4 16.45 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -70.2 -40.94 74.3 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -1.073 . . . . 0.0 109.791 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.406 ' CD2' ' O ' ' A' ' 54' ' ' SER . 44.0 m-70 -91.82 0.59 57.48 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.519 -0.738 . . . . 0.0 110.982 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -52.42 126.07 30.33 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.2 mt -96.53 -9.42 29.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 122.032 -0.687 . . . . 0.0 110.128 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.5 tpp -59.95 -37.03 78.39 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.35 -0.844 . . . . 0.0 110.006 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -74.37 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.513 -0.742 . . . . 0.0 111.983 -178.087 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -69.98 -39.99 75.6 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.237 -0.915 . . . . 0.0 110.455 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.433 ' CD2' HG22 ' A' ' 37' ' ' VAL . 87.3 m-85 -117.39 100.95 52.99 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.04 -20.92 16.31 Favored 'Trans proline' 0 C--N 1.318 -1.046 0 O-C-N 123.307 1.161 . . . . 0.0 111.367 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 30.2 m -127.84 148.32 50.46 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.371 -0.831 . . . . 0.0 111.017 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.7 tp -67.13 120.44 13.72 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.784 -0.573 . . . . 0.0 110.374 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 150.46 30.02 0.05 OUTLIER Glycine 0 N--CA 1.495 2.603 0 C-N-CA 119.891 -1.147 . . . . 0.0 110.963 179.49 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.415 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 31.7 mt-10 -153.18 -48.67 0.1 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.226 -1.161 . . . . 0.0 110.325 179.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.433 HG22 ' CD2' ' A' ' 31' ' ' TYR . 3.2 t -60.55 -60.48 10.5 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.411 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -75.67 -27.57 8.86 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.113 1.059 . . . . 0.0 109.466 177.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.406 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.27 -58.93 0.67 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.414 -2.274 . . . . 0.0 107.414 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.49 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 165.89 -73.57 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.615 0 C-N-CA 123.666 0.786 . . . . 0.0 109.356 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.49 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -86.21 19.19 1.43 Allowed 'Trans proline' 0 N--CA 1.493 1.465 0 CA-C-N 119.306 0.788 . . . . 0.0 111.16 178.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -118.37 37.03 4.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.059 -1.026 . . . . 0.0 110.18 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.4 p -120.71 141.23 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-O 121.757 0.789 . . . . 0.0 110.716 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.99 171.38 42.92 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.08 152.24 32.63 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.452 HG23 ' CE1' ' A' ' 83' ' ' PHE . 13.7 pt -141.88 156.81 65.41 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.665 -0.903 . . . . 0.0 109.742 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.3 -20.5 36.93 Favored 'Trans proline' 0 N--CA 1.499 1.841 0 C-N-CA 121.399 1.4 . . . . 0.0 113.966 -177.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -88.92 20.68 3.44 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.805 -1.184 . . . . 0.0 112.541 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.423 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 40.7 mt -120.02 120.0 61.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.074 -1.016 . . . . 0.0 108.398 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.48 -41.82 21.19 Favored 'General case' 0 N--CA 1.499 2.015 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -176.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 174.83 -138.96 4.6 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 118.323 -1.894 . . . . 0.0 112.171 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 26.3 t90 -39.95 -30.06 0.08 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -146.72 68.52 1.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.998 -1.064 . . . . 0.0 111.24 -178.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.406 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 2.1 t -64.51 136.87 96.94 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.622 -0.674 . . . . 0.0 110.586 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.29 -20.55 21.06 Favored 'Trans proline' 0 C--N 1.32 -0.968 0 O-C-N 123.303 1.159 . . . . 0.0 110.605 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.9 m -99.84 14.82 29.03 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.499 -0.751 . . . . 0.0 110.806 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 23.4 t -72.75 151.12 42.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.238 -0.913 . . . . 0.0 110.061 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.18 21.75 78.62 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 80.4 m -106.58 140.01 40.13 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.515 -0.991 . . . . 0.0 110.277 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 42.3 t -78.59 136.21 37.46 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.687 -178.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.436 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -137.21 146.24 44.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.647 -0.658 . . . . 0.0 110.016 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -116.28 136.46 52.98 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.222 -0.924 . . . . 0.0 110.099 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -114.25 129.99 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.543 -0.723 . . . . 0.0 110.887 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 51.1 m -119.92 144.96 47.16 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.723 -0.611 . . . . 0.0 110.501 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.433 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.6 pt -123.44 164.33 28.85 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.307 -0.871 . . . . 0.0 111.11 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.433 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.28 -26.88 82.53 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.428 1.419 . . . . 0.0 112.574 -178.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -63.45 -39.71 95.2 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.317 -0.864 . . . . 0.0 109.741 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 115.26 61.65 0.37 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -160.6 153.29 20.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.832 -0.805 . . . . 0.0 109.077 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 84.0 p -150.65 158.49 44.21 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 122.18 0.99 . . . . 0.0 112.021 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 27.6 pt -138.7 162.77 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.27 123.83 48.89 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 118.859 -1.136 . . . . 0.0 109.794 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.422 HD11 HG22 ' A' ' 73' ' ' ILE . 48.5 mm -117.13 131.99 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -98.65 132.38 44.1 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.152 -0.968 . . . . 0.0 108.783 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.89 148.35 10.44 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.6 p -159.96 -35.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.792 -0.828 . . . . 0.0 110.406 179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -128.94 165.28 21.38 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.885 -1.134 . . . . 0.0 110.449 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.423 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 79.4 p -82.54 159.78 22.73 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.656 -0.653 . . . . 0.0 110.521 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -127.49 135.4 8.73 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -65.44 -39.95 92.67 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.923 -0.751 . . . . 0.0 109.608 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 176.29 70.28 0.05 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.46 -163.18 33.35 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.59 -1.29 . . . . 0.0 110.766 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.452 ' CE1' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -123.34 136.61 54.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 122.025 -0.691 . . . . 0.0 109.415 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -137.97 126.89 24.02 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.389 -0.925 . . . . 0.0 108.808 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.8 m -133.63 176.8 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.08 -1.012 . . . . 0.0 111.128 -178.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.3 m-20 -56.47 150.25 35.17 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.91 -25.68 67.11 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 O-C-N 123.367 1.193 . . . . 0.0 110.763 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.8 m -70.8 -40.03 72.77 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.976 -1.078 . . . . 0.0 109.308 178.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.03 91.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.04 -49.93 75.74 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.868 -0.52 . . . . 0.0 110.586 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.1 m -60.11 -39.94 87.98 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.439 -0.788 . . . . 0.0 110.606 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.8 mtmt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.273 -179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 45.9 tp -71.6 -46.12 60.16 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 120.047 -0.661 . . . . 0.0 111.357 -178.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.1 t -89.46 -41.39 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.4 -0.812 . . . . 0.0 111.334 -177.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 125.2 -27.25 5.37 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.7 p -158.85 162.32 36.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.551 -0.97 . . . . 0.0 110.024 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.9 p -91.97 1.57 57.1 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.478 -0.764 . . . . 0.0 111.372 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.66 -34.08 77.05 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.36 -41.5 80.25 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.45 -0.781 . . . . 0.0 111.456 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.41 -80.47 1.82 Allowed Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.3 ttm180 -129.0 136.82 50.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.575 -0.956 . . . . 0.0 109.918 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.6 t -119.02 117.29 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.243 -0.91 . . . . 0.0 110.299 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -83.84 171.57 12.98 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.525 0.679 . . . . 0.0 110.65 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.52 52.0 1.87 Allowed 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.623 -0.673 . . . . 0.0 111.06 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.4 t -103.24 129.81 54.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 C-N-CA 119.279 -0.968 . . . . 0.0 110.607 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -90.64 137.92 31.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.309 -0.87 . . . . 0.0 109.6 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 53.8 p90 -140.04 145.83 38.24 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.902 -0.499 . . . . 0.0 110.835 -178.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 29.6 m -151.1 151.58 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.216 -0.928 . . . . 0.0 111.273 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.436 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.0 tt0 -72.37 141.05 48.75 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.682 -0.636 . . . . 0.0 110.47 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 15.7 m -137.03 170.03 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -64.21 148.85 49.14 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.175 -0.953 . . . . 0.0 110.645 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -60.08 -39.77 87.21 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.495 -0.753 . . . . 0.0 110.84 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 89.3 p -52.24 -37.41 55.13 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.413 -0.805 . . . . 0.0 110.614 -178.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.31 -39.27 93.57 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.583 -0.698 . . . . 0.0 111.089 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -59.97 -50.02 75.4 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.394 -0.816 . . . . 0.0 110.064 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 86.9 mt -69.84 -39.98 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.715 -0.616 . . . . 0.0 110.773 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -39.98 96.24 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.39 -0.819 . . . . 0.0 110.521 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -72.66 -47.32 27.41 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.174 -1.171 . . . . 0.0 110.174 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.99 -40.78 90.33 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.502 -0.999 . . . . 0.0 110.707 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.5 t30 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.276 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.013 0.435 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.2 t -113.68 139.19 49.27 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.672 0.749 . . . . 0.0 111.045 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 36.3 pt -111.02 147.65 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.83 -0.544 . . . . 0.0 109.797 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.1 m -146.09 -171.52 3.73 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -140.12 150.01 43.75 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.119 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -126.67 148.07 63.33 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.521 -0.737 . . . . 0.0 110.216 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -86.57 14.14 2.53 Favored 'Trans proline' 0 C--N 1.317 -1.09 0 O-C-N 123.399 1.21 . . . . 0.0 111.636 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.405 HD12 ' CZ ' ' A' ' 9' ' ' TYR . 1.4 pt -100.1 10.06 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.029 -1.044 . . . . 0.0 111.666 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.405 ' CZ ' HD12 ' A' ' 8' ' ' ILE . 21.9 m-85 -123.46 66.64 1.0 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.701 1.239 . . . . 0.0 110.259 178.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.07 172.76 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.459 -1.246 . . . . 0.0 108.447 176.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.03 -31.97 67.51 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -175.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -89.76 11.98 18.44 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.332 -1.347 . . . . 0.0 111.9 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.3 119.56 13.77 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.281 -0.887 . . . . 0.0 110.043 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 52.6 m -69.18 135.85 51.24 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.757 -0.777 . . . . 0.0 108.958 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 57.1 mtp -70.21 -14.59 62.69 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 120.211 -0.596 . . . . 0.0 111.926 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.65 -18.61 74.08 Favored Glycine 0 N--CA 1.495 2.6 0 O-C-N 120.848 -1.157 . . . . 0.0 110.654 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 70.4 m -88.06 -9.64 52.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.289 -1.124 . . . . 0.0 111.615 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 p -101.74 169.66 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.029 -1.044 . . . . 0.0 110.495 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -59.14 -39.76 83.39 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.568 -0.708 . . . . 0.0 110.594 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.31 82.84 3.08 Favored 'General case' 0 N--CA 1.5 2.025 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 -84.26 0.42 Allowed 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.794 -1.191 . . . . 0.0 113.395 -177.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -143.8 12.56 1.67 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.564 -1.335 . . . . 0.0 112.752 -177.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.89 -149.19 0.11 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -67.22 -39.89 86.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.891 -0.77 . . . . 0.0 110.456 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.563 ' NE2' ' N ' ' A' ' 54' ' ' SER . 11.8 p80 -97.86 6.2 48.08 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.31 138.79 35.53 Favored Glycine 0 N--CA 1.5 2.91 0 O-C-N 121.055 -1.028 . . . . 0.0 110.659 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -102.31 -5.68 23.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.885 -0.774 . . . . 0.0 110.724 179.262 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.8 ttm -60.44 -33.1 72.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.23 -0.919 . . . . 0.0 110.486 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.79 -72.15 0.06 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.566 -0.709 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -70.0 -40.16 75.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.185 -0.947 . . . . 0.0 110.079 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.414 ' CD2' HG23 ' A' ' 37' ' ' VAL . 60.8 m-85 -122.86 95.16 46.66 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.875 -0.516 . . . . 0.0 109.769 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.63 -19.32 32.13 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 O-C-N 123.398 1.209 . . . . 0.0 111.556 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.7 m -122.61 140.9 52.3 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.296 -0.878 . . . . 0.0 110.736 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.7 tp -61.65 119.91 9.59 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.912 -0.492 . . . . 0.0 110.317 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.77 33.36 0.04 OUTLIER Glycine 0 N--CA 1.496 2.679 0 C-N-CA 119.948 -1.12 . . . . 0.0 110.797 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.66 -45.98 0.06 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.195 -1.179 . . . . 0.0 110.013 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.419 ' CB ' ' CD ' ' A' ' 38' ' ' PRO . 3.2 t -62.69 -60.78 8.93 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 178.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.419 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 50.2 Cg_endo -75.97 -28.15 7.88 Favored 'Trans proline' 0 N--CA 1.485 1.028 0 N-CA-C 109.236 -1.102 . . . . 0.0 109.236 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.402 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.98 -60.93 0.65 Allowed Glycine 0 N--CA 1.486 2.019 0 N-CA-C 107.284 -2.326 . . . . 0.0 107.284 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.59 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.2 t80 164.04 -52.9 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.573 0 C-N-CA 123.381 0.672 . . . . 0.0 109.705 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.59 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.4 Cg_endo -101.78 13.94 0.37 Allowed 'Trans proline' 0 C--N 1.324 -0.742 0 C-N-CA 121.457 1.438 . . . . 0.0 111.486 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -123.46 40.73 3.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -0.928 . . . . 0.0 110.112 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.2 p -115.44 135.74 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 CA-C-O 121.602 0.715 . . . . 0.0 110.681 -179.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -163.94 170.0 39.06 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -90.37 164.82 30.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.421 ' HB ' ' HD2' ' A' ' 47' ' ' PRO . 5.2 pt -150.92 163.47 23.64 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.74 -0.859 . . . . 0.0 110.12 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 55.6 Cg_endo -73.69 -15.05 24.41 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 121.43 1.42 . . . . 0.0 113.337 -177.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 79.5 m-20 -90.37 12.7 17.58 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.852 -1.155 . . . . 0.0 112.829 -177.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.405 ' CD1' ' CG1' ' A' ' 46' ' ' ILE . 71.9 mt -110.8 129.92 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.068 -1.02 . . . . 0.0 110.18 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.41 -46.45 12.52 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.537 -0.727 . . . . 0.0 112.159 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 164.76 -138.91 5.52 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.895 -1.621 . . . . 0.0 111.371 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.426 ' CE3' ' HB2' ' A' ' 53' ' ' ASP . 71.0 t90 -39.81 -28.78 0.05 Allowed 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -179.005 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.522 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 24.6 t70 -141.09 63.96 1.43 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.281 -0.887 . . . . 0.0 110.576 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.563 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 4.8 t -79.86 139.35 53.83 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.696 -0.627 . . . . 0.0 110.414 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -78.4 -16.63 13.45 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.331 1.174 . . . . 0.0 111.45 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.0 p -98.05 4.84 49.21 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.208 -0.932 . . . . 0.0 112.607 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.59 140.36 58.14 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.738 -1.226 . . . . 0.0 109.73 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.97 -7.93 80.75 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 120.332 -0.937 . . . . 0.0 110.871 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.4 m -69.42 149.84 47.91 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.117 -1.225 . . . . 0.0 109.514 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.6 130.58 45.14 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.987 -0.446 . . . . 0.0 111.341 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -128.15 140.27 52.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.483 -0.761 . . . . 0.0 109.2 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -103.16 132.68 49.24 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 64.9 t -110.02 124.56 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.621 -0.674 . . . . 0.0 110.499 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.5 m -118.66 135.79 54.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.913 -0.492 . . . . 0.0 110.633 -178.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.428 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.9 pt -115.66 163.58 20.31 Favored Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.461 -0.775 . . . . 0.0 110.723 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.428 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.65 -27.29 76.0 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 121.411 1.407 . . . . 0.0 113.15 -178.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -62.62 -40.0 95.59 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.132 -0.98 . . . . 0.0 109.582 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.9 60.06 0.29 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -155.05 151.11 27.99 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 89.6 p -149.83 153.34 36.6 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.029 0.919 . . . . 0.0 111.747 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.6 pt -139.14 163.09 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -105.51 129.42 53.8 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.871 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 73' ' ' ILE . 48.9 mm -116.09 128.18 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.662 -0.649 . . . . 0.0 109.614 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 60.3 ttt180 -100.05 137.96 37.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.28 -0.888 . . . . 0.0 108.888 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -53.43 148.21 16.11 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.423 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.2 p -159.92 -43.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.837 -0.802 . . . . 0.0 109.164 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.423 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 22.8 t70 -132.39 165.48 24.17 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.475 -0.766 . . . . 0.0 109.844 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.4 p -107.62 161.59 14.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 110.158 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -145.01 173.57 25.41 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.1 mtm180 -60.28 -40.03 88.99 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.8 -0.824 . . . . 0.0 112.05 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.06 95.39 0.1 OUTLIER Glycine 0 N--CA 1.504 3.182 0 C-N-CA 119.373 -1.394 . . . . 0.0 111.816 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.64 -164.82 29.96 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -123.31 120.24 32.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.625 -0.927 . . . . 0.0 109.241 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -119.09 130.06 55.4 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 27.5 m -130.02 174.68 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.036 0 O-C-N 121.088 -1.007 . . . . 0.0 111.725 -178.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -57.9 156.8 17.52 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.554 -0.716 . . . . 0.0 109.935 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.36 -27.73 47.3 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.471 1.248 . . . . 0.0 110.705 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.03 -40.08 75.38 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.012 -1.055 . . . . 0.0 109.485 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.84 -40.13 87.85 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.03 -49.96 75.6 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.783 -0.573 . . . . 0.0 110.678 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 66.6 m -59.97 -38.7 83.29 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.532 -0.73 . . . . 0.0 110.601 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -68.25 -39.81 82.12 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.883 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 54.6 tp -70.0 -42.73 72.68 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.597 -0.689 . . . . 0.0 111.886 -179.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -98.66 -36.91 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 O-C-N 121.221 -0.925 . . . . 0.0 111.709 -177.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.47 -28.83 6.11 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -151.59 162.68 40.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.993 . . . . 0.0 110.394 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.3 p -100.97 14.05 33.18 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.913 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -70.03 -36.68 75.23 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.421 -0.799 . . . . 0.0 111.012 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.87 -40.04 87.3 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.514 -0.742 . . . . 0.0 110.894 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.13 -65.75 2.52 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 -143.19 151.65 40.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.579 -0.954 . . . . 0.0 110.313 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -121.86 121.41 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.548 -0.72 . . . . 0.0 109.979 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -90.13 172.19 8.99 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.342 -0.849 . . . . 0.0 110.635 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 64.5 t30 60.05 47.93 9.1 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.546 -0.722 . . . . 0.0 110.441 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.6 t -96.68 124.49 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 119.832 -0.747 . . . . 0.0 110.38 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -82.68 139.92 33.41 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 119.253 -0.979 . . . . 0.0 108.741 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 42.3 p90 -135.96 141.86 44.49 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.361 0.601 . . . . 0.0 111.505 -178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.9 m -147.52 145.8 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.769 -0.582 . . . . 0.0 110.847 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -72.08 138.2 47.64 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.635 -0.666 . . . . 0.0 110.069 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.1 m -129.91 162.06 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.738 -0.601 . . . . 0.0 110.3 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -59.65 144.85 46.7 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.483 -0.761 . . . . 0.0 110.301 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.5 tt -60.02 -38.26 82.15 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.658 -0.651 . . . . 0.0 111.108 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.6 m -56.28 -39.11 72.14 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.531 -0.731 . . . . 0.0 110.384 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -59.98 -39.98 87.55 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.429 -0.794 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 76.6 m -61.86 -48.63 79.68 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.364 -0.835 . . . . 0.0 110.718 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 86.3 mt -70.05 -39.99 77.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.653 -0.654 . . . . 0.0 110.668 -178.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.12 -40.03 95.3 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.465 -0.772 . . . . 0.0 110.29 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.88 -47.08 49.44 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -40.26 88.64 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.999 . . . . 0.0 110.5 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.7 t30 . . . . . 0 N--CA 1.502 2.163 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.848 179.791 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.3 m . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 120.876 0.37 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -111.23 141.35 44.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.621 -0.674 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.401 ' O ' ' HA ' ' A' ' 101' ' ' ARG . 42.7 pt -116.1 149.24 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.822 -0.549 . . . . 0.0 110.803 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 m -147.3 -172.1 3.94 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -142.83 147.28 35.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.158 -0.964 . . . . 0.0 110.852 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -135.73 152.96 76.98 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 110.079 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -88.15 37.13 0.43 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.318 1.167 . . . . 0.0 111.031 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.434 HG21 ' CD2' ' A' ' 9' ' ' TYR . 6.0 tp -106.7 -3.46 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.438 -0.789 . . . . 0.0 111.077 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.434 ' CD2' HG21 ' A' ' 8' ' ' ILE . 42.9 m-85 -122.08 76.91 1.34 Allowed 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 122.769 1.271 . . . . 0.0 111.257 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -108.61 169.97 8.32 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.671 177.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.93 -32.69 71.02 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 -176.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -87.99 11.5 15.78 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 120.503 -1.373 . . . . 0.0 112.336 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 40.1 tp -74.61 121.5 21.7 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.2 -0.937 . . . . 0.0 110.227 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.4 m -67.4 138.99 57.12 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.696 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.2 mmm -68.29 -13.7 62.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.73 -0.606 . . . . 0.0 111.797 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -72.32 -14.49 76.95 Favored Glycine 0 N--CA 1.497 2.703 0 O-C-N 120.98 -1.075 . . . . 0.0 111.312 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.3 t -92.84 -14.88 27.14 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.125 -1.22 . . . . 0.0 111.405 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.431 HG23 ' N ' ' A' ' 19' ' ' ALA . 11.9 p -90.05 165.2 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.246 -0.909 . . . . 0.0 111.0 -178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.431 ' N ' HG23 ' A' ' 18' ' ' VAL . . . -56.96 -45.38 82.9 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.573 -0.705 . . . . 0.0 110.347 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.8 m -80.89 80.08 7.44 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.32 -80.42 0.43 Allowed 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.116 -0.99 . . . . 0.0 113.216 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -138.86 10.08 2.62 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.102 -0.999 . . . . 0.0 112.605 -177.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.61 -150.46 0.45 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -65.65 -40.04 92.05 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.67 -0.9 . . . . 0.0 109.867 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.428 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 22.5 m-70 -99.94 8.95 43.69 Favored 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.464 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.19 137.54 49.16 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.5 mt -98.65 -4.05 34.68 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.812 -0.817 . . . . 0.0 110.262 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 54.6 ttm -60.1 -39.55 86.56 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.324 -0.86 . . . . 0.0 110.763 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.83 -75.55 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.443 -0.785 . . . . 0.0 111.723 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -70.06 -40.01 75.32 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.425 -0.797 . . . . 0.0 110.387 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.417 ' CD2' HG21 ' A' ' 37' ' ' VAL . 94.4 m-85 -119.18 89.43 39.54 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.869 -0.519 . . . . 0.0 110.896 -178.081 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.07 -4.71 15.79 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 O-C-N 123.251 1.132 . . . . 0.0 111.073 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 17.5 p -131.41 155.35 47.47 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.147 -0.971 . . . . 0.0 110.219 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 58.2 tp -85.1 113.11 21.25 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.326 -0.55 . . . . 0.0 109.769 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 155.24 33.4 0.03 OUTLIER Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.609 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.401 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 2.6 mt-10 -157.8 -47.77 0.06 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.248 -1.148 . . . . 0.0 109.954 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.425 ' HB ' ' HD3' ' A' ' 38' ' ' PRO . 2.4 t -62.25 -58.0 19.98 Favored Pre-proline 0 N--CA 1.497 1.877 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.425 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.3 Cg_endo -78.66 -31.62 2.46 Favored 'Trans proline' 0 C--N 1.319 -0.995 0 O-C-N 123.282 1.148 . . . . 0.0 109.29 177.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.26 -61.73 0.66 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.568 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 5.3 t80 161.21 -50.85 0.0 OUTLIER Pre-proline 0 N--CA 1.514 2.752 0 C-N-CA 123.664 0.785 . . . . 0.0 110.19 177.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.568 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 50.5 Cg_endo -101.87 18.41 0.25 Allowed 'Trans proline' 0 C--N 1.326 -0.652 0 C-N-CA 121.744 1.629 . . . . 0.0 111.62 -177.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 74.9 m-20 -135.95 55.85 1.85 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.253 -0.904 . . . . 0.0 110.277 -178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -130.32 141.8 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 CA-C-O 121.681 0.753 . . . . 0.0 110.524 -179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -172.27 179.18 44.03 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.78 154.61 27.02 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.319 -1.912 . . . . 0.0 108.319 178.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.454 HG13 HG12 ' A' ' 49' ' ' ILE . 5.7 pt -143.44 160.05 52.74 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.512 -0.993 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -69.07 -17.83 40.51 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.142 1.228 . . . . 0.0 114.033 -177.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -93.65 25.41 3.54 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.71 -1.244 . . . . 0.0 112.387 -178.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.454 HG12 HG13 ' A' ' 46' ' ' ILE . 37.1 mm -119.94 120.1 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.024 -1.047 . . . . 0.0 109.012 178.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.55 -44.12 29.62 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.195 -0.941 . . . . 0.0 111.977 -178.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.26 -141.55 6.87 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.078 -1.534 . . . . 0.0 111.424 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 49.3 t90 -41.49 -29.43 0.16 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -178.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -141.44 57.21 1.52 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.021 -1.049 . . . . 0.0 111.206 -178.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 18.2 m -69.05 144.34 95.39 Favored Pre-proline 0 N--CA 1.493 1.713 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.673 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.428 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.6 Cg_endo -74.15 -14.41 23.3 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.328 1.173 . . . . 0.0 111.619 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 70.3 m -103.43 18.4 21.9 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.385 -0.822 . . . . 0.0 111.735 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.401 ' HB2' ' HB3' ' A' ' 25' ' ' HIS . 3.5 m -69.97 139.94 52.89 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.987 -1.071 . . . . 0.0 109.112 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.33 27.66 57.22 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 97.7 m -106.52 138.15 43.22 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.507 -0.996 . . . . 0.0 110.164 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.405 ' HB2' ' HA ' ' A' ' 112' ' ' LEU . 53.2 t -80.04 131.59 35.81 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.389 0.614 . . . . 0.0 110.889 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.439 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.5 m95 -133.99 152.15 51.74 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.541 -0.724 . . . . 0.0 109.379 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.2 tttm -121.69 138.15 54.46 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 120.933 -1.105 . . . . 0.0 110.583 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -113.7 126.79 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.615 -0.678 . . . . 0.0 111.344 -178.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.9 m -119.54 141.14 49.49 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.742 -0.599 . . . . 0.0 110.48 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.447 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 10.9 pt -119.95 163.93 25.16 Favored Pre-proline 0 N--CA 1.503 2.183 0 O-C-N 121.186 -0.947 . . . . 0.0 110.906 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.9 Cg_endo -62.1 -27.56 79.12 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.564 1.509 . . . . 0.0 113.201 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -62.51 -39.95 95.17 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.244 -0.91 . . . . 0.0 110.045 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.09 60.31 0.31 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -159.92 151.11 19.48 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 86.1 p -151.64 157.77 42.58 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.007 0.908 . . . . 0.0 111.664 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 41.8 pt -137.83 161.65 32.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -102.12 121.29 41.93 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 118.581 -1.248 . . . . 0.0 109.187 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.3 mm -110.78 130.6 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 52.4 ttt180 -99.33 132.82 44.39 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.112 -0.993 . . . . 0.0 109.251 -179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.9 146.67 13.25 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.404 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 7.5 p -169.76 -33.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.863 -0.787 . . . . 0.0 110.323 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.434 ' OD2' ' CZ ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.0 171.89 12.3 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 120.925 -1.11 . . . . 0.0 108.711 179.737 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -98.09 142.43 29.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.669 -0.644 . . . . 0.0 109.791 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -114.5 144.79 18.45 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -89.22 103.4 16.02 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.578 -0.954 . . . . 0.0 110.526 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 50.12 56.98 10.73 Favored Glycine 0 N--CA 1.497 2.765 0 O-C-N 121.681 -0.637 . . . . 0.0 111.724 178.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.6 -163.5 33.59 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.045 -1.55 . . . . 0.0 111.915 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.454 ' CE1' HG23 ' A' ' 46' ' ' ILE 0.263 0.1 OUTLIER -123.25 122.5 38.52 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -178.908 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -124.12 129.91 51.65 Favored 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 118.892 -1.123 . . . . 0.0 109.83 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.3 m -132.31 172.88 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.376 -178.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -54.15 156.79 5.12 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.551 -0.718 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.64 -18.72 32.7 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.477 1.251 . . . . 0.0 110.051 179.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -80.02 -40.97 26.71 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.088 -1.008 . . . . 0.0 108.991 178.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.59 89.24 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -59.99 -50.05 75.26 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.808 -0.557 . . . . 0.0 110.573 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.3 m -59.92 -40.05 87.57 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.929 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -69.0 -40.13 78.89 Favored 'General case' 0 N--CA 1.495 1.803 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.29 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 49.7 tp -71.97 -43.36 65.27 Favored 'General case' 0 N--CA 1.496 1.871 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.478 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -92.34 -40.51 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.462 -0.774 . . . . 0.0 111.54 -177.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 126.63 -34.96 3.03 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 95.2 p -152.69 164.63 37.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.664 -0.903 . . . . 0.0 110.262 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 69.8 p -90.18 2.61 55.17 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.42 -0.8 . . . . 0.0 111.194 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -69.94 -27.75 65.01 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.327 -0.858 . . . . 0.0 110.738 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.01 -41.72 83.7 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.57 -0.706 . . . . 0.0 110.619 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.56 -80.7 1.63 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 59.9 ttp180 -130.86 138.88 50.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.565 -0.962 . . . . 0.0 111.042 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.54 114.65 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.608 -0.682 . . . . 0.0 110.428 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -82.46 171.02 14.6 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.665 -0.647 . . . . 0.0 110.588 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.7 t30 60.13 48.35 8.48 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.743 -0.598 . . . . 0.0 111.828 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.7 t -98.1 124.56 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.325 179.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t-20 -82.57 134.24 35.19 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.931 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 54.4 p90 -135.75 140.85 44.67 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.8 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.01 154.67 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.237 -0.914 . . . . 0.0 111.001 -179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.439 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.4 tt0 -74.64 141.53 44.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.713 -0.617 . . . . 0.0 109.834 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.0 m -139.06 168.89 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 120.047 -0.661 . . . . 0.0 109.553 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -59.92 144.34 49.19 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.356 -0.84 . . . . 0.0 110.964 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.405 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 9.4 tt -59.9 -36.18 76.43 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.562 -0.711 . . . . 0.0 111.035 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.4 m -56.48 -39.16 72.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.502 -0.749 . . . . 0.0 109.836 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -61.52 -38.57 87.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.562 -0.711 . . . . 0.0 110.859 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.22 -49.61 76.94 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.301 -0.874 . . . . 0.0 109.846 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.417 HD11 HG21 ' A' ' 116' ' ' ILE . 83.7 mt -69.83 -39.92 78.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.632 -0.668 . . . . 0.0 110.662 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -65.02 -40.49 94.95 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.463 -0.773 . . . . 0.0 110.643 -179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.12 -43.75 70.29 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.99 94.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.765 -0.844 . . . . 0.0 110.264 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.389 -179.86 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.1 m . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 p -112.47 141.95 45.6 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 122.15 0.976 . . . . 0.0 111.575 -178.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.2 pt -119.97 150.02 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.965 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 7.6 m -144.87 -173.0 3.95 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -140.44 147.5 39.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.477 -0.764 . . . . 0.0 109.489 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -138.55 147.68 55.89 Favored Pre-proline 0 N--CA 1.491 1.593 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.823 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -74.39 -6.08 17.83 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 O-C-N 123.455 1.239 . . . . 0.0 110.532 178.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.406 HG23 ' CE2' ' A' ' 9' ' ' TYR . 7.3 tp -64.43 -15.86 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.36 -0.837 . . . . 0.0 111.095 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.406 ' CE2' HG23 ' A' ' 8' ' ' ILE . 43.2 m-85 -112.5 69.31 0.69 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 122.72 1.248 . . . . 0.0 110.786 178.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.28 170.03 8.16 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.523 -1.217 . . . . 0.0 108.309 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.9 -32.44 70.75 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -175.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -89.64 11.49 19.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 120.344 -1.473 . . . . 0.0 112.182 -177.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.404 HD22 ' HA ' ' A' ' 9' ' ' TYR . 28.5 tp -71.6 126.32 29.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.317 -0.864 . . . . 0.0 109.974 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.5 p -70.7 136.9 49.33 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.247 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 94.6 mmm -64.66 -15.1 60.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.802 -0.561 . . . . 0.0 111.823 -178.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.66 -12.49 84.43 Favored Glycine 0 N--CA 1.494 2.537 0 O-C-N 121.066 -1.021 . . . . 0.0 111.297 -179.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -85.88 -7.21 58.85 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.113 -1.228 . . . . 0.0 111.935 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.0 p -101.4 168.89 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.03 -1.044 . . . . 0.0 110.672 -179.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.03 -42.38 94.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.605 -0.685 . . . . 0.0 109.881 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 70.42 8.47 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.2 p -92.86 -74.89 0.51 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.782 -0.573 . . . . 0.0 109.691 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -130.01 169.93 14.63 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 121.17 -149.0 17.41 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -179.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -73.48 -44.16 58.58 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.641 -0.917 . . . . 0.0 111.05 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.427 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 44.8 m-70 -98.28 8.9 44.18 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.297 -0.877 . . . . 0.0 110.711 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.2 129.94 46.7 Favored Glycine 0 N--CA 1.496 2.657 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.8 mt -100.03 -4.21 30.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 122.041 -0.682 . . . . 0.0 110.245 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 57.2 ttm -61.67 -37.88 85.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.241 -0.912 . . . . 0.0 109.876 179.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.5 -74.11 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.671 -0.643 . . . . 0.0 112.059 -177.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -69.96 -40.38 75.44 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.273 -0.892 . . . . 0.0 110.659 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.457 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 53.9 m-85 -120.25 86.3 37.91 Favored Pre-proline 0 N--CA 1.492 1.664 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -178.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.37 -11.18 30.75 Favored 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.383 1.202 . . . . 0.0 111.145 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -130.04 141.19 50.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.177 -0.952 . . . . 0.0 110.105 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -69.68 117.46 11.32 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.684 -0.635 . . . . 0.0 110.491 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.43 33.59 0.03 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.079 179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -159.8 -46.07 0.05 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.176 -1.19 . . . . 0.0 110.64 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.457 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 2.6 t -63.0 -59.33 12.75 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.359 -0.838 . . . . 0.0 108.83 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.41 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 47.2 Cg_endo -74.35 -31.77 7.08 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 123.222 1.117 . . . . 0.0 109.408 178.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.437 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 134.57 -63.39 0.61 Allowed Glycine 0 N--CA 1.486 1.979 0 N-CA-C 107.116 -2.393 . . . . 0.0 107.116 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.587 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 161.19 -55.12 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.7 0 C-N-CA 123.457 0.703 . . . . 0.0 110.484 177.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.68 3.52 0.7 Allowed 'Trans proline' 0 C--N 1.322 -0.828 0 C-N-CA 121.068 1.178 . . . . 0.0 112.09 -178.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 72' ' ' PHE . 19.3 m120 -120.19 42.13 3.03 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 0.0 109.415 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.6 p -109.89 142.64 21.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.742 0.782 . . . . 0.0 109.145 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -167.36 172.99 42.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.91 161.54 29.43 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.0 pt -144.49 159.44 51.51 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.705 -0.879 . . . . 0.0 110.684 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -71.25 -14.91 31.68 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.511 1.474 . . . . 0.0 113.115 -178.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -91.55 19.45 6.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.016 -1.053 . . . . 0.0 111.948 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.474 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 62.4 mt -119.97 120.22 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.89 . . . . 0.0 108.938 177.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.69 -41.32 21.51 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -177.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 177.29 -126.32 1.09 Allowed Glycine 0 N--CA 1.492 2.38 0 C-N-CA 118.144 -1.979 . . . . 0.0 112.741 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -40.01 -34.6 0.3 Allowed 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -177.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 39.9 p-10 -172.08 82.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.719 -1.238 . . . . 0.0 109.713 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.1 t -68.25 150.65 97.64 Favored Pre-proline 0 N--CA 1.495 1.793 0 O-C-N 121.69 -0.631 . . . . 0.0 110.678 -178.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.427 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 41.1 Cg_endo -66.96 -15.86 48.1 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 123.513 1.27 . . . . 0.0 111.194 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -106.84 9.73 30.86 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.327 -0.858 . . . . 0.0 111.446 -179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -60.84 141.86 56.7 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.846 -1.159 . . . . 0.0 109.947 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.8 17.13 58.69 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 16.8 p -91.49 167.31 12.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.282 -1.128 . . . . 0.0 110.055 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -110.13 136.09 49.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.943 -0.473 . . . . 0.0 110.64 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -132.02 137.63 47.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.497 -0.752 . . . . 0.0 109.096 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 77.4 tttt -100.88 133.31 45.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.298 -0.876 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.9 t -109.98 120.49 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.616 -0.678 . . . . 0.0 109.71 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 44.7 m -116.98 141.89 47.65 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.742 -0.599 . . . . 0.0 111.312 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.424 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 36.8 pt -119.61 163.4 27.57 Favored Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.539 -0.726 . . . . 0.0 110.508 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.424 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -61.95 -24.69 77.2 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.744 1.391 . . . . 0.0 112.675 -178.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -63.84 -40.08 95.73 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.226 -0.921 . . . . 0.0 109.723 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.67 62.02 0.3 Allowed Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 35.8 t-20 -160.06 153.16 21.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.661 -0.905 . . . . 0.0 109.214 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.2 p -150.04 160.1 43.9 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.18 0.991 . . . . 0.0 112.246 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.446 HG23 HD12 ' A' ' 71' ' ' ILE . 12.6 tt -138.96 159.38 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.416 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 93.1 m-85 -104.36 122.35 45.29 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.474 HD12 HG21 ' A' ' 73' ' ' ILE . 47.1 mm -114.85 130.01 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.469 -0.77 . . . . 0.0 110.314 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . 0.406 ' CD ' HG11 ' A' ' 37' ' ' VAL . 5.2 ttp-105 -97.65 139.43 33.55 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.01 146.69 50.51 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -153.1 -43.55 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 122.072 -0.664 . . . . 0.0 109.369 179.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.419 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 18.1 t70 -115.37 162.46 17.1 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.237 -0.915 . . . . 0.0 110.352 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.474 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 26.4 t -79.64 156.8 27.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.818 -0.551 . . . . 0.0 109.608 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -140.62 126.42 3.14 Favored Glycine 0 N--CA 1.482 1.721 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.401 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -59.92 -40.0 87.38 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -167.77 169.13 41.1 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 107.875 -2.09 . . . . 0.0 107.875 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 64.52 -166.84 29.81 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.186 -1.185 . . . . 0.0 112.571 177.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -139.17 139.78 37.66 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 122.225 -0.573 . . . . 0.0 110.754 -178.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.41 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 0.9 OUTLIER -123.58 130.24 52.38 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.019 -1.051 . . . . 0.0 110.14 178.495 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.4 m -129.02 166.53 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.873 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.8 m-20 -54.61 153.65 10.29 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.53 -0.731 . . . . 0.0 110.19 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.24 -30.03 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.498 1.262 . . . . 0.0 110.241 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -69.92 -40.09 75.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.094 -1.004 . . . . 0.0 108.603 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.02 -38.28 85.66 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.11 -49.48 77.47 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.311 0.577 . . . . 0.0 110.099 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.8 m -59.96 -39.73 86.6 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.707 -0.621 . . . . 0.0 110.947 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -68.65 -39.99 80.44 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.707 -178.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 52.7 tp -69.94 -40.62 75.37 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.475 -0.765 . . . . 0.0 112.047 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -96.65 -35.98 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.218 0 O-C-N 121.246 -0.909 . . . . 0.0 111.363 -177.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.77 -38.73 2.27 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.291 -1.924 . . . . 0.0 108.291 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 23.1 t -150.0 133.58 16.65 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.836 -0.802 . . . . 0.0 109.271 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.5 t -90.67 66.69 6.22 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.366 -0.834 . . . . 0.0 110.628 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -114.83 -27.18 7.51 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.624 -0.673 . . . . 0.0 110.637 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.08 -39.93 87.8 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -0.76 . . . . 0.0 110.567 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 103.15 -50.94 0.87 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -157.84 160.02 37.29 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.709 -0.877 . . . . 0.0 110.237 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.52 129.97 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 109.83 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -98.14 169.9 9.28 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.206 -179.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 61.6 t30 59.91 41.34 17.93 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.564 -0.71 . . . . 0.0 110.219 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 61.3 t -89.26 122.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.23 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 -80.52 136.13 36.23 Favored 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.12 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 39.6 p90 -134.87 140.98 46.22 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-O 121.278 0.561 . . . . 0.0 111.532 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.36 144.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.714 -0.616 . . . . 0.0 110.61 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -73.21 144.43 46.79 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.612 -0.68 . . . . 0.0 110.318 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.92 168.89 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.618 -0.676 . . . . 0.0 110.509 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -59.96 144.15 49.86 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.547 -0.721 . . . . 0.0 110.448 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -60.79 -40.03 91.07 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.567 -0.708 . . . . 0.0 110.998 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.9 m -54.61 -35.57 63.53 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.612 -0.68 . . . . 0.0 111.592 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -69.99 -22.13 63.16 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.169 -0.957 . . . . 0.0 111.457 -178.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 96.5 m -75.65 -48.64 21.23 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.2 -0.938 . . . . 0.0 109.35 178.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 94.8 mt -69.96 -40.03 78.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 CA-C-O 121.32 0.581 . . . . 0.0 109.773 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -67.18 -40.03 86.5 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.66 -0.65 . . . . 0.0 110.129 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.7 -49.96 39.64 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.68 -39.92 90.26 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.551 -0.97 . . . . 0.0 110.39 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.316 -179.774 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.431 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.5 m . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.438 0.637 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.41 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 54.5 m -113.14 145.19 41.37 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.034 0.921 . . . . 0.0 111.035 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.6 pt -115.19 146.36 19.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.25 -172.45 3.87 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.9 p90 -143.87 149.95 37.7 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.075 178.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.72 149.18 72.71 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.547 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -85.12 9.26 4.21 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.39 1.205 . . . . 0.0 111.276 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.439 HD11 ' CE2' ' A' ' 9' ' ' TYR . 1.3 pt -90.05 -0.21 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.113 -0.992 . . . . 0.0 111.068 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.439 ' CE2' HD11 ' A' ' 8' ' ' ILE . 21.7 m-85 -117.35 66.8 0.73 Allowed 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.543 1.164 . . . . 0.0 109.569 178.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.7 170.64 8.04 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 114.834 -1.076 . . . . 0.0 108.231 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.68 -31.42 64.43 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -89.02 12.93 14.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 120.513 -1.367 . . . . 0.0 112.033 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.418 ' CD2' ' O ' ' A' ' 8' ' ' ILE . 0.4 OUTLIER -71.04 118.42 13.8 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.253 -0.904 . . . . 0.0 110.091 -179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.6 m -68.22 137.63 54.94 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 121.702 0.763 . . . . 0.0 110.43 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 5.3 mmt -62.26 -20.02 63.83 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -73.85 -13.68 80.53 Favored Glycine 0 N--CA 1.498 2.79 0 O-C-N 121.037 -1.04 . . . . 0.0 112.079 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.5 -7.77 46.44 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.944 -1.327 . . . . 0.0 112.183 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.03 169.97 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.93 -1.106 . . . . 0.0 110.19 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' TRP . . . -57.05 -43.5 82.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.279 -0.888 . . . . 0.0 109.711 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.18 83.41 6.06 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.4 m -94.12 -80.0 0.41 Allowed 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.254 -0.904 . . . . 0.0 112.557 -177.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -140.93 11.83 2.23 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.201 -0.937 . . . . 0.0 112.553 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.32 -146.12 0.31 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -69.29 -39.99 77.99 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.812 -0.817 . . . . 0.0 109.268 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 80.7 m-70 -91.48 0.92 57.45 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.689 -0.632 . . . . 0.0 110.696 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.85 132.35 44.37 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.9 mt -98.82 -5.46 31.05 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 122.125 -0.633 . . . . 0.0 110.149 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' N ' ' A' ' 16' ' ' GLY . 55.6 ttm -63.24 -37.77 88.54 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.277 -0.889 . . . . 0.0 111.262 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -74.05 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.522 -0.736 . . . . 0.0 111.667 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -70.04 -39.9 75.44 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 109.687 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.438 ' CD1' ' HB3' ' A' ' 36' ' ' GLU . 44.2 m-85 -120.15 85.39 35.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -66.53 -12.14 34.55 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 O-C-N 123.258 1.136 . . . . 0.0 111.228 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.9 m -129.18 146.98 50.99 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.228 -0.92 . . . . 0.0 110.349 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 45.1 tp -72.61 119.73 17.24 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.714 -0.616 . . . . 0.0 110.779 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.34 34.19 0.04 OUTLIER Glycine 0 N--CA 1.496 2.642 0 C-N-CA 120.067 -1.063 . . . . 0.0 110.485 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.438 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 21.7 tp10 -158.09 -49.18 0.06 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.298 -1.119 . . . . 0.0 110.485 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.425 HG22 ' CD2' ' A' ' 31' ' ' TYR . 2.7 t -60.63 -59.43 13.88 Favored Pre-proline 0 N--CA 1.499 2.001 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.415 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 51.2 Cg_endo -76.02 -29.78 6.36 Favored 'Trans proline' 0 N--CA 1.487 1.129 0 O-C-N 123.258 1.136 . . . . 0.0 109.335 177.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.85 -63.0 0.63 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 -178.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.454 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.9 t80 165.18 -72.22 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.571 0 C-N-CA 123.42 0.688 . . . . 0.0 110.017 177.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.454 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 57.4 Cg_endo -79.09 -18.99 10.99 Favored 'Trans proline' 0 N--CA 1.492 1.424 0 O-C-N 122.409 0.689 . . . . 0.0 111.579 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.0 m-20 -93.93 55.74 2.16 Favored 'General case' 0 N--CA 1.489 1.491 0 CA-C-O 121.8 0.809 . . . . 0.0 109.71 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.7 p -118.92 129.33 75.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-O 121.385 0.612 . . . . 0.0 109.655 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -161.68 167.59 36.51 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 119.991 -1.099 . . . . 0.0 111.279 -179.216 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.68 164.92 29.33 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.415 ' CG1' ' CD1' ' A' ' 49' ' ' ILE . 10.8 pt -143.55 165.87 22.78 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.824 -0.81 . . . . 0.0 109.762 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 82' ' ' GLY . 56.9 Cg_endo -77.12 -10.57 17.86 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 120.972 1.115 . . . . 0.0 113.125 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -95.41 16.65 16.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.071 -1.018 . . . . 0.0 111.916 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.434 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 63.7 mt -109.34 121.31 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.048 -1.032 . . . . 0.0 109.256 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.52 -42.34 43.56 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.426 -0.796 . . . . 0.0 113.13 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.97 -132.59 2.69 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.576 -1.773 . . . . 0.0 112.013 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.429 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 39.3 t90 -44.59 -30.68 0.95 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -178.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -143.62 63.2 1.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.358 -0.839 . . . . 0.0 110.134 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.426 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.8 p -66.24 136.32 95.21 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.804 -0.56 . . . . 0.0 111.118 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -73.54 -21.34 19.54 Favored 'Trans proline' 0 C--N 1.32 -0.974 0 O-C-N 123.338 1.178 . . . . 0.0 111.104 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.4 m -96.48 12.01 32.96 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.388 -0.82 . . . . 0.0 111.089 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.56 143.75 56.85 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.124 -0.985 . . . . 0.0 109.713 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.04 25.27 58.08 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 m -106.28 137.35 44.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.487 -1.007 . . . . 0.0 109.857 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.67 131.13 35.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.911 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.41 ' CD1' HD11 ' A' ' 46' ' ' ILE . 80.2 m95 -130.31 138.56 50.51 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.3 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -107.32 135.65 48.47 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.272 -0.893 . . . . 0.0 109.518 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.7 t -111.6 127.82 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.188 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 95.4 m -120.03 139.15 52.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.967 -0.458 . . . . 0.0 110.637 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.434 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 34.3 pt -117.74 163.73 22.88 Favored Pre-proline 0 N--CA 1.5 2.051 0 O-C-N 121.363 -0.836 . . . . 0.0 110.557 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.434 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -61.54 -23.04 75.94 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.371 1.381 . . . . 0.0 112.689 -178.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -66.52 -40.02 88.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.375 -0.828 . . . . 0.0 109.697 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.29 57.4 0.32 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -150.78 148.62 28.73 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.3 p -151.09 156.23 40.61 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-O 121.93 0.871 . . . . 0.0 111.372 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.6 pt -139.46 164.23 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -109.09 126.59 53.35 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.097 -1.041 . . . . 0.0 108.785 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.421 ' CD1' ' CG1' ' A' ' 85' ' ' VAL . 87.6 mt -129.38 140.0 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.688 -178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -98.04 139.5 33.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.547 -0.72 . . . . 0.0 109.872 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.71 150.28 39.06 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 11.9 p -149.45 -39.56 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.751 -0.852 . . . . 0.0 109.901 179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -129.32 168.02 16.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.224 -0.922 . . . . 0.0 110.5 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.434 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 40.6 t -75.28 155.89 36.21 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.618 0.723 . . . . 0.0 111.739 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -137.66 132.26 5.84 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -60.02 -33.05 71.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 109.871 178.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.31 82.37 0.05 OUTLIER Glycine 0 N--CA 1.498 2.788 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.599 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 151.97 -151.66 23.52 Favored Glycine 0 N--CA 1.499 2.866 0 C-N-CA 119.893 -1.146 . . . . 0.0 110.516 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -136.02 130.77 34.06 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.295 -1.121 . . . . 0.0 111.381 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.458 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 4.4 t-20 -115.61 127.52 55.28 Favored 'General case' 0 N--CA 1.502 2.152 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 178.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.2 m -129.95 164.62 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.363 -177.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-20 -54.54 157.1 5.41 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.328 -0.857 . . . . 0.0 109.897 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.37 -14.35 43.79 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.268 1.141 . . . . 0.0 110.657 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.7 m -82.71 -39.14 22.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.975 -1.078 . . . . 0.0 109.314 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.77 -39.82 84.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.448 -0.783 . . . . 0.0 109.037 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -59.99 -50.02 75.4 Favored 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 120.081 -0.648 . . . . 0.0 110.762 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 73.2 m -60.14 -39.97 88.21 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.368 -0.832 . . . . 0.0 111.071 -178.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -69.68 -40.0 76.66 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.871 -0.732 . . . . 0.0 111.062 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 60.2 tp -70.62 -43.7 68.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.602 -0.686 . . . . 0.0 111.557 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.0 -42.61 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.402 -0.811 . . . . 0.0 111.579 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -20.22 7.93 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.3 t -156.21 159.52 39.02 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.213 -1.169 . . . . 0.0 110.944 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 65.7 p -98.42 6.89 46.86 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.543 -0.723 . . . . 0.0 110.812 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -69.17 -36.76 77.7 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.362 -0.836 . . . . 0.0 111.708 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.52 -40.12 86.09 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.379 -0.826 . . . . 0.0 110.696 -178.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 82.89 -75.03 2.44 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -127.78 133.17 49.46 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.631 -0.923 . . . . 0.0 109.857 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.14 120.14 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.467 -0.771 . . . . 0.0 110.116 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.41 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 28.1 p-10 -86.16 178.43 7.2 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.359 0.599 . . . . 0.0 110.707 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.0 t-20 58.88 49.62 9.56 Favored 'General case' 0 N--CA 1.499 2.013 0 CA-C-O 121.28 0.562 . . . . 0.0 111.235 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.431 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 62.5 t -105.77 129.03 59.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.577 -179.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -86.61 137.07 32.78 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 118.936 -1.105 . . . . 0.0 109.477 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -135.45 141.52 45.41 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.93 -0.481 . . . . 0.0 110.536 -178.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.0 m -148.09 148.17 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.527 -0.733 . . . . 0.0 111.037 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -76.18 143.52 41.05 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.595 -0.691 . . . . 0.0 110.236 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -137.79 167.83 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.578 -0.701 . . . . 0.0 110.561 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -61.52 148.26 42.66 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.403 -0.81 . . . . 0.0 110.749 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.11 -40.07 94.63 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.517 -0.739 . . . . 0.0 112.075 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 82.1 p -53.12 -37.34 61.68 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.263 -0.898 . . . . 0.0 111.023 -178.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -61.12 -37.93 84.54 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.518 -0.739 . . . . 0.0 112.005 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 82.5 m -67.37 -46.29 73.77 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.119 -0.988 . . . . 0.0 110.415 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.2 mt -70.04 -39.94 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 120.109 -0.636 . . . . 0.0 110.518 -178.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.69 -39.98 88.34 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.13 -46.19 44.92 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.03 -44.15 94.83 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.625 -0.926 . . . . 0.0 110.473 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 13.5 m120 . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.186 179.823 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.291 0.567 . . . . 0.0 111.401 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 80.2 p -111.78 139.85 46.91 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.738 -0.601 . . . . 0.0 109.764 179.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.9 pt -110.86 144.77 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.734 -0.604 . . . . 0.0 110.854 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.35 -176.02 4.57 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.118 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -140.09 141.62 36.15 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.453 179.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -135.71 151.66 74.67 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.441 -0.787 . . . . 0.0 110.433 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -77.12 0.07 10.09 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.421 1.221 . . . . 0.0 111.506 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.417 HG21 ' CD2' ' A' ' 9' ' ' TYR . 7.4 tp -69.54 -14.03 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.276 -0.89 . . . . 0.0 111.274 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.417 ' CD2' HG21 ' A' ' 8' ' ' ILE . 36.7 m-85 -116.72 69.01 0.74 Allowed 'General case' 0 N--CA 1.493 1.683 0 CA-C-O 122.507 1.146 . . . . 0.0 111.335 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.35 168.67 8.92 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.0 -32.02 70.47 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -88.13 12.08 14.57 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.44 -1.412 . . . . 0.0 112.199 -177.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 41.6 tp -73.75 122.36 22.26 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.419 -0.801 . . . . 0.0 109.714 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.6 m -66.29 137.39 56.91 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.8 mmm -64.32 -18.99 65.14 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.902 -0.499 . . . . 0.0 111.247 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.423 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -72.2 -14.38 76.64 Favored Glycine 0 N--CA 1.493 2.499 0 O-C-N 121.073 -1.017 . . . . 0.0 110.752 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.7 p -91.63 -15.65 28.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -1.194 . . . . 0.0 111.146 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.05 162.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.931 . . . . 0.0 109.63 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -54.93 -44.35 74.2 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.556 -0.715 . . . . 0.0 110.332 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 83.89 5.83 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.52 -79.98 0.48 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.295 -0.878 . . . . 0.0 113.152 -177.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -136.72 10.11 3.12 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.108 -0.995 . . . . 0.0 113.098 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.43 -152.77 0.89 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -64.25 -39.95 95.01 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.571 -0.958 . . . . 0.0 108.586 177.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 72.8 m-70 -90.15 0.46 57.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.748 -0.595 . . . . 0.0 110.207 179.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.05 133.96 52.48 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 66.0 mt -102.47 1.13 34.78 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 122.06 -0.67 . . . . 0.0 110.226 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.423 ' CE ' ' N ' ' A' ' 16' ' ' GLY . 60.3 tpp -59.99 -38.48 82.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.315 -0.866 . . . . 0.0 111.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -66.41 0.46 Allowed 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.469 -0.769 . . . . 0.0 112.203 -176.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -75.13 -41.4 58.48 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -120.05 87.46 39.06 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.845 -0.534 . . . . 0.0 109.665 -178.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.3 -8.08 22.66 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.4 1.211 . . . . 0.0 111.543 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -133.51 146.47 51.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.26 -0.9 . . . . 0.0 110.5 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 29.1 tp -71.04 119.17 14.79 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.695 -0.628 . . . . 0.0 110.664 -179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.19 32.89 0.04 OUTLIER Glycine 0 N--CA 1.498 2.774 0 C-N-CA 120.007 -1.092 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -157.39 -48.63 0.07 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -1.122 . . . . 0.0 110.159 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.407 ' CB ' ' CD ' ' A' ' 38' ' ' PRO . 2.5 t -60.39 -58.61 18.06 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.407 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 54.2 Cg_endo -77.63 -30.8 3.67 Favored 'Trans proline' 0 C--N 1.318 -1.04 0 O-C-N 123.217 1.114 . . . . 0.0 109.537 177.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.97 -63.86 0.62 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 107.272 -2.331 . . . . 0.0 107.272 -178.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.625 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.1 t80 164.53 -56.72 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.581 0 C-N-CA 123.37 0.668 . . . . 0.0 110.231 177.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.625 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 51.2 Cg_endo -101.03 15.55 0.37 Allowed 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 121.313 1.342 . . . . 0.0 111.246 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -125.32 47.52 2.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.296 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.407 ' CG2' HG13 ' A' ' 76' ' ' VAL . 14.6 p -125.47 140.04 49.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.914 0.864 . . . . 0.0 110.435 -179.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.87 175.35 42.76 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.62 159.47 29.43 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.445 ' CD1' HG12 ' A' ' 49' ' ' ILE . 1.1 pt -148.78 159.67 37.43 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.584 -0.95 . . . . 0.0 109.94 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -68.18 -15.9 43.49 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 121.245 1.297 . . . . 0.0 113.829 -177.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -91.7 21.26 4.87 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 120.706 -1.246 . . . . 0.0 113.129 -177.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.461 HD11 HG23 ' A' ' 49' ' ' ILE . 47.8 mm -112.28 122.59 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 177.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.63 -44.38 34.39 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.302 -0.874 . . . . 0.0 111.199 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 164.83 -134.93 3.5 Favored Glycine 0 N--CA 1.484 1.886 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.425 -179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 64.4 t90 -43.83 -26.78 0.28 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -179.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -145.4 72.81 1.33 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.921 . . . . 0.0 110.578 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.414 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 3.4 t -70.35 134.3 86.97 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.773 -0.58 . . . . 0.0 111.528 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.8 -23.98 16.01 Favored 'Trans proline' 0 C--N 1.32 -0.941 0 O-C-N 123.413 1.218 . . . . 0.0 110.545 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.42 12.44 33.23 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.445 -0.784 . . . . 0.0 111.058 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.7 t -72.21 148.8 45.2 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.335 -0.853 . . . . 0.0 110.584 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.86 43.15 9.14 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 8.5 m -130.62 168.74 16.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.707 -0.878 . . . . 0.0 108.684 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 16.8 t -113.38 148.6 35.49 Favored 'General case' 0 N--CA 1.511 2.596 0 O-C-N 121.118 -0.989 . . . . 0.0 113.143 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.481 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 31.5 m95 -139.82 145.35 38.03 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.027 -1.046 . . . . 0.0 110.36 177.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -105.53 129.84 53.72 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 177.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.1 t -110.63 129.95 64.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.316 -0.865 . . . . 0.0 109.95 -178.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 47.1 m -121.63 138.79 54.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.849 -0.532 . . . . 0.0 111.61 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.479 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.6 pt -114.35 166.09 12.32 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.534 -0.729 . . . . 0.0 109.809 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.479 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.44 -25.9 76.26 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 O-C-N 123.217 1.114 . . . . 0.0 112.928 -178.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -64.81 -37.83 88.95 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.052 -1.03 . . . . 0.0 109.751 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.93 65.32 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -162.02 153.15 18.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.769 -0.842 . . . . 0.0 108.867 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 71.5 p -152.8 162.38 41.35 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 122.197 0.999 . . . . 0.0 112.456 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.9 pt -139.39 162.3 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.128 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -107.48 127.15 53.35 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.246 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 90.2 mt -125.9 134.93 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 110.493 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 65.9 ttt180 -95.49 133.92 38.93 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -63.59 144.17 48.8 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 120.296 -0.954 . . . . 0.0 110.76 -178.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.407 HG13 ' CG2' ' A' ' 43' ' ' VAL . 10.1 p -142.67 -41.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 122.104 -0.645 . . . . 0.0 109.906 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.403 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 6.3 t0 -133.67 171.57 13.95 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.114 -0.991 . . . . 0.0 109.496 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.402 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 43.9 t -83.75 146.66 28.05 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.443 -0.785 . . . . 0.0 110.635 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -108.12 148.71 16.73 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -89.07 101.67 14.32 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.487 -1.008 . . . . 0.0 110.601 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 52.79 53.46 32.99 Favored Glycine 0 N--CA 1.498 2.791 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.24 170.08 14.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.929 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.427 ' CD2' HG22 ' A' ' 46' ' ' ILE . 36.3 m-85 -93.13 128.94 39.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.749 -0.853 . . . . 0.0 109.996 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.7 t-20 -120.24 130.84 54.7 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.2 m -129.99 174.35 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.694 -178.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -55.51 156.8 7.99 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.658 -0.651 . . . . 0.0 109.966 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.7 -27.43 38.26 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.387 1.204 . . . . 0.0 109.706 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -71.28 -40.19 71.07 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.24 -39.56 86.21 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.3 t80 -59.99 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.737 -0.602 . . . . 0.0 110.514 179.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 58.0 m -59.82 -36.92 77.78 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.534 -0.729 . . . . 0.0 110.631 -178.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -69.72 -40.02 76.5 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.805 -0.758 . . . . 0.0 111.258 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 52.6 tp -69.95 -41.81 74.06 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.472 -0.768 . . . . 0.0 111.688 -178.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 94.9 t -100.2 -36.12 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.117 0 O-C-N 121.164 -0.96 . . . . 0.0 111.413 -178.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 117.84 -30.62 6.05 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.0 m -143.03 155.12 44.57 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.48 -1.012 . . . . 0.0 110.897 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.0 p -90.23 1.53 56.39 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.521 -0.737 . . . . 0.0 110.989 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.95 -22.18 63.2 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.381 -0.824 . . . . 0.0 110.702 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.29 -45.27 88.25 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.382 -0.824 . . . . 0.0 110.717 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.68 -77.45 2.11 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 43.0 ttm180 -135.44 132.1 37.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.641 -0.917 . . . . 0.0 110.682 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 57.5 t -116.19 115.97 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.523 -0.736 . . . . 0.0 109.739 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 2.8 t0 -84.37 172.53 11.69 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.766 0.794 . . . . 0.0 111.375 -178.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.6 t30 60.07 40.02 19.03 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.807 -0.558 . . . . 0.0 111.591 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 62.8 t -81.65 127.43 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.126 179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -91.88 139.98 30.13 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.064 -1.054 . . . . 0.0 108.989 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -140.81 147.22 38.69 Favored 'General case' 0 N--CA 1.493 1.684 0 CA-C-O 121.502 0.668 . . . . 0.0 112.129 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.9 142.57 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.747 -0.595 . . . . 0.0 109.813 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.481 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 62.3 tt0 -84.93 140.44 31.1 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.459 -0.775 . . . . 0.0 110.843 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 27.1 m -129.93 175.32 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -62.62 150.75 39.9 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.391 -0.818 . . . . 0.0 111.004 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.06 -39.94 87.76 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.74 -0.6 . . . . 0.0 110.795 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 61.9 m -52.55 -35.66 54.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.59 -0.694 . . . . 0.0 111.186 -178.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.1 -40.01 93.95 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.426 -0.796 . . . . 0.0 110.967 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.06 -49.34 77.77 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.293 -0.879 . . . . 0.0 110.14 179.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.7 mt -70.03 -39.94 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.611 -0.681 . . . . 0.0 110.834 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -66.19 -40.07 90.14 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.453 -0.78 . . . . 0.0 110.829 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.99 -57.48 3.02 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 -178.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.83 -43.2 94.68 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.518 -0.989 . . . . 0.0 110.469 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.0 t30 . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 117.796 -1.097 . . . . 0.0 110.916 179.83 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 121.187 0.517 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 p -112.67 147.01 37.66 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.707 -0.62 . . . . 0.0 111.019 -179.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 24.7 pt -113.8 147.9 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.796 -0.565 . . . . 0.0 110.161 179.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.84 -172.34 3.89 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -142.22 149.34 39.52 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.519 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -139.09 152.99 71.08 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.377 -0.827 . . . . 0.0 110.078 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -83.55 2.36 8.38 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 O-C-N 123.407 1.214 . . . . 0.0 111.39 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.425 ' O ' ' HG ' ' A' ' 13' ' ' LEU . 26.2 mm -76.5 -2.79 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.16 -0.962 . . . . 0.0 111.165 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -127.34 64.64 1.33 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 122.347 1.07 . . . . 0.0 110.765 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.15 173.97 6.21 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.04 -32.17 70.66 Favored 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -175.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -89.41 12.28 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 120.446 1.475 . . . . 0.0 112.084 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 8' ' ' ILE . 0.1 OUTLIER -69.71 114.55 8.02 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.303 -0.873 . . . . 0.0 109.301 179.426 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m -62.76 139.4 58.68 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.801 0.81 . . . . 0.0 110.631 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.1 mmm -62.56 -26.38 68.55 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.985 -179.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -19.44 76.44 Favored Glycine 0 N--CA 1.494 2.507 0 O-C-N 121.126 -0.984 . . . . 0.0 110.896 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 75.4 m -86.46 -17.77 33.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.228 -1.16 . . . . 0.0 111.375 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.98 160.02 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.328 -0.858 . . . . 0.0 109.676 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.17 -41.82 65.57 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.58 -0.7 . . . . 0.0 111.164 -178.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 82.92 4.83 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.294 -0.879 . . . . 0.0 108.835 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 m -91.42 -79.34 0.37 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.26 -0.9 . . . . 0.0 113.014 -177.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 t30 -144.09 14.82 1.69 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.772 -1.205 . . . . 0.0 112.474 -178.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.49 -147.19 0.37 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 108.671 -1.772 . . . . 0.0 108.671 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -69.58 -39.97 76.99 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.622 -0.928 . . . . 0.0 108.85 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.431 ' CD2' ' O ' ' A' ' 54' ' ' SER . 56.0 m-70 -89.93 0.04 57.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.698 -0.626 . . . . 0.0 110.208 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.74 133.05 52.3 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 65.0 mt -103.73 -0.07 29.86 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 122.139 -0.624 . . . . 0.0 110.47 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -64.0 -35.46 80.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.274 -0.891 . . . . 0.0 111.068 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.69 -66.16 0.47 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.41 -0.806 . . . . 0.0 111.883 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.418 ' HG3' ' CD2' ' A' ' 31' ' ' TYR . 28.1 pt20 -72.71 -40.5 66.13 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.126 -0.984 . . . . 0.0 110.775 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.418 ' CD2' ' HG3' ' A' ' 30' ' ' GLN . 53.9 m-85 -126.73 91.04 48.22 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.429 -0.794 . . . . 0.0 109.428 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.54 -9.89 27.41 Favored 'Trans proline' 0 N--CA 1.488 1.161 0 O-C-N 123.554 1.292 . . . . 0.0 112.04 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.9 m -129.03 143.95 51.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.098 -1.001 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 21.2 tp -69.93 120.02 15.02 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.878 -0.514 . . . . 0.0 110.546 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 147.36 30.32 0.07 OUTLIER Glycine 0 N--CA 1.496 2.697 0 C-N-CA 119.927 -1.13 . . . . 0.0 110.822 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -154.13 -50.9 0.09 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.26 -1.141 . . . . 0.0 110.286 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.429 HG12 ' CD ' ' A' ' 74' ' ' ARG . 2.7 t -61.66 -59.47 13.29 Favored Pre-proline 0 N--CA 1.497 1.904 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.413 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 46.0 Cg_endo -74.08 -32.08 7.25 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 O-C-N 123.258 1.136 . . . . 0.0 109.24 177.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.429 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 131.21 -65.05 0.6 Allowed Glycine 0 N--CA 1.484 1.856 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.476 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.7 t80 163.94 -69.66 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.793 0 C-N-CA 123.522 0.729 . . . . 0.0 110.393 177.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.476 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.9 Cg_endo -80.61 -0.22 10.47 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 120.387 0.725 . . . . 0.0 112.714 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -111.24 53.66 0.7 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.872 -1.143 . . . . 0.0 110.425 -178.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.4 p -132.44 141.09 46.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 121.859 0.838 . . . . 0.0 110.054 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.69 175.39 43.24 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.401 ' O ' ' CG2' ' A' ' 46' ' ' ILE . . . -87.51 157.67 29.13 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 179.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.409 HG13 HG12 ' A' ' 49' ' ' ILE . 1.7 pt -156.01 160.06 31.07 Favored Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.592 -0.946 . . . . 0.0 109.771 179.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -67.02 -23.49 46.45 Favored 'Trans proline' 0 N--CA 1.502 1.983 0 C-N-CA 121.643 1.562 . . . . 0.0 115.291 -176.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -77.03 -5.02 47.13 Favored 'General case' 0 N--CA 1.506 2.374 0 O-C-N 120.381 -1.45 . . . . 0.0 112.497 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.481 HG21 HD13 ' A' ' 49' ' ' ILE . 43.1 mm -89.71 121.34 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.992 -1.067 . . . . 0.0 108.45 178.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.65 -43.55 47.07 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.243 -0.91 . . . . 0.0 111.537 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.98 -131.73 2.43 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.004 -1.569 . . . . 0.0 110.771 -179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 61.9 t90 -48.71 -26.02 2.11 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.886 -0.773 . . . . 0.0 112.749 -178.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.8 64.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.184 -0.948 . . . . 0.0 110.713 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.431 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 7.9 p -63.5 133.64 95.57 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.648 -0.658 . . . . 0.0 110.986 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.64 -19.47 27.9 Favored 'Trans proline' 0 N--CA 1.485 1.011 0 O-C-N 123.212 1.112 . . . . 0.0 110.911 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 54.0 p -99.04 10.8 40.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.378 -0.827 . . . . 0.0 111.025 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.13 143.1 58.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.135 -0.978 . . . . 0.0 110.056 -179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.41 26.01 48.92 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 17.1 p -100.01 134.99 42.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.453 -1.027 . . . . 0.0 110.615 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 42.0 t -81.49 131.11 35.27 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.795 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.468 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 85.6 m95 -133.6 143.58 48.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.387 -0.82 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 tttm -110.67 130.98 55.43 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -111.02 129.73 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.349 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 69.0 m -120.04 135.55 54.89 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.868 -0.52 . . . . 0.0 110.604 -178.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.447 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 8.7 pt -113.8 164.83 14.92 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.425 -0.797 . . . . 0.0 110.849 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -62.96 -27.93 74.79 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.241 1.294 . . . . 0.0 112.937 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -64.58 -40.0 94.76 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.239 -0.913 . . . . 0.0 109.701 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.18 60.01 0.28 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 179.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -153.7 148.7 26.71 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.699 -0.883 . . . . 0.0 108.745 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 47.1 m -149.37 155.49 40.56 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 119.3 -0.96 . . . . 0.0 112.233 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.3 pt -140.76 166.9 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.71 125.45 53.51 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.404 179.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 96.9 mt -124.1 138.63 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.466 -0.771 . . . . 0.0 110.518 -179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . 0.429 ' CD ' HG12 ' A' ' 37' ' ' VAL . 1.9 ttp-105 -100.85 146.47 27.27 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.586 -0.696 . . . . 0.0 109.745 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.407 ' HA2' ' CD1' ' A' ' 46' ' ' ILE . . . -68.11 151.33 51.81 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.406 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 9.6 p -154.81 -44.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.826 -0.808 . . . . 0.0 109.522 179.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.406 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 5.2 t0 -129.62 169.82 14.56 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.059 -1.025 . . . . 0.0 109.622 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.411 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 92.6 p -101.57 160.07 14.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.577 -0.702 . . . . 0.0 111.055 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.96 155.06 21.62 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 75.4 mtp85 -59.97 -31.41 69.87 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.484 -1.01 . . . . 0.0 109.679 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -176.69 -179.8 47.3 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 50.83 -178.88 0.04 OUTLIER Glycine 0 N--CA 1.496 2.675 0 O-C-N 121.434 -1.039 . . . . 0.0 111.87 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 42.7 m-85 -107.74 127.46 53.71 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.891 -0.77 . . . . 0.0 109.008 178.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -117.83 127.73 54.16 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.511 -0.875 . . . . 0.0 108.64 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.438 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.4 m -130.79 172.37 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.697 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -55.58 152.79 16.96 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.534 -0.729 . . . . 0.0 109.528 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.21 -26.33 57.0 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.35 1.184 . . . . 0.0 110.186 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.08 -40.24 75.13 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.076 -1.015 . . . . 0.0 109.346 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.03 -40.57 87.24 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -60.71 -50.08 74.9 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.719 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.1 m -61.14 -39.96 92.01 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.403 -0.811 . . . . 0.0 111.273 -178.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 56.3 mtmt -69.99 -40.05 75.55 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.999 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 tp -69.91 -42.93 72.69 Favored 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.365 -179.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.22 -41.6 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 O-C-N 121.45 -0.781 . . . . 0.0 111.83 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.72 -34.5 4.05 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.3 m -142.44 153.67 43.91 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.524 -0.986 . . . . 0.0 110.14 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.6 p -90.28 3.49 53.46 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.477 -0.765 . . . . 0.0 110.976 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.98 -26.22 63.99 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.423 -0.798 . . . . 0.0 111.158 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.94 -39.92 87.19 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.413 -0.804 . . . . 0.0 110.513 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.75 -79.49 1.84 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -131.8 138.87 48.71 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.694 -0.886 . . . . 0.0 110.47 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.0 t -120.32 116.97 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.804 178.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -80.55 170.14 16.74 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.656 0.741 . . . . 0.0 111.346 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 60.0 39.93 19.37 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.007 0.432 . . . . 0.0 111.816 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 78.5 t -85.48 127.52 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.134 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -87.36 140.05 29.93 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.14 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -139.22 144.5 38.5 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.579 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -144.69 141.68 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.498 -0.751 . . . . 0.0 111.231 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.468 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.2 tt0 -73.45 135.01 44.09 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.561 -0.712 . . . . 0.0 109.755 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.27 173.09 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.437 179.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -60.34 149.71 32.88 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.357 -0.839 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.4 tt -59.93 -39.08 84.29 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.505 -0.747 . . . . 0.0 110.58 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.9 m -53.5 -38.01 63.28 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.557 -0.714 . . . . 0.0 110.57 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -60.22 -39.93 88.35 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.496 -0.753 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.07 -49.83 76.11 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.257 -0.902 . . . . 0.0 110.246 179.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 90.4 mt -69.25 -39.99 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.704 -0.622 . . . . 0.0 110.253 -179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.63 -39.93 95.37 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.401 -0.812 . . . . 0.0 110.281 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.81 -41.82 81.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.35 -39.97 94.86 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.75 -0.853 . . . . 0.0 110.305 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.9 p30 . . . . . 0 N--CA 1.495 1.815 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.551 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.51 0.671 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.9 p -114.61 153.99 29.15 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.874 -0.516 . . . . 0.0 110.545 -179.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.41 HG23 HD13 ' A' ' 3' ' ' ILE . 39.5 pt -119.99 150.05 22.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.476 -0.765 . . . . 0.0 110.534 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 p -147.84 -171.76 3.89 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -141.5 142.47 33.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.465 178.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -133.78 150.01 73.47 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.476 -0.765 . . . . 0.0 110.208 179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -78.87 -0.93 11.18 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 O-C-N 123.377 1.199 . . . . 0.0 111.114 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.437 HG22 ' CE2' ' A' ' 9' ' ' TYR . 6.4 tp -71.67 -15.22 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.244 -0.91 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.437 ' CE2' HG22 ' A' ' 8' ' ' ILE . 34.3 m-85 -114.88 68.53 0.7 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 122.613 1.197 . . . . 0.0 110.553 178.466 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.24 170.06 8.09 Favored 'General case' 0 N--CA 1.492 1.67 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.599 177.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.91 -34.42 73.19 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 -175.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -88.22 13.53 11.27 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.417 -1.427 . . . . 0.0 112.422 -176.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 43.9 tp -75.56 122.82 24.47 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.355 -0.841 . . . . 0.0 110.091 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.8 m -65.73 137.62 57.4 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.801 -0.76 . . . . 0.0 109.627 179.533 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 96.4 mmm -64.22 -19.08 65.11 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.823 -0.548 . . . . 0.0 111.313 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.5 -16.55 78.93 Favored Glycine 0 N--CA 1.495 2.59 0 O-C-N 120.95 -1.094 . . . . 0.0 110.986 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.1 m -88.18 -13.78 40.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.165 -1.197 . . . . 0.0 111.599 -179.148 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.04 159.54 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.149 -0.97 . . . . 0.0 108.869 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -49.07 -41.36 35.04 Favored 'General case' 0 N--CA 1.507 2.418 0 O-C-N 121.266 -0.896 . . . . 0.0 110.562 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -78.23 87.14 4.31 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.8 m -99.4 -82.31 0.44 Allowed 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.117 -0.989 . . . . 0.0 112.954 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -137.91 9.58 2.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.087 -1.008 . . . . 0.0 112.922 -178.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.08 -148.0 0.5 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.801 -1.72 . . . . 0.0 108.801 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -63.03 -40.01 96.47 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.625 -0.927 . . . . 0.0 109.526 178.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 89.6 m-70 -94.6 8.56 41.89 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.567 -0.708 . . . . 0.0 111.151 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.15 127.42 35.89 Favored Glycine 0 N--CA 1.502 3.064 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.491 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 91.2 mt -102.47 -11.46 18.55 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 122.03 -0.688 . . . . 0.0 111.532 -178.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 ttp -60.03 -27.32 66.81 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.261 -0.899 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.52 -61.75 2.27 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.425 -0.797 . . . . 0.0 112.898 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -69.96 -40.01 75.69 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 120.88 -1.137 . . . . 0.0 111.36 -178.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.519 ' CE1' ' CG2' ' A' ' 37' ' ' VAL . 3.8 p90 -136.21 104.76 9.49 Favored Pre-proline 0 C--N 1.302 -1.491 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.42 -11.15 29.01 Favored 'Trans proline' 0 N--CA 1.485 0.98 0 O-C-N 123.482 1.254 . . . . 0.0 111.647 -178.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -126.85 135.76 51.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.245 -0.91 . . . . 0.0 109.761 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 39.4 tp -61.46 126.05 25.95 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.522 -0.736 . . . . 0.0 109.858 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 148.79 27.77 0.06 OUTLIER Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.538 -1.315 . . . . 0.0 111.787 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -144.99 -47.91 0.24 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.074 -1.25 . . . . 0.0 110.917 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.519 ' CG2' ' CE1' ' A' ' 31' ' ' TYR . 1.7 t -67.42 -55.45 15.02 Favored Pre-proline 0 N--CA 1.496 1.844 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.389 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.406 ' HD2' ' N ' ' A' ' 37' ' ' VAL . 42.5 Cg_endo -76.19 -31.44 4.77 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.396 1.208 . . . . 0.0 108.988 178.079 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.424 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 129.77 -64.6 0.6 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.6 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.1 t80 164.38 -56.74 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.595 0 C-N-CA 123.33 0.652 . . . . 0.0 110.844 177.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.6 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.7 Cg_endo -97.42 16.84 0.61 Allowed 'Trans proline' 0 N--CA 1.481 0.773 0 C-N-CA 120.982 1.121 . . . . 0.0 112.044 -177.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -126.12 47.49 2.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.2 -0.937 . . . . 0.0 109.758 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.2 p -128.09 142.43 43.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.596 0.712 . . . . 0.0 109.78 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -166.56 170.43 41.09 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 -179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -83.79 158.58 35.36 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 178.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.447 HG13 HG12 ' A' ' 49' ' ' ILE . 1.5 pt -147.81 156.2 44.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.439 -1.036 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.66 -12.22 34.79 Favored 'Trans proline' 0 N--CA 1.504 2.119 0 C-N-CA 121.934 1.756 . . . . 0.0 114.668 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -96.72 21.31 9.61 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 120.491 -1.381 . . . . 0.0 112.796 -177.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.447 HG12 HG13 ' A' ' 46' ' ' ILE . 48.9 mm -110.7 129.98 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.37 -0.831 . . . . 0.0 108.807 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.15 -48.26 11.54 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.786 . . . . 0.0 112.256 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.53 -129.04 1.8 Allowed Glycine 0 N--CA 1.488 2.119 0 C-N-CA 118.806 -1.664 . . . . 0.0 111.384 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 20.1 t90 -50.2 -24.99 3.18 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.89 -0.771 . . . . 0.0 112.881 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.93 71.3 1.22 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.402 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.414 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 11.2 t -70.04 130.37 89.87 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.865 -0.522 . . . . 0.0 111.075 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.36 -21.47 30.65 Favored 'Trans proline' 0 N--CA 1.486 1.053 0 O-C-N 123.246 1.13 . . . . 0.0 110.566 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -98.52 13.48 31.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.445 -0.785 . . . . 0.0 110.983 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -70.98 147.18 48.91 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.182 -0.949 . . . . 0.0 110.271 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.1 35.37 44.02 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 95.6 m -119.59 135.17 54.91 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.503 -0.998 . . . . 0.0 110.484 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -78.96 145.64 33.88 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.053 -178.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.451 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 96.0 m95 -148.38 143.98 27.19 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.801 -0.562 . . . . 0.0 109.537 178.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -107.36 134.89 49.76 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.305 -0.872 . . . . 0.0 109.134 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 123.34 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.496 -0.752 . . . . 0.0 110.216 -179.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.2 m -118.42 139.71 50.98 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.893 -0.505 . . . . 0.0 110.378 -179.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.451 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 21.0 pt -119.58 164.29 22.62 Favored Pre-proline 0 N--CA 1.5 2.044 0 O-C-N 121.471 -0.768 . . . . 0.0 110.881 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.451 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 36.6 Cg_endo -60.58 -24.11 77.42 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 121.445 1.43 . . . . 0.0 112.794 -178.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -65.55 -36.61 84.28 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.217 -0.927 . . . . 0.0 109.712 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.11 63.41 0.47 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -163.82 153.99 15.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.755 -0.85 . . . . 0.0 108.988 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 95.6 p -155.43 158.38 38.51 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.583 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.6 pt -140.02 166.72 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -104.96 125.78 51.32 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.612 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.472 HD11 HG21 ' A' ' 73' ' ' ILE . 48.4 mm -117.98 130.06 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.75 -0.594 . . . . 0.0 109.621 -179.582 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . 0.439 ' CD ' HG11 ' A' ' 37' ' ' VAL . 1.3 ttp-105 -99.23 139.52 34.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.524 -0.735 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.59 148.04 42.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 3.8 p -155.66 -41.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.807 -0.819 . . . . 0.0 109.798 179.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -134.58 175.18 9.77 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.145 -0.972 . . . . 0.0 109.767 179.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.409 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 28.8 t -103.81 154.81 19.17 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.471 -0.768 . . . . 0.0 111.521 -179.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.77 147.75 16.66 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.9 mtt180 -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.648 -0.913 . . . . 0.0 110.742 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -177.39 73.65 0.07 OUTLIER Glycine 0 N--CA 1.495 2.585 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.638 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.65 147.33 4.54 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.467 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.445 ' CD2' HG23 ' A' ' 46' ' ' ILE . 32.5 m-85 -73.02 135.16 44.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 122.031 -0.688 . . . . 0.0 110.506 179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.3 131.01 46.87 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 178.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.4 m -131.72 173.73 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.636 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -55.17 152.16 15.77 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 109.927 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.27 -27.55 55.89 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.422 1.222 . . . . 0.0 110.11 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.02 -40.02 75.46 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.952 -1.092 . . . . 0.0 109.048 178.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.92 -40.16 87.59 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.432 -0.793 . . . . 0.0 108.977 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.47 -49.95 75.51 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.799 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 38.9 m -60.02 -39.56 86.25 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.657 -0.652 . . . . 0.0 111.28 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.9 mttm -68.89 -40.02 79.41 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.499 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 41.4 tp -70.78 -42.74 69.95 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.8 -0.76 . . . . 0.0 111.627 -178.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.1 t -97.74 -40.39 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.201 -0.937 . . . . 0.0 111.733 -177.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 118.17 -37.7 3.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.9 m -134.69 149.62 50.52 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.608 -0.937 . . . . 0.0 110.199 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 70.8 p -94.02 3.98 54.56 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.421 -0.799 . . . . 0.0 111.053 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -69.93 -27.64 64.93 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.43 -0.794 . . . . 0.0 111.164 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.97 87.75 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.495 -0.753 . . . . 0.0 110.67 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.28 -60.45 3.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.2 ptt180 -153.61 156.91 38.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.616 -0.932 . . . . 0.0 110.546 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -125.44 117.24 49.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.45 -0.781 . . . . 0.0 109.672 179.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -81.09 169.99 16.74 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.49 -0.756 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 56.4 t30 61.64 47.92 6.05 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.573 -0.704 . . . . 0.0 111.646 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 81.1 t -96.17 124.75 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.031 179.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -84.92 145.76 27.61 Favored 'General case' 0 N--CA 1.493 1.675 0 C-N-CA 119.779 -0.768 . . . . 0.0 109.281 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.02 147.2 40.04 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.833 -0.542 . . . . 0.0 111.598 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.8 m -147.27 148.66 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.653 -0.654 . . . . 0.0 110.829 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.451 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 16.9 tt0 -82.98 140.93 32.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.656 -0.652 . . . . 0.0 110.314 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.4 m -132.54 168.8 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 120.211 -0.595 . . . . 0.0 109.742 179.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -59.97 149.05 33.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.296 -0.878 . . . . 0.0 109.925 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -40.0 88.03 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.408 -0.807 . . . . 0.0 110.94 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 54.0 p -55.45 -35.54 65.57 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.556 -0.715 . . . . 0.0 110.665 -178.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -60.0 -38.39 82.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.435 -0.79 . . . . 0.0 110.075 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 85.8 m -69.63 -39.93 76.86 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.8 mm -64.09 -43.94 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 120.274 -0.571 . . . . 0.0 109.845 -178.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -70.0 -40.02 75.53 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.76 -0.588 . . . . 0.0 110.547 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.44 -51.63 46.86 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.57 -40.04 94.83 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.588 -0.948 . . . . 0.0 110.249 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.087 -179.87 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.428 HG21 ' CD1' ' A' ' 107' ' ' TYR . 29.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.351 0.596 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.9 m -111.36 137.26 49.36 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 37.8 pt -109.75 146.69 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.6 -0.688 . . . . 0.0 110.354 -179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.9 m -143.29 -174.59 4.25 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -142.73 150.0 39.51 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.985 179.067 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.55 152.7 77.03 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.504 -0.748 . . . . 0.0 109.755 179.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -84.52 -12.0 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 O-C-N 123.348 1.183 . . . . 0.0 112.659 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.449 HG13 ' N ' ' A' ' 9' ' ' TYR . 35.9 pt -70.05 -39.91 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 120.871 -1.143 . . . . 0.0 111.333 -178.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.449 ' N ' HG13 ' A' ' 8' ' ' ILE . 46.3 m-85 -72.94 65.22 0.73 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 122.652 1.215 . . . . 0.0 111.712 -178.653 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.89 170.46 7.86 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.55 -34.84 73.18 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -87.83 8.99 23.35 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.016 -1.474 . . . . 0.0 111.542 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 45.3 tp -70.01 122.13 18.76 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.303 -0.873 . . . . 0.0 109.424 179.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.1 m -68.31 135.59 52.12 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.413 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 87.0 mtp -70.07 -15.23 62.96 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.16 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -15.87 72.74 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 120.805 -1.184 . . . . 0.0 110.168 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -88.55 -6.67 57.42 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -1.142 . . . . 0.0 111.735 -179.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.409 HG23 ' HB2' ' A' ' 77' ' ' ASP . 10.8 p -96.74 165.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.997 -1.064 . . . . 0.0 110.603 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.33 94.07 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.783 -0.573 . . . . 0.0 110.907 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.1 m -76.98 71.72 3.5 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.383 -0.823 . . . . 0.0 110.186 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 4.2 p -108.36 111.9 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.467 -0.771 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 51.99 -139.71 0.96 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.592 -0.692 . . . . 0.0 110.561 -179.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.458 ' CA ' ' CH2' ' A' ' 52' ' ' TRP . . . 66.02 -156.12 50.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -74.25 -41.03 61.94 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.684 -0.892 . . . . 0.0 112.025 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.403 ' CD2' ' O ' ' A' ' 54' ' ' SER . 79.5 m-70 -99.69 10.04 42.04 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.074 -1.016 . . . . 0.0 111.51 -178.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.78 130.85 51.17 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 120.073 -1.06 . . . . 0.0 110.523 -179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.0 mt -100.6 -5.93 26.02 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.071 -0.664 . . . . 0.0 110.12 178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 34.3 tpp -59.95 -36.08 76.31 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.281 -0.887 . . . . 0.0 109.599 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.24 -72.46 0.05 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.723 -0.611 . . . . 0.0 111.784 -178.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -69.95 -39.99 75.72 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.349 -0.845 . . . . 0.0 110.223 -179.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.427 ' CD2' HG22 ' A' ' 37' ' ' VAL . 75.8 m-85 -120.38 102.31 45.65 Favored Pre-proline 0 N--CA 1.491 1.596 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 -178.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.97 -22.39 19.75 Favored 'Trans proline' 0 C--N 1.316 -1.154 0 O-C-N 123.322 1.17 . . . . 0.0 111.381 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.1 m -122.69 144.23 49.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.327 -0.858 . . . . 0.0 110.711 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 52.9 tp -64.94 120.82 13.29 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.855 -0.528 . . . . 0.0 110.088 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.29 32.17 0.04 OUTLIER Glycine 0 N--CA 1.496 2.698 0 C-N-CA 119.906 -1.14 . . . . 0.0 110.993 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.424 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 19.1 mt-10 -156.09 -48.17 0.08 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.335 -1.097 . . . . 0.0 109.979 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.427 HG22 ' CD2' ' A' ' 31' ' ' TYR . 2.6 t -62.95 -59.48 12.38 Favored Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 46.9 Cg_endo -73.73 -32.29 7.65 Favored 'Trans proline' 0 C--N 1.318 -1.066 0 N-CA-C 108.733 -1.295 . . . . 0.0 108.733 177.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 130.1 -63.46 0.63 Allowed Glycine 0 N--CA 1.487 2.049 0 N-CA-C 107.197 -2.361 . . . . 0.0 107.197 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.613 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.5 t80 163.32 -53.58 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.556 0 C-N-CA 123.601 0.76 . . . . 0.0 109.91 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.613 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.2 Cg_endo -100.55 12.95 0.49 Allowed 'Trans proline' 0 C--N 1.324 -0.728 0 C-N-CA 121.29 1.327 . . . . 0.0 111.198 -179.029 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 46.6 m-20 -125.15 52.19 1.61 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.216 -0.928 . . . . 0.0 109.765 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.4 p -126.21 136.71 60.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 CA-C-O 121.538 0.685 . . . . 0.0 110.283 -179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.414 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -165.8 171.26 40.91 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.81 160.14 29.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.899 -1.681 . . . . 0.0 108.899 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.466 HG23 ' CE1' ' A' ' 83' ' ' PHE . 8.8 pt -146.65 158.63 45.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.806 -0.82 . . . . 0.0 110.414 179.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.14 -16.41 35.94 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.713 1.609 . . . . 0.0 113.63 -178.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -89.94 18.69 5.47 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.816 -1.177 . . . . 0.0 112.577 -177.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 56.0 mt -119.99 123.17 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.146 -0.971 . . . . 0.0 109.05 177.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.58 -43.64 16.8 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 113.388 0.885 . . . . 0.0 113.388 -177.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 179.54 -125.33 0.96 Allowed Glycine 0 N--CA 1.493 2.452 0 C-N-CA 118.119 -1.991 . . . . 0.0 112.909 -178.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.458 ' CH2' ' CA ' ' A' ' 23' ' ' GLY . 6.8 t90 -40.32 -32.8 0.2 Allowed 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 114.56 1.319 . . . . 0.0 114.56 -176.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 40.9 p-10 -174.15 76.83 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.493 -1.38 . . . . 0.0 109.975 178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.403 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 25.4 p -62.74 155.11 72.01 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.636 -0.665 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 -14.36 40.05 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.566 1.298 . . . . 0.0 110.813 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 6.2 m -102.36 7.79 40.4 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.315 -0.865 . . . . 0.0 111.841 -179.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 41.5 t -65.4 143.65 57.59 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 120.755 -1.216 . . . . 0.0 110.109 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.26 6.45 81.35 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 20.9 p -77.67 158.12 29.85 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.149 -1.207 . . . . 0.0 110.998 179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.41 120.02 40.01 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.19 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.425 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -121.36 139.97 52.73 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.39 -0.819 . . . . 0.0 110.934 179.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -105.92 134.14 49.52 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.436 ' CG2' ' CE2' ' A' ' 83' ' ' PHE . 62.8 t -111.69 125.62 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.587 -0.696 . . . . 0.0 110.47 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 58.8 m -116.41 134.8 54.46 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.692 -0.63 . . . . 0.0 110.552 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.446 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 12.8 pt -116.29 164.04 19.56 Favored Pre-proline 0 N--CA 1.503 2.179 0 O-C-N 121.407 -0.808 . . . . 0.0 111.331 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -63.38 -27.36 71.12 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 121.679 1.586 . . . . 0.0 113.296 -178.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -64.67 -40.03 94.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.064 -1.023 . . . . 0.0 109.917 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 119.92 58.53 0.25 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -154.7 148.43 25.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.72 -0.871 . . . . 0.0 108.666 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 74.9 m -146.44 143.74 29.22 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.738 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.9 pt -134.3 164.35 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -107.13 127.92 53.93 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 118.948 -1.101 . . . . 0.0 109.829 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.431 HD11 HG22 ' A' ' 73' ' ' ILE . 48.5 mm -112.79 130.01 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 ttt180 -98.6 134.89 40.91 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.179 -0.95 . . . . 0.0 109.244 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.96 147.04 30.76 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.416 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -155.4 -44.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.416 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 14.4 t70 -128.73 166.38 19.08 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.2 -0.937 . . . . 0.0 109.563 178.75 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 83.5 p -88.88 161.16 16.84 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.579 -0.701 . . . . 0.0 110.338 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.56 142.97 14.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 88.4 mtt-85 -60.08 -34.01 72.86 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.941 . . . . 0.0 110.009 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.24 75.65 0.04 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.62 149.93 5.1 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.99 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.466 ' CE1' HG23 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -66.53 140.07 57.97 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.855 -0.791 . . . . 0.0 110.491 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.414 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 52.3 t-20 -136.77 119.0 15.56 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.361 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.3 m -130.24 176.11 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 C-N-CA 119.102 -1.039 . . . . 0.0 112.449 -177.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.2 m-20 -56.18 157.58 8.67 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.578 -0.701 . . . . 0.0 109.937 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -70.35 -28.17 22.76 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.407 1.214 . . . . 0.0 110.166 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -70.36 -41.41 73.18 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.033 -1.042 . . . . 0.0 109.549 178.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.0 -40.09 90.86 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -60.05 -49.93 75.74 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.401 -0.52 . . . . 0.0 110.708 178.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.7 m -60.01 -39.71 86.73 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.44 -0.788 . . . . 0.0 111.416 -178.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -69.61 -39.99 76.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.563 -0.711 . . . . 0.0 111.274 -178.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 61.0 tp -71.31 -43.46 67.04 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.587 -0.696 . . . . 0.0 111.296 -179.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.6 t -93.32 -40.55 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.473 -0.767 . . . . 0.0 111.293 -178.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.29 -38.78 2.47 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 74.5 m -142.28 156.93 45.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.674 -0.897 . . . . 0.0 110.416 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 67.2 p -89.95 4.17 50.87 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.776 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.98 -26.65 64.19 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.452 -0.78 . . . . 0.0 110.445 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.01 93.21 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.57 -0.706 . . . . 0.0 110.385 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.33 -75.35 2.39 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -133.42 136.63 45.34 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.558 -0.966 . . . . 0.0 110.572 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.8 t -116.8 113.76 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.438 -0.788 . . . . 0.0 109.76 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -86.84 170.58 11.56 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-O 121.848 0.832 . . . . 0.0 111.608 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.2 t30 60.07 40.01 19.04 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.505 0.669 . . . . 0.0 110.333 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.404 ' CG1' HG13 ' A' ' 63' ' ' VAL . 93.8 t -90.73 122.01 41.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -80.0 140.4 36.59 Favored 'General case' 0 N--CA 1.493 1.707 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.651 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . 0.428 ' CD1' HG21 ' A' ' 1' ' ' VAL . 42.2 p90 -139.27 143.88 38.14 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.882 -0.512 . . . . 0.0 111.231 -178.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.5 m -145.54 139.99 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 111.17 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.425 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 57.3 tt0 -72.66 140.01 47.66 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.364 178.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.8 m -138.48 177.7 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.836 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 47.4 t0 -59.89 146.19 43.07 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.665 -0.647 . . . . 0.0 109.976 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.3 tt -60.0 -37.95 81.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.456 -0.777 . . . . 0.0 110.514 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.7 p -52.71 -35.14 55.22 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.517 -0.739 . . . . 0.0 110.595 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -66.45 -36.3 82.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.511 -0.743 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -62.96 -50.18 71.79 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.264 -0.898 . . . . 0.0 110.038 179.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 90.0 mt -69.3 -40.03 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.748 -0.595 . . . . 0.0 110.457 -179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -65.44 -40.02 92.75 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.44 -0.787 . . . . 0.0 110.158 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.58 -42.18 97.51 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.05 91.1 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.675 -0.897 . . . . 0.0 109.945 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 66.5 t30 . . . . . 0 N--CA 1.5 2.058 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.645 179.898 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.375 0.607 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.0 m -111.77 140.7 46.19 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.661 0.744 . . . . 0.0 110.241 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.6 pt -112.18 147.36 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.755 -0.591 . . . . 0.0 110.487 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.0 p -145.78 -173.24 4.09 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.417 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.1 p90 -142.5 148.88 38.4 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.656 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -124.95 150.38 66.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.468 -0.77 . . . . 0.0 109.608 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -84.55 -7.77 9.64 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 O-C-N 123.303 1.159 . . . . 0.0 112.854 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.457 HG21 HD12 ' A' ' 8' ' ' ILE . 41.0 pt -70.02 -40.09 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.201 0 O-C-N 120.887 -1.133 . . . . 0.0 111.102 -179.356 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.455 ' N ' HG13 ' A' ' 8' ' ' ILE . 38.0 m-85 -72.13 66.86 0.64 Allowed 'General case' 0 N--CA 1.496 1.827 0 CA-C-O 122.684 1.23 . . . . 0.0 111.756 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.69 172.2 6.95 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.126 176.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.17 71.57 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -90.3 11.33 21.62 Favored 'General case' 0 N--CA 1.501 2.09 0 C-N-CA 118.078 -1.449 . . . . 0.0 112.424 -177.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.2 tp -72.63 123.87 24.11 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.214 -0.928 . . . . 0.0 109.956 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 48.4 t -69.54 136.31 51.2 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.027 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.1 mmm -69.98 -15.95 63.11 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.856 -0.527 . . . . 0.0 111.717 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.93 -11.18 66.12 Favored Glycine 0 N--CA 1.495 2.632 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.8 m -93.15 -11.97 31.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.254 -1.144 . . . . 0.0 111.708 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.402 HG22 ' O ' ' A' ' 76' ' ' VAL . 7.1 p -92.45 165.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.17 -0.956 . . . . 0.0 110.46 -179.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -57.98 -45.3 86.98 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.642 -0.661 . . . . 0.0 110.093 -179.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.23 80.32 6.68 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.97 -80.02 0.4 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.485 -0.76 . . . . 0.0 112.903 -177.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -139.91 9.43 2.36 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.217 -0.927 . . . . 0.0 112.917 -178.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.47 -143.97 0.24 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -69.97 -40.02 75.64 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.647 -0.914 . . . . 0.0 109.71 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -90.38 2.37 55.65 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.457 -0.777 . . . . 0.0 110.815 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.03 126.42 33.21 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.423 -1.071 . . . . 0.0 110.423 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 96.1 mt -100.09 0.93 41.71 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 122.132 -0.628 . . . . 0.0 110.21 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 56.6 ttm -68.13 -30.65 69.84 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.364 -0.835 . . . . 0.0 110.339 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.0 -71.8 0.06 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.553 -0.717 . . . . 0.0 111.53 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 37.2 mt-30 -69.97 -40.1 75.6 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.285 -0.884 . . . . 0.0 109.99 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.431 ' CD1' ' HB3' ' A' ' 36' ' ' GLU . 66.5 m-85 -123.16 95.07 46.29 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.843 -0.536 . . . . 0.0 110.049 -179.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.02 -18.75 27.32 Favored 'Trans proline' 0 C--N 1.318 -1.054 0 O-C-N 123.411 1.216 . . . . 0.0 111.483 -179.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.5 m -121.39 149.32 43.16 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.257 -0.902 . . . . 0.0 110.435 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.1 tp -70.64 119.89 15.46 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.793 -0.567 . . . . 0.0 110.422 -179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.29 33.46 0.05 OUTLIER Glycine 0 N--CA 1.495 2.609 0 C-N-CA 120.104 -1.046 . . . . 0.0 110.593 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.431 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 1.6 mt-10 -157.71 -49.91 0.07 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.206 -1.173 . . . . 0.0 110.422 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.414 ' HB ' ' HD3' ' A' ' 38' ' ' PRO . 2.6 t -60.1 -58.61 18.11 Favored Pre-proline 0 N--CA 1.502 2.125 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.414 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -78.54 -29.23 3.84 Favored 'Trans proline' 0 N--CA 1.486 1.079 0 N-CA-C 109.008 -1.189 . . . . 0.0 109.008 176.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 125.4 -64.88 0.56 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 106.676 -2.57 . . . . 0.0 106.676 -178.151 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.545 ' CB ' ' HD3' ' A' ' 41' ' ' PRO . 0.1 OUTLIER 167.98 -58.88 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.377 0 O-C-N 122.277 -0.543 . . . . 0.0 109.962 177.091 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.545 ' HD3' ' CB ' ' A' ' 40' ' ' PHE . 53.4 Cg_endo -95.57 16.87 0.83 Allowed 'Trans proline' 0 C--N 1.325 -0.68 0 O-C-N 123.071 1.037 . . . . 0.0 109.806 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -123.32 38.8 4.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.469 -0.769 . . . . 0.0 109.526 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.8 p -127.89 140.87 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.527 0.679 . . . . 0.0 110.915 -178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.68 175.18 42.69 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.46 161.76 30.13 Favored Glycine 0 N--CA 1.498 2.807 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 179.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.451 ' CG2' ' CD2' ' A' ' 83' ' ' PHE . 0.5 OUTLIER -161.26 164.79 18.01 Favored Pre-proline 0 N--CA 1.503 2.21 0 CA-C-N 118.457 1.128 . . . . 0.0 111.422 -179.097 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.24 -22.27 25.79 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 121.439 1.426 . . . . 0.0 114.593 -177.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -83.94 3.25 34.95 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.382 -1.449 . . . . 0.0 112.762 -177.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.452 HG22 HD12 ' A' ' 49' ' ' ILE . 45.6 mm -97.38 128.94 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.37 -51.01 7.29 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.409 -0.807 . . . . 0.0 111.961 -178.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 174.68 -135.94 3.3 Favored Glycine 0 N--CA 1.487 2.098 0 C-N-CA 118.882 -1.628 . . . . 0.0 111.241 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.411 ' CE3' ' OD2' ' A' ' 53' ' ' ASP . 9.4 t90 -42.74 -27.22 0.16 Allowed 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.411 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 47.2 m-20 -147.0 62.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.208 -0.932 . . . . 0.0 110.901 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 5.1 p -56.96 132.9 79.91 Favored Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.436 -0.79 . . . . 0.0 110.461 -179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.63 -21.16 22.38 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 O-C-N 123.252 1.133 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 38.8 m -96.15 9.47 40.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.456 -0.777 . . . . 0.0 111.043 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -64.0 141.65 58.69 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.327 -0.858 . . . . 0.0 110.265 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 95.33 -24.97 26.64 Favored Glycine 0 N--CA 1.5 2.933 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 178.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.1 m -56.93 161.32 3.02 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.257 -1.143 . . . . 0.0 110.622 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 42.5 t -113.46 152.32 30.28 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.969 -0.457 . . . . 0.0 111.307 -179.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -142.53 149.04 38.58 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.241 -0.912 . . . . 0.0 110.75 178.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.3 tttp -110.71 129.56 55.8 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.2 t -110.9 129.75 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.316 -0.865 . . . . 0.0 110.383 -178.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.5 m -121.12 140.18 52.33 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.842 -0.536 . . . . 0.0 111.381 -178.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.447 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.2 pt -119.27 164.65 20.3 Favored Pre-proline 0 N--CA 1.5 2.057 0 O-C-N 121.499 -0.751 . . . . 0.0 110.311 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.1 Cg_endo -63.5 -24.07 70.61 Favored 'Trans proline' 0 N--CA 1.495 1.613 0 O-C-N 123.404 1.213 . . . . 0.0 112.593 -178.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.3 t-20 -64.47 -39.99 94.86 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.237 -0.915 . . . . 0.0 109.61 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.65 60.56 0.32 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -159.99 150.78 19.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.704 -0.88 . . . . 0.0 109.145 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.411 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.8 m -149.4 157.38 43.26 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 121.992 0.901 . . . . 0.0 112.029 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 71' ' ' ILE . 36.8 pt -140.06 165.84 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -107.61 130.25 54.91 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.128 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.11 130.04 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.691 -0.631 . . . . 0.0 110.726 -178.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -101.24 135.33 42.88 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -62.24 149.34 47.92 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.124 -1.036 . . . . 0.0 111.386 -177.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.427 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 2.6 p -152.63 -45.75 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.427 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 10.3 t70 -129.49 169.04 15.46 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.34 -0.85 . . . . 0.0 109.517 179.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 82.9 p -103.9 159.94 15.23 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.604 -0.685 . . . . 0.0 110.111 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.52 156.64 21.96 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -60.03 -35.78 75.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.674 -0.898 . . . . 0.0 109.109 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -171.32 177.55 44.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 51.54 -168.32 0.56 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 121.355 -1.085 . . . . 0.0 111.567 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.451 ' CD2' ' CG2' ' A' ' 46' ' ' ILE . 32.4 m-85 -120.0 139.06 53.06 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.965 -0.727 . . . . 0.0 109.15 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 33.4 t-20 -129.29 128.48 43.28 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.3 m -130.72 172.07 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.088 -1.008 . . . . 0.0 112.025 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -55.84 152.77 18.8 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.29 -0.881 . . . . 0.0 109.663 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.36 -21.35 61.22 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 O-C-N 123.386 1.203 . . . . 0.0 110.732 -179.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.2 m -78.76 -40.04 34.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.928 -1.107 . . . . 0.0 109.33 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.68 -40.03 88.38 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -60.01 -49.87 75.99 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.794 -0.566 . . . . 0.0 110.447 179.088 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -59.99 -38.74 83.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.583 -0.698 . . . . 0.0 110.661 -178.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -69.87 -39.87 76.06 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.141 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 61.2 tp -70.14 -43.97 69.82 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.507 -0.746 . . . . 0.0 111.283 -179.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.51 -39.88 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.298 -0.876 . . . . 0.0 111.461 -178.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 119.89 -35.19 3.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 64.2 m -140.03 150.83 44.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.525 -0.985 . . . . 0.0 110.889 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.8 p -89.57 3.74 51.56 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.516 -0.74 . . . . 0.0 110.627 179.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -70.08 -28.32 65.33 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.441 -0.787 . . . . 0.0 110.951 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.17 -40.03 84.37 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.456 -0.777 . . . . 0.0 110.417 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.57 -79.6 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.0 ttm180 -129.85 132.69 46.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.659 -0.906 . . . . 0.0 110.219 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.5 t -119.34 120.06 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.396 -0.815 . . . . 0.0 110.276 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.401 ' O ' ' HB2' ' A' ' 104' ' ' ASN . 9.3 t70 -85.05 173.11 10.75 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.42 0.629 . . . . 0.0 110.876 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 94.9 m-20 60.04 39.97 19.19 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-O 121.091 0.472 . . . . 0.0 111.569 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 63.0 t -86.95 122.58 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -82.25 134.58 35.29 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.173 -1.011 . . . . 0.0 109.425 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -136.28 142.72 43.97 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.325 0.583 . . . . 0.0 111.323 -178.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -144.07 140.05 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.731 -0.606 . . . . 0.0 110.184 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -71.43 140.75 50.2 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.698 . . . . 0.0 110.422 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -136.57 173.26 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.829 178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -61.12 149.67 36.54 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.386 -0.822 . . . . 0.0 110.833 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.5 tt -59.98 -39.3 85.21 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.456 -0.778 . . . . 0.0 110.794 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 62.8 m -53.85 -39.44 65.63 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 110.226 -178.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -60.25 -39.3 86.24 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.606 -0.684 . . . . 0.0 110.988 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -59.97 -49.37 77.94 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.238 -0.914 . . . . 0.0 110.059 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 85.7 mt -69.84 -40.03 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.704 -0.622 . . . . 0.0 110.57 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.18 -40.0 95.18 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.342 -0.849 . . . . 0.0 110.316 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.45 -39.97 79.65 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.26 -39.96 88.62 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.604 -0.939 . . . . 0.0 110.276 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.194 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.863 0.363 . . . . 0.0 110.66 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.3 m -110.95 141.73 44.0 Favored 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.832 0.825 . . . . 0.0 111.332 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.427 HG12 HG21 ' A' ' 105' ' ' VAL . 45.8 pt -119.93 149.94 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.89 -0.507 . . . . 0.0 110.407 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 67.6 m -143.97 -174.08 4.17 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -141.5 150.0 41.63 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.362 -0.836 . . . . 0.0 110.538 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -132.88 144.73 54.07 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.609 -0.682 . . . . 0.0 109.543 179.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.6 -4.46 14.13 Favored 'Trans proline' 0 C--N 1.317 -1.11 0 O-C-N 123.381 1.201 . . . . 0.0 112.405 -178.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.9 pt -69.99 -40.03 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 120.899 -1.126 . . . . 0.0 110.439 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.464 ' N ' HG13 ' A' ' 8' ' ' ILE . 30.8 m-85 -74.52 66.66 1.42 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 122.815 1.293 . . . . 0.0 110.611 -178.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.72 171.62 7.26 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 114.307 -1.315 . . . . 0.0 108.458 177.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.83 -34.47 73.13 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -175.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -89.1 10.1 23.03 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.45 -1.406 . . . . 0.0 111.966 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 58.7 tp -71.16 122.87 20.93 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.359 -0.838 . . . . 0.0 109.431 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.3 m -68.89 136.84 53.25 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.705 0.764 . . . . 0.0 110.199 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 89.4 mmm -65.58 -16.98 64.23 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.471 -179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.57 -16.59 77.65 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.012 -1.055 . . . . 0.0 111.069 -179.208 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 79.6 p -90.33 -17.65 26.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.138 -1.213 . . . . 0.0 111.256 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.6 p -89.97 155.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.333 -0.854 . . . . 0.0 109.598 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -48.41 -40.02 24.53 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.513 -0.742 . . . . 0.0 110.406 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.29 82.59 4.58 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -92.51 -83.41 0.3 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.895 -1.128 . . . . 0.0 112.596 -177.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -154.5 18.02 0.47 Allowed 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.802 -1.186 . . . . 0.0 112.339 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.06 -141.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -70.13 -42.56 72.45 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.692 -0.887 . . . . 0.0 109.634 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.601 ' NE2' ' N ' ' A' ' 54' ' ' SER . 8.2 p80 -97.31 4.48 50.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.477 -0.765 . . . . 0.0 110.861 -179.715 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.56 144.43 37.42 Favored Glycine 0 N--CA 1.494 2.541 0 O-C-N 121.14 -0.975 . . . . 0.0 110.734 -179.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 94.5 mt -99.58 -3.05 34.16 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.825 -0.809 . . . . 0.0 110.539 179.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 55.3 tpp -60.12 -36.39 77.38 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.562 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.89 -77.79 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.423 -0.798 . . . . 0.0 111.977 -177.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -69.98 -39.99 75.63 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.38 -0.825 . . . . 0.0 111.053 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -119.99 88.44 40.65 Favored Pre-proline 0 N--CA 1.493 1.698 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.59 -16.51 42.65 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.353 1.186 . . . . 0.0 111.51 -178.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.5 m -125.6 140.21 52.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.214 -0.929 . . . . 0.0 110.308 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 51.2 tp -68.55 119.74 13.47 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.68 -0.637 . . . . 0.0 110.65 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.31 32.78 0.04 OUTLIER Glycine 0 N--CA 1.497 2.713 0 C-N-CA 119.96 -1.114 . . . . 0.0 110.782 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 -156.14 -49.55 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.161 -1.199 . . . . 0.0 110.603 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.423 ' CB ' ' CD ' ' A' ' 38' ' ' PRO . 2.4 t -61.18 -59.64 13.1 Favored Pre-proline 0 N--CA 1.499 2.008 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 48.5 Cg_endo -75.38 -31.76 5.5 Favored 'Trans proline' 0 C--N 1.318 -1.075 0 N-CA-C 108.872 -1.241 . . . . 0.0 108.872 177.64 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.438 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.69 -64.22 0.62 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 107.316 -2.314 . . . . 0.0 107.316 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.467 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 163.54 -68.32 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.645 0 C-N-CA 123.533 0.733 . . . . 0.0 109.555 177.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.467 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.4 Cg_endo -80.41 -0.54 10.71 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 O-C-N 122.734 0.86 . . . . 0.0 111.423 179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -109.95 57.18 0.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.195 -0.94 . . . . 0.0 109.449 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.4 p -129.62 135.66 60.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-O 121.551 0.691 . . . . 0.0 110.557 -179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -165.12 173.01 40.91 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.94 163.79 28.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.404 HG13 ' CG1' ' A' ' 49' ' ' ILE . 1.0 OUTLIER -143.73 157.02 59.2 Favored Pre-proline 0 N--CA 1.495 1.81 0 O-C-N 121.698 -0.884 . . . . 0.0 110.19 179.336 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.48 -9.26 25.48 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.567 1.511 . . . . 0.0 113.044 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -99.01 28.16 4.58 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.918 -1.114 . . . . 0.0 112.239 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.436 HG22 HD12 ' A' ' 49' ' ' ILE . 48.6 mm -119.58 121.57 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.085 -1.01 . . . . 0.0 109.36 179.185 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.5 -43.01 57.94 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.323 -0.86 . . . . 0.0 111.487 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 163.96 -133.33 2.99 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 119.296 -1.43 . . . . 0.0 111.141 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 71.4 t90 -51.11 -23.69 3.39 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.562 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 21.5 t70 -143.99 64.4 1.32 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.362 -0.836 . . . . 0.0 110.427 -178.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.601 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 44.0 m -79.37 142.36 58.34 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.431 -0.793 . . . . 0.0 111.03 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.47 -19.27 15.02 Favored 'Trans proline' 0 C--N 1.317 -1.119 0 O-C-N 123.421 1.222 . . . . 0.0 111.031 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.44 9.86 42.17 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.228 -0.92 . . . . 0.0 112.109 -178.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.431 ' HB3' ' ND1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -72.06 154.09 41.33 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.912 -1.117 . . . . 0.0 108.776 178.982 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.405 ' HA2' ' CZ ' ' A' ' 74' ' ' ARG . . . 78.61 10.02 86.55 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 96.3 m -99.88 139.96 34.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.306 -1.114 . . . . 0.0 109.706 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.4 m -80.12 143.59 33.78 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.299 0.571 . . . . 0.0 111.063 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.41 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 70.1 m95 -145.39 133.64 21.68 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.443 -0.785 . . . . 0.0 109.871 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -108.53 141.55 40.26 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.181 -0.949 . . . . 0.0 110.571 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.4 t -112.95 127.89 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 CA-C-O 121.385 0.612 . . . . 0.0 110.977 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 m -120.03 143.5 48.05 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.702 -0.624 . . . . 0.0 110.254 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.455 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 9.5 pt -120.74 164.15 24.97 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.171 -0.955 . . . . 0.0 111.218 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.2 Cg_endo -61.49 -26.24 80.71 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 121.682 1.588 . . . . 0.0 113.067 -178.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -63.42 -35.67 81.18 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.227 -0.921 . . . . 0.0 109.761 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.59 63.17 0.46 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -164.42 157.23 17.15 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.774 -0.839 . . . . 0.0 109.209 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 73.9 p -154.74 159.74 40.88 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 122.025 0.917 . . . . 0.0 111.515 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 21.7 pt -133.61 164.27 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -103.61 125.0 49.86 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 118.319 -1.353 . . . . 0.0 109.895 -178.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -119.78 123.54 71.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.621 -0.674 . . . . 0.0 109.911 -178.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . 0.405 ' CZ ' ' HA2' ' A' ' 58' ' ' GLY . 0.0 OUTLIER -93.69 133.66 36.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.406 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -54.8 144.77 30.28 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.462 HG11 ' N ' ' A' ' 77' ' ' ASP . 13.4 p -168.35 -28.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.802 -0.822 . . . . 0.0 111.138 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.462 ' N ' HG11 ' A' ' 76' ' ' VAL . 5.4 m-20 -126.07 170.0 12.2 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.721 -1.237 . . . . 0.0 110.258 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.426 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.5 t -101.4 151.92 21.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.7 -0.625 . . . . 0.0 110.686 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.73 144.32 16.24 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.084 -1.207 . . . . 0.0 110.084 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -60.66 -31.45 70.68 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.78 -0.835 . . . . 0.0 109.978 178.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.65 80.81 0.05 OUTLIER Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.72 -176.94 29.07 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.447 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 57.7 m-85 -113.17 130.96 56.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.438 -1.036 . . . . 0.0 109.58 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 36.8 t-20 -120.88 130.96 54.13 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.7 m -130.22 171.8 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.175 -0.953 . . . . 0.0 112.258 -177.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.2 m-20 -54.07 155.83 6.04 Favored Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.588 -0.695 . . . . 0.0 110.321 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.86 -18.12 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.409 1.215 . . . . 0.0 110.761 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.6 m -80.82 -39.76 26.09 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.965 -1.085 . . . . 0.0 109.208 178.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.37 -39.08 85.65 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.451 ' CE1' ' HA ' ' A' ' 97' ' ' THR . 25.3 t80 -59.99 -50.0 75.44 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.634 -0.666 . . . . 0.0 110.762 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -59.98 -38.95 84.02 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.58 -0.7 . . . . 0.0 111.103 -178.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -64.63 -40.02 94.74 Favored 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.962 -0.695 . . . . 0.0 111.562 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 59.8 tp -69.03 -42.54 76.22 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.637 -0.665 . . . . 0.0 111.9 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 49.0 t -100.25 -9.98 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.302 0 O-C-N 121.228 -0.92 . . . . 0.0 111.927 -178.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 99.5 -29.27 12.3 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 -178.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 97.1 p -155.62 159.84 39.96 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.451 ' HA ' ' CE1' ' A' ' 90' ' ' PHE . 2.8 t -109.06 24.69 12.76 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.113 -0.992 . . . . 0.0 111.086 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -73.82 -22.83 59.66 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.555 -0.715 . . . . 0.0 111.067 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.95 -44.8 94.18 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.365 -0.834 . . . . 0.0 110.971 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.15 -68.07 0.53 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -140.25 135.52 32.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.946 . . . . 0.0 110.383 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 68.6 t -119.57 119.7 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -0.824 . . . . 0.0 110.155 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.9 p-10 -87.95 175.07 7.95 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-O 121.563 0.697 . . . . 0.0 111.181 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.3 t30 59.98 40.86 18.34 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.705 -0.622 . . . . 0.0 110.943 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.427 HG21 HG12 ' A' ' 3' ' ' ILE . 91.3 t -93.86 121.38 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.992 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -79.91 139.77 36.97 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 119.353 -0.939 . . . . 0.0 109.299 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -136.67 142.22 43.17 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.864 -0.523 . . . . 0.0 110.517 -179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -148.33 150.35 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.616 -0.678 . . . . 0.0 110.581 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.41 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 61.2 tt0 -90.19 138.81 31.22 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.542 -0.724 . . . . 0.0 110.516 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.49 177.46 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.591 -0.693 . . . . 0.0 110.257 179.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.91 142.96 52.7 Favored 'General case' 0 N--CA 1.496 1.84 0 CA-C-O 121.582 0.706 . . . . 0.0 110.952 -178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.5 tt -60.11 -38.42 82.96 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.814 -0.554 . . . . 0.0 110.769 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 83.3 p -54.31 -37.01 64.33 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.561 -0.712 . . . . 0.0 111.359 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -70.07 -19.94 63.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.432 -0.793 . . . . 0.0 110.506 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 28.2 m -73.63 -52.17 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 86.5 mt -70.0 -39.99 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.523 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -69.67 -40.0 76.69 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 120.025 -0.67 . . . . 0.0 110.108 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.27 -53.02 19.58 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -44.52 94.52 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.523 -0.987 . . . . 0.0 110.582 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.216 -179.901 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.089 0.471 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -113.28 140.48 47.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.742 -0.599 . . . . 0.0 109.958 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 38.5 pt -104.61 145.41 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.649 -0.657 . . . . 0.0 110.055 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m -145.72 -171.6 3.72 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 51.7 p90 -146.16 150.0 35.04 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.41 179.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -129.01 146.17 59.62 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -81.07 -8.05 13.09 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.264 1.139 . . . . 0.0 112.449 -178.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.476 HG13 ' N ' ' A' ' 9' ' ' TYR . 37.5 pt -67.92 -40.09 82.83 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 120.889 -1.132 . . . . 0.0 110.789 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.476 ' N ' HG13 ' A' ' 8' ' ' ILE . 52.3 m-85 -72.77 67.71 0.82 Allowed 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 122.9 1.333 . . . . 0.0 111.443 -178.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.1 171.1 7.49 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.065 176.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.94 -33.92 71.15 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -175.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -91.09 11.56 22.74 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.599 -1.313 . . . . 0.0 112.354 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 35.3 tp -70.02 123.37 21.38 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.289 -0.882 . . . . 0.0 109.844 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.26 136.12 49.59 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.642 0.734 . . . . 0.0 110.078 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.8 mmm -68.81 -16.68 63.85 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.979 -0.451 . . . . 0.0 111.869 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.77 -14.67 70.44 Favored Glycine 0 N--CA 1.495 2.586 0 O-C-N 120.917 -1.115 . . . . 0.0 111.309 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.2 t -91.05 -8.01 50.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.129 -1.218 . . . . 0.0 112.051 -178.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.426 HG21 ' N ' ' A' ' 19' ' ' ALA . 8.6 p -96.01 167.82 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.107 -0.996 . . . . 0.0 110.26 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.426 ' N ' HG21 ' A' ' 18' ' ' VAL . . . -59.39 -44.49 92.76 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.51 -0.744 . . . . 0.0 109.988 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.4 m -81.76 81.75 7.68 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.522 -0.736 . . . . 0.0 109.112 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -101.29 -79.57 0.51 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.619 -0.676 . . . . 0.0 112.594 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -131.6 10.18 4.73 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.282 -0.886 . . . . 0.0 112.723 -178.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.429 ' HA2' ' CH2' ' A' ' 52' ' ' TRP . . . -73.61 -148.27 1.17 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -64.7 -39.92 94.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 110.865 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.422 ' CG ' ' O ' ' A' ' 54' ' ' SER . 69.1 m-70 -101.16 15.87 27.31 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.331 -0.856 . . . . 0.0 111.231 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.69 131.32 51.99 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.2 mt -97.46 -4.83 37.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.903 -0.763 . . . . 0.0 110.466 179.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 38.3 tpp -60.87 -34.7 75.02 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.331 -0.855 . . . . 0.0 110.635 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.69 -76.75 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.48 -0.762 . . . . 0.0 111.96 -177.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . 0.415 ' NE2' ' CE2' ' A' ' 31' ' ' TYR . 12.7 tt0 -69.91 -39.99 75.86 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.433 -0.792 . . . . 0.0 110.367 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.444 ' CD2' HG21 ' A' ' 37' ' ' VAL . 58.0 m-85 -120.99 93.3 48.84 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.648 -0.658 . . . . 0.0 109.981 -179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.07 -10.65 27.86 Favored 'Trans proline' 0 C--N 1.318 -1.069 0 O-C-N 123.413 1.217 . . . . 0.0 111.132 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.3 p -126.83 154.04 44.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.326 -0.859 . . . . 0.0 110.269 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.1 tp -78.09 116.03 18.25 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.51 34.0 0.03 OUTLIER Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.76 -48.04 0.07 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 110.613 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.444 HG21 ' CD2' ' A' ' 31' ' ' TYR . 2.2 t -61.33 -57.78 23.21 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 108.591 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.402 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.7 Cg_endo -78.8 -28.4 4.13 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 O-C-N 123.307 1.161 . . . . 0.0 109.485 178.179 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.83 -61.13 0.65 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 107.503 -2.239 . . . . 0.0 107.503 -178.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.593 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 163.24 -54.78 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.605 0 C-N-CA 123.414 0.685 . . . . 0.0 110.042 177.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.593 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.38 15.28 0.3 Allowed 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 121.563 1.509 . . . . 0.0 111.448 -178.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -125.37 39.9 3.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.358 -0.839 . . . . 0.0 109.244 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.4 p -123.66 147.52 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 CA-C-O 121.674 0.749 . . . . 0.0 110.264 -178.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -174.48 175.97 46.79 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.94 149.41 37.82 Favored Glycine 0 N--CA 1.484 1.839 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.42 HG13 HG12 ' A' ' 49' ' ' ILE . 1.1 pp -142.37 139.19 17.29 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.545 -0.974 . . . . 0.0 108.847 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -58.89 -10.51 9.91 Favored 'Trans proline' 0 N--CA 1.505 2.202 0 C-N-CA 122.046 1.831 . . . . 0.0 115.261 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -96.19 30.63 2.41 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 120.529 -1.357 . . . . 0.0 111.899 -178.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.469 HD13 HG23 ' A' ' 49' ' ' ILE . 50.8 mm -119.99 125.99 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.142 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.82 -44.62 15.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.551 -0.718 . . . . 0.0 111.78 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.11 -130.6 1.96 Allowed Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.406 -179.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.429 ' CH2' ' HA2' ' A' ' 23' ' ' GLY . 5.5 t90 -40.21 -30.04 0.09 Allowed 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 -177.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -158.97 72.98 0.59 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.689 -1.257 . . . . 0.0 110.83 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.422 ' O ' ' CG ' ' A' ' 25' ' ' HIS . 4.0 t -54.53 140.32 57.19 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.671 -0.643 . . . . 0.0 111.317 -178.887 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.41 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -72.81 -20.42 22.61 Favored 'Trans proline' 0 C--N 1.319 -1.006 0 O-C-N 123.412 1.217 . . . . 0.0 110.558 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 18.9 m -103.93 14.85 29.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.347 -0.846 . . . . 0.0 111.294 -179.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.0 t -67.74 144.68 55.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.117 -0.99 . . . . 0.0 110.383 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.13 8.31 82.06 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 p -80.6 159.71 25.33 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 179.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 41.9 t -110.79 137.54 48.32 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.789 -178.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.447 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 81.9 m95 -142.96 155.88 44.77 Favored 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.12 -0.988 . . . . 0.0 111.394 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 68.7 tttt -112.18 132.25 55.0 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 177.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.05 129.9 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.557 -0.715 . . . . 0.0 109.723 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.3 m -120.68 142.18 49.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.749 -0.595 . . . . 0.0 111.362 -178.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.432 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 48.0 pt -119.74 164.37 22.4 Favored Pre-proline 0 N--CA 1.499 2.022 0 O-C-N 121.496 -0.753 . . . . 0.0 110.209 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.432 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.35 -26.02 76.72 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.174 1.25 . . . . 0.0 112.891 -178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -64.76 -39.96 94.48 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.218 -0.926 . . . . 0.0 109.907 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.1 60.75 0.29 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -160.45 153.51 21.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.603 -0.939 . . . . 0.0 109.339 178.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.0 p -151.71 159.68 43.89 Favored 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 122.12 0.962 . . . . 0.0 112.149 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.8 pt -139.91 164.13 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -105.27 127.18 52.81 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 118.86 -1.136 . . . . 0.0 109.784 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -115.89 130.03 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.627 -0.671 . . . . 0.0 110.134 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 51.4 ttt180 -100.67 136.91 39.79 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.64 149.71 39.8 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.947 -178.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 7.0 p -167.47 -35.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.809 -0.818 . . . . 0.0 110.635 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -129.89 174.48 9.7 Favored 'General case' 0 N--CA 1.508 2.435 0 O-C-N 120.748 -1.22 . . . . 0.0 108.948 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.421 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 36.9 t -98.59 143.14 29.31 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.357 -0.84 . . . . 0.0 110.535 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -107.89 140.29 15.38 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 -81.96 58.2 3.8 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.724 -0.868 . . . . 0.0 111.589 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.99 58.17 1.62 Allowed Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 151.15 5.42 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.791 -1.195 . . . . 0.0 110.386 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -73.68 145.18 45.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.866 -0.785 . . . . 0.0 110.963 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -139.55 130.69 26.55 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.457 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.1 m -132.28 172.5 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.057 -1.027 . . . . 0.0 112.202 -178.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.7 m-20 -54.69 150.8 16.81 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.275 -0.891 . . . . 0.0 109.823 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.43 -18.3 63.96 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.321 1.169 . . . . 0.0 110.656 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 86.1 m -78.73 -40.01 34.7 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.934 -1.104 . . . . 0.0 109.376 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.34 -39.11 82.0 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.509 -0.744 . . . . 0.0 109.107 179.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -59.99 -49.93 75.75 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.767 -0.583 . . . . 0.0 110.704 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.8 m -60.05 -37.37 79.63 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.406 -0.809 . . . . 0.0 110.623 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -70.0 -39.96 75.58 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.043 -179.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 52.7 tp -70.01 -44.25 69.73 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.569 -0.707 . . . . 0.0 111.428 -179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 63.0 t -96.37 -39.92 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.304 -0.873 . . . . 0.0 111.561 -177.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.53 -29.43 4.99 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.7 p -152.66 160.65 43.16 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.461 -1.023 . . . . 0.0 110.457 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 72.7 p -94.62 8.17 43.25 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.532 -0.73 . . . . 0.0 110.857 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -69.15 -36.07 77.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.42 -0.8 . . . . 0.0 110.677 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.75 87.0 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.525 -0.735 . . . . 0.0 110.284 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.38 -63.54 3.64 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 21.3 ptt180 -150.8 157.59 43.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.673 -0.898 . . . . 0.0 110.745 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.2 t -128.09 122.26 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.553 -0.717 . . . . 0.0 110.223 179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -82.87 169.12 16.43 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.603 -0.686 . . . . 0.0 110.961 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t30 60.01 43.22 14.84 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.62 -0.675 . . . . 0.0 111.306 179.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 63.7 t -87.21 130.02 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 C-N-CA 120.06 -0.656 . . . . 0.0 109.966 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -87.19 139.43 30.57 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.804 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -139.9 144.32 37.1 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.914 -0.491 . . . . 0.0 111.173 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.95 143.2 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.529 -0.732 . . . . 0.0 110.734 179.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.447 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 66.1 tt0 -75.72 134.33 40.54 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.603 -0.685 . . . . 0.0 110.009 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.34 172.7 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.554 -0.716 . . . . 0.0 110.237 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -60.11 146.07 44.47 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.513 -0.742 . . . . 0.0 110.986 -179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.1 tt -60.96 -37.22 81.64 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.621 -0.674 . . . . 0.0 110.796 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.8 m -55.23 -40.07 70.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.51 -0.744 . . . . 0.0 110.221 -178.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -59.98 -37.41 79.55 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.731 -0.606 . . . . 0.0 110.317 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -63.32 -46.65 85.67 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.369 -0.832 . . . . 0.0 110.116 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.451 HD13 HG23 ' A' ' 116' ' ' ILE . 88.0 mt -70.02 -40.01 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.554 -0.717 . . . . 0.0 110.738 -178.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -66.88 -40.06 87.67 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.468 -0.77 . . . . 0.0 110.498 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.85 -48.08 51.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.97 94.34 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.598 -0.942 . . . . 0.0 110.603 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 118.047 -0.977 . . . . 0.0 110.265 -179.894 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.205 0.526 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t -111.18 137.72 48.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.628 -0.67 . . . . 0.0 109.3 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 42.1 pt -113.98 147.7 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.729 -0.607 . . . . 0.0 111.018 -179.096 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.06 -170.09 3.34 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -141.82 148.1 38.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.41 -0.806 . . . . 0.0 110.337 178.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -127.05 148.61 66.52 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.46 -0.775 . . . . 0.0 109.825 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -82.57 -7.43 11.63 Favored 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.391 1.206 . . . . 0.0 112.367 -179.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 9' ' ' TYR . 27.4 pt -72.93 -42.29 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.139 0 O-C-N 120.933 -1.104 . . . . 0.0 110.885 -179.025 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.459 ' N ' HG13 ' A' ' 8' ' ' ILE . 31.9 m-85 -72.29 67.18 0.68 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 122.651 1.215 . . . . 0.0 111.049 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.55 171.05 7.58 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.327 176.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.04 -34.16 73.02 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -175.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -90.05 10.62 23.51 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.416 -1.314 . . . . 0.0 112.136 -177.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 53.4 tp -71.02 126.05 28.53 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 178.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.1 t -69.95 136.02 50.07 Favored 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.791 0.805 . . . . 0.0 110.454 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.2 mmm -66.43 -19.07 65.7 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.436 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.27 -14.06 63.48 Favored Glycine 0 N--CA 1.493 2.456 0 O-C-N 121.044 -1.035 . . . . 0.0 110.776 -179.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.9 m -93.16 -14.59 26.97 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -1.161 . . . . 0.0 111.796 -178.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.04 160.04 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 120.996 -1.065 . . . . 0.0 110.708 -179.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -57.59 -42.63 83.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.699 -0.626 . . . . 0.0 110.565 -179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.0 m -81.64 72.89 8.7 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -101.78 -76.59 0.57 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.705 -0.622 . . . . 0.0 110.628 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -127.27 168.87 14.16 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.108 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.35 -154.81 16.49 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.52 -2.232 . . . . 0.0 107.52 -177.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -70.2 -39.92 74.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.292 -1.122 . . . . 0.0 110.271 179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 58.8 m-70 -94.09 0.71 56.04 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.454 -0.779 . . . . 0.0 111.194 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.59 127.65 37.64 Favored Glycine 0 N--CA 1.495 2.611 0 O-C-N 120.964 -1.085 . . . . 0.0 110.423 -179.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.5 mt -100.04 -5.19 28.44 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 122.012 -0.699 . . . . 0.0 110.072 178.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.2 ttm -63.04 -37.72 88.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.28 -0.887 . . . . 0.0 109.764 179.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.92 -73.45 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.611 -0.681 . . . . 0.0 111.506 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -69.94 -40.05 75.72 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.157 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.423 ' CG ' HG22 ' A' ' 37' ' ' VAL . 35.6 m-85 -120.36 89.89 44.44 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.864 -0.523 . . . . 0.0 109.801 -178.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.07 -10.01 25.38 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 O-C-N 123.196 1.103 . . . . 0.0 111.049 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 31.0 m -130.01 142.13 50.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.231 -0.918 . . . . 0.0 110.366 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 35.4 tp -69.94 119.25 13.87 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.642 -0.661 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.76 32.6 0.04 OUTLIER Glycine 0 N--CA 1.497 2.746 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.985 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -156.95 -44.95 0.07 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -1.16 . . . . 0.0 110.096 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.423 HG22 ' CG ' ' A' ' 31' ' ' TYR . 2.7 t -63.62 -59.03 12.75 Favored Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.552 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 53.5 Cg_endo -76.82 -29.22 5.63 Favored 'Trans proline' 0 N--CA 1.487 1.109 0 O-C-N 123.271 1.143 . . . . 0.0 109.55 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 127.63 -61.92 0.64 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.603 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 164.69 -54.74 0.0 OUTLIER Pre-proline 0 N--CA 1.509 2.503 0 C-N-CA 123.368 0.667 . . . . 0.0 109.885 177.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.603 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.2 Cg_endo -102.21 11.81 0.39 Allowed 'Trans proline' 0 C--N 1.325 -0.702 0 C-N-CA 121.473 1.448 . . . . 0.0 111.419 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -117.61 31.16 6.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.244 -0.91 . . . . 0.0 110.059 -178.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.401 ' CG2' ' CG1' ' A' ' 76' ' ' VAL . 15.0 p -110.46 139.92 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.561 0.696 . . . . 0.0 110.943 -179.306 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.5 173.79 42.59 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.32 163.72 25.38 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.457 ' CD1' HG12 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -154.27 162.53 26.7 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.806 -0.82 . . . . 0.0 109.888 179.015 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -67.33 -16.94 49.23 Favored 'Trans proline' 0 N--CA 1.5 1.902 0 C-N-CA 121.502 1.468 . . . . 0.0 113.95 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.401 ' HB2' ' CD1' ' A' ' 46' ' ' ILE . 94.4 m-20 -89.39 15.83 8.53 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.541 -1.349 . . . . 0.0 113.025 -177.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 46' ' ' ILE . 43.0 mm -108.02 122.63 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.72 -45.47 29.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.305 -0.872 . . . . 0.0 111.664 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.3 -127.81 1.66 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 118.983 -1.58 . . . . 0.0 110.95 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 49.1 t90 -48.92 -26.03 2.25 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.897 -0.767 . . . . 0.0 112.841 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -147.27 63.13 1.16 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.169 -0.957 . . . . 0.0 111.379 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.414 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 4.5 p -63.68 141.72 97.96 Favored Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.359 -0.838 . . . . 0.0 110.87 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.411 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -80.69 -21.74 6.98 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 O-C-N 123.41 1.216 . . . . 0.0 111.599 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.6 m -95.11 11.63 31.5 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.357 -0.84 . . . . 0.0 111.183 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -72.14 146.29 47.54 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.209 -0.932 . . . . 0.0 110.304 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.78 22.83 52.13 Favored Glycine 0 N--CA 1.495 2.568 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.098 178.064 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.1 m -109.29 170.65 7.92 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -1.11 . . . . 0.0 109.009 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 2.1 m -118.96 148.2 43.22 Favored 'General case' 0 N--CA 1.51 2.556 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -177.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.459 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 67.9 m95 -144.34 149.67 36.55 Favored 'General case' 0 N--CA 1.51 2.565 0 O-C-N 121.116 -0.99 . . . . 0.0 110.219 175.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.3 ttpt -101.46 131.2 47.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 176.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.8 t -108.61 124.47 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.64 -178.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 94.3 m -120.03 130.03 54.52 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-O 121.189 0.519 . . . . 0.0 111.42 -178.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.467 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.4 pt -106.85 166.15 11.63 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.789 -0.569 . . . . 0.0 110.492 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.467 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.7 Cg_endo -63.92 -27.56 66.77 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 O-C-N 123.347 1.183 . . . . 0.0 112.605 -178.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -64.3 -39.92 94.89 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.169 -0.957 . . . . 0.0 109.734 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.46 58.3 0.32 Allowed Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -150.72 147.32 27.19 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 178.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 49.1 m -147.25 152.36 38.19 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.859 -1.136 . . . . 0.0 112.652 -179.467 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 37.7 pt -140.13 161.66 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.31 129.76 47.34 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.093 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.0 mm -116.58 129.97 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 109.782 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 58.6 ttt180 -101.32 133.31 46.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.965 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -52.52 149.59 10.06 Favored Glycine 0 N--CA 1.498 2.795 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 77' ' ' ASP . 14.9 p -174.48 -28.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.652 -0.91 . . . . 0.0 111.121 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.41 ' OD2' ' CE1' ' A' ' 9' ' ' TYR . 5.2 m-20 -129.75 167.47 18.02 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.717 -1.239 . . . . 0.0 109.422 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 77.7 p -97.84 155.89 16.84 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -0.835 . . . . 0.0 110.771 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.94 139.52 11.01 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -61.04 -39.9 91.56 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.837 -0.802 . . . . 0.0 110.209 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.61 73.53 0.08 OUTLIER Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 155.22 -163.34 31.45 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.89 -1.148 . . . . 0.0 110.298 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.477 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 39.8 m-85 -125.63 121.56 33.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.919 -0.753 . . . . 0.0 109.113 179.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -116.08 130.24 56.71 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 26.9 m -129.18 173.47 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -178.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.9 m-20 -56.53 158.2 8.55 Favored Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.544 -0.722 . . . . 0.0 110.021 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.83 -28.66 36.13 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.453 1.238 . . . . 0.0 111.06 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -70.03 -39.96 75.44 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.993 -1.067 . . . . 0.0 109.26 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.87 -41.31 87.47 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.64 -50.0 75.27 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.804 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -60.18 -40.04 88.58 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.515 -0.741 . . . . 0.0 110.839 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.27 -39.56 86.06 Favored 'General case' 0 N--CA 1.495 1.797 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.207 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 65.5 tp -69.95 -41.66 74.25 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.835 -178.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -98.89 -36.65 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.255 -0.903 . . . . 0.0 111.722 -177.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.04 -27.43 6.75 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.8 p -153.07 160.46 42.95 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.552 -0.97 . . . . 0.0 109.81 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 60.9 p -90.87 6.82 42.92 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.366 -0.834 . . . . 0.0 110.793 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -69.98 -25.91 63.84 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.31 -0.868 . . . . 0.0 110.87 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.17 77.03 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.466 -0.771 . . . . 0.0 110.949 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.94 -80.46 1.76 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 19.1 ttm180 -137.07 139.94 41.66 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.677 -0.896 . . . . 0.0 110.119 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.24 119.93 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.523 -0.736 . . . . 0.0 110.231 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -90.43 169.7 10.84 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.754 0.787 . . . . 0.0 111.176 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 28.8 t30 59.95 40.05 19.4 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.695 -0.628 . . . . 0.0 111.497 179.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 81.5 t -84.41 126.98 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -92.58 152.26 19.7 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.13 -1.028 . . . . 0.0 108.87 179.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -146.82 150.0 34.43 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.631 -0.668 . . . . 0.0 112.074 -177.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -141.32 134.73 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.745 -0.597 . . . . 0.0 110.097 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.459 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 55.6 tt0 -72.46 141.61 48.6 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.524 0.678 . . . . 0.0 110.979 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.0 m -132.27 172.07 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -60.0 143.98 50.42 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.453 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.03 -39.97 87.74 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.385 -0.822 . . . . 0.0 110.226 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.3 t -51.29 -33.98 31.08 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.615 -0.678 . . . . 0.0 111.28 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -65.38 -39.99 92.94 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.482 -0.761 . . . . 0.0 110.935 -179.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 86.8 m -60.42 -47.76 84.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.393 -0.817 . . . . 0.0 110.243 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.431 HD12 HG22 ' A' ' 116' ' ' ILE . 88.1 mt -69.96 -40.02 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.955 -0.466 . . . . 0.0 110.772 -179.118 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -66.48 -39.99 89.08 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.498 -0.751 . . . . 0.0 110.866 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -78.68 -60.06 2.7 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.159 -178.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.13 93.59 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.418 -1.048 . . . . 0.0 110.738 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.402 -179.784 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.992 0.425 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.5 p -112.95 145.86 40.04 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.686 -0.634 . . . . 0.0 110.085 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 45.1 pt -120.01 149.96 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.626 -0.671 . . . . 0.0 110.743 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -145.62 -172.37 3.88 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -140.96 145.44 36.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.325 -0.859 . . . . 0.0 110.199 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.73 149.48 64.83 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.409 -0.807 . . . . 0.0 110.005 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.94 48.25 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.074 0 O-C-N 123.432 1.227 . . . . 0.0 110.602 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.44 HG22 ' CD2' ' A' ' 9' ' ' TYR . 7.6 tp -118.79 -6.79 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.527 -0.733 . . . . 0.0 111.052 -179.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.44 ' CD2' HG22 ' A' ' 8' ' ' ILE . 29.2 m-85 -122.69 70.94 1.01 Allowed 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 122.62 1.2 . . . . 0.0 110.182 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.54 171.45 7.56 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 114.597 -1.183 . . . . 0.0 107.921 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.56 -28.71 60.8 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.37 12.26 21.07 Favored 'General case' 0 N--CA 1.498 1.966 0 C-N-CA 118.323 -1.351 . . . . 0.0 112.236 -177.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.55 116.62 10.17 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.205 -0.934 . . . . 0.0 109.817 179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -65.88 137.74 57.39 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.837 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 93.9 mmm -67.77 -16.37 64.08 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.87 -0.519 . . . . 0.0 111.715 -178.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.14 -13.82 82.4 Favored Glycine 0 N--CA 1.495 2.607 0 O-C-N 120.849 -1.157 . . . . 0.0 110.626 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -94.98 -17.68 21.74 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.19 -1.183 . . . . 0.0 111.708 -178.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.2 p -87.21 159.16 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.186 -179.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -53.44 -40.0 64.85 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.198 -0.939 . . . . 0.0 110.301 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 62.8 m -78.88 82.61 5.06 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -90.45 -80.73 0.32 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.048 -1.032 . . . . 0.0 112.875 -177.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.5 p-10 -154.88 20.55 0.45 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.734 -1.229 . . . . 0.0 112.535 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.22 -144.91 0.04 OUTLIER Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -69.63 -39.93 76.84 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.821 -0.811 . . . . 0.0 109.808 178.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.47 ' NE2' ' N ' ' A' ' 54' ' ' SER . 2.3 p80 -95.57 4.57 53.02 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.468 -0.77 . . . . 0.0 110.098 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.76 140.75 43.55 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.183 -0.948 . . . . 0.0 111.174 -178.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 91.2 mt -104.34 -0.04 28.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 122.049 -0.677 . . . . 0.0 110.389 178.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.7 ttm -60.05 -35.06 74.32 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 110.521 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.51 -73.22 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.458 -0.776 . . . . 0.0 111.398 -177.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -70.36 -39.99 74.29 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.372 -0.83 . . . . 0.0 110.121 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.425 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 54.1 m-85 -116.97 86.47 19.8 Favored Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -178.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.31 -26.93 24.45 Favored 'Trans proline' 0 C--N 1.317 -1.101 0 O-C-N 123.39 1.205 . . . . 0.0 110.955 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 15.1 m -116.89 161.26 19.61 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.359 -0.838 . . . . 0.0 110.41 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -86.59 114.92 23.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.769 -0.582 . . . . 0.0 111.292 -178.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 156.49 37.09 0.02 OUTLIER Glycine 0 N--CA 1.497 2.734 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -162.2 -48.26 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.376 -1.073 . . . . 0.0 110.578 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.425 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 2.8 t -59.96 -59.36 14.11 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.407 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.3 Cg_endo -76.76 -31.98 3.77 Favored 'Trans proline' 0 C--N 1.317 -1.131 0 N-CA-C 109.007 -1.189 . . . . 0.0 109.007 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 133.68 -60.95 0.65 Allowed Glycine 0 N--CA 1.486 1.977 0 N-CA-C 107.498 -2.241 . . . . 0.0 107.498 -178.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.568 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.1 t80 157.9 -51.06 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.665 0 C-N-CA 123.877 0.871 . . . . 0.0 109.936 177.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.568 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 52.9 Cg_endo -101.0 5.61 0.62 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.595 1.53 . . . . 0.0 112.039 -177.612 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -122.36 47.57 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.975 . . . . 0.0 109.961 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.3 p -117.66 141.11 37.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.869 0.843 . . . . 0.0 110.181 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -169.79 176.19 43.7 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -92.22 165.06 28.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.466 ' CG2' ' CD2' ' A' ' 83' ' ' PHE . 0.9 OUTLIER -154.8 161.0 30.39 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.631 -0.923 . . . . 0.0 109.801 178.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -66.7 -35.01 29.95 Favored 'Trans proline' 0 N--CA 1.502 2.015 0 C-N-CA 121.777 1.651 . . . . 0.0 115.2 -175.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -68.95 -10.0 55.02 Favored 'General case' 0 N--CA 1.507 2.398 0 O-C-N 120.736 -1.227 . . . . 0.0 113.24 -177.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.419 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 35.1 mm -81.23 129.23 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 O-C-N 120.717 -1.24 . . . . 0.0 109.417 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.12 -49.64 7.17 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.325 -0.859 . . . . 0.0 112.108 -178.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 174.55 -139.35 4.85 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.995 -1.574 . . . . 0.0 111.608 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 70.7 t90 -49.01 -24.58 1.58 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.765 -0.844 . . . . 0.0 112.914 -178.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.453 ' HA ' ' CD2' ' A' ' 25' ' ' HIS . 14.7 t70 -142.27 71.93 1.36 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.191 -0.943 . . . . 0.0 109.583 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.47 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 9.8 p -82.65 136.91 44.72 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.937 -0.477 . . . . 0.0 110.318 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -78.6 -16.81 13.03 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 O-C-N 123.318 1.167 . . . . 0.0 111.167 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.3 m -97.39 4.19 50.74 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.316 -0.865 . . . . 0.0 112.543 -178.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.1 t -66.58 142.53 57.46 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.905 -1.122 . . . . 0.0 110.421 -179.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 94.13 -7.71 72.76 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.574 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 22.4 p -70.44 157.77 37.22 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 118.9 1.35 . . . . 0.0 110.743 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -107.21 130.8 54.68 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.939 -0.476 . . . . 0.0 110.553 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.439 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 92.9 m95 -135.17 147.62 49.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.279 -0.888 . . . . 0.0 110.561 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -106.42 135.55 47.73 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 70' ' ' SER . 72.0 t -108.2 123.88 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.65 -0.656 . . . . 0.0 109.382 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 41.3 m -119.59 137.31 53.93 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.111 0.481 . . . . 0.0 111.075 -178.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.436 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 35.1 pt -115.72 164.26 18.08 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.676 -0.64 . . . . 0.0 110.401 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.436 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.09 -25.18 80.77 Favored 'Trans proline' 0 N--CA 1.497 1.683 0 C-N-CA 121.268 1.312 . . . . 0.0 112.514 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -63.23 -40.0 96.21 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.256 -0.903 . . . . 0.0 109.706 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 114.61 60.72 0.38 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -159.95 151.99 20.49 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.717 -0.873 . . . . 0.0 108.854 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 61.3 p -155.48 161.07 41.02 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.115 -1.034 . . . . 0.0 112.428 -179.316 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 37.8 pt -137.36 166.48 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -105.52 127.04 52.79 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.665 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.434 HG22 HD12 ' A' ' 73' ' ' ILE . 46.3 mm -120.04 129.95 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 121.463 -0.773 . . . . 0.0 110.547 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 -100.42 140.04 35.24 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.443 -0.786 . . . . 0.0 109.016 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.02 149.45 41.5 Favored Glycine 0 N--CA 1.494 2.538 0 CA-C-O 122.019 0.788 . . . . 0.0 111.575 -178.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.0 p -159.0 -39.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 122.017 -0.696 . . . . 0.0 109.653 178.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -135.86 170.2 16.36 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 120.963 -1.086 . . . . 0.0 109.517 179.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.419 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 5.6 t -95.52 160.4 14.53 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.296 -0.877 . . . . 0.0 111.828 -178.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.85 149.14 18.71 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 63.6 mtt180 -60.07 -33.98 72.81 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.655 -0.909 . . . . 0.0 110.586 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.4 79.48 0.05 OUTLIER Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.44 169.0 13.4 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.466 ' CD2' ' CG2' ' A' ' 46' ' ' ILE . 19.1 m-85 -91.24 120.13 31.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.953 . . . . 0.0 109.817 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -114.27 130.46 56.65 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 178.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 34.9 m -134.86 176.59 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.029 -1.044 . . . . 0.0 111.869 -178.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -57.42 152.7 31.68 Favored Pre-proline 0 N--CA 1.496 1.855 0 C-N-CA 120.133 -0.627 . . . . 0.0 110.051 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.64 -22.69 64.34 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.353 1.186 . . . . 0.0 110.408 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -73.13 -41.03 64.41 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.015 -1.053 . . . . 0.0 108.745 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.85 -39.76 87.68 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -59.98 -49.98 75.55 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.127 179.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 12.1 p -60.01 -35.53 75.25 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.44 -0.787 . . . . 0.0 110.77 -179.114 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 55.9 mttm -69.95 -40.03 75.71 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.342 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 67.1 tp -70.49 -46.08 64.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 0.0 111.41 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -101.76 -38.13 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.172 0 O-C-N 121.288 -0.883 . . . . 0.0 111.655 -177.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 -18.88 16.46 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 41.8 p -158.8 151.96 22.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.249 -1.148 . . . . 0.0 110.519 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.1 p -93.89 8.51 41.0 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.632 -0.667 . . . . 0.0 110.917 179.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.44 -0.788 . . . . 0.0 110.552 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.0 85.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.608 -0.683 . . . . 0.0 110.92 -178.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -59.4 3.19 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 108.538 -1.825 . . . . 0.0 108.538 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 53.9 ptt85 -150.1 157.14 42.81 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.792 -0.828 . . . . 0.0 109.946 179.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.7 t -128.35 126.23 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.468 -0.77 . . . . 0.0 109.719 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -90.19 169.0 11.51 Favored 'General case' 0 N--CA 1.496 1.867 0 CA-C-O 121.771 0.796 . . . . 0.0 111.75 -178.562 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 53.2 t30 60.07 40.02 19.05 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 121.402 0.62 . . . . 0.0 111.002 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 79.9 t -85.17 129.68 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.506 179.259 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -88.27 138.83 31.09 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.234 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.1 p90 -132.99 140.85 47.98 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.34 0.59 . . . . 0.0 110.824 -178.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 18.8 m -143.83 139.94 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.755 -0.59 . . . . 0.0 110.987 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.439 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 54.9 tt0 -77.32 139.08 39.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.702 -0.624 . . . . 0.0 110.292 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 34.6 m -130.02 165.35 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.61 -0.681 . . . . 0.0 110.649 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -55.42 139.97 41.55 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.585 -0.697 . . . . 0.0 110.753 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.2 tt -60.83 -39.98 91.06 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.646 -0.659 . . . . 0.0 110.825 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.0 m -54.45 -37.87 65.69 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.577 -0.702 . . . . 0.0 111.112 -177.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -65.73 -36.9 84.91 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.558 -0.714 . . . . 0.0 111.12 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 81.0 m -63.05 -44.43 95.86 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.177 -0.952 . . . . 0.0 109.913 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 80.3 mt -69.64 -39.96 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.099 -179.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -66.4 -40.05 89.39 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.469 -0.769 . . . . 0.0 110.467 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -74.31 -56.52 5.12 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.26 93.94 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.445 -1.032 . . . . 0.0 110.256 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.7 t30 . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 117.832 -1.08 . . . . 0.0 111.054 179.611 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.2 m . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.438 0.637 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 33.9 t -114.09 142.35 46.31 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.381 0.61 . . . . 0.0 110.668 -178.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 42.9 pt -114.25 149.96 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.353 0.596 . . . . 0.0 110.887 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 23.0 m -146.35 -172.82 4.03 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.166 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.416 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -140.06 149.32 42.98 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.82 179.106 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.38 148.9 71.75 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.457 -0.777 . . . . 0.0 109.435 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -84.0 -9.05 9.86 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.275 1.145 . . . . 0.0 112.636 -178.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.454 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.2 pt -70.01 -40.06 78.09 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.227 0 O-C-N 120.953 -1.092 . . . . 0.0 110.984 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.454 ' N ' HG13 ' A' ' 8' ' ' ILE . 50.9 m-85 -73.3 67.3 0.97 Allowed 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 122.877 1.322 . . . . 0.0 111.324 -178.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.93 171.55 7.28 Favored 'General case' 0 N--CA 1.49 1.55 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.203 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.97 -34.45 71.81 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -175.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -89.95 10.94 22.03 Favored 'General case' 0 N--CA 1.501 2.11 0 C-N-CA 118.285 -1.366 . . . . 0.0 112.507 -177.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.0 tp -70.61 124.45 24.28 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.245 -0.909 . . . . 0.0 109.666 179.343 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 61.5 p -70.76 137.66 49.81 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.672 0.748 . . . . 0.0 110.092 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.9 mmm -66.41 -19.1 65.71 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.938 -0.476 . . . . 0.0 112.025 -178.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.78 -15.39 75.85 Favored Glycine 0 N--CA 1.495 2.626 0 O-C-N 120.95 -1.094 . . . . 0.0 111.296 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.9 p -89.04 -7.52 55.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.208 -1.172 . . . . 0.0 111.9 -178.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 19' ' ' ALA . 9.8 p -99.86 169.47 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.098 -1.001 . . . . 0.0 110.638 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.407 ' N ' HG23 ' A' ' 18' ' ' VAL . . . -58.89 -44.49 91.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.525 -0.734 . . . . 0.0 109.796 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.1 m -80.04 80.71 6.42 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -101.19 -81.56 0.48 Allowed 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.262 -0.899 . . . . 0.0 113.247 -177.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -131.12 11.14 5.02 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.139 -0.976 . . . . 0.0 113.025 -177.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.68 -153.49 3.43 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 179.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -65.93 -40.06 91.05 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.517 -0.99 . . . . 0.0 109.691 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 83.7 m-70 -91.0 6.31 45.3 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -0.797 . . . . 0.0 110.734 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -59.43 134.62 51.71 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.6 mt -101.16 -4.47 27.19 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 122.024 -0.692 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 59.4 ttm -62.22 -37.03 83.79 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.273 -0.892 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.11 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.608 -0.683 . . . . 0.0 111.896 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -69.09 -39.99 78.67 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.367 -0.833 . . . . 0.0 109.743 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.433 ' CD2' HG22 ' A' ' 37' ' ' VAL . 48.7 m-85 -119.94 91.69 45.8 Favored Pre-proline 0 N--CA 1.491 1.608 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.92 -18.67 40.95 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.293 1.154 . . . . 0.0 111.241 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 90.6 m -123.75 141.27 52.18 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.229 -0.919 . . . . 0.0 110.026 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 41.7 tp -65.9 120.75 13.62 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.77 -0.581 . . . . 0.0 111.036 -179.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.29 32.41 0.04 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.862 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.419 ' CB ' ' CD1' ' A' ' 31' ' ' TYR . 25.0 mt-10 -155.29 -49.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -1.128 . . . . 0.0 110.448 178.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.433 HG22 ' CD2' ' A' ' 31' ' ' TYR . 3.1 t -60.27 -60.81 9.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.423 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 50.6 Cg_endo -74.79 -28.6 9.43 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 N-CA-C 108.979 -1.2 . . . . 0.0 108.979 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.43 -61.32 0.65 Allowed Glycine 0 N--CA 1.484 1.872 0 N-CA-C 107.017 -2.433 . . . . 0.0 107.017 -178.587 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.469 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.8 t80 165.48 -72.7 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.578 0 C-N-CA 123.377 0.671 . . . . 0.0 110.083 177.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.469 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -83.01 -8.58 10.94 Favored 'Trans proline' 0 N--CA 1.493 1.497 0 CA-C-N 118.995 0.677 . . . . 0.0 112.174 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -97.91 34.29 1.93 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.134 -0.979 . . . . 0.0 110.51 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.6 p -109.95 137.3 42.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.665 0.745 . . . . 0.0 109.498 179.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.402 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.62 172.89 43.22 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.044 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.54 156.34 29.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.456 HG21 ' CE2' ' A' ' 83' ' ' PHE . 81.3 mt -139.97 150.46 62.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.426 ' HD2' ' CG2' ' A' ' 46' ' ' ILE . 37.3 Cg_endo -59.36 -10.15 10.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.349 1.184 . . . . 0.0 113.626 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -94.58 -12.54 27.3 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.693 -1.254 . . . . 0.0 112.329 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.493 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 51.3 mm -75.08 119.67 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 C-N-CA 118.601 -1.24 . . . . 0.0 108.397 178.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.74 -45.3 21.47 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.26 -0.9 . . . . 0.0 112.529 -178.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 169.9 -138.91 5.28 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.918 -179.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 36.8 t90 -42.79 -28.81 0.27 Allowed 'General case' 0 N--CA 1.502 2.175 0 O-C-N 121.956 -0.731 . . . . 0.0 112.769 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -142.62 65.34 1.35 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.339 -0.851 . . . . 0.0 110.112 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.426 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 3.0 p -66.39 134.51 94.58 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.643 -0.661 . . . . 0.0 110.899 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -74.93 -23.48 13.9 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 O-C-N 123.45 1.237 . . . . 0.0 111.05 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.62 15.19 14.89 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 111.385 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t -78.28 151.62 32.91 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 110.054 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 71.08 29.89 68.31 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.7 m -117.16 132.97 56.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.59 -0.947 . . . . 0.0 109.963 179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -81.07 145.5 31.07 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -177.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.456 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -149.34 150.09 31.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 110.471 178.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -108.45 132.03 54.2 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.3 t -108.9 127.36 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.49 -0.756 . . . . 0.0 109.597 -179.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 88.0 m -120.06 136.66 54.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.942 -0.474 . . . . 0.0 110.939 -178.135 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.441 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 38.0 pt -115.95 164.82 16.36 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.541 -0.724 . . . . 0.0 110.568 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.8 -25.1 74.61 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 C-N-CA 121.236 1.29 . . . . 0.0 112.66 -178.569 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -64.89 -40.0 94.41 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.23 -0.919 . . . . 0.0 109.794 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.75 61.09 0.32 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.271 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -160.01 150.64 18.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.758 -0.848 . . . . 0.0 108.831 179.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 67.0 p -151.56 157.41 42.19 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.247 -0.981 . . . . 0.0 112.248 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.3 pt -139.34 165.05 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -103.36 125.76 50.15 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.274 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.5 mm -119.8 131.01 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.707 -0.621 . . . . 0.0 110.246 -178.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 -99.38 137.06 38.42 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.439 -0.788 . . . . 0.0 109.079 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.18 150.74 28.62 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.45 HG11 ' N ' ' A' ' 77' ' ' ASP . 11.9 p -169.54 -28.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.679 -0.895 . . . . 0.0 111.307 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.45 ' N ' HG11 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -130.0 166.98 18.99 Favored 'General case' 0 N--CA 1.505 2.306 0 O-C-N 120.585 -1.322 . . . . 0.0 109.712 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.493 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 48.2 t -94.68 144.51 25.55 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.482 -0.761 . . . . 0.0 111.024 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -126.29 141.67 13.0 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -60.68 -28.38 68.57 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.759 -0.847 . . . . 0.0 109.814 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.04 79.92 0.05 OUTLIER Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.27 163.79 11.21 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.827 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.456 ' CE2' HG21 ' A' ' 46' ' ' ILE . 16.1 m-85 -92.16 115.33 27.99 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.666 -0.902 . . . . 0.0 109.915 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 57.7 t-20 -109.04 131.99 54.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.343 -0.848 . . . . 0.0 109.028 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.3 m -132.44 175.52 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.185 0 O-C-N 120.961 -1.087 . . . . 0.0 111.833 -178.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -55.73 156.69 8.83 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.41 -0.806 . . . . 0.0 109.953 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.07 -22.37 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.295 1.155 . . . . 0.0 110.65 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -76.28 -40.03 52.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.021 -1.049 . . . . 0.0 108.953 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.26 -39.87 89.76 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -60.04 -50.03 75.31 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.202 -0.599 . . . . 0.0 110.486 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 56.9 m -59.96 -39.5 85.82 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.546 -0.721 . . . . 0.0 110.709 -178.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 57.1 mtmt -70.03 -40.05 75.41 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.789 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 65.4 tp -70.02 -43.4 71.42 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.65 -0.656 . . . . 0.0 111.492 -179.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.2 t -96.2 -39.82 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 O-C-N 121.262 -0.899 . . . . 0.0 111.258 -178.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.63 -38.96 2.55 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.8 m -139.98 152.2 46.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.686 -0.891 . . . . 0.0 110.182 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.6 p -90.71 6.33 44.51 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.403 -0.81 . . . . 0.0 111.169 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -70.04 -29.22 66.2 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.478 -0.764 . . . . 0.0 110.736 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.05 -40.09 84.02 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.538 -0.726 . . . . 0.0 110.625 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -74.48 1.68 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 12.1 ptt-85 -144.74 149.54 35.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.681 -0.894 . . . . 0.0 110.271 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.94 119.36 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.487 -0.758 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.404 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 5.0 t0 -83.84 173.49 11.21 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.723 -0.611 . . . . 0.0 110.604 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 60.01 45.75 11.72 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.636 -0.665 . . . . 0.0 110.998 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.405 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 73.7 t -95.53 128.06 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.493 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -85.4 136.1 33.6 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.092 -1.005 . . . . 0.0 109.639 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.8 p90 -132.87 140.98 48.18 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.134 0.492 . . . . 0.0 110.738 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.2 m -144.62 141.21 23.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.609 -0.682 . . . . 0.0 110.979 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.456 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 58.6 tt0 -70.93 140.73 51.05 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.536 -0.727 . . . . 0.0 110.334 178.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.23 167.44 26.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.105 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -61.28 148.26 41.76 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.414 -0.804 . . . . 0.0 110.325 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.73 -40.05 96.0 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.433 -0.792 . . . . 0.0 111.133 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 53.4 m -56.29 -38.18 70.88 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.583 -0.698 . . . . 0.0 110.587 -178.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.09 -35.71 75.81 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.432 -0.792 . . . . 0.0 110.287 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 80.5 m -70.04 -39.99 75.41 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.522 -0.736 . . . . 0.0 109.383 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 50.6 mm -66.77 -40.04 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 CA-C-O 121.473 0.654 . . . . 0.0 109.395 -178.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -69.98 -39.96 75.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.818 -0.551 . . . . 0.0 110.299 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.88 -57.73 5.67 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.96 -41.64 92.37 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.507 -0.996 . . . . 0.0 110.704 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.301 -179.889 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.8 m . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.464 0.65 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.1 t -113.57 140.19 48.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.746 -0.596 . . . . 0.0 109.744 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 37.4 pt -109.16 148.14 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 111.042 -179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.72 -170.82 3.61 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -144.71 150.01 36.58 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.967 179.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -130.29 148.58 70.39 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.566 -0.709 . . . . 0.0 109.554 178.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.79 -6.58 12.43 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 O-C-N 123.247 1.13 . . . . 0.0 112.46 -179.117 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.452 HG13 ' N ' ' A' ' 9' ' ' TYR . 30.1 pt -69.98 -40.0 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 120.865 -1.147 . . . . 0.0 110.925 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.452 ' N ' HG13 ' A' ' 8' ' ' ILE . 40.5 m-85 -74.17 67.24 1.33 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-O 122.774 1.273 . . . . 0.0 111.132 -178.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.19 171.86 7.12 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 114.299 -1.319 . . . . 0.0 108.146 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.05 -33.93 72.72 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.98 10.22 24.84 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.428 -1.42 . . . . 0.0 112.316 -177.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.0 tp -70.33 123.33 21.46 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.263 -0.898 . . . . 0.0 109.703 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.1 m -69.14 136.63 52.46 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.783 -0.767 . . . . 0.0 109.961 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 96.6 mmm -67.21 -17.72 64.94 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 122.03 -0.419 . . . . 0.0 111.65 -178.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -70.75 -14.7 73.01 Favored Glycine 0 N--CA 1.495 2.612 0 O-C-N 120.955 -1.091 . . . . 0.0 111.095 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -88.43 -9.44 52.55 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.203 -1.175 . . . . 0.0 111.787 -179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.54 168.49 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.072 -1.017 . . . . 0.0 110.092 -179.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -57.8 -44.8 86.57 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.542 -0.724 . . . . 0.0 109.939 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.5 m -81.28 84.05 6.71 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.4 m -99.95 -79.95 0.48 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.56 -0.712 . . . . 0.0 112.88 -178.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -131.09 9.93 4.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.24 -0.912 . . . . 0.0 112.77 -178.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.41 -153.2 1.83 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.755 -1.738 . . . . 0.0 108.755 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -70.01 -39.95 75.53 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.789 -0.83 . . . . 0.0 109.648 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.425 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 75.5 m-70 -90.03 0.21 57.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.625 -0.672 . . . . 0.0 110.866 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.71 137.89 49.06 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.0 mt -99.02 -5.22 30.8 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.916 -0.755 . . . . 0.0 110.251 178.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.401 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.1 ttm -60.01 -37.2 79.01 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.307 -0.871 . . . . 0.0 110.97 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.94 -74.84 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.497 -0.752 . . . . 0.0 111.798 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -70.0 -39.97 75.57 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.433 -0.792 . . . . 0.0 110.359 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.453 ' CD2' ' CG2' ' A' ' 37' ' ' VAL . 27.6 m-85 -120.02 93.27 47.73 Favored Pre-proline 0 N--CA 1.496 1.83 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -178.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -69.82 -21.87 32.62 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.423 1.223 . . . . 0.0 111.347 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.4 m -123.21 145.9 48.27 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 109.939 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 40.6 tp -68.68 121.15 15.86 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -0.756 . . . . 0.0 110.753 -179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.88 33.78 0.03 OUTLIER Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.774 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -160.31 -44.12 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.159 -1.201 . . . . 0.0 110.142 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.453 ' CG2' ' CD2' ' A' ' 31' ' ' TYR . 3.5 t -60.54 -61.28 8.28 Favored Pre-proline 0 N--CA 1.498 1.967 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.426 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -77.59 -26.11 7.4 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.108 1.057 . . . . 0.0 109.598 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.58 -62.0 0.63 Allowed Glycine 0 N--CA 1.486 1.988 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.496 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.0 t80 166.74 -72.45 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.449 0 C-N-CA 123.267 0.627 . . . . 0.0 109.632 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.496 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 60.2 Cg_endo -84.65 10.7 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 CA-C-N 118.912 0.647 . . . . 0.0 111.647 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -114.54 35.7 4.11 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.011 -1.056 . . . . 0.0 110.015 -178.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.1 p -117.54 143.36 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-O 121.455 0.645 . . . . 0.0 110.11 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.04 166.67 39.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.38 151.37 44.97 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 177.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.428 ' CD1' HG13 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -144.22 142.9 20.61 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.431 -1.04 . . . . 0.0 109.351 179.698 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -61.38 -13.02 26.55 Favored 'Trans proline' 0 N--CA 1.507 2.271 0 C-N-CA 122.193 1.929 . . . . 0.0 115.188 -177.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -92.9 20.1 6.99 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.45 -1.406 . . . . 0.0 112.139 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.428 HG13 ' CD1' ' A' ' 46' ' ' ILE . 57.8 mt -118.57 127.67 75.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.301 -0.875 . . . . 0.0 109.038 177.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.0 -45.35 13.2 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 175.18 -141.17 5.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.403 -1.856 . . . . 0.0 112.194 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 25.3 t90 -39.97 -29.87 0.08 Allowed 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 -178.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -146.15 64.14 1.22 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.985 -1.072 . . . . 0.0 111.325 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.417 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 6.5 t -66.27 139.39 96.34 Favored Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.45 -0.781 . . . . 0.0 110.866 -179.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.425 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -78.05 -20.66 11.37 Favored 'Trans proline' 0 C--N 1.32 -0.959 0 O-C-N 123.4 1.211 . . . . 0.0 110.65 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 17.8 m -92.97 11.54 27.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.484 -0.76 . . . . 0.0 111.231 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.6 t -69.66 145.16 52.61 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.093 -1.004 . . . . 0.0 109.766 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.45 41.9 12.6 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.1 m -120.01 129.95 54.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.397 -1.06 . . . . 0.0 110.477 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 50.1 t -81.29 143.03 32.55 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.513 -178.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 71.9 m95 -146.4 155.62 42.72 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.526 178.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -114.11 130.19 56.59 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.6 129.59 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.405 -0.809 . . . . 0.0 109.706 -178.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.3 m -121.12 141.07 51.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.803 -0.561 . . . . 0.0 111.459 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.42 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.0 pt -117.62 163.58 23.35 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.521 -0.737 . . . . 0.0 110.036 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.42 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -62.32 -25.35 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 121.184 1.256 . . . . 0.0 112.507 -178.461 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -64.84 -39.01 92.88 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.384 -0.822 . . . . 0.0 109.715 179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.47 61.6 0.33 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -160.58 153.07 20.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.709 -0.877 . . . . 0.0 109.007 178.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.401 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -151.26 158.72 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.207 1.003 . . . . 0.0 112.352 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 pt -139.89 164.73 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.162 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -106.58 127.0 52.98 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 118.879 -1.128 . . . . 0.0 109.928 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.37 131.89 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.622 -0.674 . . . . 0.0 110.582 -179.123 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 53.9 ttt180 -102.21 136.49 41.96 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.27 149.54 42.17 Favored Glycine 0 N--CA 1.494 2.557 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.318 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 5.7 p -156.91 -42.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.743 -0.857 . . . . 0.0 110.118 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.411 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 12.3 t70 -128.34 169.99 13.6 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.109 -0.995 . . . . 0.0 110.06 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 41.8 t -87.67 156.85 19.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.426 -0.796 . . . . 0.0 111.081 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.43 137.34 10.92 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -63.08 -39.87 96.0 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.734 -0.862 . . . . 0.0 110.162 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -178.15 69.96 0.08 OUTLIER Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.74 172.09 18.19 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -98.63 122.53 41.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.652 -0.911 . . . . 0.0 110.334 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -115.05 130.31 56.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.391 -0.818 . . . . 0.0 109.048 179.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.42 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 35.6 m -132.97 174.47 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 120.933 -1.104 . . . . 0.0 111.741 -178.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -54.74 150.9 16.6 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.53 -0.731 . . . . 0.0 109.92 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.6 -21.01 59.97 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.404 1.213 . . . . 0.0 110.76 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 67.7 m -75.79 -39.95 56.02 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.065 -1.022 . . . . 0.0 109.23 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.77 -40.03 88.08 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.422 -0.798 . . . . 0.0 109.116 178.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -60.03 -49.68 76.72 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.807 -0.558 . . . . 0.0 110.632 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.6 m -60.04 -36.99 78.5 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.824 . . . . 0.0 110.787 -178.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -69.95 -40.07 75.67 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.412 -179.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.401 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 56.1 tp -70.39 -44.16 68.58 Favored 'General case' 0 N--CA 1.496 1.851 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.554 -178.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 91.1 t -95.39 -38.61 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.311 -0.868 . . . . 0.0 111.394 -177.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -27.35 6.07 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 43.7 t -156.04 161.19 40.46 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.466 -1.02 . . . . 0.0 110.292 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 68.3 p -97.81 13.24 31.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 111.151 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.99 -36.54 75.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.481 -0.762 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.02 -41.16 91.59 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.444 -0.785 . . . . 0.0 111.05 -178.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.28 -63.48 2.02 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 -179.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -149.37 153.45 37.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.59 -0.947 . . . . 0.0 110.57 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.1 118.94 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.456 -0.777 . . . . 0.0 110.149 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -81.87 169.44 16.84 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.577 -0.702 . . . . 0.0 111.181 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 63.7 t30 59.85 50.06 7.29 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.548 -0.72 . . . . 0.0 110.731 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 66.9 t -94.05 128.73 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.902 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -86.9 140.61 29.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.417 -0.913 . . . . 0.0 109.491 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -139.11 141.87 38.11 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.167 0.508 . . . . 0.0 110.736 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 m -141.14 139.89 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.695 -0.628 . . . . 0.0 110.161 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -77.4 136.86 38.44 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.964 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -134.22 -179.13 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.257 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.41 150.94 47.55 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.406 -0.809 . . . . 0.0 111.075 -179.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.7 tt -62.06 -40.0 94.29 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.559 -0.713 . . . . 0.0 111.389 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 55.8 m -54.28 -39.37 66.84 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.443 -0.785 . . . . 0.0 110.222 -178.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -59.99 -37.65 80.29 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.632 -0.668 . . . . 0.0 110.223 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -68.15 -42.43 80.09 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.49 -0.756 . . . . 0.0 109.481 178.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.0 mm -64.88 -40.52 89.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.023 -0.671 . . . . 0.0 109.853 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -70.05 -39.92 75.41 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.697 -0.627 . . . . 0.0 110.483 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.6 -53.14 37.07 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.05 -43.94 97.24 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.512 -0.993 . . . . 0.0 110.548 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 48.6 t30 . . . . . 0 N--CA 1.501 2.082 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.006 -179.824 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.411 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 35.4 m . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.25 0.548 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.415 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 24.8 t -114.63 141.18 48.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.536 -0.728 . . . . 0.0 110.39 -179.428 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 39.3 pt -107.8 147.72 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.679 -0.638 . . . . 0.0 110.6 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.42 -171.89 3.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.8 p90 -142.87 147.32 35.18 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.35 -0.844 . . . . 0.0 110.802 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -137.7 155.22 75.17 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.488 178.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -88.28 48.06 1.37 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.275 1.145 . . . . 0.0 110.659 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 tp -123.01 -8.65 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.48 -0.763 . . . . 0.0 111.276 -179.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.408 ' HA ' HD23 ' A' ' 13' ' ' LEU . 35.3 m-85 -118.54 67.65 0.77 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 122.525 1.155 . . . . 0.0 110.947 178.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.02 170.37 7.9 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.679 177.082 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.424 ' HB3' ' CE1' ' A' ' 40' ' ' PHE . . . -59.6 -32.71 70.64 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 114.115 1.154 . . . . 0.0 114.115 -175.497 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -89.63 13.91 12.94 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 120.424 1.466 . . . . 0.0 112.5 -177.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 9' ' ' TYR . 64.0 tp -73.1 125.94 28.85 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.413 -0.804 . . . . 0.0 110.792 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.18 135.54 49.18 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 97.6 mmm -66.36 -15.86 63.61 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.777 -0.577 . . . . 0.0 112.048 -178.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.404 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.62 -13.86 80.05 Favored Glycine 0 N--CA 1.497 2.701 0 O-C-N 120.977 -1.077 . . . . 0.0 111.337 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 -11.05 47.2 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.054 -1.262 . . . . 0.0 112.063 -178.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.5 p -93.72 168.25 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.068 -1.02 . . . . 0.0 110.041 -179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.09 85.58 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.472 -0.768 . . . . 0.0 109.816 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.03 82.94 2.89 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.586 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.9 m -90.29 -79.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.989 -1.069 . . . . 0.0 112.894 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.401 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 17.9 p30 -143.56 14.21 1.77 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 120.631 -1.293 . . . . 0.0 112.428 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.64 -146.95 0.38 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -66.58 -40.51 88.97 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . 0.407 ' CD2' ' O ' ' A' ' 54' ' ' SER . 64.1 m-70 -90.02 0.56 57.05 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.798 -0.564 . . . . 0.0 110.265 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -55.05 130.4 47.08 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.492 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 84.3 mt -104.87 -5.98 20.62 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 122.146 -0.62 . . . . 0.0 111.203 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' MET . . . . . 0.404 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 44.4 ttm -59.96 -35.63 75.39 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.292 -0.88 . . . . 0.0 110.825 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.43 -63.1 1.26 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -67.26 -40.04 86.18 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.213 -0.93 . . . . 0.0 111.288 -177.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.494 ' CE1' ' CG2' ' A' ' 37' ' ' VAL . 5.5 p90 -143.64 113.72 5.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.879 . . . . 0.0 109.128 179.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.65 -1.62 10.1 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.443 1.233 . . . . 0.0 112.582 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.64 -172.1 2.21 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.995 -1.066 . . . . 0.0 109.71 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -116.51 129.96 56.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.605 -0.685 . . . . 0.0 110.852 -178.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.86 -40.82 1.27 Allowed Glycine 0 N--CA 1.489 2.172 0 C-N-CA 120.077 -1.059 . . . . 0.0 111.044 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -62.42 -39.94 94.93 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.182 -1.187 . . . . 0.0 111.483 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.494 ' CG2' ' CE1' ' A' ' 31' ' ' TYR . 3.2 t -87.62 -61.36 0.24 Allowed Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.336 -0.852 . . . . 0.0 112.699 -178.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.406 ' CD ' ' CB ' ' A' ' 37' ' ' VAL . 37.4 Cg_endo -64.54 -48.49 4.29 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 O-C-N 123.009 1.005 . . . . 0.0 113.063 -177.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.427 ' O ' ' HD2' ' A' ' 41' ' ' PRO . . . 122.77 67.87 0.23 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 106.541 -2.624 . . . . 0.0 106.541 -177.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.497 ' CD2' ' HD3' ' A' ' 41' ' ' PRO . 8.8 t80 19.65 -78.99 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.343 0 N-CA-C 115.101 1.519 . . . . 0.0 115.101 -178.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.497 ' HD3' ' CD2' ' A' ' 40' ' ' PHE . 58.7 Cg_endo -81.91 17.8 1.48 Allowed 'Trans proline' 0 N--CA 1.499 1.804 0 CA-C-N 120.07 1.061 . . . . 0.0 112.588 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -123.79 47.33 2.06 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.836 -1.165 . . . . 0.0 110.201 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.0 p -129.39 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 122.064 0.935 . . . . 0.0 110.334 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.08 175.31 42.3 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.32 161.75 31.6 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 1.1 pt -147.46 152.1 41.35 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.64 -0.917 . . . . 0.0 110.063 179.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.69 -14.7 46.15 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.954 1.77 . . . . 0.0 113.763 -178.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -90.6 23.25 3.11 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 120.591 -1.318 . . . . 0.0 112.259 -178.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.474 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 49.8 mm -113.77 126.91 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.17 13.0 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.311 -0.868 . . . . 0.0 112.077 -178.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 173.23 -134.34 2.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 118.715 -1.707 . . . . 0.0 111.719 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 53.5 t90 -46.06 -28.48 1.2 Allowed 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -178.255 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -146.65 61.19 1.21 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.024 -1.048 . . . . 0.0 110.986 -179.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.407 ' O ' ' CD2' ' A' ' 25' ' ' HIS . 35.1 p -61.95 140.07 95.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.49 -0.756 . . . . 0.0 110.444 -179.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.18 -21.8 19.89 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 123.328 1.172 . . . . 0.0 111.151 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.9 m -93.85 13.62 21.98 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.449 -0.782 . . . . 0.0 111.158 -179.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 2.2 t -73.17 145.43 46.32 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.259 -0.9 . . . . 0.0 110.561 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.58 22.79 71.81 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 86.8 m -104.22 139.11 39.71 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.358 -1.084 . . . . 0.0 110.751 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 46.5 t -80.12 132.96 36.03 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.545 -179.037 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TRP . . . . . 0.403 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.7 m95 -134.36 147.32 50.51 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -0.76 . . . . 0.0 110.074 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -107.86 131.55 54.38 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.366 -0.834 . . . . 0.0 109.725 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.95 121.03 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.557 0.694 . . . . 0.0 110.252 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 97.8 m -119.99 146.03 46.23 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.859 -0.525 . . . . 0.0 110.575 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.453 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 17.2 pt -122.12 164.51 25.25 Favored Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.473 -0.767 . . . . 0.0 110.98 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -61.31 -25.94 81.09 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.561 1.507 . . . . 0.0 112.837 -178.611 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -66.08 -40.0 90.48 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.248 -0.907 . . . . 0.0 110.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.45 61.11 0.3 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -160.07 151.6 19.81 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.652 -0.911 . . . . 0.0 108.829 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.9 p -155.6 164.99 37.9 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 122.287 1.041 . . . . 0.0 112.193 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 40.0 pt -144.52 165.63 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -106.29 122.64 46.64 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.265 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 66.2 mt -120.02 131.41 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.857 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.8 ttt180 -95.25 136.5 35.53 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.663 -0.648 . . . . 0.0 109.407 -179.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.39 149.72 31.43 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 110.336 -1.106 . . . . 0.0 110.336 -178.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.41 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 4.1 p -154.7 -44.08 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.723 -0.869 . . . . 0.0 109.513 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.41 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 11.9 t70 -131.87 169.02 16.84 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 178.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' SER . . . . . 0.474 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 95.5 p -91.91 157.78 16.65 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.4 -0.813 . . . . 0.0 111.618 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -124.2 146.16 16.16 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -60.66 -31.04 70.29 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.649 -0.912 . . . . 0.0 110.174 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.09 76.45 0.04 OUTLIER Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.562 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.82 154.93 6.26 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.115 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.41 114.59 6.22 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.931 -0.746 . . . . 0.0 110.376 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -111.15 119.07 37.74 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 26.8 m -131.1 176.95 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 120.89 -1.131 . . . . 0.0 112.474 -177.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.5 m-20 -55.7 150.9 24.41 Favored Pre-proline 0 N--CA 1.493 1.713 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.214 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.43 -17.27 57.26 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.395 1.208 . . . . 0.0 110.142 178.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 98.1 m -81.28 -40.66 23.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.916 -1.115 . . . . 0.0 109.182 178.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -39.84 91.12 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -60.06 -49.94 75.68 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.754 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.5 m -60.68 -40.0 90.53 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.429 -0.794 . . . . 0.0 111.108 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -68.48 -39.99 81.15 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.35 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 57.8 tp -73.31 -43.24 61.25 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.576 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 51.2 t -91.57 -42.36 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 121.344 -0.848 . . . . 0.0 111.52 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.27 -31.74 3.56 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 90.1 p -154.39 165.88 34.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.502 -0.999 . . . . 0.0 110.457 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.7 p -94.23 -0.05 55.37 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.451 -0.781 . . . . 0.0 111.756 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -70.95 -26.3 63.11 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.336 -0.853 . . . . 0.0 111.675 -179.065 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -39.98 87.86 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.322 -0.861 . . . . 0.0 110.898 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.68 -67.46 2.17 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -152.1 160.01 43.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.553 -0.969 . . . . 0.0 110.998 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.11 112.73 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.952 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.415 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.1 p-10 -80.06 170.01 17.05 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.464 0.65 . . . . 0.0 111.113 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 59.98 40.02 19.36 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.627 -0.67 . . . . 0.0 111.597 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.411 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 94.5 t -85.15 129.94 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.417 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -86.72 139.49 30.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.002 -1.061 . . . . 0.0 109.545 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -138.02 143.3 40.52 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 122.0 -0.438 . . . . 0.0 110.763 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -149.07 149.02 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.545 -0.722 . . . . 0.0 110.706 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.403 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 58.9 tt0 -76.75 139.98 40.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.599 -0.688 . . . . 0.0 110.269 179.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.6 168.26 24.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -57.6 144.83 35.93 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.378 -0.826 . . . . 0.0 110.563 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 9.6 tt -59.91 -36.75 77.64 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.224 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 91.0 p -54.07 -36.14 62.82 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.491 -0.756 . . . . 0.0 110.502 -179.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -66.67 -39.58 88.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 111.179 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -59.97 -49.16 78.78 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.306 -0.871 . . . . 0.0 109.797 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.426 HD13 HG23 ' A' ' 116' ' ' ILE . 93.4 mt -69.81 -39.98 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.687 -0.633 . . . . 0.0 110.687 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -64.0 -39.94 95.25 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.35 -0.844 . . . . 0.0 111.052 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.14 -50.83 20.73 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.94 91.62 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.574 -0.957 . . . . 0.0 110.524 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.063 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.555 0.693 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 79.9 p -111.33 139.9 46.35 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.456 0.646 . . . . 0.0 109.49 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.624 HG12 HG21 ' A' ' 105' ' ' VAL . 39.6 pt -118.13 149.98 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.837 -0.54 . . . . 0.0 111.273 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.1 OUTLIER -146.15 -169.55 3.28 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.757 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.412 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.5 p90 -141.58 148.07 38.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.417 -0.802 . . . . 0.0 110.178 178.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.49 143.48 43.32 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.406 -0.809 . . . . 0.0 109.777 179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.73 -9.86 17.05 Favored 'Trans proline' 0 C--N 1.318 -1.078 0 O-C-N 123.324 1.171 . . . . 0.0 112.331 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 9' ' ' TYR . 44.5 pt -70.01 -39.95 77.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 120.968 -1.082 . . . . 0.0 111.434 -179.119 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.601 ' HA ' HD22 ' A' ' 13' ' ' LEU . 51.5 m-85 -72.14 67.5 0.67 Allowed 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 122.752 1.263 . . . . 0.0 111.72 -178.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.55 170.04 8.12 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.054 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.491 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.41 -34.38 68.85 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -175.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -90.92 12.12 20.56 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 118.431 -1.308 . . . . 0.0 112.265 -177.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.601 HD22 ' HA ' ' A' ' 9' ' ' TYR . 36.4 tp -72.53 123.71 23.73 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.246 -0.908 . . . . 0.0 110.2 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -70.54 137.35 50.06 Favored 'General case' 0 N--CA 1.49 1.573 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.035 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.806 ' O ' HG12 ' A' ' 18' ' ' VAL . 34.6 mtt -70.08 -15.39 62.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.802 -0.561 . . . . 0.0 111.915 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.63 -15.37 68.53 Favored Glycine 0 N--CA 1.494 2.559 0 O-C-N 120.793 -1.192 . . . . 0.0 110.878 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 91.0 p -87.98 -4.45 58.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.192 -1.181 . . . . 0.0 112.157 -178.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.806 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -103.5 168.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.001 -1.062 . . . . 0.0 110.801 -179.2 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.72 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.04 -39.29 85.4 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.471 -0.768 . . . . 0.0 110.644 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.76 67.72 3.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.291 -0.881 . . . . 0.0 110.088 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.6 m -108.71 110.13 21.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.155 -0.966 . . . . 0.0 110.565 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 m120 51.66 -140.98 0.84 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.714 -0.616 . . . . 0.0 111.11 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.43 -155.95 49.02 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -78.07 -41.82 34.2 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.428 -1.042 . . . . 0.0 111.066 179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -89.94 2.14 55.42 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.181 -0.949 . . . . 0.0 111.748 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.55 131.81 49.36 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.002 -1.061 . . . . 0.0 111.15 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.508 HD13 HG11 ' A' ' 37' ' ' VAL . 80.7 mt -96.28 -11.57 25.76 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 122.091 -0.652 . . . . 0.0 110.005 178.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.416 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 60.5 ttm -60.05 -34.42 73.38 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.267 -0.896 . . . . 0.0 110.836 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -74.41 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.558 -0.714 . . . . 0.0 111.691 -178.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -70.04 -39.97 75.43 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.347 -0.846 . . . . 0.0 109.938 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.454 ' CD2' HG23 ' A' ' 37' ' ' VAL . 70.1 m-85 -120.67 89.69 45.19 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.9 Cg_endo -70.82 -4.97 15.83 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.317 1.167 . . . . 0.0 112.298 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.7 m -135.13 149.1 49.94 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.019 -1.051 . . . . 0.0 110.406 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.943 HD11 HG21 ' A' ' 43' ' ' VAL . 28.9 tp -72.45 117.59 14.31 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.758 -0.589 . . . . 0.0 110.528 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.89 32.36 0.04 OUTLIER Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.992 -1.099 . . . . 0.0 110.924 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -158.81 -46.28 0.06 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.195 -1.18 . . . . 0.0 110.21 179.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 27' ' ' LEU . 3.0 t -61.05 -59.92 12.29 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.471 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 52.5 Cg_endo -76.63 -28.35 6.68 Favored 'Trans proline' 0 N--CA 1.487 1.146 0 O-C-N 123.182 1.096 . . . . 0.0 109.371 177.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.3 -62.35 0.63 Allowed Glycine 0 N--CA 1.488 2.146 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 -178.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.675 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 165.27 -58.73 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.467 0 C-N-CA 123.248 0.619 . . . . 0.0 109.804 177.444 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.675 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.23 18.19 0.33 Allowed 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 121.076 1.184 . . . . 0.0 110.937 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -126.94 42.48 3.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.315 -0.866 . . . . 0.0 109.499 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.943 HG21 HD11 ' A' ' 34' ' ' LEU . 12.3 p -123.58 140.77 46.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-O 121.563 0.697 . . . . 0.0 109.73 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.554 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.59 169.09 40.46 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -80.08 157.53 41.19 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.624 -1.79 . . . . 0.0 108.624 178.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.57 HD12 ' H ' ' A' ' 48' ' ' ASP . 1.2 pp -146.23 145.21 23.39 Favored Pre-proline 0 N--CA 1.486 1.361 0 O-C-N 121.48 -1.012 . . . . 0.0 109.221 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.446 ' HD2' ' CE1' ' A' ' 83' ' ' PHE . 38.0 Cg_endo -61.73 -7.19 8.71 Favored 'Trans proline' 0 N--CA 1.506 2.249 0 C-N-CA 122.197 1.931 . . . . 0.0 115.075 -177.784 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.57 ' H ' HD12 ' A' ' 46' ' ' ILE . 91.4 m-20 -97.46 23.0 8.09 Favored 'General case' 0 N--CA 1.504 2.252 0 O-C-N 120.5 -1.375 . . . . 0.0 112.446 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.645 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.4 mm -110.13 130.1 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.245 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.17 -48.1 9.48 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.423 -0.798 . . . . 0.0 112.613 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.72 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.67 -131.48 1.67 Allowed Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.609 -1.758 . . . . 0.0 111.926 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 11.8 t90 -54.79 -22.9 15.77 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 -178.006 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.416 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 42.1 m-20 -147.94 62.51 1.12 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.008 -1.057 . . . . 0.0 110.754 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.645 ' CB ' HG23 ' A' ' 49' ' ' ILE . 50.0 p -58.6 141.97 83.57 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.476 -0.765 . . . . 0.0 110.967 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -77.45 -21.4 11.64 Favored 'Trans proline' 0 C--N 1.319 -0.991 0 O-C-N 123.39 1.205 . . . . 0.0 110.752 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.8 m -97.89 13.81 29.34 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.507 -0.746 . . . . 0.0 111.073 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -68.05 141.34 56.2 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.152 -0.967 . . . . 0.0 109.628 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.8 42.38 11.32 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.2 m -120.03 130.05 54.53 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.395 -1.062 . . . . 0.0 110.198 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 49.1 t -80.14 139.94 36.6 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.097 -177.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.435 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 64.3 m95 -145.27 150.88 37.44 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.543 -0.723 . . . . 0.0 110.376 178.205 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -109.63 133.02 53.59 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -110.03 128.89 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.443 -0.786 . . . . 0.0 109.727 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 29.5 m -119.98 142.67 48.57 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.831 -0.543 . . . . 0.0 111.662 -177.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.444 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 23.4 pt -119.67 163.55 26.84 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.709 -0.619 . . . . 0.0 110.279 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.54 -23.56 74.88 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 121.3 1.334 . . . . 0.0 112.672 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -66.38 -40.01 89.42 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.274 -0.891 . . . . 0.0 109.83 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.89 60.42 0.29 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -160.02 150.6 18.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.629 -0.924 . . . . 0.0 109.088 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.1 m -151.06 156.91 42.06 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.037 0.923 . . . . 0.0 112.03 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.486 HG12 HD13 ' A' ' 93' ' ' LEU . 39.6 pt -138.0 165.71 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -106.92 127.5 53.49 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 118.964 -1.094 . . . . 0.0 110.145 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.6 mm -115.78 129.96 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.748 -0.595 . . . . 0.0 110.094 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.499 ' HD3' HG12 ' A' ' 37' ' ' VAL . 38.9 ttt180 -99.81 135.03 41.84 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.14 148.29 24.94 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 44' ' ' GLY . 4.8 p -159.9 -37.98 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.767 -0.843 . . . . 0.0 110.057 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.514 ' HB2' HG23 ' A' ' 18' ' ' VAL . 31.3 t70 -133.18 169.96 16.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.002 -1.061 . . . . 0.0 109.495 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.422 ' CA ' ' HB ' ' A' ' 49' ' ' ILE . 86.9 p -97.26 160.05 14.56 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.409 -0.807 . . . . 0.0 110.899 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.94 141.74 12.94 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -60.73 -39.93 90.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.808 -0.819 . . . . 0.0 110.663 178.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.35 71.73 0.09 OUTLIER Glycine 0 N--CA 1.494 2.535 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.63 168.91 15.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.604 ' HB2' HG22 ' A' ' 3' ' ' ILE . 96.3 m-85 -98.49 128.57 44.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.755 -0.85 . . . . 0.0 109.948 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 47.6 t-20 -120.63 131.02 54.4 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.378 -0.826 . . . . 0.0 109.531 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.2 m -131.09 174.06 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.064 -1.023 . . . . 0.0 111.387 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.1 m-20 -55.78 153.14 17.16 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.355 -0.841 . . . . 0.0 109.996 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.76 -26.23 53.0 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 123.381 1.2 . . . . 0.0 110.019 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.9 m -70.72 -39.98 73.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.092 -1.005 . . . . 0.0 108.982 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.73 79.04 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -60.08 -50.02 75.37 Favored 'General case' 0 N--CA 1.499 2.018 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.689 179.121 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.8 m -60.04 -38.61 83.28 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.482 -0.761 . . . . 0.0 110.463 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.07 -39.75 75.46 Favored 'General case' 0 N--CA 1.493 1.694 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.937 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.486 HD13 HG12 ' A' ' 71' ' ' ILE . 47.9 tp -70.07 -43.58 70.86 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.555 -0.715 . . . . 0.0 111.668 -179.257 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -95.01 -37.63 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.134 0 O-C-N 121.251 -0.906 . . . . 0.0 110.967 -178.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.26 5.5 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.0 p -156.7 168.76 26.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -1.013 . . . . 0.0 110.121 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 55.1 p -96.77 8.41 44.35 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 110.801 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.04 -29.59 66.66 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.374 -0.829 . . . . 0.0 110.409 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.1 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.565 -0.709 . . . . 0.0 110.54 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 79.02 -83.67 1.28 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 29.2 ttt180 -130.03 133.13 46.53 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.627 -0.926 . . . . 0.0 110.133 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.68 120.13 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.489 -0.757 . . . . 0.0 110.304 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 43.7 p-10 -83.23 174.81 10.43 Favored 'General case' 0 N--CA 1.494 1.746 0 CA-C-O 121.718 0.77 . . . . 0.0 111.544 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 57.7 t30 59.99 40.66 18.56 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.704 -0.622 . . . . 0.0 112.013 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.624 HG21 HG12 ' A' ' 3' ' ' ILE . 59.3 t -88.91 127.34 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.937 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -85.14 138.32 32.46 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 119.328 -0.949 . . . . 0.0 109.871 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -134.57 140.48 46.15 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.351 0.596 . . . . 0.0 110.746 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 m -142.67 145.25 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.668 -0.645 . . . . 0.0 109.916 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.435 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 55.4 tt0 -85.03 141.62 30.16 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -136.18 176.96 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.718 -0.614 . . . . 0.0 110.088 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -62.03 149.57 40.59 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.443 -0.786 . . . . 0.0 110.575 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.581 HD21 HD11 ' A' ' 116' ' ' ILE . 8.0 tt -60.08 -39.93 87.77 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.488 -0.757 . . . . 0.0 110.992 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 t -51.39 -38.94 55.99 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.424 -0.798 . . . . 0.0 110.822 -178.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -60.91 -39.99 91.45 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.49 -0.756 . . . . 0.0 111.274 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -61.53 -48.22 82.01 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.323 -0.861 . . . . 0.0 110.109 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.581 HD11 HD21 ' A' ' 112' ' ' LEU . 96.5 mt -67.84 -39.92 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.663 -0.648 . . . . 0.0 110.557 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -65.59 -40.0 92.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.463 -0.773 . . . . 0.0 110.571 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.96 -49.37 35.23 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.54 89.46 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.576 -0.955 . . . . 0.0 110.605 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.7 m120 . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 117.93 -1.034 . . . . 0.0 110.273 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 105' ' ' VAL . 27.6 m . . . . . 0 N--CA 1.499 1.994 0 CA-C-O 120.975 0.416 . . . . 0.0 110.415 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 50.5 m -113.3 143.01 45.15 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.537 -0.727 . . . . 0.0 110.795 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.439 HG22 ' HB2' ' A' ' 83' ' ' PHE . 27.9 pt -114.36 149.93 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.81 -0.556 . . . . 0.0 110.861 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.5 p -147.07 -173.46 4.25 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.411 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.1 p90 -142.11 153.33 44.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.355 -0.841 . . . . 0.0 110.246 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.442 ' OD1' HD12 ' A' ' 8' ' ' ILE . 0.9 OUTLIER -132.78 145.94 59.24 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.404 -0.81 . . . . 0.0 110.359 -179.592 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 6' ' ' ASP . 53.2 Cg_endo -88.43 49.75 1.56 Allowed 'Trans proline' 0 N--CA 1.486 1.077 0 O-C-N 123.219 1.115 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.663 ' O ' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -134.05 5.88 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.562 0 O-C-N 120.751 -1.218 . . . . 0.0 110.936 178.196 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.558 ' CE2' HD11 ' A' ' 8' ' ' ILE . 31.5 m-85 -114.15 67.2 0.68 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 122.873 1.321 . . . . 0.0 109.442 178.386 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.31 170.83 7.83 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.858 177.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.98 -32.87 71.24 Favored 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -88.9 11.5 17.85 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.464 -1.397 . . . . 0.0 112.176 -177.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.663 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.5 tp -72.27 125.1 26.51 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.301 -0.874 . . . . 0.0 109.987 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.4 m -70.38 136.19 49.42 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.276 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.715 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -65.26 -16.72 63.85 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.85 -0.531 . . . . 0.0 111.683 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.66 -11.49 80.54 Favored Glycine 0 N--CA 1.496 2.687 0 O-C-N 121.003 -1.061 . . . . 0.0 111.284 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.4 m -89.96 -4.85 57.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.034 -1.274 . . . . 0.0 112.055 -178.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 15' ' ' MET . 9.4 p -100.7 169.02 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.966 -1.084 . . . . 0.0 110.434 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.754 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.06 87.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.15 69.0 4.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.499 -0.751 . . . . 0.0 109.884 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.3 m -108.58 110.81 22.36 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.181 -0.949 . . . . 0.0 110.783 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.406 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 12.6 t-20 50.09 -141.47 0.71 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.747 -0.596 . . . . 0.0 111.406 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 64.64 -150.63 51.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.55 -46.26 16.06 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.977 . . . . 0.0 111.494 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 54' ' ' SER . 73.8 m-70 -89.99 1.99 55.65 Favored 'General case' 0 N--CA 1.504 2.262 0 O-C-N 121.209 -0.932 . . . . 0.0 111.84 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.406 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -54.9 134.24 47.72 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 121.004 -1.06 . . . . 0.0 111.126 -179.019 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.812 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -100.03 -6.86 25.79 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 122.003 -0.704 . . . . 0.0 110.066 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.4 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.5 ttm -60.3 -35.47 75.67 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.258 -0.901 . . . . 0.0 110.088 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.75 -73.74 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.706 -0.622 . . . . 0.0 111.733 -177.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -69.93 -40.04 75.76 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.345 -0.847 . . . . 0.0 110.241 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.5 m-85 -119.81 91.25 44.93 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.53 -11.79 31.91 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.298 1.157 . . . . 0.0 111.579 -178.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.6 m -130.02 143.42 50.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.229 -0.92 . . . . 0.0 110.489 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.875 HD11 HG21 ' A' ' 43' ' ' VAL . 40.4 tp -67.91 119.99 13.46 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.781 -0.574 . . . . 0.0 110.117 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.8 32.53 0.05 OUTLIER Glycine 0 N--CA 1.495 2.623 0 C-N-CA 120.008 -1.092 . . . . 0.0 110.56 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 15.1 mt-10 -155.34 -46.42 0.08 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.312 -1.11 . . . . 0.0 110.14 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.812 HG11 HD13 ' A' ' 27' ' ' LEU . 2.9 t -61.84 -59.61 12.74 Favored Pre-proline 0 N--CA 1.496 1.844 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -76.23 -29.27 6.51 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 N-CA-C 109.184 -1.121 . . . . 0.0 109.184 177.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 128.5 -60.73 0.66 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 107.433 -2.267 . . . . 0.0 107.433 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.608 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 4.5 t80 162.41 -52.5 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.705 0 C-N-CA 123.595 0.758 . . . . 0.0 109.95 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.608 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.07 19.04 0.23 Allowed 'Trans proline' 0 C--N 1.322 -0.819 0 C-N-CA 121.392 1.395 . . . . 0.0 111.347 -178.432 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.8 m-20 -131.81 49.87 2.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.292 -0.88 . . . . 0.0 110.236 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 34' ' ' LEU . 10.4 p -125.97 139.57 51.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-O 121.598 0.713 . . . . 0.0 109.961 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 84' ' ' ASN . . . -169.4 174.28 43.77 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.28 159.28 32.22 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.573 HG22 ' CE1' ' A' ' 83' ' ' PHE . 1.4 pt -149.98 158.09 37.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.662 -0.905 . . . . 0.0 110.634 179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.22 -13.22 35.65 Favored 'Trans proline' 0 N--CA 1.499 1.811 0 C-N-CA 121.419 1.413 . . . . 0.0 114.328 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -94.9 22.23 6.72 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 120.563 -1.336 . . . . 0.0 112.819 -177.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.616 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.5 mm -113.12 129.59 68.55 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.073 -1.017 . . . . 0.0 108.52 178.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.73 12.34 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.395 -0.816 . . . . 0.0 112.229 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.754 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 170.64 -129.56 1.83 Allowed Glycine 0 N--CA 1.489 2.227 0 C-N-CA 118.813 -1.66 . . . . 0.0 111.139 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 44.7 t90 -52.1 -22.35 4.09 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.962 -0.728 . . . . 0.0 112.601 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -149.44 65.75 1.01 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.042 -1.036 . . . . 0.0 110.933 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.616 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.0 p -63.47 135.01 96.07 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.548 -0.72 . . . . 0.0 110.855 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.58 -20.76 23.03 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.333 1.175 . . . . 0.0 110.692 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.493 ' O ' HG23 ' A' ' 59' ' ' THR . 13.7 m -98.1 11.53 37.39 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.489 -0.757 . . . . 0.0 111.116 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -65.98 145.29 56.07 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.176 -0.953 . . . . 0.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.24 29.21 34.26 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.493 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -101.6 147.69 26.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.532 -0.981 . . . . 0.0 110.548 179.48 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.688 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.6 t -97.73 126.96 43.35 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.655 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.491 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 97.5 m95 -131.04 147.67 52.65 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.344 -0.848 . . . . 0.0 110.709 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.7 tttp -109.06 130.7 55.48 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.5 t -110.78 122.56 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.561 -0.712 . . . . 0.0 110.298 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' HG13 ' A' ' 105' ' ' VAL . 98.4 m -121.47 138.73 54.16 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.662 -0.649 . . . . 0.0 110.842 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.491 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 11.1 pt -113.59 165.54 13.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.631 -0.668 . . . . 0.0 110.777 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.491 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.43 -24.88 75.8 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 121.361 1.374 . . . . 0.0 112.825 -178.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -65.32 -39.87 93.01 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.223 -0.923 . . . . 0.0 109.99 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.19 60.07 0.28 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -160.33 152.18 20.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.669 -0.901 . . . . 0.0 108.887 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.418 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -153.75 158.9 41.65 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.047 -1.061 . . . . 0.0 112.373 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.0 pt -139.92 163.38 24.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -104.2 129.15 51.97 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.958 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.0 130.01 71.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.733 -0.604 . . . . 0.0 109.55 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.565 ' HD3' HG12 ' A' ' 37' ' ' VAL . 67.2 ttt180 -100.39 136.28 40.52 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.296 -0.878 . . . . 0.0 109.299 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -56.75 146.73 34.38 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -178.178 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.487 HG22 HG21 ' A' ' 18' ' ' VAL . 5.4 p -158.26 -42.51 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.816 -0.814 . . . . 0.0 109.461 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.527 ' HB2' HG23 ' A' ' 18' ' ' VAL . 16.9 t70 -130.43 168.94 16.17 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.225 -0.922 . . . . 0.0 109.522 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -97.44 160.66 14.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.515 -0.74 . . . . 0.0 111.637 -179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.03 149.37 19.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 65.0 mtt180 -61.88 -33.09 73.59 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.66 -0.906 . . . . 0.0 110.928 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.43 81.57 0.05 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.3 149.99 5.39 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.897 -1.144 . . . . 0.0 110.351 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.573 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -65.78 136.37 56.12 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.968 -0.725 . . . . 0.0 110.388 179.503 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.428 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 56.9 t-20 -134.93 124.23 24.63 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.143 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.9 m -133.81 176.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.133 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.9 m-20 -57.65 154.49 25.34 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.675 -0.64 . . . . 0.0 110.253 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.53 -26.86 46.66 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.468 1.246 . . . . 0.0 110.604 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.0 -40.54 75.23 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.919 -1.113 . . . . 0.0 108.632 178.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.88 -39.92 87.65 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -60.01 -50.06 75.21 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.85 -0.531 . . . . 0.0 110.474 179.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.5 m -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.424 -0.798 . . . . 0.0 110.538 -178.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -69.4 -40.08 77.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.79 -0.764 . . . . 0.0 111.493 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.418 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 40.6 tp -71.49 -43.02 67.32 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.525 -0.734 . . . . 0.0 111.504 -178.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.5 t -96.26 -39.63 9.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.309 -0.87 . . . . 0.0 111.492 -177.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.79 7.42 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.3 p -144.78 157.95 43.98 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.453 -1.027 . . . . 0.0 110.117 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.53 15.77 28.14 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.422 -0.799 . . . . 0.0 110.574 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -93.35 -15.0 26.2 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.452 -0.78 . . . . 0.0 110.761 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.93 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.231 -0.918 . . . . 0.0 110.405 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 86.82 -77.01 2.03 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.415 ' NE ' ' HB3' ' A' ' 2' ' ' SER . 61.6 ttt180 -137.82 135.62 36.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.595 -0.944 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 56.3 t -120.05 119.24 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.421 -0.799 . . . . 0.0 109.477 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.0 p-10 -85.18 177.05 8.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.792 0.806 . . . . 0.0 112.078 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 60.06 40.0 19.09 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.919 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.474 HG13 ' O ' ' A' ' 64' ' ' THR . 86.3 t -95.41 123.27 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.231 179.012 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -84.5 146.72 27.44 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.762 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.428 ' C ' HG13 ' A' ' 108' ' ' VAL . 52.2 p90 -142.14 148.74 38.79 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.923 -0.486 . . . . 0.0 110.907 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.428 HG13 ' C ' ' A' ' 107' ' ' TYR . 24.4 m -149.93 144.91 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 O-C-N 121.348 -0.845 . . . . 0.0 111.782 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.491 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 55.1 tt0 -70.01 140.99 52.98 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.707 -0.62 . . . . 0.0 109.886 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.688 HG23 ' SG ' ' A' ' 60' ' ' CYS . 30.5 m -139.95 172.78 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.992 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -59.86 145.51 45.36 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.382 -0.824 . . . . 0.0 110.862 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.464 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.4 tt -59.99 -40.09 87.94 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.378 -0.826 . . . . 0.0 110.201 179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 70.6 m -54.92 -37.9 66.96 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.627 -0.671 . . . . 0.0 109.847 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -59.98 -39.99 87.56 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.56 -0.712 . . . . 0.0 110.059 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.8 m -64.04 -45.35 89.27 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.489 -0.757 . . . . 0.0 109.225 178.473 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.2 mm -62.89 -45.72 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.259 0.552 . . . . 0.0 110.137 -178.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -66.53 -40.01 88.9 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.796 -0.565 . . . . 0.0 110.553 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.78 -42.93 99.81 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.56 -40.0 94.77 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.574 -0.957 . . . . 0.0 110.535 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 33.6 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.306 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 120.982 0.42 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.4 t -112.96 139.94 48.18 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.695 . . . . 0.0 110.44 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.671 HG21 HG11 ' A' ' 105' ' ' VAL . 44.9 pt -107.71 145.68 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.688 -0.632 . . . . 0.0 110.693 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 3.9 m -144.33 -174.25 4.25 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 45.8 p90 -141.29 147.36 38.06 Favored 'General case' 0 N--CA 1.492 1.671 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.043 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -124.81 145.18 48.96 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.504 -0.747 . . . . 0.0 109.169 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -82.51 -10.08 11.03 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.274 1.144 . . . . 0.0 112.733 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.828 ' O ' HD23 ' A' ' 13' ' ' LEU . 48.9 pt -70.03 -40.04 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 120.947 -1.096 . . . . 0.0 111.37 -179.183 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.475 ' N ' HG13 ' A' ' 8' ' ' ILE . 42.6 m-85 -73.11 67.34 0.9 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 122.874 1.321 . . . . 0.0 111.698 -178.729 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.91 173.86 6.12 Favored 'General case' 0 N--CA 1.489 1.505 0 CA-C-N 114.401 -1.272 . . . . 0.0 108.107 176.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.5 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -56.71 -30.35 63.4 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -175.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -89.99 11.55 20.23 Favored 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 118.237 -1.385 . . . . 0.0 112.262 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.828 HD23 ' O ' ' A' ' 8' ' ' ILE . 0.4 OUTLIER -67.51 119.78 12.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.295 -0.878 . . . . 0.0 109.878 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.454 ' N ' HD13 ' A' ' 13' ' ' LEU . 50.5 m -70.11 137.01 50.78 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.759 0.79 . . . . 0.0 110.007 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.776 ' O ' HG12 ' A' ' 18' ' ' VAL . 95.4 mmm -64.24 -21.87 66.74 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.885 -0.51 . . . . 0.0 111.634 -179.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.436 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.32 -16.07 77.13 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 121.065 -1.022 . . . . 0.0 111.514 -178.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.4 m -90.0 -4.71 57.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.121 -1.223 . . . . 0.0 111.923 -178.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.776 HG12 ' O ' ' A' ' 15' ' ' MET . 9.9 p -101.04 168.64 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.959 -1.088 . . . . 0.0 110.618 -179.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.673 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.0 -42.73 94.87 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.476 -0.765 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.5 m -80.47 71.98 7.33 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.85 -76.96 0.51 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.507 -0.746 . . . . 0.0 109.952 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -127.84 168.55 15.02 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.648 -0.658 . . . . 0.0 109.584 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.21 -154.95 16.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 -178.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -70.72 -42.77 70.15 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -1.109 . . . . 0.0 110.186 179.243 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.56 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 19.7 m80 -92.61 3.35 55.73 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.412 -0.805 . . . . 0.0 110.836 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.05 129.74 48.07 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.45 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.407 HD13 HH21 ' A' ' 74' ' ' ARG . 85.8 mt -99.71 -3.12 33.64 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 122.039 -0.683 . . . . 0.0 110.21 179.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.436 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 58.8 tpp -60.01 -38.59 83.11 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.336 -0.853 . . . . 0.0 110.365 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.77 -75.05 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.68 -0.637 . . . . 0.0 112.195 -177.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -70.05 -41.17 74.56 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.325 -0.86 . . . . 0.0 111.446 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.641 ' CG ' HG23 ' A' ' 37' ' ' VAL . 97.6 m-85 -122.84 86.4 50.21 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.648 -0.657 . . . . 0.0 110.474 -178.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.06 -7.42 21.36 Favored 'Trans proline' 0 C--N 1.317 -1.099 0 O-C-N 123.387 1.203 . . . . 0.0 111.475 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.3 m -130.02 142.98 50.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.05 -1.031 . . . . 0.0 110.189 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.906 HD11 HG21 ' A' ' 43' ' ' VAL . 39.6 tp -75.4 117.83 17.62 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.78 -0.575 . . . . 0.0 110.644 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.05 30.29 0.05 OUTLIER Glycine 0 N--CA 1.496 2.676 0 C-N-CA 120.092 -1.052 . . . . 0.0 110.812 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 8.9 mt-10 -153.66 -52.79 0.1 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.218 -1.166 . . . . 0.0 110.336 179.641 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.641 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -60.65 -59.63 13.24 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 45.7 Cg_endo -73.36 -32.45 8.09 Favored 'Trans proline' 0 N--CA 1.486 1.068 0 N-CA-C 109.114 -1.148 . . . . 0.0 109.114 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.81 -64.35 0.61 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 107.739 -2.144 . . . . 0.0 107.739 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 162.75 -55.8 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.787 0 C-N-CA 123.477 0.711 . . . . 0.0 110.627 177.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -101.07 13.09 0.44 Allowed 'Trans proline' 0 N--CA 1.48 0.715 0 C-N-CA 121.348 1.365 . . . . 0.0 111.522 -178.333 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -122.21 45.76 2.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.223 -179.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.906 HG21 HD11 ' A' ' 34' ' ' LEU . 12.6 p -126.78 141.06 47.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.832 0.825 . . . . 0.0 110.19 -179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.84 173.3 43.4 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.568 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.26 159.23 30.85 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.009 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.768 HD11 ' HA2' ' A' ' 75' ' ' GLY . 1.0 OUTLIER -153.38 160.18 31.25 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.581 -0.952 . . . . 0.0 109.493 179.564 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.14 -37.67 31.26 Favored 'Trans proline' 0 N--CA 1.505 2.184 0 C-N-CA 121.831 1.687 . . . . 0.0 116.125 -175.056 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -69.7 -9.95 56.4 Favored 'General case' 0 N--CA 1.509 2.493 0 O-C-N 120.561 -1.337 . . . . 0.0 112.974 -176.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 54' ' ' SER . 44.4 mm -77.04 125.04 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 O-C-N 120.713 -1.242 . . . . 0.0 108.527 178.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.18 -46.78 12.31 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.261 -0.899 . . . . 0.0 112.568 -178.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.673 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 171.94 -137.5 4.33 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.716 -1.707 . . . . 0.0 111.54 -179.311 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 58.2 t90 -42.88 -29.62 0.34 Allowed 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.671 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.401 ' HB2' ' CE3' ' A' ' 52' ' ' TRP . 25.4 t70 -144.98 62.27 1.31 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 110.508 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.579 ' CB ' HG23 ' A' ' 49' ' ' ILE . 12.5 p -61.82 139.31 95.55 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.651 -0.656 . . . . 0.0 110.651 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.56 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 51.3 Cg_endo -76.17 -21.36 13.81 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 O-C-N 123.373 1.196 . . . . 0.0 111.113 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.7 m -94.05 14.49 19.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.491 -0.755 . . . . 0.0 111.296 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.3 t -73.85 147.89 42.86 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.16 35.31 53.51 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.421 HG22 ' NE1' ' A' ' 61' ' ' TRP . 89.2 m -119.68 131.55 55.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.595 -0.944 . . . . 0.0 109.882 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.04 145.66 33.73 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.871 -177.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.445 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -149.83 149.34 30.35 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.684 -0.635 . . . . 0.0 110.124 178.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -112.16 135.55 52.67 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.6 t -108.77 126.77 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.8 m -119.22 140.39 50.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.964 -0.46 . . . . 0.0 110.834 -178.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.449 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 39.3 pt -119.16 164.2 22.58 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.616 -0.677 . . . . 0.0 110.531 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.1 -24.41 79.28 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 121.273 1.315 . . . . 0.0 112.338 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -63.89 -40.02 95.54 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.272 -0.892 . . . . 0.0 109.58 179.373 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.95 62.57 0.41 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 48.6 t-20 -162.01 153.45 18.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.708 -0.878 . . . . 0.0 108.975 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.4 p -154.64 160.96 41.75 Favored 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 119.261 -0.975 . . . . 0.0 112.329 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.527 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.0 pt -136.35 164.44 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -108.65 126.75 53.31 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.16 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.782 HD13 HG11 ' A' ' 85' ' ' VAL . 88.0 mt -129.99 140.0 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.254 -0.904 . . . . 0.0 111.454 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.466 ' CD ' HG12 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -100.87 144.35 29.94 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.868 -0.52 . . . . 0.0 109.654 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.768 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.54 151.06 46.93 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -179.478 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.559 HG11 HG22 ' A' ' 43' ' ' VAL . 2.7 p -155.73 -44.1 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 178.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.466 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.9 t70 -130.3 170.0 14.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 178.603 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.7 t -101.48 159.94 14.86 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.775 . . . . 0.0 111.318 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -130.13 154.32 20.5 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.1 mtt180 -59.97 -31.56 70.01 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.555 -0.967 . . . . 0.0 110.403 179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.17 81.73 0.05 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 119.979 -1.105 . . . . 0.0 110.571 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.06 163.9 11.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.161 -1.176 . . . . 0.0 110.161 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.577 ' CD2' HG22 ' A' ' 46' ' ' ILE . 28.0 m-85 -88.36 118.63 28.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.512 -0.993 . . . . 0.0 109.746 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.406 ' HA ' ' O ' ' A' ' 4' ' ' SER . 54.6 t-20 -113.04 128.71 56.57 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.782 HG11 HD13 ' A' ' 73' ' ' ILE . 34.5 m -130.02 172.56 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 120.862 -1.149 . . . . 0.0 112.008 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 -56.52 156.22 12.26 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.504 -0.748 . . . . 0.0 109.594 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.44 -28.49 54.11 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.276 1.145 . . . . 0.0 110.663 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -70.28 -40.63 74.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.99 -1.069 . . . . 0.0 109.382 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.65 89.2 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -60.02 -49.84 76.08 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.826 -0.546 . . . . 0.0 110.311 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.9 m -60.11 -39.98 88.11 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.586 -0.696 . . . . 0.0 110.754 -178.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -68.67 -39.98 80.35 Favored 'General case' 0 N--CA 1.495 1.813 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.172 -178.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.402 HD13 HG23 ' A' ' 71' ' ' ILE . 63.1 tp -70.27 -42.9 71.52 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.627 -0.67 . . . . 0.0 111.749 -178.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 92.7 t -97.05 -39.93 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.312 -0.868 . . . . 0.0 111.829 -177.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.07 -25.75 7.36 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 80.9 p -149.93 161.03 43.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.351 -1.088 . . . . 0.0 110.317 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 77.4 p -99.1 1.87 45.54 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.477 -0.765 . . . . 0.0 111.298 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -69.96 -28.65 65.73 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.388 -0.82 . . . . 0.0 111.466 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.82 -40.63 89.06 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.396 -0.815 . . . . 0.0 111.272 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 89.42 -66.26 2.98 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -151.23 155.99 39.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.486 -1.008 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.97 117.65 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.551 -0.718 . . . . 0.0 109.785 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -80.62 169.51 17.55 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.474 -0.766 . . . . 0.0 110.427 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 60.0 51.81 5.62 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.628 -0.67 . . . . 0.0 111.347 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.671 HG11 HG21 ' A' ' 3' ' ' ILE . 65.8 t -98.66 129.99 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.434 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -89.04 138.68 31.19 Favored 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.804 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.405 ' C ' HG13 ' A' ' 108' ' ' VAL . 38.3 p90 -133.3 140.98 47.75 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.907 -0.496 . . . . 0.0 110.557 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -146.03 143.0 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.589 -0.694 . . . . 0.0 111.242 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.445 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.2 tt0 -70.88 139.78 50.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.681 -0.637 . . . . 0.0 110.444 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.07 163.27 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.098 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -59.62 141.38 55.12 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.543 -0.723 . . . . 0.0 110.478 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.0 -40.0 87.7 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.598 -0.689 . . . . 0.0 111.391 -179.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 78.6 p -55.72 -34.23 64.95 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.503 -0.748 . . . . 0.0 110.935 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -69.92 -28.08 65.31 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.348 -0.845 . . . . 0.0 111.339 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 97.3 m -69.96 -46.45 65.22 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.23 -0.919 . . . . 0.0 109.179 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 89.2 mt -69.96 -40.01 78.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.143 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -64.56 -40.0 94.78 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.459 -0.776 . . . . 0.0 110.618 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -83.81 -60.01 2.02 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.454 -0.879 . . . . 0.0 110.93 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.04 -42.52 94.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.611 -0.934 . . . . 0.0 111.202 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.502 2.172 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.727 -179.711 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.573 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.694 0.759 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.9 p -111.81 138.94 47.73 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.712 HG23 HG21 ' A' ' 105' ' ' VAL . 29.9 pt -108.78 145.36 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.801 -0.562 . . . . 0.0 110.481 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.4 p -144.22 -173.32 3.98 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 39.4 p90 -140.02 141.24 36.32 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.456 -0.777 . . . . 0.0 110.696 179.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.14 150.07 50.55 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.483 -0.761 . . . . 0.0 109.284 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -82.83 -10.53 10.51 Favored 'Trans proline' 0 C--N 1.318 -1.067 0 O-C-N 123.105 1.055 . . . . 0.0 112.551 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.9 pt -70.06 -39.96 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.002 -1.061 . . . . 0.0 111.62 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.687 ' HA ' HD22 ' A' ' 13' ' ' LEU . 53.7 m-85 -73.2 67.51 0.95 Allowed 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 122.875 1.321 . . . . 0.0 111.907 -178.32 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.8 169.65 8.36 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.854 176.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.521 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.87 -35.09 70.48 Favored 'General case' 0 N--CA 1.497 1.912 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -90.23 10.39 24.86 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 120.497 -1.377 . . . . 0.0 112.295 -177.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 9' ' ' TYR . 34.8 tp -68.49 123.45 20.85 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -0.865 . . . . 0.0 109.829 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.3 m -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.806 -0.758 . . . . 0.0 109.775 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.811 ' O ' HG12 ' A' ' 18' ' ' VAL . 86.6 mtp -69.96 -15.28 63.02 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.91 -0.494 . . . . 0.0 111.864 -178.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.58 -15.95 73.59 Favored Glycine 0 N--CA 1.496 2.654 0 O-C-N 121.021 -1.049 . . . . 0.0 110.816 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.5 m -90.05 -4.99 57.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.175 -1.191 . . . . 0.0 111.716 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.811 HG12 ' O ' ' A' ' 15' ' ' MET . 14.8 p -102.26 168.96 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.026 -1.046 . . . . 0.0 110.877 -179.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.7 89.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.575 -0.703 . . . . 0.0 110.368 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 54.1 m -83.45 74.84 10.05 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.2 m -100.41 -77.04 0.54 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.385 -0.822 . . . . 0.0 110.388 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -129.68 169.98 14.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 0.0 110.485 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.46 -154.4 16.45 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -70.2 -40.94 74.3 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -1.073 . . . . 0.0 109.791 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.553 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 16.5 m80 -91.82 0.59 57.48 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.519 -0.738 . . . . 0.0 110.982 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -52.42 126.07 30.33 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HB2' ' HE2' ' A' ' 15' ' ' MET . 87.2 mt -96.53 -9.42 29.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 122.032 -0.687 . . . . 0.0 110.128 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.5 tpp -59.95 -37.03 78.39 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.35 -0.844 . . . . 0.0 110.006 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -74.37 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.513 -0.742 . . . . 0.0 111.983 -178.087 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -69.98 -39.99 75.6 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.237 -0.915 . . . . 0.0 110.455 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD2' HG23 ' A' ' 37' ' ' VAL . 87.3 m-85 -117.39 100.95 52.99 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.04 -20.92 16.31 Favored 'Trans proline' 0 C--N 1.318 -1.046 0 O-C-N 123.307 1.161 . . . . 0.0 111.367 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 30.2 m -127.84 148.32 50.46 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.371 -0.831 . . . . 0.0 111.017 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.97 HD21 HG11 ' A' ' 43' ' ' VAL . 57.7 tp -67.13 120.44 13.72 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.784 -0.573 . . . . 0.0 110.374 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.46 30.02 0.05 OUTLIER Glycine 0 N--CA 1.495 2.603 0 C-N-CA 119.891 -1.147 . . . . 0.0 110.963 179.49 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 31.7 mt-10 -153.18 -48.67 0.1 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.226 -1.161 . . . . 0.0 110.325 179.09 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.551 HG23 ' CD2' ' A' ' 31' ' ' TYR . 3.2 t -60.55 -60.48 10.5 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.461 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -75.67 -27.57 8.86 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.113 1.059 . . . . 0.0 109.466 177.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.406 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.27 -58.93 0.67 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.414 -2.274 . . . . 0.0 107.414 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.565 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 165.89 -73.57 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.615 0 C-N-CA 123.666 0.786 . . . . 0.0 109.356 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.565 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -86.21 19.19 1.43 Allowed 'Trans proline' 0 N--CA 1.493 1.465 0 CA-C-N 119.306 0.788 . . . . 0.0 111.16 178.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -118.37 37.03 4.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.059 -1.026 . . . . 0.0 110.18 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.97 HG11 HD21 ' A' ' 34' ' ' LEU . 12.4 p -120.71 141.23 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-O 121.757 0.789 . . . . 0.0 110.716 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.99 171.38 42.92 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.08 152.24 32.63 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.761 HG22 ' CE1' ' A' ' 83' ' ' PHE . 13.7 pt -141.88 156.81 65.41 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.665 -0.903 . . . . 0.0 109.742 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.3 -20.5 36.93 Favored 'Trans proline' 0 N--CA 1.499 1.841 0 C-N-CA 121.399 1.4 . . . . 0.0 113.966 -177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -88.92 20.68 3.44 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.805 -1.184 . . . . 0.0 112.541 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.835 HG23 ' CB ' ' A' ' 54' ' ' SER . 40.7 mt -120.02 120.0 61.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.074 -1.016 . . . . 0.0 108.398 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.48 -41.82 21.19 Favored 'General case' 0 N--CA 1.499 2.015 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -176.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.563 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.83 -138.96 4.6 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 118.323 -1.894 . . . . 0.0 112.171 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.504 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 26.3 t90 -39.95 -30.06 0.08 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -146.72 68.52 1.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.998 -1.064 . . . . 0.0 111.24 -178.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.835 ' CB ' HG23 ' A' ' 49' ' ' ILE . 2.1 t -64.51 136.87 96.94 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.622 -0.674 . . . . 0.0 110.586 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.553 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 48.6 Cg_endo -73.29 -20.55 21.06 Favored 'Trans proline' 0 C--N 1.32 -0.968 0 O-C-N 123.303 1.159 . . . . 0.0 110.605 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.9 m -99.84 14.82 29.03 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.499 -0.751 . . . . 0.0 110.806 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 23.4 t -72.75 151.12 42.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.238 -0.913 . . . . 0.0 110.061 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.18 21.75 78.62 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 80.4 m -106.58 140.01 40.13 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.515 -0.991 . . . . 0.0 110.277 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.703 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.3 t -78.59 136.21 37.46 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.687 -178.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.434 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -137.21 146.24 44.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.647 -0.658 . . . . 0.0 110.016 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -116.28 136.46 52.98 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.222 -0.924 . . . . 0.0 110.099 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -114.25 129.99 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.543 -0.723 . . . . 0.0 110.887 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 51.1 m -119.92 144.96 47.16 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.723 -0.611 . . . . 0.0 110.501 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.453 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.6 pt -123.44 164.33 28.85 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.307 -0.871 . . . . 0.0 111.11 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.28 -26.88 82.53 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.428 1.419 . . . . 0.0 112.574 -178.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -63.45 -39.71 95.2 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.317 -0.864 . . . . 0.0 109.741 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 115.26 61.65 0.37 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -160.6 153.29 20.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.832 -0.805 . . . . 0.0 109.077 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.402 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 84.0 p -150.65 158.49 44.21 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 122.18 0.99 . . . . 0.0 112.021 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.455 HG12 HD13 ' A' ' 93' ' ' LEU . 27.6 pt -138.7 162.77 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.27 123.83 48.89 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 118.859 -1.136 . . . . 0.0 109.794 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.403 HG13 HG11 ' A' ' 85' ' ' VAL . 48.5 mm -117.13 131.99 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.489 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.5 ttt180 -98.65 132.38 44.1 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.152 -0.968 . . . . 0.0 108.783 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.89 148.35 10.44 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.555 HG11 HG22 ' A' ' 43' ' ' VAL . 5.6 p -159.96 -35.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.792 -0.828 . . . . 0.0 110.406 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.456 ' HB2' HG23 ' A' ' 18' ' ' VAL . 28.4 t70 -128.94 165.28 21.38 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.885 -1.134 . . . . 0.0 110.449 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.443 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 79.4 p -82.54 159.78 22.73 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.656 -0.653 . . . . 0.0 110.521 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -127.49 135.4 8.73 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -65.44 -39.95 92.67 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.923 -0.751 . . . . 0.0 109.608 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 176.29 70.28 0.05 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.46 -163.18 33.35 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.59 -1.29 . . . . 0.0 110.766 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.761 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -123.34 136.61 54.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 122.025 -0.691 . . . . 0.0 109.415 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 45.3 t-20 -137.97 126.89 24.02 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.389 -0.925 . . . . 0.0 108.808 178.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.8 m -133.63 176.8 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.08 -1.012 . . . . 0.0 111.128 -178.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.3 m-20 -56.47 150.25 35.17 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.91 -25.68 67.11 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 O-C-N 123.367 1.193 . . . . 0.0 110.763 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' HE2' ' A' ' 92' ' ' LYS . 89.8 m -70.8 -40.03 72.77 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.976 -1.078 . . . . 0.0 109.308 178.423 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.03 91.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.04 -49.93 75.74 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.868 -0.52 . . . . 0.0 110.586 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.1 m -60.11 -39.94 87.98 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.439 -0.788 . . . . 0.0 110.606 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.434 ' HE2' HG22 ' A' ' 88' ' ' THR . 57.8 mtmt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.273 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.455 HD13 HG12 ' A' ' 71' ' ' ILE . 45.9 tp -71.6 -46.12 60.16 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 120.047 -0.661 . . . . 0.0 111.357 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.1 t -89.46 -41.39 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.4 -0.812 . . . . 0.0 111.334 -177.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 125.2 -27.25 5.37 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.7 p -158.85 162.32 36.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.551 -0.97 . . . . 0.0 110.024 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.9 p -91.97 1.57 57.1 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.478 -0.764 . . . . 0.0 111.372 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.66 -34.08 77.05 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.36 -41.5 80.25 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.45 -0.781 . . . . 0.0 111.456 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.41 -80.47 1.82 Allowed Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.3 ttm180 -129.0 136.82 50.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.575 -0.956 . . . . 0.0 109.918 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.6 t -119.02 117.29 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.243 -0.91 . . . . 0.0 110.299 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -83.84 171.57 12.98 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.525 0.679 . . . . 0.0 110.65 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.52 52.0 1.87 Allowed 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.623 -0.673 . . . . 0.0 111.06 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.712 HG21 HG23 ' A' ' 3' ' ' ILE . 60.4 t -103.24 129.81 54.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 C-N-CA 119.279 -0.968 . . . . 0.0 110.607 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -90.64 137.92 31.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.309 -0.87 . . . . 0.0 109.6 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.469 ' C ' HG13 ' A' ' 108' ' ' VAL . 53.8 p90 -140.04 145.83 38.24 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.902 -0.499 . . . . 0.0 110.835 -178.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.469 HG13 ' C ' ' A' ' 107' ' ' TYR . 29.6 m -151.1 151.58 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.216 -0.928 . . . . 0.0 111.273 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.434 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.0 tt0 -72.37 141.05 48.75 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.682 -0.636 . . . . 0.0 110.47 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.703 HG23 ' SG ' ' A' ' 60' ' ' CYS . 15.7 m -137.03 170.03 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -64.21 148.85 49.14 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.175 -0.953 . . . . 0.0 110.645 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.543 HD21 HD11 ' A' ' 116' ' ' ILE . 9.4 tt -60.08 -39.77 87.21 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.495 -0.753 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 89.3 p -52.24 -37.41 55.13 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.413 -0.805 . . . . 0.0 110.614 -178.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.31 -39.27 93.57 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.583 -0.698 . . . . 0.0 111.089 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -59.97 -50.02 75.4 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.394 -0.816 . . . . 0.0 110.064 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 112' ' ' LEU . 86.9 mt -69.84 -39.98 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.715 -0.616 . . . . 0.0 110.773 -179.235 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -39.98 96.24 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.39 -0.819 . . . . 0.0 110.521 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -72.66 -47.32 27.41 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.174 -1.171 . . . . 0.0 110.174 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.99 -40.78 90.33 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.502 -0.999 . . . . 0.0 110.707 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.5 t30 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.276 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.013 0.435 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.2 t -113.68 139.19 49.27 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.672 0.749 . . . . 0.0 111.045 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.77 HG12 HG21 ' A' ' 105' ' ' VAL . 36.3 pt -111.02 147.65 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.83 -0.544 . . . . 0.0 109.797 179.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.1 m -146.09 -171.52 3.73 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.418 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 47.7 p90 -140.12 150.01 43.75 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.119 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -126.67 148.07 63.33 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.521 -0.737 . . . . 0.0 110.216 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -86.57 14.14 2.53 Favored 'Trans proline' 0 C--N 1.317 -1.09 0 O-C-N 123.399 1.21 . . . . 0.0 111.636 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 1.4 pt -100.1 10.06 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.029 -1.044 . . . . 0.0 111.666 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -123.46 66.64 1.0 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.701 1.239 . . . . 0.0 110.259 178.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.07 172.76 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.459 -1.246 . . . . 0.0 108.447 176.592 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.03 -31.97 67.51 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -175.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -89.76 11.98 18.44 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.332 -1.347 . . . . 0.0 111.9 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 14' ' ' SER . 0.6 OUTLIER -69.3 119.56 13.77 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.281 -0.887 . . . . 0.0 110.043 179.875 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.47 ' N ' HD13 ' A' ' 13' ' ' LEU . 52.6 m -69.18 135.85 51.24 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.757 -0.777 . . . . 0.0 108.958 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.726 ' O ' HG12 ' A' ' 18' ' ' VAL . 57.1 mtp -70.21 -14.59 62.69 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 120.211 -0.596 . . . . 0.0 111.926 -179.234 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.65 -18.61 74.08 Favored Glycine 0 N--CA 1.495 2.6 0 O-C-N 120.848 -1.157 . . . . 0.0 110.654 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 70.4 m -88.06 -9.64 52.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.289 -1.124 . . . . 0.0 111.615 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 15' ' ' MET . 9.7 p -101.74 169.66 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.029 -1.044 . . . . 0.0 110.495 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.14 -39.76 83.39 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.568 -0.708 . . . . 0.0 110.594 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.31 82.84 3.08 Favored 'General case' 0 N--CA 1.5 2.025 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 -84.26 0.42 Allowed 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.794 -1.191 . . . . 0.0 113.395 -177.003 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -143.8 12.56 1.67 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.564 -1.335 . . . . 0.0 112.752 -177.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.89 -149.19 0.11 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -67.22 -39.89 86.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.891 -0.77 . . . . 0.0 110.456 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.603 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 11.8 p80 -97.86 6.2 48.08 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.31 138.79 35.53 Favored Glycine 0 N--CA 1.5 2.91 0 O-C-N 121.055 -1.028 . . . . 0.0 110.659 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.871 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -102.31 -5.68 23.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.885 -0.774 . . . . 0.0 110.724 179.262 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.8 ttm -60.44 -33.1 72.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.23 -0.919 . . . . 0.0 110.486 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.79 -72.15 0.06 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.566 -0.709 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -70.0 -40.16 75.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.185 -0.947 . . . . 0.0 110.079 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.422 ' CD2' HG23 ' A' ' 37' ' ' VAL . 60.8 m-85 -122.86 95.16 46.66 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.875 -0.516 . . . . 0.0 109.769 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.63 -19.32 32.13 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 O-C-N 123.398 1.209 . . . . 0.0 111.556 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.7 m -122.61 140.9 52.3 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.296 -0.878 . . . . 0.0 110.736 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.853 HD11 HG21 ' A' ' 43' ' ' VAL . 40.7 tp -61.65 119.91 9.59 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.912 -0.492 . . . . 0.0 110.317 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.77 33.36 0.04 OUTLIER Glycine 0 N--CA 1.496 2.679 0 C-N-CA 119.948 -1.12 . . . . 0.0 110.797 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.66 -45.98 0.06 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.195 -1.179 . . . . 0.0 110.013 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.871 HG11 HD13 ' A' ' 27' ' ' LEU . 3.2 t -62.69 -60.78 8.93 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 178.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.47 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.2 Cg_endo -75.97 -28.15 7.88 Favored 'Trans proline' 0 N--CA 1.485 1.028 0 N-CA-C 109.236 -1.102 . . . . 0.0 109.236 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.402 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.98 -60.93 0.65 Allowed Glycine 0 N--CA 1.486 2.019 0 N-CA-C 107.284 -2.326 . . . . 0.0 107.284 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.622 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.2 t80 164.04 -52.9 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.573 0 C-N-CA 123.381 0.672 . . . . 0.0 109.705 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.4 Cg_endo -101.78 13.94 0.37 Allowed 'Trans proline' 0 C--N 1.324 -0.742 0 C-N-CA 121.457 1.438 . . . . 0.0 111.486 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -123.46 40.73 3.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -0.928 . . . . 0.0 110.112 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.853 HG21 HD11 ' A' ' 34' ' ' LEU . 12.2 p -115.44 135.74 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 CA-C-O 121.602 0.715 . . . . 0.0 110.681 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.432 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -163.94 170.0 39.06 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.471 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -90.37 164.82 30.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.482 HG22 ' CD2' ' A' ' 83' ' ' PHE . 5.2 pt -150.92 163.47 23.64 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.74 -0.859 . . . . 0.0 110.12 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 55.6 Cg_endo -73.69 -15.05 24.41 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 121.43 1.42 . . . . 0.0 113.337 -177.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.412 ' HB2' HD12 ' A' ' 46' ' ' ILE . 79.5 m-20 -90.37 12.7 17.58 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.852 -1.155 . . . . 0.0 112.829 -177.621 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.784 HG23 ' CB ' ' A' ' 54' ' ' SER . 71.9 mt -110.8 129.92 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.068 -1.02 . . . . 0.0 110.18 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.41 -46.45 12.52 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.537 -0.727 . . . . 0.0 112.159 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.76 -138.91 5.52 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.895 -1.621 . . . . 0.0 111.371 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.492 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.0 t90 -39.81 -28.78 0.05 Allowed 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -179.005 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.603 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 24.6 t70 -141.09 63.96 1.43 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.281 -0.887 . . . . 0.0 110.576 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.784 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.8 t -79.86 139.35 53.83 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.696 -0.627 . . . . 0.0 110.414 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -78.4 -16.63 13.45 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.331 1.174 . . . . 0.0 111.45 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.0 p -98.05 4.84 49.21 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.208 -0.932 . . . . 0.0 112.607 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.424 ' HB3' ' HD1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -61.59 140.36 58.14 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.738 -1.226 . . . . 0.0 109.73 -179.604 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.97 -7.93 80.75 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 120.332 -0.937 . . . . 0.0 110.871 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.4 m -69.42 149.84 47.91 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.117 -1.225 . . . . 0.0 109.514 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.6 130.58 45.14 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.987 -0.446 . . . . 0.0 111.341 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -128.15 140.27 52.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.483 -0.761 . . . . 0.0 109.2 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.452 ' HB2' HG11 ' A' ' 110' ' ' VAL . 86.8 tttt -103.16 132.68 49.24 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.418 HG13 HG11 ' A' ' 105' ' ' VAL . 64.9 t -110.02 124.56 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.621 -0.674 . . . . 0.0 110.499 -179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.5 m -118.66 135.79 54.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.913 -0.492 . . . . 0.0 110.633 -178.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.443 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.9 pt -115.66 163.58 20.31 Favored Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.461 -0.775 . . . . 0.0 110.723 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.65 -27.29 76.0 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 121.411 1.407 . . . . 0.0 113.15 -178.189 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -62.62 -40.0 95.59 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.132 -0.98 . . . . 0.0 109.582 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.9 60.06 0.29 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -155.05 151.11 27.99 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 89.6 p -149.83 153.34 36.6 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.029 0.919 . . . . 0.0 111.747 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.446 HG23 HD13 ' A' ' 93' ' ' LEU . 31.6 pt -139.14 163.09 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -105.51 129.42 53.8 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.871 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.568 ' CD1' HG11 ' A' ' 85' ' ' VAL . 48.9 mm -116.09 128.18 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.662 -0.649 . . . . 0.0 109.614 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.607 ' HD3' HG12 ' A' ' 37' ' ' VAL . 60.3 ttt180 -100.05 137.96 37.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.28 -0.888 . . . . 0.0 108.888 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -53.43 148.21 16.11 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.593 HG11 HG22 ' A' ' 43' ' ' VAL . 3.2 p -159.92 -43.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.837 -0.802 . . . . 0.0 109.164 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.534 ' HB2' HG23 ' A' ' 18' ' ' VAL . 22.8 t70 -132.39 165.48 24.17 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.475 -0.766 . . . . 0.0 109.844 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.4 p -107.62 161.59 14.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 110.158 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -145.01 173.57 25.41 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.1 mtm180 -60.28 -40.03 88.99 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.8 -0.824 . . . . 0.0 112.05 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.06 95.39 0.1 OUTLIER Glycine 0 N--CA 1.504 3.182 0 C-N-CA 119.373 -1.394 . . . . 0.0 111.816 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 150.64 -164.82 29.96 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 3' ' ' ILE . 95.7 m-85 -123.31 120.24 32.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.625 -0.927 . . . . 0.0 109.241 178.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -119.09 130.06 55.4 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 ' CD1' ' A' ' 73' ' ' ILE . 27.5 m -130.02 174.68 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.036 0 O-C-N 121.088 -1.007 . . . . 0.0 111.725 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -57.9 156.8 17.52 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.554 -0.716 . . . . 0.0 109.935 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.36 -27.73 47.3 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.471 1.248 . . . . 0.0 110.705 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.03 -40.08 75.38 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.012 -1.055 . . . . 0.0 109.485 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.84 -40.13 87.85 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.03 -49.96 75.6 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.783 -0.573 . . . . 0.0 110.678 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 66.6 m -59.97 -38.7 83.29 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.532 -0.73 . . . . 0.0 110.601 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -68.25 -39.81 82.12 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.883 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.446 HD13 HG23 ' A' ' 71' ' ' ILE . 54.6 tp -70.0 -42.73 72.68 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.597 -0.689 . . . . 0.0 111.886 -179.098 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -98.66 -36.91 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 O-C-N 121.221 -0.925 . . . . 0.0 111.709 -177.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.47 -28.83 6.11 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -151.59 162.68 40.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.993 . . . . 0.0 110.394 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.3 p -100.97 14.05 33.18 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.913 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -70.03 -36.68 75.23 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.421 -0.799 . . . . 0.0 111.012 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.87 -40.04 87.3 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.514 -0.742 . . . . 0.0 110.894 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.13 -65.75 2.52 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 -143.19 151.65 40.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.579 -0.954 . . . . 0.0 110.313 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -121.86 121.41 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.548 -0.72 . . . . 0.0 109.979 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -90.13 172.19 8.99 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.342 -0.849 . . . . 0.0 110.635 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 64.5 t30 60.05 47.93 9.1 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.546 -0.722 . . . . 0.0 110.441 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.77 HG21 HG12 ' A' ' 3' ' ' ILE . 96.6 t -96.68 124.49 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 119.832 -0.747 . . . . 0.0 110.38 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -82.68 139.92 33.41 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 119.253 -0.979 . . . . 0.0 108.741 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.418 ' C ' HG13 ' A' ' 108' ' ' VAL . 42.3 p90 -135.96 141.86 44.49 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.361 0.601 . . . . 0.0 111.505 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.418 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -147.52 145.8 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.769 -0.582 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -72.08 138.2 47.64 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.635 -0.666 . . . . 0.0 110.069 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LYS . 35.1 m -129.91 162.06 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.738 -0.601 . . . . 0.0 110.3 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -59.65 144.85 46.7 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.483 -0.761 . . . . 0.0 110.301 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.5 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -60.02 -38.26 82.15 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.658 -0.651 . . . . 0.0 111.108 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.6 m -56.28 -39.11 72.14 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.531 -0.731 . . . . 0.0 110.384 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -59.98 -39.98 87.55 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.429 -0.794 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 76.6 m -61.86 -48.63 79.68 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.364 -0.835 . . . . 0.0 110.718 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.5 HD11 HD21 ' A' ' 112' ' ' LEU . 86.3 mt -70.05 -39.99 77.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.653 -0.654 . . . . 0.0 110.668 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.12 -40.03 95.3 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.465 -0.772 . . . . 0.0 110.29 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.88 -47.08 49.44 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -40.26 88.64 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.999 . . . . 0.0 110.5 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.7 t30 . . . . . 0 N--CA 1.502 2.163 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.848 179.791 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.425 HG23 ' HB ' ' A' ' 105' ' ' VAL . 28.3 m . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 120.876 0.37 . . . . 0.0 110.437 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -111.23 141.35 44.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.621 -0.674 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.555 HG22 ' HB3' ' A' ' 83' ' ' PHE . 42.7 pt -116.1 149.24 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.822 -0.549 . . . . 0.0 110.803 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 m -147.3 -172.1 3.94 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -142.83 147.28 35.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.158 -0.964 . . . . 0.0 110.852 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -135.73 152.96 76.98 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 110.079 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -88.15 37.13 0.43 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.318 1.167 . . . . 0.0 111.031 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.598 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.0 tp -106.7 -3.46 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.438 -0.789 . . . . 0.0 111.077 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.494 ' CD2' HG23 ' A' ' 8' ' ' ILE . 42.9 m-85 -122.08 76.91 1.34 Allowed 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 122.769 1.271 . . . . 0.0 111.257 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -108.61 169.97 8.32 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.671 177.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.93 -32.69 71.02 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 -176.027 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -87.99 11.5 15.78 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 120.503 -1.373 . . . . 0.0 112.336 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.598 HD22 ' O ' ' A' ' 8' ' ' ILE . 40.1 tp -74.61 121.5 21.7 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.2 -0.937 . . . . 0.0 110.227 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.4 m -67.4 138.99 57.12 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.696 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.747 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -68.29 -13.7 62.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.73 -0.606 . . . . 0.0 111.797 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -72.32 -14.49 76.95 Favored Glycine 0 N--CA 1.497 2.703 0 O-C-N 120.98 -1.075 . . . . 0.0 111.312 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.3 t -92.84 -14.88 27.14 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.125 -1.22 . . . . 0.0 111.405 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.747 HG12 ' O ' ' A' ' 15' ' ' MET . 11.9 p -90.05 165.2 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.246 -0.909 . . . . 0.0 111.0 -178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -56.96 -45.38 82.9 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.573 -0.705 . . . . 0.0 110.347 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.8 m -80.89 80.08 7.44 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.32 -80.42 0.43 Allowed 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.116 -0.99 . . . . 0.0 113.216 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -138.86 10.08 2.62 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.102 -0.999 . . . . 0.0 112.605 -177.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.61 -150.46 0.45 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -65.65 -40.04 92.05 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.67 -0.9 . . . . 0.0 109.867 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.565 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 13.2 m80 -99.94 8.95 43.69 Favored 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.464 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.19 137.54 49.16 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.647 HD13 HG11 ' A' ' 37' ' ' VAL . 88.5 mt -98.65 -4.05 34.68 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.812 -0.817 . . . . 0.0 110.262 179.082 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 54.6 ttm -60.1 -39.55 86.56 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.324 -0.86 . . . . 0.0 110.763 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.83 -75.55 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.443 -0.785 . . . . 0.0 111.723 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -70.06 -40.01 75.32 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.425 -0.797 . . . . 0.0 110.387 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 37' ' ' VAL . 94.4 m-85 -119.18 89.43 39.54 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.869 -0.519 . . . . 0.0 110.896 -178.081 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.07 -4.71 15.79 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 O-C-N 123.251 1.132 . . . . 0.0 111.073 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 17.5 p -131.41 155.35 47.47 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.147 -0.971 . . . . 0.0 110.219 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.925 HD11 HG21 ' A' ' 43' ' ' VAL . 58.2 tp -85.1 113.11 21.25 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.326 -0.55 . . . . 0.0 109.769 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 155.24 33.4 0.03 OUTLIER Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.609 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 2.6 mt-10 -157.8 -47.77 0.06 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.248 -1.148 . . . . 0.0 109.954 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.647 HG11 HD13 ' A' ' 27' ' ' LEU . 2.4 t -62.25 -58.0 19.98 Favored Pre-proline 0 N--CA 1.497 1.877 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.661 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.517 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.3 Cg_endo -78.66 -31.62 2.46 Favored 'Trans proline' 0 C--N 1.319 -0.995 0 O-C-N 123.282 1.148 . . . . 0.0 109.29 177.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.26 -61.73 0.66 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.588 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 5.3 t80 161.21 -50.85 0.0 OUTLIER Pre-proline 0 N--CA 1.514 2.752 0 C-N-CA 123.664 0.785 . . . . 0.0 110.19 177.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.588 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 50.5 Cg_endo -101.87 18.41 0.25 Allowed 'Trans proline' 0 C--N 1.326 -0.652 0 C-N-CA 121.744 1.629 . . . . 0.0 111.62 -177.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.4 ' HB3' ' O ' ' A' ' 72' ' ' PHE . 74.9 m-20 -135.95 55.85 1.85 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.253 -0.904 . . . . 0.0 110.277 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.926 HG23 HG11 ' A' ' 76' ' ' VAL . 12.6 p -130.32 141.8 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 CA-C-O 121.681 0.753 . . . . 0.0 110.524 -179.519 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -172.27 179.18 44.03 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.429 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.78 154.61 27.02 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.319 -1.912 . . . . 0.0 108.319 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.616 HG22 ' CE1' ' A' ' 83' ' ' PHE . 5.7 pt -143.44 160.05 52.74 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.512 -0.993 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -69.07 -17.83 40.51 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.142 1.228 . . . . 0.0 114.033 -177.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -93.65 25.41 3.54 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.71 -1.244 . . . . 0.0 112.387 -178.142 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.509 HG12 HG13 ' A' ' 46' ' ' ILE . 37.1 mm -119.94 120.1 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.024 -1.047 . . . . 0.0 109.012 178.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.55 -44.12 29.62 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.195 -0.941 . . . . 0.0 111.977 -178.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.26 -141.55 6.87 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.078 -1.534 . . . . 0.0 111.424 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.488 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.3 t90 -41.49 -29.43 0.16 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -178.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -141.44 57.21 1.52 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.021 -1.049 . . . . 0.0 111.206 -178.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.41 ' HB3' ' HA ' ' A' ' 49' ' ' ILE . 18.2 m -69.05 144.34 95.39 Favored Pre-proline 0 N--CA 1.493 1.713 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.673 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.565 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.6 Cg_endo -74.15 -14.41 23.3 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.328 1.173 . . . . 0.0 111.619 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 70.3 m -103.43 18.4 21.9 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.385 -0.822 . . . . 0.0 111.735 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.467 ' HB2' ' HB3' ' A' ' 25' ' ' HIS . 3.5 m -69.97 139.94 52.89 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.987 -1.071 . . . . 0.0 109.112 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.33 27.66 57.22 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 97.7 m -106.52 138.15 43.22 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.507 -0.996 . . . . 0.0 110.164 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.634 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.2 t -80.04 131.59 35.81 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.389 0.614 . . . . 0.0 110.889 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.444 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.5 m95 -133.99 152.15 51.74 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.541 -0.724 . . . . 0.0 109.379 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.2 tttm -121.69 138.15 54.46 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 120.933 -1.105 . . . . 0.0 110.583 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.444 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.7 t -113.7 126.79 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.615 -0.678 . . . . 0.0 111.344 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.9 m -119.54 141.14 49.49 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.742 -0.599 . . . . 0.0 110.48 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 10.9 pt -119.95 163.93 25.16 Favored Pre-proline 0 N--CA 1.503 2.183 0 O-C-N 121.186 -0.947 . . . . 0.0 110.906 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.9 Cg_endo -62.1 -27.56 79.12 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.564 1.509 . . . . 0.0 113.201 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -62.51 -39.95 95.17 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.244 -0.91 . . . . 0.0 110.045 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.09 60.31 0.31 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -159.92 151.11 19.48 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 86.1 p -151.64 157.77 42.58 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.007 0.908 . . . . 0.0 111.664 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.491 HD12 HD11 ' A' ' 73' ' ' ILE . 41.8 pt -137.83 161.65 32.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.4 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 97.2 m-85 -102.12 121.29 41.93 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 118.581 -1.248 . . . . 0.0 109.187 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.491 HD11 HD12 ' A' ' 71' ' ' ILE . 48.3 mm -110.78 130.6 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.524 ' HD3' HG12 ' A' ' 37' ' ' VAL . 52.4 ttt180 -99.33 132.82 44.39 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.112 -0.993 . . . . 0.0 109.251 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.9 146.67 13.25 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.926 HG11 HG23 ' A' ' 43' ' ' VAL . 7.5 p -169.76 -33.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.863 -0.787 . . . . 0.0 110.323 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.521 ' CG ' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -130.0 171.89 12.3 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 120.925 -1.11 . . . . 0.0 108.711 179.737 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -98.09 142.43 29.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.669 -0.644 . . . . 0.0 109.791 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -114.5 144.79 18.45 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -89.22 103.4 16.02 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.578 -0.954 . . . . 0.0 110.526 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 50.12 56.98 10.73 Favored Glycine 0 N--CA 1.497 2.765 0 O-C-N 121.681 -0.637 . . . . 0.0 111.724 178.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.6 -163.5 33.59 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.045 -1.55 . . . . 0.0 111.915 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.616 ' CE1' HG22 ' A' ' 46' ' ' ILE 0.263 0.1 OUTLIER -123.25 122.5 38.52 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -178.908 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -124.12 129.91 51.65 Favored 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 118.892 -1.123 . . . . 0.0 109.83 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.3 m -132.31 172.88 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.376 -178.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -54.15 156.79 5.12 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.551 -0.718 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.64 -18.72 32.7 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.477 1.251 . . . . 0.0 110.051 179.297 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -80.02 -40.97 26.71 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.088 -1.008 . . . . 0.0 108.991 178.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.59 89.24 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -59.99 -50.05 75.26 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.808 -0.557 . . . . 0.0 110.573 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.3 m -59.92 -40.05 87.57 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.929 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -69.0 -40.13 78.89 Favored 'General case' 0 N--CA 1.495 1.803 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.29 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 49.7 tp -71.97 -43.36 65.27 Favored 'General case' 0 N--CA 1.496 1.871 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.478 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -92.34 -40.51 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.462 -0.774 . . . . 0.0 111.54 -177.59 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 126.63 -34.96 3.03 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 95.2 p -152.69 164.63 37.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.664 -0.903 . . . . 0.0 110.262 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 69.8 p -90.18 2.61 55.17 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.42 -0.8 . . . . 0.0 111.194 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -69.94 -27.75 65.01 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.327 -0.858 . . . . 0.0 110.738 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.01 -41.72 83.7 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.57 -0.706 . . . . 0.0 110.619 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.56 -80.7 1.63 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 59.9 ttp180 -130.86 138.88 50.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.565 -0.962 . . . . 0.0 111.042 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.54 114.65 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.608 -0.682 . . . . 0.0 110.428 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -82.46 171.02 14.6 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.665 -0.647 . . . . 0.0 110.588 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.7 t30 60.13 48.35 8.48 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.743 -0.598 . . . . 0.0 111.828 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.443 HG11 HG21 ' A' ' 3' ' ' ILE . 60.7 t -98.1 124.56 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.325 179.276 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t-20 -82.57 134.24 35.19 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.931 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.421 ' C ' HG13 ' A' ' 108' ' ' VAL . 54.4 p90 -135.75 140.85 44.67 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.8 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.421 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.1 m -150.01 154.67 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.237 -0.914 . . . . 0.0 111.001 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.444 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.4 tt0 -74.64 141.53 44.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.713 -0.617 . . . . 0.0 109.834 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.634 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.0 m -139.06 168.89 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 120.047 -0.661 . . . . 0.0 109.553 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -59.92 144.34 49.19 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.356 -0.84 . . . . 0.0 110.964 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.481 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.4 tt -59.9 -36.18 76.43 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.562 -0.711 . . . . 0.0 111.035 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.4 m -56.48 -39.16 72.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.502 -0.749 . . . . 0.0 109.836 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -61.52 -38.57 87.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.562 -0.711 . . . . 0.0 110.859 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.22 -49.61 76.94 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.301 -0.874 . . . . 0.0 109.846 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.434 HD11 HD21 ' A' ' 112' ' ' LEU . 83.7 mt -69.83 -39.92 78.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.632 -0.668 . . . . 0.0 110.662 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -65.02 -40.49 94.95 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.463 -0.773 . . . . 0.0 110.643 -179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.12 -43.75 70.29 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.99 94.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.765 -0.844 . . . . 0.0 110.264 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.389 -179.86 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.486 HG11 ' CE1' ' A' ' 107' ' ' TYR . 35.1 m . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 p -112.47 141.95 45.6 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 122.15 0.976 . . . . 0.0 111.575 -178.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.782 HG12 HG21 ' A' ' 105' ' ' VAL . 35.2 pt -119.97 150.02 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.965 179.52 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 7.6 m -144.87 -173.0 3.95 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -140.44 147.5 39.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.477 -0.764 . . . . 0.0 109.489 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.658 ' HB3' HG22 ' A' ' 8' ' ' ILE . 8.5 m-20 -138.55 147.68 55.89 Favored Pre-proline 0 N--CA 1.491 1.593 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.823 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -74.39 -6.08 17.83 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 O-C-N 123.455 1.239 . . . . 0.0 110.532 178.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.67 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.3 tp -64.43 -15.86 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.36 -0.837 . . . . 0.0 111.095 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.532 ' CD2' HG23 ' A' ' 8' ' ' ILE . 43.2 m-85 -112.5 69.31 0.69 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 122.72 1.248 . . . . 0.0 110.786 178.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.28 170.03 8.16 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.523 -1.217 . . . . 0.0 108.309 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.9 -32.44 70.75 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -175.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -89.64 11.49 19.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 120.344 -1.473 . . . . 0.0 112.182 -177.341 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.67 HD22 ' O ' ' A' ' 8' ' ' ILE . 28.5 tp -71.6 126.32 29.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.317 -0.864 . . . . 0.0 109.974 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.5 p -70.7 136.9 49.33 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.247 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.611 ' O ' HG12 ' A' ' 18' ' ' VAL . 94.6 mmm -64.66 -15.1 60.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.802 -0.561 . . . . 0.0 111.823 -178.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.66 -12.49 84.43 Favored Glycine 0 N--CA 1.494 2.537 0 O-C-N 121.066 -1.021 . . . . 0.0 111.297 -179.13 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -85.88 -7.21 58.85 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.113 -1.228 . . . . 0.0 111.935 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.611 HG12 ' O ' ' A' ' 15' ' ' MET . 11.0 p -101.4 168.89 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.03 -1.044 . . . . 0.0 110.672 -179.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.03 -42.38 94.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.605 -0.685 . . . . 0.0 109.881 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 70.42 8.47 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.2 p -92.86 -74.89 0.51 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.782 -0.573 . . . . 0.0 109.691 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -130.01 169.93 14.63 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 121.17 -149.0 17.41 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -179.194 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -73.48 -44.16 58.58 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.641 -0.917 . . . . 0.0 111.05 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.555 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m80 -98.28 8.9 44.18 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.297 -0.877 . . . . 0.0 110.711 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.2 129.94 46.7 Favored Glycine 0 N--CA 1.496 2.657 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.8 mt -100.03 -4.21 30.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 122.041 -0.682 . . . . 0.0 110.245 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 57.2 ttm -61.67 -37.88 85.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.241 -0.912 . . . . 0.0 109.876 179.066 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.5 -74.11 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.671 -0.643 . . . . 0.0 112.059 -177.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -69.96 -40.38 75.44 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.273 -0.892 . . . . 0.0 110.659 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.555 ' CG ' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -120.25 86.3 37.91 Favored Pre-proline 0 N--CA 1.492 1.664 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -178.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.37 -11.18 30.75 Favored 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.383 1.202 . . . . 0.0 111.145 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -130.04 141.19 50.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.177 -0.952 . . . . 0.0 110.105 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.975 HD11 HG21 ' A' ' 43' ' ' VAL . 34.7 tp -69.68 117.46 11.32 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.684 -0.635 . . . . 0.0 110.491 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.43 33.59 0.03 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.079 179.35 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -159.8 -46.07 0.05 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.176 -1.19 . . . . 0.0 110.64 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.555 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -63.0 -59.33 12.75 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.359 -0.838 . . . . 0.0 108.83 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.44 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 47.2 Cg_endo -74.35 -31.77 7.08 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 123.222 1.117 . . . . 0.0 109.408 178.148 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.437 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 134.57 -63.39 0.61 Allowed Glycine 0 N--CA 1.486 1.979 0 N-CA-C 107.116 -2.393 . . . . 0.0 107.116 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.61 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 161.19 -55.12 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.7 0 C-N-CA 123.457 0.703 . . . . 0.0 110.484 177.411 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.813 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.4 Cg_endo -100.68 3.52 0.7 Allowed 'Trans proline' 0 C--N 1.322 -0.828 0 C-N-CA 121.068 1.178 . . . . 0.0 112.09 -178.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.471 HD22 HD11 ' A' ' 71' ' ' ILE . 19.3 m120 -120.19 42.13 3.03 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 0.0 109.415 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.975 HG21 HD11 ' A' ' 34' ' ' LEU . 7.6 p -109.89 142.64 21.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.742 0.782 . . . . 0.0 109.145 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -167.36 172.99 42.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.91 161.54 29.43 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 HD12 ' A' ' 49' ' ' ILE . 18.0 pt -144.49 159.44 51.51 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.705 -0.879 . . . . 0.0 110.684 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HD2' ' CE2' ' A' ' 83' ' ' PHE . 53.7 Cg_endo -71.25 -14.91 31.68 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.511 1.474 . . . . 0.0 113.115 -178.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -91.55 19.45 6.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.016 -1.053 . . . . 0.0 111.948 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.507 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 62.4 mt -119.97 120.22 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.89 . . . . 0.0 108.938 177.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.69 -41.32 21.51 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -177.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 177.29 -126.32 1.09 Allowed Glycine 0 N--CA 1.492 2.38 0 C-N-CA 118.144 -1.979 . . . . 0.0 112.741 -178.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -40.01 -34.6 0.3 Allowed 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -177.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 39.9 p-10 -172.08 82.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.719 -1.238 . . . . 0.0 109.713 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.461 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 8.1 t -68.25 150.65 97.64 Favored Pre-proline 0 N--CA 1.495 1.793 0 O-C-N 121.69 -0.631 . . . . 0.0 110.678 -178.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 41.1 Cg_endo -66.96 -15.86 48.1 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 123.513 1.27 . . . . 0.0 111.194 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' THR . 57.7 m -106.84 9.73 30.86 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.327 -0.858 . . . . 0.0 111.446 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -60.84 141.86 56.7 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.846 -1.159 . . . . 0.0 109.947 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.8 17.13 58.69 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.594 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -91.49 167.31 12.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.282 -1.128 . . . . 0.0 110.055 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -110.13 136.09 49.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.943 -0.473 . . . . 0.0 110.64 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -132.02 137.63 47.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.497 -0.752 . . . . 0.0 109.096 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 77.4 tttt -100.88 133.31 45.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.298 -0.876 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.9 t -109.98 120.49 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.616 -0.678 . . . . 0.0 109.71 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 44.7 m -116.98 141.89 47.65 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.742 -0.599 . . . . 0.0 111.312 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.446 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 36.8 pt -119.61 163.4 27.57 Favored Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.539 -0.726 . . . . 0.0 110.508 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -61.95 -24.69 77.2 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.744 1.391 . . . . 0.0 112.675 -178.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -63.84 -40.08 95.73 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.226 -0.921 . . . . 0.0 109.723 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.67 62.02 0.3 Allowed Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 35.8 t-20 -160.06 153.16 21.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.661 -0.905 . . . . 0.0 109.214 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.679 ' HA ' HD11 ' A' ' 93' ' ' LEU . 83.2 p -150.04 160.1 43.9 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.18 0.991 . . . . 0.0 112.246 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.471 HD11 HD22 ' A' ' 42' ' ' ASN . 12.6 tt -138.96 159.38 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.436 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 93.1 m-85 -104.36 122.35 45.29 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 47.1 mm -114.85 130.01 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.469 -0.77 . . . . 0.0 110.314 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.686 HH12 HG23 ' A' ' 43' ' ' VAL . 5.2 ttp-105 -97.65 139.43 33.55 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.01 146.69 50.51 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -153.1 -43.55 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 122.072 -0.664 . . . . 0.0 109.369 179.229 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.419 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 18.1 t70 -115.37 162.46 17.1 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.237 -0.915 . . . . 0.0 110.352 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.507 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 26.4 t -79.64 156.8 27.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.818 -0.551 . . . . 0.0 109.608 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -140.62 126.42 3.14 Favored Glycine 0 N--CA 1.482 1.721 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.401 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -59.92 -40.0 87.38 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -167.77 169.13 41.1 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 107.875 -2.09 . . . . 0.0 107.875 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 64.52 -166.84 29.81 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.186 -1.185 . . . . 0.0 112.571 177.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.546 ' HB2' HG22 ' A' ' 3' ' ' ILE . 80.1 m-85 -139.17 139.78 37.66 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 122.225 -0.573 . . . . 0.0 110.754 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.41 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 0.9 OUTLIER -123.58 130.24 52.38 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.019 -1.051 . . . . 0.0 110.14 178.495 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.4 m -129.02 166.53 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.873 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.8 m-20 -54.61 153.65 10.29 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.53 -0.731 . . . . 0.0 110.19 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.24 -30.03 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.498 1.262 . . . . 0.0 110.241 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -69.92 -40.09 75.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.094 -1.004 . . . . 0.0 108.603 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.813 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -67.02 -38.28 85.66 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.528 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.11 -49.48 77.47 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.311 0.577 . . . . 0.0 110.099 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.8 m -59.96 -39.73 86.6 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.707 -0.621 . . . . 0.0 110.947 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -68.65 -39.99 80.44 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.707 -178.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.679 HD11 ' HA ' ' A' ' 70' ' ' SER . 52.7 tp -69.94 -40.62 75.37 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.475 -0.765 . . . . 0.0 112.047 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -96.65 -35.98 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.218 0 O-C-N 121.246 -0.909 . . . . 0.0 111.363 -177.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.77 -38.73 2.27 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.291 -1.924 . . . . 0.0 108.291 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 23.1 t -150.0 133.58 16.65 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.836 -0.802 . . . . 0.0 109.271 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.565 HG23 ' O ' ' A' ' 97' ' ' THR . 9.5 t -90.67 66.69 6.22 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.366 -0.834 . . . . 0.0 110.628 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -114.83 -27.18 7.51 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.624 -0.673 . . . . 0.0 110.637 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.08 -39.93 87.8 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -0.76 . . . . 0.0 110.567 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 103.15 -50.94 0.87 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -157.84 160.02 37.29 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.709 -0.877 . . . . 0.0 110.237 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.52 129.97 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 109.83 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -98.14 169.9 9.28 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.206 -179.47 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 61.6 t30 59.91 41.34 17.93 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.564 -0.71 . . . . 0.0 110.219 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.782 HG21 HG12 ' A' ' 3' ' ' ILE . 61.3 t -89.26 122.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.23 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 -80.52 136.13 36.23 Favored 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.12 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.486 ' CE1' HG11 ' A' ' 1' ' ' VAL . 39.6 p90 -134.87 140.98 46.22 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-O 121.278 0.561 . . . . 0.0 111.532 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.36 144.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.714 -0.616 . . . . 0.0 110.61 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -73.21 144.43 46.79 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.612 -0.68 . . . . 0.0 110.318 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.92 168.89 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.618 -0.676 . . . . 0.0 110.509 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -59.96 144.15 49.86 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.547 -0.721 . . . . 0.0 110.448 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.448 HD21 ' CD1' ' A' ' 116' ' ' ILE . 9.4 tt -60.79 -40.03 91.07 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.567 -0.708 . . . . 0.0 110.998 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.9 m -54.61 -35.57 63.53 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.612 -0.68 . . . . 0.0 111.592 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -69.99 -22.13 63.16 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.169 -0.957 . . . . 0.0 111.457 -178.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 96.5 m -75.65 -48.64 21.23 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.2 -0.938 . . . . 0.0 109.35 178.126 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.448 ' CD1' HD21 ' A' ' 112' ' ' LEU . 94.8 mt -69.96 -40.03 78.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 CA-C-O 121.32 0.581 . . . . 0.0 109.773 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -67.18 -40.03 86.5 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.66 -0.65 . . . . 0.0 110.129 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.7 -49.96 39.64 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.68 -39.92 90.26 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.551 -0.97 . . . . 0.0 110.39 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.316 -179.774 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.482 HG21 ' CD1' ' A' ' 107' ' ' TYR . 34.5 m . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.438 0.637 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 m -113.14 145.19 41.37 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.034 0.921 . . . . 0.0 111.035 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.673 HG12 HG21 ' A' ' 105' ' ' VAL . 19.6 pt -115.19 146.36 19.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.25 -172.45 3.87 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.671 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.9 p90 -143.87 149.95 37.7 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.075 178.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.72 149.18 72.71 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.547 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -85.12 9.26 4.21 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.39 1.205 . . . . 0.0 111.276 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.418 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.3 pt -90.05 -0.21 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.113 -0.992 . . . . 0.0 111.068 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 m-85 -117.35 66.8 0.73 Allowed 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.543 1.164 . . . . 0.0 109.569 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.7 170.64 8.04 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 114.834 -1.076 . . . . 0.0 108.231 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.68 -31.42 64.43 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -89.02 12.93 14.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 120.513 -1.367 . . . . 0.0 112.033 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.458 ' HA ' HD22 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -71.04 118.42 13.8 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.253 -0.904 . . . . 0.0 110.091 -179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.456 ' N ' HD13 ' A' ' 13' ' ' LEU . 40.6 m -68.22 137.63 54.94 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 121.702 0.763 . . . . 0.0 110.43 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.575 ' O ' HG12 ' A' ' 18' ' ' VAL . 5.3 mmt -62.26 -20.02 63.83 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -73.85 -13.68 80.53 Favored Glycine 0 N--CA 1.498 2.79 0 O-C-N 121.037 -1.04 . . . . 0.0 112.079 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.5 -7.77 46.44 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.944 -1.327 . . . . 0.0 112.183 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.773 HG21 HG22 ' A' ' 76' ' ' VAL . 9.5 p -100.03 169.97 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.93 -1.106 . . . . 0.0 110.19 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.783 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.05 -43.5 82.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.279 -0.888 . . . . 0.0 109.711 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.18 83.41 6.06 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.4 m -94.12 -80.0 0.41 Allowed 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.254 -0.904 . . . . 0.0 112.557 -177.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -140.93 11.83 2.23 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.201 -0.937 . . . . 0.0 112.553 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.32 -146.12 0.31 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -69.29 -39.99 77.99 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.812 -0.817 . . . . 0.0 109.268 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.522 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 29.1 m80 -91.48 0.92 57.45 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.689 -0.632 . . . . 0.0 110.696 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.85 132.35 44.37 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.562 HD22 HG21 ' A' ' 37' ' ' VAL . 85.9 mt -98.82 -5.46 31.05 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 122.125 -0.633 . . . . 0.0 110.149 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.428 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.6 ttm -63.24 -37.77 88.54 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.277 -0.889 . . . . 0.0 111.262 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -74.05 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.522 -0.736 . . . . 0.0 111.667 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -70.04 -39.9 75.44 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 109.687 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.45 ' CD2' HG23 ' A' ' 37' ' ' VAL . 44.2 m-85 -120.15 85.39 35.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.018 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 39.6 Cg_endo -66.53 -12.14 34.55 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 O-C-N 123.258 1.136 . . . . 0.0 111.228 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.9 m -129.18 146.98 50.99 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.228 -0.92 . . . . 0.0 110.349 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.74 HD11 HG21 ' A' ' 43' ' ' VAL . 45.1 tp -72.61 119.73 17.24 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.714 -0.616 . . . . 0.0 110.779 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.34 34.19 0.04 OUTLIER Glycine 0 N--CA 1.496 2.642 0 C-N-CA 120.067 -1.063 . . . . 0.0 110.485 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.448 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 21.7 tp10 -158.09 -49.18 0.06 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.298 -1.119 . . . . 0.0 110.485 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.562 HG21 HD22 ' A' ' 27' ' ' LEU . 2.7 t -60.63 -59.43 13.88 Favored Pre-proline 0 N--CA 1.499 2.001 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.456 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.2 Cg_endo -76.02 -29.78 6.36 Favored 'Trans proline' 0 N--CA 1.487 1.129 0 O-C-N 123.258 1.136 . . . . 0.0 109.335 177.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.85 -63.0 0.63 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 -178.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.522 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.9 t80 165.18 -72.22 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.571 0 C-N-CA 123.42 0.688 . . . . 0.0 110.017 177.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 57.4 Cg_endo -79.09 -18.99 10.99 Favored 'Trans proline' 0 N--CA 1.492 1.424 0 O-C-N 122.409 0.689 . . . . 0.0 111.579 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.0 m-20 -93.93 55.74 2.16 Favored 'General case' 0 N--CA 1.489 1.491 0 CA-C-O 121.8 0.809 . . . . 0.0 109.71 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.74 HG21 HD11 ' A' ' 34' ' ' LEU . 11.7 p -118.92 129.33 75.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-O 121.385 0.612 . . . . 0.0 109.655 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -161.68 167.59 36.51 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 119.991 -1.099 . . . . 0.0 111.279 -179.216 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.68 164.92 29.33 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 83' ' ' PHE . 10.8 pt -143.55 165.87 22.78 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.824 -0.81 . . . . 0.0 109.762 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 56.9 Cg_endo -77.12 -10.57 17.86 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 120.972 1.115 . . . . 0.0 113.125 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -95.41 16.65 16.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.071 -1.018 . . . . 0.0 111.916 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.802 HG23 ' CB ' ' A' ' 54' ' ' SER . 63.7 mt -109.34 121.31 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.048 -1.032 . . . . 0.0 109.256 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.52 -42.34 43.56 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.426 -0.796 . . . . 0.0 113.13 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.783 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 165.97 -132.59 2.69 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.576 -1.773 . . . . 0.0 112.013 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.526 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 39.3 t90 -44.59 -30.68 0.95 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -178.14 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -143.62 63.2 1.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.358 -0.839 . . . . 0.0 110.134 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.802 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.8 p -66.24 136.32 95.21 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.804 -0.56 . . . . 0.0 111.118 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.522 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 49.4 Cg_endo -73.54 -21.34 19.54 Favored 'Trans proline' 0 C--N 1.32 -0.974 0 O-C-N 123.338 1.178 . . . . 0.0 111.104 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.4 m -96.48 12.01 32.96 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.388 -0.82 . . . . 0.0 111.089 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.56 143.75 56.85 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.124 -0.985 . . . . 0.0 109.713 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.04 25.27 58.08 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 m -106.28 137.35 44.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.487 -1.007 . . . . 0.0 109.857 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.67 131.13 35.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.911 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -130.31 138.56 50.51 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -107.32 135.65 48.47 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.272 -0.893 . . . . 0.0 109.518 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.7 t -111.6 127.82 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.188 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 95.4 m -120.03 139.15 52.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.967 -0.458 . . . . 0.0 110.637 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.456 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 34.3 pt -117.74 163.73 22.88 Favored Pre-proline 0 N--CA 1.5 2.051 0 O-C-N 121.363 -0.836 . . . . 0.0 110.557 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -61.54 -23.04 75.94 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.371 1.381 . . . . 0.0 112.689 -178.616 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -66.52 -40.02 88.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.375 -0.828 . . . . 0.0 109.697 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.29 57.4 0.32 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -150.78 148.62 28.73 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.3 p -151.09 156.23 40.61 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-O 121.93 0.871 . . . . 0.0 111.372 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.657 ' CD1' HD11 ' A' ' 73' ' ' ILE . 43.6 pt -139.46 164.23 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -109.09 126.59 53.35 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.097 -1.041 . . . . 0.0 108.785 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.784 HD13 ' CG1' ' A' ' 85' ' ' VAL . 87.6 mt -129.38 140.0 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.688 -178.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -98.04 139.5 33.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.547 -0.72 . . . . 0.0 109.872 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.71 150.28 39.06 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.773 HG22 HG21 ' A' ' 18' ' ' VAL . 11.9 p -149.45 -39.56 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.751 -0.852 . . . . 0.0 109.901 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.436 ' N ' HG13 ' A' ' 76' ' ' VAL . 15.7 t70 -129.32 168.02 16.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.224 -0.922 . . . . 0.0 110.5 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.478 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 40.6 t -75.28 155.89 36.21 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.618 0.723 . . . . 0.0 111.739 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -137.66 132.26 5.84 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -60.02 -33.05 71.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 109.871 178.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.31 82.37 0.05 OUTLIER Glycine 0 N--CA 1.498 2.788 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.599 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 151.97 -151.66 23.52 Favored Glycine 0 N--CA 1.499 2.866 0 C-N-CA 119.893 -1.146 . . . . 0.0 110.516 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 46' ' ' ILE . 87.0 m-85 -136.02 130.77 34.06 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.295 -1.121 . . . . 0.0 111.381 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.458 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 4.4 t-20 -115.61 127.52 55.28 Favored 'General case' 0 N--CA 1.502 2.152 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 178.307 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.784 ' CG1' HD13 ' A' ' 73' ' ' ILE . 33.2 m -129.95 164.62 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.363 -177.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-20 -54.54 157.1 5.41 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.328 -0.857 . . . . 0.0 109.897 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.37 -14.35 43.79 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.268 1.141 . . . . 0.0 110.657 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.7 m -82.71 -39.14 22.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.975 -1.078 . . . . 0.0 109.314 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.77 -39.82 84.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.448 -0.783 . . . . 0.0 109.037 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -59.99 -50.02 75.4 Favored 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 120.081 -0.648 . . . . 0.0 110.762 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 73.2 m -60.14 -39.97 88.21 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.368 -0.832 . . . . 0.0 111.071 -178.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -69.68 -40.0 76.66 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.871 -0.732 . . . . 0.0 111.062 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 60.2 tp -70.62 -43.7 68.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.602 -0.686 . . . . 0.0 111.557 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.0 -42.61 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.402 -0.811 . . . . 0.0 111.579 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -20.22 7.93 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.3 t -156.21 159.52 39.02 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.213 -1.169 . . . . 0.0 110.944 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 65.7 p -98.42 6.89 46.86 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.543 -0.723 . . . . 0.0 110.812 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -69.17 -36.76 77.7 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.362 -0.836 . . . . 0.0 111.708 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.52 -40.12 86.09 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.379 -0.826 . . . . 0.0 110.696 -178.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 82.89 -75.03 2.44 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -127.78 133.17 49.46 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.631 -0.923 . . . . 0.0 109.857 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.14 120.14 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.467 -0.771 . . . . 0.0 110.116 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -86.16 178.43 7.2 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.359 0.599 . . . . 0.0 110.707 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.0 t-20 58.88 49.62 9.56 Favored 'General case' 0 N--CA 1.499 2.013 0 CA-C-O 121.28 0.562 . . . . 0.0 111.235 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.673 HG21 HG12 ' A' ' 3' ' ' ILE . 62.5 t -105.77 129.03 59.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.577 -179.381 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -86.61 137.07 32.78 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 118.936 -1.105 . . . . 0.0 109.477 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.482 ' CD1' HG21 ' A' ' 1' ' ' VAL . 38.0 p90 -135.45 141.52 45.41 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.93 -0.481 . . . . 0.0 110.536 -178.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.449 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.0 m -148.09 148.17 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.527 -0.733 . . . . 0.0 111.037 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -76.18 143.52 41.05 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.595 -0.691 . . . . 0.0 110.236 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -137.79 167.83 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.578 -0.701 . . . . 0.0 110.561 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -61.52 148.26 42.66 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.403 -0.81 . . . . 0.0 110.749 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.509 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.6 tt -62.11 -40.07 94.63 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.517 -0.739 . . . . 0.0 112.075 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 82.1 p -53.12 -37.34 61.68 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.263 -0.898 . . . . 0.0 111.023 -178.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -61.12 -37.93 84.54 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.518 -0.739 . . . . 0.0 112.005 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 82.5 m -67.37 -46.29 73.77 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.119 -0.988 . . . . 0.0 110.415 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.509 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.2 mt -70.04 -39.94 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 120.109 -0.636 . . . . 0.0 110.518 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.69 -39.98 88.34 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.13 -46.19 44.92 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.03 -44.15 94.83 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.625 -0.926 . . . . 0.0 110.473 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 13.5 m120 . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.186 179.823 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.434 HG23 ' HB ' ' A' ' 105' ' ' VAL . 27.3 m . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.291 0.567 . . . . 0.0 111.401 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.2 p -111.78 139.85 46.91 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.738 -0.601 . . . . 0.0 109.764 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.726 HG23 HG21 ' A' ' 105' ' ' VAL . 27.9 pt -110.86 144.77 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.734 -0.604 . . . . 0.0 110.854 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.35 -176.02 4.57 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.118 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -140.09 141.62 36.15 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.453 179.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -135.71 151.66 74.67 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.441 -0.787 . . . . 0.0 110.433 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -77.12 0.07 10.09 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.421 1.221 . . . . 0.0 111.506 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.74 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.4 tp -69.54 -14.03 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.276 -0.89 . . . . 0.0 111.274 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.537 ' CD2' HG23 ' A' ' 8' ' ' ILE . 36.7 m-85 -116.72 69.01 0.74 Allowed 'General case' 0 N--CA 1.493 1.683 0 CA-C-O 122.507 1.146 . . . . 0.0 111.335 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.35 168.67 8.92 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.723 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.0 -32.02 70.47 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -88.13 12.08 14.57 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.44 -1.412 . . . . 0.0 112.199 -177.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 8' ' ' ILE . 41.6 tp -73.75 122.36 22.26 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.419 -0.801 . . . . 0.0 109.714 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.6 m -66.29 137.39 56.91 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.72 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -64.32 -18.99 65.14 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.902 -0.499 . . . . 0.0 111.247 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.2 -14.38 76.64 Favored Glycine 0 N--CA 1.493 2.499 0 O-C-N 121.073 -1.017 . . . . 0.0 110.752 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.7 p -91.63 -15.65 28.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -1.194 . . . . 0.0 111.146 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.996 HG21 HG22 ' A' ' 76' ' ' VAL . 7.2 p -90.05 162.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.931 . . . . 0.0 109.63 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.818 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -54.93 -44.35 74.2 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.556 -0.715 . . . . 0.0 110.332 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 83.89 5.83 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.52 -79.98 0.48 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.295 -0.878 . . . . 0.0 113.152 -177.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -136.72 10.11 3.12 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.108 -0.995 . . . . 0.0 113.098 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.43 -152.77 0.89 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -64.25 -39.95 95.01 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.571 -0.958 . . . . 0.0 108.586 177.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.436 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 25.8 m80 -90.15 0.46 57.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.748 -0.595 . . . . 0.0 110.207 179.197 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.05 133.96 52.48 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.619 HD13 HG11 ' A' ' 37' ' ' VAL . 66.0 mt -102.47 1.13 34.78 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 122.06 -0.67 . . . . 0.0 110.226 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.425 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 60.3 tpp -59.99 -38.48 82.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.315 -0.866 . . . . 0.0 111.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -66.41 0.46 Allowed 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.469 -0.769 . . . . 0.0 112.203 -176.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -75.13 -41.4 58.48 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.423 ' CD2' HG23 ' A' ' 37' ' ' VAL . 46.2 m-85 -120.05 87.46 39.06 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.845 -0.534 . . . . 0.0 109.665 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.3 -8.08 22.66 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.4 1.211 . . . . 0.0 111.543 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -133.51 146.47 51.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.26 -0.9 . . . . 0.0 110.5 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.816 HD11 HG21 ' A' ' 43' ' ' VAL . 29.1 tp -71.04 119.17 14.79 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.695 -0.628 . . . . 0.0 110.664 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.19 32.89 0.04 OUTLIER Glycine 0 N--CA 1.498 2.774 0 C-N-CA 120.007 -1.092 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -157.39 -48.63 0.07 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -1.122 . . . . 0.0 110.159 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.619 HG11 HD13 ' A' ' 27' ' ' LEU . 2.5 t -60.39 -58.61 18.06 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.489 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.2 Cg_endo -77.63 -30.8 3.67 Favored 'Trans proline' 0 C--N 1.318 -1.04 0 O-C-N 123.217 1.114 . . . . 0.0 109.537 177.514 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 129.97 -63.86 0.62 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 107.272 -2.331 . . . . 0.0 107.272 -178.439 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.723 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 164.53 -56.72 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.581 0 C-N-CA 123.37 0.668 . . . . 0.0 110.231 177.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.664 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 51.2 Cg_endo -101.03 15.55 0.37 Allowed 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 121.313 1.342 . . . . 0.0 111.246 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -125.32 47.52 2.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.296 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.816 HG21 HD11 ' A' ' 34' ' ' LEU . 14.6 p -125.47 140.04 49.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.914 0.864 . . . . 0.0 110.435 -179.055 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.87 175.35 42.76 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.441 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -88.62 159.47 29.43 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.689 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.1 pt -148.78 159.67 37.43 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.584 -0.95 . . . . 0.0 109.94 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -68.18 -15.9 43.49 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 121.245 1.297 . . . . 0.0 113.829 -177.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.568 ' H ' HD12 ' A' ' 46' ' ' ILE . 86.2 m-20 -91.7 21.26 4.87 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 120.706 -1.246 . . . . 0.0 113.129 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.596 HG23 ' CB ' ' A' ' 54' ' ' SER . 47.8 mm -112.28 122.59 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 177.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.63 -44.38 34.39 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.302 -0.874 . . . . 0.0 111.199 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.818 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.83 -134.93 3.5 Favored Glycine 0 N--CA 1.484 1.886 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.425 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.472 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 64.4 t90 -43.83 -26.78 0.28 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -145.4 72.81 1.33 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.921 . . . . 0.0 110.578 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.596 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.4 t -70.35 134.3 86.97 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.773 -0.58 . . . . 0.0 111.528 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.436 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 48.6 Cg_endo -73.8 -23.98 16.01 Favored 'Trans proline' 0 C--N 1.32 -0.941 0 O-C-N 123.413 1.218 . . . . 0.0 110.545 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.42 12.44 33.23 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.445 -0.784 . . . . 0.0 111.058 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.7 t -72.21 148.8 45.2 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.335 -0.853 . . . . 0.0 110.584 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.86 43.15 9.14 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.41 ' O ' ' HG3' ' A' ' 74' ' ' ARG . 8.5 m -130.62 168.74 16.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.707 -0.878 . . . . 0.0 108.684 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 16.8 t -113.38 148.6 35.49 Favored 'General case' 0 N--CA 1.511 2.596 0 O-C-N 121.118 -0.989 . . . . 0.0 113.143 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.481 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 31.5 m95 -139.82 145.35 38.03 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.027 -1.046 . . . . 0.0 110.36 177.256 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 83.4 tttt -105.53 129.84 53.72 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.1 t -110.63 129.95 64.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.316 -0.865 . . . . 0.0 109.95 -178.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 47.1 m -121.63 138.79 54.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.849 -0.532 . . . . 0.0 111.61 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.511 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.6 pt -114.35 166.09 12.32 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.534 -0.729 . . . . 0.0 109.809 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.44 -25.9 76.26 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 O-C-N 123.217 1.114 . . . . 0.0 112.928 -178.132 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -64.81 -37.83 88.95 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.052 -1.03 . . . . 0.0 109.751 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.93 65.32 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -162.02 153.15 18.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.769 -0.842 . . . . 0.0 108.867 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 71.5 p -152.8 162.38 41.35 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 122.197 0.999 . . . . 0.0 112.456 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.426 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.9 pt -139.39 162.3 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.128 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -107.48 127.15 53.35 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.246 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.702 HD13 HG11 ' A' ' 85' ' ' VAL . 90.2 mt -125.9 134.93 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 110.493 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.546 ' HD3' HG12 ' A' ' 37' ' ' VAL . 65.9 ttt180 -95.49 133.92 38.93 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -63.59 144.17 48.8 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 120.296 -0.954 . . . . 0.0 110.76 -178.087 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.996 HG22 HG21 ' A' ' 18' ' ' VAL . 10.1 p -142.67 -41.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 122.104 -0.645 . . . . 0.0 109.906 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.579 ' HB2' HG23 ' A' ' 18' ' ' VAL . 6.3 t0 -133.67 171.57 13.95 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.114 -0.991 . . . . 0.0 109.496 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.9 t -83.75 146.66 28.05 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.443 -0.785 . . . . 0.0 110.635 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -108.12 148.71 16.73 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -89.07 101.67 14.32 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.487 -1.008 . . . . 0.0 110.601 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 52.79 53.46 32.99 Favored Glycine 0 N--CA 1.498 2.791 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.24 170.08 14.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.929 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.689 ' CD2' HG22 ' A' ' 46' ' ' ILE . 36.3 m-85 -93.13 128.94 39.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.749 -0.853 . . . . 0.0 109.996 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.7 t-20 -120.24 130.84 54.7 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.702 HG11 HD13 ' A' ' 73' ' ' ILE . 34.2 m -129.99 174.35 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.694 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -55.51 156.8 7.99 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.658 -0.651 . . . . 0.0 109.966 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.7 -27.43 38.26 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.387 1.204 . . . . 0.0 109.706 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.417 HG22 ' HE3' ' A' ' 92' ' ' LYS . 94.3 m -71.28 -40.19 71.07 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.24 -39.56 86.21 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.3 t80 -59.99 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.737 -0.602 . . . . 0.0 110.514 179.302 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 58.0 m -59.82 -36.92 77.78 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.534 -0.729 . . . . 0.0 110.631 -178.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.417 ' HE3' HG22 ' A' ' 88' ' ' THR . 98.3 mttt -69.72 -40.02 76.5 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.805 -0.758 . . . . 0.0 111.258 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.508 ' HG ' HG21 ' A' ' 65' ' ' ILE . 52.6 tp -69.95 -41.81 74.06 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.472 -0.768 . . . . 0.0 111.688 -178.659 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 94.9 t -100.2 -36.12 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.117 0 O-C-N 121.164 -0.96 . . . . 0.0 111.413 -178.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 117.84 -30.62 6.05 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.0 m -143.03 155.12 44.57 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.48 -1.012 . . . . 0.0 110.897 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.0 p -90.23 1.53 56.39 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.521 -0.737 . . . . 0.0 110.989 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.95 -22.18 63.2 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.381 -0.824 . . . . 0.0 110.702 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.29 -45.27 88.25 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.382 -0.824 . . . . 0.0 110.717 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.68 -77.45 2.11 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 43.0 ttm180 -135.44 132.1 37.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.641 -0.917 . . . . 0.0 110.682 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 57.5 t -116.19 115.97 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.523 -0.736 . . . . 0.0 109.739 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -84.37 172.53 11.69 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.766 0.794 . . . . 0.0 111.375 -178.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.6 t30 60.07 40.02 19.03 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.807 -0.558 . . . . 0.0 111.591 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.726 HG21 HG23 ' A' ' 3' ' ' ILE . 62.8 t -81.65 127.43 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.126 179.124 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -91.88 139.98 30.13 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.064 -1.054 . . . . 0.0 108.989 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.7 p90 -140.81 147.22 38.69 Favored 'General case' 0 N--CA 1.493 1.684 0 CA-C-O 121.502 0.668 . . . . 0.0 112.129 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.9 142.57 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.747 -0.595 . . . . 0.0 109.813 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.481 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 62.3 tt0 -84.93 140.44 31.1 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.459 -0.775 . . . . 0.0 110.843 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 27.1 m -129.93 175.32 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -62.62 150.75 39.9 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.391 -0.818 . . . . 0.0 111.004 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.506 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.1 tt -60.06 -39.94 87.76 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.74 -0.6 . . . . 0.0 110.795 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 61.9 m -52.55 -35.66 54.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.59 -0.694 . . . . 0.0 111.186 -178.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.1 -40.01 93.95 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.426 -0.796 . . . . 0.0 110.967 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.06 -49.34 77.77 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.293 -0.879 . . . . 0.0 110.14 179.647 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.506 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.7 mt -70.03 -39.94 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.611 -0.681 . . . . 0.0 110.834 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -66.19 -40.07 90.14 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.453 -0.78 . . . . 0.0 110.829 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.99 -57.48 3.02 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 -178.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.83 -43.2 94.68 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.518 -0.989 . . . . 0.0 110.469 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.0 t30 . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 117.796 -1.097 . . . . 0.0 110.916 179.83 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 121.187 0.517 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 p -112.67 147.01 37.66 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.707 -0.62 . . . . 0.0 111.019 -179.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.726 HG21 HG11 ' A' ' 105' ' ' VAL . 24.7 pt -113.8 147.9 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.796 -0.565 . . . . 0.0 110.161 179.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -145.84 -172.34 3.89 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.373 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -142.22 149.34 39.52 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.519 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -139.09 152.99 71.08 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.377 -0.827 . . . . 0.0 110.078 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -83.55 2.36 8.38 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 O-C-N 123.407 1.214 . . . . 0.0 111.39 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 8' ' ' ILE . 26.2 mm -76.5 -2.79 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.16 -0.962 . . . . 0.0 111.165 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -127.34 64.64 1.33 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 122.347 1.07 . . . . 0.0 110.765 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.15 173.97 6.21 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.602 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.04 -32.17 70.66 Favored 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -175.239 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -89.41 12.28 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 120.446 1.475 . . . . 0.0 112.084 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 8' ' ' ILE . 0.1 OUTLIER -69.71 114.55 8.02 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.303 -0.873 . . . . 0.0 109.301 179.426 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m -62.76 139.4 58.68 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.801 0.81 . . . . 0.0 110.631 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.68 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.1 mmm -62.56 -26.38 68.55 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.985 -179.415 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -19.44 76.44 Favored Glycine 0 N--CA 1.494 2.507 0 O-C-N 121.126 -0.984 . . . . 0.0 110.896 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 75.4 m -86.46 -17.77 33.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.228 -1.16 . . . . 0.0 111.375 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.927 HG21 HG22 ' A' ' 76' ' ' VAL . 7.3 p -89.98 160.02 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.328 -0.858 . . . . 0.0 109.676 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.17 -41.82 65.57 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.58 -0.7 . . . . 0.0 111.164 -178.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 82.92 4.83 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.294 -0.879 . . . . 0.0 108.835 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 m -91.42 -79.34 0.37 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.26 -0.9 . . . . 0.0 113.014 -177.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 t30 -144.09 14.82 1.69 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.772 -1.205 . . . . 0.0 112.474 -178.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.49 -147.19 0.37 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 108.671 -1.772 . . . . 0.0 108.671 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -69.58 -39.97 76.99 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.622 -0.928 . . . . 0.0 108.85 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.565 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 19.4 m80 -89.93 0.04 57.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.698 -0.626 . . . . 0.0 110.208 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.74 133.05 52.3 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.567 HD13 HH21 ' A' ' 74' ' ' ARG . 65.0 mt -103.73 -0.07 29.86 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 122.139 -0.624 . . . . 0.0 110.47 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -64.0 -35.46 80.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.274 -0.891 . . . . 0.0 111.068 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.69 -66.16 0.47 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.41 -0.806 . . . . 0.0 111.883 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLN . . . . . 0.436 ' HG3' ' N ' ' A' ' 31' ' ' TYR . 28.1 pt20 -72.71 -40.5 66.13 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.126 -0.984 . . . . 0.0 110.775 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.683 ' CD2' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -126.73 91.04 48.22 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.429 -0.794 . . . . 0.0 109.428 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.54 -9.89 27.41 Favored 'Trans proline' 0 N--CA 1.488 1.161 0 O-C-N 123.554 1.292 . . . . 0.0 112.04 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.9 m -129.03 143.95 51.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.098 -1.001 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.996 HD11 HG21 ' A' ' 43' ' ' VAL . 21.2 tp -69.93 120.02 15.02 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.878 -0.514 . . . . 0.0 110.546 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 147.36 30.32 0.07 OUTLIER Glycine 0 N--CA 1.496 2.697 0 C-N-CA 119.927 -1.13 . . . . 0.0 110.822 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -154.13 -50.9 0.09 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.26 -1.141 . . . . 0.0 110.286 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.683 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.7 t -61.66 -59.47 13.29 Favored Pre-proline 0 N--CA 1.497 1.904 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.439 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.0 Cg_endo -74.08 -32.08 7.25 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 O-C-N 123.258 1.136 . . . . 0.0 109.24 177.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.429 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 131.21 -65.05 0.6 Allowed Glycine 0 N--CA 1.484 1.856 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.329 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.602 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 1.7 t80 163.94 -69.66 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.793 0 C-N-CA 123.522 0.729 . . . . 0.0 110.393 177.398 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.547 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.9 Cg_endo -80.61 -0.22 10.47 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 120.387 0.725 . . . . 0.0 112.714 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -111.24 53.66 0.7 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.872 -1.143 . . . . 0.0 110.425 -178.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.996 HG21 HD11 ' A' ' 34' ' ' LEU . 14.4 p -132.44 141.09 46.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 121.859 0.838 . . . . 0.0 110.054 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.69 175.39 43.24 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.652 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.51 157.67 29.13 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 179.091 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.739 HD11 ' CA ' ' A' ' 75' ' ' GLY . 1.7 pt -156.01 160.06 31.07 Favored Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.592 -0.946 . . . . 0.0 109.771 179.128 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -67.02 -23.49 46.45 Favored 'Trans proline' 0 N--CA 1.502 1.983 0 C-N-CA 121.643 1.562 . . . . 0.0 115.291 -176.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -77.03 -5.02 47.13 Favored 'General case' 0 N--CA 1.506 2.374 0 O-C-N 120.381 -1.45 . . . . 0.0 112.497 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.587 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.1 mm -89.71 121.34 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.992 -1.067 . . . . 0.0 108.45 178.553 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.65 -43.55 47.07 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.243 -0.91 . . . . 0.0 111.537 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.98 -131.73 2.43 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.004 -1.569 . . . . 0.0 110.771 -179.618 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.478 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 61.9 t90 -48.71 -26.02 2.11 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.886 -0.773 . . . . 0.0 112.749 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.8 64.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.184 -0.948 . . . . 0.0 110.713 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.587 ' CB ' HG23 ' A' ' 49' ' ' ILE . 7.9 p -63.5 133.64 95.57 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.648 -0.658 . . . . 0.0 110.986 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.565 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.4 Cg_endo -71.64 -19.47 27.9 Favored 'Trans proline' 0 N--CA 1.485 1.011 0 O-C-N 123.212 1.112 . . . . 0.0 110.911 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 59' ' ' THR . 54.0 p -99.04 10.8 40.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.378 -0.827 . . . . 0.0 111.025 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -65.13 143.1 58.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.135 -0.978 . . . . 0.0 110.056 -179.757 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.41 26.01 48.92 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.431 HG23 ' O ' ' A' ' 56' ' ' SER . 17.1 p -100.01 134.99 42.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.453 -1.027 . . . . 0.0 110.615 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.472 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.0 t -81.49 131.11 35.27 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.795 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.474 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 85.6 m95 -133.6 143.58 48.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.387 -0.82 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 tttm -110.67 130.98 55.43 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -111.02 129.73 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.349 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 69.0 m -120.04 135.55 54.89 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.868 -0.52 . . . . 0.0 110.604 -178.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.479 ' CG2' HD21 ' A' ' 93' ' ' LEU . 8.7 pt -113.8 164.83 14.92 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.425 -0.797 . . . . 0.0 110.849 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -62.96 -27.93 74.79 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.241 1.294 . . . . 0.0 112.937 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.401 ' HB3' ' CD1' ' A' ' 65' ' ' ILE . 38.1 t30 -64.58 -40.0 94.76 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.239 -0.913 . . . . 0.0 109.701 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 69' ' ' ASN . . . 118.18 60.01 0.28 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.46 ' ND2' ' O ' ' A' ' 68' ' ' GLY . 19.3 m120 -153.7 148.7 26.71 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.699 -0.883 . . . . 0.0 108.745 178.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 47.1 m -149.37 155.49 40.56 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 119.3 -0.96 . . . . 0.0 112.233 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 43.3 pt -140.76 166.9 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.71 125.45 53.51 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.404 179.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.624 HD13 HG11 ' A' ' 85' ' ' VAL . 96.9 mt -124.1 138.63 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.466 -0.771 . . . . 0.0 110.518 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.567 HH21 HD13 ' A' ' 27' ' ' LEU . 1.9 ttp-105 -100.85 146.47 27.27 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.586 -0.696 . . . . 0.0 109.745 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.739 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -68.11 151.33 51.81 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.927 HG22 HG21 ' A' ' 18' ' ' VAL . 9.6 p -154.81 -44.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.826 -0.808 . . . . 0.0 109.522 179.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.571 ' HB2' HG23 ' A' ' 18' ' ' VAL . 5.2 t0 -129.62 169.82 14.56 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.059 -1.025 . . . . 0.0 109.622 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' ILE . 92.6 p -101.57 160.07 14.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.577 -0.702 . . . . 0.0 111.055 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.96 155.06 21.62 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 75.4 mtp85 -59.97 -31.41 69.87 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.484 -1.01 . . . . 0.0 109.679 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -176.69 -179.8 47.3 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 50.83 -178.88 0.04 OUTLIER Glycine 0 N--CA 1.496 2.675 0 O-C-N 121.434 -1.039 . . . . 0.0 111.87 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.612 ' CD2' HG22 ' A' ' 46' ' ' ILE . 42.7 m-85 -107.74 127.46 53.71 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.891 -0.77 . . . . 0.0 109.008 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 41.7 t-20 -117.83 127.73 54.16 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.511 -0.875 . . . . 0.0 108.64 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.624 HG11 HD13 ' A' ' 73' ' ' ILE . 34.4 m -130.79 172.37 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.697 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -55.58 152.79 16.96 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.534 -0.729 . . . . 0.0 109.528 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.21 -26.33 57.0 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.35 1.184 . . . . 0.0 110.186 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.773 HG22 ' HE2' ' A' ' 92' ' ' LYS . 94.3 m -70.08 -40.24 75.13 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.076 -1.015 . . . . 0.0 109.346 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.03 -40.57 87.24 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -60.71 -50.08 74.9 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.719 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.1 m -61.14 -39.96 92.01 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.403 -0.811 . . . . 0.0 111.273 -178.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.773 ' HE2' HG22 ' A' ' 88' ' ' THR . 56.3 mtmt -69.99 -40.05 75.55 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.999 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.479 HD21 ' CG2' ' A' ' 65' ' ' ILE . 48.0 tp -69.91 -42.93 72.69 Favored 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.365 -179.175 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.22 -41.6 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 O-C-N 121.45 -0.781 . . . . 0.0 111.83 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.72 -34.5 4.05 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.3 m -142.44 153.67 43.91 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.524 -0.986 . . . . 0.0 110.14 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.6 p -90.28 3.49 53.46 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.477 -0.765 . . . . 0.0 110.976 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.98 -26.22 63.99 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.423 -0.798 . . . . 0.0 111.158 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.94 -39.92 87.19 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.413 -0.804 . . . . 0.0 110.513 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.75 -79.49 1.84 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 50.5 ttp180 -131.8 138.87 48.71 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.694 -0.886 . . . . 0.0 110.47 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 105' ' ' VAL . 63.0 t -120.32 116.97 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.804 178.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -80.55 170.14 16.74 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.656 0.741 . . . . 0.0 111.346 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 60.0 39.93 19.37 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.007 0.432 . . . . 0.0 111.816 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.726 HG11 HG21 ' A' ' 3' ' ' ILE . 78.5 t -85.48 127.52 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.134 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -87.36 140.05 29.93 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.14 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -139.22 144.5 38.5 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.579 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -144.69 141.68 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.498 -0.751 . . . . 0.0 111.231 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.474 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.2 tt0 -73.45 135.01 44.09 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.561 -0.712 . . . . 0.0 109.755 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.472 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.5 m -132.27 173.09 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.437 179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -60.34 149.71 32.88 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.357 -0.839 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.463 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.4 tt -59.93 -39.08 84.29 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.505 -0.747 . . . . 0.0 110.58 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.9 m -53.5 -38.01 63.28 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.557 -0.714 . . . . 0.0 110.57 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -60.22 -39.93 88.35 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.496 -0.753 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.07 -49.83 76.11 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.257 -0.902 . . . . 0.0 110.246 179.311 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.432 HD11 HD21 ' A' ' 112' ' ' LEU . 90.4 mt -69.25 -39.99 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.704 -0.622 . . . . 0.0 110.253 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.63 -39.93 95.37 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.401 -0.812 . . . . 0.0 110.281 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.81 -41.82 81.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.35 -39.97 94.86 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.75 -0.853 . . . . 0.0 110.305 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.9 p30 . . . . . 0 N--CA 1.495 1.815 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.551 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.51 0.671 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.9 p -114.61 153.99 29.15 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.874 -0.516 . . . . 0.0 110.545 -179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.495 HG21 HG11 ' A' ' 105' ' ' VAL . 39.5 pt -119.99 150.05 22.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.476 -0.765 . . . . 0.0 110.534 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 p -147.84 -171.76 3.89 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.342 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.4 p90 -141.5 142.47 33.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.465 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.73 ' HB3' HG22 ' A' ' 8' ' ' ILE . 4.5 m-20 -133.78 150.01 73.47 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.476 -0.765 . . . . 0.0 110.208 179.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -78.87 -0.93 11.18 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 O-C-N 123.377 1.199 . . . . 0.0 111.114 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.792 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.4 tp -71.67 -15.22 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.244 -0.91 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CD2' HG23 ' A' ' 8' ' ' ILE . 34.3 m-85 -114.88 68.53 0.7 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 122.613 1.197 . . . . 0.0 110.553 178.466 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.24 170.06 8.09 Favored 'General case' 0 N--CA 1.492 1.67 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.599 177.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.716 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.91 -34.42 73.19 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 -175.744 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -88.22 13.53 11.27 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.417 -1.427 . . . . 0.0 112.422 -176.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.792 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.9 tp -75.56 122.82 24.47 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.355 -0.841 . . . . 0.0 110.091 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.8 m -65.73 137.62 57.4 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.801 -0.76 . . . . 0.0 109.627 179.533 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.8 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.4 mmm -64.22 -19.08 65.11 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.823 -0.548 . . . . 0.0 111.313 -179.248 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.5 -16.55 78.93 Favored Glycine 0 N--CA 1.495 2.59 0 O-C-N 120.95 -1.094 . . . . 0.0 110.986 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.1 m -88.18 -13.78 40.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.165 -1.197 . . . . 0.0 111.599 -179.148 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 15' ' ' MET . 13.0 p -90.04 159.54 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.149 -0.97 . . . . 0.0 108.869 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.769 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -49.07 -41.36 35.04 Favored 'General case' 0 N--CA 1.507 2.418 0 O-C-N 121.266 -0.896 . . . . 0.0 110.562 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -78.23 87.14 4.31 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.8 m -99.4 -82.31 0.44 Allowed 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.117 -0.989 . . . . 0.0 112.954 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -137.91 9.58 2.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.087 -1.008 . . . . 0.0 112.922 -178.03 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.08 -148.0 0.5 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.801 -1.72 . . . . 0.0 108.801 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -63.03 -40.01 96.47 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.625 -0.927 . . . . 0.0 109.526 178.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 89.6 m-70 -94.6 8.56 41.89 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.567 -0.708 . . . . 0.0 111.151 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.15 127.42 35.89 Favored Glycine 0 N--CA 1.502 3.064 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 91.2 mt -102.47 -11.46 18.55 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 122.03 -0.688 . . . . 0.0 111.532 -178.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 ttp -60.03 -27.32 66.81 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.261 -0.899 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.52 -61.75 2.27 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.425 -0.797 . . . . 0.0 112.898 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -69.96 -40.01 75.69 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 120.88 -1.137 . . . . 0.0 111.36 -178.108 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.615 ' CE1' HG21 ' A' ' 37' ' ' VAL . 3.8 p90 -136.21 104.76 9.49 Favored Pre-proline 0 C--N 1.302 -1.491 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.42 -11.15 29.01 Favored 'Trans proline' 0 N--CA 1.485 0.98 0 O-C-N 123.482 1.254 . . . . 0.0 111.647 -178.283 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -126.85 135.76 51.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.245 -0.91 . . . . 0.0 109.761 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.949 HD21 HG11 ' A' ' 43' ' ' VAL . 39.4 tp -61.46 126.05 25.95 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.522 -0.736 . . . . 0.0 109.858 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 148.79 27.77 0.06 OUTLIER Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.538 -1.315 . . . . 0.0 111.787 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -144.99 -47.91 0.24 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.074 -1.25 . . . . 0.0 110.917 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.615 HG21 ' CE1' ' A' ' 31' ' ' TYR . 1.7 t -67.42 -55.45 15.02 Favored Pre-proline 0 N--CA 1.496 1.844 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.389 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD2' ' N ' ' A' ' 37' ' ' VAL . 42.5 Cg_endo -76.19 -31.44 4.77 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.396 1.208 . . . . 0.0 108.988 178.079 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.424 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 129.77 -64.6 0.6 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.716 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 2.1 t80 164.38 -56.74 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.595 0 C-N-CA 123.33 0.652 . . . . 0.0 110.844 177.491 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.638 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.7 Cg_endo -97.42 16.84 0.61 Allowed 'Trans proline' 0 N--CA 1.481 0.773 0 C-N-CA 120.982 1.121 . . . . 0.0 112.044 -177.892 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -126.12 47.49 2.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.2 -0.937 . . . . 0.0 109.758 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.949 HG11 HD21 ' A' ' 34' ' ' LEU . 10.2 p -128.09 142.43 43.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.596 0.712 . . . . 0.0 109.78 -179.617 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.56 170.43 41.09 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.453 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -83.79 158.58 35.36 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 178.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.698 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.5 pt -147.81 156.2 44.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.439 -1.036 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.66 -12.22 34.79 Favored 'Trans proline' 0 N--CA 1.504 2.119 0 C-N-CA 121.934 1.756 . . . . 0.0 114.668 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -96.72 21.31 9.61 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 120.491 -1.381 . . . . 0.0 112.796 -177.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 54' ' ' SER . 48.9 mm -110.7 129.98 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.37 -0.831 . . . . 0.0 108.807 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.15 -48.26 11.54 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.786 . . . . 0.0 112.256 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.769 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.53 -129.04 1.8 Allowed Glycine 0 N--CA 1.488 2.119 0 C-N-CA 118.806 -1.664 . . . . 0.0 111.384 -179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.454 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 20.1 t90 -50.2 -24.99 3.18 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.89 -0.771 . . . . 0.0 112.881 -178.255 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.93 71.3 1.22 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.402 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.634 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.2 t -70.04 130.37 89.87 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.865 -0.522 . . . . 0.0 111.075 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.36 -21.47 30.65 Favored 'Trans proline' 0 N--CA 1.486 1.053 0 O-C-N 123.246 1.13 . . . . 0.0 110.566 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -98.52 13.48 31.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.445 -0.785 . . . . 0.0 110.983 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -70.98 147.18 48.91 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.182 -0.949 . . . . 0.0 110.271 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.1 35.37 44.02 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.065 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 95.6 m -119.59 135.17 54.91 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.503 -0.998 . . . . 0.0 110.484 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -78.96 145.64 33.88 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.053 -178.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.449 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 96.0 m95 -148.38 143.98 27.19 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.801 -0.562 . . . . 0.0 109.537 178.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -107.36 134.89 49.76 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.305 -0.872 . . . . 0.0 109.134 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 123.34 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.496 -0.752 . . . . 0.0 110.216 -179.229 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.2 m -118.42 139.71 50.98 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.893 -0.505 . . . . 0.0 110.378 -179.088 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.472 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 21.0 pt -119.58 164.29 22.62 Favored Pre-proline 0 N--CA 1.5 2.044 0 O-C-N 121.471 -0.768 . . . . 0.0 110.881 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 36.6 Cg_endo -60.58 -24.11 77.42 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 121.445 1.43 . . . . 0.0 112.794 -178.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -65.55 -36.61 84.28 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.217 -0.927 . . . . 0.0 109.712 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.11 63.41 0.47 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -163.82 153.99 15.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.755 -0.85 . . . . 0.0 108.988 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 95.6 p -155.43 158.38 38.51 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.583 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.6 pt -140.02 166.72 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.143 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -104.96 125.78 51.32 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.612 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -117.98 130.06 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.75 -0.594 . . . . 0.0 109.621 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.484 ' CD ' HG12 ' A' ' 37' ' ' VAL . 1.3 ttp-105 -99.23 139.52 34.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.524 -0.735 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.59 148.04 42.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.636 HG22 HG21 ' A' ' 18' ' ' VAL . 3.8 p -155.66 -41.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.807 -0.819 . . . . 0.0 109.798 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.647 ' OD2' HG23 ' A' ' 18' ' ' VAL . 1.9 t0 -134.58 175.18 9.77 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.145 -0.972 . . . . 0.0 109.767 179.128 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -103.81 154.81 19.17 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.471 -0.768 . . . . 0.0 111.521 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.77 147.75 16.66 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.9 mtt180 -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.648 -0.913 . . . . 0.0 110.742 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -177.39 73.65 0.07 OUTLIER Glycine 0 N--CA 1.495 2.585 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.638 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.65 147.33 4.54 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.467 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.698 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.5 m-85 -73.02 135.16 44.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 122.031 -0.688 . . . . 0.0 110.506 179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.3 131.01 46.87 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 178.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.4 m -131.72 173.73 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.636 -178.063 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -55.17 152.16 15.77 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 109.927 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.27 -27.55 55.89 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.422 1.222 . . . . 0.0 110.11 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.02 -40.02 75.46 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.952 -1.092 . . . . 0.0 109.048 178.375 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.92 -40.16 87.59 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.432 -0.793 . . . . 0.0 108.977 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.47 -49.95 75.51 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.799 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 38.9 m -60.02 -39.56 86.25 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.657 -0.652 . . . . 0.0 111.28 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.9 mttm -68.89 -40.02 79.41 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.499 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.4 HD21 ' CG2' ' A' ' 65' ' ' ILE . 41.4 tp -70.78 -42.74 69.95 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.8 -0.76 . . . . 0.0 111.627 -178.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.1 t -97.74 -40.39 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.201 -0.937 . . . . 0.0 111.733 -177.7 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 118.17 -37.7 3.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.9 m -134.69 149.62 50.52 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.608 -0.937 . . . . 0.0 110.199 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 70.8 p -94.02 3.98 54.56 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.421 -0.799 . . . . 0.0 111.053 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -69.93 -27.64 64.93 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.43 -0.794 . . . . 0.0 111.164 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.97 87.75 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.495 -0.753 . . . . 0.0 110.67 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.28 -60.45 3.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.2 ptt180 -153.61 156.91 38.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.616 -0.932 . . . . 0.0 110.546 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -125.44 117.24 49.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.45 -0.781 . . . . 0.0 109.672 179.249 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -81.09 169.99 16.74 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.49 -0.756 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 56.4 t30 61.64 47.92 6.05 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.573 -0.704 . . . . 0.0 111.646 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.495 HG11 HG21 ' A' ' 3' ' ' ILE . 81.1 t -96.17 124.75 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.031 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -84.92 145.76 27.61 Favored 'General case' 0 N--CA 1.493 1.675 0 C-N-CA 119.779 -0.768 . . . . 0.0 109.281 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.02 147.2 40.04 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.833 -0.542 . . . . 0.0 111.598 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.8 m -147.27 148.66 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.653 -0.654 . . . . 0.0 110.829 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.449 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 16.9 tt0 -82.98 140.93 32.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.656 -0.652 . . . . 0.0 110.314 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.4 m -132.54 168.8 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 120.211 -0.595 . . . . 0.0 109.742 179.236 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -59.97 149.05 33.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.296 -0.878 . . . . 0.0 109.925 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -40.0 88.03 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.408 -0.807 . . . . 0.0 110.94 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 54.0 p -55.45 -35.54 65.57 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.556 -0.715 . . . . 0.0 110.665 -178.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -60.0 -38.39 82.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.435 -0.79 . . . . 0.0 110.075 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 85.8 m -69.63 -39.93 76.86 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.665 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.8 mm -64.09 -43.94 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 120.274 -0.571 . . . . 0.0 109.845 -178.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -70.0 -40.02 75.53 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.76 -0.588 . . . . 0.0 110.547 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.44 -51.63 46.86 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.57 -40.04 94.83 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.588 -0.948 . . . . 0.0 110.249 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.087 -179.87 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.351 0.596 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.9 m -111.36 137.26 49.36 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.441 HG21 HG11 ' A' ' 105' ' ' VAL . 37.8 pt -109.75 146.69 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.6 -0.688 . . . . 0.0 110.354 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.9 m -143.29 -174.59 4.25 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -142.73 150.0 39.51 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.985 179.067 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.55 152.7 77.03 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.504 -0.748 . . . . 0.0 109.755 179.369 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -84.52 -12.0 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 O-C-N 123.348 1.183 . . . . 0.0 112.659 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.479 HG13 ' N ' ' A' ' 9' ' ' TYR . 35.9 pt -70.05 -39.91 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 120.871 -1.143 . . . . 0.0 111.333 -178.883 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.605 ' HA ' HD22 ' A' ' 13' ' ' LEU . 46.3 m-85 -72.94 65.22 0.73 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 122.652 1.215 . . . . 0.0 111.712 -178.653 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.89 170.46 7.86 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.55 -34.84 73.18 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -87.83 8.99 23.35 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.016 -1.474 . . . . 0.0 111.542 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.605 HD22 ' HA ' ' A' ' 9' ' ' TYR . 45.3 tp -70.01 122.13 18.76 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.303 -0.873 . . . . 0.0 109.424 179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.1 m -68.31 135.59 52.12 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.413 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.851 ' O ' HG12 ' A' ' 18' ' ' VAL . 87.0 mtp -70.07 -15.23 62.96 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.16 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -15.87 72.74 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 120.805 -1.184 . . . . 0.0 110.168 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -88.55 -6.67 57.42 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -1.142 . . . . 0.0 111.735 -179.254 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.851 HG12 ' O ' ' A' ' 15' ' ' MET . 10.8 p -96.74 165.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.997 -1.064 . . . . 0.0 110.603 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.633 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.01 -42.33 94.07 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.783 -0.573 . . . . 0.0 110.907 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.1 m -76.98 71.72 3.5 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.383 -0.823 . . . . 0.0 110.186 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 4.2 p -108.36 111.9 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.467 -0.771 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.41 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 13.1 t-20 51.99 -139.71 0.96 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.592 -0.692 . . . . 0.0 110.561 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.458 ' CA ' ' CH2' ' A' ' 52' ' ' TRP . . . 66.02 -156.12 50.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -74.25 -41.03 61.94 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.684 -0.892 . . . . 0.0 112.025 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.403 ' CD2' ' O ' ' A' ' 54' ' ' SER . 79.5 m-70 -99.69 10.04 42.04 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.074 -1.016 . . . . 0.0 111.51 -178.142 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -56.78 130.85 51.17 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 120.073 -1.06 . . . . 0.0 110.523 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 1.005 HD13 HG11 ' A' ' 37' ' ' VAL . 95.0 mt -100.6 -5.93 26.02 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.071 -0.664 . . . . 0.0 110.12 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 34.3 tpp -59.95 -36.08 76.31 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.281 -0.887 . . . . 0.0 109.599 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.24 -72.46 0.05 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.723 -0.611 . . . . 0.0 111.784 -178.197 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -69.95 -39.99 75.72 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.349 -0.845 . . . . 0.0 110.223 -179.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.644 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.8 m-85 -120.38 102.31 45.65 Favored Pre-proline 0 N--CA 1.491 1.596 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 -178.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.97 -22.39 19.75 Favored 'Trans proline' 0 C--N 1.316 -1.154 0 O-C-N 123.322 1.17 . . . . 0.0 111.381 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.1 m -122.69 144.23 49.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.327 -0.858 . . . . 0.0 110.711 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.663 HD21 HG11 ' A' ' 43' ' ' VAL . 52.9 tp -64.94 120.82 13.29 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.855 -0.528 . . . . 0.0 110.088 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.29 32.17 0.04 OUTLIER Glycine 0 N--CA 1.496 2.698 0 C-N-CA 119.906 -1.14 . . . . 0.0 110.993 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.446 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 19.1 mt-10 -156.09 -48.17 0.08 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.335 -1.097 . . . . 0.0 109.979 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 1.005 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -62.95 -59.48 12.38 Favored Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.436 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.9 Cg_endo -73.73 -32.29 7.65 Favored 'Trans proline' 0 C--N 1.318 -1.066 0 N-CA-C 108.733 -1.295 . . . . 0.0 108.733 177.173 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.1 -63.46 0.63 Allowed Glycine 0 N--CA 1.487 2.049 0 N-CA-C 107.197 -2.361 . . . . 0.0 107.197 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.644 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.5 t80 163.32 -53.58 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.556 0 C-N-CA 123.601 0.76 . . . . 0.0 109.91 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.666 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -100.55 12.95 0.49 Allowed 'Trans proline' 0 C--N 1.324 -0.728 0 C-N-CA 121.29 1.327 . . . . 0.0 111.198 -179.029 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 46.6 m-20 -125.15 52.19 1.61 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.216 -0.928 . . . . 0.0 109.765 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.663 HG11 HD21 ' A' ' 34' ' ' LEU . 13.4 p -126.21 136.71 60.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 CA-C-O 121.538 0.685 . . . . 0.0 110.283 -179.679 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.573 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -165.8 171.26 40.91 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.81 160.14 29.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.899 -1.681 . . . . 0.0 108.899 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.646 HG22 ' CE1' ' A' ' 83' ' ' PHE . 8.8 pt -146.65 158.63 45.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.806 -0.82 . . . . 0.0 110.414 179.101 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.14 -16.41 35.94 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.713 1.609 . . . . 0.0 113.63 -178.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -89.94 18.69 5.47 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.816 -1.177 . . . . 0.0 112.577 -177.545 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.437 ' HA ' ' CB ' ' A' ' 54' ' ' SER . 56.0 mt -119.99 123.17 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.146 -0.971 . . . . 0.0 109.05 177.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.58 -43.64 16.8 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 113.388 0.885 . . . . 0.0 113.388 -177.515 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.633 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.54 -125.33 0.96 Allowed Glycine 0 N--CA 1.493 2.452 0 C-N-CA 118.119 -1.991 . . . . 0.0 112.909 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.469 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 6.8 t90 -40.32 -32.8 0.2 Allowed 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 114.56 1.319 . . . . 0.0 114.56 -176.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 40.9 p-10 -174.15 76.83 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.493 -1.38 . . . . 0.0 109.975 178.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 25.4 p -62.74 155.11 72.01 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.636 -0.665 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 -14.36 40.05 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.566 1.298 . . . . 0.0 110.813 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 59' ' ' THR . 6.2 m -102.36 7.79 40.4 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.315 -0.865 . . . . 0.0 111.841 -179.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 41.5 t -65.4 143.65 57.59 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 120.755 -1.216 . . . . 0.0 110.109 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.26 6.45 81.35 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 56' ' ' SER . 20.9 p -77.67 158.12 29.85 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.149 -1.207 . . . . 0.0 110.998 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.41 120.02 40.01 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.19 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.431 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -121.36 139.97 52.73 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.39 -0.819 . . . . 0.0 110.934 179.498 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -105.92 134.14 49.52 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.651 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.8 t -111.69 125.62 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.587 -0.696 . . . . 0.0 110.47 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.509 ' O ' HG13 ' A' ' 105' ' ' VAL . 58.8 m -116.41 134.8 54.46 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.692 -0.63 . . . . 0.0 110.552 -178.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 12.8 pt -116.29 164.04 19.56 Favored Pre-proline 0 N--CA 1.503 2.179 0 O-C-N 121.407 -0.808 . . . . 0.0 111.331 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -63.38 -27.36 71.12 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 121.679 1.586 . . . . 0.0 113.296 -178.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -64.67 -40.03 94.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.064 -1.023 . . . . 0.0 109.917 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 119.92 58.53 0.25 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.657 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -154.7 148.43 25.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.72 -0.871 . . . . 0.0 108.666 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 74.9 m -146.44 143.74 29.22 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.738 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.553 HG23 HD13 ' A' ' 93' ' ' LEU . 33.9 pt -134.3 164.35 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -107.13 127.92 53.93 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 118.948 -1.101 . . . . 0.0 109.829 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -112.79 130.01 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.666 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.5 ttt180 -98.6 134.89 40.91 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.179 -0.95 . . . . 0.0 109.244 -179.299 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.96 147.04 30.76 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.455 HG22 HG21 ' A' ' 18' ' ' VAL . 3.7 p -155.4 -44.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.55 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.4 t70 -128.73 166.38 19.08 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.2 -0.937 . . . . 0.0 109.563 178.75 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 83.5 p -88.88 161.16 16.84 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.579 -0.701 . . . . 0.0 110.338 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.56 142.97 14.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 88.4 mtt-85 -60.08 -34.01 72.86 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.941 . . . . 0.0 110.009 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.24 75.65 0.04 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.62 149.93 5.1 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.99 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.651 ' CE2' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -66.53 140.07 57.97 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.855 -0.791 . . . . 0.0 110.491 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.414 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 52.3 t-20 -136.77 119.0 15.56 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.361 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.573 HG12 ' HA3' ' A' ' 44' ' ' GLY . 27.3 m -130.24 176.11 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 C-N-CA 119.102 -1.039 . . . . 0.0 112.449 -177.438 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.2 m-20 -56.18 157.58 8.67 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.578 -0.701 . . . . 0.0 109.937 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -70.35 -28.17 22.76 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.407 1.214 . . . . 0.0 110.166 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -70.36 -41.41 73.18 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.033 -1.042 . . . . 0.0 109.549 178.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.666 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.0 -40.09 90.86 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -60.05 -49.93 75.74 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.401 -0.52 . . . . 0.0 110.708 178.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.7 m -60.01 -39.71 86.73 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.44 -0.788 . . . . 0.0 111.416 -178.076 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -69.61 -39.99 76.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.563 -0.711 . . . . 0.0 111.274 -178.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.553 HD13 HG23 ' A' ' 71' ' ' ILE . 61.0 tp -71.31 -43.46 67.04 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.587 -0.696 . . . . 0.0 111.296 -179.399 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.6 t -93.32 -40.55 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.473 -0.767 . . . . 0.0 111.293 -178.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.29 -38.78 2.47 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 74.5 m -142.28 156.93 45.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.674 -0.897 . . . . 0.0 110.416 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 67.2 p -89.95 4.17 50.87 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.776 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.98 -26.65 64.19 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.452 -0.78 . . . . 0.0 110.445 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.01 93.21 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.57 -0.706 . . . . 0.0 110.385 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.33 -75.35 2.39 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -133.42 136.63 45.34 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.558 -0.966 . . . . 0.0 110.572 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.8 t -116.8 113.76 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.438 -0.788 . . . . 0.0 109.76 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -86.84 170.58 11.56 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-O 121.848 0.832 . . . . 0.0 111.608 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.2 t30 60.07 40.01 19.04 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.505 0.669 . . . . 0.0 110.333 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.509 HG13 ' O ' ' A' ' 64' ' ' THR . 93.8 t -90.73 122.01 41.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -80.0 140.4 36.59 Favored 'General case' 0 N--CA 1.493 1.707 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.651 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 107' ' ' TYR . 42.2 p90 -139.27 143.88 38.14 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.882 -0.512 . . . . 0.0 111.231 -178.49 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.5 m -145.54 139.99 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 111.17 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.431 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 57.3 tt0 -72.66 140.01 47.66 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.364 178.711 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.8 m -138.48 177.7 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.836 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 47.4 t0 -59.89 146.19 43.07 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.665 -0.647 . . . . 0.0 109.976 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 116' ' ' ILE . 9.3 tt -60.0 -37.95 81.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.456 -0.777 . . . . 0.0 110.514 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.7 p -52.71 -35.14 55.22 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.517 -0.739 . . . . 0.0 110.595 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -66.45 -36.3 82.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.511 -0.743 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -62.96 -50.18 71.79 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.264 -0.898 . . . . 0.0 110.038 179.033 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.47 HD11 HD21 ' A' ' 112' ' ' LEU . 90.0 mt -69.3 -40.03 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.748 -0.595 . . . . 0.0 110.457 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -65.44 -40.02 92.75 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.44 -0.787 . . . . 0.0 110.158 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.58 -42.18 97.51 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.05 91.1 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.675 -0.897 . . . . 0.0 109.945 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 66.5 t30 . . . . . 0 N--CA 1.5 2.058 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.645 179.898 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.375 0.607 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.0 m -111.77 140.7 46.19 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.661 0.744 . . . . 0.0 110.241 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.636 HG21 HG11 ' A' ' 105' ' ' VAL . 35.6 pt -112.18 147.36 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.755 -0.591 . . . . 0.0 110.487 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 4.0 p -145.78 -173.24 4.09 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.1 p90 -142.5 148.88 38.4 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.656 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -124.95 150.38 66.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.468 -0.77 . . . . 0.0 109.608 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -84.55 -7.77 9.64 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 O-C-N 123.303 1.159 . . . . 0.0 112.854 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.0 pt -70.02 -40.09 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.201 0 O-C-N 120.887 -1.133 . . . . 0.0 111.102 -179.356 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 38.0 m-85 -72.13 66.86 0.64 Allowed 'General case' 0 N--CA 1.496 1.827 0 CA-C-O 122.684 1.23 . . . . 0.0 111.756 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.69 172.2 6.95 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.126 176.675 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.17 71.57 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -90.3 11.33 21.62 Favored 'General case' 0 N--CA 1.501 2.09 0 C-N-CA 118.078 -1.449 . . . . 0.0 112.424 -177.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.456 HD22 ' HA ' ' A' ' 9' ' ' TYR . 28.2 tp -72.63 123.87 24.11 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.214 -0.928 . . . . 0.0 109.956 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 48.4 t -69.54 136.31 51.2 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.027 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.779 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.1 mmm -69.98 -15.95 63.11 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.856 -0.527 . . . . 0.0 111.717 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.418 ' CA ' ' HE1' ' A' ' 28' ' ' MET . . . -69.93 -11.18 66.12 Favored Glycine 0 N--CA 1.495 2.632 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.588 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.8 m -93.15 -11.97 31.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.254 -1.144 . . . . 0.0 111.708 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.779 HG12 ' O ' ' A' ' 15' ' ' MET . 7.1 p -92.45 165.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.17 -0.956 . . . . 0.0 110.46 -179.191 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.819 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.98 -45.3 86.98 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.642 -0.661 . . . . 0.0 110.093 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.23 80.32 6.68 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.97 -80.02 0.4 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.485 -0.76 . . . . 0.0 112.903 -177.523 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -139.91 9.43 2.36 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.217 -0.927 . . . . 0.0 112.917 -178.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.47 -143.97 0.24 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -69.97 -40.02 75.64 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.647 -0.914 . . . . 0.0 109.71 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -90.38 2.37 55.65 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.457 -0.777 . . . . 0.0 110.815 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.03 126.42 33.21 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.423 -1.071 . . . . 0.0 110.423 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.842 HD13 HG11 ' A' ' 37' ' ' VAL . 96.1 mt -100.09 0.93 41.71 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 122.132 -0.628 . . . . 0.0 110.21 178.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.418 ' HE1' ' CA ' ' A' ' 16' ' ' GLY . 56.6 ttm -68.13 -30.65 69.84 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.364 -0.835 . . . . 0.0 110.339 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.0 -71.8 0.06 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.553 -0.717 . . . . 0.0 111.53 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 37.2 mt-30 -69.97 -40.1 75.6 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.285 -0.884 . . . . 0.0 109.99 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.623 ' CD2' HG23 ' A' ' 37' ' ' VAL . 66.5 m-85 -123.16 95.07 46.29 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.843 -0.536 . . . . 0.0 110.049 -179.168 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.02 -18.75 27.32 Favored 'Trans proline' 0 C--N 1.318 -1.054 0 O-C-N 123.411 1.216 . . . . 0.0 111.483 -179.215 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.5 m -121.39 149.32 43.16 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.257 -0.902 . . . . 0.0 110.435 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 1.096 HD11 HG21 ' A' ' 43' ' ' VAL . 34.1 tp -70.64 119.89 15.46 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.793 -0.567 . . . . 0.0 110.422 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.29 33.46 0.05 OUTLIER Glycine 0 N--CA 1.495 2.609 0 C-N-CA 120.104 -1.046 . . . . 0.0 110.593 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 1.6 mt-10 -157.71 -49.91 0.07 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.206 -1.173 . . . . 0.0 110.422 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -60.1 -58.61 18.11 Favored Pre-proline 0 N--CA 1.502 2.125 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -78.54 -29.23 3.84 Favored 'Trans proline' 0 N--CA 1.486 1.079 0 N-CA-C 109.008 -1.189 . . . . 0.0 109.008 176.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 125.4 -64.88 0.56 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 106.676 -2.57 . . . . 0.0 106.676 -178.151 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.559 ' CB ' ' HD3' ' A' ' 41' ' ' PRO . 0.1 OUTLIER 167.98 -58.88 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.377 0 O-C-N 122.277 -0.543 . . . . 0.0 109.962 177.091 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.719 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 53.4 Cg_endo -95.57 16.87 0.83 Allowed 'Trans proline' 0 C--N 1.325 -0.68 0 O-C-N 123.071 1.037 . . . . 0.0 109.806 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -123.32 38.8 4.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.469 -0.769 . . . . 0.0 109.526 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.096 HG21 HD11 ' A' ' 34' ' ' LEU . 14.8 p -127.89 140.87 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.527 0.679 . . . . 0.0 110.915 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.68 175.18 42.69 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -89.46 161.76 30.13 Favored Glycine 0 N--CA 1.498 2.807 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.732 HG23 ' O ' ' A' ' 45' ' ' GLY . 0.5 OUTLIER -161.26 164.79 18.01 Favored Pre-proline 0 N--CA 1.503 2.21 0 CA-C-N 118.457 1.128 . . . . 0.0 111.422 -179.097 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.24 -22.27 25.79 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 121.439 1.426 . . . . 0.0 114.593 -177.478 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -83.94 3.25 34.95 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.382 -1.449 . . . . 0.0 112.762 -177.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.61 HG23 ' CB ' ' A' ' 54' ' ' SER . 45.6 mm -97.38 128.94 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.37 -51.01 7.29 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.409 -0.807 . . . . 0.0 111.961 -178.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.819 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.68 -135.94 3.3 Favored Glycine 0 N--CA 1.487 2.098 0 C-N-CA 118.882 -1.628 . . . . 0.0 111.241 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.458 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 9.4 t90 -42.74 -27.22 0.16 Allowed 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.411 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 47.2 m-20 -147.0 62.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.208 -0.932 . . . . 0.0 110.901 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.61 ' CB ' HG23 ' A' ' 49' ' ' ILE . 5.1 p -56.96 132.9 79.91 Favored Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.436 -0.79 . . . . 0.0 110.461 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.63 -21.16 22.38 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 O-C-N 123.252 1.133 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 38.8 m -96.15 9.47 40.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.456 -0.777 . . . . 0.0 111.043 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -64.0 141.65 58.69 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.327 -0.858 . . . . 0.0 110.265 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 95.33 -24.97 26.64 Favored Glycine 0 N--CA 1.5 2.933 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 178.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.1 m -56.93 161.32 3.02 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.257 -1.143 . . . . 0.0 110.622 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.431 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.5 t -113.46 152.32 30.28 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.969 -0.457 . . . . 0.0 111.307 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.432 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 52.6 m95 -142.53 149.04 38.58 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.241 -0.912 . . . . 0.0 110.75 178.029 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 36.3 tttp -110.71 129.56 55.8 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.2 t -110.9 129.75 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.316 -0.865 . . . . 0.0 110.383 -178.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.5 m -121.12 140.18 52.33 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.842 -0.536 . . . . 0.0 111.381 -178.544 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.2 pt -119.27 164.65 20.3 Favored Pre-proline 0 N--CA 1.5 2.057 0 O-C-N 121.499 -0.751 . . . . 0.0 110.311 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.1 Cg_endo -63.5 -24.07 70.61 Favored 'Trans proline' 0 N--CA 1.495 1.613 0 O-C-N 123.404 1.213 . . . . 0.0 112.593 -178.562 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.3 t-20 -64.47 -39.99 94.86 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.237 -0.915 . . . . 0.0 109.61 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.65 60.56 0.32 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -159.99 150.78 19.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.704 -0.88 . . . . 0.0 109.145 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.446 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.8 m -149.4 157.38 43.26 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 121.992 0.901 . . . . 0.0 112.029 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.863 HG12 HD13 ' A' ' 93' ' ' LEU . 36.8 pt -140.06 165.84 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.8 m-85 -107.61 130.25 54.91 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.128 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.11 130.04 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.691 -0.631 . . . . 0.0 110.726 -178.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.521 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.4 ttt180 -101.24 135.33 42.88 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.176 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.711 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.24 149.34 47.92 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.124 -1.036 . . . . 0.0 111.386 -177.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.48 HG11 HG22 ' A' ' 43' ' ' VAL . 2.6 p -152.63 -45.75 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.577 ' HB2' HG23 ' A' ' 18' ' ' VAL . 10.3 t70 -129.49 169.04 15.46 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.34 -0.85 . . . . 0.0 109.517 179.177 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 82.9 p -103.9 159.94 15.23 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.604 -0.685 . . . . 0.0 110.111 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.52 156.64 21.96 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -60.03 -35.78 75.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.674 -0.898 . . . . 0.0 109.109 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -171.32 177.55 44.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 51.54 -168.32 0.56 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 121.355 -1.085 . . . . 0.0 111.567 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.706 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.4 m-85 -120.0 139.06 53.06 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.965 -0.727 . . . . 0.0 109.15 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 4' ' ' SER . 33.4 t-20 -129.29 128.48 43.28 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.052 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.3 m -130.72 172.07 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.088 -1.008 . . . . 0.0 112.025 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -55.84 152.77 18.8 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.29 -0.881 . . . . 0.0 109.663 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.36 -21.35 61.22 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 O-C-N 123.386 1.203 . . . . 0.0 110.732 -179.449 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.2 m -78.76 -40.04 34.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.928 -1.107 . . . . 0.0 109.33 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.719 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.68 -40.03 88.38 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 178.667 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -60.01 -49.87 75.99 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.794 -0.566 . . . . 0.0 110.447 179.088 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -59.99 -38.74 83.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.583 -0.698 . . . . 0.0 110.661 -178.539 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -69.87 -39.87 76.06 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.141 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.863 HD13 HG12 ' A' ' 71' ' ' ILE . 61.2 tp -70.14 -43.97 69.82 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.507 -0.746 . . . . 0.0 111.283 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.51 -39.88 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.298 -0.876 . . . . 0.0 111.461 -178.094 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 119.89 -35.19 3.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 64.2 m -140.03 150.83 44.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.525 -0.985 . . . . 0.0 110.889 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.8 p -89.57 3.74 51.56 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.516 -0.74 . . . . 0.0 110.627 179.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -70.08 -28.32 65.33 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.441 -0.787 . . . . 0.0 110.951 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.17 -40.03 84.37 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.456 -0.777 . . . . 0.0 110.417 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.57 -79.6 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 37.0 ttm180 -129.85 132.69 46.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.659 -0.906 . . . . 0.0 110.219 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.5 t -119.34 120.06 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.396 -0.815 . . . . 0.0 110.276 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASP . . . . . 0.4 ' O ' ' HB2' ' A' ' 104' ' ' ASN . 9.3 t70 -85.05 173.11 10.75 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.42 0.629 . . . . 0.0 110.876 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 94.9 m-20 60.04 39.97 19.19 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-O 121.091 0.472 . . . . 0.0 111.569 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.636 HG11 HG21 ' A' ' 3' ' ' ILE . 63.0 t -86.95 122.58 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -82.25 134.58 35.29 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.173 -1.011 . . . . 0.0 109.425 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.8 p90 -136.28 142.72 43.97 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.325 0.583 . . . . 0.0 111.323 -178.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -144.07 140.05 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.731 -0.606 . . . . 0.0 110.184 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -71.43 140.75 50.2 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.698 . . . . 0.0 110.422 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.431 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.2 m -136.57 173.26 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.829 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -61.12 149.67 36.54 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.386 -0.822 . . . . 0.0 110.833 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.571 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -59.98 -39.3 85.21 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.456 -0.778 . . . . 0.0 110.794 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 62.8 m -53.85 -39.44 65.63 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 110.226 -178.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -60.25 -39.3 86.24 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.606 -0.684 . . . . 0.0 110.988 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -59.97 -49.37 77.94 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.238 -0.914 . . . . 0.0 110.059 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.571 HD11 HD21 ' A' ' 112' ' ' LEU . 85.7 mt -69.84 -40.03 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.704 -0.622 . . . . 0.0 110.57 -179.163 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.18 -40.0 95.18 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.342 -0.849 . . . . 0.0 110.316 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.45 -39.97 79.65 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.26 -39.96 88.62 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.604 -0.939 . . . . 0.0 110.276 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.194 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.863 0.363 . . . . 0.0 110.66 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.3 m -110.95 141.73 44.0 Favored 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.832 0.825 . . . . 0.0 111.332 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.512 HG21 HG11 ' A' ' 105' ' ' VAL . 45.8 pt -119.93 149.94 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.89 -0.507 . . . . 0.0 110.407 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.409 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 67.6 m -143.97 -174.08 4.17 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -141.5 150.0 41.63 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.362 -0.836 . . . . 0.0 110.538 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -132.88 144.73 54.07 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.609 -0.682 . . . . 0.0 109.543 179.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.6 -4.46 14.13 Favored 'Trans proline' 0 C--N 1.317 -1.11 0 O-C-N 123.381 1.201 . . . . 0.0 112.405 -178.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.661 HD11 ' CZ ' ' A' ' 9' ' ' TYR . 33.9 pt -69.99 -40.03 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 120.899 -1.126 . . . . 0.0 110.439 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.661 ' CZ ' HD11 ' A' ' 8' ' ' ILE . 30.8 m-85 -74.52 66.66 1.42 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 122.815 1.293 . . . . 0.0 110.611 -178.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.72 171.62 7.26 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 114.307 -1.315 . . . . 0.0 108.458 177.145 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.83 -34.47 73.13 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -175.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -89.1 10.1 23.03 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.45 -1.406 . . . . 0.0 111.966 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.478 HD22 ' O ' ' A' ' 8' ' ' ILE . 58.7 tp -71.16 122.87 20.93 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.359 -0.838 . . . . 0.0 109.431 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.3 m -68.89 136.84 53.25 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.705 0.764 . . . . 0.0 110.199 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.617 ' O ' HG12 ' A' ' 18' ' ' VAL . 89.4 mmm -65.58 -16.98 64.23 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.471 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.57 -16.59 77.65 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.012 -1.055 . . . . 0.0 111.069 -179.208 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 79.6 p -90.33 -17.65 26.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.138 -1.213 . . . . 0.0 111.256 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.896 HG23 ' OD1' ' A' ' 77' ' ' ASP . 7.6 p -89.97 155.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.333 -0.854 . . . . 0.0 109.598 -179.528 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.619 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -48.41 -40.02 24.53 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.513 -0.742 . . . . 0.0 110.406 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.29 82.59 4.58 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -92.51 -83.41 0.3 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.895 -1.128 . . . . 0.0 112.596 -177.486 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.424 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 60.3 t30 -154.5 18.02 0.47 Allowed 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.802 -1.186 . . . . 0.0 112.339 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.06 -141.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -70.13 -42.56 72.45 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.692 -0.887 . . . . 0.0 109.634 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.664 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 8.2 p80 -97.31 4.48 50.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.477 -0.765 . . . . 0.0 110.861 -179.715 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.56 144.43 37.42 Favored Glycine 0 N--CA 1.494 2.541 0 O-C-N 121.14 -0.975 . . . . 0.0 110.734 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 94.5 mt -99.58 -3.05 34.16 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.825 -0.809 . . . . 0.0 110.539 179.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.407 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.3 tpp -60.12 -36.39 77.38 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.562 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.89 -77.79 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.423 -0.798 . . . . 0.0 111.977 -177.55 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -69.98 -39.99 75.63 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.38 -0.825 . . . . 0.0 111.053 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.506 ' CD2' HG23 ' A' ' 37' ' ' VAL . 68.1 m-85 -119.99 88.44 40.65 Favored Pre-proline 0 N--CA 1.493 1.698 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.7 Cg_endo -68.59 -16.51 42.65 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.353 1.186 . . . . 0.0 111.51 -178.795 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.5 m -125.6 140.21 52.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.214 -0.929 . . . . 0.0 110.308 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.658 HD21 HG21 ' A' ' 43' ' ' VAL . 51.2 tp -68.55 119.74 13.47 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.68 -0.637 . . . . 0.0 110.65 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.31 32.78 0.04 OUTLIER Glycine 0 N--CA 1.497 2.713 0 C-N-CA 119.96 -1.114 . . . . 0.0 110.782 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 -156.14 -49.55 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.161 -1.199 . . . . 0.0 110.603 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.506 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.4 t -61.18 -59.64 13.1 Favored Pre-proline 0 N--CA 1.499 2.008 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.453 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 48.5 Cg_endo -75.38 -31.76 5.5 Favored 'Trans proline' 0 C--N 1.318 -1.075 0 N-CA-C 108.872 -1.241 . . . . 0.0 108.872 177.64 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.438 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.69 -64.22 0.62 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 107.316 -2.314 . . . . 0.0 107.316 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.539 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 163.54 -68.32 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.645 0 C-N-CA 123.533 0.733 . . . . 0.0 109.555 177.428 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.539 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.4 Cg_endo -80.41 -0.54 10.71 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 O-C-N 122.734 0.86 . . . . 0.0 111.423 179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -109.95 57.18 0.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.195 -0.94 . . . . 0.0 109.449 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.658 HG21 HD21 ' A' ' 34' ' ' LEU . 11.4 p -129.62 135.66 60.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-O 121.551 0.691 . . . . 0.0 110.557 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.698 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -165.12 173.01 40.91 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.94 163.79 28.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.802 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -143.73 157.02 59.2 Favored Pre-proline 0 N--CA 1.495 1.81 0 O-C-N 121.698 -0.884 . . . . 0.0 110.19 179.336 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.48 -9.26 25.48 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.567 1.511 . . . . 0.0 113.044 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -99.01 28.16 4.58 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.918 -1.114 . . . . 0.0 112.239 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.576 HD11 HD11 ' A' ' 46' ' ' ILE . 48.6 mm -119.58 121.57 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.085 -1.01 . . . . 0.0 109.36 179.185 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.5 -43.01 57.94 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.323 -0.86 . . . . 0.0 111.487 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.619 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 163.96 -133.33 2.99 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 119.296 -1.43 . . . . 0.0 111.141 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.483 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.4 t90 -51.11 -23.69 3.39 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -178.77 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.664 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 21.5 t70 -143.99 64.4 1.32 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.362 -0.836 . . . . 0.0 110.427 -178.846 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.601 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 44.0 m -79.37 142.36 58.34 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.431 -0.793 . . . . 0.0 111.03 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.47 -19.27 15.02 Favored 'Trans proline' 0 C--N 1.317 -1.119 0 O-C-N 123.421 1.222 . . . . 0.0 111.031 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.44 9.86 42.17 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.228 -0.92 . . . . 0.0 112.109 -178.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.465 ' HB3' ' ND1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -72.06 154.09 41.33 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.912 -1.117 . . . . 0.0 108.776 178.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.403 ' HA2' ' CZ ' ' A' ' 74' ' ' ARG . . . 78.61 10.02 86.55 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 96.3 m -99.88 139.96 34.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.306 -1.114 . . . . 0.0 109.706 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.4 m -80.12 143.59 33.78 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.299 0.571 . . . . 0.0 111.063 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 70.1 m95 -145.39 133.64 21.68 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.443 -0.785 . . . . 0.0 109.871 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -108.53 141.55 40.26 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.181 -0.949 . . . . 0.0 110.571 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 HG11 ' A' ' 105' ' ' VAL . 62.4 t -112.95 127.89 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 CA-C-O 121.385 0.612 . . . . 0.0 110.977 -179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 m -120.03 143.5 48.05 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.702 -0.624 . . . . 0.0 110.254 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.468 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 9.5 pt -120.74 164.15 24.97 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.171 -0.955 . . . . 0.0 111.218 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.468 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.2 Cg_endo -61.49 -26.24 80.71 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 121.682 1.588 . . . . 0.0 113.067 -178.658 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -63.42 -35.67 81.18 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.227 -0.921 . . . . 0.0 109.761 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.59 63.17 0.46 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.423 ' O ' HD11 ' A' ' 93' ' ' LEU . 40.4 t-20 -164.42 157.23 17.15 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.774 -0.839 . . . . 0.0 109.209 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 73.9 p -154.74 159.74 40.88 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 122.025 0.917 . . . . 0.0 111.515 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.482 HD12 HD11 ' A' ' 73' ' ' ILE . 21.7 pt -133.61 164.27 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -103.61 125.0 49.86 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 118.319 -1.353 . . . . 0.0 109.895 -178.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.482 HD11 HD12 ' A' ' 71' ' ' ILE . 48.4 mm -119.78 123.54 71.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.621 -0.674 . . . . 0.0 109.911 -178.749 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.403 ' CZ ' ' HA2' ' A' ' 58' ' ' GLY . 0.0 OUTLIER -93.69 133.66 36.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.406 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -54.8 144.77 30.28 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.698 HG12 ' O ' ' A' ' 44' ' ' GLY . 13.4 p -168.35 -28.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.802 -0.822 . . . . 0.0 111.138 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.896 ' OD1' HG23 ' A' ' 18' ' ' VAL . 5.4 m-20 -126.07 170.0 12.2 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.721 -1.237 . . . . 0.0 110.258 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.406 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.5 t -101.4 151.92 21.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.7 -0.625 . . . . 0.0 110.686 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.73 144.32 16.24 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.084 -1.207 . . . . 0.0 110.084 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -60.66 -31.45 70.68 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.78 -0.835 . . . . 0.0 109.978 178.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.65 80.81 0.05 OUTLIER Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.72 -176.94 29.07 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.802 ' CD2' HG22 ' A' ' 46' ' ' ILE . 57.7 m-85 -113.17 130.96 56.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.438 -1.036 . . . . 0.0 109.58 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.409 ' HA ' ' O ' ' A' ' 4' ' ' SER . 36.8 t-20 -120.88 130.96 54.13 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.412 HG11 HG13 ' A' ' 73' ' ' ILE . 34.7 m -130.22 171.8 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.175 -0.953 . . . . 0.0 112.258 -177.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.2 m-20 -54.07 155.83 6.04 Favored Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.588 -0.695 . . . . 0.0 110.321 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.86 -18.12 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.409 1.215 . . . . 0.0 110.761 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.6 m -80.82 -39.76 26.09 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.965 -1.085 . . . . 0.0 109.208 178.575 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.37 -39.08 85.65 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' PHE . . . . . 0.478 ' CE1' ' HA ' ' A' ' 97' ' ' THR . 25.3 t80 -59.99 -50.0 75.44 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.634 -0.666 . . . . 0.0 110.762 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.773 HG23 ' HA ' ' A' ' 96' ' ' SER . 94.4 m -59.98 -38.95 84.02 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.58 -0.7 . . . . 0.0 111.103 -178.496 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -64.63 -40.02 94.74 Favored 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.962 -0.695 . . . . 0.0 111.562 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.423 HD11 ' O ' ' A' ' 69' ' ' ASN . 59.8 tp -69.03 -42.54 76.22 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.637 -0.665 . . . . 0.0 111.9 -178.559 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 49.0 t -100.25 -9.98 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.302 0 O-C-N 121.228 -0.92 . . . . 0.0 111.927 -178.286 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 99.5 -29.27 12.3 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 -178.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.773 ' HA ' HG23 ' A' ' 91' ' ' THR . 97.1 p -155.62 159.84 39.96 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.478 ' HA ' ' CE1' ' A' ' 90' ' ' PHE . 2.8 t -109.06 24.69 12.76 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.113 -0.992 . . . . 0.0 111.086 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -73.82 -22.83 59.66 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.555 -0.715 . . . . 0.0 111.067 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.95 -44.8 94.18 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.365 -0.834 . . . . 0.0 110.971 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.15 -68.07 0.53 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -140.25 135.52 32.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.946 . . . . 0.0 110.383 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 68.6 t -119.57 119.7 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -0.824 . . . . 0.0 110.155 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.9 p-10 -87.95 175.07 7.95 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-O 121.563 0.697 . . . . 0.0 111.181 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.3 t30 59.98 40.86 18.34 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.705 -0.622 . . . . 0.0 110.943 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.512 HG11 HG21 ' A' ' 3' ' ' ILE . 91.3 t -93.86 121.38 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.992 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -79.91 139.77 36.97 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 119.353 -0.939 . . . . 0.0 109.299 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.45 ' C ' HG13 ' A' ' 108' ' ' VAL . 41.1 p90 -136.67 142.22 43.17 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.864 -0.523 . . . . 0.0 110.517 -179.346 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.45 HG13 ' C ' ' A' ' 107' ' ' TYR . 34.8 m -148.33 150.35 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.616 -0.678 . . . . 0.0 110.581 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 61.2 tt0 -90.19 138.81 31.22 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.542 -0.724 . . . . 0.0 110.516 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.49 177.46 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.591 -0.693 . . . . 0.0 110.257 179.318 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.91 142.96 52.7 Favored 'General case' 0 N--CA 1.496 1.84 0 CA-C-O 121.582 0.706 . . . . 0.0 110.952 -178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.535 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.5 tt -60.11 -38.42 82.96 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.814 -0.554 . . . . 0.0 110.769 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 83.3 p -54.31 -37.01 64.33 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.561 -0.712 . . . . 0.0 111.359 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -70.07 -19.94 63.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.432 -0.793 . . . . 0.0 110.506 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 28.2 m -73.63 -52.17 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.483 HD11 HD21 ' A' ' 112' ' ' LEU . 86.5 mt -70.0 -39.99 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.523 -179.315 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -69.67 -40.0 76.69 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 120.025 -0.67 . . . . 0.0 110.108 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.27 -53.02 19.58 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.597 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -44.52 94.52 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.523 -0.987 . . . . 0.0 110.582 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.216 -179.901 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.089 0.471 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -113.28 140.48 47.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.742 -0.599 . . . . 0.0 109.958 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.774 HG23 HG21 ' A' ' 105' ' ' VAL . 38.5 pt -104.61 145.41 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.649 -0.657 . . . . 0.0 110.055 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 1.5 m -145.72 -171.6 3.72 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 51.7 p90 -146.16 150.0 35.04 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.41 179.199 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -129.01 146.17 59.62 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.616 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -81.07 -8.05 13.09 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.264 1.139 . . . . 0.0 112.449 -178.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.505 HG13 ' N ' ' A' ' 9' ' ' TYR . 37.5 pt -67.92 -40.09 82.83 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 120.889 -1.132 . . . . 0.0 110.789 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.66 ' HA ' HD22 ' A' ' 13' ' ' LEU . 52.3 m-85 -72.77 67.71 0.82 Allowed 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 122.9 1.333 . . . . 0.0 111.443 -178.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.1 171.1 7.49 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.065 176.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.94 -33.92 71.15 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -175.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -91.09 11.56 22.74 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.599 -1.313 . . . . 0.0 112.354 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.66 HD22 ' HA ' ' A' ' 9' ' ' TYR . 35.3 tp -70.02 123.37 21.38 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.289 -0.882 . . . . 0.0 109.844 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.26 136.12 49.59 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.642 0.734 . . . . 0.0 110.078 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.788 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -68.81 -16.68 63.85 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.979 -0.451 . . . . 0.0 111.869 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.77 -14.67 70.44 Favored Glycine 0 N--CA 1.495 2.586 0 O-C-N 120.917 -1.115 . . . . 0.0 111.309 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.2 t -91.05 -8.01 50.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.129 -1.218 . . . . 0.0 112.051 -178.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 15' ' ' MET . 8.6 p -96.01 167.82 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.107 -0.996 . . . . 0.0 110.26 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.784 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.39 -44.49 92.76 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.51 -0.744 . . . . 0.0 109.988 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.4 m -81.76 81.75 7.68 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.522 -0.736 . . . . 0.0 109.112 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -101.29 -79.57 0.51 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.619 -0.676 . . . . 0.0 112.594 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -131.6 10.18 4.73 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.282 -0.886 . . . . 0.0 112.723 -178.258 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.449 ' HA2' ' CH2' ' A' ' 52' ' ' TRP . . . -73.61 -148.27 1.17 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -64.7 -39.92 94.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 110.865 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.566 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 44.8 m80 -101.16 15.87 27.31 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.331 -0.856 . . . . 0.0 111.231 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.69 131.32 51.99 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.592 HD22 HG21 ' A' ' 37' ' ' VAL . 83.2 mt -97.46 -4.83 37.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.903 -0.763 . . . . 0.0 110.466 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 38.3 tpp -60.87 -34.7 75.02 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.331 -0.855 . . . . 0.0 110.635 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.69 -76.75 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.48 -0.762 . . . . 0.0 111.96 -177.518 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -69.91 -39.99 75.86 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.433 -0.792 . . . . 0.0 110.367 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.522 ' CD2' HG23 ' A' ' 37' ' ' VAL . 58.0 m-85 -120.99 93.3 48.84 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.648 -0.658 . . . . 0.0 109.981 -179.683 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.07 -10.65 27.86 Favored 'Trans proline' 0 C--N 1.318 -1.069 0 O-C-N 123.413 1.217 . . . . 0.0 111.132 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.3 p -126.83 154.04 44.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.326 -0.859 . . . . 0.0 110.269 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 1.003 HD11 HG21 ' A' ' 43' ' ' VAL . 40.1 tp -78.09 116.03 18.25 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.51 34.0 0.03 OUTLIER Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.76 -48.04 0.07 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 110.613 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.592 HG21 HD22 ' A' ' 27' ' ' LEU . 2.2 t -61.33 -57.78 23.21 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 108.591 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.493 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.7 Cg_endo -78.8 -28.4 4.13 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 O-C-N 123.307 1.161 . . . . 0.0 109.485 178.179 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.83 -61.13 0.65 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 107.503 -2.239 . . . . 0.0 107.503 -178.616 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 163.24 -54.78 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.605 0 C-N-CA 123.414 0.685 . . . . 0.0 110.042 177.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.38 15.28 0.3 Allowed 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 121.563 1.509 . . . . 0.0 111.448 -178.398 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -125.37 39.9 3.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.358 -0.839 . . . . 0.0 109.244 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.003 HG21 HD11 ' A' ' 34' ' ' LEU . 9.4 p -123.66 147.52 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 CA-C-O 121.674 0.749 . . . . 0.0 110.264 -178.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.467 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -174.48 175.97 46.79 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.94 149.41 37.82 Favored Glycine 0 N--CA 1.484 1.839 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.466 HG13 HG12 ' A' ' 49' ' ' ILE . 1.1 pp -142.37 139.19 17.29 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.545 -0.974 . . . . 0.0 108.847 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -58.89 -10.51 9.91 Favored 'Trans proline' 0 N--CA 1.505 2.202 0 C-N-CA 122.046 1.831 . . . . 0.0 115.261 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.428 ' H ' HD12 ' A' ' 46' ' ' ILE . 84.3 m-20 -96.19 30.63 2.41 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 120.529 -1.357 . . . . 0.0 111.899 -178.44 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.571 HG23 ' HB2' ' A' ' 54' ' ' SER . 50.8 mm -119.99 125.99 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.142 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.82 -44.62 15.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.551 -0.718 . . . . 0.0 111.78 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.784 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 172.11 -130.6 1.96 Allowed Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.406 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.449 ' CH2' ' HA2' ' A' ' 23' ' ' GLY . 5.5 t90 -40.21 -30.04 0.09 Allowed 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 -177.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -158.97 72.98 0.59 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.689 -1.257 . . . . 0.0 110.83 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.571 ' HB2' HG23 ' A' ' 49' ' ' ILE . 4.0 t -54.53 140.32 57.19 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.671 -0.643 . . . . 0.0 111.317 -178.887 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.566 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -72.81 -20.42 22.61 Favored 'Trans proline' 0 C--N 1.319 -1.006 0 O-C-N 123.412 1.217 . . . . 0.0 110.558 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 59' ' ' THR . 18.9 m -103.93 14.85 29.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.347 -0.846 . . . . 0.0 111.294 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.412 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 5.0 t -67.74 144.68 55.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.117 -0.99 . . . . 0.0 110.383 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.13 8.31 82.06 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 56' ' ' SER . 25.8 p -80.6 159.71 25.33 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.536 ' SG ' HG23 ' A' ' 110' ' ' VAL . 41.9 t -110.79 137.54 48.32 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.789 -178.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 81.9 m95 -142.96 155.88 44.77 Favored 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.12 -0.988 . . . . 0.0 111.394 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 68.7 tttt -112.18 132.25 55.0 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 177.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.05 129.9 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.557 -0.715 . . . . 0.0 109.723 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.3 m -120.68 142.18 49.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.749 -0.595 . . . . 0.0 111.362 -178.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 48.0 pt -119.74 164.37 22.4 Favored Pre-proline 0 N--CA 1.499 2.022 0 O-C-N 121.496 -0.753 . . . . 0.0 110.209 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.35 -26.02 76.72 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.174 1.25 . . . . 0.0 112.891 -178.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -64.76 -39.96 94.48 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.218 -0.926 . . . . 0.0 109.907 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.1 60.75 0.29 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -160.45 153.51 21.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.603 -0.939 . . . . 0.0 109.339 178.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.45 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 88.0 p -151.71 159.68 43.89 Favored 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 122.12 0.962 . . . . 0.0 112.149 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.462 HG12 HD13 ' A' ' 93' ' ' LEU . 43.8 pt -139.91 164.13 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.268 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -105.27 127.18 52.81 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 118.86 -1.136 . . . . 0.0 109.784 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -115.89 130.03 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.627 -0.671 . . . . 0.0 110.134 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.513 ' HD3' HG12 ' A' ' 37' ' ' VAL . 51.4 ttt180 -100.67 136.91 39.79 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.407 ' HA2' HG12 ' A' ' 46' ' ' ILE . . . -59.64 149.71 39.8 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.947 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.727 HG11 ' CG2' ' A' ' 43' ' ' VAL . 7.0 p -167.47 -35.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.809 -0.818 . . . . 0.0 110.635 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.57 ' OD2' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -129.89 174.48 9.7 Favored 'General case' 0 N--CA 1.508 2.435 0 O-C-N 120.748 -1.22 . . . . 0.0 108.948 179.465 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 36.9 t -98.59 143.14 29.31 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.357 -0.84 . . . . 0.0 110.535 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -107.89 140.29 15.38 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 -81.96 58.2 3.8 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.724 -0.868 . . . . 0.0 111.589 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.99 58.17 1.62 Allowed Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.719 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 151.15 5.42 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.791 -1.195 . . . . 0.0 110.386 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -73.68 145.18 45.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.866 -0.785 . . . . 0.0 110.963 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.455 ' HA ' ' O ' ' A' ' 4' ' ' SER . 19.7 t-20 -139.55 130.69 26.55 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.423 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.467 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.1 m -132.28 172.5 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.057 -1.027 . . . . 0.0 112.202 -178.379 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.7 m-20 -54.69 150.8 16.81 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.275 -0.891 . . . . 0.0 109.823 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.43 -18.3 63.96 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.321 1.169 . . . . 0.0 110.656 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 86.1 m -78.73 -40.01 34.7 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.934 -1.104 . . . . 0.0 109.376 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.34 -39.11 82.0 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.509 -0.744 . . . . 0.0 109.107 179.15 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -59.99 -49.93 75.75 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.767 -0.583 . . . . 0.0 110.704 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.8 m -60.05 -37.37 79.63 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.406 -0.809 . . . . 0.0 110.623 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -70.0 -39.96 75.58 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.043 -179.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.462 HD13 HG12 ' A' ' 71' ' ' ILE . 52.7 tp -70.01 -44.25 69.73 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.569 -0.707 . . . . 0.0 111.428 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 63.0 t -96.37 -39.92 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.304 -0.873 . . . . 0.0 111.561 -177.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.53 -29.43 4.99 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.7 p -152.66 160.65 43.16 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.461 -1.023 . . . . 0.0 110.457 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 72.7 p -94.62 8.17 43.25 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.532 -0.73 . . . . 0.0 110.857 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -69.15 -36.07 77.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.42 -0.8 . . . . 0.0 110.677 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.75 87.0 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.525 -0.735 . . . . 0.0 110.284 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.38 -63.54 3.64 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 21.3 ptt180 -150.8 157.59 43.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.673 -0.898 . . . . 0.0 110.745 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 105' ' ' VAL . 62.2 t -128.09 122.26 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.553 -0.717 . . . . 0.0 110.223 179.397 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -82.87 169.12 16.43 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.603 -0.686 . . . . 0.0 110.961 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t30 60.01 43.22 14.84 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.62 -0.675 . . . . 0.0 111.306 179.315 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.774 HG21 HG23 ' A' ' 3' ' ' ILE . 63.7 t -87.21 130.02 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 C-N-CA 120.06 -0.656 . . . . 0.0 109.966 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -87.19 139.43 30.57 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.804 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -139.9 144.32 37.1 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.914 -0.491 . . . . 0.0 111.173 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.95 143.2 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.529 -0.732 . . . . 0.0 110.734 179.53 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 66.1 tt0 -75.72 134.33 40.54 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.603 -0.685 . . . . 0.0 110.009 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.536 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.9 m -131.34 172.7 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.554 -0.716 . . . . 0.0 110.237 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -60.11 146.07 44.47 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.513 -0.742 . . . . 0.0 110.986 -179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.695 HD21 HD11 ' A' ' 116' ' ' ILE . 10.1 tt -60.96 -37.22 81.64 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.621 -0.674 . . . . 0.0 110.796 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.8 m -55.23 -40.07 70.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.51 -0.744 . . . . 0.0 110.221 -178.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -59.98 -37.41 79.55 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.731 -0.606 . . . . 0.0 110.317 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -63.32 -46.65 85.67 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.369 -0.832 . . . . 0.0 110.116 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.695 HD11 HD21 ' A' ' 112' ' ' LEU . 88.0 mt -70.02 -40.01 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.554 -0.717 . . . . 0.0 110.738 -178.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -66.88 -40.06 87.67 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.468 -0.77 . . . . 0.0 110.498 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.85 -48.08 51.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.97 94.34 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.598 -0.942 . . . . 0.0 110.603 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 118.047 -0.977 . . . . 0.0 110.265 -179.894 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.205 0.526 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t -111.18 137.72 48.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.628 -0.67 . . . . 0.0 109.3 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.642 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.1 pt -113.98 147.7 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.729 -0.607 . . . . 0.0 111.018 -179.096 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.06 -170.09 3.34 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -141.82 148.1 38.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.41 -0.806 . . . . 0.0 110.337 178.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -127.05 148.61 66.52 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.46 -0.775 . . . . 0.0 109.825 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -82.57 -7.43 11.63 Favored 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.391 1.206 . . . . 0.0 112.367 -179.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 27.4 pt -72.93 -42.29 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.139 0 O-C-N 120.933 -1.104 . . . . 0.0 110.885 -179.025 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 31.9 m-85 -72.29 67.18 0.68 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 122.651 1.215 . . . . 0.0 111.049 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.55 171.05 7.58 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.327 176.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -60.04 -34.16 73.02 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -175.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -90.05 10.62 23.51 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.416 -1.314 . . . . 0.0 112.136 -177.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.45 HD22 ' HA ' ' A' ' 9' ' ' TYR . 53.4 tp -71.02 126.05 28.53 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 178.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.1 t -69.95 136.02 50.07 Favored 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.791 0.805 . . . . 0.0 110.454 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.741 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -66.43 -19.07 65.7 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.436 -179.189 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.27 -14.06 63.48 Favored Glycine 0 N--CA 1.493 2.456 0 O-C-N 121.044 -1.035 . . . . 0.0 110.776 -179.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.9 m -93.16 -14.59 26.97 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -1.161 . . . . 0.0 111.796 -178.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.828 HG23 ' OD2' ' A' ' 77' ' ' ASP . 7.2 p -90.04 160.04 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 120.996 -1.065 . . . . 0.0 110.708 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.59 -42.63 83.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.699 -0.626 . . . . 0.0 110.565 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.0 m -81.64 72.89 8.7 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -101.78 -76.59 0.57 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.705 -0.622 . . . . 0.0 110.628 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -127.27 168.87 14.16 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.108 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.35 -154.81 16.49 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.52 -2.232 . . . . 0.0 107.52 -177.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -70.2 -39.92 74.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.292 -1.122 . . . . 0.0 110.271 179.186 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.461 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 19.2 m80 -94.09 0.71 56.04 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.454 -0.779 . . . . 0.0 111.194 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.59 127.65 37.64 Favored Glycine 0 N--CA 1.495 2.611 0 O-C-N 120.964 -1.085 . . . . 0.0 110.423 -179.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.553 HD13 HG11 ' A' ' 37' ' ' VAL . 84.5 mt -100.04 -5.19 28.44 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 122.012 -0.699 . . . . 0.0 110.072 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.2 ttm -63.04 -37.72 88.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.28 -0.887 . . . . 0.0 109.764 179.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.92 -73.45 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.611 -0.681 . . . . 0.0 111.506 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -69.94 -40.05 75.72 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.157 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CG ' HG23 ' A' ' 37' ' ' VAL . 35.6 m-85 -120.36 89.89 44.44 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.864 -0.523 . . . . 0.0 109.801 -178.508 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.07 -10.01 25.38 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 O-C-N 123.196 1.103 . . . . 0.0 111.049 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 31.0 m -130.01 142.13 50.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.231 -0.918 . . . . 0.0 110.366 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.927 HD11 HG21 ' A' ' 43' ' ' VAL . 35.4 tp -69.94 119.25 13.87 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.642 -0.661 . . . . 0.0 110.405 -179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.76 32.6 0.04 OUTLIER Glycine 0 N--CA 1.497 2.746 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.985 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -156.95 -44.95 0.07 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -1.16 . . . . 0.0 110.096 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.553 HG11 HD13 ' A' ' 27' ' ' LEU . 2.7 t -63.62 -59.03 12.75 Favored Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.552 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.476 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.5 Cg_endo -76.82 -29.22 5.63 Favored 'Trans proline' 0 N--CA 1.487 1.109 0 O-C-N 123.271 1.143 . . . . 0.0 109.55 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 127.63 -61.92 0.64 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.635 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 164.69 -54.74 0.0 OUTLIER Pre-proline 0 N--CA 1.509 2.503 0 C-N-CA 123.368 0.667 . . . . 0.0 109.885 177.386 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.716 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -102.21 11.81 0.39 Allowed 'Trans proline' 0 C--N 1.325 -0.702 0 C-N-CA 121.473 1.448 . . . . 0.0 111.419 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -117.61 31.16 6.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.244 -0.91 . . . . 0.0 110.059 -178.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.963 ' CG2' HG11 ' A' ' 76' ' ' VAL . 15.0 p -110.46 139.92 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.561 0.696 . . . . 0.0 110.943 -179.306 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.504 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.5 173.79 42.59 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.488 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -94.32 163.72 25.38 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.787 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -154.27 162.53 26.7 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.806 -0.82 . . . . 0.0 109.888 179.015 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -67.33 -16.94 49.23 Favored 'Trans proline' 0 N--CA 1.5 1.902 0 C-N-CA 121.502 1.468 . . . . 0.0 113.95 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.546 ' H ' HD12 ' A' ' 46' ' ' ILE . 94.4 m-20 -89.39 15.83 8.53 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.541 -1.349 . . . . 0.0 113.025 -177.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.656 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.0 mm -108.02 122.63 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.201 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.72 -45.47 29.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.305 -0.872 . . . . 0.0 111.664 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.3 -127.81 1.66 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 118.983 -1.58 . . . . 0.0 110.95 -179.487 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.1 t90 -48.92 -26.03 2.25 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.897 -0.767 . . . . 0.0 112.841 -178.734 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -147.27 63.13 1.16 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.169 -0.957 . . . . 0.0 111.379 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.656 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.5 p -63.68 141.72 97.96 Favored Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.359 -0.838 . . . . 0.0 110.87 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.461 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -80.69 -21.74 6.98 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 O-C-N 123.41 1.216 . . . . 0.0 111.599 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.6 m -95.11 11.63 31.5 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.357 -0.84 . . . . 0.0 111.183 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -72.14 146.29 47.54 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.209 -0.932 . . . . 0.0 110.304 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.78 22.83 52.13 Favored Glycine 0 N--CA 1.495 2.568 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.098 178.064 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.1 m -109.29 170.65 7.92 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -1.11 . . . . 0.0 109.009 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 2.1 m -118.96 148.2 43.22 Favored 'General case' 0 N--CA 1.51 2.556 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -177.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.459 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 67.9 m95 -144.34 149.67 36.55 Favored 'General case' 0 N--CA 1.51 2.565 0 O-C-N 121.116 -0.99 . . . . 0.0 110.219 175.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.3 ttpt -101.46 131.2 47.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 176.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.444 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.8 t -108.61 124.47 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.64 -178.581 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 94.3 m -120.03 130.03 54.52 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-O 121.189 0.519 . . . . 0.0 111.42 -178.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.483 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.4 pt -106.85 166.15 11.63 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.789 -0.569 . . . . 0.0 110.492 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.7 Cg_endo -63.92 -27.56 66.77 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 O-C-N 123.347 1.183 . . . . 0.0 112.605 -178.862 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -64.3 -39.92 94.89 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.169 -0.957 . . . . 0.0 109.734 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.46 58.3 0.32 Allowed Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.468 ' HB2' HD11 ' A' ' 65' ' ' ILE . 85.1 m-20 -150.72 147.32 27.19 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 178.373 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 49.1 m -147.25 152.36 38.19 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.859 -1.136 . . . . 0.0 112.652 -179.467 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 93' ' ' LEU . 37.7 pt -140.13 161.66 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.29 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.31 129.76 47.34 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.093 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.0 mm -116.58 129.97 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 109.782 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.416 ' HD3' HG12 ' A' ' 37' ' ' VAL . 58.6 ttt180 -101.32 133.31 46.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.965 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -52.52 149.59 10.06 Favored Glycine 0 N--CA 1.498 2.795 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.963 HG11 ' CG2' ' A' ' 43' ' ' VAL . 14.9 p -174.48 -28.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.652 -0.91 . . . . 0.0 111.121 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.828 ' OD2' HG23 ' A' ' 18' ' ' VAL . 5.2 m-20 -129.75 167.47 18.02 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.717 -1.239 . . . . 0.0 109.422 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 77.7 p -97.84 155.89 16.84 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -0.835 . . . . 0.0 110.771 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.94 139.52 11.01 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -61.04 -39.9 91.56 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.837 -0.802 . . . . 0.0 110.209 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.61 73.53 0.08 OUTLIER Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 155.22 -163.34 31.45 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.89 -1.148 . . . . 0.0 110.298 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.787 ' CD2' HG22 ' A' ' 46' ' ' ILE . 39.8 m-85 -125.63 121.56 33.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.919 -0.753 . . . . 0.0 109.113 179.787 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -116.08 130.24 56.71 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.504 HG12 ' HA3' ' A' ' 44' ' ' GLY . 26.9 m -129.18 173.47 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -178.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.9 m-20 -56.53 158.2 8.55 Favored Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.544 -0.722 . . . . 0.0 110.021 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.83 -28.66 36.13 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.453 1.238 . . . . 0.0 111.06 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -70.03 -39.96 75.44 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.993 -1.067 . . . . 0.0 109.26 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.716 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.87 -41.31 87.47 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.645 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.64 -50.0 75.27 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.804 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -60.18 -40.04 88.58 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.515 -0.741 . . . . 0.0 110.839 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.27 -39.56 86.06 Favored 'General case' 0 N--CA 1.495 1.797 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.207 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.463 ' HB2' HD13 ' A' ' 71' ' ' ILE . 65.5 tp -69.95 -41.66 74.25 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.835 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -98.89 -36.65 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.255 -0.903 . . . . 0.0 111.722 -177.695 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.04 -27.43 6.75 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.8 p -153.07 160.46 42.95 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.552 -0.97 . . . . 0.0 109.81 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 60.9 p -90.87 6.82 42.92 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.366 -0.834 . . . . 0.0 110.793 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -69.98 -25.91 63.84 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.31 -0.868 . . . . 0.0 110.87 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.17 77.03 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.466 -0.771 . . . . 0.0 110.949 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.94 -80.46 1.76 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 19.1 ttm180 -137.07 139.94 41.66 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.677 -0.896 . . . . 0.0 110.119 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.24 119.93 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.523 -0.736 . . . . 0.0 110.231 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -90.43 169.7 10.84 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.754 0.787 . . . . 0.0 111.176 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 28.8 t30 59.95 40.05 19.4 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.695 -0.628 . . . . 0.0 111.497 179.349 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.512 HG21 HG12 ' A' ' 3' ' ' ILE . 81.5 t -84.41 126.98 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.709 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -92.58 152.26 19.7 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.13 -1.028 . . . . 0.0 108.87 179.179 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -146.82 150.0 34.43 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.631 -0.668 . . . . 0.0 112.074 -177.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -141.32 134.73 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.745 -0.597 . . . . 0.0 110.097 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.459 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 55.6 tt0 -72.46 141.61 48.6 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.524 0.678 . . . . 0.0 110.979 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.0 m -132.27 172.07 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -60.0 143.98 50.42 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.453 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.54 HD21 HD11 ' A' ' 116' ' ' ILE . 8.4 tt -60.03 -39.97 87.74 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.385 -0.822 . . . . 0.0 110.226 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.3 t -51.29 -33.98 31.08 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.615 -0.678 . . . . 0.0 111.28 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -65.38 -39.99 92.94 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.482 -0.761 . . . . 0.0 110.935 -179.656 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 86.8 m -60.42 -47.76 84.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.393 -0.817 . . . . 0.0 110.243 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 112' ' ' LEU . 88.1 mt -69.96 -40.02 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.955 -0.466 . . . . 0.0 110.772 -179.118 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -66.48 -39.99 89.08 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.498 -0.751 . . . . 0.0 110.866 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -78.68 -60.06 2.7 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.159 -178.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.13 93.59 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.418 -1.048 . . . . 0.0 110.738 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.402 -179.784 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.992 0.425 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.5 p -112.95 145.86 40.04 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.686 -0.634 . . . . 0.0 110.085 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 83' ' ' PHE . 45.1 pt -120.01 149.96 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.626 -0.671 . . . . 0.0 110.743 -179.529 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.415 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -145.62 -172.37 3.88 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.172 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -140.96 145.44 36.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.325 -0.859 . . . . 0.0 110.199 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.73 149.48 64.83 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.409 -0.807 . . . . 0.0 110.005 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.94 48.25 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.074 0 O-C-N 123.432 1.227 . . . . 0.0 110.602 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 9' ' ' TYR . 7.6 tp -118.79 -6.79 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.527 -0.733 . . . . 0.0 111.052 -179.232 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CD2' HG23 ' A' ' 8' ' ' ILE . 29.2 m-85 -122.69 70.94 1.01 Allowed 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 122.62 1.2 . . . . 0.0 110.182 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.54 171.45 7.56 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 114.597 -1.183 . . . . 0.0 107.921 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.646 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -56.56 -28.71 60.8 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -175.39 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.37 12.26 21.07 Favored 'General case' 0 N--CA 1.498 1.966 0 C-N-CA 118.323 -1.351 . . . . 0.0 112.236 -177.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 14' ' ' SER . 0.4 OUTLIER -69.55 116.62 10.17 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.205 -0.934 . . . . 0.0 109.817 179.779 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.424 ' N ' HD13 ' A' ' 13' ' ' LEU . 47.5 t -65.88 137.74 57.39 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.837 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.529 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.9 mmm -67.77 -16.37 64.08 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.87 -0.519 . . . . 0.0 111.715 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.14 -13.82 82.4 Favored Glycine 0 N--CA 1.495 2.607 0 O-C-N 120.849 -1.157 . . . . 0.0 110.626 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -94.98 -17.68 21.74 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.19 -1.183 . . . . 0.0 111.708 -178.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.635 HG21 HG22 ' A' ' 76' ' ' VAL . 8.2 p -87.21 159.16 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.186 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.517 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.44 -40.0 64.85 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.198 -0.939 . . . . 0.0 110.301 -179.556 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 62.8 m -78.88 82.61 5.06 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -90.45 -80.73 0.32 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.048 -1.032 . . . . 0.0 112.875 -177.412 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.461 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 24.5 p-10 -154.88 20.55 0.45 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.734 -1.229 . . . . 0.0 112.535 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.22 -144.91 0.04 OUTLIER Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -69.63 -39.93 76.84 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.821 -0.811 . . . . 0.0 109.808 178.57 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.529 ' CD2' ' HA ' ' A' ' 53' ' ' ASP . 2.3 p80 -95.57 4.57 53.02 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.468 -0.77 . . . . 0.0 110.098 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.76 140.75 43.55 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.183 -0.948 . . . . 0.0 111.174 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.574 HD13 HG11 ' A' ' 37' ' ' VAL . 91.2 mt -104.34 -0.04 28.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 122.049 -0.677 . . . . 0.0 110.389 178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.7 ttm -60.05 -35.06 74.32 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 110.521 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.51 -73.22 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.458 -0.776 . . . . 0.0 111.398 -177.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -70.36 -39.99 74.29 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.372 -0.83 . . . . 0.0 110.121 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.61 ' CG ' HG23 ' A' ' 37' ' ' VAL . 54.1 m-85 -116.97 86.47 19.8 Favored Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -178.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.31 -26.93 24.45 Favored 'Trans proline' 0 C--N 1.317 -1.101 0 O-C-N 123.39 1.205 . . . . 0.0 110.955 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 15.1 m -116.89 161.26 19.61 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.359 -0.838 . . . . 0.0 110.41 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 43' ' ' VAL . 42.3 tp -86.59 114.92 23.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.769 -0.582 . . . . 0.0 111.292 -178.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 156.49 37.09 0.02 OUTLIER Glycine 0 N--CA 1.497 2.734 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -162.2 -48.26 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.376 -1.073 . . . . 0.0 110.578 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.61 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.8 t -59.96 -59.36 14.11 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.494 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.3 Cg_endo -76.76 -31.98 3.77 Favored 'Trans proline' 0 C--N 1.317 -1.131 0 N-CA-C 109.007 -1.189 . . . . 0.0 109.007 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 133.68 -60.95 0.65 Allowed Glycine 0 N--CA 1.486 1.977 0 N-CA-C 107.498 -2.241 . . . . 0.0 107.498 -178.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.646 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 157.9 -51.06 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.665 0 C-N-CA 123.877 0.871 . . . . 0.0 109.936 177.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 52.9 Cg_endo -101.0 5.61 0.62 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.595 1.53 . . . . 0.0 112.039 -177.612 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -122.36 47.57 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.975 . . . . 0.0 109.961 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 34' ' ' LEU . 14.3 p -117.66 141.11 37.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.869 0.843 . . . . 0.0 110.181 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -169.79 176.19 43.7 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -92.22 165.06 28.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.776 HD11 ' CA ' ' A' ' 75' ' ' GLY . 0.9 OUTLIER -154.8 161.0 30.39 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.631 -0.923 . . . . 0.0 109.801 178.938 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -66.7 -35.01 29.95 Favored 'Trans proline' 0 N--CA 1.502 2.015 0 C-N-CA 121.777 1.651 . . . . 0.0 115.2 -175.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -68.95 -10.0 55.02 Favored 'General case' 0 N--CA 1.507 2.398 0 O-C-N 120.736 -1.227 . . . . 0.0 113.24 -177.425 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.1 mm -81.23 129.23 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 O-C-N 120.717 -1.24 . . . . 0.0 109.417 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.12 -49.64 7.17 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.325 -0.859 . . . . 0.0 112.108 -178.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.517 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.55 -139.35 4.85 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.995 -1.574 . . . . 0.0 111.608 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 70.7 t90 -49.01 -24.58 1.58 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.765 -0.844 . . . . 0.0 112.914 -178.49 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.529 ' HA ' ' CD2' ' A' ' 25' ' ' HIS . 14.7 t70 -142.27 71.93 1.36 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.191 -0.943 . . . . 0.0 109.583 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.47 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 9.8 p -82.65 136.91 44.72 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.937 -0.477 . . . . 0.0 110.318 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -78.6 -16.81 13.03 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 O-C-N 123.318 1.167 . . . . 0.0 111.167 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.3 m -97.39 4.19 50.74 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.316 -0.865 . . . . 0.0 112.543 -178.037 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.1 t -66.58 142.53 57.46 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.905 -1.122 . . . . 0.0 110.421 -179.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 94.13 -7.71 72.76 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.574 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 22.4 p -70.44 157.77 37.22 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 118.9 1.35 . . . . 0.0 110.743 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -107.21 130.8 54.68 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.939 -0.476 . . . . 0.0 110.553 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 92.9 m95 -135.17 147.62 49.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.279 -0.888 . . . . 0.0 110.561 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -106.42 135.55 47.73 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.0 t -108.2 123.88 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.65 -0.656 . . . . 0.0 109.382 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 41.3 m -119.59 137.31 53.93 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.111 0.481 . . . . 0.0 111.075 -178.323 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 35.1 pt -115.72 164.26 18.08 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.676 -0.64 . . . . 0.0 110.401 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.09 -25.18 80.77 Favored 'Trans proline' 0 N--CA 1.497 1.683 0 C-N-CA 121.268 1.312 . . . . 0.0 112.514 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -63.23 -40.0 96.21 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.256 -0.903 . . . . 0.0 109.706 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 114.61 60.72 0.38 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -159.95 151.99 20.49 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.717 -0.873 . . . . 0.0 108.854 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 61.3 p -155.48 161.07 41.02 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.115 -1.034 . . . . 0.0 112.428 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 73' ' ' ILE . 37.8 pt -137.36 166.48 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -105.52 127.04 52.79 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.665 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 71' ' ' ILE . 46.3 mm -120.04 129.95 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 121.463 -0.773 . . . . 0.0 110.547 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.536 ' HD3' HG12 ' A' ' 37' ' ' VAL . 59.9 ttt180 -100.42 140.04 35.24 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.443 -0.786 . . . . 0.0 109.016 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.776 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -60.02 149.45 41.5 Favored Glycine 0 N--CA 1.494 2.538 0 CA-C-O 122.019 0.788 . . . . 0.0 111.575 -178.091 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.635 HG22 HG21 ' A' ' 18' ' ' VAL . 4.0 p -159.0 -39.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 122.017 -0.696 . . . . 0.0 109.653 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.633 ' OD2' HG23 ' A' ' 18' ' ' VAL . 3.4 t70 -135.86 170.2 16.36 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 120.963 -1.086 . . . . 0.0 109.517 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.6 t -95.52 160.4 14.53 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.296 -0.877 . . . . 0.0 111.828 -178.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.85 149.14 18.71 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 63.6 mtt180 -60.07 -33.98 72.81 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.655 -0.909 . . . . 0.0 110.586 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.4 79.48 0.05 OUTLIER Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.44 169.0 13.4 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 3' ' ' ILE . 19.1 m-85 -91.24 120.13 31.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.953 . . . . 0.0 109.817 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.415 ' HA ' ' O ' ' A' ' 4' ' ' SER . 1.6 m120 -114.27 130.46 56.65 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 44' ' ' GLY . 34.9 m -134.86 176.59 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.029 -1.044 . . . . 0.0 111.869 -178.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -57.42 152.7 31.68 Favored Pre-proline 0 N--CA 1.496 1.855 0 C-N-CA 120.133 -0.627 . . . . 0.0 110.051 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.64 -22.69 64.34 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.353 1.186 . . . . 0.0 110.408 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -73.13 -41.03 64.41 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.015 -1.053 . . . . 0.0 108.745 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.85 -39.76 87.68 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -59.98 -49.98 75.55 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.127 179.188 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.464 ' CG2' HG23 ' A' ' 97' ' ' THR . 12.1 p -60.01 -35.53 75.25 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.44 -0.787 . . . . 0.0 110.77 -179.114 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 55.9 mttm -69.95 -40.03 75.71 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.342 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 67.1 tp -70.49 -46.08 64.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 0.0 111.41 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -101.76 -38.13 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.172 0 O-C-N 121.288 -0.883 . . . . 0.0 111.655 -177.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 -18.88 16.46 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 41.8 p -158.8 151.96 22.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.249 -1.148 . . . . 0.0 110.519 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.464 HG23 ' CG2' ' A' ' 91' ' ' THR . 75.1 p -93.89 8.51 41.0 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.632 -0.667 . . . . 0.0 110.917 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.44 -0.788 . . . . 0.0 110.552 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.0 85.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.608 -0.683 . . . . 0.0 110.92 -178.524 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -59.4 3.19 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 108.538 -1.825 . . . . 0.0 108.538 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 53.9 ptt85 -150.1 157.14 42.81 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.792 -0.828 . . . . 0.0 109.946 179.149 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.7 t -128.35 126.23 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.468 -0.77 . . . . 0.0 109.719 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -90.19 169.0 11.51 Favored 'General case' 0 N--CA 1.496 1.867 0 CA-C-O 121.771 0.796 . . . . 0.0 111.75 -178.562 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 53.2 t30 60.07 40.02 19.05 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 121.402 0.62 . . . . 0.0 111.002 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.519 HG21 HG12 ' A' ' 3' ' ' ILE . 79.9 t -85.17 129.68 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.506 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -88.27 138.83 31.09 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.234 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.1 p90 -132.99 140.85 47.98 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.34 0.59 . . . . 0.0 110.824 -178.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 18.8 m -143.83 139.94 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.755 -0.59 . . . . 0.0 110.987 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 54.9 tt0 -77.32 139.08 39.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.702 -0.624 . . . . 0.0 110.292 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 34.6 m -130.02 165.35 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.61 -0.681 . . . . 0.0 110.649 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -55.42 139.97 41.55 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.585 -0.697 . . . . 0.0 110.753 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.618 HD21 HD11 ' A' ' 116' ' ' ILE . 9.2 tt -60.83 -39.98 91.06 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.646 -0.659 . . . . 0.0 110.825 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.0 m -54.45 -37.87 65.69 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.577 -0.702 . . . . 0.0 111.112 -177.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -65.73 -36.9 84.91 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.558 -0.714 . . . . 0.0 111.12 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 81.0 m -63.05 -44.43 95.86 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.177 -0.952 . . . . 0.0 109.913 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.618 HD11 HD21 ' A' ' 112' ' ' LEU . 80.3 mt -69.64 -39.96 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.099 -179.22 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -66.4 -40.05 89.39 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.469 -0.769 . . . . 0.0 110.467 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -74.31 -56.52 5.12 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.26 93.94 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.445 -1.032 . . . . 0.0 110.256 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.7 t30 . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 117.832 -1.08 . . . . 0.0 111.054 179.611 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.2 m . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.438 0.637 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -114.09 142.35 46.31 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.381 0.61 . . . . 0.0 110.668 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.727 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.9 pt -114.25 149.96 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.353 0.596 . . . . 0.0 110.887 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 23.0 m -146.35 -172.82 4.03 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.166 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -140.06 149.32 42.98 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.82 179.106 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.38 148.9 71.75 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.457 -0.777 . . . . 0.0 109.435 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -84.0 -9.05 9.86 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.275 1.145 . . . . 0.0 112.636 -178.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.2 pt -70.01 -40.06 78.09 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.227 0 O-C-N 120.953 -1.092 . . . . 0.0 110.984 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.52 ' HA ' HD22 ' A' ' 13' ' ' LEU . 50.9 m-85 -73.3 67.3 0.97 Allowed 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 122.877 1.322 . . . . 0.0 111.324 -178.664 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.93 171.55 7.28 Favored 'General case' 0 N--CA 1.49 1.55 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.203 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.97 -34.45 71.81 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -175.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -89.95 10.94 22.03 Favored 'General case' 0 N--CA 1.501 2.11 0 C-N-CA 118.285 -1.366 . . . . 0.0 112.507 -177.538 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 9' ' ' TYR . 50.0 tp -70.61 124.45 24.28 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.245 -0.909 . . . . 0.0 109.666 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 61.5 p -70.76 137.66 49.81 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.672 0.748 . . . . 0.0 110.092 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.782 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.9 mmm -66.41 -19.1 65.71 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.938 -0.476 . . . . 0.0 112.025 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.78 -15.39 75.85 Favored Glycine 0 N--CA 1.495 2.626 0 O-C-N 120.95 -1.094 . . . . 0.0 111.296 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.9 p -89.04 -7.52 55.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.208 -1.172 . . . . 0.0 111.9 -178.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.782 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -99.86 169.47 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.098 -1.001 . . . . 0.0 110.638 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.782 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.89 -44.49 91.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.525 -0.734 . . . . 0.0 109.796 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.1 m -80.04 80.71 6.42 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -101.19 -81.56 0.48 Allowed 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.262 -0.899 . . . . 0.0 113.247 -177.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.1 m-20 -131.12 11.14 5.02 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.139 -0.976 . . . . 0.0 113.025 -177.862 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.68 -153.49 3.43 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 179.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -65.93 -40.06 91.05 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.517 -0.99 . . . . 0.0 109.691 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.521 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 31.0 m80 -91.0 6.31 45.3 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -0.797 . . . . 0.0 110.734 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -59.43 134.62 51.71 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.859 HD13 HG11 ' A' ' 37' ' ' VAL . 89.6 mt -101.16 -4.47 27.19 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 122.024 -0.692 . . . . 0.0 110.581 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 59.4 ttm -62.22 -37.03 83.79 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.273 -0.892 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.11 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.608 -0.683 . . . . 0.0 111.896 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -69.09 -39.99 78.67 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.367 -0.833 . . . . 0.0 109.743 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.557 ' CD2' HG23 ' A' ' 37' ' ' VAL . 48.7 m-85 -119.94 91.69 45.8 Favored Pre-proline 0 N--CA 1.491 1.608 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.92 -18.67 40.95 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.293 1.154 . . . . 0.0 111.241 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 90.6 m -123.75 141.27 52.18 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.229 -0.919 . . . . 0.0 110.026 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.897 HD11 HG21 ' A' ' 43' ' ' VAL . 41.7 tp -65.9 120.75 13.62 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.77 -0.581 . . . . 0.0 111.036 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.29 32.41 0.04 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.862 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.443 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 25.0 mt-10 -155.29 -49.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -1.128 . . . . 0.0 110.448 178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.859 HG11 HD13 ' A' ' 27' ' ' LEU . 3.1 t -60.27 -60.81 9.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.6 Cg_endo -74.79 -28.6 9.43 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 N-CA-C 108.979 -1.2 . . . . 0.0 108.979 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.43 -61.32 0.65 Allowed Glycine 0 N--CA 1.484 1.872 0 N-CA-C 107.017 -2.433 . . . . 0.0 107.017 -178.587 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.543 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.8 t80 165.48 -72.7 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.578 0 C-N-CA 123.377 0.671 . . . . 0.0 110.083 177.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.543 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -83.01 -8.58 10.94 Favored 'Trans proline' 0 N--CA 1.493 1.497 0 CA-C-N 118.995 0.677 . . . . 0.0 112.174 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -97.91 34.29 1.93 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.134 -0.979 . . . . 0.0 110.51 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.897 HG21 HD11 ' A' ' 34' ' ' LEU . 10.6 p -109.95 137.3 42.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.665 0.745 . . . . 0.0 109.498 179.277 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.701 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.62 172.89 43.22 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.044 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.54 156.34 29.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.244 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.74 HD12 ' HA2' ' A' ' 75' ' ' GLY . 81.3 mt -139.97 150.46 62.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.61 ' HD2' HG23 ' A' ' 46' ' ' ILE . 37.3 Cg_endo -59.36 -10.15 10.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.349 1.184 . . . . 0.0 113.626 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.601 ' H ' HG22 ' A' ' 46' ' ' ILE . 83.0 m-20 -94.58 -12.54 27.3 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.693 -1.254 . . . . 0.0 112.329 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.606 HG23 ' CB ' ' A' ' 54' ' ' SER . 51.3 mm -75.08 119.67 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 C-N-CA 118.601 -1.24 . . . . 0.0 108.397 178.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.74 -45.3 21.47 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.26 -0.9 . . . . 0.0 112.529 -178.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.782 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 169.9 -138.91 5.28 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.918 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 36.8 t90 -42.79 -28.81 0.27 Allowed 'General case' 0 N--CA 1.502 2.175 0 O-C-N 121.956 -0.731 . . . . 0.0 112.769 -179.292 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -142.62 65.34 1.35 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.339 -0.851 . . . . 0.0 110.112 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.606 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.0 p -66.39 134.51 94.58 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.643 -0.661 . . . . 0.0 110.899 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.521 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -74.93 -23.48 13.9 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 O-C-N 123.45 1.237 . . . . 0.0 111.05 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.62 15.19 14.89 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 111.385 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t -78.28 151.62 32.91 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 110.054 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 71.08 29.89 68.31 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.7 m -117.16 132.97 56.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.59 -0.947 . . . . 0.0 109.963 179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -81.07 145.5 31.07 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -177.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.47 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -149.34 150.09 31.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 110.471 178.137 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -108.45 132.03 54.2 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.3 t -108.9 127.36 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.49 -0.756 . . . . 0.0 109.597 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 88.0 m -120.06 136.66 54.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.942 -0.474 . . . . 0.0 110.939 -178.135 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.463 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 38.0 pt -115.95 164.82 16.36 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.541 -0.724 . . . . 0.0 110.568 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.8 -25.1 74.61 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 C-N-CA 121.236 1.29 . . . . 0.0 112.66 -178.569 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -64.89 -40.0 94.41 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.23 -0.919 . . . . 0.0 109.794 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.75 61.09 0.32 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.271 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -160.01 150.64 18.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.758 -0.848 . . . . 0.0 108.831 179.189 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.422 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 67.0 p -151.56 157.41 42.19 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.247 -0.981 . . . . 0.0 112.248 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 73' ' ' ILE . 44.3 pt -139.34 165.05 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -103.36 125.76 50.15 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.274 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 71' ' ' ILE . 49.5 mm -119.8 131.01 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.707 -0.621 . . . . 0.0 110.246 -178.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 -99.38 137.06 38.42 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.439 -0.788 . . . . 0.0 109.079 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.74 ' HA2' HD12 ' A' ' 46' ' ' ILE . . . -57.18 150.74 28.62 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.24 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 44' ' ' GLY . 11.9 p -169.54 -28.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.679 -0.895 . . . . 0.0 111.307 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.622 ' OD1' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -130.0 166.98 18.99 Favored 'General case' 0 N--CA 1.505 2.306 0 O-C-N 120.585 -1.322 . . . . 0.0 109.712 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.488 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 48.2 t -94.68 144.51 25.55 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.482 -0.761 . . . . 0.0 111.024 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -126.29 141.67 13.0 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -60.68 -28.38 68.57 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.759 -0.847 . . . . 0.0 109.814 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.04 79.92 0.05 OUTLIER Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.27 163.79 11.21 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.827 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.727 ' HB2' HG22 ' A' ' 3' ' ' ILE . 16.1 m-85 -92.16 115.33 27.99 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.666 -0.902 . . . . 0.0 109.915 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.415 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 57.7 t-20 -109.04 131.99 54.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.343 -0.848 . . . . 0.0 109.028 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.3 m -132.44 175.52 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.185 0 O-C-N 120.961 -1.087 . . . . 0.0 111.833 -178.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -55.73 156.69 8.83 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.41 -0.806 . . . . 0.0 109.953 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.07 -22.37 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.295 1.155 . . . . 0.0 110.65 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -76.28 -40.03 52.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.021 -1.049 . . . . 0.0 108.953 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.531 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.26 -39.87 89.76 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.553 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -60.04 -50.03 75.31 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.202 -0.599 . . . . 0.0 110.486 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 56.9 m -59.96 -39.5 85.82 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.546 -0.721 . . . . 0.0 110.709 -178.593 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.4 ' HE3' ' HA ' ' A' ' 89' ' ' ALA . 57.1 mtmt -70.03 -40.05 75.41 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.789 -178.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.422 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 65.4 tp -70.02 -43.4 71.42 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.65 -0.656 . . . . 0.0 111.492 -179.466 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.2 t -96.2 -39.82 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 O-C-N 121.262 -0.899 . . . . 0.0 111.258 -178.07 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.63 -38.96 2.55 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.8 m -139.98 152.2 46.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.686 -0.891 . . . . 0.0 110.182 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.6 p -90.71 6.33 44.51 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.403 -0.81 . . . . 0.0 111.169 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -70.04 -29.22 66.2 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.478 -0.764 . . . . 0.0 110.736 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.05 -40.09 84.02 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.538 -0.726 . . . . 0.0 110.625 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -74.48 1.68 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 12.1 ptt-85 -144.74 149.54 35.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.681 -0.894 . . . . 0.0 110.271 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.94 119.36 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.487 -0.758 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -83.84 173.49 11.21 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.723 -0.611 . . . . 0.0 110.604 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 60.01 45.75 11.72 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.636 -0.665 . . . . 0.0 110.998 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.405 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 73.7 t -95.53 128.06 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.493 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -85.4 136.1 33.6 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.092 -1.005 . . . . 0.0 109.639 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.8 p90 -132.87 140.98 48.18 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.134 0.492 . . . . 0.0 110.738 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.2 m -144.62 141.21 23.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.609 -0.682 . . . . 0.0 110.979 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.47 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 58.6 tt0 -70.93 140.73 51.05 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.536 -0.727 . . . . 0.0 110.334 178.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.23 167.44 26.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.105 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -61.28 148.26 41.76 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.414 -0.804 . . . . 0.0 110.325 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.73 -40.05 96.0 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.433 -0.792 . . . . 0.0 111.133 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 53.4 m -56.29 -38.18 70.88 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.583 -0.698 . . . . 0.0 110.587 -178.624 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.09 -35.71 75.81 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.432 -0.792 . . . . 0.0 110.287 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 80.5 m -70.04 -39.99 75.41 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.522 -0.736 . . . . 0.0 109.383 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 50.6 mm -66.77 -40.04 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 CA-C-O 121.473 0.654 . . . . 0.0 109.395 -178.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -69.98 -39.96 75.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.818 -0.551 . . . . 0.0 110.299 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.88 -57.73 5.67 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.96 -41.64 92.37 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.507 -0.996 . . . . 0.0 110.704 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.301 -179.889 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.456 HG23 ' HB ' ' A' ' 105' ' ' VAL . 34.8 m . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.464 0.65 . . . . 0.0 111.201 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.1 t -113.57 140.19 48.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.746 -0.596 . . . . 0.0 109.744 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.67 HG23 HG21 ' A' ' 105' ' ' VAL . 37.4 pt -109.16 148.14 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 111.042 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' SER . . . . . 0.433 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -146.72 -170.82 3.61 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.321 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 5' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 50.3 p90 -144.71 150.01 36.58 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.967 179.276 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -130.29 148.58 70.39 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.566 -0.709 . . . . 0.0 109.554 178.811 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.79 -6.58 12.43 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 O-C-N 123.247 1.13 . . . . 0.0 112.46 -179.117 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 9' ' ' TYR . 30.1 pt -69.98 -40.0 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 120.865 -1.147 . . . . 0.0 110.925 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.528 ' HA ' HD22 ' A' ' 13' ' ' LEU . 40.5 m-85 -74.17 67.24 1.33 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-O 122.774 1.273 . . . . 0.0 111.132 -178.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.19 171.86 7.12 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 114.299 -1.319 . . . . 0.0 108.146 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.05 -33.93 72.72 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.802 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.98 10.22 24.84 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.428 -1.42 . . . . 0.0 112.316 -177.276 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.528 HD22 ' HA ' ' A' ' 9' ' ' TYR . 29.0 tp -70.33 123.33 21.46 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.263 -0.898 . . . . 0.0 109.703 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.1 m -69.14 136.63 52.46 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.783 -0.767 . . . . 0.0 109.961 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.802 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.6 mmm -67.21 -17.72 64.94 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 122.03 -0.419 . . . . 0.0 111.65 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -70.75 -14.7 73.01 Favored Glycine 0 N--CA 1.495 2.612 0 O-C-N 120.955 -1.091 . . . . 0.0 111.095 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -88.43 -9.44 52.55 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.203 -1.175 . . . . 0.0 111.787 -179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.802 HG12 ' O ' ' A' ' 15' ' ' MET . 8.4 p -95.54 168.49 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.072 -1.017 . . . . 0.0 110.092 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.8 -44.8 86.57 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.542 -0.724 . . . . 0.0 109.939 -179.658 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.5 m -81.28 84.05 6.71 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.4 m -99.95 -79.95 0.48 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.56 -0.712 . . . . 0.0 112.88 -178.09 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -131.09 9.93 4.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.24 -0.912 . . . . 0.0 112.77 -178.186 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.41 -153.2 1.83 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.755 -1.738 . . . . 0.0 108.755 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -70.01 -39.95 75.53 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.789 -0.83 . . . . 0.0 109.648 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.478 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 26.4 m80 -90.03 0.21 57.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.625 -0.672 . . . . 0.0 110.866 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.71 137.89 49.06 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.67 HD13 HG11 ' A' ' 37' ' ' VAL . 75.0 mt -99.02 -5.22 30.8 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.916 -0.755 . . . . 0.0 110.251 178.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.401 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.1 ttm -60.01 -37.2 79.01 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.307 -0.871 . . . . 0.0 110.97 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.94 -74.84 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.497 -0.752 . . . . 0.0 111.798 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -70.0 -39.97 75.57 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.433 -0.792 . . . . 0.0 110.359 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.548 ' CD2' HG23 ' A' ' 37' ' ' VAL . 27.6 m-85 -120.02 93.27 47.73 Favored Pre-proline 0 N--CA 1.496 1.83 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -178.485 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -69.82 -21.87 32.62 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.423 1.223 . . . . 0.0 111.347 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.4 m -123.21 145.9 48.27 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 109.939 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 1.0 HD21 HG11 ' A' ' 43' ' ' VAL . 40.6 tp -68.68 121.15 15.86 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -0.756 . . . . 0.0 110.753 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.88 33.78 0.03 OUTLIER Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.774 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -160.31 -44.12 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.159 -1.201 . . . . 0.0 110.142 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.67 HG11 HD13 ' A' ' 27' ' ' LEU . 3.5 t -60.54 -61.28 8.28 Favored Pre-proline 0 N--CA 1.498 1.967 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -77.59 -26.11 7.4 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.108 1.057 . . . . 0.0 109.598 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.58 -62.0 0.63 Allowed Glycine 0 N--CA 1.486 1.988 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.028 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.572 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.0 t80 166.74 -72.45 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.449 0 C-N-CA 123.267 0.627 . . . . 0.0 109.632 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.572 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 60.2 Cg_endo -84.65 10.7 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 CA-C-N 118.912 0.647 . . . . 0.0 111.647 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -114.54 35.7 4.11 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.011 -1.056 . . . . 0.0 110.015 -178.604 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.0 HG11 HD21 ' A' ' 34' ' ' LEU . 13.1 p -117.54 143.36 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-O 121.455 0.645 . . . . 0.0 110.11 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.04 166.67 39.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.38 151.37 44.97 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 177.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.545 HD11 HG13 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -144.22 142.9 20.61 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.431 -1.04 . . . . 0.0 109.351 179.698 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -61.38 -13.02 26.55 Favored 'Trans proline' 0 N--CA 1.507 2.271 0 C-N-CA 122.193 1.929 . . . . 0.0 115.188 -177.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.434 ' HB2' HD12 ' A' ' 46' ' ' ILE . 94.9 m-20 -92.9 20.1 6.99 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.45 -1.406 . . . . 0.0 112.139 -178.121 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.816 HG23 ' CB ' ' A' ' 54' ' ' SER . 57.8 mt -118.57 127.67 75.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.301 -0.875 . . . . 0.0 109.038 177.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.0 -45.35 13.2 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 175.18 -141.17 5.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.403 -1.856 . . . . 0.0 112.194 -178.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.498 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 25.3 t90 -39.97 -29.87 0.08 Allowed 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 -178.105 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -146.15 64.14 1.22 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.985 -1.072 . . . . 0.0 111.325 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.816 ' CB ' HG23 ' A' ' 49' ' ' ILE . 6.5 t -66.27 139.39 96.34 Favored Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.45 -0.781 . . . . 0.0 110.866 -179.326 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.478 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -78.05 -20.66 11.37 Favored 'Trans proline' 0 C--N 1.32 -0.959 0 O-C-N 123.4 1.211 . . . . 0.0 110.65 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 17.8 m -92.97 11.54 27.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.484 -0.76 . . . . 0.0 111.231 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 6.6 t -69.66 145.16 52.61 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.093 -1.004 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.45 41.9 12.6 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.1 m -120.01 129.95 54.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.397 -1.06 . . . . 0.0 110.477 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.514 ' SG ' HG23 ' A' ' 110' ' ' VAL . 50.1 t -81.29 143.03 32.55 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.513 -178.444 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 71.9 m95 -146.4 155.62 42.72 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.526 178.231 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -114.11 130.19 56.59 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.6 129.59 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.405 -0.809 . . . . 0.0 109.706 -178.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.3 m -121.12 141.07 51.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.803 -0.561 . . . . 0.0 111.459 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.441 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.0 pt -117.62 163.58 23.35 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.521 -0.737 . . . . 0.0 110.036 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -62.32 -25.35 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 121.184 1.256 . . . . 0.0 112.507 -178.461 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -64.84 -39.01 92.88 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.384 -0.822 . . . . 0.0 109.715 179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.47 61.6 0.33 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -160.58 153.07 20.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.709 -0.877 . . . . 0.0 109.007 178.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.454 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -151.26 158.72 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.207 1.003 . . . . 0.0 112.352 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 pt -139.89 164.73 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.162 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.5 m-85 -106.58 127.0 52.98 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 118.879 -1.128 . . . . 0.0 109.928 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.37 131.89 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.622 -0.674 . . . . 0.0 110.582 -179.123 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.599 ' HD3' HG12 ' A' ' 37' ' ' VAL . 53.9 ttt180 -102.21 136.49 41.96 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.27 149.54 42.17 Favored Glycine 0 N--CA 1.494 2.557 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.318 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.593 HG22 HG21 ' A' ' 18' ' ' VAL . 5.7 p -156.91 -42.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.743 -0.857 . . . . 0.0 110.118 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.481 ' O ' HD12 ' A' ' 49' ' ' ILE . 12.3 t70 -128.34 169.99 13.6 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.109 -0.995 . . . . 0.0 110.06 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 41.8 t -87.67 156.85 19.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.426 -0.796 . . . . 0.0 111.081 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.43 137.34 10.92 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -63.08 -39.87 96.0 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.734 -0.862 . . . . 0.0 110.162 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -178.15 69.96 0.08 OUTLIER Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.74 172.09 18.19 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 3' ' ' ILE . 89.1 m-85 -98.63 122.53 41.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.652 -0.911 . . . . 0.0 110.334 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASN . . . . . 0.433 ' HA ' ' O ' ' A' ' 4' ' ' SER . 17.1 t-20 -115.05 130.31 56.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.391 -0.818 . . . . 0.0 109.048 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.423 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 35.6 m -132.97 174.47 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 120.933 -1.104 . . . . 0.0 111.741 -178.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -54.74 150.9 16.6 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.53 -0.731 . . . . 0.0 109.92 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.6 -21.01 59.97 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.404 1.213 . . . . 0.0 110.76 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 67.7 m -75.79 -39.95 56.02 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.065 -1.022 . . . . 0.0 109.23 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.77 -40.03 88.08 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.422 -0.798 . . . . 0.0 109.116 178.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -60.03 -49.68 76.72 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.807 -0.558 . . . . 0.0 110.632 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.6 m -60.04 -36.99 78.5 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.824 . . . . 0.0 110.787 -178.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -69.95 -40.07 75.67 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.412 -179.164 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.454 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 56.1 tp -70.39 -44.16 68.58 Favored 'General case' 0 N--CA 1.496 1.851 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.554 -178.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 91.1 t -95.39 -38.61 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.311 -0.868 . . . . 0.0 111.394 -177.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -27.35 6.07 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 43.7 t -156.04 161.19 40.46 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.466 -1.02 . . . . 0.0 110.292 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 68.3 p -97.81 13.24 31.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 111.151 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.99 -36.54 75.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.481 -0.762 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.02 -41.16 91.59 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.444 -0.785 . . . . 0.0 111.05 -178.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.28 -63.48 2.02 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 -179.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -149.37 153.45 37.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.59 -0.947 . . . . 0.0 110.57 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.1 118.94 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.456 -0.777 . . . . 0.0 110.149 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -81.87 169.44 16.84 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.577 -0.702 . . . . 0.0 111.181 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 63.7 t30 59.85 50.06 7.29 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.548 -0.72 . . . . 0.0 110.731 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.67 HG21 HG23 ' A' ' 3' ' ' ILE . 66.9 t -94.05 128.73 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -86.9 140.61 29.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.417 -0.913 . . . . 0.0 109.491 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -139.11 141.87 38.11 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.167 0.508 . . . . 0.0 110.736 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 m -141.14 139.89 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.695 -0.628 . . . . 0.0 110.161 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -77.4 136.86 38.44 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.964 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.514 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.3 m -134.22 -179.13 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.257 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.41 150.94 47.55 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.406 -0.809 . . . . 0.0 111.075 -179.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.455 HD11 ' NH1' ' A' ' 74' ' ' ARG . 7.7 tt -62.06 -40.0 94.29 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.559 -0.713 . . . . 0.0 111.389 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 55.8 m -54.28 -39.37 66.84 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.443 -0.785 . . . . 0.0 110.222 -178.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -59.99 -37.65 80.29 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.632 -0.668 . . . . 0.0 110.223 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -68.15 -42.43 80.09 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.49 -0.756 . . . . 0.0 109.481 178.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.0 mm -64.88 -40.52 89.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.023 -0.671 . . . . 0.0 109.853 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -70.05 -39.92 75.41 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.697 -0.627 . . . . 0.0 110.483 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.6 -53.14 37.07 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.4 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.05 -43.94 97.24 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.512 -0.993 . . . . 0.0 110.548 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 48.6 t30 . . . . . 0 N--CA 1.501 2.082 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.006 -179.824 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.418 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.4 m . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.25 0.548 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.8 t -114.63 141.18 48.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.536 -0.728 . . . . 0.0 110.39 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.755 HG22 ' HB2' ' A' ' 83' ' ' PHE . 39.3 pt -107.8 147.72 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.679 -0.638 . . . . 0.0 110.6 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.42 -171.89 3.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.8 p90 -142.87 147.32 35.18 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.35 -0.844 . . . . 0.0 110.802 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -137.7 155.22 75.17 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.488 178.708 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -88.28 48.06 1.37 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.275 1.145 . . . . 0.0 110.659 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.813 ' O ' HD22 ' A' ' 13' ' ' LEU . 8.7 tp -123.01 -8.65 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.48 -0.763 . . . . 0.0 111.276 -179.39 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 8' ' ' ILE . 35.3 m-85 -118.54 67.65 0.77 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 122.525 1.155 . . . . 0.0 110.947 178.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.02 170.37 7.9 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.679 177.082 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.82 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.6 -32.71 70.64 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 114.115 1.154 . . . . 0.0 114.115 -175.497 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -89.63 13.91 12.94 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 120.424 1.466 . . . . 0.0 112.5 -177.075 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.813 HD22 ' O ' ' A' ' 8' ' ' ILE . 64.0 tp -73.1 125.94 28.85 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.413 -0.804 . . . . 0.0 110.792 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.18 135.54 49.18 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.487 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.717 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -66.36 -15.86 63.61 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.777 -0.577 . . . . 0.0 112.048 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.62 -13.86 80.05 Favored Glycine 0 N--CA 1.497 2.701 0 O-C-N 120.977 -1.077 . . . . 0.0 111.337 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 -11.05 47.2 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.054 -1.262 . . . . 0.0 112.063 -178.705 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 15' ' ' MET . 8.5 p -93.72 168.25 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.068 -1.02 . . . . 0.0 110.041 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.24 -42.09 85.58 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.472 -0.768 . . . . 0.0 109.816 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.03 82.94 2.89 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.586 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.9 m -90.29 -79.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.989 -1.069 . . . . 0.0 112.894 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.488 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 17.9 p30 -143.56 14.21 1.77 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 120.631 -1.293 . . . . 0.0 112.428 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.64 -146.95 0.38 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -66.58 -40.51 88.97 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' HIS . . . . . 0.407 ' CD2' ' O ' ' A' ' 54' ' ' SER . 64.1 m-70 -90.02 0.56 57.05 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.798 -0.564 . . . . 0.0 110.265 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -55.05 130.4 47.08 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 84.3 mt -104.87 -5.98 20.62 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 122.146 -0.62 . . . . 0.0 111.203 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' MET . . . . . 0.404 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 44.4 ttm -59.96 -35.63 75.39 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.292 -0.88 . . . . 0.0 110.825 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.43 -63.1 1.26 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -67.26 -40.04 86.18 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.213 -0.93 . . . . 0.0 111.288 -177.456 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.69 ' CE1' HG21 ' A' ' 37' ' ' VAL . 5.5 p90 -143.64 113.72 5.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.879 . . . . 0.0 109.128 179.21 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.65 -1.62 10.1 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.443 1.233 . . . . 0.0 112.582 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' THR . . . . . 0.513 HG22 ' H ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -118.64 -172.1 2.21 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.995 -1.066 . . . . 0.0 109.71 179.786 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.764 HD11 HG21 ' A' ' 43' ' ' VAL . 61.5 tp -116.51 129.96 56.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.605 -0.685 . . . . 0.0 110.852 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.86 -40.82 1.27 Allowed Glycine 0 N--CA 1.489 2.172 0 C-N-CA 120.077 -1.059 . . . . 0.0 111.044 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -62.42 -39.94 94.93 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.182 -1.187 . . . . 0.0 111.483 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.747 HG12 ' HD3' ' A' ' 74' ' ' ARG . 3.2 t -87.62 -61.36 0.24 Allowed Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.336 -0.852 . . . . 0.0 112.699 -178.339 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PRO . . . . . 0.432 ' HG3' HD11 ' A' ' 34' ' ' LEU . 37.4 Cg_endo -64.54 -48.49 4.29 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 O-C-N 123.009 1.005 . . . . 0.0 113.063 -177.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . 0.431 ' O ' ' HD2' ' A' ' 41' ' ' PRO . . . 122.77 67.87 0.23 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 106.541 -2.624 . . . . 0.0 106.541 -177.188 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.82 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 8.8 t80 19.65 -78.99 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.343 0 N-CA-C 115.101 1.519 . . . . 0.0 115.101 -178.147 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.532 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.7 Cg_endo -81.91 17.8 1.48 Allowed 'Trans proline' 0 N--CA 1.499 1.804 0 CA-C-N 120.07 1.061 . . . . 0.0 112.588 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -123.79 47.33 2.06 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.836 -1.165 . . . . 0.0 110.201 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 34' ' ' LEU . 11.0 p -129.39 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 122.064 0.935 . . . . 0.0 110.334 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.519 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.08 175.31 42.3 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.32 161.75 31.6 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 49' ' ' ILE . 1.1 pt -147.46 152.1 41.35 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.64 -0.917 . . . . 0.0 110.063 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.69 -14.7 46.15 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.954 1.77 . . . . 0.0 113.763 -178.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -90.6 23.25 3.11 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 120.591 -1.318 . . . . 0.0 112.259 -178.416 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.558 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.8 mm -113.77 126.91 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.17 13.0 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.311 -0.868 . . . . 0.0 112.077 -178.39 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.856 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 173.23 -134.34 2.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 118.715 -1.707 . . . . 0.0 111.719 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.441 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 53.5 t90 -46.06 -28.48 1.2 Allowed 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -178.255 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -146.65 61.19 1.21 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.024 -1.048 . . . . 0.0 110.986 -179.173 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.558 ' CB ' HG23 ' A' ' 49' ' ' ILE . 35.1 p -61.95 140.07 95.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.49 -0.756 . . . . 0.0 110.444 -179.269 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.18 -21.8 19.89 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 123.328 1.172 . . . . 0.0 111.151 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.9 m -93.85 13.62 21.98 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.449 -0.782 . . . . 0.0 111.158 -179.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 2.2 t -73.17 145.43 46.32 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.259 -0.9 . . . . 0.0 110.561 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.58 22.79 71.81 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 86.8 m -104.22 139.11 39.71 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.358 -1.084 . . . . 0.0 110.751 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.439 ' SG ' HG23 ' A' ' 110' ' ' VAL . 46.5 t -80.12 132.96 36.03 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.545 -179.037 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' TRP . . . . . 0.405 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.7 m95 -134.36 147.32 50.51 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -0.76 . . . . 0.0 110.074 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -107.86 131.55 54.38 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.366 -0.834 . . . . 0.0 109.725 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.635 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.2 t -109.95 121.03 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.557 0.694 . . . . 0.0 110.252 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 97.8 m -119.99 146.03 46.23 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.859 -0.525 . . . . 0.0 110.575 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.469 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 17.2 pt -122.12 164.51 25.25 Favored Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.473 -0.767 . . . . 0.0 110.98 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -61.31 -25.94 81.09 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.561 1.507 . . . . 0.0 112.837 -178.611 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -66.08 -40.0 90.48 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.248 -0.907 . . . . 0.0 110.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.45 61.11 0.3 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -160.07 151.6 19.81 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.652 -0.911 . . . . 0.0 108.829 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.9 p -155.6 164.99 37.9 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 122.287 1.041 . . . . 0.0 112.193 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 40.0 pt -144.52 165.63 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -106.29 122.64 46.64 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.265 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.842 HD13 HG11 ' A' ' 85' ' ' VAL . 66.2 mt -120.02 131.41 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.857 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.747 ' HD3' HG12 ' A' ' 37' ' ' VAL . 24.8 ttt180 -95.25 136.5 35.53 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.663 -0.648 . . . . 0.0 109.407 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.39 149.72 31.43 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 110.336 -1.106 . . . . 0.0 110.336 -178.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.497 HG11 HG22 ' A' ' 43' ' ' VAL . 4.1 p -154.7 -44.08 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.723 -0.869 . . . . 0.0 109.513 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.556 ' HB2' HG23 ' A' ' 18' ' ' VAL . 11.9 t70 -131.87 169.02 16.84 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 178.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' SER . . . . . 0.427 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 95.5 p -91.91 157.78 16.65 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.4 -0.813 . . . . 0.0 111.618 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -124.2 146.16 16.16 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -60.66 -31.04 70.29 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.649 -0.912 . . . . 0.0 110.174 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.09 76.45 0.04 OUTLIER Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.562 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.82 154.93 6.26 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.115 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.755 ' HB2' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -67.41 114.59 6.22 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.931 -0.746 . . . . 0.0 110.376 179.289 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -111.15 119.07 37.74 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 73' ' ' ILE . 26.8 m -131.1 176.95 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 120.89 -1.131 . . . . 0.0 112.474 -177.128 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.5 m-20 -55.7 150.9 24.41 Favored Pre-proline 0 N--CA 1.493 1.713 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.214 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.43 -17.27 57.26 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.395 1.208 . . . . 0.0 110.142 178.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 98.1 m -81.28 -40.66 23.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.916 -1.115 . . . . 0.0 109.182 178.34 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -39.84 91.12 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -60.06 -49.94 75.68 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.754 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.5 m -60.68 -40.0 90.53 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.429 -0.794 . . . . 0.0 111.108 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -68.48 -39.99 81.15 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.35 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 57.8 tp -73.31 -43.24 61.25 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.576 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 51.2 t -91.57 -42.36 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 121.344 -0.848 . . . . 0.0 111.52 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.27 -31.74 3.56 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 90.1 p -154.39 165.88 34.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.502 -0.999 . . . . 0.0 110.457 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.7 p -94.23 -0.05 55.37 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.451 -0.781 . . . . 0.0 111.756 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -70.95 -26.3 63.11 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.336 -0.853 . . . . 0.0 111.675 -179.065 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -39.98 87.86 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.322 -0.861 . . . . 0.0 110.898 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.68 -67.46 2.17 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -152.1 160.01 43.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.553 -0.969 . . . . 0.0 110.998 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 105' ' ' VAL . 60.7 t -131.11 112.73 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.952 179.186 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 36.1 p-10 -80.06 170.01 17.05 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.464 0.65 . . . . 0.0 111.113 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 59.98 40.02 19.36 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.627 -0.67 . . . . 0.0 111.597 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.636 HG21 HG23 ' A' ' 3' ' ' ILE . 94.5 t -85.15 129.94 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.417 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -86.72 139.49 30.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.002 -1.061 . . . . 0.0 109.545 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.437 ' C ' HG13 ' A' ' 108' ' ' VAL . 46.8 p90 -138.02 143.3 40.52 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 122.0 -0.438 . . . . 0.0 110.763 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.437 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.0 m -149.07 149.02 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.545 -0.722 . . . . 0.0 110.706 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' GLN . . . . . 0.405 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 58.9 tt0 -76.75 139.98 40.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.599 -0.688 . . . . 0.0 110.269 179.367 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.439 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.5 m -133.6 168.26 24.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.003 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -57.6 144.83 35.93 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.378 -0.826 . . . . 0.0 110.563 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.564 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.6 tt -59.91 -36.75 77.64 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.224 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 91.0 p -54.07 -36.14 62.82 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.491 -0.756 . . . . 0.0 110.502 -179.08 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -66.67 -39.58 88.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 111.179 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -59.97 -49.16 78.78 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.306 -0.871 . . . . 0.0 109.797 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ILE . . . . . 0.491 HD11 HD21 ' A' ' 112' ' ' LEU . 93.4 mt -69.81 -39.98 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.687 -0.633 . . . . 0.0 110.687 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -64.0 -39.94 95.25 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.35 -0.844 . . . . 0.0 111.052 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.14 -50.83 20.73 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.94 91.62 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.574 -0.957 . . . . 0.0 110.524 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.063 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.555 0.693 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 79.9 p -111.33 139.9 46.35 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.456 0.646 . . . . 0.0 109.49 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.624 HG12 HG21 ' A' ' 105' ' ' VAL . 39.6 pt -118.13 149.98 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.837 -0.54 . . . . 0.0 111.273 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.1 OUTLIER -146.15 -169.55 3.28 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.757 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.412 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.5 p90 -141.58 148.07 38.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.417 -0.802 . . . . 0.0 110.178 178.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.49 143.48 43.32 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.406 -0.809 . . . . 0.0 109.777 179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.73 -9.86 17.05 Favored 'Trans proline' 0 C--N 1.318 -1.078 0 O-C-N 123.324 1.171 . . . . 0.0 112.331 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 9' ' ' TYR . 44.5 pt -70.01 -39.95 77.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 120.968 -1.082 . . . . 0.0 111.434 -179.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.601 ' HA ' HD22 ' A' ' 13' ' ' LEU . 51.5 m-85 -72.14 67.5 0.67 Allowed 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 122.752 1.263 . . . . 0.0 111.72 -178.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.55 170.04 8.12 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.054 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.491 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.41 -34.38 68.85 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -175.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -90.92 12.12 20.56 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 118.431 -1.308 . . . . 0.0 112.265 -177.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.601 HD22 ' HA ' ' A' ' 9' ' ' TYR . 36.4 tp -72.53 123.71 23.73 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.246 -0.908 . . . . 0.0 110.2 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -70.54 137.35 50.06 Favored 'General case' 0 N--CA 1.49 1.573 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.035 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.806 ' O ' HG12 ' A' ' 18' ' ' VAL . 34.6 mtt -70.08 -15.39 62.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.802 -0.561 . . . . 0.0 111.915 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.63 -15.37 68.53 Favored Glycine 0 N--CA 1.494 2.559 0 O-C-N 120.793 -1.192 . . . . 0.0 110.878 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 91.0 p -87.98 -4.45 58.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.192 -1.181 . . . . 0.0 112.157 -178.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.806 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -103.5 168.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.001 -1.062 . . . . 0.0 110.801 -179.2 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.72 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.04 -39.29 85.4 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.471 -0.768 . . . . 0.0 110.644 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.76 67.72 3.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.291 -0.881 . . . . 0.0 110.088 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.6 m -108.71 110.13 21.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.155 -0.966 . . . . 0.0 110.565 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 m120 51.66 -140.98 0.84 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.714 -0.616 . . . . 0.0 111.11 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.43 -155.95 49.02 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -78.07 -41.82 34.2 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.428 -1.042 . . . . 0.0 111.066 179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 36.7 m80 -89.94 2.14 55.42 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.181 -0.949 . . . . 0.0 111.748 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.55 131.81 49.36 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.002 -1.061 . . . . 0.0 111.15 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.508 HD13 HG11 ' A' ' 37' ' ' VAL . 80.7 mt -96.28 -11.57 25.76 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 122.091 -0.652 . . . . 0.0 110.005 178.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.416 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 60.5 ttm -60.05 -34.42 73.38 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.267 -0.896 . . . . 0.0 110.836 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -74.41 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.558 -0.714 . . . . 0.0 111.691 -178.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -70.04 -39.97 75.43 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.347 -0.846 . . . . 0.0 109.938 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.454 ' CD2' HG23 ' A' ' 37' ' ' VAL . 70.1 m-85 -120.67 89.69 45.19 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.9 Cg_endo -70.82 -4.97 15.83 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.317 1.167 . . . . 0.0 112.298 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.7 m -135.13 149.1 49.94 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.019 -1.051 . . . . 0.0 110.406 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.943 HD11 HG21 ' A' ' 43' ' ' VAL . 28.9 tp -72.45 117.59 14.31 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.758 -0.589 . . . . 0.0 110.528 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.89 32.36 0.04 OUTLIER Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.992 -1.099 . . . . 0.0 110.924 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -158.81 -46.28 0.06 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.195 -1.18 . . . . 0.0 110.21 179.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 27' ' ' LEU . 3.0 t -61.05 -59.92 12.29 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.471 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 52.5 Cg_endo -76.63 -28.35 6.68 Favored 'Trans proline' 0 N--CA 1.487 1.146 0 O-C-N 123.182 1.096 . . . . 0.0 109.371 177.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.3 -62.35 0.63 Allowed Glycine 0 N--CA 1.488 2.146 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 -178.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.675 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 165.27 -58.73 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.467 0 C-N-CA 123.248 0.619 . . . . 0.0 109.804 177.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.675 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.23 18.19 0.33 Allowed 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 121.076 1.184 . . . . 0.0 110.937 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -126.94 42.48 3.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.315 -0.866 . . . . 0.0 109.499 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.943 HG21 HD11 ' A' ' 34' ' ' LEU . 12.3 p -123.58 140.77 46.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-O 121.563 0.697 . . . . 0.0 109.73 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.554 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.59 169.09 40.46 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -80.08 157.53 41.19 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.624 -1.79 . . . . 0.0 108.624 178.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.57 HD12 ' H ' ' A' ' 48' ' ' ASP . 1.2 pp -146.23 145.21 23.39 Favored Pre-proline 0 N--CA 1.486 1.361 0 O-C-N 121.48 -1.012 . . . . 0.0 109.221 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.446 ' HD2' ' CE1' ' A' ' 83' ' ' PHE . 38.0 Cg_endo -61.73 -7.19 8.71 Favored 'Trans proline' 0 N--CA 1.506 2.249 0 C-N-CA 122.197 1.931 . . . . 0.0 115.075 -177.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.57 ' H ' HD12 ' A' ' 46' ' ' ILE . 91.4 m-20 -97.46 23.0 8.09 Favored 'General case' 0 N--CA 1.504 2.252 0 O-C-N 120.5 -1.375 . . . . 0.0 112.446 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.645 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.4 mm -110.13 130.1 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.17 -48.1 9.48 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.423 -0.798 . . . . 0.0 112.613 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.72 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.67 -131.48 1.67 Allowed Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.609 -1.758 . . . . 0.0 111.926 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 11.8 t90 -54.79 -22.9 15.77 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 -178.006 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.416 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 42.1 m-20 -147.94 62.51 1.12 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.008 -1.057 . . . . 0.0 110.754 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.645 ' CB ' HG23 ' A' ' 49' ' ' ILE . 50.0 p -58.6 141.97 83.57 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.476 -0.765 . . . . 0.0 110.967 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -77.45 -21.4 11.64 Favored 'Trans proline' 0 C--N 1.319 -0.991 0 O-C-N 123.39 1.205 . . . . 0.0 110.752 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.8 m -97.89 13.81 29.34 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.507 -0.746 . . . . 0.0 111.073 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -68.05 141.34 56.2 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.152 -0.967 . . . . 0.0 109.628 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.8 42.38 11.32 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.2 m -120.03 130.05 54.53 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.395 -1.062 . . . . 0.0 110.198 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 49.1 t -80.14 139.94 36.6 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.097 -177.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.435 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 64.3 m95 -145.27 150.88 37.44 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.543 -0.723 . . . . 0.0 110.376 178.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -109.63 133.02 53.59 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -110.03 128.89 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.443 -0.786 . . . . 0.0 109.727 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 29.5 m -119.98 142.67 48.57 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.831 -0.543 . . . . 0.0 111.662 -177.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.444 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 23.4 pt -119.67 163.55 26.84 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.709 -0.619 . . . . 0.0 110.279 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.54 -23.56 74.88 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 121.3 1.334 . . . . 0.0 112.672 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -66.38 -40.01 89.42 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.274 -0.891 . . . . 0.0 109.83 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.89 60.42 0.29 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -160.02 150.6 18.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.629 -0.924 . . . . 0.0 109.088 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.1 m -151.06 156.91 42.06 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.037 0.923 . . . . 0.0 112.03 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.486 HG12 HD13 ' A' ' 93' ' ' LEU . 39.6 pt -138.0 165.71 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -106.92 127.5 53.49 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 118.964 -1.094 . . . . 0.0 110.145 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.6 mm -115.78 129.96 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.748 -0.595 . . . . 0.0 110.094 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.499 ' HD3' HG12 ' A' ' 37' ' ' VAL . 38.9 ttt180 -99.81 135.03 41.84 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.14 148.29 24.94 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 44' ' ' GLY . 4.8 p -159.9 -37.98 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.767 -0.843 . . . . 0.0 110.057 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.514 ' HB2' HG23 ' A' ' 18' ' ' VAL . 31.3 t70 -133.18 169.96 16.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.002 -1.061 . . . . 0.0 109.495 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.422 ' CA ' ' HB ' ' A' ' 49' ' ' ILE . 86.9 p -97.26 160.05 14.56 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.409 -0.807 . . . . 0.0 110.899 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.94 141.74 12.94 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -60.73 -39.93 90.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.808 -0.819 . . . . 0.0 110.663 178.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.35 71.73 0.09 OUTLIER Glycine 0 N--CA 1.494 2.535 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.63 168.91 15.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.604 ' HB2' HG22 ' A' ' 3' ' ' ILE . 96.3 m-85 -98.49 128.57 44.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.755 -0.85 . . . . 0.0 109.948 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 47.6 t-20 -120.63 131.02 54.4 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.378 -0.826 . . . . 0.0 109.531 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.2 m -131.09 174.06 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.064 -1.023 . . . . 0.0 111.387 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.1 m-20 -55.78 153.14 17.16 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.355 -0.841 . . . . 0.0 109.996 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.76 -26.23 53.0 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 123.381 1.2 . . . . 0.0 110.019 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.9 m -70.72 -39.98 73.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.092 -1.005 . . . . 0.0 108.982 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.73 79.04 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -60.08 -50.02 75.37 Favored 'General case' 0 N--CA 1.499 2.018 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.689 179.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.8 m -60.04 -38.61 83.28 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.482 -0.761 . . . . 0.0 110.463 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.07 -39.75 75.46 Favored 'General case' 0 N--CA 1.493 1.694 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.937 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.486 HD13 HG12 ' A' ' 71' ' ' ILE . 47.9 tp -70.07 -43.58 70.86 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.555 -0.715 . . . . 0.0 111.668 -179.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -95.01 -37.63 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.134 0 O-C-N 121.251 -0.906 . . . . 0.0 110.967 -178.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.26 5.5 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.0 p -156.7 168.76 26.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -1.013 . . . . 0.0 110.121 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 55.1 p -96.77 8.41 44.35 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 110.801 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.04 -29.59 66.66 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.374 -0.829 . . . . 0.0 110.409 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.1 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.565 -0.709 . . . . 0.0 110.54 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 79.02 -83.67 1.28 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 29.2 ttt180 -130.03 133.13 46.53 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.627 -0.926 . . . . 0.0 110.133 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.68 120.13 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.489 -0.757 . . . . 0.0 110.304 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 43.7 p-10 -83.23 174.81 10.43 Favored 'General case' 0 N--CA 1.494 1.746 0 CA-C-O 121.718 0.77 . . . . 0.0 111.544 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 57.7 t30 59.99 40.66 18.56 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.704 -0.622 . . . . 0.0 112.013 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.624 HG21 HG12 ' A' ' 3' ' ' ILE . 59.3 t -88.91 127.34 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.937 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -85.14 138.32 32.46 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 119.328 -0.949 . . . . 0.0 109.871 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -134.57 140.48 46.15 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.351 0.596 . . . . 0.0 110.746 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 m -142.67 145.25 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.668 -0.645 . . . . 0.0 109.916 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.435 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 55.4 tt0 -85.03 141.62 30.16 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -136.18 176.96 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.718 -0.614 . . . . 0.0 110.088 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -62.03 149.57 40.59 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.443 -0.786 . . . . 0.0 110.575 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.581 HD21 HD11 ' A' ' 116' ' ' ILE . 8.0 tt -60.08 -39.93 87.77 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.488 -0.757 . . . . 0.0 110.992 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 t -51.39 -38.94 55.99 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.424 -0.798 . . . . 0.0 110.822 -178.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -60.91 -39.99 91.45 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.49 -0.756 . . . . 0.0 111.274 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -61.53 -48.22 82.01 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.323 -0.861 . . . . 0.0 110.109 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.581 HD11 HD21 ' A' ' 112' ' ' LEU . 96.5 mt -67.84 -39.92 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.663 -0.648 . . . . 0.0 110.557 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -65.59 -40.0 92.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.463 -0.773 . . . . 0.0 110.571 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.96 -49.37 35.23 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.54 89.46 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.576 -0.955 . . . . 0.0 110.605 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.7 m120 . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 117.93 -1.034 . . . . 0.0 110.273 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 105' ' ' VAL . 27.6 m . . . . . 0 N--CA 1.499 1.994 0 CA-C-O 120.975 0.416 . . . . 0.0 110.415 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 50.5 m -113.3 143.01 45.15 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.537 -0.727 . . . . 0.0 110.795 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.439 HG22 ' HB2' ' A' ' 83' ' ' PHE . 27.9 pt -114.36 149.93 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.81 -0.556 . . . . 0.0 110.861 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.5 p -147.07 -173.46 4.25 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.411 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.1 p90 -142.11 153.33 44.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.355 -0.841 . . . . 0.0 110.246 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.442 ' OD1' HD12 ' A' ' 8' ' ' ILE . 0.9 OUTLIER -132.78 145.94 59.24 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.404 -0.81 . . . . 0.0 110.359 -179.592 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 6' ' ' ASP . 53.2 Cg_endo -88.43 49.75 1.56 Allowed 'Trans proline' 0 N--CA 1.486 1.077 0 O-C-N 123.219 1.115 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.663 ' O ' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -134.05 5.88 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.562 0 O-C-N 120.751 -1.218 . . . . 0.0 110.936 178.196 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.558 ' CE2' HD11 ' A' ' 8' ' ' ILE . 31.5 m-85 -114.15 67.2 0.68 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 122.873 1.321 . . . . 0.0 109.442 178.386 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.31 170.83 7.83 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.858 177.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.98 -32.87 71.24 Favored 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -88.9 11.5 17.85 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.464 -1.397 . . . . 0.0 112.176 -177.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.663 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.5 tp -72.27 125.1 26.51 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.301 -0.874 . . . . 0.0 109.987 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.4 m -70.38 136.19 49.42 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.276 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.715 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -65.26 -16.72 63.85 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.85 -0.531 . . . . 0.0 111.683 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.66 -11.49 80.54 Favored Glycine 0 N--CA 1.496 2.687 0 O-C-N 121.003 -1.061 . . . . 0.0 111.284 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.4 m -89.96 -4.85 57.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.034 -1.274 . . . . 0.0 112.055 -178.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 15' ' ' MET . 9.4 p -100.7 169.02 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.966 -1.084 . . . . 0.0 110.434 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.754 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.06 87.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.15 69.0 4.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.499 -0.751 . . . . 0.0 109.884 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.3 m -108.58 110.81 22.36 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.181 -0.949 . . . . 0.0 110.783 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.406 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 12.6 t-20 50.09 -141.47 0.71 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.747 -0.596 . . . . 0.0 111.406 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 64.64 -150.63 51.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.55 -46.26 16.06 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.977 . . . . 0.0 111.494 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 54' ' ' SER . 73.8 m-70 -89.99 1.99 55.65 Favored 'General case' 0 N--CA 1.504 2.262 0 O-C-N 121.209 -0.932 . . . . 0.0 111.84 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.406 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -54.9 134.24 47.72 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 121.004 -1.06 . . . . 0.0 111.126 -179.019 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.812 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -100.03 -6.86 25.79 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 122.003 -0.704 . . . . 0.0 110.066 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.4 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.5 ttm -60.3 -35.47 75.67 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.258 -0.901 . . . . 0.0 110.088 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.75 -73.74 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.706 -0.622 . . . . 0.0 111.733 -177.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -69.93 -40.04 75.76 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.345 -0.847 . . . . 0.0 110.241 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.5 m-85 -119.81 91.25 44.93 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.53 -11.79 31.91 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.298 1.157 . . . . 0.0 111.579 -178.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.6 m -130.02 143.42 50.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.229 -0.92 . . . . 0.0 110.489 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.875 HD11 HG21 ' A' ' 43' ' ' VAL . 40.4 tp -67.91 119.99 13.46 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.781 -0.574 . . . . 0.0 110.117 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.8 32.53 0.05 OUTLIER Glycine 0 N--CA 1.495 2.623 0 C-N-CA 120.008 -1.092 . . . . 0.0 110.56 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 15.1 mt-10 -155.34 -46.42 0.08 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.312 -1.11 . . . . 0.0 110.14 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.812 HG11 HD13 ' A' ' 27' ' ' LEU . 2.9 t -61.84 -59.61 12.74 Favored Pre-proline 0 N--CA 1.496 1.844 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -76.23 -29.27 6.51 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 N-CA-C 109.184 -1.121 . . . . 0.0 109.184 177.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 128.5 -60.73 0.66 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 107.433 -2.267 . . . . 0.0 107.433 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.608 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 4.5 t80 162.41 -52.5 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.705 0 C-N-CA 123.595 0.758 . . . . 0.0 109.95 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.608 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.07 19.04 0.23 Allowed 'Trans proline' 0 C--N 1.322 -0.819 0 C-N-CA 121.392 1.395 . . . . 0.0 111.347 -178.432 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.8 m-20 -131.81 49.87 2.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.292 -0.88 . . . . 0.0 110.236 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 34' ' ' LEU . 10.4 p -125.97 139.57 51.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-O 121.598 0.713 . . . . 0.0 109.961 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 84' ' ' ASN . . . -169.4 174.28 43.77 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.28 159.28 32.22 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.573 HG22 ' CE1' ' A' ' 83' ' ' PHE . 1.4 pt -149.98 158.09 37.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.662 -0.905 . . . . 0.0 110.634 179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.22 -13.22 35.65 Favored 'Trans proline' 0 N--CA 1.499 1.811 0 C-N-CA 121.419 1.413 . . . . 0.0 114.328 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -94.9 22.23 6.72 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 120.563 -1.336 . . . . 0.0 112.819 -177.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.616 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.5 mm -113.12 129.59 68.55 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.073 -1.017 . . . . 0.0 108.52 178.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.73 12.34 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.395 -0.816 . . . . 0.0 112.229 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.754 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 170.64 -129.56 1.83 Allowed Glycine 0 N--CA 1.489 2.227 0 C-N-CA 118.813 -1.66 . . . . 0.0 111.139 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 44.7 t90 -52.1 -22.35 4.09 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.962 -0.728 . . . . 0.0 112.601 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -149.44 65.75 1.01 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.042 -1.036 . . . . 0.0 110.933 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.616 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.0 p -63.47 135.01 96.07 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.548 -0.72 . . . . 0.0 110.855 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.58 -20.76 23.03 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.333 1.175 . . . . 0.0 110.692 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.493 ' O ' HG23 ' A' ' 59' ' ' THR . 13.7 m -98.1 11.53 37.39 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.489 -0.757 . . . . 0.0 111.116 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -65.98 145.29 56.07 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.176 -0.953 . . . . 0.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.24 29.21 34.26 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.493 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -101.6 147.69 26.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.532 -0.981 . . . . 0.0 110.548 179.48 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.688 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.6 t -97.73 126.96 43.35 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.655 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.491 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 97.5 m95 -131.04 147.67 52.65 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.344 -0.848 . . . . 0.0 110.709 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.7 tttp -109.06 130.7 55.48 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.5 t -110.78 122.56 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.561 -0.712 . . . . 0.0 110.298 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' HG13 ' A' ' 105' ' ' VAL . 98.4 m -121.47 138.73 54.16 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.662 -0.649 . . . . 0.0 110.842 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.491 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 11.1 pt -113.59 165.54 13.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.631 -0.668 . . . . 0.0 110.777 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.491 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.43 -24.88 75.8 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 121.361 1.374 . . . . 0.0 112.825 -178.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -65.32 -39.87 93.01 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.223 -0.923 . . . . 0.0 109.99 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.19 60.07 0.28 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -160.33 152.18 20.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.669 -0.901 . . . . 0.0 108.887 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.418 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -153.75 158.9 41.65 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.047 -1.061 . . . . 0.0 112.373 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.0 pt -139.92 163.38 24.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -104.2 129.15 51.97 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.958 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.0 130.01 71.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.733 -0.604 . . . . 0.0 109.55 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.565 ' HD3' HG12 ' A' ' 37' ' ' VAL . 67.2 ttt180 -100.39 136.28 40.52 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.296 -0.878 . . . . 0.0 109.299 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -56.75 146.73 34.38 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -178.178 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.487 HG22 HG21 ' A' ' 18' ' ' VAL . 5.4 p -158.26 -42.51 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.816 -0.814 . . . . 0.0 109.461 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.527 ' HB2' HG23 ' A' ' 18' ' ' VAL . 16.9 t70 -130.43 168.94 16.17 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.225 -0.922 . . . . 0.0 109.522 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -97.44 160.66 14.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.515 -0.74 . . . . 0.0 111.637 -179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.03 149.37 19.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 65.0 mtt180 -61.88 -33.09 73.59 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.66 -0.906 . . . . 0.0 110.928 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.43 81.57 0.05 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.3 149.99 5.39 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.897 -1.144 . . . . 0.0 110.351 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.573 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -65.78 136.37 56.12 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.968 -0.725 . . . . 0.0 110.388 179.503 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.428 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 56.9 t-20 -134.93 124.23 24.63 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.143 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.9 m -133.81 176.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.133 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.9 m-20 -57.65 154.49 25.34 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.675 -0.64 . . . . 0.0 110.253 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.53 -26.86 46.66 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.468 1.246 . . . . 0.0 110.604 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.0 -40.54 75.23 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.919 -1.113 . . . . 0.0 108.632 178.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.88 -39.92 87.65 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -60.01 -50.06 75.21 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.85 -0.531 . . . . 0.0 110.474 179.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.5 m -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.424 -0.798 . . . . 0.0 110.538 -178.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -69.4 -40.08 77.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.79 -0.764 . . . . 0.0 111.493 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.418 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 40.6 tp -71.49 -43.02 67.32 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.525 -0.734 . . . . 0.0 111.504 -178.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.5 t -96.26 -39.63 9.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.309 -0.87 . . . . 0.0 111.492 -177.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.79 7.42 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.3 p -144.78 157.95 43.98 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.453 -1.027 . . . . 0.0 110.117 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.53 15.77 28.14 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.422 -0.799 . . . . 0.0 110.574 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -93.35 -15.0 26.2 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.452 -0.78 . . . . 0.0 110.761 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.93 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.231 -0.918 . . . . 0.0 110.405 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 86.82 -77.01 2.03 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.415 ' NE ' ' HB3' ' A' ' 2' ' ' SER . 61.6 ttt180 -137.82 135.62 36.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.595 -0.944 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 56.3 t -120.05 119.24 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.421 -0.799 . . . . 0.0 109.477 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.0 p-10 -85.18 177.05 8.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.792 0.806 . . . . 0.0 112.078 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 60.06 40.0 19.09 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.919 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.474 HG13 ' O ' ' A' ' 64' ' ' THR . 86.3 t -95.41 123.27 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.231 179.012 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -84.5 146.72 27.44 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.762 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.428 ' C ' HG13 ' A' ' 108' ' ' VAL . 52.2 p90 -142.14 148.74 38.79 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.923 -0.486 . . . . 0.0 110.907 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.428 HG13 ' C ' ' A' ' 107' ' ' TYR . 24.4 m -149.93 144.91 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 O-C-N 121.348 -0.845 . . . . 0.0 111.782 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.491 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 55.1 tt0 -70.01 140.99 52.98 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.707 -0.62 . . . . 0.0 109.886 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.688 HG23 ' SG ' ' A' ' 60' ' ' CYS . 30.5 m -139.95 172.78 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.992 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -59.86 145.51 45.36 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.382 -0.824 . . . . 0.0 110.862 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.464 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.4 tt -59.99 -40.09 87.94 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.378 -0.826 . . . . 0.0 110.201 179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 70.6 m -54.92 -37.9 66.96 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.627 -0.671 . . . . 0.0 109.847 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -59.98 -39.99 87.56 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.56 -0.712 . . . . 0.0 110.059 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.8 m -64.04 -45.35 89.27 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.489 -0.757 . . . . 0.0 109.225 178.473 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.2 mm -62.89 -45.72 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.259 0.552 . . . . 0.0 110.137 -178.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -66.53 -40.01 88.9 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.796 -0.565 . . . . 0.0 110.553 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.78 -42.93 99.81 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.56 -40.0 94.77 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.574 -0.957 . . . . 0.0 110.535 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 33.6 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.306 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 120.982 0.42 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.4 t -112.96 139.94 48.18 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.695 . . . . 0.0 110.44 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.671 HG21 HG11 ' A' ' 105' ' ' VAL . 44.9 pt -107.71 145.68 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.688 -0.632 . . . . 0.0 110.693 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 3.9 m -144.33 -174.25 4.25 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 45.8 p90 -141.29 147.36 38.06 Favored 'General case' 0 N--CA 1.492 1.671 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.043 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -124.81 145.18 48.96 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.504 -0.747 . . . . 0.0 109.169 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -82.51 -10.08 11.03 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.274 1.144 . . . . 0.0 112.733 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.828 ' O ' HD23 ' A' ' 13' ' ' LEU . 48.9 pt -70.03 -40.04 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 120.947 -1.096 . . . . 0.0 111.37 -179.183 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.475 ' N ' HG13 ' A' ' 8' ' ' ILE . 42.6 m-85 -73.11 67.34 0.9 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 122.874 1.321 . . . . 0.0 111.698 -178.729 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.91 173.86 6.12 Favored 'General case' 0 N--CA 1.489 1.505 0 CA-C-N 114.401 -1.272 . . . . 0.0 108.107 176.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.5 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -56.71 -30.35 63.4 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -175.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -89.99 11.55 20.23 Favored 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 118.237 -1.385 . . . . 0.0 112.262 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.828 HD23 ' O ' ' A' ' 8' ' ' ILE . 0.4 OUTLIER -67.51 119.78 12.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.295 -0.878 . . . . 0.0 109.878 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.454 ' N ' HD13 ' A' ' 13' ' ' LEU . 50.5 m -70.11 137.01 50.78 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.759 0.79 . . . . 0.0 110.007 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.776 ' O ' HG12 ' A' ' 18' ' ' VAL . 95.4 mmm -64.24 -21.87 66.74 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.885 -0.51 . . . . 0.0 111.634 -179.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.436 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.32 -16.07 77.13 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 121.065 -1.022 . . . . 0.0 111.514 -178.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.4 m -90.0 -4.71 57.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.121 -1.223 . . . . 0.0 111.923 -178.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.776 HG12 ' O ' ' A' ' 15' ' ' MET . 9.9 p -101.04 168.64 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.959 -1.088 . . . . 0.0 110.618 -179.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.673 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.0 -42.73 94.87 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.476 -0.765 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.5 m -80.47 71.98 7.33 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.85 -76.96 0.51 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.507 -0.746 . . . . 0.0 109.952 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -127.84 168.55 15.02 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.648 -0.658 . . . . 0.0 109.584 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.21 -154.95 16.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 -178.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -70.72 -42.77 70.15 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -1.109 . . . . 0.0 110.186 179.243 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.56 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 19.7 m80 -92.61 3.35 55.73 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.412 -0.805 . . . . 0.0 110.836 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.05 129.74 48.07 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.45 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.407 HD13 HH21 ' A' ' 74' ' ' ARG . 85.8 mt -99.71 -3.12 33.64 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 122.039 -0.683 . . . . 0.0 110.21 179.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.436 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 58.8 tpp -60.01 -38.59 83.11 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.336 -0.853 . . . . 0.0 110.365 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.77 -75.05 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.68 -0.637 . . . . 0.0 112.195 -177.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -70.05 -41.17 74.56 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.325 -0.86 . . . . 0.0 111.446 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.641 ' CG ' HG23 ' A' ' 37' ' ' VAL . 97.6 m-85 -122.84 86.4 50.21 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.648 -0.657 . . . . 0.0 110.474 -178.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.06 -7.42 21.36 Favored 'Trans proline' 0 C--N 1.317 -1.099 0 O-C-N 123.387 1.203 . . . . 0.0 111.475 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.3 m -130.02 142.98 50.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.05 -1.031 . . . . 0.0 110.189 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.906 HD11 HG21 ' A' ' 43' ' ' VAL . 39.6 tp -75.4 117.83 17.62 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.78 -0.575 . . . . 0.0 110.644 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.05 30.29 0.05 OUTLIER Glycine 0 N--CA 1.496 2.676 0 C-N-CA 120.092 -1.052 . . . . 0.0 110.812 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 8.9 mt-10 -153.66 -52.79 0.1 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.218 -1.166 . . . . 0.0 110.336 179.641 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.641 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -60.65 -59.63 13.24 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 45.7 Cg_endo -73.36 -32.45 8.09 Favored 'Trans proline' 0 N--CA 1.486 1.068 0 N-CA-C 109.114 -1.148 . . . . 0.0 109.114 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.81 -64.35 0.61 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 107.739 -2.144 . . . . 0.0 107.739 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 162.75 -55.8 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.787 0 C-N-CA 123.477 0.711 . . . . 0.0 110.627 177.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -101.07 13.09 0.44 Allowed 'Trans proline' 0 N--CA 1.48 0.715 0 C-N-CA 121.348 1.365 . . . . 0.0 111.522 -178.333 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -122.21 45.76 2.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.223 -179.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.906 HG21 HD11 ' A' ' 34' ' ' LEU . 12.6 p -126.78 141.06 47.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.832 0.825 . . . . 0.0 110.19 -179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.84 173.3 43.4 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.568 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.26 159.23 30.85 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.009 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.768 HD11 ' HA2' ' A' ' 75' ' ' GLY . 1.0 OUTLIER -153.38 160.18 31.25 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.581 -0.952 . . . . 0.0 109.493 179.564 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.14 -37.67 31.26 Favored 'Trans proline' 0 N--CA 1.505 2.184 0 C-N-CA 121.831 1.687 . . . . 0.0 116.125 -175.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -69.7 -9.95 56.4 Favored 'General case' 0 N--CA 1.509 2.493 0 O-C-N 120.561 -1.337 . . . . 0.0 112.974 -176.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 54' ' ' SER . 44.4 mm -77.04 125.04 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 O-C-N 120.713 -1.242 . . . . 0.0 108.527 178.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.18 -46.78 12.31 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.261 -0.899 . . . . 0.0 112.568 -178.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.673 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 171.94 -137.5 4.33 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.716 -1.707 . . . . 0.0 111.54 -179.311 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 58.2 t90 -42.88 -29.62 0.34 Allowed 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.401 ' HB2' ' CE3' ' A' ' 52' ' ' TRP . 25.4 t70 -144.98 62.27 1.31 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 110.508 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.579 ' CB ' HG23 ' A' ' 49' ' ' ILE . 12.5 p -61.82 139.31 95.55 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.651 -0.656 . . . . 0.0 110.651 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.56 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 51.3 Cg_endo -76.17 -21.36 13.81 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 O-C-N 123.373 1.196 . . . . 0.0 111.113 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.7 m -94.05 14.49 19.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.491 -0.755 . . . . 0.0 111.296 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.3 t -73.85 147.89 42.86 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.16 35.31 53.51 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.421 HG22 ' NE1' ' A' ' 61' ' ' TRP . 89.2 m -119.68 131.55 55.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.595 -0.944 . . . . 0.0 109.882 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.04 145.66 33.73 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.871 -177.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.445 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -149.83 149.34 30.35 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.684 -0.635 . . . . 0.0 110.124 178.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -112.16 135.55 52.67 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.6 t -108.77 126.77 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.8 m -119.22 140.39 50.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.964 -0.46 . . . . 0.0 110.834 -178.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.449 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 39.3 pt -119.16 164.2 22.58 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.616 -0.677 . . . . 0.0 110.531 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.1 -24.41 79.28 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 121.273 1.315 . . . . 0.0 112.338 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -63.89 -40.02 95.54 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.272 -0.892 . . . . 0.0 109.58 179.373 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.95 62.57 0.41 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 48.6 t-20 -162.01 153.45 18.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.708 -0.878 . . . . 0.0 108.975 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.4 p -154.64 160.96 41.75 Favored 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 119.261 -0.975 . . . . 0.0 112.329 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.527 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.0 pt -136.35 164.44 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -108.65 126.75 53.31 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.16 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.782 HD13 HG11 ' A' ' 85' ' ' VAL . 88.0 mt -129.99 140.0 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.254 -0.904 . . . . 0.0 111.454 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.466 ' CD ' HG12 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -100.87 144.35 29.94 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.868 -0.52 . . . . 0.0 109.654 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.768 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.54 151.06 46.93 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -179.478 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.559 HG11 HG22 ' A' ' 43' ' ' VAL . 2.7 p -155.73 -44.1 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 178.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.466 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.9 t70 -130.3 170.0 14.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 178.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.7 t -101.48 159.94 14.86 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.775 . . . . 0.0 111.318 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -130.13 154.32 20.5 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.1 mtt180 -59.97 -31.56 70.01 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.555 -0.967 . . . . 0.0 110.403 179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.17 81.73 0.05 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 119.979 -1.105 . . . . 0.0 110.571 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.06 163.9 11.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.161 -1.176 . . . . 0.0 110.161 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.577 ' CD2' HG22 ' A' ' 46' ' ' ILE . 28.0 m-85 -88.36 118.63 28.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.512 -0.993 . . . . 0.0 109.746 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.406 ' HA ' ' O ' ' A' ' 4' ' ' SER . 54.6 t-20 -113.04 128.71 56.57 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.782 HG11 HD13 ' A' ' 73' ' ' ILE . 34.5 m -130.02 172.56 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 120.862 -1.149 . . . . 0.0 112.008 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 -56.52 156.22 12.26 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.504 -0.748 . . . . 0.0 109.594 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.44 -28.49 54.11 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.276 1.145 . . . . 0.0 110.663 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -70.28 -40.63 74.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.99 -1.069 . . . . 0.0 109.382 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.65 89.2 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -60.02 -49.84 76.08 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.826 -0.546 . . . . 0.0 110.311 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.9 m -60.11 -39.98 88.11 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.586 -0.696 . . . . 0.0 110.754 -178.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -68.67 -39.98 80.35 Favored 'General case' 0 N--CA 1.495 1.813 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.172 -178.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.402 HD13 HG23 ' A' ' 71' ' ' ILE . 63.1 tp -70.27 -42.9 71.52 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.627 -0.67 . . . . 0.0 111.749 -178.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 92.7 t -97.05 -39.93 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.312 -0.868 . . . . 0.0 111.829 -177.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.07 -25.75 7.36 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 80.9 p -149.93 161.03 43.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.351 -1.088 . . . . 0.0 110.317 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 77.4 p -99.1 1.87 45.54 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.477 -0.765 . . . . 0.0 111.298 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -69.96 -28.65 65.73 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.388 -0.82 . . . . 0.0 111.466 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.82 -40.63 89.06 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.396 -0.815 . . . . 0.0 111.272 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 89.42 -66.26 2.98 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -151.23 155.99 39.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.486 -1.008 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.97 117.65 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.551 -0.718 . . . . 0.0 109.785 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -80.62 169.51 17.55 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.474 -0.766 . . . . 0.0 110.427 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 60.0 51.81 5.62 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.628 -0.67 . . . . 0.0 111.347 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.671 HG11 HG21 ' A' ' 3' ' ' ILE . 65.8 t -98.66 129.99 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.434 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -89.04 138.68 31.19 Favored 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.804 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.405 ' C ' HG13 ' A' ' 108' ' ' VAL . 38.3 p90 -133.3 140.98 47.75 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.907 -0.496 . . . . 0.0 110.557 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -146.03 143.0 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.589 -0.694 . . . . 0.0 111.242 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.445 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.2 tt0 -70.88 139.78 50.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.681 -0.637 . . . . 0.0 110.444 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.07 163.27 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.098 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -59.62 141.38 55.12 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.543 -0.723 . . . . 0.0 110.478 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.0 -40.0 87.7 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.598 -0.689 . . . . 0.0 111.391 -179.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 78.6 p -55.72 -34.23 64.95 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.503 -0.748 . . . . 0.0 110.935 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -69.92 -28.08 65.31 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.348 -0.845 . . . . 0.0 111.339 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 97.3 m -69.96 -46.45 65.22 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.23 -0.919 . . . . 0.0 109.179 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 89.2 mt -69.96 -40.01 78.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.143 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -64.56 -40.0 94.78 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.459 -0.776 . . . . 0.0 110.618 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -83.81 -60.01 2.02 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.454 -0.879 . . . . 0.0 110.93 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.04 -42.52 94.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.611 -0.934 . . . . 0.0 111.202 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.502 2.172 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.727 -179.711 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.573 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.694 0.759 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.9 p -111.81 138.94 47.73 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.712 HG23 HG21 ' A' ' 105' ' ' VAL . 29.9 pt -108.78 145.36 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.801 -0.562 . . . . 0.0 110.481 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.4 p -144.22 -173.32 3.98 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 39.4 p90 -140.02 141.24 36.32 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.456 -0.777 . . . . 0.0 110.696 179.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.14 150.07 50.55 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.483 -0.761 . . . . 0.0 109.284 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -82.83 -10.53 10.51 Favored 'Trans proline' 0 C--N 1.318 -1.067 0 O-C-N 123.105 1.055 . . . . 0.0 112.551 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.9 pt -70.06 -39.96 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.002 -1.061 . . . . 0.0 111.62 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.687 ' HA ' HD22 ' A' ' 13' ' ' LEU . 53.7 m-85 -73.2 67.51 0.95 Allowed 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 122.875 1.321 . . . . 0.0 111.907 -178.32 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.8 169.65 8.36 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.854 176.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.521 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.87 -35.09 70.48 Favored 'General case' 0 N--CA 1.497 1.912 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -90.23 10.39 24.86 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 120.497 -1.377 . . . . 0.0 112.295 -177.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 9' ' ' TYR . 34.8 tp -68.49 123.45 20.85 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -0.865 . . . . 0.0 109.829 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.3 m -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.806 -0.758 . . . . 0.0 109.775 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.811 ' O ' HG12 ' A' ' 18' ' ' VAL . 86.6 mtp -69.96 -15.28 63.02 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.91 -0.494 . . . . 0.0 111.864 -178.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.58 -15.95 73.59 Favored Glycine 0 N--CA 1.496 2.654 0 O-C-N 121.021 -1.049 . . . . 0.0 110.816 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.5 m -90.05 -4.99 57.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.175 -1.191 . . . . 0.0 111.716 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.811 HG12 ' O ' ' A' ' 15' ' ' MET . 14.8 p -102.26 168.96 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.026 -1.046 . . . . 0.0 110.877 -179.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.7 89.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.575 -0.703 . . . . 0.0 110.368 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 54.1 m -83.45 74.84 10.05 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.2 m -100.41 -77.04 0.54 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.385 -0.822 . . . . 0.0 110.388 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -129.68 169.98 14.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 0.0 110.485 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.46 -154.4 16.45 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -70.2 -40.94 74.3 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -1.073 . . . . 0.0 109.791 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.553 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 16.5 m80 -91.82 0.59 57.48 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.519 -0.738 . . . . 0.0 110.982 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -52.42 126.07 30.33 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HB2' ' HE2' ' A' ' 15' ' ' MET . 87.2 mt -96.53 -9.42 29.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 122.032 -0.687 . . . . 0.0 110.128 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.5 tpp -59.95 -37.03 78.39 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.35 -0.844 . . . . 0.0 110.006 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -74.37 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.513 -0.742 . . . . 0.0 111.983 -178.087 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -69.98 -39.99 75.6 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.237 -0.915 . . . . 0.0 110.455 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD2' HG23 ' A' ' 37' ' ' VAL . 87.3 m-85 -117.39 100.95 52.99 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.04 -20.92 16.31 Favored 'Trans proline' 0 C--N 1.318 -1.046 0 O-C-N 123.307 1.161 . . . . 0.0 111.367 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 30.2 m -127.84 148.32 50.46 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.371 -0.831 . . . . 0.0 111.017 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.97 HD21 HG11 ' A' ' 43' ' ' VAL . 57.7 tp -67.13 120.44 13.72 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.784 -0.573 . . . . 0.0 110.374 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.46 30.02 0.05 OUTLIER Glycine 0 N--CA 1.495 2.603 0 C-N-CA 119.891 -1.147 . . . . 0.0 110.963 179.49 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 31.7 mt-10 -153.18 -48.67 0.1 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.226 -1.161 . . . . 0.0 110.325 179.09 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.551 HG23 ' CD2' ' A' ' 31' ' ' TYR . 3.2 t -60.55 -60.48 10.5 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.461 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -75.67 -27.57 8.86 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.113 1.059 . . . . 0.0 109.466 177.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.406 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.27 -58.93 0.67 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.414 -2.274 . . . . 0.0 107.414 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.565 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 165.89 -73.57 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.615 0 C-N-CA 123.666 0.786 . . . . 0.0 109.356 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.565 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -86.21 19.19 1.43 Allowed 'Trans proline' 0 N--CA 1.493 1.465 0 CA-C-N 119.306 0.788 . . . . 0.0 111.16 178.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -118.37 37.03 4.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.059 -1.026 . . . . 0.0 110.18 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.97 HG11 HD21 ' A' ' 34' ' ' LEU . 12.4 p -120.71 141.23 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-O 121.757 0.789 . . . . 0.0 110.716 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.99 171.38 42.92 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.08 152.24 32.63 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.761 HG22 ' CE1' ' A' ' 83' ' ' PHE . 13.7 pt -141.88 156.81 65.41 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.665 -0.903 . . . . 0.0 109.742 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.3 -20.5 36.93 Favored 'Trans proline' 0 N--CA 1.499 1.841 0 C-N-CA 121.399 1.4 . . . . 0.0 113.966 -177.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -88.92 20.68 3.44 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.805 -1.184 . . . . 0.0 112.541 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.835 HG23 ' CB ' ' A' ' 54' ' ' SER . 40.7 mt -120.02 120.0 61.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.074 -1.016 . . . . 0.0 108.398 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.48 -41.82 21.19 Favored 'General case' 0 N--CA 1.499 2.015 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -176.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.563 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.83 -138.96 4.6 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 118.323 -1.894 . . . . 0.0 112.171 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.504 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 26.3 t90 -39.95 -30.06 0.08 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -146.72 68.52 1.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.998 -1.064 . . . . 0.0 111.24 -178.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.835 ' CB ' HG23 ' A' ' 49' ' ' ILE . 2.1 t -64.51 136.87 96.94 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.622 -0.674 . . . . 0.0 110.586 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.553 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 48.6 Cg_endo -73.29 -20.55 21.06 Favored 'Trans proline' 0 C--N 1.32 -0.968 0 O-C-N 123.303 1.159 . . . . 0.0 110.605 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.9 m -99.84 14.82 29.03 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.499 -0.751 . . . . 0.0 110.806 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 23.4 t -72.75 151.12 42.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.238 -0.913 . . . . 0.0 110.061 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.18 21.75 78.62 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 80.4 m -106.58 140.01 40.13 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.515 -0.991 . . . . 0.0 110.277 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.703 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.3 t -78.59 136.21 37.46 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.687 -178.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.434 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -137.21 146.24 44.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.647 -0.658 . . . . 0.0 110.016 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -116.28 136.46 52.98 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.222 -0.924 . . . . 0.0 110.099 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -114.25 129.99 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.543 -0.723 . . . . 0.0 110.887 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 51.1 m -119.92 144.96 47.16 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.723 -0.611 . . . . 0.0 110.501 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.453 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.6 pt -123.44 164.33 28.85 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.307 -0.871 . . . . 0.0 111.11 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.28 -26.88 82.53 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.428 1.419 . . . . 0.0 112.574 -178.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -63.45 -39.71 95.2 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.317 -0.864 . . . . 0.0 109.741 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 115.26 61.65 0.37 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -160.6 153.29 20.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.832 -0.805 . . . . 0.0 109.077 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.402 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 84.0 p -150.65 158.49 44.21 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 122.18 0.99 . . . . 0.0 112.021 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.455 HG12 HD13 ' A' ' 93' ' ' LEU . 27.6 pt -138.7 162.77 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.27 123.83 48.89 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 118.859 -1.136 . . . . 0.0 109.794 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.403 HG13 HG11 ' A' ' 85' ' ' VAL . 48.5 mm -117.13 131.99 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.489 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.5 ttt180 -98.65 132.38 44.1 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.152 -0.968 . . . . 0.0 108.783 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.89 148.35 10.44 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.555 HG11 HG22 ' A' ' 43' ' ' VAL . 5.6 p -159.96 -35.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.792 -0.828 . . . . 0.0 110.406 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.456 ' HB2' HG23 ' A' ' 18' ' ' VAL . 28.4 t70 -128.94 165.28 21.38 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.885 -1.134 . . . . 0.0 110.449 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.443 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 79.4 p -82.54 159.78 22.73 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.656 -0.653 . . . . 0.0 110.521 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -127.49 135.4 8.73 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -65.44 -39.95 92.67 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.923 -0.751 . . . . 0.0 109.608 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 176.29 70.28 0.05 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.46 -163.18 33.35 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.59 -1.29 . . . . 0.0 110.766 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.761 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -123.34 136.61 54.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 122.025 -0.691 . . . . 0.0 109.415 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 45.3 t-20 -137.97 126.89 24.02 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.389 -0.925 . . . . 0.0 108.808 178.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.8 m -133.63 176.8 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.08 -1.012 . . . . 0.0 111.128 -178.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.3 m-20 -56.47 150.25 35.17 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.91 -25.68 67.11 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 O-C-N 123.367 1.193 . . . . 0.0 110.763 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' HE2' ' A' ' 92' ' ' LYS . 89.8 m -70.8 -40.03 72.77 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.976 -1.078 . . . . 0.0 109.308 178.423 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.03 91.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.04 -49.93 75.74 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.868 -0.52 . . . . 0.0 110.586 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.1 m -60.11 -39.94 87.98 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.439 -0.788 . . . . 0.0 110.606 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.434 ' HE2' HG22 ' A' ' 88' ' ' THR . 57.8 mtmt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.273 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.455 HD13 HG12 ' A' ' 71' ' ' ILE . 45.9 tp -71.6 -46.12 60.16 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 120.047 -0.661 . . . . 0.0 111.357 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.1 t -89.46 -41.39 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.4 -0.812 . . . . 0.0 111.334 -177.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 125.2 -27.25 5.37 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.7 p -158.85 162.32 36.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.551 -0.97 . . . . 0.0 110.024 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.9 p -91.97 1.57 57.1 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.478 -0.764 . . . . 0.0 111.372 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.66 -34.08 77.05 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.36 -41.5 80.25 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.45 -0.781 . . . . 0.0 111.456 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.41 -80.47 1.82 Allowed Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.3 ttm180 -129.0 136.82 50.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.575 -0.956 . . . . 0.0 109.918 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.6 t -119.02 117.29 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.243 -0.91 . . . . 0.0 110.299 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -83.84 171.57 12.98 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.525 0.679 . . . . 0.0 110.65 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.52 52.0 1.87 Allowed 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.623 -0.673 . . . . 0.0 111.06 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.712 HG21 HG23 ' A' ' 3' ' ' ILE . 60.4 t -103.24 129.81 54.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 C-N-CA 119.279 -0.968 . . . . 0.0 110.607 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -90.64 137.92 31.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.309 -0.87 . . . . 0.0 109.6 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.469 ' C ' HG13 ' A' ' 108' ' ' VAL . 53.8 p90 -140.04 145.83 38.24 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.902 -0.499 . . . . 0.0 110.835 -178.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.469 HG13 ' C ' ' A' ' 107' ' ' TYR . 29.6 m -151.1 151.58 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.216 -0.928 . . . . 0.0 111.273 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.434 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.0 tt0 -72.37 141.05 48.75 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.682 -0.636 . . . . 0.0 110.47 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.703 HG23 ' SG ' ' A' ' 60' ' ' CYS . 15.7 m -137.03 170.03 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -64.21 148.85 49.14 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.175 -0.953 . . . . 0.0 110.645 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.543 HD21 HD11 ' A' ' 116' ' ' ILE . 9.4 tt -60.08 -39.77 87.21 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.495 -0.753 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 89.3 p -52.24 -37.41 55.13 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.413 -0.805 . . . . 0.0 110.614 -178.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.31 -39.27 93.57 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.583 -0.698 . . . . 0.0 111.089 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -59.97 -50.02 75.4 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.394 -0.816 . . . . 0.0 110.064 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 112' ' ' LEU . 86.9 mt -69.84 -39.98 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.715 -0.616 . . . . 0.0 110.773 -179.235 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -39.98 96.24 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.39 -0.819 . . . . 0.0 110.521 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -72.66 -47.32 27.41 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.174 -1.171 . . . . 0.0 110.174 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.99 -40.78 90.33 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.502 -0.999 . . . . 0.0 110.707 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.5 t30 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.276 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.013 0.435 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.2 t -113.68 139.19 49.27 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.672 0.749 . . . . 0.0 111.045 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.77 HG12 HG21 ' A' ' 105' ' ' VAL . 36.3 pt -111.02 147.65 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.83 -0.544 . . . . 0.0 109.797 179.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.1 m -146.09 -171.52 3.73 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.418 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 47.7 p90 -140.12 150.01 43.75 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.119 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -126.67 148.07 63.33 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.521 -0.737 . . . . 0.0 110.216 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -86.57 14.14 2.53 Favored 'Trans proline' 0 C--N 1.317 -1.09 0 O-C-N 123.399 1.21 . . . . 0.0 111.636 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 1.4 pt -100.1 10.06 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.029 -1.044 . . . . 0.0 111.666 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -123.46 66.64 1.0 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.701 1.239 . . . . 0.0 110.259 178.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.07 172.76 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.459 -1.246 . . . . 0.0 108.447 176.592 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.03 -31.97 67.51 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -175.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -89.76 11.98 18.44 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.332 -1.347 . . . . 0.0 111.9 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 14' ' ' SER . 0.6 OUTLIER -69.3 119.56 13.77 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.281 -0.887 . . . . 0.0 110.043 179.875 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.47 ' N ' HD13 ' A' ' 13' ' ' LEU . 52.6 m -69.18 135.85 51.24 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.757 -0.777 . . . . 0.0 108.958 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.726 ' O ' HG12 ' A' ' 18' ' ' VAL . 57.1 mtp -70.21 -14.59 62.69 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 120.211 -0.596 . . . . 0.0 111.926 -179.234 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.65 -18.61 74.08 Favored Glycine 0 N--CA 1.495 2.6 0 O-C-N 120.848 -1.157 . . . . 0.0 110.654 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 70.4 m -88.06 -9.64 52.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.289 -1.124 . . . . 0.0 111.615 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 15' ' ' MET . 9.7 p -101.74 169.66 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.029 -1.044 . . . . 0.0 110.495 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.14 -39.76 83.39 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.568 -0.708 . . . . 0.0 110.594 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.31 82.84 3.08 Favored 'General case' 0 N--CA 1.5 2.025 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 -84.26 0.42 Allowed 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.794 -1.191 . . . . 0.0 113.395 -177.003 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.6 m-80 -143.8 12.56 1.67 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.564 -1.335 . . . . 0.0 112.752 -177.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.89 -149.19 0.11 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -67.22 -39.89 86.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.891 -0.77 . . . . 0.0 110.456 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.603 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 11.8 p80 -97.86 6.2 48.08 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.31 138.79 35.53 Favored Glycine 0 N--CA 1.5 2.91 0 O-C-N 121.055 -1.028 . . . . 0.0 110.659 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.871 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -102.31 -5.68 23.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.885 -0.774 . . . . 0.0 110.724 179.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.8 ttm -60.44 -33.1 72.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.23 -0.919 . . . . 0.0 110.486 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.79 -72.15 0.06 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.566 -0.709 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -70.0 -40.16 75.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.185 -0.947 . . . . 0.0 110.079 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.422 ' CD2' HG23 ' A' ' 37' ' ' VAL . 60.8 m-85 -122.86 95.16 46.66 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.875 -0.516 . . . . 0.0 109.769 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.63 -19.32 32.13 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 O-C-N 123.398 1.209 . . . . 0.0 111.556 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.7 m -122.61 140.9 52.3 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.296 -0.878 . . . . 0.0 110.736 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.853 HD11 HG21 ' A' ' 43' ' ' VAL . 40.7 tp -61.65 119.91 9.59 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.912 -0.492 . . . . 0.0 110.317 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.77 33.36 0.04 OUTLIER Glycine 0 N--CA 1.496 2.679 0 C-N-CA 119.948 -1.12 . . . . 0.0 110.797 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.66 -45.98 0.06 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.195 -1.179 . . . . 0.0 110.013 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.871 HG11 HD13 ' A' ' 27' ' ' LEU . 3.2 t -62.69 -60.78 8.93 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 178.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.47 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.2 Cg_endo -75.97 -28.15 7.88 Favored 'Trans proline' 0 N--CA 1.485 1.028 0 N-CA-C 109.236 -1.102 . . . . 0.0 109.236 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.402 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.98 -60.93 0.65 Allowed Glycine 0 N--CA 1.486 2.019 0 N-CA-C 107.284 -2.326 . . . . 0.0 107.284 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.622 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.2 t80 164.04 -52.9 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.573 0 C-N-CA 123.381 0.672 . . . . 0.0 109.705 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.4 Cg_endo -101.78 13.94 0.37 Allowed 'Trans proline' 0 C--N 1.324 -0.742 0 C-N-CA 121.457 1.438 . . . . 0.0 111.486 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -123.46 40.73 3.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -0.928 . . . . 0.0 110.112 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.853 HG21 HD11 ' A' ' 34' ' ' LEU . 12.2 p -115.44 135.74 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 CA-C-O 121.602 0.715 . . . . 0.0 110.681 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.432 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -163.94 170.0 39.06 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.471 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -90.37 164.82 30.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.482 HG22 ' CD2' ' A' ' 83' ' ' PHE . 5.2 pt -150.92 163.47 23.64 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.74 -0.859 . . . . 0.0 110.12 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 55.6 Cg_endo -73.69 -15.05 24.41 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 121.43 1.42 . . . . 0.0 113.337 -177.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.412 ' HB2' HD12 ' A' ' 46' ' ' ILE . 79.5 m-20 -90.37 12.7 17.58 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.852 -1.155 . . . . 0.0 112.829 -177.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.784 HG23 ' CB ' ' A' ' 54' ' ' SER . 71.9 mt -110.8 129.92 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.068 -1.02 . . . . 0.0 110.18 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.41 -46.45 12.52 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.537 -0.727 . . . . 0.0 112.159 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.76 -138.91 5.52 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.895 -1.621 . . . . 0.0 111.371 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.492 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.0 t90 -39.81 -28.78 0.05 Allowed 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -179.005 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.603 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 24.6 t70 -141.09 63.96 1.43 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.281 -0.887 . . . . 0.0 110.576 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.784 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.8 t -79.86 139.35 53.83 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.696 -0.627 . . . . 0.0 110.414 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -78.4 -16.63 13.45 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.331 1.174 . . . . 0.0 111.45 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.0 p -98.05 4.84 49.21 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.208 -0.932 . . . . 0.0 112.607 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.424 ' HB3' ' HD1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -61.59 140.36 58.14 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.738 -1.226 . . . . 0.0 109.73 -179.604 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.97 -7.93 80.75 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 120.332 -0.937 . . . . 0.0 110.871 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.4 m -69.42 149.84 47.91 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.117 -1.225 . . . . 0.0 109.514 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.6 130.58 45.14 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.987 -0.446 . . . . 0.0 111.341 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -128.15 140.27 52.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.483 -0.761 . . . . 0.0 109.2 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.452 ' HB2' HG11 ' A' ' 110' ' ' VAL . 86.8 tttt -103.16 132.68 49.24 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.418 HG13 HG11 ' A' ' 105' ' ' VAL . 64.9 t -110.02 124.56 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.621 -0.674 . . . . 0.0 110.499 -179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.5 m -118.66 135.79 54.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.913 -0.492 . . . . 0.0 110.633 -178.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.443 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.9 pt -115.66 163.58 20.31 Favored Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.461 -0.775 . . . . 0.0 110.723 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.65 -27.29 76.0 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 121.411 1.407 . . . . 0.0 113.15 -178.189 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -62.62 -40.0 95.59 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.132 -0.98 . . . . 0.0 109.582 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.9 60.06 0.29 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -155.05 151.11 27.99 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 89.6 p -149.83 153.34 36.6 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.029 0.919 . . . . 0.0 111.747 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.446 HG23 HD13 ' A' ' 93' ' ' LEU . 31.6 pt -139.14 163.09 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -105.51 129.42 53.8 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.871 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.568 ' CD1' HG11 ' A' ' 85' ' ' VAL . 48.9 mm -116.09 128.18 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.662 -0.649 . . . . 0.0 109.614 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.607 ' HD3' HG12 ' A' ' 37' ' ' VAL . 60.3 ttt180 -100.05 137.96 37.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.28 -0.888 . . . . 0.0 108.888 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -53.43 148.21 16.11 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.593 HG11 HG22 ' A' ' 43' ' ' VAL . 3.2 p -159.92 -43.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.837 -0.802 . . . . 0.0 109.164 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.534 ' HB2' HG23 ' A' ' 18' ' ' VAL . 22.8 t70 -132.39 165.48 24.17 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.475 -0.766 . . . . 0.0 109.844 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.4 p -107.62 161.59 14.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 110.158 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -145.01 173.57 25.41 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.1 mtm180 -60.28 -40.03 88.99 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.8 -0.824 . . . . 0.0 112.05 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.06 95.39 0.1 OUTLIER Glycine 0 N--CA 1.504 3.182 0 C-N-CA 119.373 -1.394 . . . . 0.0 111.816 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 150.64 -164.82 29.96 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 3' ' ' ILE . 95.7 m-85 -123.31 120.24 32.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.625 -0.927 . . . . 0.0 109.241 178.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -119.09 130.06 55.4 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 ' CD1' ' A' ' 73' ' ' ILE . 27.5 m -130.02 174.68 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.036 0 O-C-N 121.088 -1.007 . . . . 0.0 111.725 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -57.9 156.8 17.52 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.554 -0.716 . . . . 0.0 109.935 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.36 -27.73 47.3 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.471 1.248 . . . . 0.0 110.705 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.03 -40.08 75.38 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.012 -1.055 . . . . 0.0 109.485 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.84 -40.13 87.85 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.03 -49.96 75.6 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.783 -0.573 . . . . 0.0 110.678 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 66.6 m -59.97 -38.7 83.29 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.532 -0.73 . . . . 0.0 110.601 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -68.25 -39.81 82.12 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.883 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.446 HD13 HG23 ' A' ' 71' ' ' ILE . 54.6 tp -70.0 -42.73 72.68 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.597 -0.689 . . . . 0.0 111.886 -179.098 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -98.66 -36.91 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 O-C-N 121.221 -0.925 . . . . 0.0 111.709 -177.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.47 -28.83 6.11 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -151.59 162.68 40.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.993 . . . . 0.0 110.394 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.3 p -100.97 14.05 33.18 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.913 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -70.03 -36.68 75.23 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.421 -0.799 . . . . 0.0 111.012 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.87 -40.04 87.3 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.514 -0.742 . . . . 0.0 110.894 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.13 -65.75 2.52 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 -143.19 151.65 40.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.579 -0.954 . . . . 0.0 110.313 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -121.86 121.41 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.548 -0.72 . . . . 0.0 109.979 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -90.13 172.19 8.99 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.342 -0.849 . . . . 0.0 110.635 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 64.5 t30 60.05 47.93 9.1 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.546 -0.722 . . . . 0.0 110.441 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.77 HG21 HG12 ' A' ' 3' ' ' ILE . 96.6 t -96.68 124.49 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 119.832 -0.747 . . . . 0.0 110.38 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -82.68 139.92 33.41 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 119.253 -0.979 . . . . 0.0 108.741 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.418 ' C ' HG13 ' A' ' 108' ' ' VAL . 42.3 p90 -135.96 141.86 44.49 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.361 0.601 . . . . 0.0 111.505 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.418 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -147.52 145.8 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.769 -0.582 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -72.08 138.2 47.64 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.635 -0.666 . . . . 0.0 110.069 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LYS . 35.1 m -129.91 162.06 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.738 -0.601 . . . . 0.0 110.3 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -59.65 144.85 46.7 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.483 -0.761 . . . . 0.0 110.301 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.5 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -60.02 -38.26 82.15 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.658 -0.651 . . . . 0.0 111.108 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.6 m -56.28 -39.11 72.14 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.531 -0.731 . . . . 0.0 110.384 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -59.98 -39.98 87.55 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.429 -0.794 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 76.6 m -61.86 -48.63 79.68 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.364 -0.835 . . . . 0.0 110.718 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.5 HD11 HD21 ' A' ' 112' ' ' LEU . 86.3 mt -70.05 -39.99 77.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.653 -0.654 . . . . 0.0 110.668 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.12 -40.03 95.3 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.465 -0.772 . . . . 0.0 110.29 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.88 -47.08 49.44 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -40.26 88.64 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.999 . . . . 0.0 110.5 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.7 t30 . . . . . 0 N--CA 1.502 2.163 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.848 179.791 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.425 HG23 ' HB ' ' A' ' 105' ' ' VAL . 28.3 m . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 120.876 0.37 . . . . 0.0 110.437 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -111.23 141.35 44.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.621 -0.674 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.555 HG22 ' HB3' ' A' ' 83' ' ' PHE . 42.7 pt -116.1 149.24 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.822 -0.549 . . . . 0.0 110.803 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 m -147.3 -172.1 3.94 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -142.83 147.28 35.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.158 -0.964 . . . . 0.0 110.852 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -135.73 152.96 76.98 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 110.079 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -88.15 37.13 0.43 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.318 1.167 . . . . 0.0 111.031 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.598 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.0 tp -106.7 -3.46 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.438 -0.789 . . . . 0.0 111.077 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.494 ' CD2' HG23 ' A' ' 8' ' ' ILE . 42.9 m-85 -122.08 76.91 1.34 Allowed 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 122.769 1.271 . . . . 0.0 111.257 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -108.61 169.97 8.32 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.671 177.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.93 -32.69 71.02 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 -176.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -87.99 11.5 15.78 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 120.503 -1.373 . . . . 0.0 112.336 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.598 HD22 ' O ' ' A' ' 8' ' ' ILE . 40.1 tp -74.61 121.5 21.7 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.2 -0.937 . . . . 0.0 110.227 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.4 m -67.4 138.99 57.12 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.696 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.747 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -68.29 -13.7 62.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.73 -0.606 . . . . 0.0 111.797 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -72.32 -14.49 76.95 Favored Glycine 0 N--CA 1.497 2.703 0 O-C-N 120.98 -1.075 . . . . 0.0 111.312 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.3 t -92.84 -14.88 27.14 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.125 -1.22 . . . . 0.0 111.405 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.747 HG12 ' O ' ' A' ' 15' ' ' MET . 11.9 p -90.05 165.2 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.246 -0.909 . . . . 0.0 111.0 -178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -56.96 -45.38 82.9 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.573 -0.705 . . . . 0.0 110.347 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.8 m -80.89 80.08 7.44 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.32 -80.42 0.43 Allowed 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.116 -0.99 . . . . 0.0 113.216 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -138.86 10.08 2.62 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.102 -0.999 . . . . 0.0 112.605 -177.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.61 -150.46 0.45 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -65.65 -40.04 92.05 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.67 -0.9 . . . . 0.0 109.867 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.565 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 13.2 m80 -99.94 8.95 43.69 Favored 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.464 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.19 137.54 49.16 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.647 HD13 HG11 ' A' ' 37' ' ' VAL . 88.5 mt -98.65 -4.05 34.68 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.812 -0.817 . . . . 0.0 110.262 179.082 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 54.6 ttm -60.1 -39.55 86.56 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.324 -0.86 . . . . 0.0 110.763 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.83 -75.55 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.443 -0.785 . . . . 0.0 111.723 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -70.06 -40.01 75.32 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.425 -0.797 . . . . 0.0 110.387 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 37' ' ' VAL . 94.4 m-85 -119.18 89.43 39.54 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.869 -0.519 . . . . 0.0 110.896 -178.081 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.07 -4.71 15.79 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 O-C-N 123.251 1.132 . . . . 0.0 111.073 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 17.5 p -131.41 155.35 47.47 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.147 -0.971 . . . . 0.0 110.219 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.925 HD11 HG21 ' A' ' 43' ' ' VAL . 58.2 tp -85.1 113.11 21.25 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.326 -0.55 . . . . 0.0 109.769 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 155.24 33.4 0.03 OUTLIER Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.609 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 2.6 mt-10 -157.8 -47.77 0.06 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.248 -1.148 . . . . 0.0 109.954 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.647 HG11 HD13 ' A' ' 27' ' ' LEU . 2.4 t -62.25 -58.0 19.98 Favored Pre-proline 0 N--CA 1.497 1.877 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.661 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.517 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.3 Cg_endo -78.66 -31.62 2.46 Favored 'Trans proline' 0 C--N 1.319 -0.995 0 O-C-N 123.282 1.148 . . . . 0.0 109.29 177.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.26 -61.73 0.66 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.588 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 5.3 t80 161.21 -50.85 0.0 OUTLIER Pre-proline 0 N--CA 1.514 2.752 0 C-N-CA 123.664 0.785 . . . . 0.0 110.19 177.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.588 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 50.5 Cg_endo -101.87 18.41 0.25 Allowed 'Trans proline' 0 C--N 1.326 -0.652 0 C-N-CA 121.744 1.629 . . . . 0.0 111.62 -177.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.4 ' HB3' ' O ' ' A' ' 72' ' ' PHE . 74.9 m-20 -135.95 55.85 1.85 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.253 -0.904 . . . . 0.0 110.277 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.926 HG23 HG11 ' A' ' 76' ' ' VAL . 12.6 p -130.32 141.8 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 CA-C-O 121.681 0.753 . . . . 0.0 110.524 -179.519 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -172.27 179.18 44.03 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.429 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.78 154.61 27.02 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.319 -1.912 . . . . 0.0 108.319 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.616 HG22 ' CE1' ' A' ' 83' ' ' PHE . 5.7 pt -143.44 160.05 52.74 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.512 -0.993 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -69.07 -17.83 40.51 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.142 1.228 . . . . 0.0 114.033 -177.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -93.65 25.41 3.54 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.71 -1.244 . . . . 0.0 112.387 -178.142 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.509 HG12 HG13 ' A' ' 46' ' ' ILE . 37.1 mm -119.94 120.1 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.024 -1.047 . . . . 0.0 109.012 178.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.55 -44.12 29.62 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.195 -0.941 . . . . 0.0 111.977 -178.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.26 -141.55 6.87 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.078 -1.534 . . . . 0.0 111.424 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.488 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.3 t90 -41.49 -29.43 0.16 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -178.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -141.44 57.21 1.52 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.021 -1.049 . . . . 0.0 111.206 -178.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.41 ' HB3' ' HA ' ' A' ' 49' ' ' ILE . 18.2 m -69.05 144.34 95.39 Favored Pre-proline 0 N--CA 1.493 1.713 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.673 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.565 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.6 Cg_endo -74.15 -14.41 23.3 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.328 1.173 . . . . 0.0 111.619 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 70.3 m -103.43 18.4 21.9 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.385 -0.822 . . . . 0.0 111.735 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.467 ' HB2' ' HB3' ' A' ' 25' ' ' HIS . 3.5 m -69.97 139.94 52.89 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.987 -1.071 . . . . 0.0 109.112 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.33 27.66 57.22 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 97.7 m -106.52 138.15 43.22 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.507 -0.996 . . . . 0.0 110.164 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.634 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.2 t -80.04 131.59 35.81 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.389 0.614 . . . . 0.0 110.889 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.444 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.5 m95 -133.99 152.15 51.74 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.541 -0.724 . . . . 0.0 109.379 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.2 tttm -121.69 138.15 54.46 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 120.933 -1.105 . . . . 0.0 110.583 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.444 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.7 t -113.7 126.79 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.615 -0.678 . . . . 0.0 111.344 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.9 m -119.54 141.14 49.49 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.742 -0.599 . . . . 0.0 110.48 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 10.9 pt -119.95 163.93 25.16 Favored Pre-proline 0 N--CA 1.503 2.183 0 O-C-N 121.186 -0.947 . . . . 0.0 110.906 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.9 Cg_endo -62.1 -27.56 79.12 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.564 1.509 . . . . 0.0 113.201 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -62.51 -39.95 95.17 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.244 -0.91 . . . . 0.0 110.045 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.09 60.31 0.31 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -159.92 151.11 19.48 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 86.1 p -151.64 157.77 42.58 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.007 0.908 . . . . 0.0 111.664 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.491 HD12 HD11 ' A' ' 73' ' ' ILE . 41.8 pt -137.83 161.65 32.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.4 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 97.2 m-85 -102.12 121.29 41.93 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 118.581 -1.248 . . . . 0.0 109.187 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.491 HD11 HD12 ' A' ' 71' ' ' ILE . 48.3 mm -110.78 130.6 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.524 ' HD3' HG12 ' A' ' 37' ' ' VAL . 52.4 ttt180 -99.33 132.82 44.39 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.112 -0.993 . . . . 0.0 109.251 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.9 146.67 13.25 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.926 HG11 HG23 ' A' ' 43' ' ' VAL . 7.5 p -169.76 -33.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.863 -0.787 . . . . 0.0 110.323 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.521 ' CG ' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -130.0 171.89 12.3 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 120.925 -1.11 . . . . 0.0 108.711 179.737 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -98.09 142.43 29.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.669 -0.644 . . . . 0.0 109.791 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -114.5 144.79 18.45 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -89.22 103.4 16.02 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.578 -0.954 . . . . 0.0 110.526 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 50.12 56.98 10.73 Favored Glycine 0 N--CA 1.497 2.765 0 O-C-N 121.681 -0.637 . . . . 0.0 111.724 178.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.6 -163.5 33.59 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.045 -1.55 . . . . 0.0 111.915 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.616 ' CE1' HG22 ' A' ' 46' ' ' ILE 0.263 0.1 OUTLIER -123.25 122.5 38.52 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -178.908 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -124.12 129.91 51.65 Favored 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 118.892 -1.123 . . . . 0.0 109.83 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.3 m -132.31 172.88 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.376 -178.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -54.15 156.79 5.12 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.551 -0.718 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.64 -18.72 32.7 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.477 1.251 . . . . 0.0 110.051 179.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -80.02 -40.97 26.71 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.088 -1.008 . . . . 0.0 108.991 178.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.59 89.24 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -59.99 -50.05 75.26 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.808 -0.557 . . . . 0.0 110.573 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.3 m -59.92 -40.05 87.57 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.929 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -69.0 -40.13 78.89 Favored 'General case' 0 N--CA 1.495 1.803 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.29 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 49.7 tp -71.97 -43.36 65.27 Favored 'General case' 0 N--CA 1.496 1.871 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.478 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -92.34 -40.51 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.462 -0.774 . . . . 0.0 111.54 -177.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 126.63 -34.96 3.03 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 95.2 p -152.69 164.63 37.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.664 -0.903 . . . . 0.0 110.262 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 69.8 p -90.18 2.61 55.17 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.42 -0.8 . . . . 0.0 111.194 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -69.94 -27.75 65.01 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.327 -0.858 . . . . 0.0 110.738 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.01 -41.72 83.7 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.57 -0.706 . . . . 0.0 110.619 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.56 -80.7 1.63 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 59.9 ttp180 -130.86 138.88 50.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.565 -0.962 . . . . 0.0 111.042 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.54 114.65 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.608 -0.682 . . . . 0.0 110.428 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -82.46 171.02 14.6 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.665 -0.647 . . . . 0.0 110.588 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.7 t30 60.13 48.35 8.48 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.743 -0.598 . . . . 0.0 111.828 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.443 HG11 HG21 ' A' ' 3' ' ' ILE . 60.7 t -98.1 124.56 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.325 179.276 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t-20 -82.57 134.24 35.19 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.931 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.421 ' C ' HG13 ' A' ' 108' ' ' VAL . 54.4 p90 -135.75 140.85 44.67 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.8 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.421 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.1 m -150.01 154.67 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.237 -0.914 . . . . 0.0 111.001 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.444 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.4 tt0 -74.64 141.53 44.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.713 -0.617 . . . . 0.0 109.834 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.634 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.0 m -139.06 168.89 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 120.047 -0.661 . . . . 0.0 109.553 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -59.92 144.34 49.19 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.356 -0.84 . . . . 0.0 110.964 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.481 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.4 tt -59.9 -36.18 76.43 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.562 -0.711 . . . . 0.0 111.035 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.4 m -56.48 -39.16 72.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.502 -0.749 . . . . 0.0 109.836 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -61.52 -38.57 87.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.562 -0.711 . . . . 0.0 110.859 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.22 -49.61 76.94 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.301 -0.874 . . . . 0.0 109.846 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.434 HD11 HD21 ' A' ' 112' ' ' LEU . 83.7 mt -69.83 -39.92 78.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.632 -0.668 . . . . 0.0 110.662 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -65.02 -40.49 94.95 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.463 -0.773 . . . . 0.0 110.643 -179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.12 -43.75 70.29 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.99 94.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.765 -0.844 . . . . 0.0 110.264 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.389 -179.86 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.486 HG11 ' CE1' ' A' ' 107' ' ' TYR . 35.1 m . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 p -112.47 141.95 45.6 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 122.15 0.976 . . . . 0.0 111.575 -178.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.782 HG12 HG21 ' A' ' 105' ' ' VAL . 35.2 pt -119.97 150.02 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.965 179.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 7.6 m -144.87 -173.0 3.95 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -140.44 147.5 39.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.477 -0.764 . . . . 0.0 109.489 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.658 ' HB3' HG22 ' A' ' 8' ' ' ILE . 8.5 m-20 -138.55 147.68 55.89 Favored Pre-proline 0 N--CA 1.491 1.593 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.823 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -74.39 -6.08 17.83 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 O-C-N 123.455 1.239 . . . . 0.0 110.532 178.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.67 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.3 tp -64.43 -15.86 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.36 -0.837 . . . . 0.0 111.095 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.532 ' CD2' HG23 ' A' ' 8' ' ' ILE . 43.2 m-85 -112.5 69.31 0.69 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 122.72 1.248 . . . . 0.0 110.786 178.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.28 170.03 8.16 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.523 -1.217 . . . . 0.0 108.309 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.9 -32.44 70.75 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -175.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -89.64 11.49 19.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 120.344 -1.473 . . . . 0.0 112.182 -177.341 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.67 HD22 ' O ' ' A' ' 8' ' ' ILE . 28.5 tp -71.6 126.32 29.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.317 -0.864 . . . . 0.0 109.974 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.5 p -70.7 136.9 49.33 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.247 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.611 ' O ' HG12 ' A' ' 18' ' ' VAL . 94.6 mmm -64.66 -15.1 60.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.802 -0.561 . . . . 0.0 111.823 -178.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.66 -12.49 84.43 Favored Glycine 0 N--CA 1.494 2.537 0 O-C-N 121.066 -1.021 . . . . 0.0 111.297 -179.13 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -85.88 -7.21 58.85 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.113 -1.228 . . . . 0.0 111.935 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.611 HG12 ' O ' ' A' ' 15' ' ' MET . 11.0 p -101.4 168.89 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.03 -1.044 . . . . 0.0 110.672 -179.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.03 -42.38 94.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.605 -0.685 . . . . 0.0 109.881 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 70.42 8.47 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.2 p -92.86 -74.89 0.51 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.782 -0.573 . . . . 0.0 109.691 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -130.01 169.93 14.63 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 121.17 -149.0 17.41 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -179.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -73.48 -44.16 58.58 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.641 -0.917 . . . . 0.0 111.05 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.555 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m80 -98.28 8.9 44.18 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.297 -0.877 . . . . 0.0 110.711 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.2 129.94 46.7 Favored Glycine 0 N--CA 1.496 2.657 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.8 mt -100.03 -4.21 30.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 122.041 -0.682 . . . . 0.0 110.245 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 57.2 ttm -61.67 -37.88 85.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.241 -0.912 . . . . 0.0 109.876 179.066 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.5 -74.11 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.671 -0.643 . . . . 0.0 112.059 -177.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -69.96 -40.38 75.44 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.273 -0.892 . . . . 0.0 110.659 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.555 ' CG ' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -120.25 86.3 37.91 Favored Pre-proline 0 N--CA 1.492 1.664 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -178.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.37 -11.18 30.75 Favored 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.383 1.202 . . . . 0.0 111.145 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -130.04 141.19 50.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.177 -0.952 . . . . 0.0 110.105 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.975 HD11 HG21 ' A' ' 43' ' ' VAL . 34.7 tp -69.68 117.46 11.32 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.684 -0.635 . . . . 0.0 110.491 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.43 33.59 0.03 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.079 179.35 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -159.8 -46.07 0.05 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.176 -1.19 . . . . 0.0 110.64 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.555 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -63.0 -59.33 12.75 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.359 -0.838 . . . . 0.0 108.83 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.44 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 47.2 Cg_endo -74.35 -31.77 7.08 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 123.222 1.117 . . . . 0.0 109.408 178.148 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.437 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 134.57 -63.39 0.61 Allowed Glycine 0 N--CA 1.486 1.979 0 N-CA-C 107.116 -2.393 . . . . 0.0 107.116 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.61 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 161.19 -55.12 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.7 0 C-N-CA 123.457 0.703 . . . . 0.0 110.484 177.411 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.813 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.4 Cg_endo -100.68 3.52 0.7 Allowed 'Trans proline' 0 C--N 1.322 -0.828 0 C-N-CA 121.068 1.178 . . . . 0.0 112.09 -178.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.471 HD22 HD11 ' A' ' 71' ' ' ILE . 19.3 m120 -120.19 42.13 3.03 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 0.0 109.415 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.975 HG21 HD11 ' A' ' 34' ' ' LEU . 7.6 p -109.89 142.64 21.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.742 0.782 . . . . 0.0 109.145 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -167.36 172.99 42.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.91 161.54 29.43 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 HD12 ' A' ' 49' ' ' ILE . 18.0 pt -144.49 159.44 51.51 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.705 -0.879 . . . . 0.0 110.684 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HD2' ' CE2' ' A' ' 83' ' ' PHE . 53.7 Cg_endo -71.25 -14.91 31.68 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.511 1.474 . . . . 0.0 113.115 -178.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -91.55 19.45 6.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.016 -1.053 . . . . 0.0 111.948 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.507 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 62.4 mt -119.97 120.22 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.89 . . . . 0.0 108.938 177.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.69 -41.32 21.51 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -177.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 177.29 -126.32 1.09 Allowed Glycine 0 N--CA 1.492 2.38 0 C-N-CA 118.144 -1.979 . . . . 0.0 112.741 -178.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -40.01 -34.6 0.3 Allowed 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -177.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 39.9 p-10 -172.08 82.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.719 -1.238 . . . . 0.0 109.713 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.461 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 8.1 t -68.25 150.65 97.64 Favored Pre-proline 0 N--CA 1.495 1.793 0 O-C-N 121.69 -0.631 . . . . 0.0 110.678 -178.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 41.1 Cg_endo -66.96 -15.86 48.1 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 123.513 1.27 . . . . 0.0 111.194 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' THR . 57.7 m -106.84 9.73 30.86 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.327 -0.858 . . . . 0.0 111.446 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -60.84 141.86 56.7 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.846 -1.159 . . . . 0.0 109.947 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.8 17.13 58.69 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.594 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -91.49 167.31 12.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.282 -1.128 . . . . 0.0 110.055 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -110.13 136.09 49.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.943 -0.473 . . . . 0.0 110.64 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -132.02 137.63 47.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.497 -0.752 . . . . 0.0 109.096 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 77.4 tttt -100.88 133.31 45.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.298 -0.876 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.9 t -109.98 120.49 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.616 -0.678 . . . . 0.0 109.71 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 44.7 m -116.98 141.89 47.65 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.742 -0.599 . . . . 0.0 111.312 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.446 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 36.8 pt -119.61 163.4 27.57 Favored Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.539 -0.726 . . . . 0.0 110.508 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -61.95 -24.69 77.2 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.744 1.391 . . . . 0.0 112.675 -178.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -63.84 -40.08 95.73 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.226 -0.921 . . . . 0.0 109.723 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.67 62.02 0.3 Allowed Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 35.8 t-20 -160.06 153.16 21.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.661 -0.905 . . . . 0.0 109.214 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.679 ' HA ' HD11 ' A' ' 93' ' ' LEU . 83.2 p -150.04 160.1 43.9 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.18 0.991 . . . . 0.0 112.246 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.471 HD11 HD22 ' A' ' 42' ' ' ASN . 12.6 tt -138.96 159.38 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.436 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 93.1 m-85 -104.36 122.35 45.29 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 47.1 mm -114.85 130.01 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.469 -0.77 . . . . 0.0 110.314 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.686 HH12 HG23 ' A' ' 43' ' ' VAL . 5.2 ttp-105 -97.65 139.43 33.55 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.01 146.69 50.51 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -153.1 -43.55 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 122.072 -0.664 . . . . 0.0 109.369 179.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.419 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 18.1 t70 -115.37 162.46 17.1 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.237 -0.915 . . . . 0.0 110.352 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.507 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 26.4 t -79.64 156.8 27.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.818 -0.551 . . . . 0.0 109.608 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -140.62 126.42 3.14 Favored Glycine 0 N--CA 1.482 1.721 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.401 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -59.92 -40.0 87.38 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -167.77 169.13 41.1 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 107.875 -2.09 . . . . 0.0 107.875 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 64.52 -166.84 29.81 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.186 -1.185 . . . . 0.0 112.571 177.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.546 ' HB2' HG22 ' A' ' 3' ' ' ILE . 80.1 m-85 -139.17 139.78 37.66 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 122.225 -0.573 . . . . 0.0 110.754 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.41 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 0.9 OUTLIER -123.58 130.24 52.38 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.019 -1.051 . . . . 0.0 110.14 178.495 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.4 m -129.02 166.53 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.873 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.8 m-20 -54.61 153.65 10.29 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.53 -0.731 . . . . 0.0 110.19 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.24 -30.03 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.498 1.262 . . . . 0.0 110.241 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -69.92 -40.09 75.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.094 -1.004 . . . . 0.0 108.603 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.813 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -67.02 -38.28 85.66 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.11 -49.48 77.47 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.311 0.577 . . . . 0.0 110.099 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.8 m -59.96 -39.73 86.6 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.707 -0.621 . . . . 0.0 110.947 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -68.65 -39.99 80.44 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.707 -178.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.679 HD11 ' HA ' ' A' ' 70' ' ' SER . 52.7 tp -69.94 -40.62 75.37 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.475 -0.765 . . . . 0.0 112.047 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -96.65 -35.98 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.218 0 O-C-N 121.246 -0.909 . . . . 0.0 111.363 -177.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.77 -38.73 2.27 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.291 -1.924 . . . . 0.0 108.291 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 23.1 t -150.0 133.58 16.65 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.836 -0.802 . . . . 0.0 109.271 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.565 HG23 ' O ' ' A' ' 97' ' ' THR . 9.5 t -90.67 66.69 6.22 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.366 -0.834 . . . . 0.0 110.628 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -114.83 -27.18 7.51 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.624 -0.673 . . . . 0.0 110.637 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.08 -39.93 87.8 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -0.76 . . . . 0.0 110.567 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 103.15 -50.94 0.87 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -157.84 160.02 37.29 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.709 -0.877 . . . . 0.0 110.237 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.52 129.97 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 109.83 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -98.14 169.9 9.28 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.206 -179.47 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 61.6 t30 59.91 41.34 17.93 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.564 -0.71 . . . . 0.0 110.219 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.782 HG21 HG12 ' A' ' 3' ' ' ILE . 61.3 t -89.26 122.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.23 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 -80.52 136.13 36.23 Favored 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.12 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.486 ' CE1' HG11 ' A' ' 1' ' ' VAL . 39.6 p90 -134.87 140.98 46.22 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-O 121.278 0.561 . . . . 0.0 111.532 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.36 144.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.714 -0.616 . . . . 0.0 110.61 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -73.21 144.43 46.79 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.612 -0.68 . . . . 0.0 110.318 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.92 168.89 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.618 -0.676 . . . . 0.0 110.509 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -59.96 144.15 49.86 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.547 -0.721 . . . . 0.0 110.448 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.448 HD21 ' CD1' ' A' ' 116' ' ' ILE . 9.4 tt -60.79 -40.03 91.07 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.567 -0.708 . . . . 0.0 110.998 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.9 m -54.61 -35.57 63.53 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.612 -0.68 . . . . 0.0 111.592 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -69.99 -22.13 63.16 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.169 -0.957 . . . . 0.0 111.457 -178.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 96.5 m -75.65 -48.64 21.23 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.2 -0.938 . . . . 0.0 109.35 178.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.448 ' CD1' HD21 ' A' ' 112' ' ' LEU . 94.8 mt -69.96 -40.03 78.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 CA-C-O 121.32 0.581 . . . . 0.0 109.773 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -67.18 -40.03 86.5 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.66 -0.65 . . . . 0.0 110.129 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.7 -49.96 39.64 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.68 -39.92 90.26 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.551 -0.97 . . . . 0.0 110.39 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.316 -179.774 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.482 HG21 ' CD1' ' A' ' 107' ' ' TYR . 34.5 m . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.438 0.637 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 m -113.14 145.19 41.37 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.034 0.921 . . . . 0.0 111.035 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.673 HG12 HG21 ' A' ' 105' ' ' VAL . 19.6 pt -115.19 146.36 19.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.25 -172.45 3.87 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.671 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.9 p90 -143.87 149.95 37.7 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.075 178.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.72 149.18 72.71 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.547 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -85.12 9.26 4.21 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.39 1.205 . . . . 0.0 111.276 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.418 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.3 pt -90.05 -0.21 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.113 -0.992 . . . . 0.0 111.068 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 m-85 -117.35 66.8 0.73 Allowed 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.543 1.164 . . . . 0.0 109.569 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.7 170.64 8.04 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 114.834 -1.076 . . . . 0.0 108.231 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.68 -31.42 64.43 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -89.02 12.93 14.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 120.513 -1.367 . . . . 0.0 112.033 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.458 ' HA ' HD22 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -71.04 118.42 13.8 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.253 -0.904 . . . . 0.0 110.091 -179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.456 ' N ' HD13 ' A' ' 13' ' ' LEU . 40.6 m -68.22 137.63 54.94 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 121.702 0.763 . . . . 0.0 110.43 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.575 ' O ' HG12 ' A' ' 18' ' ' VAL . 5.3 mmt -62.26 -20.02 63.83 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -73.85 -13.68 80.53 Favored Glycine 0 N--CA 1.498 2.79 0 O-C-N 121.037 -1.04 . . . . 0.0 112.079 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.5 -7.77 46.44 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.944 -1.327 . . . . 0.0 112.183 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.773 HG21 HG22 ' A' ' 76' ' ' VAL . 9.5 p -100.03 169.97 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.93 -1.106 . . . . 0.0 110.19 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.783 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.05 -43.5 82.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.279 -0.888 . . . . 0.0 109.711 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.18 83.41 6.06 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.4 m -94.12 -80.0 0.41 Allowed 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.254 -0.904 . . . . 0.0 112.557 -177.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -140.93 11.83 2.23 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.201 -0.937 . . . . 0.0 112.553 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.32 -146.12 0.31 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -69.29 -39.99 77.99 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.812 -0.817 . . . . 0.0 109.268 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.522 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 29.1 m80 -91.48 0.92 57.45 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.689 -0.632 . . . . 0.0 110.696 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.85 132.35 44.37 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.562 HD22 HG21 ' A' ' 37' ' ' VAL . 85.9 mt -98.82 -5.46 31.05 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 122.125 -0.633 . . . . 0.0 110.149 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.428 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.6 ttm -63.24 -37.77 88.54 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.277 -0.889 . . . . 0.0 111.262 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -74.05 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.522 -0.736 . . . . 0.0 111.667 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -70.04 -39.9 75.44 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 109.687 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.45 ' CD2' HG23 ' A' ' 37' ' ' VAL . 44.2 m-85 -120.15 85.39 35.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 39.6 Cg_endo -66.53 -12.14 34.55 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 O-C-N 123.258 1.136 . . . . 0.0 111.228 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.9 m -129.18 146.98 50.99 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.228 -0.92 . . . . 0.0 110.349 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.74 HD11 HG21 ' A' ' 43' ' ' VAL . 45.1 tp -72.61 119.73 17.24 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.714 -0.616 . . . . 0.0 110.779 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.34 34.19 0.04 OUTLIER Glycine 0 N--CA 1.496 2.642 0 C-N-CA 120.067 -1.063 . . . . 0.0 110.485 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.448 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 21.7 tp10 -158.09 -49.18 0.06 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.298 -1.119 . . . . 0.0 110.485 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.562 HG21 HD22 ' A' ' 27' ' ' LEU . 2.7 t -60.63 -59.43 13.88 Favored Pre-proline 0 N--CA 1.499 2.001 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.456 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.2 Cg_endo -76.02 -29.78 6.36 Favored 'Trans proline' 0 N--CA 1.487 1.129 0 O-C-N 123.258 1.136 . . . . 0.0 109.335 177.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.85 -63.0 0.63 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 -178.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.522 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.9 t80 165.18 -72.22 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.571 0 C-N-CA 123.42 0.688 . . . . 0.0 110.017 177.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 57.4 Cg_endo -79.09 -18.99 10.99 Favored 'Trans proline' 0 N--CA 1.492 1.424 0 O-C-N 122.409 0.689 . . . . 0.0 111.579 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.0 m-20 -93.93 55.74 2.16 Favored 'General case' 0 N--CA 1.489 1.491 0 CA-C-O 121.8 0.809 . . . . 0.0 109.71 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.74 HG21 HD11 ' A' ' 34' ' ' LEU . 11.7 p -118.92 129.33 75.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-O 121.385 0.612 . . . . 0.0 109.655 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -161.68 167.59 36.51 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 119.991 -1.099 . . . . 0.0 111.279 -179.216 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.68 164.92 29.33 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 83' ' ' PHE . 10.8 pt -143.55 165.87 22.78 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.824 -0.81 . . . . 0.0 109.762 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 56.9 Cg_endo -77.12 -10.57 17.86 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 120.972 1.115 . . . . 0.0 113.125 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -95.41 16.65 16.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.071 -1.018 . . . . 0.0 111.916 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.802 HG23 ' CB ' ' A' ' 54' ' ' SER . 63.7 mt -109.34 121.31 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.048 -1.032 . . . . 0.0 109.256 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.52 -42.34 43.56 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.426 -0.796 . . . . 0.0 113.13 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.783 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 165.97 -132.59 2.69 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.576 -1.773 . . . . 0.0 112.013 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.526 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 39.3 t90 -44.59 -30.68 0.95 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -178.14 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -143.62 63.2 1.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.358 -0.839 . . . . 0.0 110.134 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.802 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.8 p -66.24 136.32 95.21 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.804 -0.56 . . . . 0.0 111.118 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.522 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 49.4 Cg_endo -73.54 -21.34 19.54 Favored 'Trans proline' 0 C--N 1.32 -0.974 0 O-C-N 123.338 1.178 . . . . 0.0 111.104 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.4 m -96.48 12.01 32.96 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.388 -0.82 . . . . 0.0 111.089 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.56 143.75 56.85 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.124 -0.985 . . . . 0.0 109.713 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.04 25.27 58.08 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 m -106.28 137.35 44.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.487 -1.007 . . . . 0.0 109.857 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.67 131.13 35.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.911 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -130.31 138.56 50.51 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -107.32 135.65 48.47 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.272 -0.893 . . . . 0.0 109.518 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.7 t -111.6 127.82 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.188 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 95.4 m -120.03 139.15 52.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.967 -0.458 . . . . 0.0 110.637 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.456 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 34.3 pt -117.74 163.73 22.88 Favored Pre-proline 0 N--CA 1.5 2.051 0 O-C-N 121.363 -0.836 . . . . 0.0 110.557 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -61.54 -23.04 75.94 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.371 1.381 . . . . 0.0 112.689 -178.616 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -66.52 -40.02 88.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.375 -0.828 . . . . 0.0 109.697 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.29 57.4 0.32 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -150.78 148.62 28.73 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.3 p -151.09 156.23 40.61 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-O 121.93 0.871 . . . . 0.0 111.372 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.657 ' CD1' HD11 ' A' ' 73' ' ' ILE . 43.6 pt -139.46 164.23 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -109.09 126.59 53.35 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.097 -1.041 . . . . 0.0 108.785 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.784 HD13 ' CG1' ' A' ' 85' ' ' VAL . 87.6 mt -129.38 140.0 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.688 -178.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -98.04 139.5 33.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.547 -0.72 . . . . 0.0 109.872 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.71 150.28 39.06 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.773 HG22 HG21 ' A' ' 18' ' ' VAL . 11.9 p -149.45 -39.56 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.751 -0.852 . . . . 0.0 109.901 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.436 ' N ' HG13 ' A' ' 76' ' ' VAL . 15.7 t70 -129.32 168.02 16.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.224 -0.922 . . . . 0.0 110.5 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.478 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 40.6 t -75.28 155.89 36.21 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.618 0.723 . . . . 0.0 111.739 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -137.66 132.26 5.84 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -60.02 -33.05 71.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 109.871 178.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.31 82.37 0.05 OUTLIER Glycine 0 N--CA 1.498 2.788 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.599 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 151.97 -151.66 23.52 Favored Glycine 0 N--CA 1.499 2.866 0 C-N-CA 119.893 -1.146 . . . . 0.0 110.516 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 46' ' ' ILE . 87.0 m-85 -136.02 130.77 34.06 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.295 -1.121 . . . . 0.0 111.381 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.458 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 4.4 t-20 -115.61 127.52 55.28 Favored 'General case' 0 N--CA 1.502 2.152 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 178.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.784 ' CG1' HD13 ' A' ' 73' ' ' ILE . 33.2 m -129.95 164.62 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.363 -177.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-20 -54.54 157.1 5.41 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.328 -0.857 . . . . 0.0 109.897 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.37 -14.35 43.79 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.268 1.141 . . . . 0.0 110.657 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.7 m -82.71 -39.14 22.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.975 -1.078 . . . . 0.0 109.314 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.77 -39.82 84.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.448 -0.783 . . . . 0.0 109.037 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -59.99 -50.02 75.4 Favored 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 120.081 -0.648 . . . . 0.0 110.762 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 73.2 m -60.14 -39.97 88.21 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.368 -0.832 . . . . 0.0 111.071 -178.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -69.68 -40.0 76.66 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.871 -0.732 . . . . 0.0 111.062 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 60.2 tp -70.62 -43.7 68.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.602 -0.686 . . . . 0.0 111.557 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.0 -42.61 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.402 -0.811 . . . . 0.0 111.579 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -20.22 7.93 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.3 t -156.21 159.52 39.02 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.213 -1.169 . . . . 0.0 110.944 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 65.7 p -98.42 6.89 46.86 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.543 -0.723 . . . . 0.0 110.812 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -69.17 -36.76 77.7 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.362 -0.836 . . . . 0.0 111.708 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.52 -40.12 86.09 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.379 -0.826 . . . . 0.0 110.696 -178.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 82.89 -75.03 2.44 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -127.78 133.17 49.46 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.631 -0.923 . . . . 0.0 109.857 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.14 120.14 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.467 -0.771 . . . . 0.0 110.116 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -86.16 178.43 7.2 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.359 0.599 . . . . 0.0 110.707 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.0 t-20 58.88 49.62 9.56 Favored 'General case' 0 N--CA 1.499 2.013 0 CA-C-O 121.28 0.562 . . . . 0.0 111.235 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.673 HG21 HG12 ' A' ' 3' ' ' ILE . 62.5 t -105.77 129.03 59.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.577 -179.381 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -86.61 137.07 32.78 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 118.936 -1.105 . . . . 0.0 109.477 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.482 ' CD1' HG21 ' A' ' 1' ' ' VAL . 38.0 p90 -135.45 141.52 45.41 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.93 -0.481 . . . . 0.0 110.536 -178.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.449 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.0 m -148.09 148.17 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.527 -0.733 . . . . 0.0 111.037 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -76.18 143.52 41.05 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.595 -0.691 . . . . 0.0 110.236 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -137.79 167.83 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.578 -0.701 . . . . 0.0 110.561 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -61.52 148.26 42.66 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.403 -0.81 . . . . 0.0 110.749 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.509 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.6 tt -62.11 -40.07 94.63 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.517 -0.739 . . . . 0.0 112.075 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 82.1 p -53.12 -37.34 61.68 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.263 -0.898 . . . . 0.0 111.023 -178.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -61.12 -37.93 84.54 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.518 -0.739 . . . . 0.0 112.005 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 82.5 m -67.37 -46.29 73.77 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.119 -0.988 . . . . 0.0 110.415 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.509 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.2 mt -70.04 -39.94 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 120.109 -0.636 . . . . 0.0 110.518 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.69 -39.98 88.34 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.13 -46.19 44.92 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.03 -44.15 94.83 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.625 -0.926 . . . . 0.0 110.473 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 13.5 m120 . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.186 179.823 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.434 HG23 ' HB ' ' A' ' 105' ' ' VAL . 27.3 m . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.291 0.567 . . . . 0.0 111.401 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.2 p -111.78 139.85 46.91 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.738 -0.601 . . . . 0.0 109.764 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.726 HG23 HG21 ' A' ' 105' ' ' VAL . 27.9 pt -110.86 144.77 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.734 -0.604 . . . . 0.0 110.854 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.35 -176.02 4.57 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.118 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -140.09 141.62 36.15 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.453 179.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -135.71 151.66 74.67 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.441 -0.787 . . . . 0.0 110.433 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -77.12 0.07 10.09 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.421 1.221 . . . . 0.0 111.506 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.74 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.4 tp -69.54 -14.03 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.276 -0.89 . . . . 0.0 111.274 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.537 ' CD2' HG23 ' A' ' 8' ' ' ILE . 36.7 m-85 -116.72 69.01 0.74 Allowed 'General case' 0 N--CA 1.493 1.683 0 CA-C-O 122.507 1.146 . . . . 0.0 111.335 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.35 168.67 8.92 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.723 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.0 -32.02 70.47 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -88.13 12.08 14.57 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.44 -1.412 . . . . 0.0 112.199 -177.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 8' ' ' ILE . 41.6 tp -73.75 122.36 22.26 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.419 -0.801 . . . . 0.0 109.714 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.6 m -66.29 137.39 56.91 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.72 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -64.32 -18.99 65.14 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.902 -0.499 . . . . 0.0 111.247 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.2 -14.38 76.64 Favored Glycine 0 N--CA 1.493 2.499 0 O-C-N 121.073 -1.017 . . . . 0.0 110.752 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.7 p -91.63 -15.65 28.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -1.194 . . . . 0.0 111.146 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.996 HG21 HG22 ' A' ' 76' ' ' VAL . 7.2 p -90.05 162.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.931 . . . . 0.0 109.63 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.818 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -54.93 -44.35 74.2 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.556 -0.715 . . . . 0.0 110.332 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 83.89 5.83 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.52 -79.98 0.48 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.295 -0.878 . . . . 0.0 113.152 -177.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -136.72 10.11 3.12 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.108 -0.995 . . . . 0.0 113.098 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.43 -152.77 0.89 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -64.25 -39.95 95.01 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.571 -0.958 . . . . 0.0 108.586 177.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.436 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 25.8 m80 -90.15 0.46 57.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.748 -0.595 . . . . 0.0 110.207 179.197 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.05 133.96 52.48 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.619 HD13 HG11 ' A' ' 37' ' ' VAL . 66.0 mt -102.47 1.13 34.78 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 122.06 -0.67 . . . . 0.0 110.226 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.425 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 60.3 tpp -59.99 -38.48 82.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.315 -0.866 . . . . 0.0 111.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -66.41 0.46 Allowed 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.469 -0.769 . . . . 0.0 112.203 -176.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -75.13 -41.4 58.48 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.423 ' CD2' HG23 ' A' ' 37' ' ' VAL . 46.2 m-85 -120.05 87.46 39.06 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.845 -0.534 . . . . 0.0 109.665 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.3 -8.08 22.66 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.4 1.211 . . . . 0.0 111.543 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -133.51 146.47 51.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.26 -0.9 . . . . 0.0 110.5 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.816 HD11 HG21 ' A' ' 43' ' ' VAL . 29.1 tp -71.04 119.17 14.79 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.695 -0.628 . . . . 0.0 110.664 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.19 32.89 0.04 OUTLIER Glycine 0 N--CA 1.498 2.774 0 C-N-CA 120.007 -1.092 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -157.39 -48.63 0.07 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -1.122 . . . . 0.0 110.159 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.619 HG11 HD13 ' A' ' 27' ' ' LEU . 2.5 t -60.39 -58.61 18.06 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.489 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.2 Cg_endo -77.63 -30.8 3.67 Favored 'Trans proline' 0 C--N 1.318 -1.04 0 O-C-N 123.217 1.114 . . . . 0.0 109.537 177.514 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 129.97 -63.86 0.62 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 107.272 -2.331 . . . . 0.0 107.272 -178.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.723 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 164.53 -56.72 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.581 0 C-N-CA 123.37 0.668 . . . . 0.0 110.231 177.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.664 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 51.2 Cg_endo -101.03 15.55 0.37 Allowed 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 121.313 1.342 . . . . 0.0 111.246 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -125.32 47.52 2.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.296 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.816 HG21 HD11 ' A' ' 34' ' ' LEU . 14.6 p -125.47 140.04 49.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.914 0.864 . . . . 0.0 110.435 -179.055 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.87 175.35 42.76 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.441 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -88.62 159.47 29.43 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.689 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.1 pt -148.78 159.67 37.43 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.584 -0.95 . . . . 0.0 109.94 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -68.18 -15.9 43.49 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 121.245 1.297 . . . . 0.0 113.829 -177.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.568 ' H ' HD12 ' A' ' 46' ' ' ILE . 86.2 m-20 -91.7 21.26 4.87 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 120.706 -1.246 . . . . 0.0 113.129 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.596 HG23 ' CB ' ' A' ' 54' ' ' SER . 47.8 mm -112.28 122.59 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 177.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.63 -44.38 34.39 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.302 -0.874 . . . . 0.0 111.199 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.818 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.83 -134.93 3.5 Favored Glycine 0 N--CA 1.484 1.886 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.425 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.472 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 64.4 t90 -43.83 -26.78 0.28 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -145.4 72.81 1.33 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.921 . . . . 0.0 110.578 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.596 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.4 t -70.35 134.3 86.97 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.773 -0.58 . . . . 0.0 111.528 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.436 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 48.6 Cg_endo -73.8 -23.98 16.01 Favored 'Trans proline' 0 C--N 1.32 -0.941 0 O-C-N 123.413 1.218 . . . . 0.0 110.545 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.42 12.44 33.23 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.445 -0.784 . . . . 0.0 111.058 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.7 t -72.21 148.8 45.2 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.335 -0.853 . . . . 0.0 110.584 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.86 43.15 9.14 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.41 ' O ' ' HG3' ' A' ' 74' ' ' ARG . 8.5 m -130.62 168.74 16.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.707 -0.878 . . . . 0.0 108.684 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 16.8 t -113.38 148.6 35.49 Favored 'General case' 0 N--CA 1.511 2.596 0 O-C-N 121.118 -0.989 . . . . 0.0 113.143 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.481 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 31.5 m95 -139.82 145.35 38.03 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.027 -1.046 . . . . 0.0 110.36 177.256 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 83.4 tttt -105.53 129.84 53.72 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.1 t -110.63 129.95 64.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.316 -0.865 . . . . 0.0 109.95 -178.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 47.1 m -121.63 138.79 54.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.849 -0.532 . . . . 0.0 111.61 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.511 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.6 pt -114.35 166.09 12.32 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.534 -0.729 . . . . 0.0 109.809 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.44 -25.9 76.26 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 O-C-N 123.217 1.114 . . . . 0.0 112.928 -178.132 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -64.81 -37.83 88.95 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.052 -1.03 . . . . 0.0 109.751 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.93 65.32 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -162.02 153.15 18.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.769 -0.842 . . . . 0.0 108.867 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 71.5 p -152.8 162.38 41.35 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 122.197 0.999 . . . . 0.0 112.456 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.426 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.9 pt -139.39 162.3 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.128 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -107.48 127.15 53.35 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.246 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.702 HD13 HG11 ' A' ' 85' ' ' VAL . 90.2 mt -125.9 134.93 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 110.493 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.546 ' HD3' HG12 ' A' ' 37' ' ' VAL . 65.9 ttt180 -95.49 133.92 38.93 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -63.59 144.17 48.8 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 120.296 -0.954 . . . . 0.0 110.76 -178.087 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.996 HG22 HG21 ' A' ' 18' ' ' VAL . 10.1 p -142.67 -41.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 122.104 -0.645 . . . . 0.0 109.906 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.579 ' HB2' HG23 ' A' ' 18' ' ' VAL . 6.3 t0 -133.67 171.57 13.95 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.114 -0.991 . . . . 0.0 109.496 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.9 t -83.75 146.66 28.05 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.443 -0.785 . . . . 0.0 110.635 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -108.12 148.71 16.73 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -89.07 101.67 14.32 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.487 -1.008 . . . . 0.0 110.601 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 52.79 53.46 32.99 Favored Glycine 0 N--CA 1.498 2.791 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.24 170.08 14.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.929 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.689 ' CD2' HG22 ' A' ' 46' ' ' ILE . 36.3 m-85 -93.13 128.94 39.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.749 -0.853 . . . . 0.0 109.996 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.7 t-20 -120.24 130.84 54.7 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.702 HG11 HD13 ' A' ' 73' ' ' ILE . 34.2 m -129.99 174.35 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.694 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -55.51 156.8 7.99 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.658 -0.651 . . . . 0.0 109.966 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.7 -27.43 38.26 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.387 1.204 . . . . 0.0 109.706 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.417 HG22 ' HE3' ' A' ' 92' ' ' LYS . 94.3 m -71.28 -40.19 71.07 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.24 -39.56 86.21 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.3 t80 -59.99 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.737 -0.602 . . . . 0.0 110.514 179.302 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 58.0 m -59.82 -36.92 77.78 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.534 -0.729 . . . . 0.0 110.631 -178.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.417 ' HE3' HG22 ' A' ' 88' ' ' THR . 98.3 mttt -69.72 -40.02 76.5 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.805 -0.758 . . . . 0.0 111.258 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.508 ' HG ' HG21 ' A' ' 65' ' ' ILE . 52.6 tp -69.95 -41.81 74.06 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.472 -0.768 . . . . 0.0 111.688 -178.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 94.9 t -100.2 -36.12 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.117 0 O-C-N 121.164 -0.96 . . . . 0.0 111.413 -178.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 117.84 -30.62 6.05 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.0 m -143.03 155.12 44.57 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.48 -1.012 . . . . 0.0 110.897 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.0 p -90.23 1.53 56.39 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.521 -0.737 . . . . 0.0 110.989 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.95 -22.18 63.2 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.381 -0.824 . . . . 0.0 110.702 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.29 -45.27 88.25 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.382 -0.824 . . . . 0.0 110.717 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.68 -77.45 2.11 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 43.0 ttm180 -135.44 132.1 37.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.641 -0.917 . . . . 0.0 110.682 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 57.5 t -116.19 115.97 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.523 -0.736 . . . . 0.0 109.739 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -84.37 172.53 11.69 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.766 0.794 . . . . 0.0 111.375 -178.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.6 t30 60.07 40.02 19.03 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.807 -0.558 . . . . 0.0 111.591 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.726 HG21 HG23 ' A' ' 3' ' ' ILE . 62.8 t -81.65 127.43 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.126 179.124 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -91.88 139.98 30.13 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.064 -1.054 . . . . 0.0 108.989 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.7 p90 -140.81 147.22 38.69 Favored 'General case' 0 N--CA 1.493 1.684 0 CA-C-O 121.502 0.668 . . . . 0.0 112.129 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.9 142.57 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.747 -0.595 . . . . 0.0 109.813 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.481 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 62.3 tt0 -84.93 140.44 31.1 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.459 -0.775 . . . . 0.0 110.843 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 27.1 m -129.93 175.32 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -62.62 150.75 39.9 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.391 -0.818 . . . . 0.0 111.004 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.506 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.1 tt -60.06 -39.94 87.76 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.74 -0.6 . . . . 0.0 110.795 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 61.9 m -52.55 -35.66 54.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.59 -0.694 . . . . 0.0 111.186 -178.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.1 -40.01 93.95 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.426 -0.796 . . . . 0.0 110.967 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.06 -49.34 77.77 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.293 -0.879 . . . . 0.0 110.14 179.647 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.506 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.7 mt -70.03 -39.94 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.611 -0.681 . . . . 0.0 110.834 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -66.19 -40.07 90.14 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.453 -0.78 . . . . 0.0 110.829 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.99 -57.48 3.02 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 -178.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.83 -43.2 94.68 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.518 -0.989 . . . . 0.0 110.469 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.0 t30 . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 117.796 -1.097 . . . . 0.0 110.916 179.83 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 121.187 0.517 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 p -112.67 147.01 37.66 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.707 -0.62 . . . . 0.0 111.019 -179.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.726 HG21 HG11 ' A' ' 105' ' ' VAL . 24.7 pt -113.8 147.9 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.796 -0.565 . . . . 0.0 110.161 179.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -145.84 -172.34 3.89 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.373 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -142.22 149.34 39.52 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.519 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -139.09 152.99 71.08 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.377 -0.827 . . . . 0.0 110.078 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -83.55 2.36 8.38 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 O-C-N 123.407 1.214 . . . . 0.0 111.39 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 8' ' ' ILE . 26.2 mm -76.5 -2.79 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.16 -0.962 . . . . 0.0 111.165 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -127.34 64.64 1.33 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 122.347 1.07 . . . . 0.0 110.765 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.15 173.97 6.21 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.602 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.04 -32.17 70.66 Favored 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -175.239 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -89.41 12.28 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 120.446 1.475 . . . . 0.0 112.084 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 8' ' ' ILE . 0.1 OUTLIER -69.71 114.55 8.02 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.303 -0.873 . . . . 0.0 109.301 179.426 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m -62.76 139.4 58.68 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.801 0.81 . . . . 0.0 110.631 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.68 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.1 mmm -62.56 -26.38 68.55 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.985 -179.415 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -19.44 76.44 Favored Glycine 0 N--CA 1.494 2.507 0 O-C-N 121.126 -0.984 . . . . 0.0 110.896 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 75.4 m -86.46 -17.77 33.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.228 -1.16 . . . . 0.0 111.375 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.927 HG21 HG22 ' A' ' 76' ' ' VAL . 7.3 p -89.98 160.02 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.328 -0.858 . . . . 0.0 109.676 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.17 -41.82 65.57 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.58 -0.7 . . . . 0.0 111.164 -178.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 82.92 4.83 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.294 -0.879 . . . . 0.0 108.835 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 m -91.42 -79.34 0.37 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.26 -0.9 . . . . 0.0 113.014 -177.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 t30 -144.09 14.82 1.69 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.772 -1.205 . . . . 0.0 112.474 -178.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.49 -147.19 0.37 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 108.671 -1.772 . . . . 0.0 108.671 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -69.58 -39.97 76.99 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.622 -0.928 . . . . 0.0 108.85 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.565 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 19.4 m80 -89.93 0.04 57.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.698 -0.626 . . . . 0.0 110.208 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.74 133.05 52.3 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.567 HD13 HH21 ' A' ' 74' ' ' ARG . 65.0 mt -103.73 -0.07 29.86 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 122.139 -0.624 . . . . 0.0 110.47 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -64.0 -35.46 80.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.274 -0.891 . . . . 0.0 111.068 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.69 -66.16 0.47 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.41 -0.806 . . . . 0.0 111.883 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLN . . . . . 0.436 ' HG3' ' N ' ' A' ' 31' ' ' TYR . 28.1 pt20 -72.71 -40.5 66.13 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.126 -0.984 . . . . 0.0 110.775 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.683 ' CD2' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -126.73 91.04 48.22 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.429 -0.794 . . . . 0.0 109.428 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.54 -9.89 27.41 Favored 'Trans proline' 0 N--CA 1.488 1.161 0 O-C-N 123.554 1.292 . . . . 0.0 112.04 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.9 m -129.03 143.95 51.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.098 -1.001 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.996 HD11 HG21 ' A' ' 43' ' ' VAL . 21.2 tp -69.93 120.02 15.02 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.878 -0.514 . . . . 0.0 110.546 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 147.36 30.32 0.07 OUTLIER Glycine 0 N--CA 1.496 2.697 0 C-N-CA 119.927 -1.13 . . . . 0.0 110.822 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -154.13 -50.9 0.09 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.26 -1.141 . . . . 0.0 110.286 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.683 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.7 t -61.66 -59.47 13.29 Favored Pre-proline 0 N--CA 1.497 1.904 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.439 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.0 Cg_endo -74.08 -32.08 7.25 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 O-C-N 123.258 1.136 . . . . 0.0 109.24 177.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.429 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 131.21 -65.05 0.6 Allowed Glycine 0 N--CA 1.484 1.856 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.329 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.602 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 1.7 t80 163.94 -69.66 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.793 0 C-N-CA 123.522 0.729 . . . . 0.0 110.393 177.398 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.547 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.9 Cg_endo -80.61 -0.22 10.47 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 120.387 0.725 . . . . 0.0 112.714 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -111.24 53.66 0.7 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.872 -1.143 . . . . 0.0 110.425 -178.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.996 HG21 HD11 ' A' ' 34' ' ' LEU . 14.4 p -132.44 141.09 46.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 121.859 0.838 . . . . 0.0 110.054 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.69 175.39 43.24 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.652 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.51 157.67 29.13 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 179.091 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.739 HD11 ' CA ' ' A' ' 75' ' ' GLY . 1.7 pt -156.01 160.06 31.07 Favored Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.592 -0.946 . . . . 0.0 109.771 179.128 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -67.02 -23.49 46.45 Favored 'Trans proline' 0 N--CA 1.502 1.983 0 C-N-CA 121.643 1.562 . . . . 0.0 115.291 -176.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -77.03 -5.02 47.13 Favored 'General case' 0 N--CA 1.506 2.374 0 O-C-N 120.381 -1.45 . . . . 0.0 112.497 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.587 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.1 mm -89.71 121.34 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.992 -1.067 . . . . 0.0 108.45 178.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.65 -43.55 47.07 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.243 -0.91 . . . . 0.0 111.537 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.98 -131.73 2.43 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.004 -1.569 . . . . 0.0 110.771 -179.618 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.478 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 61.9 t90 -48.71 -26.02 2.11 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.886 -0.773 . . . . 0.0 112.749 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.8 64.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.184 -0.948 . . . . 0.0 110.713 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.587 ' CB ' HG23 ' A' ' 49' ' ' ILE . 7.9 p -63.5 133.64 95.57 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.648 -0.658 . . . . 0.0 110.986 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.565 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.4 Cg_endo -71.64 -19.47 27.9 Favored 'Trans proline' 0 N--CA 1.485 1.011 0 O-C-N 123.212 1.112 . . . . 0.0 110.911 179.409 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 59' ' ' THR . 54.0 p -99.04 10.8 40.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.378 -0.827 . . . . 0.0 111.025 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -65.13 143.1 58.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.135 -0.978 . . . . 0.0 110.056 -179.757 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.41 26.01 48.92 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.431 HG23 ' O ' ' A' ' 56' ' ' SER . 17.1 p -100.01 134.99 42.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.453 -1.027 . . . . 0.0 110.615 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.472 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.0 t -81.49 131.11 35.27 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.795 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.474 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 85.6 m95 -133.6 143.58 48.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.387 -0.82 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 tttm -110.67 130.98 55.43 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -111.02 129.73 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.349 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 69.0 m -120.04 135.55 54.89 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.868 -0.52 . . . . 0.0 110.604 -178.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.479 ' CG2' HD21 ' A' ' 93' ' ' LEU . 8.7 pt -113.8 164.83 14.92 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.425 -0.797 . . . . 0.0 110.849 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -62.96 -27.93 74.79 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.241 1.294 . . . . 0.0 112.937 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.401 ' HB3' ' CD1' ' A' ' 65' ' ' ILE . 38.1 t30 -64.58 -40.0 94.76 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.239 -0.913 . . . . 0.0 109.701 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 69' ' ' ASN . . . 118.18 60.01 0.28 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 179.327 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.46 ' ND2' ' O ' ' A' ' 68' ' ' GLY . 19.3 m120 -153.7 148.7 26.71 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.699 -0.883 . . . . 0.0 108.745 178.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 47.1 m -149.37 155.49 40.56 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 119.3 -0.96 . . . . 0.0 112.233 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 43.3 pt -140.76 166.9 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.71 125.45 53.51 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.404 179.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.624 HD13 HG11 ' A' ' 85' ' ' VAL . 96.9 mt -124.1 138.63 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.466 -0.771 . . . . 0.0 110.518 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.567 HH21 HD13 ' A' ' 27' ' ' LEU . 1.9 ttp-105 -100.85 146.47 27.27 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.586 -0.696 . . . . 0.0 109.745 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.739 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -68.11 151.33 51.81 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.927 HG22 HG21 ' A' ' 18' ' ' VAL . 9.6 p -154.81 -44.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.826 -0.808 . . . . 0.0 109.522 179.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.571 ' HB2' HG23 ' A' ' 18' ' ' VAL . 5.2 t0 -129.62 169.82 14.56 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.059 -1.025 . . . . 0.0 109.622 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' ILE . 92.6 p -101.57 160.07 14.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.577 -0.702 . . . . 0.0 111.055 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.96 155.06 21.62 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 75.4 mtp85 -59.97 -31.41 69.87 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.484 -1.01 . . . . 0.0 109.679 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -176.69 -179.8 47.3 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 50.83 -178.88 0.04 OUTLIER Glycine 0 N--CA 1.496 2.675 0 O-C-N 121.434 -1.039 . . . . 0.0 111.87 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.612 ' CD2' HG22 ' A' ' 46' ' ' ILE . 42.7 m-85 -107.74 127.46 53.71 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.891 -0.77 . . . . 0.0 109.008 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 41.7 t-20 -117.83 127.73 54.16 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.511 -0.875 . . . . 0.0 108.64 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.624 HG11 HD13 ' A' ' 73' ' ' ILE . 34.4 m -130.79 172.37 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.697 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -55.58 152.79 16.96 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.534 -0.729 . . . . 0.0 109.528 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.21 -26.33 57.0 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.35 1.184 . . . . 0.0 110.186 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.773 HG22 ' HE2' ' A' ' 92' ' ' LYS . 94.3 m -70.08 -40.24 75.13 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.076 -1.015 . . . . 0.0 109.346 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.03 -40.57 87.24 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -60.71 -50.08 74.9 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.719 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.1 m -61.14 -39.96 92.01 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.403 -0.811 . . . . 0.0 111.273 -178.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.773 ' HE2' HG22 ' A' ' 88' ' ' THR . 56.3 mtmt -69.99 -40.05 75.55 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.999 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.479 HD21 ' CG2' ' A' ' 65' ' ' ILE . 48.0 tp -69.91 -42.93 72.69 Favored 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.365 -179.175 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.22 -41.6 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 O-C-N 121.45 -0.781 . . . . 0.0 111.83 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.72 -34.5 4.05 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.3 m -142.44 153.67 43.91 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.524 -0.986 . . . . 0.0 110.14 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.6 p -90.28 3.49 53.46 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.477 -0.765 . . . . 0.0 110.976 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.98 -26.22 63.99 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.423 -0.798 . . . . 0.0 111.158 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.94 -39.92 87.19 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.413 -0.804 . . . . 0.0 110.513 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.75 -79.49 1.84 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 50.5 ttp180 -131.8 138.87 48.71 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.694 -0.886 . . . . 0.0 110.47 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 105' ' ' VAL . 63.0 t -120.32 116.97 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.804 178.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -80.55 170.14 16.74 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.656 0.741 . . . . 0.0 111.346 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 60.0 39.93 19.37 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.007 0.432 . . . . 0.0 111.816 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.726 HG11 HG21 ' A' ' 3' ' ' ILE . 78.5 t -85.48 127.52 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.134 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -87.36 140.05 29.93 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.14 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -139.22 144.5 38.5 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.579 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -144.69 141.68 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.498 -0.751 . . . . 0.0 111.231 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.474 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.2 tt0 -73.45 135.01 44.09 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.561 -0.712 . . . . 0.0 109.755 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.472 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.5 m -132.27 173.09 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.437 179.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -60.34 149.71 32.88 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.357 -0.839 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.463 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.4 tt -59.93 -39.08 84.29 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.505 -0.747 . . . . 0.0 110.58 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.9 m -53.5 -38.01 63.28 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.557 -0.714 . . . . 0.0 110.57 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -60.22 -39.93 88.35 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.496 -0.753 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.07 -49.83 76.11 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.257 -0.902 . . . . 0.0 110.246 179.311 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.432 HD11 HD21 ' A' ' 112' ' ' LEU . 90.4 mt -69.25 -39.99 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.704 -0.622 . . . . 0.0 110.253 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.63 -39.93 95.37 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.401 -0.812 . . . . 0.0 110.281 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.81 -41.82 81.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.35 -39.97 94.86 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.75 -0.853 . . . . 0.0 110.305 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.9 p30 . . . . . 0 N--CA 1.495 1.815 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.551 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.51 0.671 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.9 p -114.61 153.99 29.15 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.874 -0.516 . . . . 0.0 110.545 -179.519 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.495 HG21 HG11 ' A' ' 105' ' ' VAL . 39.5 pt -119.99 150.05 22.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.476 -0.765 . . . . 0.0 110.534 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 p -147.84 -171.76 3.89 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.342 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.4 p90 -141.5 142.47 33.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.465 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.73 ' HB3' HG22 ' A' ' 8' ' ' ILE . 4.5 m-20 -133.78 150.01 73.47 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.476 -0.765 . . . . 0.0 110.208 179.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -78.87 -0.93 11.18 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 O-C-N 123.377 1.199 . . . . 0.0 111.114 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.792 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.4 tp -71.67 -15.22 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.244 -0.91 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CD2' HG23 ' A' ' 8' ' ' ILE . 34.3 m-85 -114.88 68.53 0.7 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 122.613 1.197 . . . . 0.0 110.553 178.466 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.24 170.06 8.09 Favored 'General case' 0 N--CA 1.492 1.67 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.599 177.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.716 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.91 -34.42 73.19 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 -175.744 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -88.22 13.53 11.27 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.417 -1.427 . . . . 0.0 112.422 -176.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.792 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.9 tp -75.56 122.82 24.47 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.355 -0.841 . . . . 0.0 110.091 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.8 m -65.73 137.62 57.4 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.801 -0.76 . . . . 0.0 109.627 179.533 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.8 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.4 mmm -64.22 -19.08 65.11 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.823 -0.548 . . . . 0.0 111.313 -179.248 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.5 -16.55 78.93 Favored Glycine 0 N--CA 1.495 2.59 0 O-C-N 120.95 -1.094 . . . . 0.0 110.986 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.1 m -88.18 -13.78 40.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.165 -1.197 . . . . 0.0 111.599 -179.148 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 15' ' ' MET . 13.0 p -90.04 159.54 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.149 -0.97 . . . . 0.0 108.869 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.769 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -49.07 -41.36 35.04 Favored 'General case' 0 N--CA 1.507 2.418 0 O-C-N 121.266 -0.896 . . . . 0.0 110.562 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -78.23 87.14 4.31 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.8 m -99.4 -82.31 0.44 Allowed 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.117 -0.989 . . . . 0.0 112.954 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -137.91 9.58 2.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.087 -1.008 . . . . 0.0 112.922 -178.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.08 -148.0 0.5 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.801 -1.72 . . . . 0.0 108.801 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -63.03 -40.01 96.47 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.625 -0.927 . . . . 0.0 109.526 178.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 89.6 m-70 -94.6 8.56 41.89 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.567 -0.708 . . . . 0.0 111.151 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.15 127.42 35.89 Favored Glycine 0 N--CA 1.502 3.064 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 91.2 mt -102.47 -11.46 18.55 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 122.03 -0.688 . . . . 0.0 111.532 -178.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 ttp -60.03 -27.32 66.81 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.261 -0.899 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.52 -61.75 2.27 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.425 -0.797 . . . . 0.0 112.898 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -69.96 -40.01 75.69 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 120.88 -1.137 . . . . 0.0 111.36 -178.108 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.615 ' CE1' HG21 ' A' ' 37' ' ' VAL . 3.8 p90 -136.21 104.76 9.49 Favored Pre-proline 0 C--N 1.302 -1.491 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.42 -11.15 29.01 Favored 'Trans proline' 0 N--CA 1.485 0.98 0 O-C-N 123.482 1.254 . . . . 0.0 111.647 -178.283 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -126.85 135.76 51.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.245 -0.91 . . . . 0.0 109.761 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.949 HD21 HG11 ' A' ' 43' ' ' VAL . 39.4 tp -61.46 126.05 25.95 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.522 -0.736 . . . . 0.0 109.858 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 148.79 27.77 0.06 OUTLIER Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.538 -1.315 . . . . 0.0 111.787 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -144.99 -47.91 0.24 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.074 -1.25 . . . . 0.0 110.917 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.615 HG21 ' CE1' ' A' ' 31' ' ' TYR . 1.7 t -67.42 -55.45 15.02 Favored Pre-proline 0 N--CA 1.496 1.844 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.389 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD2' ' N ' ' A' ' 37' ' ' VAL . 42.5 Cg_endo -76.19 -31.44 4.77 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.396 1.208 . . . . 0.0 108.988 178.079 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.424 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 129.77 -64.6 0.6 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.716 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 2.1 t80 164.38 -56.74 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.595 0 C-N-CA 123.33 0.652 . . . . 0.0 110.844 177.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.638 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.7 Cg_endo -97.42 16.84 0.61 Allowed 'Trans proline' 0 N--CA 1.481 0.773 0 C-N-CA 120.982 1.121 . . . . 0.0 112.044 -177.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -126.12 47.49 2.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.2 -0.937 . . . . 0.0 109.758 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.949 HG11 HD21 ' A' ' 34' ' ' LEU . 10.2 p -128.09 142.43 43.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.596 0.712 . . . . 0.0 109.78 -179.617 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.56 170.43 41.09 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.453 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -83.79 158.58 35.36 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 178.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.698 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.5 pt -147.81 156.2 44.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.439 -1.036 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.66 -12.22 34.79 Favored 'Trans proline' 0 N--CA 1.504 2.119 0 C-N-CA 121.934 1.756 . . . . 0.0 114.668 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -96.72 21.31 9.61 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 120.491 -1.381 . . . . 0.0 112.796 -177.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 54' ' ' SER . 48.9 mm -110.7 129.98 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.37 -0.831 . . . . 0.0 108.807 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.15 -48.26 11.54 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.786 . . . . 0.0 112.256 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.769 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.53 -129.04 1.8 Allowed Glycine 0 N--CA 1.488 2.119 0 C-N-CA 118.806 -1.664 . . . . 0.0 111.384 -179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.454 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 20.1 t90 -50.2 -24.99 3.18 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.89 -0.771 . . . . 0.0 112.881 -178.255 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.93 71.3 1.22 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.402 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.634 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.2 t -70.04 130.37 89.87 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.865 -0.522 . . . . 0.0 111.075 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.36 -21.47 30.65 Favored 'Trans proline' 0 N--CA 1.486 1.053 0 O-C-N 123.246 1.13 . . . . 0.0 110.566 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -98.52 13.48 31.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.445 -0.785 . . . . 0.0 110.983 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -70.98 147.18 48.91 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.182 -0.949 . . . . 0.0 110.271 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.1 35.37 44.02 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 95.6 m -119.59 135.17 54.91 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.503 -0.998 . . . . 0.0 110.484 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -78.96 145.64 33.88 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.053 -178.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.449 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 96.0 m95 -148.38 143.98 27.19 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.801 -0.562 . . . . 0.0 109.537 178.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -107.36 134.89 49.76 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.305 -0.872 . . . . 0.0 109.134 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 123.34 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.496 -0.752 . . . . 0.0 110.216 -179.229 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.2 m -118.42 139.71 50.98 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.893 -0.505 . . . . 0.0 110.378 -179.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.472 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 21.0 pt -119.58 164.29 22.62 Favored Pre-proline 0 N--CA 1.5 2.044 0 O-C-N 121.471 -0.768 . . . . 0.0 110.881 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 36.6 Cg_endo -60.58 -24.11 77.42 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 121.445 1.43 . . . . 0.0 112.794 -178.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -65.55 -36.61 84.28 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.217 -0.927 . . . . 0.0 109.712 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.11 63.41 0.47 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -163.82 153.99 15.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.755 -0.85 . . . . 0.0 108.988 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 95.6 p -155.43 158.38 38.51 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.583 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.6 pt -140.02 166.72 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -104.96 125.78 51.32 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.612 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -117.98 130.06 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.75 -0.594 . . . . 0.0 109.621 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.484 ' CD ' HG12 ' A' ' 37' ' ' VAL . 1.3 ttp-105 -99.23 139.52 34.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.524 -0.735 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.59 148.04 42.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.636 HG22 HG21 ' A' ' 18' ' ' VAL . 3.8 p -155.66 -41.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.807 -0.819 . . . . 0.0 109.798 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.647 ' OD2' HG23 ' A' ' 18' ' ' VAL . 1.9 t0 -134.58 175.18 9.77 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.145 -0.972 . . . . 0.0 109.767 179.128 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -103.81 154.81 19.17 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.471 -0.768 . . . . 0.0 111.521 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.77 147.75 16.66 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.9 mtt180 -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.648 -0.913 . . . . 0.0 110.742 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -177.39 73.65 0.07 OUTLIER Glycine 0 N--CA 1.495 2.585 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.638 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.65 147.33 4.54 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.467 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.698 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.5 m-85 -73.02 135.16 44.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 122.031 -0.688 . . . . 0.0 110.506 179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.3 131.01 46.87 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 178.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.4 m -131.72 173.73 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.636 -178.063 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -55.17 152.16 15.77 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 109.927 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.27 -27.55 55.89 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.422 1.222 . . . . 0.0 110.11 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.02 -40.02 75.46 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.952 -1.092 . . . . 0.0 109.048 178.375 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.92 -40.16 87.59 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.432 -0.793 . . . . 0.0 108.977 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.47 -49.95 75.51 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.799 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 38.9 m -60.02 -39.56 86.25 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.657 -0.652 . . . . 0.0 111.28 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.9 mttm -68.89 -40.02 79.41 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.499 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.4 HD21 ' CG2' ' A' ' 65' ' ' ILE . 41.4 tp -70.78 -42.74 69.95 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.8 -0.76 . . . . 0.0 111.627 -178.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.1 t -97.74 -40.39 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.201 -0.937 . . . . 0.0 111.733 -177.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 118.17 -37.7 3.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.9 m -134.69 149.62 50.52 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.608 -0.937 . . . . 0.0 110.199 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 70.8 p -94.02 3.98 54.56 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.421 -0.799 . . . . 0.0 111.053 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -69.93 -27.64 64.93 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.43 -0.794 . . . . 0.0 111.164 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.97 87.75 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.495 -0.753 . . . . 0.0 110.67 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.28 -60.45 3.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.2 ptt180 -153.61 156.91 38.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.616 -0.932 . . . . 0.0 110.546 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -125.44 117.24 49.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.45 -0.781 . . . . 0.0 109.672 179.249 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -81.09 169.99 16.74 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.49 -0.756 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 56.4 t30 61.64 47.92 6.05 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.573 -0.704 . . . . 0.0 111.646 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.495 HG11 HG21 ' A' ' 3' ' ' ILE . 81.1 t -96.17 124.75 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.031 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -84.92 145.76 27.61 Favored 'General case' 0 N--CA 1.493 1.675 0 C-N-CA 119.779 -0.768 . . . . 0.0 109.281 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.02 147.2 40.04 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.833 -0.542 . . . . 0.0 111.598 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.8 m -147.27 148.66 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.653 -0.654 . . . . 0.0 110.829 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.449 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 16.9 tt0 -82.98 140.93 32.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.656 -0.652 . . . . 0.0 110.314 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.4 m -132.54 168.8 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 120.211 -0.595 . . . . 0.0 109.742 179.236 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -59.97 149.05 33.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.296 -0.878 . . . . 0.0 109.925 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -40.0 88.03 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.408 -0.807 . . . . 0.0 110.94 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 54.0 p -55.45 -35.54 65.57 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.556 -0.715 . . . . 0.0 110.665 -178.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -60.0 -38.39 82.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.435 -0.79 . . . . 0.0 110.075 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 85.8 m -69.63 -39.93 76.86 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.8 mm -64.09 -43.94 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 120.274 -0.571 . . . . 0.0 109.845 -178.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -70.0 -40.02 75.53 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.76 -0.588 . . . . 0.0 110.547 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.44 -51.63 46.86 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.57 -40.04 94.83 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.588 -0.948 . . . . 0.0 110.249 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.087 -179.87 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.351 0.596 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.9 m -111.36 137.26 49.36 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.441 HG21 HG11 ' A' ' 105' ' ' VAL . 37.8 pt -109.75 146.69 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.6 -0.688 . . . . 0.0 110.354 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.9 m -143.29 -174.59 4.25 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -142.73 150.0 39.51 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.985 179.067 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.55 152.7 77.03 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.504 -0.748 . . . . 0.0 109.755 179.369 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -84.52 -12.0 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 O-C-N 123.348 1.183 . . . . 0.0 112.659 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.479 HG13 ' N ' ' A' ' 9' ' ' TYR . 35.9 pt -70.05 -39.91 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 120.871 -1.143 . . . . 0.0 111.333 -178.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.605 ' HA ' HD22 ' A' ' 13' ' ' LEU . 46.3 m-85 -72.94 65.22 0.73 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 122.652 1.215 . . . . 0.0 111.712 -178.653 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.89 170.46 7.86 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.55 -34.84 73.18 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -87.83 8.99 23.35 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.016 -1.474 . . . . 0.0 111.542 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.605 HD22 ' HA ' ' A' ' 9' ' ' TYR . 45.3 tp -70.01 122.13 18.76 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.303 -0.873 . . . . 0.0 109.424 179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.1 m -68.31 135.59 52.12 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.413 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.851 ' O ' HG12 ' A' ' 18' ' ' VAL . 87.0 mtp -70.07 -15.23 62.96 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.16 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -15.87 72.74 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 120.805 -1.184 . . . . 0.0 110.168 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -88.55 -6.67 57.42 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -1.142 . . . . 0.0 111.735 -179.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.851 HG12 ' O ' ' A' ' 15' ' ' MET . 10.8 p -96.74 165.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.997 -1.064 . . . . 0.0 110.603 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.633 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.01 -42.33 94.07 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.783 -0.573 . . . . 0.0 110.907 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.1 m -76.98 71.72 3.5 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.383 -0.823 . . . . 0.0 110.186 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 4.2 p -108.36 111.9 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.467 -0.771 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.41 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 13.1 t-20 51.99 -139.71 0.96 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.592 -0.692 . . . . 0.0 110.561 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.458 ' CA ' ' CH2' ' A' ' 52' ' ' TRP . . . 66.02 -156.12 50.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -74.25 -41.03 61.94 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.684 -0.892 . . . . 0.0 112.025 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.403 ' CD2' ' O ' ' A' ' 54' ' ' SER . 79.5 m-70 -99.69 10.04 42.04 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.074 -1.016 . . . . 0.0 111.51 -178.142 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -56.78 130.85 51.17 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 120.073 -1.06 . . . . 0.0 110.523 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 1.005 HD13 HG11 ' A' ' 37' ' ' VAL . 95.0 mt -100.6 -5.93 26.02 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.071 -0.664 . . . . 0.0 110.12 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 34.3 tpp -59.95 -36.08 76.31 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.281 -0.887 . . . . 0.0 109.599 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.24 -72.46 0.05 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.723 -0.611 . . . . 0.0 111.784 -178.197 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -69.95 -39.99 75.72 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.349 -0.845 . . . . 0.0 110.223 -179.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.644 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.8 m-85 -120.38 102.31 45.65 Favored Pre-proline 0 N--CA 1.491 1.596 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 -178.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.97 -22.39 19.75 Favored 'Trans proline' 0 C--N 1.316 -1.154 0 O-C-N 123.322 1.17 . . . . 0.0 111.381 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.1 m -122.69 144.23 49.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.327 -0.858 . . . . 0.0 110.711 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.663 HD21 HG11 ' A' ' 43' ' ' VAL . 52.9 tp -64.94 120.82 13.29 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.855 -0.528 . . . . 0.0 110.088 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.29 32.17 0.04 OUTLIER Glycine 0 N--CA 1.496 2.698 0 C-N-CA 119.906 -1.14 . . . . 0.0 110.993 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.446 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 19.1 mt-10 -156.09 -48.17 0.08 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.335 -1.097 . . . . 0.0 109.979 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 1.005 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -62.95 -59.48 12.38 Favored Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.436 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.9 Cg_endo -73.73 -32.29 7.65 Favored 'Trans proline' 0 C--N 1.318 -1.066 0 N-CA-C 108.733 -1.295 . . . . 0.0 108.733 177.173 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.1 -63.46 0.63 Allowed Glycine 0 N--CA 1.487 2.049 0 N-CA-C 107.197 -2.361 . . . . 0.0 107.197 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.644 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.5 t80 163.32 -53.58 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.556 0 C-N-CA 123.601 0.76 . . . . 0.0 109.91 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.666 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -100.55 12.95 0.49 Allowed 'Trans proline' 0 C--N 1.324 -0.728 0 C-N-CA 121.29 1.327 . . . . 0.0 111.198 -179.029 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 46.6 m-20 -125.15 52.19 1.61 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.216 -0.928 . . . . 0.0 109.765 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.663 HG11 HD21 ' A' ' 34' ' ' LEU . 13.4 p -126.21 136.71 60.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 CA-C-O 121.538 0.685 . . . . 0.0 110.283 -179.679 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.573 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -165.8 171.26 40.91 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.81 160.14 29.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.899 -1.681 . . . . 0.0 108.899 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.646 HG22 ' CE1' ' A' ' 83' ' ' PHE . 8.8 pt -146.65 158.63 45.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.806 -0.82 . . . . 0.0 110.414 179.101 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.14 -16.41 35.94 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.713 1.609 . . . . 0.0 113.63 -178.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -89.94 18.69 5.47 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.816 -1.177 . . . . 0.0 112.577 -177.545 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.437 ' HA ' ' CB ' ' A' ' 54' ' ' SER . 56.0 mt -119.99 123.17 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.146 -0.971 . . . . 0.0 109.05 177.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.58 -43.64 16.8 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 113.388 0.885 . . . . 0.0 113.388 -177.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.633 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.54 -125.33 0.96 Allowed Glycine 0 N--CA 1.493 2.452 0 C-N-CA 118.119 -1.991 . . . . 0.0 112.909 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.469 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 6.8 t90 -40.32 -32.8 0.2 Allowed 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 114.56 1.319 . . . . 0.0 114.56 -176.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 40.9 p-10 -174.15 76.83 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.493 -1.38 . . . . 0.0 109.975 178.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 25.4 p -62.74 155.11 72.01 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.636 -0.665 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 -14.36 40.05 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.566 1.298 . . . . 0.0 110.813 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 59' ' ' THR . 6.2 m -102.36 7.79 40.4 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.315 -0.865 . . . . 0.0 111.841 -179.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 41.5 t -65.4 143.65 57.59 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 120.755 -1.216 . . . . 0.0 110.109 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.26 6.45 81.35 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 56' ' ' SER . 20.9 p -77.67 158.12 29.85 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.149 -1.207 . . . . 0.0 110.998 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.41 120.02 40.01 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.19 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.431 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -121.36 139.97 52.73 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.39 -0.819 . . . . 0.0 110.934 179.498 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -105.92 134.14 49.52 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.651 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.8 t -111.69 125.62 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.587 -0.696 . . . . 0.0 110.47 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.509 ' O ' HG13 ' A' ' 105' ' ' VAL . 58.8 m -116.41 134.8 54.46 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.692 -0.63 . . . . 0.0 110.552 -178.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 12.8 pt -116.29 164.04 19.56 Favored Pre-proline 0 N--CA 1.503 2.179 0 O-C-N 121.407 -0.808 . . . . 0.0 111.331 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -63.38 -27.36 71.12 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 121.679 1.586 . . . . 0.0 113.296 -178.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -64.67 -40.03 94.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.064 -1.023 . . . . 0.0 109.917 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 119.92 58.53 0.25 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -154.7 148.43 25.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.72 -0.871 . . . . 0.0 108.666 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 74.9 m -146.44 143.74 29.22 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.738 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.553 HG23 HD13 ' A' ' 93' ' ' LEU . 33.9 pt -134.3 164.35 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -107.13 127.92 53.93 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 118.948 -1.101 . . . . 0.0 109.829 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -112.79 130.01 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.666 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.5 ttt180 -98.6 134.89 40.91 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.179 -0.95 . . . . 0.0 109.244 -179.299 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.96 147.04 30.76 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.455 HG22 HG21 ' A' ' 18' ' ' VAL . 3.7 p -155.4 -44.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.55 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.4 t70 -128.73 166.38 19.08 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.2 -0.937 . . . . 0.0 109.563 178.75 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 83.5 p -88.88 161.16 16.84 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.579 -0.701 . . . . 0.0 110.338 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.56 142.97 14.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 88.4 mtt-85 -60.08 -34.01 72.86 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.941 . . . . 0.0 110.009 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.24 75.65 0.04 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.62 149.93 5.1 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.99 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.651 ' CE2' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -66.53 140.07 57.97 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.855 -0.791 . . . . 0.0 110.491 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.414 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 52.3 t-20 -136.77 119.0 15.56 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.361 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.573 HG12 ' HA3' ' A' ' 44' ' ' GLY . 27.3 m -130.24 176.11 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 C-N-CA 119.102 -1.039 . . . . 0.0 112.449 -177.438 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.2 m-20 -56.18 157.58 8.67 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.578 -0.701 . . . . 0.0 109.937 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -70.35 -28.17 22.76 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.407 1.214 . . . . 0.0 110.166 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -70.36 -41.41 73.18 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.033 -1.042 . . . . 0.0 109.549 178.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.666 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.0 -40.09 90.86 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -60.05 -49.93 75.74 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.401 -0.52 . . . . 0.0 110.708 178.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.7 m -60.01 -39.71 86.73 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.44 -0.788 . . . . 0.0 111.416 -178.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -69.61 -39.99 76.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.563 -0.711 . . . . 0.0 111.274 -178.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.553 HD13 HG23 ' A' ' 71' ' ' ILE . 61.0 tp -71.31 -43.46 67.04 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.587 -0.696 . . . . 0.0 111.296 -179.399 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.6 t -93.32 -40.55 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.473 -0.767 . . . . 0.0 111.293 -178.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.29 -38.78 2.47 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 74.5 m -142.28 156.93 45.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.674 -0.897 . . . . 0.0 110.416 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 67.2 p -89.95 4.17 50.87 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.776 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.98 -26.65 64.19 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.452 -0.78 . . . . 0.0 110.445 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.01 93.21 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.57 -0.706 . . . . 0.0 110.385 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.33 -75.35 2.39 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -133.42 136.63 45.34 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.558 -0.966 . . . . 0.0 110.572 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.8 t -116.8 113.76 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.438 -0.788 . . . . 0.0 109.76 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -86.84 170.58 11.56 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-O 121.848 0.832 . . . . 0.0 111.608 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.2 t30 60.07 40.01 19.04 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.505 0.669 . . . . 0.0 110.333 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.509 HG13 ' O ' ' A' ' 64' ' ' THR . 93.8 t -90.73 122.01 41.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -80.0 140.4 36.59 Favored 'General case' 0 N--CA 1.493 1.707 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.651 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 107' ' ' TYR . 42.2 p90 -139.27 143.88 38.14 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.882 -0.512 . . . . 0.0 111.231 -178.49 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.5 m -145.54 139.99 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 111.17 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.431 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 57.3 tt0 -72.66 140.01 47.66 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.364 178.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.8 m -138.48 177.7 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.836 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 47.4 t0 -59.89 146.19 43.07 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.665 -0.647 . . . . 0.0 109.976 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 116' ' ' ILE . 9.3 tt -60.0 -37.95 81.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.456 -0.777 . . . . 0.0 110.514 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.7 p -52.71 -35.14 55.22 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.517 -0.739 . . . . 0.0 110.595 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -66.45 -36.3 82.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.511 -0.743 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -62.96 -50.18 71.79 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.264 -0.898 . . . . 0.0 110.038 179.033 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.47 HD11 HD21 ' A' ' 112' ' ' LEU . 90.0 mt -69.3 -40.03 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.748 -0.595 . . . . 0.0 110.457 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -65.44 -40.02 92.75 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.44 -0.787 . . . . 0.0 110.158 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.58 -42.18 97.51 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.05 91.1 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.675 -0.897 . . . . 0.0 109.945 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 66.5 t30 . . . . . 0 N--CA 1.5 2.058 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.645 179.898 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.375 0.607 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.0 m -111.77 140.7 46.19 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.661 0.744 . . . . 0.0 110.241 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.636 HG21 HG11 ' A' ' 105' ' ' VAL . 35.6 pt -112.18 147.36 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.755 -0.591 . . . . 0.0 110.487 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 4.0 p -145.78 -173.24 4.09 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.1 p90 -142.5 148.88 38.4 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.656 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -124.95 150.38 66.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.468 -0.77 . . . . 0.0 109.608 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -84.55 -7.77 9.64 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 O-C-N 123.303 1.159 . . . . 0.0 112.854 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.0 pt -70.02 -40.09 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.201 0 O-C-N 120.887 -1.133 . . . . 0.0 111.102 -179.356 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 38.0 m-85 -72.13 66.86 0.64 Allowed 'General case' 0 N--CA 1.496 1.827 0 CA-C-O 122.684 1.23 . . . . 0.0 111.756 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.69 172.2 6.95 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.126 176.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.17 71.57 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -90.3 11.33 21.62 Favored 'General case' 0 N--CA 1.501 2.09 0 C-N-CA 118.078 -1.449 . . . . 0.0 112.424 -177.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.456 HD22 ' HA ' ' A' ' 9' ' ' TYR . 28.2 tp -72.63 123.87 24.11 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.214 -0.928 . . . . 0.0 109.956 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 48.4 t -69.54 136.31 51.2 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.027 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.779 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.1 mmm -69.98 -15.95 63.11 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.856 -0.527 . . . . 0.0 111.717 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.418 ' CA ' ' HE1' ' A' ' 28' ' ' MET . . . -69.93 -11.18 66.12 Favored Glycine 0 N--CA 1.495 2.632 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.588 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.8 m -93.15 -11.97 31.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.254 -1.144 . . . . 0.0 111.708 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.779 HG12 ' O ' ' A' ' 15' ' ' MET . 7.1 p -92.45 165.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.17 -0.956 . . . . 0.0 110.46 -179.191 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.819 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.98 -45.3 86.98 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.642 -0.661 . . . . 0.0 110.093 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.23 80.32 6.68 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.97 -80.02 0.4 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.485 -0.76 . . . . 0.0 112.903 -177.523 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -139.91 9.43 2.36 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.217 -0.927 . . . . 0.0 112.917 -178.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.47 -143.97 0.24 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -69.97 -40.02 75.64 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.647 -0.914 . . . . 0.0 109.71 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -90.38 2.37 55.65 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.457 -0.777 . . . . 0.0 110.815 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.03 126.42 33.21 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.423 -1.071 . . . . 0.0 110.423 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.842 HD13 HG11 ' A' ' 37' ' ' VAL . 96.1 mt -100.09 0.93 41.71 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 122.132 -0.628 . . . . 0.0 110.21 178.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.418 ' HE1' ' CA ' ' A' ' 16' ' ' GLY . 56.6 ttm -68.13 -30.65 69.84 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.364 -0.835 . . . . 0.0 110.339 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.0 -71.8 0.06 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.553 -0.717 . . . . 0.0 111.53 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 37.2 mt-30 -69.97 -40.1 75.6 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.285 -0.884 . . . . 0.0 109.99 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.623 ' CD2' HG23 ' A' ' 37' ' ' VAL . 66.5 m-85 -123.16 95.07 46.29 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.843 -0.536 . . . . 0.0 110.049 -179.168 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.02 -18.75 27.32 Favored 'Trans proline' 0 C--N 1.318 -1.054 0 O-C-N 123.411 1.216 . . . . 0.0 111.483 -179.215 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.5 m -121.39 149.32 43.16 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.257 -0.902 . . . . 0.0 110.435 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 1.096 HD11 HG21 ' A' ' 43' ' ' VAL . 34.1 tp -70.64 119.89 15.46 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.793 -0.567 . . . . 0.0 110.422 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.29 33.46 0.05 OUTLIER Glycine 0 N--CA 1.495 2.609 0 C-N-CA 120.104 -1.046 . . . . 0.0 110.593 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 1.6 mt-10 -157.71 -49.91 0.07 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.206 -1.173 . . . . 0.0 110.422 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -60.1 -58.61 18.11 Favored Pre-proline 0 N--CA 1.502 2.125 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -78.54 -29.23 3.84 Favored 'Trans proline' 0 N--CA 1.486 1.079 0 N-CA-C 109.008 -1.189 . . . . 0.0 109.008 176.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 125.4 -64.88 0.56 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 106.676 -2.57 . . . . 0.0 106.676 -178.151 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.559 ' CB ' ' HD3' ' A' ' 41' ' ' PRO . 0.1 OUTLIER 167.98 -58.88 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.377 0 O-C-N 122.277 -0.543 . . . . 0.0 109.962 177.091 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.719 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 53.4 Cg_endo -95.57 16.87 0.83 Allowed 'Trans proline' 0 C--N 1.325 -0.68 0 O-C-N 123.071 1.037 . . . . 0.0 109.806 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -123.32 38.8 4.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.469 -0.769 . . . . 0.0 109.526 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.096 HG21 HD11 ' A' ' 34' ' ' LEU . 14.8 p -127.89 140.87 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.527 0.679 . . . . 0.0 110.915 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.68 175.18 42.69 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -89.46 161.76 30.13 Favored Glycine 0 N--CA 1.498 2.807 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.732 HG23 ' O ' ' A' ' 45' ' ' GLY . 0.5 OUTLIER -161.26 164.79 18.01 Favored Pre-proline 0 N--CA 1.503 2.21 0 CA-C-N 118.457 1.128 . . . . 0.0 111.422 -179.097 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.24 -22.27 25.79 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 121.439 1.426 . . . . 0.0 114.593 -177.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -83.94 3.25 34.95 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.382 -1.449 . . . . 0.0 112.762 -177.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.61 HG23 ' CB ' ' A' ' 54' ' ' SER . 45.6 mm -97.38 128.94 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.37 -51.01 7.29 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.409 -0.807 . . . . 0.0 111.961 -178.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.819 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.68 -135.94 3.3 Favored Glycine 0 N--CA 1.487 2.098 0 C-N-CA 118.882 -1.628 . . . . 0.0 111.241 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.458 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 9.4 t90 -42.74 -27.22 0.16 Allowed 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.411 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 47.2 m-20 -147.0 62.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.208 -0.932 . . . . 0.0 110.901 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.61 ' CB ' HG23 ' A' ' 49' ' ' ILE . 5.1 p -56.96 132.9 79.91 Favored Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.436 -0.79 . . . . 0.0 110.461 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.63 -21.16 22.38 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 O-C-N 123.252 1.133 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 38.8 m -96.15 9.47 40.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.456 -0.777 . . . . 0.0 111.043 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -64.0 141.65 58.69 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.327 -0.858 . . . . 0.0 110.265 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 95.33 -24.97 26.64 Favored Glycine 0 N--CA 1.5 2.933 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 178.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.1 m -56.93 161.32 3.02 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.257 -1.143 . . . . 0.0 110.622 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.431 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.5 t -113.46 152.32 30.28 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.969 -0.457 . . . . 0.0 111.307 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.432 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 52.6 m95 -142.53 149.04 38.58 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.241 -0.912 . . . . 0.0 110.75 178.029 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 36.3 tttp -110.71 129.56 55.8 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.2 t -110.9 129.75 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.316 -0.865 . . . . 0.0 110.383 -178.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.5 m -121.12 140.18 52.33 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.842 -0.536 . . . . 0.0 111.381 -178.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.2 pt -119.27 164.65 20.3 Favored Pre-proline 0 N--CA 1.5 2.057 0 O-C-N 121.499 -0.751 . . . . 0.0 110.311 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.1 Cg_endo -63.5 -24.07 70.61 Favored 'Trans proline' 0 N--CA 1.495 1.613 0 O-C-N 123.404 1.213 . . . . 0.0 112.593 -178.562 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.3 t-20 -64.47 -39.99 94.86 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.237 -0.915 . . . . 0.0 109.61 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.65 60.56 0.32 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -159.99 150.78 19.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.704 -0.88 . . . . 0.0 109.145 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.446 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.8 m -149.4 157.38 43.26 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 121.992 0.901 . . . . 0.0 112.029 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.863 HG12 HD13 ' A' ' 93' ' ' LEU . 36.8 pt -140.06 165.84 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.8 m-85 -107.61 130.25 54.91 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.128 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.11 130.04 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.691 -0.631 . . . . 0.0 110.726 -178.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.521 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.4 ttt180 -101.24 135.33 42.88 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.176 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.711 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.24 149.34 47.92 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.124 -1.036 . . . . 0.0 111.386 -177.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.48 HG11 HG22 ' A' ' 43' ' ' VAL . 2.6 p -152.63 -45.75 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.577 ' HB2' HG23 ' A' ' 18' ' ' VAL . 10.3 t70 -129.49 169.04 15.46 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.34 -0.85 . . . . 0.0 109.517 179.177 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 82.9 p -103.9 159.94 15.23 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.604 -0.685 . . . . 0.0 110.111 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.52 156.64 21.96 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -60.03 -35.78 75.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.674 -0.898 . . . . 0.0 109.109 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -171.32 177.55 44.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 51.54 -168.32 0.56 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 121.355 -1.085 . . . . 0.0 111.567 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.706 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.4 m-85 -120.0 139.06 53.06 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.965 -0.727 . . . . 0.0 109.15 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 4' ' ' SER . 33.4 t-20 -129.29 128.48 43.28 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.052 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.3 m -130.72 172.07 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.088 -1.008 . . . . 0.0 112.025 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -55.84 152.77 18.8 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.29 -0.881 . . . . 0.0 109.663 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.36 -21.35 61.22 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 O-C-N 123.386 1.203 . . . . 0.0 110.732 -179.449 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.2 m -78.76 -40.04 34.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.928 -1.107 . . . . 0.0 109.33 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.719 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.68 -40.03 88.38 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 178.667 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -60.01 -49.87 75.99 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.794 -0.566 . . . . 0.0 110.447 179.088 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -59.99 -38.74 83.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.583 -0.698 . . . . 0.0 110.661 -178.539 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -69.87 -39.87 76.06 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.141 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.863 HD13 HG12 ' A' ' 71' ' ' ILE . 61.2 tp -70.14 -43.97 69.82 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.507 -0.746 . . . . 0.0 111.283 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.51 -39.88 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.298 -0.876 . . . . 0.0 111.461 -178.094 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 119.89 -35.19 3.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 64.2 m -140.03 150.83 44.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.525 -0.985 . . . . 0.0 110.889 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.8 p -89.57 3.74 51.56 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.516 -0.74 . . . . 0.0 110.627 179.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -70.08 -28.32 65.33 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.441 -0.787 . . . . 0.0 110.951 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.17 -40.03 84.37 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.456 -0.777 . . . . 0.0 110.417 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.57 -79.6 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 37.0 ttm180 -129.85 132.69 46.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.659 -0.906 . . . . 0.0 110.219 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.5 t -119.34 120.06 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.396 -0.815 . . . . 0.0 110.276 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.4 ' O ' ' HB2' ' A' ' 104' ' ' ASN . 9.3 t70 -85.05 173.11 10.75 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.42 0.629 . . . . 0.0 110.876 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 94.9 m-20 60.04 39.97 19.19 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-O 121.091 0.472 . . . . 0.0 111.569 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.636 HG11 HG21 ' A' ' 3' ' ' ILE . 63.0 t -86.95 122.58 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -82.25 134.58 35.29 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.173 -1.011 . . . . 0.0 109.425 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.8 p90 -136.28 142.72 43.97 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.325 0.583 . . . . 0.0 111.323 -178.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -144.07 140.05 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.731 -0.606 . . . . 0.0 110.184 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -71.43 140.75 50.2 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.698 . . . . 0.0 110.422 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.431 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.2 m -136.57 173.26 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.829 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -61.12 149.67 36.54 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.386 -0.822 . . . . 0.0 110.833 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.571 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -59.98 -39.3 85.21 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.456 -0.778 . . . . 0.0 110.794 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 62.8 m -53.85 -39.44 65.63 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 110.226 -178.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -60.25 -39.3 86.24 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.606 -0.684 . . . . 0.0 110.988 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -59.97 -49.37 77.94 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.238 -0.914 . . . . 0.0 110.059 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.571 HD11 HD21 ' A' ' 112' ' ' LEU . 85.7 mt -69.84 -40.03 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.704 -0.622 . . . . 0.0 110.57 -179.163 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.18 -40.0 95.18 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.342 -0.849 . . . . 0.0 110.316 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.45 -39.97 79.65 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.26 -39.96 88.62 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.604 -0.939 . . . . 0.0 110.276 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.194 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.863 0.363 . . . . 0.0 110.66 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.3 m -110.95 141.73 44.0 Favored 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.832 0.825 . . . . 0.0 111.332 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.512 HG21 HG11 ' A' ' 105' ' ' VAL . 45.8 pt -119.93 149.94 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.89 -0.507 . . . . 0.0 110.407 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.409 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 67.6 m -143.97 -174.08 4.17 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -141.5 150.0 41.63 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.362 -0.836 . . . . 0.0 110.538 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -132.88 144.73 54.07 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.609 -0.682 . . . . 0.0 109.543 179.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.6 -4.46 14.13 Favored 'Trans proline' 0 C--N 1.317 -1.11 0 O-C-N 123.381 1.201 . . . . 0.0 112.405 -178.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.661 HD11 ' CZ ' ' A' ' 9' ' ' TYR . 33.9 pt -69.99 -40.03 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 120.899 -1.126 . . . . 0.0 110.439 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.661 ' CZ ' HD11 ' A' ' 8' ' ' ILE . 30.8 m-85 -74.52 66.66 1.42 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 122.815 1.293 . . . . 0.0 110.611 -178.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.72 171.62 7.26 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 114.307 -1.315 . . . . 0.0 108.458 177.145 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.83 -34.47 73.13 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -175.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -89.1 10.1 23.03 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.45 -1.406 . . . . 0.0 111.966 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.478 HD22 ' O ' ' A' ' 8' ' ' ILE . 58.7 tp -71.16 122.87 20.93 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.359 -0.838 . . . . 0.0 109.431 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.3 m -68.89 136.84 53.25 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.705 0.764 . . . . 0.0 110.199 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.617 ' O ' HG12 ' A' ' 18' ' ' VAL . 89.4 mmm -65.58 -16.98 64.23 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.471 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.57 -16.59 77.65 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.012 -1.055 . . . . 0.0 111.069 -179.208 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 79.6 p -90.33 -17.65 26.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.138 -1.213 . . . . 0.0 111.256 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.896 HG23 ' OD1' ' A' ' 77' ' ' ASP . 7.6 p -89.97 155.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.333 -0.854 . . . . 0.0 109.598 -179.528 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.619 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -48.41 -40.02 24.53 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.513 -0.742 . . . . 0.0 110.406 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.29 82.59 4.58 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -92.51 -83.41 0.3 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.895 -1.128 . . . . 0.0 112.596 -177.486 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.424 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 60.3 t30 -154.5 18.02 0.47 Allowed 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.802 -1.186 . . . . 0.0 112.339 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.06 -141.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -70.13 -42.56 72.45 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.692 -0.887 . . . . 0.0 109.634 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.664 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 8.2 p80 -97.31 4.48 50.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.477 -0.765 . . . . 0.0 110.861 -179.715 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.56 144.43 37.42 Favored Glycine 0 N--CA 1.494 2.541 0 O-C-N 121.14 -0.975 . . . . 0.0 110.734 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 94.5 mt -99.58 -3.05 34.16 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.825 -0.809 . . . . 0.0 110.539 179.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.407 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.3 tpp -60.12 -36.39 77.38 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.562 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.89 -77.79 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.423 -0.798 . . . . 0.0 111.977 -177.55 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -69.98 -39.99 75.63 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.38 -0.825 . . . . 0.0 111.053 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.506 ' CD2' HG23 ' A' ' 37' ' ' VAL . 68.1 m-85 -119.99 88.44 40.65 Favored Pre-proline 0 N--CA 1.493 1.698 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.7 Cg_endo -68.59 -16.51 42.65 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.353 1.186 . . . . 0.0 111.51 -178.795 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.5 m -125.6 140.21 52.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.214 -0.929 . . . . 0.0 110.308 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.658 HD21 HG21 ' A' ' 43' ' ' VAL . 51.2 tp -68.55 119.74 13.47 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.68 -0.637 . . . . 0.0 110.65 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.31 32.78 0.04 OUTLIER Glycine 0 N--CA 1.497 2.713 0 C-N-CA 119.96 -1.114 . . . . 0.0 110.782 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 -156.14 -49.55 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.161 -1.199 . . . . 0.0 110.603 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.506 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.4 t -61.18 -59.64 13.1 Favored Pre-proline 0 N--CA 1.499 2.008 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.453 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 48.5 Cg_endo -75.38 -31.76 5.5 Favored 'Trans proline' 0 C--N 1.318 -1.075 0 N-CA-C 108.872 -1.241 . . . . 0.0 108.872 177.64 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.438 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.69 -64.22 0.62 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 107.316 -2.314 . . . . 0.0 107.316 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.539 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 163.54 -68.32 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.645 0 C-N-CA 123.533 0.733 . . . . 0.0 109.555 177.428 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.539 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.4 Cg_endo -80.41 -0.54 10.71 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 O-C-N 122.734 0.86 . . . . 0.0 111.423 179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -109.95 57.18 0.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.195 -0.94 . . . . 0.0 109.449 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.658 HG21 HD21 ' A' ' 34' ' ' LEU . 11.4 p -129.62 135.66 60.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-O 121.551 0.691 . . . . 0.0 110.557 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.698 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -165.12 173.01 40.91 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.94 163.79 28.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.802 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -143.73 157.02 59.2 Favored Pre-proline 0 N--CA 1.495 1.81 0 O-C-N 121.698 -0.884 . . . . 0.0 110.19 179.336 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.48 -9.26 25.48 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.567 1.511 . . . . 0.0 113.044 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -99.01 28.16 4.58 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.918 -1.114 . . . . 0.0 112.239 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.576 HD11 HD11 ' A' ' 46' ' ' ILE . 48.6 mm -119.58 121.57 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.085 -1.01 . . . . 0.0 109.36 179.185 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.5 -43.01 57.94 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.323 -0.86 . . . . 0.0 111.487 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.619 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 163.96 -133.33 2.99 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 119.296 -1.43 . . . . 0.0 111.141 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.483 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.4 t90 -51.11 -23.69 3.39 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -178.77 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.664 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 21.5 t70 -143.99 64.4 1.32 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.362 -0.836 . . . . 0.0 110.427 -178.846 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.601 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 44.0 m -79.37 142.36 58.34 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.431 -0.793 . . . . 0.0 111.03 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.47 -19.27 15.02 Favored 'Trans proline' 0 C--N 1.317 -1.119 0 O-C-N 123.421 1.222 . . . . 0.0 111.031 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.44 9.86 42.17 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.228 -0.92 . . . . 0.0 112.109 -178.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.465 ' HB3' ' ND1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -72.06 154.09 41.33 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.912 -1.117 . . . . 0.0 108.776 178.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.403 ' HA2' ' CZ ' ' A' ' 74' ' ' ARG . . . 78.61 10.02 86.55 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 96.3 m -99.88 139.96 34.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.306 -1.114 . . . . 0.0 109.706 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.4 m -80.12 143.59 33.78 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.299 0.571 . . . . 0.0 111.063 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 70.1 m95 -145.39 133.64 21.68 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.443 -0.785 . . . . 0.0 109.871 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -108.53 141.55 40.26 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.181 -0.949 . . . . 0.0 110.571 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 HG11 ' A' ' 105' ' ' VAL . 62.4 t -112.95 127.89 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 CA-C-O 121.385 0.612 . . . . 0.0 110.977 -179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 m -120.03 143.5 48.05 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.702 -0.624 . . . . 0.0 110.254 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.468 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 9.5 pt -120.74 164.15 24.97 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.171 -0.955 . . . . 0.0 111.218 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.468 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.2 Cg_endo -61.49 -26.24 80.71 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 121.682 1.588 . . . . 0.0 113.067 -178.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -63.42 -35.67 81.18 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.227 -0.921 . . . . 0.0 109.761 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.59 63.17 0.46 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.423 ' O ' HD11 ' A' ' 93' ' ' LEU . 40.4 t-20 -164.42 157.23 17.15 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.774 -0.839 . . . . 0.0 109.209 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 73.9 p -154.74 159.74 40.88 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 122.025 0.917 . . . . 0.0 111.515 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.482 HD12 HD11 ' A' ' 73' ' ' ILE . 21.7 pt -133.61 164.27 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -103.61 125.0 49.86 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 118.319 -1.353 . . . . 0.0 109.895 -178.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.482 HD11 HD12 ' A' ' 71' ' ' ILE . 48.4 mm -119.78 123.54 71.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.621 -0.674 . . . . 0.0 109.911 -178.749 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.403 ' CZ ' ' HA2' ' A' ' 58' ' ' GLY . 0.0 OUTLIER -93.69 133.66 36.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.406 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -54.8 144.77 30.28 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.698 HG12 ' O ' ' A' ' 44' ' ' GLY . 13.4 p -168.35 -28.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.802 -0.822 . . . . 0.0 111.138 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.896 ' OD1' HG23 ' A' ' 18' ' ' VAL . 5.4 m-20 -126.07 170.0 12.2 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.721 -1.237 . . . . 0.0 110.258 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.406 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.5 t -101.4 151.92 21.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.7 -0.625 . . . . 0.0 110.686 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.73 144.32 16.24 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.084 -1.207 . . . . 0.0 110.084 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -60.66 -31.45 70.68 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.78 -0.835 . . . . 0.0 109.978 178.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.65 80.81 0.05 OUTLIER Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.72 -176.94 29.07 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.802 ' CD2' HG22 ' A' ' 46' ' ' ILE . 57.7 m-85 -113.17 130.96 56.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.438 -1.036 . . . . 0.0 109.58 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.409 ' HA ' ' O ' ' A' ' 4' ' ' SER . 36.8 t-20 -120.88 130.96 54.13 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.412 HG11 HG13 ' A' ' 73' ' ' ILE . 34.7 m -130.22 171.8 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.175 -0.953 . . . . 0.0 112.258 -177.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.2 m-20 -54.07 155.83 6.04 Favored Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.588 -0.695 . . . . 0.0 110.321 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.86 -18.12 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.409 1.215 . . . . 0.0 110.761 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.6 m -80.82 -39.76 26.09 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.965 -1.085 . . . . 0.0 109.208 178.575 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.37 -39.08 85.65 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.478 ' CE1' ' HA ' ' A' ' 97' ' ' THR . 25.3 t80 -59.99 -50.0 75.44 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.634 -0.666 . . . . 0.0 110.762 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.773 HG23 ' HA ' ' A' ' 96' ' ' SER . 94.4 m -59.98 -38.95 84.02 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.58 -0.7 . . . . 0.0 111.103 -178.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -64.63 -40.02 94.74 Favored 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.962 -0.695 . . . . 0.0 111.562 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.423 HD11 ' O ' ' A' ' 69' ' ' ASN . 59.8 tp -69.03 -42.54 76.22 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.637 -0.665 . . . . 0.0 111.9 -178.559 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 49.0 t -100.25 -9.98 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.302 0 O-C-N 121.228 -0.92 . . . . 0.0 111.927 -178.286 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 99.5 -29.27 12.3 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 -178.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.773 ' HA ' HG23 ' A' ' 91' ' ' THR . 97.1 p -155.62 159.84 39.96 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.478 ' HA ' ' CE1' ' A' ' 90' ' ' PHE . 2.8 t -109.06 24.69 12.76 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.113 -0.992 . . . . 0.0 111.086 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -73.82 -22.83 59.66 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.555 -0.715 . . . . 0.0 111.067 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.95 -44.8 94.18 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.365 -0.834 . . . . 0.0 110.971 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.15 -68.07 0.53 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -140.25 135.52 32.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.946 . . . . 0.0 110.383 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 68.6 t -119.57 119.7 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -0.824 . . . . 0.0 110.155 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.9 p-10 -87.95 175.07 7.95 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-O 121.563 0.697 . . . . 0.0 111.181 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.3 t30 59.98 40.86 18.34 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.705 -0.622 . . . . 0.0 110.943 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.512 HG11 HG21 ' A' ' 3' ' ' ILE . 91.3 t -93.86 121.38 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.992 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -79.91 139.77 36.97 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 119.353 -0.939 . . . . 0.0 109.299 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.45 ' C ' HG13 ' A' ' 108' ' ' VAL . 41.1 p90 -136.67 142.22 43.17 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.864 -0.523 . . . . 0.0 110.517 -179.346 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.45 HG13 ' C ' ' A' ' 107' ' ' TYR . 34.8 m -148.33 150.35 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.616 -0.678 . . . . 0.0 110.581 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 61.2 tt0 -90.19 138.81 31.22 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.542 -0.724 . . . . 0.0 110.516 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.49 177.46 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.591 -0.693 . . . . 0.0 110.257 179.318 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.91 142.96 52.7 Favored 'General case' 0 N--CA 1.496 1.84 0 CA-C-O 121.582 0.706 . . . . 0.0 110.952 -178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.535 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.5 tt -60.11 -38.42 82.96 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.814 -0.554 . . . . 0.0 110.769 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 83.3 p -54.31 -37.01 64.33 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.561 -0.712 . . . . 0.0 111.359 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -70.07 -19.94 63.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.432 -0.793 . . . . 0.0 110.506 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 28.2 m -73.63 -52.17 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.483 HD11 HD21 ' A' ' 112' ' ' LEU . 86.5 mt -70.0 -39.99 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.523 -179.315 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -69.67 -40.0 76.69 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 120.025 -0.67 . . . . 0.0 110.108 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.27 -53.02 19.58 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.597 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -44.52 94.52 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.523 -0.987 . . . . 0.0 110.582 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.216 -179.901 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.089 0.471 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -113.28 140.48 47.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.742 -0.599 . . . . 0.0 109.958 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.774 HG23 HG21 ' A' ' 105' ' ' VAL . 38.5 pt -104.61 145.41 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.649 -0.657 . . . . 0.0 110.055 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 1.5 m -145.72 -171.6 3.72 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 51.7 p90 -146.16 150.0 35.04 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.41 179.199 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -129.01 146.17 59.62 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -81.07 -8.05 13.09 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.264 1.139 . . . . 0.0 112.449 -178.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.505 HG13 ' N ' ' A' ' 9' ' ' TYR . 37.5 pt -67.92 -40.09 82.83 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 120.889 -1.132 . . . . 0.0 110.789 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.66 ' HA ' HD22 ' A' ' 13' ' ' LEU . 52.3 m-85 -72.77 67.71 0.82 Allowed 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 122.9 1.333 . . . . 0.0 111.443 -178.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.1 171.1 7.49 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.065 176.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.94 -33.92 71.15 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -175.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -91.09 11.56 22.74 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.599 -1.313 . . . . 0.0 112.354 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.66 HD22 ' HA ' ' A' ' 9' ' ' TYR . 35.3 tp -70.02 123.37 21.38 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.289 -0.882 . . . . 0.0 109.844 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.26 136.12 49.59 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.642 0.734 . . . . 0.0 110.078 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.788 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -68.81 -16.68 63.85 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.979 -0.451 . . . . 0.0 111.869 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.77 -14.67 70.44 Favored Glycine 0 N--CA 1.495 2.586 0 O-C-N 120.917 -1.115 . . . . 0.0 111.309 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.2 t -91.05 -8.01 50.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.129 -1.218 . . . . 0.0 112.051 -178.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 15' ' ' MET . 8.6 p -96.01 167.82 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.107 -0.996 . . . . 0.0 110.26 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.784 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.39 -44.49 92.76 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.51 -0.744 . . . . 0.0 109.988 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.4 m -81.76 81.75 7.68 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.522 -0.736 . . . . 0.0 109.112 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -101.29 -79.57 0.51 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.619 -0.676 . . . . 0.0 112.594 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -131.6 10.18 4.73 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.282 -0.886 . . . . 0.0 112.723 -178.258 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.449 ' HA2' ' CH2' ' A' ' 52' ' ' TRP . . . -73.61 -148.27 1.17 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -64.7 -39.92 94.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 110.865 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.566 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 44.8 m80 -101.16 15.87 27.31 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.331 -0.856 . . . . 0.0 111.231 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.69 131.32 51.99 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.592 HD22 HG21 ' A' ' 37' ' ' VAL . 83.2 mt -97.46 -4.83 37.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.903 -0.763 . . . . 0.0 110.466 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 38.3 tpp -60.87 -34.7 75.02 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.331 -0.855 . . . . 0.0 110.635 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.69 -76.75 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.48 -0.762 . . . . 0.0 111.96 -177.518 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 56.6 tt0 -69.91 -39.99 75.86 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.433 -0.792 . . . . 0.0 110.367 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.522 ' CD2' HG23 ' A' ' 37' ' ' VAL . 58.0 m-85 -120.99 93.3 48.84 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.648 -0.658 . . . . 0.0 109.981 -179.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.07 -10.65 27.86 Favored 'Trans proline' 0 C--N 1.318 -1.069 0 O-C-N 123.413 1.217 . . . . 0.0 111.132 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.3 p -126.83 154.04 44.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.326 -0.859 . . . . 0.0 110.269 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 1.003 HD11 HG21 ' A' ' 43' ' ' VAL . 40.1 tp -78.09 116.03 18.25 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.51 34.0 0.03 OUTLIER Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.76 -48.04 0.07 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 110.613 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.592 HG21 HD22 ' A' ' 27' ' ' LEU . 2.2 t -61.33 -57.78 23.21 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 108.591 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.493 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.7 Cg_endo -78.8 -28.4 4.13 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 O-C-N 123.307 1.161 . . . . 0.0 109.485 178.179 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.83 -61.13 0.65 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 107.503 -2.239 . . . . 0.0 107.503 -178.616 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 163.24 -54.78 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.605 0 C-N-CA 123.414 0.685 . . . . 0.0 110.042 177.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.38 15.28 0.3 Allowed 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 121.563 1.509 . . . . 0.0 111.448 -178.398 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -125.37 39.9 3.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.358 -0.839 . . . . 0.0 109.244 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.003 HG21 HD11 ' A' ' 34' ' ' LEU . 9.4 p -123.66 147.52 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 CA-C-O 121.674 0.749 . . . . 0.0 110.264 -178.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.467 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -174.48 175.97 46.79 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.94 149.41 37.82 Favored Glycine 0 N--CA 1.484 1.839 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.466 HG13 HG12 ' A' ' 49' ' ' ILE . 1.1 pp -142.37 139.19 17.29 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.545 -0.974 . . . . 0.0 108.847 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -58.89 -10.51 9.91 Favored 'Trans proline' 0 N--CA 1.505 2.202 0 C-N-CA 122.046 1.831 . . . . 0.0 115.261 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.428 ' H ' HD12 ' A' ' 46' ' ' ILE . 84.3 m-20 -96.19 30.63 2.41 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 120.529 -1.357 . . . . 0.0 111.899 -178.44 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.571 HG23 ' HB2' ' A' ' 54' ' ' SER . 50.8 mm -119.99 125.99 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.142 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.82 -44.62 15.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.551 -0.718 . . . . 0.0 111.78 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.784 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 172.11 -130.6 1.96 Allowed Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.406 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.449 ' CH2' ' HA2' ' A' ' 23' ' ' GLY . 5.5 t90 -40.21 -30.04 0.09 Allowed 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 -177.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -158.97 72.98 0.59 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.689 -1.257 . . . . 0.0 110.83 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.571 ' HB2' HG23 ' A' ' 49' ' ' ILE . 4.0 t -54.53 140.32 57.19 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.671 -0.643 . . . . 0.0 111.317 -178.887 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.566 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -72.81 -20.42 22.61 Favored 'Trans proline' 0 C--N 1.319 -1.006 0 O-C-N 123.412 1.217 . . . . 0.0 110.558 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 59' ' ' THR . 18.9 m -103.93 14.85 29.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.347 -0.846 . . . . 0.0 111.294 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.412 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 5.0 t -67.74 144.68 55.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.117 -0.99 . . . . 0.0 110.383 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.13 8.31 82.06 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 56' ' ' SER . 25.8 p -80.6 159.71 25.33 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.536 ' SG ' HG23 ' A' ' 110' ' ' VAL . 41.9 t -110.79 137.54 48.32 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.789 -178.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 81.9 m95 -142.96 155.88 44.77 Favored 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.12 -0.988 . . . . 0.0 111.394 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 68.7 tttt -112.18 132.25 55.0 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 177.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.05 129.9 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.557 -0.715 . . . . 0.0 109.723 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.3 m -120.68 142.18 49.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.749 -0.595 . . . . 0.0 111.362 -178.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 48.0 pt -119.74 164.37 22.4 Favored Pre-proline 0 N--CA 1.499 2.022 0 O-C-N 121.496 -0.753 . . . . 0.0 110.209 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.35 -26.02 76.72 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.174 1.25 . . . . 0.0 112.891 -178.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -64.76 -39.96 94.48 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.218 -0.926 . . . . 0.0 109.907 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.1 60.75 0.29 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -160.45 153.51 21.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.603 -0.939 . . . . 0.0 109.339 178.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.45 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 88.0 p -151.71 159.68 43.89 Favored 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 122.12 0.962 . . . . 0.0 112.149 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.462 HG12 HD13 ' A' ' 93' ' ' LEU . 43.8 pt -139.91 164.13 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.268 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -105.27 127.18 52.81 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 118.86 -1.136 . . . . 0.0 109.784 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -115.89 130.03 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.627 -0.671 . . . . 0.0 110.134 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.513 ' HD3' HG12 ' A' ' 37' ' ' VAL . 51.4 ttt180 -100.67 136.91 39.79 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.407 ' HA2' HG12 ' A' ' 46' ' ' ILE . . . -59.64 149.71 39.8 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.947 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.727 HG11 ' CG2' ' A' ' 43' ' ' VAL . 7.0 p -167.47 -35.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.809 -0.818 . . . . 0.0 110.635 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.57 ' OD2' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -129.89 174.48 9.7 Favored 'General case' 0 N--CA 1.508 2.435 0 O-C-N 120.748 -1.22 . . . . 0.0 108.948 179.465 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 36.9 t -98.59 143.14 29.31 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.357 -0.84 . . . . 0.0 110.535 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -107.89 140.29 15.38 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 -81.96 58.2 3.8 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.724 -0.868 . . . . 0.0 111.589 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.99 58.17 1.62 Allowed Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 151.15 5.42 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.791 -1.195 . . . . 0.0 110.386 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -73.68 145.18 45.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.866 -0.785 . . . . 0.0 110.963 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.455 ' HA ' ' O ' ' A' ' 4' ' ' SER . 19.7 t-20 -139.55 130.69 26.55 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.423 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.467 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.1 m -132.28 172.5 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.057 -1.027 . . . . 0.0 112.202 -178.379 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.7 m-20 -54.69 150.8 16.81 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.275 -0.891 . . . . 0.0 109.823 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.43 -18.3 63.96 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.321 1.169 . . . . 0.0 110.656 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 86.1 m -78.73 -40.01 34.7 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.934 -1.104 . . . . 0.0 109.376 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.34 -39.11 82.0 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.509 -0.744 . . . . 0.0 109.107 179.15 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -59.99 -49.93 75.75 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.767 -0.583 . . . . 0.0 110.704 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.8 m -60.05 -37.37 79.63 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.406 -0.809 . . . . 0.0 110.623 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -70.0 -39.96 75.58 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.043 -179.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.462 HD13 HG12 ' A' ' 71' ' ' ILE . 52.7 tp -70.01 -44.25 69.73 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.569 -0.707 . . . . 0.0 111.428 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 63.0 t -96.37 -39.92 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.304 -0.873 . . . . 0.0 111.561 -177.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.53 -29.43 4.99 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.7 p -152.66 160.65 43.16 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.461 -1.023 . . . . 0.0 110.457 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 72.7 p -94.62 8.17 43.25 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.532 -0.73 . . . . 0.0 110.857 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -69.15 -36.07 77.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.42 -0.8 . . . . 0.0 110.677 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.75 87.0 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.525 -0.735 . . . . 0.0 110.284 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.38 -63.54 3.64 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 21.3 ptt180 -150.8 157.59 43.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.673 -0.898 . . . . 0.0 110.745 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 105' ' ' VAL . 62.2 t -128.09 122.26 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.553 -0.717 . . . . 0.0 110.223 179.397 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -82.87 169.12 16.43 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.603 -0.686 . . . . 0.0 110.961 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t30 60.01 43.22 14.84 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.62 -0.675 . . . . 0.0 111.306 179.315 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.774 HG21 HG23 ' A' ' 3' ' ' ILE . 63.7 t -87.21 130.02 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 C-N-CA 120.06 -0.656 . . . . 0.0 109.966 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -87.19 139.43 30.57 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.804 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -139.9 144.32 37.1 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.914 -0.491 . . . . 0.0 111.173 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.95 143.2 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.529 -0.732 . . . . 0.0 110.734 179.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 66.1 tt0 -75.72 134.33 40.54 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.603 -0.685 . . . . 0.0 110.009 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.536 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.9 m -131.34 172.7 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.554 -0.716 . . . . 0.0 110.237 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -60.11 146.07 44.47 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.513 -0.742 . . . . 0.0 110.986 -179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.695 HD21 HD11 ' A' ' 116' ' ' ILE . 10.1 tt -60.96 -37.22 81.64 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.621 -0.674 . . . . 0.0 110.796 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.8 m -55.23 -40.07 70.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.51 -0.744 . . . . 0.0 110.221 -178.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -59.98 -37.41 79.55 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.731 -0.606 . . . . 0.0 110.317 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -63.32 -46.65 85.67 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.369 -0.832 . . . . 0.0 110.116 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.695 HD11 HD21 ' A' ' 112' ' ' LEU . 88.0 mt -70.02 -40.01 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.554 -0.717 . . . . 0.0 110.738 -178.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -66.88 -40.06 87.67 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.468 -0.77 . . . . 0.0 110.498 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.85 -48.08 51.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.97 94.34 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.598 -0.942 . . . . 0.0 110.603 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 118.047 -0.977 . . . . 0.0 110.265 -179.894 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.205 0.526 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t -111.18 137.72 48.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.628 -0.67 . . . . 0.0 109.3 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.642 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.1 pt -113.98 147.7 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.729 -0.607 . . . . 0.0 111.018 -179.096 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.06 -170.09 3.34 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -141.82 148.1 38.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.41 -0.806 . . . . 0.0 110.337 178.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -127.05 148.61 66.52 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.46 -0.775 . . . . 0.0 109.825 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -82.57 -7.43 11.63 Favored 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.391 1.206 . . . . 0.0 112.367 -179.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 27.4 pt -72.93 -42.29 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.139 0 O-C-N 120.933 -1.104 . . . . 0.0 110.885 -179.025 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 31.9 m-85 -72.29 67.18 0.68 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 122.651 1.215 . . . . 0.0 111.049 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.55 171.05 7.58 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.327 176.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -60.04 -34.16 73.02 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -175.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -90.05 10.62 23.51 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.416 -1.314 . . . . 0.0 112.136 -177.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.45 HD22 ' HA ' ' A' ' 9' ' ' TYR . 53.4 tp -71.02 126.05 28.53 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 178.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.1 t -69.95 136.02 50.07 Favored 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.791 0.805 . . . . 0.0 110.454 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.741 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -66.43 -19.07 65.7 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.436 -179.189 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.27 -14.06 63.48 Favored Glycine 0 N--CA 1.493 2.456 0 O-C-N 121.044 -1.035 . . . . 0.0 110.776 -179.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.9 m -93.16 -14.59 26.97 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -1.161 . . . . 0.0 111.796 -178.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.828 HG23 ' OD2' ' A' ' 77' ' ' ASP . 7.2 p -90.04 160.04 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 120.996 -1.065 . . . . 0.0 110.708 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.59 -42.63 83.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.699 -0.626 . . . . 0.0 110.565 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.0 m -81.64 72.89 8.7 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -101.78 -76.59 0.57 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.705 -0.622 . . . . 0.0 110.628 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -127.27 168.87 14.16 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.108 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.35 -154.81 16.49 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.52 -2.232 . . . . 0.0 107.52 -177.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -70.2 -39.92 74.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.292 -1.122 . . . . 0.0 110.271 179.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.461 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 19.2 m80 -94.09 0.71 56.04 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.454 -0.779 . . . . 0.0 111.194 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.59 127.65 37.64 Favored Glycine 0 N--CA 1.495 2.611 0 O-C-N 120.964 -1.085 . . . . 0.0 110.423 -179.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.553 HD13 HG11 ' A' ' 37' ' ' VAL . 84.5 mt -100.04 -5.19 28.44 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 122.012 -0.699 . . . . 0.0 110.072 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.2 ttm -63.04 -37.72 88.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.28 -0.887 . . . . 0.0 109.764 179.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.92 -73.45 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.611 -0.681 . . . . 0.0 111.506 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -69.94 -40.05 75.72 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.157 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CG ' HG23 ' A' ' 37' ' ' VAL . 35.6 m-85 -120.36 89.89 44.44 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.864 -0.523 . . . . 0.0 109.801 -178.508 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.07 -10.01 25.38 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 O-C-N 123.196 1.103 . . . . 0.0 111.049 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 31.0 m -130.01 142.13 50.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.231 -0.918 . . . . 0.0 110.366 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.927 HD11 HG21 ' A' ' 43' ' ' VAL . 35.4 tp -69.94 119.25 13.87 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.642 -0.661 . . . . 0.0 110.405 -179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.76 32.6 0.04 OUTLIER Glycine 0 N--CA 1.497 2.746 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.985 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -156.95 -44.95 0.07 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -1.16 . . . . 0.0 110.096 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.553 HG11 HD13 ' A' ' 27' ' ' LEU . 2.7 t -63.62 -59.03 12.75 Favored Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.552 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.476 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.5 Cg_endo -76.82 -29.22 5.63 Favored 'Trans proline' 0 N--CA 1.487 1.109 0 O-C-N 123.271 1.143 . . . . 0.0 109.55 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 127.63 -61.92 0.64 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.635 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 164.69 -54.74 0.0 OUTLIER Pre-proline 0 N--CA 1.509 2.503 0 C-N-CA 123.368 0.667 . . . . 0.0 109.885 177.386 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.716 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -102.21 11.81 0.39 Allowed 'Trans proline' 0 C--N 1.325 -0.702 0 C-N-CA 121.473 1.448 . . . . 0.0 111.419 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -117.61 31.16 6.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.244 -0.91 . . . . 0.0 110.059 -178.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.963 ' CG2' HG11 ' A' ' 76' ' ' VAL . 15.0 p -110.46 139.92 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.561 0.696 . . . . 0.0 110.943 -179.306 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.504 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.5 173.79 42.59 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.488 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -94.32 163.72 25.38 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.787 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -154.27 162.53 26.7 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.806 -0.82 . . . . 0.0 109.888 179.015 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -67.33 -16.94 49.23 Favored 'Trans proline' 0 N--CA 1.5 1.902 0 C-N-CA 121.502 1.468 . . . . 0.0 113.95 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.546 ' H ' HD12 ' A' ' 46' ' ' ILE . 94.4 m-20 -89.39 15.83 8.53 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.541 -1.349 . . . . 0.0 113.025 -177.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.656 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.0 mm -108.02 122.63 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.201 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.72 -45.47 29.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.305 -0.872 . . . . 0.0 111.664 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.3 -127.81 1.66 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 118.983 -1.58 . . . . 0.0 110.95 -179.487 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.1 t90 -48.92 -26.03 2.25 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.897 -0.767 . . . . 0.0 112.841 -178.734 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -147.27 63.13 1.16 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.169 -0.957 . . . . 0.0 111.379 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.656 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.5 p -63.68 141.72 97.96 Favored Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.359 -0.838 . . . . 0.0 110.87 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.461 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -80.69 -21.74 6.98 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 O-C-N 123.41 1.216 . . . . 0.0 111.599 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.6 m -95.11 11.63 31.5 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.357 -0.84 . . . . 0.0 111.183 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -72.14 146.29 47.54 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.209 -0.932 . . . . 0.0 110.304 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.78 22.83 52.13 Favored Glycine 0 N--CA 1.495 2.568 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.098 178.064 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.1 m -109.29 170.65 7.92 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -1.11 . . . . 0.0 109.009 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 2.1 m -118.96 148.2 43.22 Favored 'General case' 0 N--CA 1.51 2.556 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -177.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.459 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 67.9 m95 -144.34 149.67 36.55 Favored 'General case' 0 N--CA 1.51 2.565 0 O-C-N 121.116 -0.99 . . . . 0.0 110.219 175.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.3 ttpt -101.46 131.2 47.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 176.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.444 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.8 t -108.61 124.47 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.64 -178.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 94.3 m -120.03 130.03 54.52 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-O 121.189 0.519 . . . . 0.0 111.42 -178.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.483 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.4 pt -106.85 166.15 11.63 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.789 -0.569 . . . . 0.0 110.492 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.7 Cg_endo -63.92 -27.56 66.77 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 O-C-N 123.347 1.183 . . . . 0.0 112.605 -178.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -64.3 -39.92 94.89 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.169 -0.957 . . . . 0.0 109.734 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.46 58.3 0.32 Allowed Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.468 ' HB2' HD11 ' A' ' 65' ' ' ILE . 85.1 m-20 -150.72 147.32 27.19 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 178.373 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 49.1 m -147.25 152.36 38.19 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.859 -1.136 . . . . 0.0 112.652 -179.467 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 93' ' ' LEU . 37.7 pt -140.13 161.66 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.29 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.31 129.76 47.34 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.093 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.0 mm -116.58 129.97 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 109.782 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.416 ' HD3' HG12 ' A' ' 37' ' ' VAL . 58.6 ttt180 -101.32 133.31 46.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.965 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -52.52 149.59 10.06 Favored Glycine 0 N--CA 1.498 2.795 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.963 HG11 ' CG2' ' A' ' 43' ' ' VAL . 14.9 p -174.48 -28.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.652 -0.91 . . . . 0.0 111.121 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.828 ' OD2' HG23 ' A' ' 18' ' ' VAL . 5.2 m-20 -129.75 167.47 18.02 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.717 -1.239 . . . . 0.0 109.422 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 77.7 p -97.84 155.89 16.84 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -0.835 . . . . 0.0 110.771 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.94 139.52 11.01 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -61.04 -39.9 91.56 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.837 -0.802 . . . . 0.0 110.209 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.61 73.53 0.08 OUTLIER Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 155.22 -163.34 31.45 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.89 -1.148 . . . . 0.0 110.298 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.787 ' CD2' HG22 ' A' ' 46' ' ' ILE . 39.8 m-85 -125.63 121.56 33.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.919 -0.753 . . . . 0.0 109.113 179.787 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -116.08 130.24 56.71 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.504 HG12 ' HA3' ' A' ' 44' ' ' GLY . 26.9 m -129.18 173.47 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -178.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.9 m-20 -56.53 158.2 8.55 Favored Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.544 -0.722 . . . . 0.0 110.021 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.83 -28.66 36.13 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.453 1.238 . . . . 0.0 111.06 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -70.03 -39.96 75.44 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.993 -1.067 . . . . 0.0 109.26 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.716 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.87 -41.31 87.47 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.645 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.64 -50.0 75.27 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.804 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -60.18 -40.04 88.58 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.515 -0.741 . . . . 0.0 110.839 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.27 -39.56 86.06 Favored 'General case' 0 N--CA 1.495 1.797 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.207 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.463 ' HB2' HD13 ' A' ' 71' ' ' ILE . 65.5 tp -69.95 -41.66 74.25 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.835 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -98.89 -36.65 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.255 -0.903 . . . . 0.0 111.722 -177.695 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.04 -27.43 6.75 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.8 p -153.07 160.46 42.95 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.552 -0.97 . . . . 0.0 109.81 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 60.9 p -90.87 6.82 42.92 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.366 -0.834 . . . . 0.0 110.793 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -69.98 -25.91 63.84 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.31 -0.868 . . . . 0.0 110.87 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.17 77.03 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.466 -0.771 . . . . 0.0 110.949 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.94 -80.46 1.76 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 19.1 ttm180 -137.07 139.94 41.66 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.677 -0.896 . . . . 0.0 110.119 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.24 119.93 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.523 -0.736 . . . . 0.0 110.231 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -90.43 169.7 10.84 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.754 0.787 . . . . 0.0 111.176 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 28.8 t30 59.95 40.05 19.4 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.695 -0.628 . . . . 0.0 111.497 179.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.512 HG21 HG12 ' A' ' 3' ' ' ILE . 81.5 t -84.41 126.98 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.709 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -92.58 152.26 19.7 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.13 -1.028 . . . . 0.0 108.87 179.179 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -146.82 150.0 34.43 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.631 -0.668 . . . . 0.0 112.074 -177.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -141.32 134.73 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.745 -0.597 . . . . 0.0 110.097 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.459 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 55.6 tt0 -72.46 141.61 48.6 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.524 0.678 . . . . 0.0 110.979 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.0 m -132.27 172.07 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -60.0 143.98 50.42 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.453 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.54 HD21 HD11 ' A' ' 116' ' ' ILE . 8.4 tt -60.03 -39.97 87.74 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.385 -0.822 . . . . 0.0 110.226 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.3 t -51.29 -33.98 31.08 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.615 -0.678 . . . . 0.0 111.28 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -65.38 -39.99 92.94 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.482 -0.761 . . . . 0.0 110.935 -179.656 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 86.8 m -60.42 -47.76 84.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.393 -0.817 . . . . 0.0 110.243 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 112' ' ' LEU . 88.1 mt -69.96 -40.02 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.955 -0.466 . . . . 0.0 110.772 -179.118 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -66.48 -39.99 89.08 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.498 -0.751 . . . . 0.0 110.866 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -78.68 -60.06 2.7 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.159 -178.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.13 93.59 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.418 -1.048 . . . . 0.0 110.738 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.402 -179.784 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.992 0.425 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.5 p -112.95 145.86 40.04 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.686 -0.634 . . . . 0.0 110.085 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 83' ' ' PHE . 45.1 pt -120.01 149.96 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.626 -0.671 . . . . 0.0 110.743 -179.529 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.415 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -145.62 -172.37 3.88 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.172 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -140.96 145.44 36.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.325 -0.859 . . . . 0.0 110.199 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.73 149.48 64.83 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.409 -0.807 . . . . 0.0 110.005 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.94 48.25 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.074 0 O-C-N 123.432 1.227 . . . . 0.0 110.602 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 9' ' ' TYR . 7.6 tp -118.79 -6.79 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.527 -0.733 . . . . 0.0 111.052 -179.232 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CD2' HG23 ' A' ' 8' ' ' ILE . 29.2 m-85 -122.69 70.94 1.01 Allowed 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 122.62 1.2 . . . . 0.0 110.182 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.54 171.45 7.56 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 114.597 -1.183 . . . . 0.0 107.921 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.646 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -56.56 -28.71 60.8 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -175.39 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.37 12.26 21.07 Favored 'General case' 0 N--CA 1.498 1.966 0 C-N-CA 118.323 -1.351 . . . . 0.0 112.236 -177.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 14' ' ' SER . 0.4 OUTLIER -69.55 116.62 10.17 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.205 -0.934 . . . . 0.0 109.817 179.779 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.424 ' N ' HD13 ' A' ' 13' ' ' LEU . 47.5 t -65.88 137.74 57.39 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.837 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.529 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.9 mmm -67.77 -16.37 64.08 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.87 -0.519 . . . . 0.0 111.715 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.14 -13.82 82.4 Favored Glycine 0 N--CA 1.495 2.607 0 O-C-N 120.849 -1.157 . . . . 0.0 110.626 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -94.98 -17.68 21.74 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.19 -1.183 . . . . 0.0 111.708 -178.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.635 HG21 HG22 ' A' ' 76' ' ' VAL . 8.2 p -87.21 159.16 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.186 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.517 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.44 -40.0 64.85 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.198 -0.939 . . . . 0.0 110.301 -179.556 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 62.8 m -78.88 82.61 5.06 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -90.45 -80.73 0.32 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.048 -1.032 . . . . 0.0 112.875 -177.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.461 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 24.5 p-10 -154.88 20.55 0.45 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.734 -1.229 . . . . 0.0 112.535 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.22 -144.91 0.04 OUTLIER Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -69.63 -39.93 76.84 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.821 -0.811 . . . . 0.0 109.808 178.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.529 ' CD2' ' HA ' ' A' ' 53' ' ' ASP . 2.3 p80 -95.57 4.57 53.02 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.468 -0.77 . . . . 0.0 110.098 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.76 140.75 43.55 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.183 -0.948 . . . . 0.0 111.174 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.574 HD13 HG11 ' A' ' 37' ' ' VAL . 91.2 mt -104.34 -0.04 28.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 122.049 -0.677 . . . . 0.0 110.389 178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.7 ttm -60.05 -35.06 74.32 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 110.521 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.51 -73.22 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.458 -0.776 . . . . 0.0 111.398 -177.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -70.36 -39.99 74.29 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.372 -0.83 . . . . 0.0 110.121 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.61 ' CG ' HG23 ' A' ' 37' ' ' VAL . 54.1 m-85 -116.97 86.47 19.8 Favored Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -178.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.31 -26.93 24.45 Favored 'Trans proline' 0 C--N 1.317 -1.101 0 O-C-N 123.39 1.205 . . . . 0.0 110.955 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 15.1 m -116.89 161.26 19.61 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.359 -0.838 . . . . 0.0 110.41 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 43' ' ' VAL . 42.3 tp -86.59 114.92 23.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.769 -0.582 . . . . 0.0 111.292 -178.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 156.49 37.09 0.02 OUTLIER Glycine 0 N--CA 1.497 2.734 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -162.2 -48.26 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.376 -1.073 . . . . 0.0 110.578 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.61 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.8 t -59.96 -59.36 14.11 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.494 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.3 Cg_endo -76.76 -31.98 3.77 Favored 'Trans proline' 0 C--N 1.317 -1.131 0 N-CA-C 109.007 -1.189 . . . . 0.0 109.007 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 133.68 -60.95 0.65 Allowed Glycine 0 N--CA 1.486 1.977 0 N-CA-C 107.498 -2.241 . . . . 0.0 107.498 -178.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.646 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 157.9 -51.06 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.665 0 C-N-CA 123.877 0.871 . . . . 0.0 109.936 177.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 52.9 Cg_endo -101.0 5.61 0.62 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.595 1.53 . . . . 0.0 112.039 -177.612 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -122.36 47.57 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.975 . . . . 0.0 109.961 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 34' ' ' LEU . 14.3 p -117.66 141.11 37.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.869 0.843 . . . . 0.0 110.181 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -169.79 176.19 43.7 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -92.22 165.06 28.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.776 HD11 ' CA ' ' A' ' 75' ' ' GLY . 0.9 OUTLIER -154.8 161.0 30.39 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.631 -0.923 . . . . 0.0 109.801 178.938 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -66.7 -35.01 29.95 Favored 'Trans proline' 0 N--CA 1.502 2.015 0 C-N-CA 121.777 1.651 . . . . 0.0 115.2 -175.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -68.95 -10.0 55.02 Favored 'General case' 0 N--CA 1.507 2.398 0 O-C-N 120.736 -1.227 . . . . 0.0 113.24 -177.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.1 mm -81.23 129.23 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 O-C-N 120.717 -1.24 . . . . 0.0 109.417 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.12 -49.64 7.17 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.325 -0.859 . . . . 0.0 112.108 -178.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.517 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.55 -139.35 4.85 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.995 -1.574 . . . . 0.0 111.608 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 70.7 t90 -49.01 -24.58 1.58 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.765 -0.844 . . . . 0.0 112.914 -178.49 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.529 ' HA ' ' CD2' ' A' ' 25' ' ' HIS . 14.7 t70 -142.27 71.93 1.36 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.191 -0.943 . . . . 0.0 109.583 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.47 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 9.8 p -82.65 136.91 44.72 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.937 -0.477 . . . . 0.0 110.318 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -78.6 -16.81 13.03 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 O-C-N 123.318 1.167 . . . . 0.0 111.167 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.3 m -97.39 4.19 50.74 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.316 -0.865 . . . . 0.0 112.543 -178.037 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.1 t -66.58 142.53 57.46 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.905 -1.122 . . . . 0.0 110.421 -179.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 94.13 -7.71 72.76 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.574 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 22.4 p -70.44 157.77 37.22 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 118.9 1.35 . . . . 0.0 110.743 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -107.21 130.8 54.68 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.939 -0.476 . . . . 0.0 110.553 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 92.9 m95 -135.17 147.62 49.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.279 -0.888 . . . . 0.0 110.561 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -106.42 135.55 47.73 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.0 t -108.2 123.88 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.65 -0.656 . . . . 0.0 109.382 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 41.3 m -119.59 137.31 53.93 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.111 0.481 . . . . 0.0 111.075 -178.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 35.1 pt -115.72 164.26 18.08 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.676 -0.64 . . . . 0.0 110.401 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.09 -25.18 80.77 Favored 'Trans proline' 0 N--CA 1.497 1.683 0 C-N-CA 121.268 1.312 . . . . 0.0 112.514 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -63.23 -40.0 96.21 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.256 -0.903 . . . . 0.0 109.706 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 114.61 60.72 0.38 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -159.95 151.99 20.49 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.717 -0.873 . . . . 0.0 108.854 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 61.3 p -155.48 161.07 41.02 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.115 -1.034 . . . . 0.0 112.428 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 73' ' ' ILE . 37.8 pt -137.36 166.48 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -105.52 127.04 52.79 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.665 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 71' ' ' ILE . 46.3 mm -120.04 129.95 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 121.463 -0.773 . . . . 0.0 110.547 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.536 ' HD3' HG12 ' A' ' 37' ' ' VAL . 59.9 ttt180 -100.42 140.04 35.24 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.443 -0.786 . . . . 0.0 109.016 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.776 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -60.02 149.45 41.5 Favored Glycine 0 N--CA 1.494 2.538 0 CA-C-O 122.019 0.788 . . . . 0.0 111.575 -178.091 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.635 HG22 HG21 ' A' ' 18' ' ' VAL . 4.0 p -159.0 -39.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 122.017 -0.696 . . . . 0.0 109.653 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.633 ' OD2' HG23 ' A' ' 18' ' ' VAL . 3.4 t70 -135.86 170.2 16.36 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 120.963 -1.086 . . . . 0.0 109.517 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.6 t -95.52 160.4 14.53 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.296 -0.877 . . . . 0.0 111.828 -178.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.85 149.14 18.71 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 63.6 mtt180 -60.07 -33.98 72.81 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.655 -0.909 . . . . 0.0 110.586 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.4 79.48 0.05 OUTLIER Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.44 169.0 13.4 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 3' ' ' ILE . 19.1 m-85 -91.24 120.13 31.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.953 . . . . 0.0 109.817 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.415 ' HA ' ' O ' ' A' ' 4' ' ' SER . 1.6 m120 -114.27 130.46 56.65 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 44' ' ' GLY . 34.9 m -134.86 176.59 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.029 -1.044 . . . . 0.0 111.869 -178.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -57.42 152.7 31.68 Favored Pre-proline 0 N--CA 1.496 1.855 0 C-N-CA 120.133 -0.627 . . . . 0.0 110.051 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.64 -22.69 64.34 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.353 1.186 . . . . 0.0 110.408 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -73.13 -41.03 64.41 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.015 -1.053 . . . . 0.0 108.745 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.85 -39.76 87.68 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -59.98 -49.98 75.55 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.127 179.188 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.464 ' CG2' HG23 ' A' ' 97' ' ' THR . 12.1 p -60.01 -35.53 75.25 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.44 -0.787 . . . . 0.0 110.77 -179.114 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 55.9 mttm -69.95 -40.03 75.71 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.342 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 67.1 tp -70.49 -46.08 64.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 0.0 111.41 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -101.76 -38.13 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.172 0 O-C-N 121.288 -0.883 . . . . 0.0 111.655 -177.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 -18.88 16.46 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 41.8 p -158.8 151.96 22.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.249 -1.148 . . . . 0.0 110.519 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.464 HG23 ' CG2' ' A' ' 91' ' ' THR . 75.1 p -93.89 8.51 41.0 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.632 -0.667 . . . . 0.0 110.917 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.44 -0.788 . . . . 0.0 110.552 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.0 85.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.608 -0.683 . . . . 0.0 110.92 -178.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -59.4 3.19 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 108.538 -1.825 . . . . 0.0 108.538 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 53.9 ptt85 -150.1 157.14 42.81 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.792 -0.828 . . . . 0.0 109.946 179.149 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.7 t -128.35 126.23 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.468 -0.77 . . . . 0.0 109.719 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -90.19 169.0 11.51 Favored 'General case' 0 N--CA 1.496 1.867 0 CA-C-O 121.771 0.796 . . . . 0.0 111.75 -178.562 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 53.2 t30 60.07 40.02 19.05 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 121.402 0.62 . . . . 0.0 111.002 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.519 HG21 HG12 ' A' ' 3' ' ' ILE . 79.9 t -85.17 129.68 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.506 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -88.27 138.83 31.09 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.234 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.1 p90 -132.99 140.85 47.98 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.34 0.59 . . . . 0.0 110.824 -178.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 18.8 m -143.83 139.94 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.755 -0.59 . . . . 0.0 110.987 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 54.9 tt0 -77.32 139.08 39.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.702 -0.624 . . . . 0.0 110.292 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 34.6 m -130.02 165.35 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.61 -0.681 . . . . 0.0 110.649 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -55.42 139.97 41.55 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.585 -0.697 . . . . 0.0 110.753 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.618 HD21 HD11 ' A' ' 116' ' ' ILE . 9.2 tt -60.83 -39.98 91.06 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.646 -0.659 . . . . 0.0 110.825 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.0 m -54.45 -37.87 65.69 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.577 -0.702 . . . . 0.0 111.112 -177.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -65.73 -36.9 84.91 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.558 -0.714 . . . . 0.0 111.12 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 81.0 m -63.05 -44.43 95.86 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.177 -0.952 . . . . 0.0 109.913 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.618 HD11 HD21 ' A' ' 112' ' ' LEU . 80.3 mt -69.64 -39.96 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.099 -179.22 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -66.4 -40.05 89.39 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.469 -0.769 . . . . 0.0 110.467 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -74.31 -56.52 5.12 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.26 93.94 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.445 -1.032 . . . . 0.0 110.256 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.7 t30 . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 117.832 -1.08 . . . . 0.0 111.054 179.611 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.2 m . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.438 0.637 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -114.09 142.35 46.31 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.381 0.61 . . . . 0.0 110.668 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.727 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.9 pt -114.25 149.96 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.353 0.596 . . . . 0.0 110.887 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 23.0 m -146.35 -172.82 4.03 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.166 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -140.06 149.32 42.98 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.82 179.106 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.38 148.9 71.75 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.457 -0.777 . . . . 0.0 109.435 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -84.0 -9.05 9.86 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.275 1.145 . . . . 0.0 112.636 -178.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.2 pt -70.01 -40.06 78.09 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.227 0 O-C-N 120.953 -1.092 . . . . 0.0 110.984 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.52 ' HA ' HD22 ' A' ' 13' ' ' LEU . 50.9 m-85 -73.3 67.3 0.97 Allowed 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 122.877 1.322 . . . . 0.0 111.324 -178.664 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.93 171.55 7.28 Favored 'General case' 0 N--CA 1.49 1.55 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.203 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.97 -34.45 71.81 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -175.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -89.95 10.94 22.03 Favored 'General case' 0 N--CA 1.501 2.11 0 C-N-CA 118.285 -1.366 . . . . 0.0 112.507 -177.538 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 9' ' ' TYR . 50.0 tp -70.61 124.45 24.28 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.245 -0.909 . . . . 0.0 109.666 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 61.5 p -70.76 137.66 49.81 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.672 0.748 . . . . 0.0 110.092 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.782 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.9 mmm -66.41 -19.1 65.71 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.938 -0.476 . . . . 0.0 112.025 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.78 -15.39 75.85 Favored Glycine 0 N--CA 1.495 2.626 0 O-C-N 120.95 -1.094 . . . . 0.0 111.296 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.9 p -89.04 -7.52 55.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.208 -1.172 . . . . 0.0 111.9 -178.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.782 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -99.86 169.47 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.098 -1.001 . . . . 0.0 110.638 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.782 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.89 -44.49 91.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.525 -0.734 . . . . 0.0 109.796 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.1 m -80.04 80.71 6.42 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -101.19 -81.56 0.48 Allowed 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.262 -0.899 . . . . 0.0 113.247 -177.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.1 m-20 -131.12 11.14 5.02 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.139 -0.976 . . . . 0.0 113.025 -177.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.68 -153.49 3.43 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 179.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -65.93 -40.06 91.05 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.517 -0.99 . . . . 0.0 109.691 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.521 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 31.0 m80 -91.0 6.31 45.3 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -0.797 . . . . 0.0 110.734 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -59.43 134.62 51.71 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.859 HD13 HG11 ' A' ' 37' ' ' VAL . 89.6 mt -101.16 -4.47 27.19 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 122.024 -0.692 . . . . 0.0 110.581 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 59.4 ttm -62.22 -37.03 83.79 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.273 -0.892 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.11 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.608 -0.683 . . . . 0.0 111.896 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -69.09 -39.99 78.67 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.367 -0.833 . . . . 0.0 109.743 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.557 ' CD2' HG23 ' A' ' 37' ' ' VAL . 48.7 m-85 -119.94 91.69 45.8 Favored Pre-proline 0 N--CA 1.491 1.608 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.92 -18.67 40.95 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.293 1.154 . . . . 0.0 111.241 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 90.6 m -123.75 141.27 52.18 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.229 -0.919 . . . . 0.0 110.026 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.897 HD11 HG21 ' A' ' 43' ' ' VAL . 41.7 tp -65.9 120.75 13.62 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.77 -0.581 . . . . 0.0 111.036 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.29 32.41 0.04 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.862 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.443 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 25.0 mt-10 -155.29 -49.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -1.128 . . . . 0.0 110.448 178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.859 HG11 HD13 ' A' ' 27' ' ' LEU . 3.1 t -60.27 -60.81 9.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.6 Cg_endo -74.79 -28.6 9.43 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 N-CA-C 108.979 -1.2 . . . . 0.0 108.979 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.43 -61.32 0.65 Allowed Glycine 0 N--CA 1.484 1.872 0 N-CA-C 107.017 -2.433 . . . . 0.0 107.017 -178.587 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.543 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.8 t80 165.48 -72.7 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.578 0 C-N-CA 123.377 0.671 . . . . 0.0 110.083 177.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.543 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -83.01 -8.58 10.94 Favored 'Trans proline' 0 N--CA 1.493 1.497 0 CA-C-N 118.995 0.677 . . . . 0.0 112.174 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -97.91 34.29 1.93 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.134 -0.979 . . . . 0.0 110.51 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.897 HG21 HD11 ' A' ' 34' ' ' LEU . 10.6 p -109.95 137.3 42.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.665 0.745 . . . . 0.0 109.498 179.277 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.701 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.62 172.89 43.22 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.044 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.54 156.34 29.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.244 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.74 HD12 ' HA2' ' A' ' 75' ' ' GLY . 81.3 mt -139.97 150.46 62.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.61 ' HD2' HG23 ' A' ' 46' ' ' ILE . 37.3 Cg_endo -59.36 -10.15 10.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.349 1.184 . . . . 0.0 113.626 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.601 ' H ' HG22 ' A' ' 46' ' ' ILE . 83.0 m-20 -94.58 -12.54 27.3 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.693 -1.254 . . . . 0.0 112.329 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.606 HG23 ' CB ' ' A' ' 54' ' ' SER . 51.3 mm -75.08 119.67 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 C-N-CA 118.601 -1.24 . . . . 0.0 108.397 178.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.74 -45.3 21.47 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.26 -0.9 . . . . 0.0 112.529 -178.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.782 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 169.9 -138.91 5.28 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.918 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 36.8 t90 -42.79 -28.81 0.27 Allowed 'General case' 0 N--CA 1.502 2.175 0 O-C-N 121.956 -0.731 . . . . 0.0 112.769 -179.292 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -142.62 65.34 1.35 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.339 -0.851 . . . . 0.0 110.112 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.606 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.0 p -66.39 134.51 94.58 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.643 -0.661 . . . . 0.0 110.899 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.521 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -74.93 -23.48 13.9 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 O-C-N 123.45 1.237 . . . . 0.0 111.05 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.62 15.19 14.89 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 111.385 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t -78.28 151.62 32.91 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 110.054 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 71.08 29.89 68.31 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.7 m -117.16 132.97 56.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.59 -0.947 . . . . 0.0 109.963 179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -81.07 145.5 31.07 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -177.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.47 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -149.34 150.09 31.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 110.471 178.137 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -108.45 132.03 54.2 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.3 t -108.9 127.36 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.49 -0.756 . . . . 0.0 109.597 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 88.0 m -120.06 136.66 54.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.942 -0.474 . . . . 0.0 110.939 -178.135 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.463 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 38.0 pt -115.95 164.82 16.36 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.541 -0.724 . . . . 0.0 110.568 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.8 -25.1 74.61 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 C-N-CA 121.236 1.29 . . . . 0.0 112.66 -178.569 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -64.89 -40.0 94.41 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.23 -0.919 . . . . 0.0 109.794 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.75 61.09 0.32 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.271 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -160.01 150.64 18.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.758 -0.848 . . . . 0.0 108.831 179.189 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.422 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 67.0 p -151.56 157.41 42.19 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.247 -0.981 . . . . 0.0 112.248 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 73' ' ' ILE . 44.3 pt -139.34 165.05 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -103.36 125.76 50.15 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.274 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 71' ' ' ILE . 49.5 mm -119.8 131.01 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.707 -0.621 . . . . 0.0 110.246 -178.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 -99.38 137.06 38.42 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.439 -0.788 . . . . 0.0 109.079 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.74 ' HA2' HD12 ' A' ' 46' ' ' ILE . . . -57.18 150.74 28.62 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.24 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 44' ' ' GLY . 11.9 p -169.54 -28.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.679 -0.895 . . . . 0.0 111.307 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.622 ' OD1' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -130.0 166.98 18.99 Favored 'General case' 0 N--CA 1.505 2.306 0 O-C-N 120.585 -1.322 . . . . 0.0 109.712 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.488 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 48.2 t -94.68 144.51 25.55 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.482 -0.761 . . . . 0.0 111.024 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -126.29 141.67 13.0 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -60.68 -28.38 68.57 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.759 -0.847 . . . . 0.0 109.814 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.04 79.92 0.05 OUTLIER Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.27 163.79 11.21 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.827 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.727 ' HB2' HG22 ' A' ' 3' ' ' ILE . 16.1 m-85 -92.16 115.33 27.99 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.666 -0.902 . . . . 0.0 109.915 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.415 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 57.7 t-20 -109.04 131.99 54.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.343 -0.848 . . . . 0.0 109.028 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.3 m -132.44 175.52 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.185 0 O-C-N 120.961 -1.087 . . . . 0.0 111.833 -178.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -55.73 156.69 8.83 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.41 -0.806 . . . . 0.0 109.953 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.07 -22.37 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.295 1.155 . . . . 0.0 110.65 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -76.28 -40.03 52.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.021 -1.049 . . . . 0.0 108.953 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.531 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.26 -39.87 89.76 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.553 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -60.04 -50.03 75.31 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.202 -0.599 . . . . 0.0 110.486 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 56.9 m -59.96 -39.5 85.82 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.546 -0.721 . . . . 0.0 110.709 -178.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.4 ' HE3' ' HA ' ' A' ' 89' ' ' ALA . 57.1 mtmt -70.03 -40.05 75.41 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.789 -178.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.422 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 65.4 tp -70.02 -43.4 71.42 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.65 -0.656 . . . . 0.0 111.492 -179.466 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.2 t -96.2 -39.82 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 O-C-N 121.262 -0.899 . . . . 0.0 111.258 -178.07 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.63 -38.96 2.55 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.8 m -139.98 152.2 46.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.686 -0.891 . . . . 0.0 110.182 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.6 p -90.71 6.33 44.51 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.403 -0.81 . . . . 0.0 111.169 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -70.04 -29.22 66.2 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.478 -0.764 . . . . 0.0 110.736 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.05 -40.09 84.02 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.538 -0.726 . . . . 0.0 110.625 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -74.48 1.68 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 12.1 ptt-85 -144.74 149.54 35.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.681 -0.894 . . . . 0.0 110.271 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.94 119.36 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.487 -0.758 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -83.84 173.49 11.21 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.723 -0.611 . . . . 0.0 110.604 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 60.01 45.75 11.72 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.636 -0.665 . . . . 0.0 110.998 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.405 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 73.7 t -95.53 128.06 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.493 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -85.4 136.1 33.6 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.092 -1.005 . . . . 0.0 109.639 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.8 p90 -132.87 140.98 48.18 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.134 0.492 . . . . 0.0 110.738 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.2 m -144.62 141.21 23.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.609 -0.682 . . . . 0.0 110.979 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.47 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 58.6 tt0 -70.93 140.73 51.05 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.536 -0.727 . . . . 0.0 110.334 178.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.23 167.44 26.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.105 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -61.28 148.26 41.76 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.414 -0.804 . . . . 0.0 110.325 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.73 -40.05 96.0 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.433 -0.792 . . . . 0.0 111.133 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 53.4 m -56.29 -38.18 70.88 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.583 -0.698 . . . . 0.0 110.587 -178.624 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.09 -35.71 75.81 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.432 -0.792 . . . . 0.0 110.287 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 80.5 m -70.04 -39.99 75.41 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.522 -0.736 . . . . 0.0 109.383 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 50.6 mm -66.77 -40.04 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 CA-C-O 121.473 0.654 . . . . 0.0 109.395 -178.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -69.98 -39.96 75.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.818 -0.551 . . . . 0.0 110.299 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.88 -57.73 5.67 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.96 -41.64 92.37 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.507 -0.996 . . . . 0.0 110.704 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.301 -179.889 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.456 HG23 ' HB ' ' A' ' 105' ' ' VAL . 34.8 m . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.464 0.65 . . . . 0.0 111.201 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.1 t -113.57 140.19 48.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.746 -0.596 . . . . 0.0 109.744 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.67 HG23 HG21 ' A' ' 105' ' ' VAL . 37.4 pt -109.16 148.14 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 111.042 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.433 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -146.72 -170.82 3.61 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.321 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 50.3 p90 -144.71 150.01 36.58 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.967 179.276 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -130.29 148.58 70.39 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.566 -0.709 . . . . 0.0 109.554 178.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.79 -6.58 12.43 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 O-C-N 123.247 1.13 . . . . 0.0 112.46 -179.117 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 9' ' ' TYR . 30.1 pt -69.98 -40.0 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 120.865 -1.147 . . . . 0.0 110.925 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.528 ' HA ' HD22 ' A' ' 13' ' ' LEU . 40.5 m-85 -74.17 67.24 1.33 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-O 122.774 1.273 . . . . 0.0 111.132 -178.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.19 171.86 7.12 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 114.299 -1.319 . . . . 0.0 108.146 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.05 -33.93 72.72 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.98 10.22 24.84 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.428 -1.42 . . . . 0.0 112.316 -177.276 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.528 HD22 ' HA ' ' A' ' 9' ' ' TYR . 29.0 tp -70.33 123.33 21.46 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.263 -0.898 . . . . 0.0 109.703 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.1 m -69.14 136.63 52.46 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.783 -0.767 . . . . 0.0 109.961 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.802 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.6 mmm -67.21 -17.72 64.94 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 122.03 -0.419 . . . . 0.0 111.65 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -70.75 -14.7 73.01 Favored Glycine 0 N--CA 1.495 2.612 0 O-C-N 120.955 -1.091 . . . . 0.0 111.095 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -88.43 -9.44 52.55 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.203 -1.175 . . . . 0.0 111.787 -179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.802 HG12 ' O ' ' A' ' 15' ' ' MET . 8.4 p -95.54 168.49 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.072 -1.017 . . . . 0.0 110.092 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.8 -44.8 86.57 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.542 -0.724 . . . . 0.0 109.939 -179.658 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.5 m -81.28 84.05 6.71 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.4 m -99.95 -79.95 0.48 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.56 -0.712 . . . . 0.0 112.88 -178.09 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -131.09 9.93 4.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.24 -0.912 . . . . 0.0 112.77 -178.186 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.41 -153.2 1.83 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.755 -1.738 . . . . 0.0 108.755 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -70.01 -39.95 75.53 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.789 -0.83 . . . . 0.0 109.648 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.478 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 26.4 m80 -90.03 0.21 57.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.625 -0.672 . . . . 0.0 110.866 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.71 137.89 49.06 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.67 HD13 HG11 ' A' ' 37' ' ' VAL . 75.0 mt -99.02 -5.22 30.8 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.916 -0.755 . . . . 0.0 110.251 178.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.401 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.1 ttm -60.01 -37.2 79.01 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.307 -0.871 . . . . 0.0 110.97 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.94 -74.84 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.497 -0.752 . . . . 0.0 111.798 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -70.0 -39.97 75.57 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.433 -0.792 . . . . 0.0 110.359 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.548 ' CD2' HG23 ' A' ' 37' ' ' VAL . 27.6 m-85 -120.02 93.27 47.73 Favored Pre-proline 0 N--CA 1.496 1.83 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -178.485 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -69.82 -21.87 32.62 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.423 1.223 . . . . 0.0 111.347 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.4 m -123.21 145.9 48.27 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 109.939 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 1.0 HD21 HG11 ' A' ' 43' ' ' VAL . 40.6 tp -68.68 121.15 15.86 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -0.756 . . . . 0.0 110.753 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.88 33.78 0.03 OUTLIER Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.774 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -160.31 -44.12 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.159 -1.201 . . . . 0.0 110.142 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.67 HG11 HD13 ' A' ' 27' ' ' LEU . 3.5 t -60.54 -61.28 8.28 Favored Pre-proline 0 N--CA 1.498 1.967 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -77.59 -26.11 7.4 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.108 1.057 . . . . 0.0 109.598 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.58 -62.0 0.63 Allowed Glycine 0 N--CA 1.486 1.988 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.028 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.572 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.0 t80 166.74 -72.45 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.449 0 C-N-CA 123.267 0.627 . . . . 0.0 109.632 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.572 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 60.2 Cg_endo -84.65 10.7 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 CA-C-N 118.912 0.647 . . . . 0.0 111.647 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -114.54 35.7 4.11 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.011 -1.056 . . . . 0.0 110.015 -178.604 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.0 HG11 HD21 ' A' ' 34' ' ' LEU . 13.1 p -117.54 143.36 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-O 121.455 0.645 . . . . 0.0 110.11 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.04 166.67 39.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.38 151.37 44.97 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 177.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.545 HD11 HG13 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -144.22 142.9 20.61 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.431 -1.04 . . . . 0.0 109.351 179.698 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -61.38 -13.02 26.55 Favored 'Trans proline' 0 N--CA 1.507 2.271 0 C-N-CA 122.193 1.929 . . . . 0.0 115.188 -177.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.434 ' HB2' HD12 ' A' ' 46' ' ' ILE . 94.9 m-20 -92.9 20.1 6.99 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.45 -1.406 . . . . 0.0 112.139 -178.121 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.816 HG23 ' CB ' ' A' ' 54' ' ' SER . 57.8 mt -118.57 127.67 75.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.301 -0.875 . . . . 0.0 109.038 177.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.0 -45.35 13.2 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 175.18 -141.17 5.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.403 -1.856 . . . . 0.0 112.194 -178.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.498 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 25.3 t90 -39.97 -29.87 0.08 Allowed 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 -178.105 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -146.15 64.14 1.22 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.985 -1.072 . . . . 0.0 111.325 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.816 ' CB ' HG23 ' A' ' 49' ' ' ILE . 6.5 t -66.27 139.39 96.34 Favored Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.45 -0.781 . . . . 0.0 110.866 -179.326 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.478 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -78.05 -20.66 11.37 Favored 'Trans proline' 0 C--N 1.32 -0.959 0 O-C-N 123.4 1.211 . . . . 0.0 110.65 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 17.8 m -92.97 11.54 27.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.484 -0.76 . . . . 0.0 111.231 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 6.6 t -69.66 145.16 52.61 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.093 -1.004 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.45 41.9 12.6 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.1 m -120.01 129.95 54.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.397 -1.06 . . . . 0.0 110.477 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.514 ' SG ' HG23 ' A' ' 110' ' ' VAL . 50.1 t -81.29 143.03 32.55 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.513 -178.444 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 71.9 m95 -146.4 155.62 42.72 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.526 178.231 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -114.11 130.19 56.59 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.6 129.59 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.405 -0.809 . . . . 0.0 109.706 -178.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.3 m -121.12 141.07 51.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.803 -0.561 . . . . 0.0 111.459 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.441 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.0 pt -117.62 163.58 23.35 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.521 -0.737 . . . . 0.0 110.036 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -62.32 -25.35 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 121.184 1.256 . . . . 0.0 112.507 -178.461 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -64.84 -39.01 92.88 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.384 -0.822 . . . . 0.0 109.715 179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.47 61.6 0.33 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -160.58 153.07 20.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.709 -0.877 . . . . 0.0 109.007 178.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.454 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -151.26 158.72 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.207 1.003 . . . . 0.0 112.352 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 pt -139.89 164.73 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.162 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.5 m-85 -106.58 127.0 52.98 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 118.879 -1.128 . . . . 0.0 109.928 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.37 131.89 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.622 -0.674 . . . . 0.0 110.582 -179.123 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.599 ' HD3' HG12 ' A' ' 37' ' ' VAL . 53.9 ttt180 -102.21 136.49 41.96 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.27 149.54 42.17 Favored Glycine 0 N--CA 1.494 2.557 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.318 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.593 HG22 HG21 ' A' ' 18' ' ' VAL . 5.7 p -156.91 -42.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.743 -0.857 . . . . 0.0 110.118 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.481 ' O ' HD12 ' A' ' 49' ' ' ILE . 12.3 t70 -128.34 169.99 13.6 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.109 -0.995 . . . . 0.0 110.06 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 41.8 t -87.67 156.85 19.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.426 -0.796 . . . . 0.0 111.081 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.43 137.34 10.92 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -63.08 -39.87 96.0 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.734 -0.862 . . . . 0.0 110.162 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -178.15 69.96 0.08 OUTLIER Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.74 172.09 18.19 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 3' ' ' ILE . 89.1 m-85 -98.63 122.53 41.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.652 -0.911 . . . . 0.0 110.334 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.433 ' HA ' ' O ' ' A' ' 4' ' ' SER . 17.1 t-20 -115.05 130.31 56.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.391 -0.818 . . . . 0.0 109.048 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.423 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 35.6 m -132.97 174.47 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 120.933 -1.104 . . . . 0.0 111.741 -178.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -54.74 150.9 16.6 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.53 -0.731 . . . . 0.0 109.92 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.6 -21.01 59.97 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.404 1.213 . . . . 0.0 110.76 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 67.7 m -75.79 -39.95 56.02 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.065 -1.022 . . . . 0.0 109.23 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.77 -40.03 88.08 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.422 -0.798 . . . . 0.0 109.116 178.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -60.03 -49.68 76.72 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.807 -0.558 . . . . 0.0 110.632 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.6 m -60.04 -36.99 78.5 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.824 . . . . 0.0 110.787 -178.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -69.95 -40.07 75.67 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.412 -179.164 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.454 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 56.1 tp -70.39 -44.16 68.58 Favored 'General case' 0 N--CA 1.496 1.851 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.554 -178.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 91.1 t -95.39 -38.61 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.311 -0.868 . . . . 0.0 111.394 -177.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -27.35 6.07 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 43.7 t -156.04 161.19 40.46 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.466 -1.02 . . . . 0.0 110.292 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 68.3 p -97.81 13.24 31.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 111.151 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.99 -36.54 75.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.481 -0.762 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.02 -41.16 91.59 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.444 -0.785 . . . . 0.0 111.05 -178.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.28 -63.48 2.02 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 -179.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -149.37 153.45 37.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.59 -0.947 . . . . 0.0 110.57 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.1 118.94 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.456 -0.777 . . . . 0.0 110.149 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -81.87 169.44 16.84 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.577 -0.702 . . . . 0.0 111.181 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 63.7 t30 59.85 50.06 7.29 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.548 -0.72 . . . . 0.0 110.731 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.67 HG21 HG23 ' A' ' 3' ' ' ILE . 66.9 t -94.05 128.73 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -86.9 140.61 29.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.417 -0.913 . . . . 0.0 109.491 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -139.11 141.87 38.11 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.167 0.508 . . . . 0.0 110.736 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 m -141.14 139.89 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.695 -0.628 . . . . 0.0 110.161 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -77.4 136.86 38.44 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.964 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.514 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.3 m -134.22 -179.13 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.257 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.41 150.94 47.55 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.406 -0.809 . . . . 0.0 111.075 -179.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.455 HD11 ' NH1' ' A' ' 74' ' ' ARG . 7.7 tt -62.06 -40.0 94.29 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.559 -0.713 . . . . 0.0 111.389 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 55.8 m -54.28 -39.37 66.84 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.443 -0.785 . . . . 0.0 110.222 -178.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -59.99 -37.65 80.29 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.632 -0.668 . . . . 0.0 110.223 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -68.15 -42.43 80.09 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.49 -0.756 . . . . 0.0 109.481 178.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.0 mm -64.88 -40.52 89.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.023 -0.671 . . . . 0.0 109.853 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -70.05 -39.92 75.41 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.697 -0.627 . . . . 0.0 110.483 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.6 -53.14 37.07 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.4 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.05 -43.94 97.24 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.512 -0.993 . . . . 0.0 110.548 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 48.6 t30 . . . . . 0 N--CA 1.501 2.082 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.006 -179.824 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.418 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.4 m . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.25 0.548 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.8 t -114.63 141.18 48.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.536 -0.728 . . . . 0.0 110.39 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.755 HG22 ' HB2' ' A' ' 83' ' ' PHE . 39.3 pt -107.8 147.72 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.679 -0.638 . . . . 0.0 110.6 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.42 -171.89 3.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.8 p90 -142.87 147.32 35.18 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.35 -0.844 . . . . 0.0 110.802 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -137.7 155.22 75.17 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.488 178.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -88.28 48.06 1.37 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.275 1.145 . . . . 0.0 110.659 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.813 ' O ' HD22 ' A' ' 13' ' ' LEU . 8.7 tp -123.01 -8.65 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.48 -0.763 . . . . 0.0 111.276 -179.39 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 8' ' ' ILE . 35.3 m-85 -118.54 67.65 0.77 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 122.525 1.155 . . . . 0.0 110.947 178.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.02 170.37 7.9 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.679 177.082 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.82 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.6 -32.71 70.64 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 114.115 1.154 . . . . 0.0 114.115 -175.497 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -89.63 13.91 12.94 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 120.424 1.466 . . . . 0.0 112.5 -177.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.813 HD22 ' O ' ' A' ' 8' ' ' ILE . 64.0 tp -73.1 125.94 28.85 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.413 -0.804 . . . . 0.0 110.792 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.18 135.54 49.18 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.487 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.717 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -66.36 -15.86 63.61 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.777 -0.577 . . . . 0.0 112.048 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.404 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.62 -13.86 80.05 Favored Glycine 0 N--CA 1.497 2.701 0 O-C-N 120.977 -1.077 . . . . 0.0 111.337 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 -11.05 47.2 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.054 -1.262 . . . . 0.0 112.063 -178.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 15' ' ' MET . 8.5 p -93.72 168.25 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.068 -1.02 . . . . 0.0 110.041 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.24 -42.09 85.58 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.472 -0.768 . . . . 0.0 109.816 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.03 82.94 2.89 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.586 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.9 m -90.29 -79.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.989 -1.069 . . . . 0.0 112.894 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.488 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 17.9 p30 -143.56 14.21 1.77 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 120.631 -1.293 . . . . 0.0 112.428 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.64 -146.95 0.38 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -66.58 -40.51 88.97 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' HIS . . . . . 0.407 ' CD2' ' O ' ' A' ' 54' ' ' SER . 64.1 m-70 -90.02 0.56 57.05 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.798 -0.564 . . . . 0.0 110.265 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -55.05 130.4 47.08 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 84.3 mt -104.87 -5.98 20.62 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 122.146 -0.62 . . . . 0.0 111.203 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' MET . . . . . 0.404 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 44.4 ttm -59.96 -35.63 75.39 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.292 -0.88 . . . . 0.0 110.825 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.43 -63.1 1.26 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -67.26 -40.04 86.18 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.213 -0.93 . . . . 0.0 111.288 -177.456 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.69 ' CE1' HG21 ' A' ' 37' ' ' VAL . 5.5 p90 -143.64 113.72 5.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.879 . . . . 0.0 109.128 179.21 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.65 -1.62 10.1 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.443 1.233 . . . . 0.0 112.582 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' THR . . . . . 0.513 HG22 ' H ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -118.64 -172.1 2.21 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.995 -1.066 . . . . 0.0 109.71 179.786 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.764 HD11 HG21 ' A' ' 43' ' ' VAL . 61.5 tp -116.51 129.96 56.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.605 -0.685 . . . . 0.0 110.852 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.86 -40.82 1.27 Allowed Glycine 0 N--CA 1.489 2.172 0 C-N-CA 120.077 -1.059 . . . . 0.0 111.044 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -62.42 -39.94 94.93 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.182 -1.187 . . . . 0.0 111.483 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.747 HG12 ' HD3' ' A' ' 74' ' ' ARG . 3.2 t -87.62 -61.36 0.24 Allowed Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.336 -0.852 . . . . 0.0 112.699 -178.339 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.432 ' HG3' HD11 ' A' ' 34' ' ' LEU . 37.4 Cg_endo -64.54 -48.49 4.29 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 O-C-N 123.009 1.005 . . . . 0.0 113.063 -177.813 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.431 ' O ' ' HD2' ' A' ' 41' ' ' PRO . . . 122.77 67.87 0.23 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 106.541 -2.624 . . . . 0.0 106.541 -177.188 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.82 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 8.8 t80 19.65 -78.99 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.343 0 N-CA-C 115.101 1.519 . . . . 0.0 115.101 -178.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.532 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.7 Cg_endo -81.91 17.8 1.48 Allowed 'Trans proline' 0 N--CA 1.499 1.804 0 CA-C-N 120.07 1.061 . . . . 0.0 112.588 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -123.79 47.33 2.06 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.836 -1.165 . . . . 0.0 110.201 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 34' ' ' LEU . 11.0 p -129.39 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 122.064 0.935 . . . . 0.0 110.334 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.519 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.08 175.31 42.3 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.32 161.75 31.6 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 49' ' ' ILE . 1.1 pt -147.46 152.1 41.35 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.64 -0.917 . . . . 0.0 110.063 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.69 -14.7 46.15 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.954 1.77 . . . . 0.0 113.763 -178.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -90.6 23.25 3.11 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 120.591 -1.318 . . . . 0.0 112.259 -178.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.558 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.8 mm -113.77 126.91 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.17 13.0 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.311 -0.868 . . . . 0.0 112.077 -178.39 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.856 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 173.23 -134.34 2.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 118.715 -1.707 . . . . 0.0 111.719 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.441 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 53.5 t90 -46.06 -28.48 1.2 Allowed 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -178.255 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -146.65 61.19 1.21 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.024 -1.048 . . . . 0.0 110.986 -179.173 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.558 ' CB ' HG23 ' A' ' 49' ' ' ILE . 35.1 p -61.95 140.07 95.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.49 -0.756 . . . . 0.0 110.444 -179.269 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.18 -21.8 19.89 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 123.328 1.172 . . . . 0.0 111.151 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.9 m -93.85 13.62 21.98 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.449 -0.782 . . . . 0.0 111.158 -179.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 2.2 t -73.17 145.43 46.32 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.259 -0.9 . . . . 0.0 110.561 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.58 22.79 71.81 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 86.8 m -104.22 139.11 39.71 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.358 -1.084 . . . . 0.0 110.751 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.439 ' SG ' HG23 ' A' ' 110' ' ' VAL . 46.5 t -80.12 132.96 36.03 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.545 -179.037 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TRP . . . . . 0.405 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.7 m95 -134.36 147.32 50.51 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -0.76 . . . . 0.0 110.074 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -107.86 131.55 54.38 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.366 -0.834 . . . . 0.0 109.725 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.635 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.2 t -109.95 121.03 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.557 0.694 . . . . 0.0 110.252 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 97.8 m -119.99 146.03 46.23 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.859 -0.525 . . . . 0.0 110.575 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.469 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 17.2 pt -122.12 164.51 25.25 Favored Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.473 -0.767 . . . . 0.0 110.98 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -61.31 -25.94 81.09 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.561 1.507 . . . . 0.0 112.837 -178.611 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -66.08 -40.0 90.48 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.248 -0.907 . . . . 0.0 110.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.45 61.11 0.3 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -160.07 151.6 19.81 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.652 -0.911 . . . . 0.0 108.829 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.9 p -155.6 164.99 37.9 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 122.287 1.041 . . . . 0.0 112.193 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 40.0 pt -144.52 165.63 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -106.29 122.64 46.64 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.265 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.842 HD13 HG11 ' A' ' 85' ' ' VAL . 66.2 mt -120.02 131.41 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.857 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.747 ' HD3' HG12 ' A' ' 37' ' ' VAL . 24.8 ttt180 -95.25 136.5 35.53 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.663 -0.648 . . . . 0.0 109.407 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.39 149.72 31.43 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 110.336 -1.106 . . . . 0.0 110.336 -178.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.497 HG11 HG22 ' A' ' 43' ' ' VAL . 4.1 p -154.7 -44.08 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.723 -0.869 . . . . 0.0 109.513 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.556 ' HB2' HG23 ' A' ' 18' ' ' VAL . 11.9 t70 -131.87 169.02 16.84 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 178.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' SER . . . . . 0.427 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 95.5 p -91.91 157.78 16.65 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.4 -0.813 . . . . 0.0 111.618 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -124.2 146.16 16.16 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -60.66 -31.04 70.29 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.649 -0.912 . . . . 0.0 110.174 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.09 76.45 0.04 OUTLIER Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.562 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.82 154.93 6.26 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.115 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.755 ' HB2' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -67.41 114.59 6.22 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.931 -0.746 . . . . 0.0 110.376 179.289 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -111.15 119.07 37.74 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 73' ' ' ILE . 26.8 m -131.1 176.95 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 120.89 -1.131 . . . . 0.0 112.474 -177.128 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.5 m-20 -55.7 150.9 24.41 Favored Pre-proline 0 N--CA 1.493 1.713 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.214 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.43 -17.27 57.26 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.395 1.208 . . . . 0.0 110.142 178.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 98.1 m -81.28 -40.66 23.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.916 -1.115 . . . . 0.0 109.182 178.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -39.84 91.12 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -60.06 -49.94 75.68 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.754 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.5 m -60.68 -40.0 90.53 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.429 -0.794 . . . . 0.0 111.108 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -68.48 -39.99 81.15 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.35 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 57.8 tp -73.31 -43.24 61.25 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.576 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 51.2 t -91.57 -42.36 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 121.344 -0.848 . . . . 0.0 111.52 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.27 -31.74 3.56 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 90.1 p -154.39 165.88 34.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.502 -0.999 . . . . 0.0 110.457 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.7 p -94.23 -0.05 55.37 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.451 -0.781 . . . . 0.0 111.756 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -70.95 -26.3 63.11 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.336 -0.853 . . . . 0.0 111.675 -179.065 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -39.98 87.86 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.322 -0.861 . . . . 0.0 110.898 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.68 -67.46 2.17 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -152.1 160.01 43.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.553 -0.969 . . . . 0.0 110.998 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 105' ' ' VAL . 60.7 t -131.11 112.73 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.952 179.186 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 36.1 p-10 -80.06 170.01 17.05 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.464 0.65 . . . . 0.0 111.113 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 59.98 40.02 19.36 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.627 -0.67 . . . . 0.0 111.597 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.636 HG21 HG23 ' A' ' 3' ' ' ILE . 94.5 t -85.15 129.94 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.417 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -86.72 139.49 30.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.002 -1.061 . . . . 0.0 109.545 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.437 ' C ' HG13 ' A' ' 108' ' ' VAL . 46.8 p90 -138.02 143.3 40.52 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 122.0 -0.438 . . . . 0.0 110.763 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.437 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.0 m -149.07 149.02 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.545 -0.722 . . . . 0.0 110.706 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.405 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 58.9 tt0 -76.75 139.98 40.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.599 -0.688 . . . . 0.0 110.269 179.367 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.439 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.5 m -133.6 168.26 24.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -57.6 144.83 35.93 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.378 -0.826 . . . . 0.0 110.563 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.564 ' C ' HD23 ' A' ' 112' ' ' LEU . 9.6 tt -59.91 -36.75 77.64 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.224 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 91.0 p -54.07 -36.14 62.82 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.491 -0.756 . . . . 0.0 110.502 -179.08 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -66.67 -39.58 88.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 111.179 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -59.97 -49.16 78.78 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.306 -0.871 . . . . 0.0 109.797 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.491 HD11 HD21 ' A' ' 112' ' ' LEU . 93.4 mt -69.81 -39.98 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.687 -0.633 . . . . 0.0 110.687 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -64.0 -39.94 95.25 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.35 -0.844 . . . . 0.0 111.052 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.14 -50.83 20.73 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.94 91.62 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.574 -0.957 . . . . 0.0 110.524 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.063 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.555 0.693 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 79.9 p -111.33 139.9 46.35 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.456 0.646 . . . . 0.0 109.49 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.624 HG12 HG21 ' A' ' 105' ' ' VAL . 39.6 pt -118.13 149.98 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.837 -0.54 . . . . 0.0 111.273 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.1 OUTLIER -146.15 -169.55 3.28 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.757 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.412 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.5 p90 -141.58 148.07 38.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.417 -0.802 . . . . 0.0 110.178 178.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.49 143.48 43.32 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.406 -0.809 . . . . 0.0 109.777 179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.73 -9.86 17.05 Favored 'Trans proline' 0 C--N 1.318 -1.078 0 O-C-N 123.324 1.171 . . . . 0.0 112.331 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 9' ' ' TYR . 44.5 pt -70.01 -39.95 77.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 120.968 -1.082 . . . . 0.0 111.434 -179.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.601 ' HA ' HD22 ' A' ' 13' ' ' LEU . 51.5 m-85 -72.14 67.5 0.67 Allowed 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 122.752 1.263 . . . . 0.0 111.72 -178.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.55 170.04 8.12 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.054 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.491 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.41 -34.38 68.85 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -175.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -90.92 12.12 20.56 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 118.431 -1.308 . . . . 0.0 112.265 -177.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.601 HD22 ' HA ' ' A' ' 9' ' ' TYR . 36.4 tp -72.53 123.71 23.73 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.246 -0.908 . . . . 0.0 110.2 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -70.54 137.35 50.06 Favored 'General case' 0 N--CA 1.49 1.573 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.035 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.806 ' O ' HG12 ' A' ' 18' ' ' VAL . 34.6 mtt -70.08 -15.39 62.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.802 -0.561 . . . . 0.0 111.915 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.63 -15.37 68.53 Favored Glycine 0 N--CA 1.494 2.559 0 O-C-N 120.793 -1.192 . . . . 0.0 110.878 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 91.0 p -87.98 -4.45 58.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.192 -1.181 . . . . 0.0 112.157 -178.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.806 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -103.5 168.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.001 -1.062 . . . . 0.0 110.801 -179.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.72 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.04 -39.29 85.4 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.471 -0.768 . . . . 0.0 110.644 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.76 67.72 3.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.291 -0.881 . . . . 0.0 110.088 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.6 m -108.71 110.13 21.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.155 -0.966 . . . . 0.0 110.565 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 m120 51.66 -140.98 0.84 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.714 -0.616 . . . . 0.0 111.11 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.43 -155.95 49.02 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -78.07 -41.82 34.2 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.428 -1.042 . . . . 0.0 111.066 179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.401 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 87.5 m-70 -89.94 2.14 55.42 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.181 -0.949 . . . . 0.0 111.748 -178.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.55 131.81 49.36 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.002 -1.061 . . . . 0.0 111.15 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.508 HD13 HG11 ' A' ' 37' ' ' VAL . 80.7 mt -96.28 -11.57 25.76 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 122.091 -0.652 . . . . 0.0 110.005 178.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.416 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 60.5 ttm -60.05 -34.42 73.38 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.267 -0.896 . . . . 0.0 110.836 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -74.41 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.558 -0.714 . . . . 0.0 111.691 -178.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -70.04 -39.97 75.43 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.347 -0.846 . . . . 0.0 109.938 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.454 ' CD2' HG23 ' A' ' 37' ' ' VAL . 70.1 m-85 -120.67 89.69 45.19 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.9 Cg_endo -70.82 -4.97 15.83 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.317 1.167 . . . . 0.0 112.298 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.7 m -135.13 149.1 49.94 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.019 -1.051 . . . . 0.0 110.406 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.943 HD11 HG21 ' A' ' 43' ' ' VAL . 28.9 tp -72.45 117.59 14.31 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.758 -0.589 . . . . 0.0 110.528 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.89 32.36 0.04 OUTLIER Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.992 -1.099 . . . . 0.0 110.924 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -158.81 -46.28 0.06 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.195 -1.18 . . . . 0.0 110.21 179.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 27' ' ' LEU . 3.0 t -61.05 -59.92 12.29 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.471 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 52.5 Cg_endo -76.63 -28.35 6.68 Favored 'Trans proline' 0 N--CA 1.487 1.146 0 O-C-N 123.182 1.096 . . . . 0.0 109.371 177.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.3 -62.35 0.63 Allowed Glycine 0 N--CA 1.488 2.146 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 -178.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.675 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 165.27 -58.73 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.467 0 C-N-CA 123.248 0.619 . . . . 0.0 109.804 177.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.675 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.23 18.19 0.33 Allowed 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 121.076 1.184 . . . . 0.0 110.937 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -126.94 42.48 3.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.315 -0.866 . . . . 0.0 109.499 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.943 HG21 HD11 ' A' ' 34' ' ' LEU . 12.3 p -123.58 140.77 46.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-O 121.563 0.697 . . . . 0.0 109.73 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.554 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.59 169.09 40.46 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -80.08 157.53 41.19 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.624 -1.79 . . . . 0.0 108.624 178.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.57 HD12 ' H ' ' A' ' 48' ' ' ASP . 1.2 pp -146.23 145.21 23.39 Favored Pre-proline 0 N--CA 1.486 1.361 0 O-C-N 121.48 -1.012 . . . . 0.0 109.221 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.446 ' HD2' ' CE1' ' A' ' 83' ' ' PHE . 38.0 Cg_endo -61.73 -7.19 8.71 Favored 'Trans proline' 0 N--CA 1.506 2.249 0 C-N-CA 122.197 1.931 . . . . 0.0 115.075 -177.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.57 ' H ' HD12 ' A' ' 46' ' ' ILE . 91.4 m-20 -97.46 23.0 8.09 Favored 'General case' 0 N--CA 1.504 2.252 0 O-C-N 120.5 -1.375 . . . . 0.0 112.446 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.645 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.4 mm -110.13 130.1 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.17 -48.1 9.48 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.423 -0.798 . . . . 0.0 112.613 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.72 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.67 -131.48 1.67 Allowed Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.609 -1.758 . . . . 0.0 111.926 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 11.8 t90 -54.79 -22.9 15.77 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 -178.006 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.416 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 42.1 m-20 -147.94 62.51 1.12 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.008 -1.057 . . . . 0.0 110.754 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.645 ' CB ' HG23 ' A' ' 49' ' ' ILE . 50.0 p -58.6 141.97 83.57 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.476 -0.765 . . . . 0.0 110.967 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.401 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.9 Cg_endo -77.45 -21.4 11.64 Favored 'Trans proline' 0 C--N 1.319 -0.991 0 O-C-N 123.39 1.205 . . . . 0.0 110.752 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.8 m -97.89 13.81 29.34 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.507 -0.746 . . . . 0.0 111.073 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -68.05 141.34 56.2 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.152 -0.967 . . . . 0.0 109.628 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.8 42.38 11.32 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.2 m -120.03 130.05 54.53 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.395 -1.062 . . . . 0.0 110.198 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 49.1 t -80.14 139.94 36.6 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.097 -177.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.435 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 64.3 m95 -145.27 150.88 37.44 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.543 -0.723 . . . . 0.0 110.376 178.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -109.63 133.02 53.59 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -110.03 128.89 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.443 -0.786 . . . . 0.0 109.727 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 29.5 m -119.98 142.67 48.57 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.831 -0.543 . . . . 0.0 111.662 -177.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.444 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 23.4 pt -119.67 163.55 26.84 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.709 -0.619 . . . . 0.0 110.279 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.54 -23.56 74.88 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 121.3 1.334 . . . . 0.0 112.672 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -66.38 -40.01 89.42 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.274 -0.891 . . . . 0.0 109.83 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.89 60.42 0.29 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -160.02 150.6 18.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.629 -0.924 . . . . 0.0 109.088 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.1 m -151.06 156.91 42.06 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.037 0.923 . . . . 0.0 112.03 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.486 HG12 HD13 ' A' ' 93' ' ' LEU . 39.6 pt -138.0 165.71 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -106.92 127.5 53.49 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 118.964 -1.094 . . . . 0.0 110.145 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.6 mm -115.78 129.96 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.748 -0.595 . . . . 0.0 110.094 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.499 ' HD3' HG12 ' A' ' 37' ' ' VAL . 38.9 ttt180 -99.81 135.03 41.84 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.14 148.29 24.94 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 44' ' ' GLY . 4.8 p -159.9 -37.98 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.767 -0.843 . . . . 0.0 110.057 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.514 ' HB2' HG23 ' A' ' 18' ' ' VAL . 31.3 t70 -133.18 169.96 16.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.002 -1.061 . . . . 0.0 109.495 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.422 ' CA ' ' HB ' ' A' ' 49' ' ' ILE . 86.9 p -97.26 160.05 14.56 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.409 -0.807 . . . . 0.0 110.899 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.94 141.74 12.94 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -60.73 -39.93 90.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.808 -0.819 . . . . 0.0 110.663 178.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.35 71.73 0.09 OUTLIER Glycine 0 N--CA 1.494 2.535 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.63 168.91 15.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.604 ' HB2' HG22 ' A' ' 3' ' ' ILE . 96.3 m-85 -98.49 128.57 44.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.755 -0.85 . . . . 0.0 109.948 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 47.6 t-20 -120.63 131.02 54.4 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.378 -0.826 . . . . 0.0 109.531 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.2 m -131.09 174.06 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.064 -1.023 . . . . 0.0 111.387 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.1 m-20 -55.78 153.14 17.16 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.355 -0.841 . . . . 0.0 109.996 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.76 -26.23 53.0 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 123.381 1.2 . . . . 0.0 110.019 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.9 m -70.72 -39.98 73.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.092 -1.005 . . . . 0.0 108.982 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.73 79.04 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -60.08 -50.02 75.37 Favored 'General case' 0 N--CA 1.499 2.018 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.689 179.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.8 m -60.04 -38.61 83.28 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.482 -0.761 . . . . 0.0 110.463 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.07 -39.75 75.46 Favored 'General case' 0 N--CA 1.493 1.694 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.937 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.486 HD13 HG12 ' A' ' 71' ' ' ILE . 47.9 tp -70.07 -43.58 70.86 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.555 -0.715 . . . . 0.0 111.668 -179.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -95.01 -37.63 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.134 0 O-C-N 121.251 -0.906 . . . . 0.0 110.967 -178.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.26 5.5 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.0 p -156.7 168.76 26.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -1.013 . . . . 0.0 110.121 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 55.1 p -96.77 8.41 44.35 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 110.801 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.04 -29.59 66.66 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.374 -0.829 . . . . 0.0 110.409 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.1 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.565 -0.709 . . . . 0.0 110.54 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 79.02 -83.67 1.28 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 29.2 ttt180 -130.03 133.13 46.53 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.627 -0.926 . . . . 0.0 110.133 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.68 120.13 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.489 -0.757 . . . . 0.0 110.304 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 43.7 p-10 -83.23 174.81 10.43 Favored 'General case' 0 N--CA 1.494 1.746 0 CA-C-O 121.718 0.77 . . . . 0.0 111.544 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 57.7 t30 59.99 40.66 18.56 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.704 -0.622 . . . . 0.0 112.013 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.624 HG21 HG12 ' A' ' 3' ' ' ILE . 59.3 t -88.91 127.34 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.937 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -85.14 138.32 32.46 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 119.328 -0.949 . . . . 0.0 109.871 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -134.57 140.48 46.15 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.351 0.596 . . . . 0.0 110.746 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 m -142.67 145.25 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.668 -0.645 . . . . 0.0 109.916 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.435 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 55.4 tt0 -85.03 141.62 30.16 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -136.18 176.96 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.718 -0.614 . . . . 0.0 110.088 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -62.03 149.57 40.59 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.443 -0.786 . . . . 0.0 110.575 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.581 HD21 HD11 ' A' ' 116' ' ' ILE . 8.0 tt -60.08 -39.93 87.77 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.488 -0.757 . . . . 0.0 110.992 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 t -51.39 -38.94 55.99 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.424 -0.798 . . . . 0.0 110.822 -178.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -60.91 -39.99 91.45 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.49 -0.756 . . . . 0.0 111.274 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -61.53 -48.22 82.01 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.323 -0.861 . . . . 0.0 110.109 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.581 HD11 HD21 ' A' ' 112' ' ' LEU . 96.5 mt -67.84 -39.92 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.663 -0.648 . . . . 0.0 110.557 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -65.59 -40.0 92.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.463 -0.773 . . . . 0.0 110.571 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.96 -49.37 35.23 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.54 89.46 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.576 -0.955 . . . . 0.0 110.605 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.7 m120 . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 117.93 -1.034 . . . . 0.0 110.273 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 105' ' ' VAL . 27.6 m . . . . . 0 N--CA 1.499 1.994 0 CA-C-O 120.975 0.416 . . . . 0.0 110.415 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 50.5 m -113.3 143.01 45.15 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.537 -0.727 . . . . 0.0 110.795 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.439 HG22 ' HB2' ' A' ' 83' ' ' PHE . 27.9 pt -114.36 149.93 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.81 -0.556 . . . . 0.0 110.861 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.5 p -147.07 -173.46 4.25 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.411 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.1 p90 -142.11 153.33 44.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.355 -0.841 . . . . 0.0 110.246 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.442 ' OD1' HD12 ' A' ' 8' ' ' ILE . 0.9 OUTLIER -132.78 145.94 59.24 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.404 -0.81 . . . . 0.0 110.359 -179.592 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 6' ' ' ASP . 53.2 Cg_endo -88.43 49.75 1.56 Allowed 'Trans proline' 0 N--CA 1.486 1.077 0 O-C-N 123.219 1.115 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.663 ' O ' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -134.05 5.88 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.562 0 O-C-N 120.751 -1.218 . . . . 0.0 110.936 178.196 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.558 ' CE2' HD11 ' A' ' 8' ' ' ILE . 31.5 m-85 -114.15 67.2 0.68 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 122.873 1.321 . . . . 0.0 109.442 178.386 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.31 170.83 7.83 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.858 177.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.98 -32.87 71.24 Favored 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -88.9 11.5 17.85 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.464 -1.397 . . . . 0.0 112.176 -177.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.663 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.5 tp -72.27 125.1 26.51 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.301 -0.874 . . . . 0.0 109.987 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.4 m -70.38 136.19 49.42 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.276 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.715 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -65.26 -16.72 63.85 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.85 -0.531 . . . . 0.0 111.683 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.66 -11.49 80.54 Favored Glycine 0 N--CA 1.496 2.687 0 O-C-N 121.003 -1.061 . . . . 0.0 111.284 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.4 m -89.96 -4.85 57.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.034 -1.274 . . . . 0.0 112.055 -178.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 15' ' ' MET . 9.4 p -100.7 169.02 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.966 -1.084 . . . . 0.0 110.434 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.754 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.06 87.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.15 69.0 4.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.499 -0.751 . . . . 0.0 109.884 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.3 m -108.58 110.81 22.36 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.181 -0.949 . . . . 0.0 110.783 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.406 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 12.6 t-20 50.09 -141.47 0.71 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.747 -0.596 . . . . 0.0 111.406 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 64.64 -150.63 51.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.55 -46.26 16.06 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.977 . . . . 0.0 111.494 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 54' ' ' SER . 73.8 m-70 -89.99 1.99 55.65 Favored 'General case' 0 N--CA 1.504 2.262 0 O-C-N 121.209 -0.932 . . . . 0.0 111.84 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.406 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -54.9 134.24 47.72 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 121.004 -1.06 . . . . 0.0 111.126 -179.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.812 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -100.03 -6.86 25.79 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 122.003 -0.704 . . . . 0.0 110.066 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.4 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.5 ttm -60.3 -35.47 75.67 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.258 -0.901 . . . . 0.0 110.088 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.75 -73.74 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.706 -0.622 . . . . 0.0 111.733 -177.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -69.93 -40.04 75.76 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.345 -0.847 . . . . 0.0 110.241 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.5 m-85 -119.81 91.25 44.93 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.53 -11.79 31.91 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.298 1.157 . . . . 0.0 111.579 -178.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.6 m -130.02 143.42 50.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.229 -0.92 . . . . 0.0 110.489 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.875 HD11 HG21 ' A' ' 43' ' ' VAL . 40.4 tp -67.91 119.99 13.46 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.781 -0.574 . . . . 0.0 110.117 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.8 32.53 0.05 OUTLIER Glycine 0 N--CA 1.495 2.623 0 C-N-CA 120.008 -1.092 . . . . 0.0 110.56 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 15.1 mt-10 -155.34 -46.42 0.08 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.312 -1.11 . . . . 0.0 110.14 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.812 HG11 HD13 ' A' ' 27' ' ' LEU . 2.9 t -61.84 -59.61 12.74 Favored Pre-proline 0 N--CA 1.496 1.844 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -76.23 -29.27 6.51 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 N-CA-C 109.184 -1.121 . . . . 0.0 109.184 177.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 128.5 -60.73 0.66 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 107.433 -2.267 . . . . 0.0 107.433 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.608 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 4.5 t80 162.41 -52.5 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.705 0 C-N-CA 123.595 0.758 . . . . 0.0 109.95 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.608 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.07 19.04 0.23 Allowed 'Trans proline' 0 C--N 1.322 -0.819 0 C-N-CA 121.392 1.395 . . . . 0.0 111.347 -178.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.8 m-20 -131.81 49.87 2.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.292 -0.88 . . . . 0.0 110.236 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 34' ' ' LEU . 10.4 p -125.97 139.57 51.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-O 121.598 0.713 . . . . 0.0 109.961 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 84' ' ' ASN . . . -169.4 174.28 43.77 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.28 159.28 32.22 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.573 HG22 ' CE1' ' A' ' 83' ' ' PHE . 1.4 pt -149.98 158.09 37.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.662 -0.905 . . . . 0.0 110.634 179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.22 -13.22 35.65 Favored 'Trans proline' 0 N--CA 1.499 1.811 0 C-N-CA 121.419 1.413 . . . . 0.0 114.328 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -94.9 22.23 6.72 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 120.563 -1.336 . . . . 0.0 112.819 -177.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.616 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.5 mm -113.12 129.59 68.55 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.073 -1.017 . . . . 0.0 108.52 178.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.73 12.34 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.395 -0.816 . . . . 0.0 112.229 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.754 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 170.64 -129.56 1.83 Allowed Glycine 0 N--CA 1.489 2.227 0 C-N-CA 118.813 -1.66 . . . . 0.0 111.139 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 44.7 t90 -52.1 -22.35 4.09 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.962 -0.728 . . . . 0.0 112.601 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -149.44 65.75 1.01 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.042 -1.036 . . . . 0.0 110.933 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.616 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.0 p -63.47 135.01 96.07 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.548 -0.72 . . . . 0.0 110.855 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.58 -20.76 23.03 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.333 1.175 . . . . 0.0 110.692 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.493 ' O ' HG23 ' A' ' 59' ' ' THR . 13.7 m -98.1 11.53 37.39 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.489 -0.757 . . . . 0.0 111.116 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -65.98 145.29 56.07 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.176 -0.953 . . . . 0.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.24 29.21 34.26 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.493 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -101.6 147.69 26.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.532 -0.981 . . . . 0.0 110.548 179.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.688 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.6 t -97.73 126.96 43.35 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.655 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.491 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 97.5 m95 -131.04 147.67 52.65 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.344 -0.848 . . . . 0.0 110.709 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.7 tttp -109.06 130.7 55.48 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.5 t -110.78 122.56 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.561 -0.712 . . . . 0.0 110.298 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' HG13 ' A' ' 105' ' ' VAL . 98.4 m -121.47 138.73 54.16 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.662 -0.649 . . . . 0.0 110.842 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.491 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 11.1 pt -113.59 165.54 13.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.631 -0.668 . . . . 0.0 110.777 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.491 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.43 -24.88 75.8 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 121.361 1.374 . . . . 0.0 112.825 -178.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -65.32 -39.87 93.01 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.223 -0.923 . . . . 0.0 109.99 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.19 60.07 0.28 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -160.33 152.18 20.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.669 -0.901 . . . . 0.0 108.887 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.418 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -153.75 158.9 41.65 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.047 -1.061 . . . . 0.0 112.373 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.0 pt -139.92 163.38 24.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -104.2 129.15 51.97 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.958 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.0 130.01 71.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.733 -0.604 . . . . 0.0 109.55 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.565 ' HD3' HG12 ' A' ' 37' ' ' VAL . 67.2 ttt180 -100.39 136.28 40.52 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.296 -0.878 . . . . 0.0 109.299 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -56.75 146.73 34.38 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -178.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.487 HG22 HG21 ' A' ' 18' ' ' VAL . 5.4 p -158.26 -42.51 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.816 -0.814 . . . . 0.0 109.461 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.527 ' HB2' HG23 ' A' ' 18' ' ' VAL . 16.9 t70 -130.43 168.94 16.17 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.225 -0.922 . . . . 0.0 109.522 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -97.44 160.66 14.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.515 -0.74 . . . . 0.0 111.637 -179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.03 149.37 19.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 65.0 mtt180 -61.88 -33.09 73.59 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.66 -0.906 . . . . 0.0 110.928 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.43 81.57 0.05 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.3 149.99 5.39 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.897 -1.144 . . . . 0.0 110.351 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.573 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -65.78 136.37 56.12 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.968 -0.725 . . . . 0.0 110.388 179.503 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.428 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 56.9 t-20 -134.93 124.23 24.63 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.143 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.9 m -133.81 176.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.133 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.9 m-20 -57.65 154.49 25.34 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.675 -0.64 . . . . 0.0 110.253 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.53 -26.86 46.66 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.468 1.246 . . . . 0.0 110.604 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.0 -40.54 75.23 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.919 -1.113 . . . . 0.0 108.632 178.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.88 -39.92 87.65 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -60.01 -50.06 75.21 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.85 -0.531 . . . . 0.0 110.474 179.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.5 m -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.424 -0.798 . . . . 0.0 110.538 -178.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -69.4 -40.08 77.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.79 -0.764 . . . . 0.0 111.493 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.418 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 40.6 tp -71.49 -43.02 67.32 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.525 -0.734 . . . . 0.0 111.504 -178.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.5 t -96.26 -39.63 9.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.309 -0.87 . . . . 0.0 111.492 -177.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.79 7.42 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.3 p -144.78 157.95 43.98 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.453 -1.027 . . . . 0.0 110.117 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.53 15.77 28.14 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.422 -0.799 . . . . 0.0 110.574 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -93.35 -15.0 26.2 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.452 -0.78 . . . . 0.0 110.761 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.93 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.231 -0.918 . . . . 0.0 110.405 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 86.82 -77.01 2.03 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.415 ' NE ' ' HB3' ' A' ' 2' ' ' SER . 61.6 ttt180 -137.82 135.62 36.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.595 -0.944 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 56.3 t -120.05 119.24 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.421 -0.799 . . . . 0.0 109.477 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.0 p-10 -85.18 177.05 8.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.792 0.806 . . . . 0.0 112.078 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 60.06 40.0 19.09 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.919 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.474 HG13 ' O ' ' A' ' 64' ' ' THR . 86.3 t -95.41 123.27 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.231 179.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -84.5 146.72 27.44 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.762 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.428 ' C ' HG13 ' A' ' 108' ' ' VAL . 52.2 p90 -142.14 148.74 38.79 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.923 -0.486 . . . . 0.0 110.907 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.428 HG13 ' C ' ' A' ' 107' ' ' TYR . 24.4 m -149.93 144.91 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 O-C-N 121.348 -0.845 . . . . 0.0 111.782 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.491 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 55.1 tt0 -70.01 140.99 52.98 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.707 -0.62 . . . . 0.0 109.886 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.688 HG23 ' SG ' ' A' ' 60' ' ' CYS . 30.5 m -139.95 172.78 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.992 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -59.86 145.51 45.36 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.382 -0.824 . . . . 0.0 110.862 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.464 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.4 tt -59.99 -40.09 87.94 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.378 -0.826 . . . . 0.0 110.201 179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 70.6 m -54.92 -37.9 66.96 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.627 -0.671 . . . . 0.0 109.847 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -59.98 -39.99 87.56 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.56 -0.712 . . . . 0.0 110.059 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.8 m -64.04 -45.35 89.27 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.489 -0.757 . . . . 0.0 109.225 178.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.2 mm -62.89 -45.72 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.259 0.552 . . . . 0.0 110.137 -178.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -66.53 -40.01 88.9 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.796 -0.565 . . . . 0.0 110.553 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.78 -42.93 99.81 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.56 -40.0 94.77 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.574 -0.957 . . . . 0.0 110.535 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 33.6 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.306 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 120.982 0.42 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.4 t -112.96 139.94 48.18 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.695 . . . . 0.0 110.44 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.671 HG21 HG11 ' A' ' 105' ' ' VAL . 44.9 pt -107.71 145.68 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.688 -0.632 . . . . 0.0 110.693 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 3.9 m -144.33 -174.25 4.25 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 45.8 p90 -141.29 147.36 38.06 Favored 'General case' 0 N--CA 1.492 1.671 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.043 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -124.81 145.18 48.96 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.504 -0.747 . . . . 0.0 109.169 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -82.51 -10.08 11.03 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.274 1.144 . . . . 0.0 112.733 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.828 ' O ' HD23 ' A' ' 13' ' ' LEU . 48.9 pt -70.03 -40.04 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 120.947 -1.096 . . . . 0.0 111.37 -179.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.475 ' N ' HG13 ' A' ' 8' ' ' ILE . 42.6 m-85 -73.11 67.34 0.9 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 122.874 1.321 . . . . 0.0 111.698 -178.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.91 173.86 6.12 Favored 'General case' 0 N--CA 1.489 1.505 0 CA-C-N 114.401 -1.272 . . . . 0.0 108.107 176.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.5 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -56.71 -30.35 63.4 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -175.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -89.99 11.55 20.23 Favored 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 118.237 -1.385 . . . . 0.0 112.262 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.828 HD23 ' O ' ' A' ' 8' ' ' ILE . 0.4 OUTLIER -67.51 119.78 12.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.295 -0.878 . . . . 0.0 109.878 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.454 ' N ' HD13 ' A' ' 13' ' ' LEU . 50.5 m -70.11 137.01 50.78 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.759 0.79 . . . . 0.0 110.007 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.776 ' O ' HG12 ' A' ' 18' ' ' VAL . 95.4 mmm -64.24 -21.87 66.74 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.885 -0.51 . . . . 0.0 111.634 -179.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.436 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.32 -16.07 77.13 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 121.065 -1.022 . . . . 0.0 111.514 -178.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.4 m -90.0 -4.71 57.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.121 -1.223 . . . . 0.0 111.923 -178.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.776 HG12 ' O ' ' A' ' 15' ' ' MET . 9.9 p -101.04 168.64 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.959 -1.088 . . . . 0.0 110.618 -179.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.673 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.0 -42.73 94.87 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.476 -0.765 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.5 m -80.47 71.98 7.33 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.85 -76.96 0.51 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.507 -0.746 . . . . 0.0 109.952 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -127.84 168.55 15.02 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.648 -0.658 . . . . 0.0 109.584 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.21 -154.95 16.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 -178.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -70.72 -42.77 70.15 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -1.109 . . . . 0.0 110.186 179.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.417 ' CD2' ' O ' ' A' ' 54' ' ' SER . 54.7 m-70 -92.61 3.35 55.73 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.412 -0.805 . . . . 0.0 110.836 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.05 129.74 48.07 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.407 HD13 HH21 ' A' ' 74' ' ' ARG . 85.8 mt -99.71 -3.12 33.64 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 122.039 -0.683 . . . . 0.0 110.21 179.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.436 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 58.8 tpp -60.01 -38.59 83.11 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.336 -0.853 . . . . 0.0 110.365 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.77 -75.05 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.68 -0.637 . . . . 0.0 112.195 -177.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -70.05 -41.17 74.56 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.325 -0.86 . . . . 0.0 111.446 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.641 ' CG ' HG23 ' A' ' 37' ' ' VAL . 97.6 m-85 -122.84 86.4 50.21 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.648 -0.657 . . . . 0.0 110.474 -178.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.06 -7.42 21.36 Favored 'Trans proline' 0 C--N 1.317 -1.099 0 O-C-N 123.387 1.203 . . . . 0.0 111.475 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.3 m -130.02 142.98 50.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.05 -1.031 . . . . 0.0 110.189 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.906 HD11 HG21 ' A' ' 43' ' ' VAL . 39.6 tp -75.4 117.83 17.62 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.78 -0.575 . . . . 0.0 110.644 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.05 30.29 0.05 OUTLIER Glycine 0 N--CA 1.496 2.676 0 C-N-CA 120.092 -1.052 . . . . 0.0 110.812 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 8.9 mt-10 -153.66 -52.79 0.1 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.218 -1.166 . . . . 0.0 110.336 179.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.641 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -60.65 -59.63 13.24 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 45.7 Cg_endo -73.36 -32.45 8.09 Favored 'Trans proline' 0 N--CA 1.486 1.068 0 N-CA-C 109.114 -1.148 . . . . 0.0 109.114 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.81 -64.35 0.61 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 107.739 -2.144 . . . . 0.0 107.739 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 162.75 -55.8 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.787 0 C-N-CA 123.477 0.711 . . . . 0.0 110.627 177.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -101.07 13.09 0.44 Allowed 'Trans proline' 0 N--CA 1.48 0.715 0 C-N-CA 121.348 1.365 . . . . 0.0 111.522 -178.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -122.21 45.76 2.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.223 -179.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.906 HG21 HD11 ' A' ' 34' ' ' LEU . 12.6 p -126.78 141.06 47.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.832 0.825 . . . . 0.0 110.19 -179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.84 173.3 43.4 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.568 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.26 159.23 30.85 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.768 HD11 ' HA2' ' A' ' 75' ' ' GLY . 1.0 OUTLIER -153.38 160.18 31.25 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.581 -0.952 . . . . 0.0 109.493 179.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.14 -37.67 31.26 Favored 'Trans proline' 0 N--CA 1.505 2.184 0 C-N-CA 121.831 1.687 . . . . 0.0 116.125 -175.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -69.7 -9.95 56.4 Favored 'General case' 0 N--CA 1.509 2.493 0 O-C-N 120.561 -1.337 . . . . 0.0 112.974 -176.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 54' ' ' SER . 44.4 mm -77.04 125.04 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 O-C-N 120.713 -1.242 . . . . 0.0 108.527 178.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.18 -46.78 12.31 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.261 -0.899 . . . . 0.0 112.568 -178.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.673 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 171.94 -137.5 4.33 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.716 -1.707 . . . . 0.0 111.54 -179.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 58.2 t90 -42.88 -29.62 0.34 Allowed 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.401 ' HB2' ' CE3' ' A' ' 52' ' ' TRP . 25.4 t70 -144.98 62.27 1.31 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 110.508 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.579 ' CB ' HG23 ' A' ' 49' ' ' ILE . 12.5 p -61.82 139.31 95.55 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.651 -0.656 . . . . 0.0 110.651 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -76.17 -21.36 13.81 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 O-C-N 123.373 1.196 . . . . 0.0 111.113 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.7 m -94.05 14.49 19.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.491 -0.755 . . . . 0.0 111.296 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.3 t -73.85 147.89 42.86 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.16 35.31 53.51 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.421 HG22 ' NE1' ' A' ' 61' ' ' TRP . 89.2 m -119.68 131.55 55.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.595 -0.944 . . . . 0.0 109.882 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.04 145.66 33.73 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.871 -177.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.445 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -149.83 149.34 30.35 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.684 -0.635 . . . . 0.0 110.124 178.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -112.16 135.55 52.67 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.6 t -108.77 126.77 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.8 m -119.22 140.39 50.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.964 -0.46 . . . . 0.0 110.834 -178.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.449 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 39.3 pt -119.16 164.2 22.58 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.616 -0.677 . . . . 0.0 110.531 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.1 -24.41 79.28 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 121.273 1.315 . . . . 0.0 112.338 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -63.89 -40.02 95.54 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.272 -0.892 . . . . 0.0 109.58 179.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.95 62.57 0.41 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 48.6 t-20 -162.01 153.45 18.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.708 -0.878 . . . . 0.0 108.975 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.4 p -154.64 160.96 41.75 Favored 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 119.261 -0.975 . . . . 0.0 112.329 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.527 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.0 pt -136.35 164.44 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -108.65 126.75 53.31 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.16 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.782 HD13 HG11 ' A' ' 85' ' ' VAL . 88.0 mt -129.99 140.0 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.254 -0.904 . . . . 0.0 111.454 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.466 ' CD ' HG12 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -100.87 144.35 29.94 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.868 -0.52 . . . . 0.0 109.654 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.768 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.54 151.06 46.93 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -179.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.559 HG11 HG22 ' A' ' 43' ' ' VAL . 2.7 p -155.73 -44.1 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 178.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.466 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.9 t70 -130.3 170.0 14.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 178.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.7 t -101.48 159.94 14.86 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.775 . . . . 0.0 111.318 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -130.13 154.32 20.5 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.1 mtt180 -59.97 -31.56 70.01 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.555 -0.967 . . . . 0.0 110.403 179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.17 81.73 0.05 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 119.979 -1.105 . . . . 0.0 110.571 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.06 163.9 11.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.161 -1.176 . . . . 0.0 110.161 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.577 ' CD2' HG22 ' A' ' 46' ' ' ILE . 28.0 m-85 -88.36 118.63 28.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.512 -0.993 . . . . 0.0 109.746 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.406 ' HA ' ' O ' ' A' ' 4' ' ' SER . 54.6 t-20 -113.04 128.71 56.57 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.782 HG11 HD13 ' A' ' 73' ' ' ILE . 34.5 m -130.02 172.56 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 120.862 -1.149 . . . . 0.0 112.008 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 -56.52 156.22 12.26 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.504 -0.748 . . . . 0.0 109.594 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.44 -28.49 54.11 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.276 1.145 . . . . 0.0 110.663 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -70.28 -40.63 74.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.99 -1.069 . . . . 0.0 109.382 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.65 89.2 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -60.02 -49.84 76.08 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.826 -0.546 . . . . 0.0 110.311 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.9 m -60.11 -39.98 88.11 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.586 -0.696 . . . . 0.0 110.754 -178.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -68.67 -39.98 80.35 Favored 'General case' 0 N--CA 1.495 1.813 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.172 -178.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.402 HD13 HG23 ' A' ' 71' ' ' ILE . 63.1 tp -70.27 -42.9 71.52 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.627 -0.67 . . . . 0.0 111.749 -178.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 92.7 t -97.05 -39.93 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.312 -0.868 . . . . 0.0 111.829 -177.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.07 -25.75 7.36 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 80.9 p -149.93 161.03 43.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.351 -1.088 . . . . 0.0 110.317 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 77.4 p -99.1 1.87 45.54 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.477 -0.765 . . . . 0.0 111.298 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -69.96 -28.65 65.73 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.388 -0.82 . . . . 0.0 111.466 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.82 -40.63 89.06 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.396 -0.815 . . . . 0.0 111.272 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 89.42 -66.26 2.98 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -151.23 155.99 39.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.486 -1.008 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.97 117.65 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.551 -0.718 . . . . 0.0 109.785 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -80.62 169.51 17.55 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.474 -0.766 . . . . 0.0 110.427 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 60.0 51.81 5.62 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.628 -0.67 . . . . 0.0 111.347 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.671 HG11 HG21 ' A' ' 3' ' ' ILE . 65.8 t -98.66 129.99 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.434 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -89.04 138.68 31.19 Favored 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.804 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.405 ' C ' HG13 ' A' ' 108' ' ' VAL . 38.3 p90 -133.3 140.98 47.75 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.907 -0.496 . . . . 0.0 110.557 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -146.03 143.0 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.589 -0.694 . . . . 0.0 111.242 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.445 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.2 tt0 -70.88 139.78 50.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.681 -0.637 . . . . 0.0 110.444 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.07 163.27 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.098 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -59.62 141.38 55.12 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.543 -0.723 . . . . 0.0 110.478 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.0 -40.0 87.7 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.598 -0.689 . . . . 0.0 111.391 -179.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 78.6 p -55.72 -34.23 64.95 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.503 -0.748 . . . . 0.0 110.935 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -69.92 -28.08 65.31 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.348 -0.845 . . . . 0.0 111.339 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 97.3 m -69.96 -46.45 65.22 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.23 -0.919 . . . . 0.0 109.179 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 89.2 mt -69.96 -40.01 78.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.143 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -64.56 -40.0 94.78 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.459 -0.776 . . . . 0.0 110.618 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -83.81 -60.01 2.02 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.454 -0.879 . . . . 0.0 110.93 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.04 -42.52 94.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.611 -0.934 . . . . 0.0 111.202 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.502 2.172 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.727 -179.711 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.573 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.694 0.759 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.9 p -111.81 138.94 47.73 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.712 HG23 HG21 ' A' ' 105' ' ' VAL . 29.9 pt -108.78 145.36 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.801 -0.562 . . . . 0.0 110.481 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.4 p -144.22 -173.32 3.98 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 39.4 p90 -140.02 141.24 36.32 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.456 -0.777 . . . . 0.0 110.696 179.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.14 150.07 50.55 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.483 -0.761 . . . . 0.0 109.284 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -82.83 -10.53 10.51 Favored 'Trans proline' 0 C--N 1.318 -1.067 0 O-C-N 123.105 1.055 . . . . 0.0 112.551 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.9 pt -70.06 -39.96 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.002 -1.061 . . . . 0.0 111.62 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.687 ' HA ' HD22 ' A' ' 13' ' ' LEU . 53.7 m-85 -73.2 67.51 0.95 Allowed 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 122.875 1.321 . . . . 0.0 111.907 -178.32 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.8 169.65 8.36 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.854 176.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.521 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.87 -35.09 70.48 Favored 'General case' 0 N--CA 1.497 1.912 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -90.23 10.39 24.86 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 120.497 -1.377 . . . . 0.0 112.295 -177.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 9' ' ' TYR . 34.8 tp -68.49 123.45 20.85 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -0.865 . . . . 0.0 109.829 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.3 m -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.806 -0.758 . . . . 0.0 109.775 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.811 ' O ' HG12 ' A' ' 18' ' ' VAL . 86.6 mtp -69.96 -15.28 63.02 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.91 -0.494 . . . . 0.0 111.864 -178.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.58 -15.95 73.59 Favored Glycine 0 N--CA 1.496 2.654 0 O-C-N 121.021 -1.049 . . . . 0.0 110.816 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.5 m -90.05 -4.99 57.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.175 -1.191 . . . . 0.0 111.716 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.811 HG12 ' O ' ' A' ' 15' ' ' MET . 14.8 p -102.26 168.96 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.026 -1.046 . . . . 0.0 110.877 -179.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.7 89.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.575 -0.703 . . . . 0.0 110.368 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 54.1 m -83.45 74.84 10.05 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.2 m -100.41 -77.04 0.54 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.385 -0.822 . . . . 0.0 110.388 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -129.68 169.98 14.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 0.0 110.485 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.46 -154.4 16.45 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -70.2 -40.94 74.3 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -1.073 . . . . 0.0 109.791 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.406 ' CD2' ' O ' ' A' ' 54' ' ' SER . 44.0 m-70 -91.82 0.59 57.48 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.519 -0.738 . . . . 0.0 110.982 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -52.42 126.07 30.33 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HB2' ' HE2' ' A' ' 15' ' ' MET . 87.2 mt -96.53 -9.42 29.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 122.032 -0.687 . . . . 0.0 110.128 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.5 tpp -59.95 -37.03 78.39 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.35 -0.844 . . . . 0.0 110.006 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -74.37 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.513 -0.742 . . . . 0.0 111.983 -178.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -69.98 -39.99 75.6 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.237 -0.915 . . . . 0.0 110.455 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD2' HG23 ' A' ' 37' ' ' VAL . 87.3 m-85 -117.39 100.95 52.99 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.04 -20.92 16.31 Favored 'Trans proline' 0 C--N 1.318 -1.046 0 O-C-N 123.307 1.161 . . . . 0.0 111.367 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 30.2 m -127.84 148.32 50.46 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.371 -0.831 . . . . 0.0 111.017 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.97 HD21 HG11 ' A' ' 43' ' ' VAL . 57.7 tp -67.13 120.44 13.72 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.784 -0.573 . . . . 0.0 110.374 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.46 30.02 0.05 OUTLIER Glycine 0 N--CA 1.495 2.603 0 C-N-CA 119.891 -1.147 . . . . 0.0 110.963 179.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 31.7 mt-10 -153.18 -48.67 0.1 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.226 -1.161 . . . . 0.0 110.325 179.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.551 HG23 ' CD2' ' A' ' 31' ' ' TYR . 3.2 t -60.55 -60.48 10.5 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.461 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -75.67 -27.57 8.86 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.113 1.059 . . . . 0.0 109.466 177.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.406 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.27 -58.93 0.67 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.414 -2.274 . . . . 0.0 107.414 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.565 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 165.89 -73.57 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.615 0 C-N-CA 123.666 0.786 . . . . 0.0 109.356 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.565 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -86.21 19.19 1.43 Allowed 'Trans proline' 0 N--CA 1.493 1.465 0 CA-C-N 119.306 0.788 . . . . 0.0 111.16 178.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -118.37 37.03 4.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.059 -1.026 . . . . 0.0 110.18 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.97 HG11 HD21 ' A' ' 34' ' ' LEU . 12.4 p -120.71 141.23 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-O 121.757 0.789 . . . . 0.0 110.716 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.99 171.38 42.92 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.08 152.24 32.63 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.761 HG22 ' CE1' ' A' ' 83' ' ' PHE . 13.7 pt -141.88 156.81 65.41 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.665 -0.903 . . . . 0.0 109.742 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.3 -20.5 36.93 Favored 'Trans proline' 0 N--CA 1.499 1.841 0 C-N-CA 121.399 1.4 . . . . 0.0 113.966 -177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -88.92 20.68 3.44 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.805 -1.184 . . . . 0.0 112.541 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.835 HG23 ' CB ' ' A' ' 54' ' ' SER . 40.7 mt -120.02 120.0 61.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.074 -1.016 . . . . 0.0 108.398 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.48 -41.82 21.19 Favored 'General case' 0 N--CA 1.499 2.015 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -176.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.563 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.83 -138.96 4.6 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 118.323 -1.894 . . . . 0.0 112.171 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.504 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 26.3 t90 -39.95 -30.06 0.08 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -146.72 68.52 1.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.998 -1.064 . . . . 0.0 111.24 -178.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.835 ' CB ' HG23 ' A' ' 49' ' ' ILE . 2.1 t -64.51 136.87 96.94 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.622 -0.674 . . . . 0.0 110.586 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.29 -20.55 21.06 Favored 'Trans proline' 0 C--N 1.32 -0.968 0 O-C-N 123.303 1.159 . . . . 0.0 110.605 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.9 m -99.84 14.82 29.03 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.499 -0.751 . . . . 0.0 110.806 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 23.4 t -72.75 151.12 42.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.238 -0.913 . . . . 0.0 110.061 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.18 21.75 78.62 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 80.4 m -106.58 140.01 40.13 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.515 -0.991 . . . . 0.0 110.277 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.703 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.3 t -78.59 136.21 37.46 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.687 -178.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.434 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -137.21 146.24 44.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.647 -0.658 . . . . 0.0 110.016 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -116.28 136.46 52.98 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.222 -0.924 . . . . 0.0 110.099 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -114.25 129.99 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.543 -0.723 . . . . 0.0 110.887 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 51.1 m -119.92 144.96 47.16 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.723 -0.611 . . . . 0.0 110.501 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.453 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.6 pt -123.44 164.33 28.85 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.307 -0.871 . . . . 0.0 111.11 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.28 -26.88 82.53 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.428 1.419 . . . . 0.0 112.574 -178.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -63.45 -39.71 95.2 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.317 -0.864 . . . . 0.0 109.741 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 115.26 61.65 0.37 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -160.6 153.29 20.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.832 -0.805 . . . . 0.0 109.077 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.402 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 84.0 p -150.65 158.49 44.21 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 122.18 0.99 . . . . 0.0 112.021 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.455 HG12 HD13 ' A' ' 93' ' ' LEU . 27.6 pt -138.7 162.77 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.27 123.83 48.89 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 118.859 -1.136 . . . . 0.0 109.794 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.403 HG13 HG11 ' A' ' 85' ' ' VAL . 48.5 mm -117.13 131.99 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.489 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.5 ttt180 -98.65 132.38 44.1 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.152 -0.968 . . . . 0.0 108.783 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.89 148.35 10.44 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.555 HG11 HG22 ' A' ' 43' ' ' VAL . 5.6 p -159.96 -35.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.792 -0.828 . . . . 0.0 110.406 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.456 ' HB2' HG23 ' A' ' 18' ' ' VAL . 28.4 t70 -128.94 165.28 21.38 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.885 -1.134 . . . . 0.0 110.449 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.443 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 79.4 p -82.54 159.78 22.73 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.656 -0.653 . . . . 0.0 110.521 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -127.49 135.4 8.73 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -65.44 -39.95 92.67 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.923 -0.751 . . . . 0.0 109.608 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 176.29 70.28 0.05 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.46 -163.18 33.35 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.59 -1.29 . . . . 0.0 110.766 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.761 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -123.34 136.61 54.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 122.025 -0.691 . . . . 0.0 109.415 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 45.3 t-20 -137.97 126.89 24.02 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.389 -0.925 . . . . 0.0 108.808 178.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.8 m -133.63 176.8 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.08 -1.012 . . . . 0.0 111.128 -178.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.3 m-20 -56.47 150.25 35.17 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.91 -25.68 67.11 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 O-C-N 123.367 1.193 . . . . 0.0 110.763 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' HE2' ' A' ' 92' ' ' LYS . 89.8 m -70.8 -40.03 72.77 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.976 -1.078 . . . . 0.0 109.308 178.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.03 91.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.04 -49.93 75.74 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.868 -0.52 . . . . 0.0 110.586 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.1 m -60.11 -39.94 87.98 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.439 -0.788 . . . . 0.0 110.606 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.434 ' HE2' HG22 ' A' ' 88' ' ' THR . 57.8 mtmt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.273 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.455 HD13 HG12 ' A' ' 71' ' ' ILE . 45.9 tp -71.6 -46.12 60.16 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 120.047 -0.661 . . . . 0.0 111.357 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.1 t -89.46 -41.39 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.4 -0.812 . . . . 0.0 111.334 -177.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 125.2 -27.25 5.37 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.7 p -158.85 162.32 36.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.551 -0.97 . . . . 0.0 110.024 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.9 p -91.97 1.57 57.1 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.478 -0.764 . . . . 0.0 111.372 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.66 -34.08 77.05 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.36 -41.5 80.25 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.45 -0.781 . . . . 0.0 111.456 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.41 -80.47 1.82 Allowed Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.3 ttm180 -129.0 136.82 50.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.575 -0.956 . . . . 0.0 109.918 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.6 t -119.02 117.29 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.243 -0.91 . . . . 0.0 110.299 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -83.84 171.57 12.98 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.525 0.679 . . . . 0.0 110.65 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.52 52.0 1.87 Allowed 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.623 -0.673 . . . . 0.0 111.06 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.712 HG21 HG23 ' A' ' 3' ' ' ILE . 60.4 t -103.24 129.81 54.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 C-N-CA 119.279 -0.968 . . . . 0.0 110.607 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -90.64 137.92 31.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.309 -0.87 . . . . 0.0 109.6 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.469 ' C ' HG13 ' A' ' 108' ' ' VAL . 53.8 p90 -140.04 145.83 38.24 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.902 -0.499 . . . . 0.0 110.835 -178.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.469 HG13 ' C ' ' A' ' 107' ' ' TYR . 29.6 m -151.1 151.58 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.216 -0.928 . . . . 0.0 111.273 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.434 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.0 tt0 -72.37 141.05 48.75 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.682 -0.636 . . . . 0.0 110.47 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.703 HG23 ' SG ' ' A' ' 60' ' ' CYS . 15.7 m -137.03 170.03 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -64.21 148.85 49.14 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.175 -0.953 . . . . 0.0 110.645 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.543 HD21 HD11 ' A' ' 116' ' ' ILE . 9.4 tt -60.08 -39.77 87.21 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.495 -0.753 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 89.3 p -52.24 -37.41 55.13 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.413 -0.805 . . . . 0.0 110.614 -178.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.31 -39.27 93.57 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.583 -0.698 . . . . 0.0 111.089 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -59.97 -50.02 75.4 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.394 -0.816 . . . . 0.0 110.064 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 112' ' ' LEU . 86.9 mt -69.84 -39.98 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.715 -0.616 . . . . 0.0 110.773 -179.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -39.98 96.24 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.39 -0.819 . . . . 0.0 110.521 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -72.66 -47.32 27.41 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.174 -1.171 . . . . 0.0 110.174 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.99 -40.78 90.33 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.502 -0.999 . . . . 0.0 110.707 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.5 t30 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.276 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.013 0.435 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.2 t -113.68 139.19 49.27 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.672 0.749 . . . . 0.0 111.045 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.77 HG12 HG21 ' A' ' 105' ' ' VAL . 36.3 pt -111.02 147.65 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.83 -0.544 . . . . 0.0 109.797 179.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.1 m -146.09 -171.52 3.73 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.418 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 47.7 p90 -140.12 150.01 43.75 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.119 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -126.67 148.07 63.33 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.521 -0.737 . . . . 0.0 110.216 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -86.57 14.14 2.53 Favored 'Trans proline' 0 C--N 1.317 -1.09 0 O-C-N 123.399 1.21 . . . . 0.0 111.636 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 1.4 pt -100.1 10.06 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.029 -1.044 . . . . 0.0 111.666 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -123.46 66.64 1.0 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.701 1.239 . . . . 0.0 110.259 178.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.07 172.76 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.459 -1.246 . . . . 0.0 108.447 176.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.03 -31.97 67.51 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -175.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -89.76 11.98 18.44 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.332 -1.347 . . . . 0.0 111.9 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 14' ' ' SER . 0.6 OUTLIER -69.3 119.56 13.77 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.281 -0.887 . . . . 0.0 110.043 179.875 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.47 ' N ' HD13 ' A' ' 13' ' ' LEU . 52.6 m -69.18 135.85 51.24 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.757 -0.777 . . . . 0.0 108.958 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.726 ' O ' HG12 ' A' ' 18' ' ' VAL . 57.1 mtp -70.21 -14.59 62.69 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 120.211 -0.596 . . . . 0.0 111.926 -179.234 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.65 -18.61 74.08 Favored Glycine 0 N--CA 1.495 2.6 0 O-C-N 120.848 -1.157 . . . . 0.0 110.654 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 70.4 m -88.06 -9.64 52.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.289 -1.124 . . . . 0.0 111.615 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 15' ' ' MET . 9.7 p -101.74 169.66 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.029 -1.044 . . . . 0.0 110.495 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.14 -39.76 83.39 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.568 -0.708 . . . . 0.0 110.594 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.31 82.84 3.08 Favored 'General case' 0 N--CA 1.5 2.025 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 -84.26 0.42 Allowed 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.794 -1.191 . . . . 0.0 113.395 -177.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -143.8 12.56 1.67 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.564 -1.335 . . . . 0.0 112.752 -177.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.89 -149.19 0.11 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -67.22 -39.89 86.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.891 -0.77 . . . . 0.0 110.456 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.603 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 11.8 p80 -97.86 6.2 48.08 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.31 138.79 35.53 Favored Glycine 0 N--CA 1.5 2.91 0 O-C-N 121.055 -1.028 . . . . 0.0 110.659 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.871 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -102.31 -5.68 23.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.885 -0.774 . . . . 0.0 110.724 179.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.8 ttm -60.44 -33.1 72.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.23 -0.919 . . . . 0.0 110.486 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.79 -72.15 0.06 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.566 -0.709 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -70.0 -40.16 75.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.185 -0.947 . . . . 0.0 110.079 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.422 ' CD2' HG23 ' A' ' 37' ' ' VAL . 60.8 m-85 -122.86 95.16 46.66 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.875 -0.516 . . . . 0.0 109.769 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.63 -19.32 32.13 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 O-C-N 123.398 1.209 . . . . 0.0 111.556 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.7 m -122.61 140.9 52.3 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.296 -0.878 . . . . 0.0 110.736 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.853 HD11 HG21 ' A' ' 43' ' ' VAL . 40.7 tp -61.65 119.91 9.59 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.912 -0.492 . . . . 0.0 110.317 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.77 33.36 0.04 OUTLIER Glycine 0 N--CA 1.496 2.679 0 C-N-CA 119.948 -1.12 . . . . 0.0 110.797 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.66 -45.98 0.06 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.195 -1.179 . . . . 0.0 110.013 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.871 HG11 HD13 ' A' ' 27' ' ' LEU . 3.2 t -62.69 -60.78 8.93 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 178.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.47 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.2 Cg_endo -75.97 -28.15 7.88 Favored 'Trans proline' 0 N--CA 1.485 1.028 0 N-CA-C 109.236 -1.102 . . . . 0.0 109.236 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.402 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.98 -60.93 0.65 Allowed Glycine 0 N--CA 1.486 2.019 0 N-CA-C 107.284 -2.326 . . . . 0.0 107.284 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.622 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.2 t80 164.04 -52.9 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.573 0 C-N-CA 123.381 0.672 . . . . 0.0 109.705 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.4 Cg_endo -101.78 13.94 0.37 Allowed 'Trans proline' 0 C--N 1.324 -0.742 0 C-N-CA 121.457 1.438 . . . . 0.0 111.486 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -123.46 40.73 3.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -0.928 . . . . 0.0 110.112 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.853 HG21 HD11 ' A' ' 34' ' ' LEU . 12.2 p -115.44 135.74 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 CA-C-O 121.602 0.715 . . . . 0.0 110.681 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.432 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -163.94 170.0 39.06 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.471 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -90.37 164.82 30.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.482 HG22 ' CD2' ' A' ' 83' ' ' PHE . 5.2 pt -150.92 163.47 23.64 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.74 -0.859 . . . . 0.0 110.12 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 55.6 Cg_endo -73.69 -15.05 24.41 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 121.43 1.42 . . . . 0.0 113.337 -177.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.412 ' HB2' HD12 ' A' ' 46' ' ' ILE . 79.5 m-20 -90.37 12.7 17.58 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.852 -1.155 . . . . 0.0 112.829 -177.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.784 HG23 ' CB ' ' A' ' 54' ' ' SER . 71.9 mt -110.8 129.92 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.068 -1.02 . . . . 0.0 110.18 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.41 -46.45 12.52 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.537 -0.727 . . . . 0.0 112.159 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.76 -138.91 5.52 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.895 -1.621 . . . . 0.0 111.371 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.492 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.0 t90 -39.81 -28.78 0.05 Allowed 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -179.005 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.603 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 24.6 t70 -141.09 63.96 1.43 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.281 -0.887 . . . . 0.0 110.576 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.784 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.8 t -79.86 139.35 53.83 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.696 -0.627 . . . . 0.0 110.414 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -78.4 -16.63 13.45 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.331 1.174 . . . . 0.0 111.45 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.0 p -98.05 4.84 49.21 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.208 -0.932 . . . . 0.0 112.607 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.424 ' HB3' ' HD1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -61.59 140.36 58.14 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.738 -1.226 . . . . 0.0 109.73 -179.604 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.97 -7.93 80.75 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 120.332 -0.937 . . . . 0.0 110.871 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.4 m -69.42 149.84 47.91 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.117 -1.225 . . . . 0.0 109.514 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.6 130.58 45.14 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.987 -0.446 . . . . 0.0 111.341 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -128.15 140.27 52.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.483 -0.761 . . . . 0.0 109.2 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.452 ' HB2' HG11 ' A' ' 110' ' ' VAL . 86.8 tttt -103.16 132.68 49.24 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.418 HG13 HG11 ' A' ' 105' ' ' VAL . 64.9 t -110.02 124.56 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.621 -0.674 . . . . 0.0 110.499 -179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.5 m -118.66 135.79 54.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.913 -0.492 . . . . 0.0 110.633 -178.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.443 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.9 pt -115.66 163.58 20.31 Favored Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.461 -0.775 . . . . 0.0 110.723 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.65 -27.29 76.0 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 121.411 1.407 . . . . 0.0 113.15 -178.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -62.62 -40.0 95.59 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.132 -0.98 . . . . 0.0 109.582 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.9 60.06 0.29 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -155.05 151.11 27.99 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 89.6 p -149.83 153.34 36.6 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.029 0.919 . . . . 0.0 111.747 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.446 HG23 HD13 ' A' ' 93' ' ' LEU . 31.6 pt -139.14 163.09 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -105.51 129.42 53.8 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.871 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.568 ' CD1' HG11 ' A' ' 85' ' ' VAL . 48.9 mm -116.09 128.18 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.662 -0.649 . . . . 0.0 109.614 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.607 ' HD3' HG12 ' A' ' 37' ' ' VAL . 60.3 ttt180 -100.05 137.96 37.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.28 -0.888 . . . . 0.0 108.888 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -53.43 148.21 16.11 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.593 HG11 HG22 ' A' ' 43' ' ' VAL . 3.2 p -159.92 -43.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.837 -0.802 . . . . 0.0 109.164 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.534 ' HB2' HG23 ' A' ' 18' ' ' VAL . 22.8 t70 -132.39 165.48 24.17 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.475 -0.766 . . . . 0.0 109.844 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.4 p -107.62 161.59 14.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 110.158 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -145.01 173.57 25.41 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.1 mtm180 -60.28 -40.03 88.99 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.8 -0.824 . . . . 0.0 112.05 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.06 95.39 0.1 OUTLIER Glycine 0 N--CA 1.504 3.182 0 C-N-CA 119.373 -1.394 . . . . 0.0 111.816 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 150.64 -164.82 29.96 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 3' ' ' ILE . 95.7 m-85 -123.31 120.24 32.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.625 -0.927 . . . . 0.0 109.241 178.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -119.09 130.06 55.4 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 ' CD1' ' A' ' 73' ' ' ILE . 27.5 m -130.02 174.68 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.036 0 O-C-N 121.088 -1.007 . . . . 0.0 111.725 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -57.9 156.8 17.52 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.554 -0.716 . . . . 0.0 109.935 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.36 -27.73 47.3 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.471 1.248 . . . . 0.0 110.705 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.03 -40.08 75.38 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.012 -1.055 . . . . 0.0 109.485 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.84 -40.13 87.85 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.03 -49.96 75.6 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.783 -0.573 . . . . 0.0 110.678 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 66.6 m -59.97 -38.7 83.29 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.532 -0.73 . . . . 0.0 110.601 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -68.25 -39.81 82.12 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.883 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.446 HD13 HG23 ' A' ' 71' ' ' ILE . 54.6 tp -70.0 -42.73 72.68 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.597 -0.689 . . . . 0.0 111.886 -179.098 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -98.66 -36.91 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 O-C-N 121.221 -0.925 . . . . 0.0 111.709 -177.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.47 -28.83 6.11 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -151.59 162.68 40.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.993 . . . . 0.0 110.394 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.3 p -100.97 14.05 33.18 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.913 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -70.03 -36.68 75.23 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.421 -0.799 . . . . 0.0 111.012 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.87 -40.04 87.3 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.514 -0.742 . . . . 0.0 110.894 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.13 -65.75 2.52 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 -143.19 151.65 40.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.579 -0.954 . . . . 0.0 110.313 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -121.86 121.41 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.548 -0.72 . . . . 0.0 109.979 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -90.13 172.19 8.99 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.342 -0.849 . . . . 0.0 110.635 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 64.5 t30 60.05 47.93 9.1 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.546 -0.722 . . . . 0.0 110.441 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.77 HG21 HG12 ' A' ' 3' ' ' ILE . 96.6 t -96.68 124.49 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 119.832 -0.747 . . . . 0.0 110.38 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -82.68 139.92 33.41 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 119.253 -0.979 . . . . 0.0 108.741 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.418 ' C ' HG13 ' A' ' 108' ' ' VAL . 42.3 p90 -135.96 141.86 44.49 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.361 0.601 . . . . 0.0 111.505 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.418 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -147.52 145.8 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.769 -0.582 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -72.08 138.2 47.64 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.635 -0.666 . . . . 0.0 110.069 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LYS . 35.1 m -129.91 162.06 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.738 -0.601 . . . . 0.0 110.3 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -59.65 144.85 46.7 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.483 -0.761 . . . . 0.0 110.301 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.5 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -60.02 -38.26 82.15 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.658 -0.651 . . . . 0.0 111.108 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.6 m -56.28 -39.11 72.14 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.531 -0.731 . . . . 0.0 110.384 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -59.98 -39.98 87.55 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.429 -0.794 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 76.6 m -61.86 -48.63 79.68 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.364 -0.835 . . . . 0.0 110.718 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.5 HD11 HD21 ' A' ' 112' ' ' LEU . 86.3 mt -70.05 -39.99 77.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.653 -0.654 . . . . 0.0 110.668 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.12 -40.03 95.3 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.465 -0.772 . . . . 0.0 110.29 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.88 -47.08 49.44 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -40.26 88.64 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.999 . . . . 0.0 110.5 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.7 t30 . . . . . 0 N--CA 1.502 2.163 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.848 179.791 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.425 HG23 ' HB ' ' A' ' 105' ' ' VAL . 28.3 m . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 120.876 0.37 . . . . 0.0 110.437 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -111.23 141.35 44.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.621 -0.674 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.555 HG22 ' HB3' ' A' ' 83' ' ' PHE . 42.7 pt -116.1 149.24 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.822 -0.549 . . . . 0.0 110.803 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 m -147.3 -172.1 3.94 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -142.83 147.28 35.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.158 -0.964 . . . . 0.0 110.852 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -135.73 152.96 76.98 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 110.079 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -88.15 37.13 0.43 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.318 1.167 . . . . 0.0 111.031 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.598 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.0 tp -106.7 -3.46 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.438 -0.789 . . . . 0.0 111.077 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.494 ' CD2' HG23 ' A' ' 8' ' ' ILE . 42.9 m-85 -122.08 76.91 1.34 Allowed 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 122.769 1.271 . . . . 0.0 111.257 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -108.61 169.97 8.32 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.671 177.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.93 -32.69 71.02 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 -176.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -87.99 11.5 15.78 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 120.503 -1.373 . . . . 0.0 112.336 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.598 HD22 ' O ' ' A' ' 8' ' ' ILE . 40.1 tp -74.61 121.5 21.7 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.2 -0.937 . . . . 0.0 110.227 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.4 m -67.4 138.99 57.12 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.696 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.747 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -68.29 -13.7 62.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.73 -0.606 . . . . 0.0 111.797 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -72.32 -14.49 76.95 Favored Glycine 0 N--CA 1.497 2.703 0 O-C-N 120.98 -1.075 . . . . 0.0 111.312 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.3 t -92.84 -14.88 27.14 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.125 -1.22 . . . . 0.0 111.405 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.747 HG12 ' O ' ' A' ' 15' ' ' MET . 11.9 p -90.05 165.2 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.246 -0.909 . . . . 0.0 111.0 -178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -56.96 -45.38 82.9 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.573 -0.705 . . . . 0.0 110.347 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.8 m -80.89 80.08 7.44 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.32 -80.42 0.43 Allowed 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.116 -0.99 . . . . 0.0 113.216 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -138.86 10.08 2.62 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.102 -0.999 . . . . 0.0 112.605 -177.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.61 -150.46 0.45 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -65.65 -40.04 92.05 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.67 -0.9 . . . . 0.0 109.867 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.467 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . 22.5 m-70 -99.94 8.95 43.69 Favored 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.464 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.19 137.54 49.16 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.647 HD13 HG11 ' A' ' 37' ' ' VAL . 88.5 mt -98.65 -4.05 34.68 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.812 -0.817 . . . . 0.0 110.262 179.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 54.6 ttm -60.1 -39.55 86.56 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.324 -0.86 . . . . 0.0 110.763 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.83 -75.55 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.443 -0.785 . . . . 0.0 111.723 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -70.06 -40.01 75.32 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.425 -0.797 . . . . 0.0 110.387 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 37' ' ' VAL . 94.4 m-85 -119.18 89.43 39.54 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.869 -0.519 . . . . 0.0 110.896 -178.081 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.07 -4.71 15.79 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 O-C-N 123.251 1.132 . . . . 0.0 111.073 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 17.5 p -131.41 155.35 47.47 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.147 -0.971 . . . . 0.0 110.219 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.925 HD11 HG21 ' A' ' 43' ' ' VAL . 58.2 tp -85.1 113.11 21.25 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.326 -0.55 . . . . 0.0 109.769 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 155.24 33.4 0.03 OUTLIER Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.609 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 2.6 mt-10 -157.8 -47.77 0.06 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.248 -1.148 . . . . 0.0 109.954 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.647 HG11 HD13 ' A' ' 27' ' ' LEU . 2.4 t -62.25 -58.0 19.98 Favored Pre-proline 0 N--CA 1.497 1.877 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.661 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.517 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.3 Cg_endo -78.66 -31.62 2.46 Favored 'Trans proline' 0 C--N 1.319 -0.995 0 O-C-N 123.282 1.148 . . . . 0.0 109.29 177.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.26 -61.73 0.66 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.588 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 5.3 t80 161.21 -50.85 0.0 OUTLIER Pre-proline 0 N--CA 1.514 2.752 0 C-N-CA 123.664 0.785 . . . . 0.0 110.19 177.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.588 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 50.5 Cg_endo -101.87 18.41 0.25 Allowed 'Trans proline' 0 C--N 1.326 -0.652 0 C-N-CA 121.744 1.629 . . . . 0.0 111.62 -177.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.4 ' HB3' ' O ' ' A' ' 72' ' ' PHE . 74.9 m-20 -135.95 55.85 1.85 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.253 -0.904 . . . . 0.0 110.277 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.926 HG23 HG11 ' A' ' 76' ' ' VAL . 12.6 p -130.32 141.8 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 CA-C-O 121.681 0.753 . . . . 0.0 110.524 -179.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -172.27 179.18 44.03 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.429 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.78 154.61 27.02 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.319 -1.912 . . . . 0.0 108.319 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.616 HG22 ' CE1' ' A' ' 83' ' ' PHE . 5.7 pt -143.44 160.05 52.74 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.512 -0.993 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -69.07 -17.83 40.51 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.142 1.228 . . . . 0.0 114.033 -177.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -93.65 25.41 3.54 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.71 -1.244 . . . . 0.0 112.387 -178.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.509 HG12 HG13 ' A' ' 46' ' ' ILE . 37.1 mm -119.94 120.1 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.024 -1.047 . . . . 0.0 109.012 178.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.55 -44.12 29.62 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.195 -0.941 . . . . 0.0 111.977 -178.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.26 -141.55 6.87 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.078 -1.534 . . . . 0.0 111.424 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.488 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.3 t90 -41.49 -29.43 0.16 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -178.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -141.44 57.21 1.52 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.021 -1.049 . . . . 0.0 111.206 -178.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.41 ' HB3' ' HA ' ' A' ' 49' ' ' ILE . 18.2 m -69.05 144.34 95.39 Favored Pre-proline 0 N--CA 1.493 1.713 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.673 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.449 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.6 Cg_endo -74.15 -14.41 23.3 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.328 1.173 . . . . 0.0 111.619 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 70.3 m -103.43 18.4 21.9 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.385 -0.822 . . . . 0.0 111.735 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.467 ' HB2' ' HB3' ' A' ' 25' ' ' HIS . 3.5 m -69.97 139.94 52.89 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.987 -1.071 . . . . 0.0 109.112 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.33 27.66 57.22 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 97.7 m -106.52 138.15 43.22 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.507 -0.996 . . . . 0.0 110.164 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.634 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.2 t -80.04 131.59 35.81 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.389 0.614 . . . . 0.0 110.889 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.444 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.5 m95 -133.99 152.15 51.74 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.541 -0.724 . . . . 0.0 109.379 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.2 tttm -121.69 138.15 54.46 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 120.933 -1.105 . . . . 0.0 110.583 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.444 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.7 t -113.7 126.79 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.615 -0.678 . . . . 0.0 111.344 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.9 m -119.54 141.14 49.49 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.742 -0.599 . . . . 0.0 110.48 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 10.9 pt -119.95 163.93 25.16 Favored Pre-proline 0 N--CA 1.503 2.183 0 O-C-N 121.186 -0.947 . . . . 0.0 110.906 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.9 Cg_endo -62.1 -27.56 79.12 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.564 1.509 . . . . 0.0 113.201 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -62.51 -39.95 95.17 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.244 -0.91 . . . . 0.0 110.045 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.09 60.31 0.31 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -159.92 151.11 19.48 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 86.1 p -151.64 157.77 42.58 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.007 0.908 . . . . 0.0 111.664 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.491 HD12 HD11 ' A' ' 73' ' ' ILE . 41.8 pt -137.83 161.65 32.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.4 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 97.2 m-85 -102.12 121.29 41.93 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 118.581 -1.248 . . . . 0.0 109.187 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.491 HD11 HD12 ' A' ' 71' ' ' ILE . 48.3 mm -110.78 130.6 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.524 ' HD3' HG12 ' A' ' 37' ' ' VAL . 52.4 ttt180 -99.33 132.82 44.39 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.112 -0.993 . . . . 0.0 109.251 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.9 146.67 13.25 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.926 HG11 HG23 ' A' ' 43' ' ' VAL . 7.5 p -169.76 -33.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.863 -0.787 . . . . 0.0 110.323 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.521 ' CG ' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -130.0 171.89 12.3 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 120.925 -1.11 . . . . 0.0 108.711 179.737 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -98.09 142.43 29.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.669 -0.644 . . . . 0.0 109.791 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -114.5 144.79 18.45 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -89.22 103.4 16.02 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.578 -0.954 . . . . 0.0 110.526 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 50.12 56.98 10.73 Favored Glycine 0 N--CA 1.497 2.765 0 O-C-N 121.681 -0.637 . . . . 0.0 111.724 178.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.6 -163.5 33.59 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.045 -1.55 . . . . 0.0 111.915 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.616 ' CE1' HG22 ' A' ' 46' ' ' ILE 0.263 0.1 OUTLIER -123.25 122.5 38.52 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -178.908 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -124.12 129.91 51.65 Favored 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 118.892 -1.123 . . . . 0.0 109.83 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.3 m -132.31 172.88 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.376 -178.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -54.15 156.79 5.12 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.551 -0.718 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.64 -18.72 32.7 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.477 1.251 . . . . 0.0 110.051 179.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -80.02 -40.97 26.71 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.088 -1.008 . . . . 0.0 108.991 178.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.59 89.24 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -59.99 -50.05 75.26 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.808 -0.557 . . . . 0.0 110.573 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.3 m -59.92 -40.05 87.57 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.929 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -69.0 -40.13 78.89 Favored 'General case' 0 N--CA 1.495 1.803 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.29 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 49.7 tp -71.97 -43.36 65.27 Favored 'General case' 0 N--CA 1.496 1.871 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.478 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -92.34 -40.51 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.462 -0.774 . . . . 0.0 111.54 -177.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 126.63 -34.96 3.03 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 95.2 p -152.69 164.63 37.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.664 -0.903 . . . . 0.0 110.262 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 69.8 p -90.18 2.61 55.17 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.42 -0.8 . . . . 0.0 111.194 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -69.94 -27.75 65.01 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.327 -0.858 . . . . 0.0 110.738 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.01 -41.72 83.7 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.57 -0.706 . . . . 0.0 110.619 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.56 -80.7 1.63 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 59.9 ttp180 -130.86 138.88 50.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.565 -0.962 . . . . 0.0 111.042 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.54 114.65 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.608 -0.682 . . . . 0.0 110.428 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -82.46 171.02 14.6 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.665 -0.647 . . . . 0.0 110.588 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.7 t30 60.13 48.35 8.48 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.743 -0.598 . . . . 0.0 111.828 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.443 HG11 HG21 ' A' ' 3' ' ' ILE . 60.7 t -98.1 124.56 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.325 179.276 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t-20 -82.57 134.24 35.19 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.931 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.421 ' C ' HG13 ' A' ' 108' ' ' VAL . 54.4 p90 -135.75 140.85 44.67 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.8 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.421 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.1 m -150.01 154.67 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.237 -0.914 . . . . 0.0 111.001 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.444 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.4 tt0 -74.64 141.53 44.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.713 -0.617 . . . . 0.0 109.834 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.634 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.0 m -139.06 168.89 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 120.047 -0.661 . . . . 0.0 109.553 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -59.92 144.34 49.19 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.356 -0.84 . . . . 0.0 110.964 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.481 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.4 tt -59.9 -36.18 76.43 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.562 -0.711 . . . . 0.0 111.035 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.4 m -56.48 -39.16 72.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.502 -0.749 . . . . 0.0 109.836 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -61.52 -38.57 87.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.562 -0.711 . . . . 0.0 110.859 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.22 -49.61 76.94 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.301 -0.874 . . . . 0.0 109.846 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.434 HD11 HD21 ' A' ' 112' ' ' LEU . 83.7 mt -69.83 -39.92 78.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.632 -0.668 . . . . 0.0 110.662 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -65.02 -40.49 94.95 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.463 -0.773 . . . . 0.0 110.643 -179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.12 -43.75 70.29 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.99 94.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.765 -0.844 . . . . 0.0 110.264 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.389 -179.86 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.486 HG11 ' CE1' ' A' ' 107' ' ' TYR . 35.1 m . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 p -112.47 141.95 45.6 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 122.15 0.976 . . . . 0.0 111.575 -178.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.782 HG12 HG21 ' A' ' 105' ' ' VAL . 35.2 pt -119.97 150.02 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.965 179.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 7.6 m -144.87 -173.0 3.95 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -140.44 147.5 39.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.477 -0.764 . . . . 0.0 109.489 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.658 ' HB3' HG22 ' A' ' 8' ' ' ILE . 8.5 m-20 -138.55 147.68 55.89 Favored Pre-proline 0 N--CA 1.491 1.593 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.823 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -74.39 -6.08 17.83 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 O-C-N 123.455 1.239 . . . . 0.0 110.532 178.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.67 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.3 tp -64.43 -15.86 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.36 -0.837 . . . . 0.0 111.095 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.532 ' CD2' HG23 ' A' ' 8' ' ' ILE . 43.2 m-85 -112.5 69.31 0.69 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 122.72 1.248 . . . . 0.0 110.786 178.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.28 170.03 8.16 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.523 -1.217 . . . . 0.0 108.309 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.9 -32.44 70.75 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -175.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -89.64 11.49 19.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 120.344 -1.473 . . . . 0.0 112.182 -177.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.67 HD22 ' O ' ' A' ' 8' ' ' ILE . 28.5 tp -71.6 126.32 29.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.317 -0.864 . . . . 0.0 109.974 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.5 p -70.7 136.9 49.33 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.247 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.611 ' O ' HG12 ' A' ' 18' ' ' VAL . 94.6 mmm -64.66 -15.1 60.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.802 -0.561 . . . . 0.0 111.823 -178.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.66 -12.49 84.43 Favored Glycine 0 N--CA 1.494 2.537 0 O-C-N 121.066 -1.021 . . . . 0.0 111.297 -179.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -85.88 -7.21 58.85 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.113 -1.228 . . . . 0.0 111.935 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.611 HG12 ' O ' ' A' ' 15' ' ' MET . 11.0 p -101.4 168.89 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.03 -1.044 . . . . 0.0 110.672 -179.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.03 -42.38 94.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.605 -0.685 . . . . 0.0 109.881 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 70.42 8.47 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.2 p -92.86 -74.89 0.51 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.782 -0.573 . . . . 0.0 109.691 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -130.01 169.93 14.63 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 121.17 -149.0 17.41 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -179.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -73.48 -44.16 58.58 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.641 -0.917 . . . . 0.0 111.05 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 44.8 m-70 -98.28 8.9 44.18 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.297 -0.877 . . . . 0.0 110.711 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.2 129.94 46.7 Favored Glycine 0 N--CA 1.496 2.657 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.8 mt -100.03 -4.21 30.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 122.041 -0.682 . . . . 0.0 110.245 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 57.2 ttm -61.67 -37.88 85.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.241 -0.912 . . . . 0.0 109.876 179.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.5 -74.11 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.671 -0.643 . . . . 0.0 112.059 -177.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -69.96 -40.38 75.44 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.273 -0.892 . . . . 0.0 110.659 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.555 ' CG ' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -120.25 86.3 37.91 Favored Pre-proline 0 N--CA 1.492 1.664 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -178.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.37 -11.18 30.75 Favored 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.383 1.202 . . . . 0.0 111.145 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -130.04 141.19 50.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.177 -0.952 . . . . 0.0 110.105 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.975 HD11 HG21 ' A' ' 43' ' ' VAL . 34.7 tp -69.68 117.46 11.32 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.684 -0.635 . . . . 0.0 110.491 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.43 33.59 0.03 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.079 179.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -159.8 -46.07 0.05 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.176 -1.19 . . . . 0.0 110.64 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.555 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -63.0 -59.33 12.75 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.359 -0.838 . . . . 0.0 108.83 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.44 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 47.2 Cg_endo -74.35 -31.77 7.08 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 123.222 1.117 . . . . 0.0 109.408 178.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.437 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 134.57 -63.39 0.61 Allowed Glycine 0 N--CA 1.486 1.979 0 N-CA-C 107.116 -2.393 . . . . 0.0 107.116 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.61 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 161.19 -55.12 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.7 0 C-N-CA 123.457 0.703 . . . . 0.0 110.484 177.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.813 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.4 Cg_endo -100.68 3.52 0.7 Allowed 'Trans proline' 0 C--N 1.322 -0.828 0 C-N-CA 121.068 1.178 . . . . 0.0 112.09 -178.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.471 HD22 HD11 ' A' ' 71' ' ' ILE . 19.3 m120 -120.19 42.13 3.03 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 0.0 109.415 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.975 HG21 HD11 ' A' ' 34' ' ' LEU . 7.6 p -109.89 142.64 21.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.742 0.782 . . . . 0.0 109.145 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -167.36 172.99 42.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.91 161.54 29.43 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 HD12 ' A' ' 49' ' ' ILE . 18.0 pt -144.49 159.44 51.51 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.705 -0.879 . . . . 0.0 110.684 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HD2' ' CE2' ' A' ' 83' ' ' PHE . 53.7 Cg_endo -71.25 -14.91 31.68 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.511 1.474 . . . . 0.0 113.115 -178.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -91.55 19.45 6.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.016 -1.053 . . . . 0.0 111.948 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.507 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 62.4 mt -119.97 120.22 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.89 . . . . 0.0 108.938 177.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.69 -41.32 21.51 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -177.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 177.29 -126.32 1.09 Allowed Glycine 0 N--CA 1.492 2.38 0 C-N-CA 118.144 -1.979 . . . . 0.0 112.741 -178.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -40.01 -34.6 0.3 Allowed 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -177.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 39.9 p-10 -172.08 82.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.719 -1.238 . . . . 0.0 109.713 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.461 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 8.1 t -68.25 150.65 97.64 Favored Pre-proline 0 N--CA 1.495 1.793 0 O-C-N 121.69 -0.631 . . . . 0.0 110.678 -178.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.462 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 41.1 Cg_endo -66.96 -15.86 48.1 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 123.513 1.27 . . . . 0.0 111.194 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' THR . 57.7 m -106.84 9.73 30.86 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.327 -0.858 . . . . 0.0 111.446 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -60.84 141.86 56.7 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.846 -1.159 . . . . 0.0 109.947 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.8 17.13 58.69 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.594 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -91.49 167.31 12.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.282 -1.128 . . . . 0.0 110.055 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -110.13 136.09 49.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.943 -0.473 . . . . 0.0 110.64 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -132.02 137.63 47.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.497 -0.752 . . . . 0.0 109.096 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 77.4 tttt -100.88 133.31 45.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.298 -0.876 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.9 t -109.98 120.49 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.616 -0.678 . . . . 0.0 109.71 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 44.7 m -116.98 141.89 47.65 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.742 -0.599 . . . . 0.0 111.312 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.446 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 36.8 pt -119.61 163.4 27.57 Favored Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.539 -0.726 . . . . 0.0 110.508 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -61.95 -24.69 77.2 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.744 1.391 . . . . 0.0 112.675 -178.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -63.84 -40.08 95.73 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.226 -0.921 . . . . 0.0 109.723 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.67 62.02 0.3 Allowed Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 35.8 t-20 -160.06 153.16 21.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.661 -0.905 . . . . 0.0 109.214 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.679 ' HA ' HD11 ' A' ' 93' ' ' LEU . 83.2 p -150.04 160.1 43.9 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.18 0.991 . . . . 0.0 112.246 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.471 HD11 HD22 ' A' ' 42' ' ' ASN . 12.6 tt -138.96 159.38 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.436 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 93.1 m-85 -104.36 122.35 45.29 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 47.1 mm -114.85 130.01 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.469 -0.77 . . . . 0.0 110.314 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.686 HH12 HG23 ' A' ' 43' ' ' VAL . 5.2 ttp-105 -97.65 139.43 33.55 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.01 146.69 50.51 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -153.1 -43.55 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 122.072 -0.664 . . . . 0.0 109.369 179.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.419 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 18.1 t70 -115.37 162.46 17.1 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.237 -0.915 . . . . 0.0 110.352 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.507 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 26.4 t -79.64 156.8 27.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.818 -0.551 . . . . 0.0 109.608 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -140.62 126.42 3.14 Favored Glycine 0 N--CA 1.482 1.721 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.401 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -59.92 -40.0 87.38 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -167.77 169.13 41.1 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 107.875 -2.09 . . . . 0.0 107.875 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 64.52 -166.84 29.81 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.186 -1.185 . . . . 0.0 112.571 177.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.546 ' HB2' HG22 ' A' ' 3' ' ' ILE . 80.1 m-85 -139.17 139.78 37.66 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 122.225 -0.573 . . . . 0.0 110.754 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.41 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 0.9 OUTLIER -123.58 130.24 52.38 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.019 -1.051 . . . . 0.0 110.14 178.495 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.4 m -129.02 166.53 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.873 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.8 m-20 -54.61 153.65 10.29 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.53 -0.731 . . . . 0.0 110.19 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.24 -30.03 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.498 1.262 . . . . 0.0 110.241 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -69.92 -40.09 75.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.094 -1.004 . . . . 0.0 108.603 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.813 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -67.02 -38.28 85.66 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.11 -49.48 77.47 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.311 0.577 . . . . 0.0 110.099 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.8 m -59.96 -39.73 86.6 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.707 -0.621 . . . . 0.0 110.947 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -68.65 -39.99 80.44 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.707 -178.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.679 HD11 ' HA ' ' A' ' 70' ' ' SER . 52.7 tp -69.94 -40.62 75.37 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.475 -0.765 . . . . 0.0 112.047 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -96.65 -35.98 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.218 0 O-C-N 121.246 -0.909 . . . . 0.0 111.363 -177.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.77 -38.73 2.27 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.291 -1.924 . . . . 0.0 108.291 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 23.1 t -150.0 133.58 16.65 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.836 -0.802 . . . . 0.0 109.271 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.565 HG23 ' O ' ' A' ' 97' ' ' THR . 9.5 t -90.67 66.69 6.22 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.366 -0.834 . . . . 0.0 110.628 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -114.83 -27.18 7.51 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.624 -0.673 . . . . 0.0 110.637 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.08 -39.93 87.8 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -0.76 . . . . 0.0 110.567 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 103.15 -50.94 0.87 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -157.84 160.02 37.29 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.709 -0.877 . . . . 0.0 110.237 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.52 129.97 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 109.83 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -98.14 169.9 9.28 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.206 -179.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 61.6 t30 59.91 41.34 17.93 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.564 -0.71 . . . . 0.0 110.219 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.782 HG21 HG12 ' A' ' 3' ' ' ILE . 61.3 t -89.26 122.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.23 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 -80.52 136.13 36.23 Favored 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.12 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.486 ' CE1' HG11 ' A' ' 1' ' ' VAL . 39.6 p90 -134.87 140.98 46.22 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-O 121.278 0.561 . . . . 0.0 111.532 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.36 144.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.714 -0.616 . . . . 0.0 110.61 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -73.21 144.43 46.79 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.612 -0.68 . . . . 0.0 110.318 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.92 168.89 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.618 -0.676 . . . . 0.0 110.509 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -59.96 144.15 49.86 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.547 -0.721 . . . . 0.0 110.448 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.448 HD21 ' CD1' ' A' ' 116' ' ' ILE . 9.4 tt -60.79 -40.03 91.07 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.567 -0.708 . . . . 0.0 110.998 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.9 m -54.61 -35.57 63.53 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.612 -0.68 . . . . 0.0 111.592 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -69.99 -22.13 63.16 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.169 -0.957 . . . . 0.0 111.457 -178.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 96.5 m -75.65 -48.64 21.23 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.2 -0.938 . . . . 0.0 109.35 178.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.448 ' CD1' HD21 ' A' ' 112' ' ' LEU . 94.8 mt -69.96 -40.03 78.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 CA-C-O 121.32 0.581 . . . . 0.0 109.773 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -67.18 -40.03 86.5 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.66 -0.65 . . . . 0.0 110.129 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.7 -49.96 39.64 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.68 -39.92 90.26 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.551 -0.97 . . . . 0.0 110.39 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.316 -179.774 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.482 HG21 ' CD1' ' A' ' 107' ' ' TYR . 34.5 m . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.438 0.637 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 m -113.14 145.19 41.37 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.034 0.921 . . . . 0.0 111.035 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.673 HG12 HG21 ' A' ' 105' ' ' VAL . 19.6 pt -115.19 146.36 19.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.25 -172.45 3.87 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.9 p90 -143.87 149.95 37.7 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.075 178.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.72 149.18 72.71 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.547 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -85.12 9.26 4.21 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.39 1.205 . . . . 0.0 111.276 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.418 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.3 pt -90.05 -0.21 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.113 -0.992 . . . . 0.0 111.068 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 m-85 -117.35 66.8 0.73 Allowed 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.543 1.164 . . . . 0.0 109.569 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.7 170.64 8.04 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 114.834 -1.076 . . . . 0.0 108.231 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.68 -31.42 64.43 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -89.02 12.93 14.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 120.513 -1.367 . . . . 0.0 112.033 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.458 ' HA ' HD22 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -71.04 118.42 13.8 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.253 -0.904 . . . . 0.0 110.091 -179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.456 ' N ' HD13 ' A' ' 13' ' ' LEU . 40.6 m -68.22 137.63 54.94 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 121.702 0.763 . . . . 0.0 110.43 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.575 ' O ' HG12 ' A' ' 18' ' ' VAL . 5.3 mmt -62.26 -20.02 63.83 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -73.85 -13.68 80.53 Favored Glycine 0 N--CA 1.498 2.79 0 O-C-N 121.037 -1.04 . . . . 0.0 112.079 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.5 -7.77 46.44 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.944 -1.327 . . . . 0.0 112.183 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.773 HG21 HG22 ' A' ' 76' ' ' VAL . 9.5 p -100.03 169.97 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.93 -1.106 . . . . 0.0 110.19 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.783 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.05 -43.5 82.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.279 -0.888 . . . . 0.0 109.711 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.18 83.41 6.06 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.4 m -94.12 -80.0 0.41 Allowed 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.254 -0.904 . . . . 0.0 112.557 -177.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -140.93 11.83 2.23 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.201 -0.937 . . . . 0.0 112.553 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.32 -146.12 0.31 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -69.29 -39.99 77.99 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.812 -0.817 . . . . 0.0 109.268 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 80.7 m-70 -91.48 0.92 57.45 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.689 -0.632 . . . . 0.0 110.696 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.85 132.35 44.37 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.562 HD22 HG21 ' A' ' 37' ' ' VAL . 85.9 mt -98.82 -5.46 31.05 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 122.125 -0.633 . . . . 0.0 110.149 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.428 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.6 ttm -63.24 -37.77 88.54 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.277 -0.889 . . . . 0.0 111.262 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -74.05 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.522 -0.736 . . . . 0.0 111.667 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -70.04 -39.9 75.44 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 109.687 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.45 ' CD2' HG23 ' A' ' 37' ' ' VAL . 44.2 m-85 -120.15 85.39 35.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 39.6 Cg_endo -66.53 -12.14 34.55 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 O-C-N 123.258 1.136 . . . . 0.0 111.228 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.9 m -129.18 146.98 50.99 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.228 -0.92 . . . . 0.0 110.349 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.74 HD11 HG21 ' A' ' 43' ' ' VAL . 45.1 tp -72.61 119.73 17.24 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.714 -0.616 . . . . 0.0 110.779 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.34 34.19 0.04 OUTLIER Glycine 0 N--CA 1.496 2.642 0 C-N-CA 120.067 -1.063 . . . . 0.0 110.485 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.448 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 21.7 tp10 -158.09 -49.18 0.06 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.298 -1.119 . . . . 0.0 110.485 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.562 HG21 HD22 ' A' ' 27' ' ' LEU . 2.7 t -60.63 -59.43 13.88 Favored Pre-proline 0 N--CA 1.499 2.001 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.456 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.2 Cg_endo -76.02 -29.78 6.36 Favored 'Trans proline' 0 N--CA 1.487 1.129 0 O-C-N 123.258 1.136 . . . . 0.0 109.335 177.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.85 -63.0 0.63 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 -178.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.522 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.9 t80 165.18 -72.22 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.571 0 C-N-CA 123.42 0.688 . . . . 0.0 110.017 177.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 57.4 Cg_endo -79.09 -18.99 10.99 Favored 'Trans proline' 0 N--CA 1.492 1.424 0 O-C-N 122.409 0.689 . . . . 0.0 111.579 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.0 m-20 -93.93 55.74 2.16 Favored 'General case' 0 N--CA 1.489 1.491 0 CA-C-O 121.8 0.809 . . . . 0.0 109.71 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.74 HG21 HD11 ' A' ' 34' ' ' LEU . 11.7 p -118.92 129.33 75.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-O 121.385 0.612 . . . . 0.0 109.655 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -161.68 167.59 36.51 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 119.991 -1.099 . . . . 0.0 111.279 -179.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.68 164.92 29.33 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 83' ' ' PHE . 10.8 pt -143.55 165.87 22.78 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.824 -0.81 . . . . 0.0 109.762 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 56.9 Cg_endo -77.12 -10.57 17.86 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 120.972 1.115 . . . . 0.0 113.125 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -95.41 16.65 16.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.071 -1.018 . . . . 0.0 111.916 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.802 HG23 ' CB ' ' A' ' 54' ' ' SER . 63.7 mt -109.34 121.31 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.048 -1.032 . . . . 0.0 109.256 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.52 -42.34 43.56 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.426 -0.796 . . . . 0.0 113.13 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.783 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 165.97 -132.59 2.69 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.576 -1.773 . . . . 0.0 112.013 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.526 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 39.3 t90 -44.59 -30.68 0.95 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -178.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -143.62 63.2 1.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.358 -0.839 . . . . 0.0 110.134 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.802 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.8 p -66.24 136.32 95.21 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.804 -0.56 . . . . 0.0 111.118 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -73.54 -21.34 19.54 Favored 'Trans proline' 0 C--N 1.32 -0.974 0 O-C-N 123.338 1.178 . . . . 0.0 111.104 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.4 m -96.48 12.01 32.96 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.388 -0.82 . . . . 0.0 111.089 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.56 143.75 56.85 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.124 -0.985 . . . . 0.0 109.713 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.04 25.27 58.08 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 m -106.28 137.35 44.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.487 -1.007 . . . . 0.0 109.857 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.67 131.13 35.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.911 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -130.31 138.56 50.51 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -107.32 135.65 48.47 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.272 -0.893 . . . . 0.0 109.518 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.7 t -111.6 127.82 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.188 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 95.4 m -120.03 139.15 52.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.967 -0.458 . . . . 0.0 110.637 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.456 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 34.3 pt -117.74 163.73 22.88 Favored Pre-proline 0 N--CA 1.5 2.051 0 O-C-N 121.363 -0.836 . . . . 0.0 110.557 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -61.54 -23.04 75.94 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.371 1.381 . . . . 0.0 112.689 -178.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -66.52 -40.02 88.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.375 -0.828 . . . . 0.0 109.697 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.29 57.4 0.32 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -150.78 148.62 28.73 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.3 p -151.09 156.23 40.61 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-O 121.93 0.871 . . . . 0.0 111.372 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.657 ' CD1' HD11 ' A' ' 73' ' ' ILE . 43.6 pt -139.46 164.23 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -109.09 126.59 53.35 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.097 -1.041 . . . . 0.0 108.785 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.784 HD13 ' CG1' ' A' ' 85' ' ' VAL . 87.6 mt -129.38 140.0 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.688 -178.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -98.04 139.5 33.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.547 -0.72 . . . . 0.0 109.872 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.71 150.28 39.06 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.773 HG22 HG21 ' A' ' 18' ' ' VAL . 11.9 p -149.45 -39.56 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.751 -0.852 . . . . 0.0 109.901 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.436 ' N ' HG13 ' A' ' 76' ' ' VAL . 15.7 t70 -129.32 168.02 16.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.224 -0.922 . . . . 0.0 110.5 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.478 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 40.6 t -75.28 155.89 36.21 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.618 0.723 . . . . 0.0 111.739 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -137.66 132.26 5.84 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -60.02 -33.05 71.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 109.871 178.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.31 82.37 0.05 OUTLIER Glycine 0 N--CA 1.498 2.788 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.599 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 151.97 -151.66 23.52 Favored Glycine 0 N--CA 1.499 2.866 0 C-N-CA 119.893 -1.146 . . . . 0.0 110.516 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 46' ' ' ILE . 87.0 m-85 -136.02 130.77 34.06 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.295 -1.121 . . . . 0.0 111.381 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.458 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 4.4 t-20 -115.61 127.52 55.28 Favored 'General case' 0 N--CA 1.502 2.152 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 178.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.784 ' CG1' HD13 ' A' ' 73' ' ' ILE . 33.2 m -129.95 164.62 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.363 -177.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-20 -54.54 157.1 5.41 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.328 -0.857 . . . . 0.0 109.897 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.37 -14.35 43.79 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.268 1.141 . . . . 0.0 110.657 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.7 m -82.71 -39.14 22.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.975 -1.078 . . . . 0.0 109.314 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.77 -39.82 84.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.448 -0.783 . . . . 0.0 109.037 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -59.99 -50.02 75.4 Favored 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 120.081 -0.648 . . . . 0.0 110.762 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 73.2 m -60.14 -39.97 88.21 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.368 -0.832 . . . . 0.0 111.071 -178.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -69.68 -40.0 76.66 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.871 -0.732 . . . . 0.0 111.062 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 60.2 tp -70.62 -43.7 68.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.602 -0.686 . . . . 0.0 111.557 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.0 -42.61 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.402 -0.811 . . . . 0.0 111.579 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -20.22 7.93 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.3 t -156.21 159.52 39.02 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.213 -1.169 . . . . 0.0 110.944 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 65.7 p -98.42 6.89 46.86 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.543 -0.723 . . . . 0.0 110.812 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -69.17 -36.76 77.7 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.362 -0.836 . . . . 0.0 111.708 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.52 -40.12 86.09 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.379 -0.826 . . . . 0.0 110.696 -178.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 82.89 -75.03 2.44 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -127.78 133.17 49.46 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.631 -0.923 . . . . 0.0 109.857 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.14 120.14 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.467 -0.771 . . . . 0.0 110.116 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -86.16 178.43 7.2 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.359 0.599 . . . . 0.0 110.707 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.0 t-20 58.88 49.62 9.56 Favored 'General case' 0 N--CA 1.499 2.013 0 CA-C-O 121.28 0.562 . . . . 0.0 111.235 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.673 HG21 HG12 ' A' ' 3' ' ' ILE . 62.5 t -105.77 129.03 59.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.577 -179.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -86.61 137.07 32.78 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 118.936 -1.105 . . . . 0.0 109.477 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.482 ' CD1' HG21 ' A' ' 1' ' ' VAL . 38.0 p90 -135.45 141.52 45.41 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.93 -0.481 . . . . 0.0 110.536 -178.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.449 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.0 m -148.09 148.17 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.527 -0.733 . . . . 0.0 111.037 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -76.18 143.52 41.05 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.595 -0.691 . . . . 0.0 110.236 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -137.79 167.83 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.578 -0.701 . . . . 0.0 110.561 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -61.52 148.26 42.66 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.403 -0.81 . . . . 0.0 110.749 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.509 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.6 tt -62.11 -40.07 94.63 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.517 -0.739 . . . . 0.0 112.075 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 82.1 p -53.12 -37.34 61.68 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.263 -0.898 . . . . 0.0 111.023 -178.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -61.12 -37.93 84.54 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.518 -0.739 . . . . 0.0 112.005 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 82.5 m -67.37 -46.29 73.77 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.119 -0.988 . . . . 0.0 110.415 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.509 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.2 mt -70.04 -39.94 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 120.109 -0.636 . . . . 0.0 110.518 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.69 -39.98 88.34 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.13 -46.19 44.92 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.03 -44.15 94.83 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.625 -0.926 . . . . 0.0 110.473 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 13.5 m120 . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.186 179.823 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.434 HG23 ' HB ' ' A' ' 105' ' ' VAL . 27.3 m . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.291 0.567 . . . . 0.0 111.401 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.2 p -111.78 139.85 46.91 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.738 -0.601 . . . . 0.0 109.764 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.726 HG23 HG21 ' A' ' 105' ' ' VAL . 27.9 pt -110.86 144.77 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.734 -0.604 . . . . 0.0 110.854 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.35 -176.02 4.57 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.118 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -140.09 141.62 36.15 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.453 179.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -135.71 151.66 74.67 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.441 -0.787 . . . . 0.0 110.433 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -77.12 0.07 10.09 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.421 1.221 . . . . 0.0 111.506 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.74 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.4 tp -69.54 -14.03 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.276 -0.89 . . . . 0.0 111.274 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.537 ' CD2' HG23 ' A' ' 8' ' ' ILE . 36.7 m-85 -116.72 69.01 0.74 Allowed 'General case' 0 N--CA 1.493 1.683 0 CA-C-O 122.507 1.146 . . . . 0.0 111.335 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.35 168.67 8.92 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.723 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.0 -32.02 70.47 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -88.13 12.08 14.57 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.44 -1.412 . . . . 0.0 112.199 -177.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 8' ' ' ILE . 41.6 tp -73.75 122.36 22.26 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.419 -0.801 . . . . 0.0 109.714 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.6 m -66.29 137.39 56.91 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.72 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -64.32 -18.99 65.14 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.902 -0.499 . . . . 0.0 111.247 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.2 -14.38 76.64 Favored Glycine 0 N--CA 1.493 2.499 0 O-C-N 121.073 -1.017 . . . . 0.0 110.752 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.7 p -91.63 -15.65 28.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -1.194 . . . . 0.0 111.146 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.996 HG21 HG22 ' A' ' 76' ' ' VAL . 7.2 p -90.05 162.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.931 . . . . 0.0 109.63 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.818 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -54.93 -44.35 74.2 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.556 -0.715 . . . . 0.0 110.332 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 83.89 5.83 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.52 -79.98 0.48 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.295 -0.878 . . . . 0.0 113.152 -177.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -136.72 10.11 3.12 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.108 -0.995 . . . . 0.0 113.098 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.43 -152.77 0.89 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -64.25 -39.95 95.01 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.571 -0.958 . . . . 0.0 108.586 177.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 72.8 m-70 -90.15 0.46 57.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.748 -0.595 . . . . 0.0 110.207 179.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.05 133.96 52.48 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.619 HD13 HG11 ' A' ' 37' ' ' VAL . 66.0 mt -102.47 1.13 34.78 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 122.06 -0.67 . . . . 0.0 110.226 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.425 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 60.3 tpp -59.99 -38.48 82.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.315 -0.866 . . . . 0.0 111.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -66.41 0.46 Allowed 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.469 -0.769 . . . . 0.0 112.203 -176.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -75.13 -41.4 58.48 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.423 ' CD2' HG23 ' A' ' 37' ' ' VAL . 46.2 m-85 -120.05 87.46 39.06 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.845 -0.534 . . . . 0.0 109.665 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.3 -8.08 22.66 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.4 1.211 . . . . 0.0 111.543 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -133.51 146.47 51.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.26 -0.9 . . . . 0.0 110.5 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.816 HD11 HG21 ' A' ' 43' ' ' VAL . 29.1 tp -71.04 119.17 14.79 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.695 -0.628 . . . . 0.0 110.664 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.19 32.89 0.04 OUTLIER Glycine 0 N--CA 1.498 2.774 0 C-N-CA 120.007 -1.092 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -157.39 -48.63 0.07 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -1.122 . . . . 0.0 110.159 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.619 HG11 HD13 ' A' ' 27' ' ' LEU . 2.5 t -60.39 -58.61 18.06 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.489 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.2 Cg_endo -77.63 -30.8 3.67 Favored 'Trans proline' 0 C--N 1.318 -1.04 0 O-C-N 123.217 1.114 . . . . 0.0 109.537 177.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 129.97 -63.86 0.62 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 107.272 -2.331 . . . . 0.0 107.272 -178.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.723 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 164.53 -56.72 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.581 0 C-N-CA 123.37 0.668 . . . . 0.0 110.231 177.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.664 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 51.2 Cg_endo -101.03 15.55 0.37 Allowed 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 121.313 1.342 . . . . 0.0 111.246 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -125.32 47.52 2.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.296 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.816 HG21 HD11 ' A' ' 34' ' ' LEU . 14.6 p -125.47 140.04 49.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.914 0.864 . . . . 0.0 110.435 -179.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.87 175.35 42.76 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.441 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -88.62 159.47 29.43 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.689 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.1 pt -148.78 159.67 37.43 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.584 -0.95 . . . . 0.0 109.94 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -68.18 -15.9 43.49 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 121.245 1.297 . . . . 0.0 113.829 -177.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.568 ' H ' HD12 ' A' ' 46' ' ' ILE . 86.2 m-20 -91.7 21.26 4.87 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 120.706 -1.246 . . . . 0.0 113.129 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.596 HG23 ' CB ' ' A' ' 54' ' ' SER . 47.8 mm -112.28 122.59 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 177.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.63 -44.38 34.39 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.302 -0.874 . . . . 0.0 111.199 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.818 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.83 -134.93 3.5 Favored Glycine 0 N--CA 1.484 1.886 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.425 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.472 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 64.4 t90 -43.83 -26.78 0.28 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -145.4 72.81 1.33 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.921 . . . . 0.0 110.578 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.596 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.4 t -70.35 134.3 86.97 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.773 -0.58 . . . . 0.0 111.528 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.8 -23.98 16.01 Favored 'Trans proline' 0 C--N 1.32 -0.941 0 O-C-N 123.413 1.218 . . . . 0.0 110.545 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.42 12.44 33.23 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.445 -0.784 . . . . 0.0 111.058 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.7 t -72.21 148.8 45.2 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.335 -0.853 . . . . 0.0 110.584 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.86 43.15 9.14 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.41 ' O ' ' HG3' ' A' ' 74' ' ' ARG . 8.5 m -130.62 168.74 16.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.707 -0.878 . . . . 0.0 108.684 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 16.8 t -113.38 148.6 35.49 Favored 'General case' 0 N--CA 1.511 2.596 0 O-C-N 121.118 -0.989 . . . . 0.0 113.143 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.481 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 31.5 m95 -139.82 145.35 38.03 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.027 -1.046 . . . . 0.0 110.36 177.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 83.4 tttt -105.53 129.84 53.72 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.1 t -110.63 129.95 64.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.316 -0.865 . . . . 0.0 109.95 -178.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 47.1 m -121.63 138.79 54.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.849 -0.532 . . . . 0.0 111.61 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.511 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.6 pt -114.35 166.09 12.32 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.534 -0.729 . . . . 0.0 109.809 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.44 -25.9 76.26 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 O-C-N 123.217 1.114 . . . . 0.0 112.928 -178.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -64.81 -37.83 88.95 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.052 -1.03 . . . . 0.0 109.751 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.93 65.32 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -162.02 153.15 18.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.769 -0.842 . . . . 0.0 108.867 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 71.5 p -152.8 162.38 41.35 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 122.197 0.999 . . . . 0.0 112.456 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.426 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.9 pt -139.39 162.3 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.128 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -107.48 127.15 53.35 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.246 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.702 HD13 HG11 ' A' ' 85' ' ' VAL . 90.2 mt -125.9 134.93 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 110.493 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.546 ' HD3' HG12 ' A' ' 37' ' ' VAL . 65.9 ttt180 -95.49 133.92 38.93 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -63.59 144.17 48.8 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 120.296 -0.954 . . . . 0.0 110.76 -178.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.996 HG22 HG21 ' A' ' 18' ' ' VAL . 10.1 p -142.67 -41.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 122.104 -0.645 . . . . 0.0 109.906 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.579 ' HB2' HG23 ' A' ' 18' ' ' VAL . 6.3 t0 -133.67 171.57 13.95 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.114 -0.991 . . . . 0.0 109.496 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.9 t -83.75 146.66 28.05 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.443 -0.785 . . . . 0.0 110.635 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -108.12 148.71 16.73 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -89.07 101.67 14.32 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.487 -1.008 . . . . 0.0 110.601 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 52.79 53.46 32.99 Favored Glycine 0 N--CA 1.498 2.791 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.24 170.08 14.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.929 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.689 ' CD2' HG22 ' A' ' 46' ' ' ILE . 36.3 m-85 -93.13 128.94 39.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.749 -0.853 . . . . 0.0 109.996 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.7 t-20 -120.24 130.84 54.7 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.702 HG11 HD13 ' A' ' 73' ' ' ILE . 34.2 m -129.99 174.35 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.694 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -55.51 156.8 7.99 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.658 -0.651 . . . . 0.0 109.966 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.7 -27.43 38.26 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.387 1.204 . . . . 0.0 109.706 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.417 HG22 ' HE3' ' A' ' 92' ' ' LYS . 94.3 m -71.28 -40.19 71.07 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.24 -39.56 86.21 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.3 t80 -59.99 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.737 -0.602 . . . . 0.0 110.514 179.302 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 58.0 m -59.82 -36.92 77.78 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.534 -0.729 . . . . 0.0 110.631 -178.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.417 ' HE3' HG22 ' A' ' 88' ' ' THR . 98.3 mttt -69.72 -40.02 76.5 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.805 -0.758 . . . . 0.0 111.258 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.508 ' HG ' HG21 ' A' ' 65' ' ' ILE . 52.6 tp -69.95 -41.81 74.06 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.472 -0.768 . . . . 0.0 111.688 -178.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 94.9 t -100.2 -36.12 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.117 0 O-C-N 121.164 -0.96 . . . . 0.0 111.413 -178.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 117.84 -30.62 6.05 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.0 m -143.03 155.12 44.57 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.48 -1.012 . . . . 0.0 110.897 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.0 p -90.23 1.53 56.39 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.521 -0.737 . . . . 0.0 110.989 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.95 -22.18 63.2 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.381 -0.824 . . . . 0.0 110.702 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.29 -45.27 88.25 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.382 -0.824 . . . . 0.0 110.717 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.68 -77.45 2.11 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 43.0 ttm180 -135.44 132.1 37.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.641 -0.917 . . . . 0.0 110.682 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 57.5 t -116.19 115.97 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.523 -0.736 . . . . 0.0 109.739 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -84.37 172.53 11.69 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.766 0.794 . . . . 0.0 111.375 -178.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.6 t30 60.07 40.02 19.03 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.807 -0.558 . . . . 0.0 111.591 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.726 HG21 HG23 ' A' ' 3' ' ' ILE . 62.8 t -81.65 127.43 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.126 179.124 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -91.88 139.98 30.13 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.064 -1.054 . . . . 0.0 108.989 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.7 p90 -140.81 147.22 38.69 Favored 'General case' 0 N--CA 1.493 1.684 0 CA-C-O 121.502 0.668 . . . . 0.0 112.129 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.9 142.57 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.747 -0.595 . . . . 0.0 109.813 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.481 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 62.3 tt0 -84.93 140.44 31.1 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.459 -0.775 . . . . 0.0 110.843 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 27.1 m -129.93 175.32 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -62.62 150.75 39.9 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.391 -0.818 . . . . 0.0 111.004 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.506 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.1 tt -60.06 -39.94 87.76 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.74 -0.6 . . . . 0.0 110.795 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 61.9 m -52.55 -35.66 54.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.59 -0.694 . . . . 0.0 111.186 -178.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.1 -40.01 93.95 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.426 -0.796 . . . . 0.0 110.967 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.06 -49.34 77.77 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.293 -0.879 . . . . 0.0 110.14 179.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.506 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.7 mt -70.03 -39.94 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.611 -0.681 . . . . 0.0 110.834 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -66.19 -40.07 90.14 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.453 -0.78 . . . . 0.0 110.829 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.99 -57.48 3.02 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 -178.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.83 -43.2 94.68 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.518 -0.989 . . . . 0.0 110.469 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.0 t30 . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 117.796 -1.097 . . . . 0.0 110.916 179.83 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 121.187 0.517 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 p -112.67 147.01 37.66 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.707 -0.62 . . . . 0.0 111.019 -179.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.726 HG21 HG11 ' A' ' 105' ' ' VAL . 24.7 pt -113.8 147.9 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.796 -0.565 . . . . 0.0 110.161 179.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -145.84 -172.34 3.89 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.373 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -142.22 149.34 39.52 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.519 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -139.09 152.99 71.08 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.377 -0.827 . . . . 0.0 110.078 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -83.55 2.36 8.38 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 O-C-N 123.407 1.214 . . . . 0.0 111.39 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 8' ' ' ILE . 26.2 mm -76.5 -2.79 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.16 -0.962 . . . . 0.0 111.165 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -127.34 64.64 1.33 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 122.347 1.07 . . . . 0.0 110.765 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.15 173.97 6.21 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.602 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.04 -32.17 70.66 Favored 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -175.239 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -89.41 12.28 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 120.446 1.475 . . . . 0.0 112.084 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 8' ' ' ILE . 0.1 OUTLIER -69.71 114.55 8.02 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.303 -0.873 . . . . 0.0 109.301 179.426 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m -62.76 139.4 58.68 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.801 0.81 . . . . 0.0 110.631 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.68 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.1 mmm -62.56 -26.38 68.55 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.985 -179.415 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -19.44 76.44 Favored Glycine 0 N--CA 1.494 2.507 0 O-C-N 121.126 -0.984 . . . . 0.0 110.896 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 75.4 m -86.46 -17.77 33.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.228 -1.16 . . . . 0.0 111.375 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.927 HG21 HG22 ' A' ' 76' ' ' VAL . 7.3 p -89.98 160.02 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.328 -0.858 . . . . 0.0 109.676 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.17 -41.82 65.57 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.58 -0.7 . . . . 0.0 111.164 -178.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 82.92 4.83 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.294 -0.879 . . . . 0.0 108.835 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 m -91.42 -79.34 0.37 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.26 -0.9 . . . . 0.0 113.014 -177.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 t30 -144.09 14.82 1.69 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.772 -1.205 . . . . 0.0 112.474 -178.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.49 -147.19 0.37 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 108.671 -1.772 . . . . 0.0 108.671 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -69.58 -39.97 76.99 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.622 -0.928 . . . . 0.0 108.85 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.431 ' CD2' ' O ' ' A' ' 54' ' ' SER . 56.0 m-70 -89.93 0.04 57.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.698 -0.626 . . . . 0.0 110.208 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.74 133.05 52.3 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.567 HD13 HH21 ' A' ' 74' ' ' ARG . 65.0 mt -103.73 -0.07 29.86 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 122.139 -0.624 . . . . 0.0 110.47 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -64.0 -35.46 80.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.274 -0.891 . . . . 0.0 111.068 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.69 -66.16 0.47 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.41 -0.806 . . . . 0.0 111.883 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.436 ' HG3' ' N ' ' A' ' 31' ' ' TYR . 28.1 pt20 -72.71 -40.5 66.13 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.126 -0.984 . . . . 0.0 110.775 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.683 ' CD2' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -126.73 91.04 48.22 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.429 -0.794 . . . . 0.0 109.428 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.54 -9.89 27.41 Favored 'Trans proline' 0 N--CA 1.488 1.161 0 O-C-N 123.554 1.292 . . . . 0.0 112.04 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.9 m -129.03 143.95 51.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.098 -1.001 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.996 HD11 HG21 ' A' ' 43' ' ' VAL . 21.2 tp -69.93 120.02 15.02 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.878 -0.514 . . . . 0.0 110.546 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 147.36 30.32 0.07 OUTLIER Glycine 0 N--CA 1.496 2.697 0 C-N-CA 119.927 -1.13 . . . . 0.0 110.822 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -154.13 -50.9 0.09 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.26 -1.141 . . . . 0.0 110.286 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.683 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.7 t -61.66 -59.47 13.29 Favored Pre-proline 0 N--CA 1.497 1.904 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.439 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.0 Cg_endo -74.08 -32.08 7.25 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 O-C-N 123.258 1.136 . . . . 0.0 109.24 177.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.429 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 131.21 -65.05 0.6 Allowed Glycine 0 N--CA 1.484 1.856 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.602 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 1.7 t80 163.94 -69.66 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.793 0 C-N-CA 123.522 0.729 . . . . 0.0 110.393 177.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.547 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.9 Cg_endo -80.61 -0.22 10.47 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 120.387 0.725 . . . . 0.0 112.714 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -111.24 53.66 0.7 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.872 -1.143 . . . . 0.0 110.425 -178.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.996 HG21 HD11 ' A' ' 34' ' ' LEU . 14.4 p -132.44 141.09 46.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 121.859 0.838 . . . . 0.0 110.054 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.69 175.39 43.24 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.652 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.51 157.67 29.13 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 179.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.739 HD11 ' CA ' ' A' ' 75' ' ' GLY . 1.7 pt -156.01 160.06 31.07 Favored Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.592 -0.946 . . . . 0.0 109.771 179.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -67.02 -23.49 46.45 Favored 'Trans proline' 0 N--CA 1.502 1.983 0 C-N-CA 121.643 1.562 . . . . 0.0 115.291 -176.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -77.03 -5.02 47.13 Favored 'General case' 0 N--CA 1.506 2.374 0 O-C-N 120.381 -1.45 . . . . 0.0 112.497 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.587 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.1 mm -89.71 121.34 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.992 -1.067 . . . . 0.0 108.45 178.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.65 -43.55 47.07 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.243 -0.91 . . . . 0.0 111.537 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.98 -131.73 2.43 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.004 -1.569 . . . . 0.0 110.771 -179.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.478 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 61.9 t90 -48.71 -26.02 2.11 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.886 -0.773 . . . . 0.0 112.749 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.8 64.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.184 -0.948 . . . . 0.0 110.713 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.587 ' CB ' HG23 ' A' ' 49' ' ' ILE . 7.9 p -63.5 133.64 95.57 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.648 -0.658 . . . . 0.0 110.986 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.64 -19.47 27.9 Favored 'Trans proline' 0 N--CA 1.485 1.011 0 O-C-N 123.212 1.112 . . . . 0.0 110.911 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 59' ' ' THR . 54.0 p -99.04 10.8 40.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.378 -0.827 . . . . 0.0 111.025 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -65.13 143.1 58.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.135 -0.978 . . . . 0.0 110.056 -179.757 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.41 26.01 48.92 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.431 HG23 ' O ' ' A' ' 56' ' ' SER . 17.1 p -100.01 134.99 42.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.453 -1.027 . . . . 0.0 110.615 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.472 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.0 t -81.49 131.11 35.27 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.795 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.474 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 85.6 m95 -133.6 143.58 48.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.387 -0.82 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 tttm -110.67 130.98 55.43 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -111.02 129.73 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.349 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 69.0 m -120.04 135.55 54.89 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.868 -0.52 . . . . 0.0 110.604 -178.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.479 ' CG2' HD21 ' A' ' 93' ' ' LEU . 8.7 pt -113.8 164.83 14.92 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.425 -0.797 . . . . 0.0 110.849 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -62.96 -27.93 74.79 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.241 1.294 . . . . 0.0 112.937 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.401 ' HB3' ' CD1' ' A' ' 65' ' ' ILE . 22.5 t-20 -64.58 -40.0 94.76 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.239 -0.913 . . . . 0.0 109.701 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.18 60.01 0.28 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 179.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -153.7 148.7 26.71 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.699 -0.883 . . . . 0.0 108.745 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 47.1 m -149.37 155.49 40.56 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 119.3 -0.96 . . . . 0.0 112.233 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 43.3 pt -140.76 166.9 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.71 125.45 53.51 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.404 179.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.624 HD13 HG11 ' A' ' 85' ' ' VAL . 96.9 mt -124.1 138.63 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.466 -0.771 . . . . 0.0 110.518 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.567 HH21 HD13 ' A' ' 27' ' ' LEU . 1.9 ttp-105 -100.85 146.47 27.27 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.586 -0.696 . . . . 0.0 109.745 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.739 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -68.11 151.33 51.81 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.927 HG22 HG21 ' A' ' 18' ' ' VAL . 9.6 p -154.81 -44.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.826 -0.808 . . . . 0.0 109.522 179.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.571 ' HB2' HG23 ' A' ' 18' ' ' VAL . 5.2 t0 -129.62 169.82 14.56 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.059 -1.025 . . . . 0.0 109.622 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' ILE . 92.6 p -101.57 160.07 14.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.577 -0.702 . . . . 0.0 111.055 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.96 155.06 21.62 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 75.4 mtp85 -59.97 -31.41 69.87 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.484 -1.01 . . . . 0.0 109.679 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -176.69 -179.8 47.3 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 50.83 -178.88 0.04 OUTLIER Glycine 0 N--CA 1.496 2.675 0 O-C-N 121.434 -1.039 . . . . 0.0 111.87 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.612 ' CD2' HG22 ' A' ' 46' ' ' ILE . 42.7 m-85 -107.74 127.46 53.71 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.891 -0.77 . . . . 0.0 109.008 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 41.7 t-20 -117.83 127.73 54.16 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.511 -0.875 . . . . 0.0 108.64 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.624 HG11 HD13 ' A' ' 73' ' ' ILE . 34.4 m -130.79 172.37 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.697 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -55.58 152.79 16.96 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.534 -0.729 . . . . 0.0 109.528 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.21 -26.33 57.0 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.35 1.184 . . . . 0.0 110.186 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.773 HG22 ' HE2' ' A' ' 92' ' ' LYS . 94.3 m -70.08 -40.24 75.13 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.076 -1.015 . . . . 0.0 109.346 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.03 -40.57 87.24 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -60.71 -50.08 74.9 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.719 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.1 m -61.14 -39.96 92.01 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.403 -0.811 . . . . 0.0 111.273 -178.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.773 ' HE2' HG22 ' A' ' 88' ' ' THR . 56.3 mtmt -69.99 -40.05 75.55 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.999 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.479 HD21 ' CG2' ' A' ' 65' ' ' ILE . 48.0 tp -69.91 -42.93 72.69 Favored 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.365 -179.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.22 -41.6 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 O-C-N 121.45 -0.781 . . . . 0.0 111.83 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.72 -34.5 4.05 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.3 m -142.44 153.67 43.91 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.524 -0.986 . . . . 0.0 110.14 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.6 p -90.28 3.49 53.46 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.477 -0.765 . . . . 0.0 110.976 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.98 -26.22 63.99 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.423 -0.798 . . . . 0.0 111.158 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.94 -39.92 87.19 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.413 -0.804 . . . . 0.0 110.513 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.75 -79.49 1.84 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 50.5 ttp180 -131.8 138.87 48.71 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.694 -0.886 . . . . 0.0 110.47 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 105' ' ' VAL . 63.0 t -120.32 116.97 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.804 178.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -80.55 170.14 16.74 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.656 0.741 . . . . 0.0 111.346 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 60.0 39.93 19.37 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.007 0.432 . . . . 0.0 111.816 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.726 HG11 HG21 ' A' ' 3' ' ' ILE . 78.5 t -85.48 127.52 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.134 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -87.36 140.05 29.93 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.14 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -139.22 144.5 38.5 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.579 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -144.69 141.68 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.498 -0.751 . . . . 0.0 111.231 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.474 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.2 tt0 -73.45 135.01 44.09 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.561 -0.712 . . . . 0.0 109.755 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.472 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.5 m -132.27 173.09 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.437 179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -60.34 149.71 32.88 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.357 -0.839 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.463 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.4 tt -59.93 -39.08 84.29 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.505 -0.747 . . . . 0.0 110.58 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.9 m -53.5 -38.01 63.28 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.557 -0.714 . . . . 0.0 110.57 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -60.22 -39.93 88.35 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.496 -0.753 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.07 -49.83 76.11 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.257 -0.902 . . . . 0.0 110.246 179.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.432 HD11 HD21 ' A' ' 112' ' ' LEU . 90.4 mt -69.25 -39.99 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.704 -0.622 . . . . 0.0 110.253 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.63 -39.93 95.37 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.401 -0.812 . . . . 0.0 110.281 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.81 -41.82 81.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.35 -39.97 94.86 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.75 -0.853 . . . . 0.0 110.305 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.9 p30 . . . . . 0 N--CA 1.495 1.815 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.551 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.51 0.671 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.9 p -114.61 153.99 29.15 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.874 -0.516 . . . . 0.0 110.545 -179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.495 HG21 HG11 ' A' ' 105' ' ' VAL . 39.5 pt -119.99 150.05 22.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.476 -0.765 . . . . 0.0 110.534 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 p -147.84 -171.76 3.89 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.4 p90 -141.5 142.47 33.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.465 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.73 ' HB3' HG22 ' A' ' 8' ' ' ILE . 4.5 m-20 -133.78 150.01 73.47 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.476 -0.765 . . . . 0.0 110.208 179.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -78.87 -0.93 11.18 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 O-C-N 123.377 1.199 . . . . 0.0 111.114 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.792 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.4 tp -71.67 -15.22 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.244 -0.91 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CD2' HG23 ' A' ' 8' ' ' ILE . 34.3 m-85 -114.88 68.53 0.7 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 122.613 1.197 . . . . 0.0 110.553 178.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.24 170.06 8.09 Favored 'General case' 0 N--CA 1.492 1.67 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.599 177.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.716 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.91 -34.42 73.19 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 -175.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -88.22 13.53 11.27 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.417 -1.427 . . . . 0.0 112.422 -176.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.792 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.9 tp -75.56 122.82 24.47 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.355 -0.841 . . . . 0.0 110.091 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.8 m -65.73 137.62 57.4 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.801 -0.76 . . . . 0.0 109.627 179.533 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.8 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.4 mmm -64.22 -19.08 65.11 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.823 -0.548 . . . . 0.0 111.313 -179.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.5 -16.55 78.93 Favored Glycine 0 N--CA 1.495 2.59 0 O-C-N 120.95 -1.094 . . . . 0.0 110.986 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.1 m -88.18 -13.78 40.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.165 -1.197 . . . . 0.0 111.599 -179.148 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 15' ' ' MET . 13.0 p -90.04 159.54 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.149 -0.97 . . . . 0.0 108.869 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.769 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -49.07 -41.36 35.04 Favored 'General case' 0 N--CA 1.507 2.418 0 O-C-N 121.266 -0.896 . . . . 0.0 110.562 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -78.23 87.14 4.31 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.8 m -99.4 -82.31 0.44 Allowed 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.117 -0.989 . . . . 0.0 112.954 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -137.91 9.58 2.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.087 -1.008 . . . . 0.0 112.922 -178.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.08 -148.0 0.5 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.801 -1.72 . . . . 0.0 108.801 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -63.03 -40.01 96.47 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.625 -0.927 . . . . 0.0 109.526 178.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 89.6 m-70 -94.6 8.56 41.89 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.567 -0.708 . . . . 0.0 111.151 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.15 127.42 35.89 Favored Glycine 0 N--CA 1.502 3.064 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 91.2 mt -102.47 -11.46 18.55 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 122.03 -0.688 . . . . 0.0 111.532 -178.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 ttp -60.03 -27.32 66.81 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.261 -0.899 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.52 -61.75 2.27 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.425 -0.797 . . . . 0.0 112.898 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -69.96 -40.01 75.69 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 120.88 -1.137 . . . . 0.0 111.36 -178.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.615 ' CE1' HG21 ' A' ' 37' ' ' VAL . 3.8 p90 -136.21 104.76 9.49 Favored Pre-proline 0 C--N 1.302 -1.491 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.42 -11.15 29.01 Favored 'Trans proline' 0 N--CA 1.485 0.98 0 O-C-N 123.482 1.254 . . . . 0.0 111.647 -178.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -126.85 135.76 51.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.245 -0.91 . . . . 0.0 109.761 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.949 HD21 HG11 ' A' ' 43' ' ' VAL . 39.4 tp -61.46 126.05 25.95 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.522 -0.736 . . . . 0.0 109.858 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 148.79 27.77 0.06 OUTLIER Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.538 -1.315 . . . . 0.0 111.787 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -144.99 -47.91 0.24 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.074 -1.25 . . . . 0.0 110.917 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.615 HG21 ' CE1' ' A' ' 31' ' ' TYR . 1.7 t -67.42 -55.45 15.02 Favored Pre-proline 0 N--CA 1.496 1.844 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.389 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD2' ' N ' ' A' ' 37' ' ' VAL . 42.5 Cg_endo -76.19 -31.44 4.77 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.396 1.208 . . . . 0.0 108.988 178.079 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.424 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 129.77 -64.6 0.6 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.716 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 2.1 t80 164.38 -56.74 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.595 0 C-N-CA 123.33 0.652 . . . . 0.0 110.844 177.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.638 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.7 Cg_endo -97.42 16.84 0.61 Allowed 'Trans proline' 0 N--CA 1.481 0.773 0 C-N-CA 120.982 1.121 . . . . 0.0 112.044 -177.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -126.12 47.49 2.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.2 -0.937 . . . . 0.0 109.758 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.949 HG11 HD21 ' A' ' 34' ' ' LEU . 10.2 p -128.09 142.43 43.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.596 0.712 . . . . 0.0 109.78 -179.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.56 170.43 41.09 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.453 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -83.79 158.58 35.36 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 178.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.698 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.5 pt -147.81 156.2 44.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.439 -1.036 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.66 -12.22 34.79 Favored 'Trans proline' 0 N--CA 1.504 2.119 0 C-N-CA 121.934 1.756 . . . . 0.0 114.668 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -96.72 21.31 9.61 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 120.491 -1.381 . . . . 0.0 112.796 -177.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 54' ' ' SER . 48.9 mm -110.7 129.98 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.37 -0.831 . . . . 0.0 108.807 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.15 -48.26 11.54 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.786 . . . . 0.0 112.256 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.769 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.53 -129.04 1.8 Allowed Glycine 0 N--CA 1.488 2.119 0 C-N-CA 118.806 -1.664 . . . . 0.0 111.384 -179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.454 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 20.1 t90 -50.2 -24.99 3.18 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.89 -0.771 . . . . 0.0 112.881 -178.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.93 71.3 1.22 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.402 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.634 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.2 t -70.04 130.37 89.87 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.865 -0.522 . . . . 0.0 111.075 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.36 -21.47 30.65 Favored 'Trans proline' 0 N--CA 1.486 1.053 0 O-C-N 123.246 1.13 . . . . 0.0 110.566 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -98.52 13.48 31.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.445 -0.785 . . . . 0.0 110.983 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -70.98 147.18 48.91 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.182 -0.949 . . . . 0.0 110.271 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.1 35.37 44.02 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 95.6 m -119.59 135.17 54.91 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.503 -0.998 . . . . 0.0 110.484 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -78.96 145.64 33.88 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.053 -178.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.449 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 96.0 m95 -148.38 143.98 27.19 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.801 -0.562 . . . . 0.0 109.537 178.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -107.36 134.89 49.76 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.305 -0.872 . . . . 0.0 109.134 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 123.34 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.496 -0.752 . . . . 0.0 110.216 -179.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.2 m -118.42 139.71 50.98 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.893 -0.505 . . . . 0.0 110.378 -179.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.472 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 21.0 pt -119.58 164.29 22.62 Favored Pre-proline 0 N--CA 1.5 2.044 0 O-C-N 121.471 -0.768 . . . . 0.0 110.881 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 36.6 Cg_endo -60.58 -24.11 77.42 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 121.445 1.43 . . . . 0.0 112.794 -178.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -65.55 -36.61 84.28 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.217 -0.927 . . . . 0.0 109.712 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.11 63.41 0.47 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -163.82 153.99 15.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.755 -0.85 . . . . 0.0 108.988 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 95.6 p -155.43 158.38 38.51 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.583 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.6 pt -140.02 166.72 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -104.96 125.78 51.32 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.612 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -117.98 130.06 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.75 -0.594 . . . . 0.0 109.621 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.484 ' CD ' HG12 ' A' ' 37' ' ' VAL . 1.3 ttp-105 -99.23 139.52 34.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.524 -0.735 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.59 148.04 42.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.636 HG22 HG21 ' A' ' 18' ' ' VAL . 3.8 p -155.66 -41.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.807 -0.819 . . . . 0.0 109.798 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.647 ' OD2' HG23 ' A' ' 18' ' ' VAL . 1.9 t0 -134.58 175.18 9.77 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.145 -0.972 . . . . 0.0 109.767 179.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -103.81 154.81 19.17 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.471 -0.768 . . . . 0.0 111.521 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.77 147.75 16.66 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.9 mtt180 -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.648 -0.913 . . . . 0.0 110.742 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -177.39 73.65 0.07 OUTLIER Glycine 0 N--CA 1.495 2.585 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.638 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.65 147.33 4.54 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.467 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.698 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.5 m-85 -73.02 135.16 44.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 122.031 -0.688 . . . . 0.0 110.506 179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.3 131.01 46.87 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 178.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.4 m -131.72 173.73 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.636 -178.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -55.17 152.16 15.77 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 109.927 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.27 -27.55 55.89 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.422 1.222 . . . . 0.0 110.11 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.02 -40.02 75.46 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.952 -1.092 . . . . 0.0 109.048 178.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.92 -40.16 87.59 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.432 -0.793 . . . . 0.0 108.977 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.47 -49.95 75.51 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.799 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 38.9 m -60.02 -39.56 86.25 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.657 -0.652 . . . . 0.0 111.28 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.9 mttm -68.89 -40.02 79.41 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.499 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.4 HD21 ' CG2' ' A' ' 65' ' ' ILE . 41.4 tp -70.78 -42.74 69.95 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.8 -0.76 . . . . 0.0 111.627 -178.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.1 t -97.74 -40.39 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.201 -0.937 . . . . 0.0 111.733 -177.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 118.17 -37.7 3.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.9 m -134.69 149.62 50.52 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.608 -0.937 . . . . 0.0 110.199 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 70.8 p -94.02 3.98 54.56 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.421 -0.799 . . . . 0.0 111.053 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -69.93 -27.64 64.93 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.43 -0.794 . . . . 0.0 111.164 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.97 87.75 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.495 -0.753 . . . . 0.0 110.67 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.28 -60.45 3.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.2 ptt180 -153.61 156.91 38.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.616 -0.932 . . . . 0.0 110.546 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -125.44 117.24 49.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.45 -0.781 . . . . 0.0 109.672 179.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -81.09 169.99 16.74 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.49 -0.756 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 56.4 t30 61.64 47.92 6.05 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.573 -0.704 . . . . 0.0 111.646 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.495 HG11 HG21 ' A' ' 3' ' ' ILE . 81.1 t -96.17 124.75 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.031 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -84.92 145.76 27.61 Favored 'General case' 0 N--CA 1.493 1.675 0 C-N-CA 119.779 -0.768 . . . . 0.0 109.281 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.02 147.2 40.04 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.833 -0.542 . . . . 0.0 111.598 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.8 m -147.27 148.66 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.653 -0.654 . . . . 0.0 110.829 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.449 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 16.9 tt0 -82.98 140.93 32.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.656 -0.652 . . . . 0.0 110.314 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.4 m -132.54 168.8 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 120.211 -0.595 . . . . 0.0 109.742 179.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -59.97 149.05 33.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.296 -0.878 . . . . 0.0 109.925 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -40.0 88.03 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.408 -0.807 . . . . 0.0 110.94 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 54.0 p -55.45 -35.54 65.57 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.556 -0.715 . . . . 0.0 110.665 -178.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -60.0 -38.39 82.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.435 -0.79 . . . . 0.0 110.075 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 85.8 m -69.63 -39.93 76.86 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.8 mm -64.09 -43.94 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 120.274 -0.571 . . . . 0.0 109.845 -178.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -70.0 -40.02 75.53 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.76 -0.588 . . . . 0.0 110.547 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.44 -51.63 46.86 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.57 -40.04 94.83 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.588 -0.948 . . . . 0.0 110.249 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.087 -179.87 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.351 0.596 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.9 m -111.36 137.26 49.36 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.441 HG21 HG11 ' A' ' 105' ' ' VAL . 37.8 pt -109.75 146.69 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.6 -0.688 . . . . 0.0 110.354 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.9 m -143.29 -174.59 4.25 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -142.73 150.0 39.51 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.985 179.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.55 152.7 77.03 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.504 -0.748 . . . . 0.0 109.755 179.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -84.52 -12.0 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 O-C-N 123.348 1.183 . . . . 0.0 112.659 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.479 HG13 ' N ' ' A' ' 9' ' ' TYR . 35.9 pt -70.05 -39.91 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 120.871 -1.143 . . . . 0.0 111.333 -178.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.605 ' HA ' HD22 ' A' ' 13' ' ' LEU . 46.3 m-85 -72.94 65.22 0.73 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 122.652 1.215 . . . . 0.0 111.712 -178.653 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.89 170.46 7.86 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.55 -34.84 73.18 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -87.83 8.99 23.35 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.016 -1.474 . . . . 0.0 111.542 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.605 HD22 ' HA ' ' A' ' 9' ' ' TYR . 45.3 tp -70.01 122.13 18.76 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.303 -0.873 . . . . 0.0 109.424 179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.1 m -68.31 135.59 52.12 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.413 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.851 ' O ' HG12 ' A' ' 18' ' ' VAL . 87.0 mtp -70.07 -15.23 62.96 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.16 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -15.87 72.74 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 120.805 -1.184 . . . . 0.0 110.168 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -88.55 -6.67 57.42 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -1.142 . . . . 0.0 111.735 -179.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.851 HG12 ' O ' ' A' ' 15' ' ' MET . 10.8 p -96.74 165.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.997 -1.064 . . . . 0.0 110.603 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.633 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.01 -42.33 94.07 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.783 -0.573 . . . . 0.0 110.907 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.1 m -76.98 71.72 3.5 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.383 -0.823 . . . . 0.0 110.186 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 4.2 p -108.36 111.9 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.467 -0.771 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.41 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 13.1 t-20 51.99 -139.71 0.96 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.592 -0.692 . . . . 0.0 110.561 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.458 ' CA ' ' CH2' ' A' ' 52' ' ' TRP . . . 66.02 -156.12 50.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -74.25 -41.03 61.94 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.684 -0.892 . . . . 0.0 112.025 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.403 ' CD2' ' O ' ' A' ' 54' ' ' SER . 79.5 m-70 -99.69 10.04 42.04 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.074 -1.016 . . . . 0.0 111.51 -178.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.41 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -56.78 130.85 51.17 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 120.073 -1.06 . . . . 0.0 110.523 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 1.005 HD13 HG11 ' A' ' 37' ' ' VAL . 95.0 mt -100.6 -5.93 26.02 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.071 -0.664 . . . . 0.0 110.12 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 34.3 tpp -59.95 -36.08 76.31 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.281 -0.887 . . . . 0.0 109.599 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.24 -72.46 0.05 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.723 -0.611 . . . . 0.0 111.784 -178.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -69.95 -39.99 75.72 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.349 -0.845 . . . . 0.0 110.223 -179.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.644 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.8 m-85 -120.38 102.31 45.65 Favored Pre-proline 0 N--CA 1.491 1.596 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 -178.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.97 -22.39 19.75 Favored 'Trans proline' 0 C--N 1.316 -1.154 0 O-C-N 123.322 1.17 . . . . 0.0 111.381 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.1 m -122.69 144.23 49.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.327 -0.858 . . . . 0.0 110.711 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.663 HD21 HG11 ' A' ' 43' ' ' VAL . 52.9 tp -64.94 120.82 13.29 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.855 -0.528 . . . . 0.0 110.088 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.29 32.17 0.04 OUTLIER Glycine 0 N--CA 1.496 2.698 0 C-N-CA 119.906 -1.14 . . . . 0.0 110.993 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.446 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 19.1 mt-10 -156.09 -48.17 0.08 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.335 -1.097 . . . . 0.0 109.979 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 1.005 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -62.95 -59.48 12.38 Favored Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.436 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.9 Cg_endo -73.73 -32.29 7.65 Favored 'Trans proline' 0 C--N 1.318 -1.066 0 N-CA-C 108.733 -1.295 . . . . 0.0 108.733 177.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.1 -63.46 0.63 Allowed Glycine 0 N--CA 1.487 2.049 0 N-CA-C 107.197 -2.361 . . . . 0.0 107.197 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.644 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.5 t80 163.32 -53.58 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.556 0 C-N-CA 123.601 0.76 . . . . 0.0 109.91 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.666 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -100.55 12.95 0.49 Allowed 'Trans proline' 0 C--N 1.324 -0.728 0 C-N-CA 121.29 1.327 . . . . 0.0 111.198 -179.029 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 46.6 m-20 -125.15 52.19 1.61 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.216 -0.928 . . . . 0.0 109.765 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.663 HG11 HD21 ' A' ' 34' ' ' LEU . 13.4 p -126.21 136.71 60.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 CA-C-O 121.538 0.685 . . . . 0.0 110.283 -179.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.573 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -165.8 171.26 40.91 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.81 160.14 29.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.899 -1.681 . . . . 0.0 108.899 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.646 HG22 ' CE1' ' A' ' 83' ' ' PHE . 8.8 pt -146.65 158.63 45.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.806 -0.82 . . . . 0.0 110.414 179.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.14 -16.41 35.94 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.713 1.609 . . . . 0.0 113.63 -178.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -89.94 18.69 5.47 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.816 -1.177 . . . . 0.0 112.577 -177.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.437 ' HA ' ' CB ' ' A' ' 54' ' ' SER . 56.0 mt -119.99 123.17 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.146 -0.971 . . . . 0.0 109.05 177.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.58 -43.64 16.8 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 113.388 0.885 . . . . 0.0 113.388 -177.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.633 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.54 -125.33 0.96 Allowed Glycine 0 N--CA 1.493 2.452 0 C-N-CA 118.119 -1.991 . . . . 0.0 112.909 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.469 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 6.8 t90 -40.32 -32.8 0.2 Allowed 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 114.56 1.319 . . . . 0.0 114.56 -176.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 40.9 p-10 -174.15 76.83 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.493 -1.38 . . . . 0.0 109.975 178.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 25.4 p -62.74 155.11 72.01 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.636 -0.665 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 -14.36 40.05 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.566 1.298 . . . . 0.0 110.813 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 59' ' ' THR . 6.2 m -102.36 7.79 40.4 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.315 -0.865 . . . . 0.0 111.841 -179.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 41.5 t -65.4 143.65 57.59 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 120.755 -1.216 . . . . 0.0 110.109 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.26 6.45 81.35 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 56' ' ' SER . 20.9 p -77.67 158.12 29.85 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.149 -1.207 . . . . 0.0 110.998 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.41 120.02 40.01 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.19 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.431 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -121.36 139.97 52.73 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.39 -0.819 . . . . 0.0 110.934 179.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -105.92 134.14 49.52 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.651 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.8 t -111.69 125.62 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.587 -0.696 . . . . 0.0 110.47 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.509 ' O ' HG13 ' A' ' 105' ' ' VAL . 58.8 m -116.41 134.8 54.46 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.692 -0.63 . . . . 0.0 110.552 -178.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 12.8 pt -116.29 164.04 19.56 Favored Pre-proline 0 N--CA 1.503 2.179 0 O-C-N 121.407 -0.808 . . . . 0.0 111.331 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -63.38 -27.36 71.12 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 121.679 1.586 . . . . 0.0 113.296 -178.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -64.67 -40.03 94.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.064 -1.023 . . . . 0.0 109.917 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 119.92 58.53 0.25 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -154.7 148.43 25.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.72 -0.871 . . . . 0.0 108.666 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 74.9 m -146.44 143.74 29.22 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.738 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.553 HG23 HD13 ' A' ' 93' ' ' LEU . 33.9 pt -134.3 164.35 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -107.13 127.92 53.93 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 118.948 -1.101 . . . . 0.0 109.829 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -112.79 130.01 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.666 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.5 ttt180 -98.6 134.89 40.91 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.179 -0.95 . . . . 0.0 109.244 -179.299 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.96 147.04 30.76 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.455 HG22 HG21 ' A' ' 18' ' ' VAL . 3.7 p -155.4 -44.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.55 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.4 t70 -128.73 166.38 19.08 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.2 -0.937 . . . . 0.0 109.563 178.75 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 83.5 p -88.88 161.16 16.84 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.579 -0.701 . . . . 0.0 110.338 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.56 142.97 14.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 88.4 mtt-85 -60.08 -34.01 72.86 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.941 . . . . 0.0 110.009 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.24 75.65 0.04 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.62 149.93 5.1 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.99 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.651 ' CE2' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -66.53 140.07 57.97 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.855 -0.791 . . . . 0.0 110.491 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.414 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 52.3 t-20 -136.77 119.0 15.56 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.573 HG12 ' HA3' ' A' ' 44' ' ' GLY . 27.3 m -130.24 176.11 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 C-N-CA 119.102 -1.039 . . . . 0.0 112.449 -177.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.2 m-20 -56.18 157.58 8.67 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.578 -0.701 . . . . 0.0 109.937 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -70.35 -28.17 22.76 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.407 1.214 . . . . 0.0 110.166 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -70.36 -41.41 73.18 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.033 -1.042 . . . . 0.0 109.549 178.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.666 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.0 -40.09 90.86 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -60.05 -49.93 75.74 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.401 -0.52 . . . . 0.0 110.708 178.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.7 m -60.01 -39.71 86.73 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.44 -0.788 . . . . 0.0 111.416 -178.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -69.61 -39.99 76.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.563 -0.711 . . . . 0.0 111.274 -178.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.553 HD13 HG23 ' A' ' 71' ' ' ILE . 61.0 tp -71.31 -43.46 67.04 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.587 -0.696 . . . . 0.0 111.296 -179.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.6 t -93.32 -40.55 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.473 -0.767 . . . . 0.0 111.293 -178.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.29 -38.78 2.47 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 74.5 m -142.28 156.93 45.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.674 -0.897 . . . . 0.0 110.416 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 67.2 p -89.95 4.17 50.87 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.776 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.98 -26.65 64.19 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.452 -0.78 . . . . 0.0 110.445 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.01 93.21 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.57 -0.706 . . . . 0.0 110.385 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.33 -75.35 2.39 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -133.42 136.63 45.34 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.558 -0.966 . . . . 0.0 110.572 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.8 t -116.8 113.76 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.438 -0.788 . . . . 0.0 109.76 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -86.84 170.58 11.56 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-O 121.848 0.832 . . . . 0.0 111.608 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.2 t30 60.07 40.01 19.04 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.505 0.669 . . . . 0.0 110.333 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.509 HG13 ' O ' ' A' ' 64' ' ' THR . 93.8 t -90.73 122.01 41.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -80.0 140.4 36.59 Favored 'General case' 0 N--CA 1.493 1.707 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.651 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 107' ' ' TYR . 42.2 p90 -139.27 143.88 38.14 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.882 -0.512 . . . . 0.0 111.231 -178.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.5 m -145.54 139.99 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 111.17 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.431 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 57.3 tt0 -72.66 140.01 47.66 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.364 178.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.8 m -138.48 177.7 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.836 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 47.4 t0 -59.89 146.19 43.07 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.665 -0.647 . . . . 0.0 109.976 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 116' ' ' ILE . 9.3 tt -60.0 -37.95 81.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.456 -0.777 . . . . 0.0 110.514 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.7 p -52.71 -35.14 55.22 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.517 -0.739 . . . . 0.0 110.595 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -66.45 -36.3 82.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.511 -0.743 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -62.96 -50.18 71.79 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.264 -0.898 . . . . 0.0 110.038 179.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.47 HD11 HD21 ' A' ' 112' ' ' LEU . 90.0 mt -69.3 -40.03 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.748 -0.595 . . . . 0.0 110.457 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -65.44 -40.02 92.75 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.44 -0.787 . . . . 0.0 110.158 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.58 -42.18 97.51 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.05 91.1 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.675 -0.897 . . . . 0.0 109.945 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 66.5 t30 . . . . . 0 N--CA 1.5 2.058 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.645 179.898 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.375 0.607 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.0 m -111.77 140.7 46.19 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.661 0.744 . . . . 0.0 110.241 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.636 HG21 HG11 ' A' ' 105' ' ' VAL . 35.6 pt -112.18 147.36 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.755 -0.591 . . . . 0.0 110.487 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 4.0 p -145.78 -173.24 4.09 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.1 p90 -142.5 148.88 38.4 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.656 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -124.95 150.38 66.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.468 -0.77 . . . . 0.0 109.608 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -84.55 -7.77 9.64 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 O-C-N 123.303 1.159 . . . . 0.0 112.854 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.0 pt -70.02 -40.09 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.201 0 O-C-N 120.887 -1.133 . . . . 0.0 111.102 -179.356 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 38.0 m-85 -72.13 66.86 0.64 Allowed 'General case' 0 N--CA 1.496 1.827 0 CA-C-O 122.684 1.23 . . . . 0.0 111.756 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.69 172.2 6.95 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.126 176.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.17 71.57 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -90.3 11.33 21.62 Favored 'General case' 0 N--CA 1.501 2.09 0 C-N-CA 118.078 -1.449 . . . . 0.0 112.424 -177.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.456 HD22 ' HA ' ' A' ' 9' ' ' TYR . 28.2 tp -72.63 123.87 24.11 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.214 -0.928 . . . . 0.0 109.956 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 48.4 t -69.54 136.31 51.2 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.027 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.779 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.1 mmm -69.98 -15.95 63.11 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.856 -0.527 . . . . 0.0 111.717 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.418 ' CA ' ' HE1' ' A' ' 28' ' ' MET . . . -69.93 -11.18 66.12 Favored Glycine 0 N--CA 1.495 2.632 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.8 m -93.15 -11.97 31.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.254 -1.144 . . . . 0.0 111.708 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.779 HG12 ' O ' ' A' ' 15' ' ' MET . 7.1 p -92.45 165.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.17 -0.956 . . . . 0.0 110.46 -179.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.819 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.98 -45.3 86.98 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.642 -0.661 . . . . 0.0 110.093 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.23 80.32 6.68 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.97 -80.02 0.4 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.485 -0.76 . . . . 0.0 112.903 -177.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -139.91 9.43 2.36 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.217 -0.927 . . . . 0.0 112.917 -178.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.47 -143.97 0.24 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -69.97 -40.02 75.64 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.647 -0.914 . . . . 0.0 109.71 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -90.38 2.37 55.65 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.457 -0.777 . . . . 0.0 110.815 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.03 126.42 33.21 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.423 -1.071 . . . . 0.0 110.423 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.842 HD13 HG11 ' A' ' 37' ' ' VAL . 96.1 mt -100.09 0.93 41.71 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 122.132 -0.628 . . . . 0.0 110.21 178.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.418 ' HE1' ' CA ' ' A' ' 16' ' ' GLY . 56.6 ttm -68.13 -30.65 69.84 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.364 -0.835 . . . . 0.0 110.339 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.0 -71.8 0.06 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.553 -0.717 . . . . 0.0 111.53 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 37.2 mt-30 -69.97 -40.1 75.6 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.285 -0.884 . . . . 0.0 109.99 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.623 ' CD2' HG23 ' A' ' 37' ' ' VAL . 66.5 m-85 -123.16 95.07 46.29 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.843 -0.536 . . . . 0.0 110.049 -179.168 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.02 -18.75 27.32 Favored 'Trans proline' 0 C--N 1.318 -1.054 0 O-C-N 123.411 1.216 . . . . 0.0 111.483 -179.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.5 m -121.39 149.32 43.16 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.257 -0.902 . . . . 0.0 110.435 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 1.096 HD11 HG21 ' A' ' 43' ' ' VAL . 34.1 tp -70.64 119.89 15.46 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.793 -0.567 . . . . 0.0 110.422 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.29 33.46 0.05 OUTLIER Glycine 0 N--CA 1.495 2.609 0 C-N-CA 120.104 -1.046 . . . . 0.0 110.593 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 1.6 mt-10 -157.71 -49.91 0.07 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.206 -1.173 . . . . 0.0 110.422 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -60.1 -58.61 18.11 Favored Pre-proline 0 N--CA 1.502 2.125 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -78.54 -29.23 3.84 Favored 'Trans proline' 0 N--CA 1.486 1.079 0 N-CA-C 109.008 -1.189 . . . . 0.0 109.008 176.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 125.4 -64.88 0.56 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 106.676 -2.57 . . . . 0.0 106.676 -178.151 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.559 ' CB ' ' HD3' ' A' ' 41' ' ' PRO . 0.1 OUTLIER 167.98 -58.88 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.377 0 O-C-N 122.277 -0.543 . . . . 0.0 109.962 177.091 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.719 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 53.4 Cg_endo -95.57 16.87 0.83 Allowed 'Trans proline' 0 C--N 1.325 -0.68 0 O-C-N 123.071 1.037 . . . . 0.0 109.806 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -123.32 38.8 4.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.469 -0.769 . . . . 0.0 109.526 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.096 HG21 HD11 ' A' ' 34' ' ' LEU . 14.8 p -127.89 140.87 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.527 0.679 . . . . 0.0 110.915 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.68 175.18 42.69 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -89.46 161.76 30.13 Favored Glycine 0 N--CA 1.498 2.807 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.732 HG23 ' O ' ' A' ' 45' ' ' GLY . 0.5 OUTLIER -161.26 164.79 18.01 Favored Pre-proline 0 N--CA 1.503 2.21 0 CA-C-N 118.457 1.128 . . . . 0.0 111.422 -179.097 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.24 -22.27 25.79 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 121.439 1.426 . . . . 0.0 114.593 -177.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -83.94 3.25 34.95 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.382 -1.449 . . . . 0.0 112.762 -177.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.61 HG23 ' CB ' ' A' ' 54' ' ' SER . 45.6 mm -97.38 128.94 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.37 -51.01 7.29 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.409 -0.807 . . . . 0.0 111.961 -178.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.819 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.68 -135.94 3.3 Favored Glycine 0 N--CA 1.487 2.098 0 C-N-CA 118.882 -1.628 . . . . 0.0 111.241 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.458 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 9.4 t90 -42.74 -27.22 0.16 Allowed 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.411 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 47.2 m-20 -147.0 62.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.208 -0.932 . . . . 0.0 110.901 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.61 ' CB ' HG23 ' A' ' 49' ' ' ILE . 5.1 p -56.96 132.9 79.91 Favored Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.436 -0.79 . . . . 0.0 110.461 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.63 -21.16 22.38 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 O-C-N 123.252 1.133 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 38.8 m -96.15 9.47 40.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.456 -0.777 . . . . 0.0 111.043 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -64.0 141.65 58.69 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.327 -0.858 . . . . 0.0 110.265 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 95.33 -24.97 26.64 Favored Glycine 0 N--CA 1.5 2.933 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 178.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.1 m -56.93 161.32 3.02 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.257 -1.143 . . . . 0.0 110.622 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.431 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.5 t -113.46 152.32 30.28 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.969 -0.457 . . . . 0.0 111.307 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.432 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 52.6 m95 -142.53 149.04 38.58 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.241 -0.912 . . . . 0.0 110.75 178.029 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 36.3 tttp -110.71 129.56 55.8 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.2 t -110.9 129.75 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.316 -0.865 . . . . 0.0 110.383 -178.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.5 m -121.12 140.18 52.33 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.842 -0.536 . . . . 0.0 111.381 -178.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.2 pt -119.27 164.65 20.3 Favored Pre-proline 0 N--CA 1.5 2.057 0 O-C-N 121.499 -0.751 . . . . 0.0 110.311 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.1 Cg_endo -63.5 -24.07 70.61 Favored 'Trans proline' 0 N--CA 1.495 1.613 0 O-C-N 123.404 1.213 . . . . 0.0 112.593 -178.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.3 t-20 -64.47 -39.99 94.86 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.237 -0.915 . . . . 0.0 109.61 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.65 60.56 0.32 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -159.99 150.78 19.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.704 -0.88 . . . . 0.0 109.145 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.446 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.8 m -149.4 157.38 43.26 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 121.992 0.901 . . . . 0.0 112.029 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.863 HG12 HD13 ' A' ' 93' ' ' LEU . 36.8 pt -140.06 165.84 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.8 m-85 -107.61 130.25 54.91 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.128 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.11 130.04 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.691 -0.631 . . . . 0.0 110.726 -178.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.521 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.4 ttt180 -101.24 135.33 42.88 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.176 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.711 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.24 149.34 47.92 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.124 -1.036 . . . . 0.0 111.386 -177.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.48 HG11 HG22 ' A' ' 43' ' ' VAL . 2.6 p -152.63 -45.75 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.577 ' HB2' HG23 ' A' ' 18' ' ' VAL . 10.3 t70 -129.49 169.04 15.46 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.34 -0.85 . . . . 0.0 109.517 179.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 82.9 p -103.9 159.94 15.23 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.604 -0.685 . . . . 0.0 110.111 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.52 156.64 21.96 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -60.03 -35.78 75.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.674 -0.898 . . . . 0.0 109.109 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -171.32 177.55 44.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 51.54 -168.32 0.56 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 121.355 -1.085 . . . . 0.0 111.567 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.706 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.4 m-85 -120.0 139.06 53.06 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.965 -0.727 . . . . 0.0 109.15 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 4' ' ' SER . 33.4 t-20 -129.29 128.48 43.28 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.052 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.3 m -130.72 172.07 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.088 -1.008 . . . . 0.0 112.025 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -55.84 152.77 18.8 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.29 -0.881 . . . . 0.0 109.663 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.36 -21.35 61.22 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 O-C-N 123.386 1.203 . . . . 0.0 110.732 -179.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.2 m -78.76 -40.04 34.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.928 -1.107 . . . . 0.0 109.33 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.719 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.68 -40.03 88.38 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 178.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -60.01 -49.87 75.99 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.794 -0.566 . . . . 0.0 110.447 179.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -59.99 -38.74 83.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.583 -0.698 . . . . 0.0 110.661 -178.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -69.87 -39.87 76.06 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.141 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.863 HD13 HG12 ' A' ' 71' ' ' ILE . 61.2 tp -70.14 -43.97 69.82 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.507 -0.746 . . . . 0.0 111.283 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.51 -39.88 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.298 -0.876 . . . . 0.0 111.461 -178.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 119.89 -35.19 3.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 64.2 m -140.03 150.83 44.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.525 -0.985 . . . . 0.0 110.889 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.8 p -89.57 3.74 51.56 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.516 -0.74 . . . . 0.0 110.627 179.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -70.08 -28.32 65.33 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.441 -0.787 . . . . 0.0 110.951 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.17 -40.03 84.37 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.456 -0.777 . . . . 0.0 110.417 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.57 -79.6 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 37.0 ttm180 -129.85 132.69 46.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.659 -0.906 . . . . 0.0 110.219 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.5 t -119.34 120.06 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.396 -0.815 . . . . 0.0 110.276 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . 0.4 ' O ' ' HB2' ' A' ' 104' ' ' ASN . 9.3 t70 -85.05 173.11 10.75 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.42 0.629 . . . . 0.0 110.876 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 94.9 m-20 60.04 39.97 19.19 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-O 121.091 0.472 . . . . 0.0 111.569 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.636 HG11 HG21 ' A' ' 3' ' ' ILE . 63.0 t -86.95 122.58 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -82.25 134.58 35.29 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.173 -1.011 . . . . 0.0 109.425 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.8 p90 -136.28 142.72 43.97 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.325 0.583 . . . . 0.0 111.323 -178.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -144.07 140.05 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.731 -0.606 . . . . 0.0 110.184 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -71.43 140.75 50.2 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.698 . . . . 0.0 110.422 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.431 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.2 m -136.57 173.26 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.829 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -61.12 149.67 36.54 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.386 -0.822 . . . . 0.0 110.833 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.571 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -59.98 -39.3 85.21 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.456 -0.778 . . . . 0.0 110.794 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 62.8 m -53.85 -39.44 65.63 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 110.226 -178.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -60.25 -39.3 86.24 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.606 -0.684 . . . . 0.0 110.988 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -59.97 -49.37 77.94 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.238 -0.914 . . . . 0.0 110.059 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.571 HD11 HD21 ' A' ' 112' ' ' LEU . 85.7 mt -69.84 -40.03 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.704 -0.622 . . . . 0.0 110.57 -179.163 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.18 -40.0 95.18 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.342 -0.849 . . . . 0.0 110.316 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.45 -39.97 79.65 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.26 -39.96 88.62 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.604 -0.939 . . . . 0.0 110.276 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.194 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.863 0.363 . . . . 0.0 110.66 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.3 m -110.95 141.73 44.0 Favored 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.832 0.825 . . . . 0.0 111.332 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.512 HG21 HG11 ' A' ' 105' ' ' VAL . 45.8 pt -119.93 149.94 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.89 -0.507 . . . . 0.0 110.407 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.409 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 67.6 m -143.97 -174.08 4.17 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -141.5 150.0 41.63 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.362 -0.836 . . . . 0.0 110.538 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -132.88 144.73 54.07 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.609 -0.682 . . . . 0.0 109.543 179.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.6 -4.46 14.13 Favored 'Trans proline' 0 C--N 1.317 -1.11 0 O-C-N 123.381 1.201 . . . . 0.0 112.405 -178.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.661 HD11 ' CZ ' ' A' ' 9' ' ' TYR . 33.9 pt -69.99 -40.03 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 120.899 -1.126 . . . . 0.0 110.439 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.661 ' CZ ' HD11 ' A' ' 8' ' ' ILE . 30.8 m-85 -74.52 66.66 1.42 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 122.815 1.293 . . . . 0.0 110.611 -178.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.72 171.62 7.26 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 114.307 -1.315 . . . . 0.0 108.458 177.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.83 -34.47 73.13 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -175.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -89.1 10.1 23.03 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.45 -1.406 . . . . 0.0 111.966 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.478 HD22 ' O ' ' A' ' 8' ' ' ILE . 58.7 tp -71.16 122.87 20.93 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.359 -0.838 . . . . 0.0 109.431 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.3 m -68.89 136.84 53.25 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.705 0.764 . . . . 0.0 110.199 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.617 ' O ' HG12 ' A' ' 18' ' ' VAL . 89.4 mmm -65.58 -16.98 64.23 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.471 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.57 -16.59 77.65 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.012 -1.055 . . . . 0.0 111.069 -179.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 79.6 p -90.33 -17.65 26.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.138 -1.213 . . . . 0.0 111.256 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.896 HG23 ' OD1' ' A' ' 77' ' ' ASP . 7.6 p -89.97 155.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.333 -0.854 . . . . 0.0 109.598 -179.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.619 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -48.41 -40.02 24.53 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.513 -0.742 . . . . 0.0 110.406 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.29 82.59 4.58 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -92.51 -83.41 0.3 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.895 -1.128 . . . . 0.0 112.596 -177.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.424 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 60.3 t30 -154.5 18.02 0.47 Allowed 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.802 -1.186 . . . . 0.0 112.339 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.06 -141.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -70.13 -42.56 72.45 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.692 -0.887 . . . . 0.0 109.634 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.664 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 8.2 p80 -97.31 4.48 50.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.477 -0.765 . . . . 0.0 110.861 -179.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.56 144.43 37.42 Favored Glycine 0 N--CA 1.494 2.541 0 O-C-N 121.14 -0.975 . . . . 0.0 110.734 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 94.5 mt -99.58 -3.05 34.16 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.825 -0.809 . . . . 0.0 110.539 179.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.407 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.3 tpp -60.12 -36.39 77.38 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.562 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.89 -77.79 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.423 -0.798 . . . . 0.0 111.977 -177.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -69.98 -39.99 75.63 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.38 -0.825 . . . . 0.0 111.053 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.506 ' CD2' HG23 ' A' ' 37' ' ' VAL . 68.1 m-85 -119.99 88.44 40.65 Favored Pre-proline 0 N--CA 1.493 1.698 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.7 Cg_endo -68.59 -16.51 42.65 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.353 1.186 . . . . 0.0 111.51 -178.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.5 m -125.6 140.21 52.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.214 -0.929 . . . . 0.0 110.308 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.658 HD21 HG21 ' A' ' 43' ' ' VAL . 51.2 tp -68.55 119.74 13.47 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.68 -0.637 . . . . 0.0 110.65 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.31 32.78 0.04 OUTLIER Glycine 0 N--CA 1.497 2.713 0 C-N-CA 119.96 -1.114 . . . . 0.0 110.782 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 -156.14 -49.55 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.161 -1.199 . . . . 0.0 110.603 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.506 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.4 t -61.18 -59.64 13.1 Favored Pre-proline 0 N--CA 1.499 2.008 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.453 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 48.5 Cg_endo -75.38 -31.76 5.5 Favored 'Trans proline' 0 C--N 1.318 -1.075 0 N-CA-C 108.872 -1.241 . . . . 0.0 108.872 177.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.438 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.69 -64.22 0.62 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 107.316 -2.314 . . . . 0.0 107.316 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.539 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 163.54 -68.32 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.645 0 C-N-CA 123.533 0.733 . . . . 0.0 109.555 177.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.539 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.4 Cg_endo -80.41 -0.54 10.71 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 O-C-N 122.734 0.86 . . . . 0.0 111.423 179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -109.95 57.18 0.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.195 -0.94 . . . . 0.0 109.449 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.658 HG21 HD21 ' A' ' 34' ' ' LEU . 11.4 p -129.62 135.66 60.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-O 121.551 0.691 . . . . 0.0 110.557 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.698 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -165.12 173.01 40.91 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.94 163.79 28.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.802 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -143.73 157.02 59.2 Favored Pre-proline 0 N--CA 1.495 1.81 0 O-C-N 121.698 -0.884 . . . . 0.0 110.19 179.336 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.48 -9.26 25.48 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.567 1.511 . . . . 0.0 113.044 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -99.01 28.16 4.58 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.918 -1.114 . . . . 0.0 112.239 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.576 HD11 HD11 ' A' ' 46' ' ' ILE . 48.6 mm -119.58 121.57 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.085 -1.01 . . . . 0.0 109.36 179.185 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.5 -43.01 57.94 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.323 -0.86 . . . . 0.0 111.487 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.619 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 163.96 -133.33 2.99 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 119.296 -1.43 . . . . 0.0 111.141 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.483 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.4 t90 -51.11 -23.69 3.39 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -178.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.664 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 21.5 t70 -143.99 64.4 1.32 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.362 -0.836 . . . . 0.0 110.427 -178.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.601 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 44.0 m -79.37 142.36 58.34 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.431 -0.793 . . . . 0.0 111.03 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.47 -19.27 15.02 Favored 'Trans proline' 0 C--N 1.317 -1.119 0 O-C-N 123.421 1.222 . . . . 0.0 111.031 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.44 9.86 42.17 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.228 -0.92 . . . . 0.0 112.109 -178.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.465 ' HB3' ' ND1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -72.06 154.09 41.33 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.912 -1.117 . . . . 0.0 108.776 178.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.403 ' HA2' ' CZ ' ' A' ' 74' ' ' ARG . . . 78.61 10.02 86.55 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 96.3 m -99.88 139.96 34.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.306 -1.114 . . . . 0.0 109.706 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.4 m -80.12 143.59 33.78 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.299 0.571 . . . . 0.0 111.063 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 70.1 m95 -145.39 133.64 21.68 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.443 -0.785 . . . . 0.0 109.871 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -108.53 141.55 40.26 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.181 -0.949 . . . . 0.0 110.571 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 HG11 ' A' ' 105' ' ' VAL . 62.4 t -112.95 127.89 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 CA-C-O 121.385 0.612 . . . . 0.0 110.977 -179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 m -120.03 143.5 48.05 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.702 -0.624 . . . . 0.0 110.254 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.468 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 9.5 pt -120.74 164.15 24.97 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.171 -0.955 . . . . 0.0 111.218 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.468 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.2 Cg_endo -61.49 -26.24 80.71 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 121.682 1.588 . . . . 0.0 113.067 -178.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -63.42 -35.67 81.18 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.227 -0.921 . . . . 0.0 109.761 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.59 63.17 0.46 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.423 ' O ' HD11 ' A' ' 93' ' ' LEU . 40.4 t-20 -164.42 157.23 17.15 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.774 -0.839 . . . . 0.0 109.209 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 73.9 p -154.74 159.74 40.88 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 122.025 0.917 . . . . 0.0 111.515 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.482 HD12 HD11 ' A' ' 73' ' ' ILE . 21.7 pt -133.61 164.27 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -103.61 125.0 49.86 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 118.319 -1.353 . . . . 0.0 109.895 -178.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.482 HD11 HD12 ' A' ' 71' ' ' ILE . 48.4 mm -119.78 123.54 71.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.621 -0.674 . . . . 0.0 109.911 -178.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.403 ' CZ ' ' HA2' ' A' ' 58' ' ' GLY . 0.0 OUTLIER -93.69 133.66 36.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.406 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -54.8 144.77 30.28 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.698 HG12 ' O ' ' A' ' 44' ' ' GLY . 13.4 p -168.35 -28.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.802 -0.822 . . . . 0.0 111.138 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.896 ' OD1' HG23 ' A' ' 18' ' ' VAL . 5.4 m-20 -126.07 170.0 12.2 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.721 -1.237 . . . . 0.0 110.258 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.406 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.5 t -101.4 151.92 21.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.7 -0.625 . . . . 0.0 110.686 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.73 144.32 16.24 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.084 -1.207 . . . . 0.0 110.084 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -60.66 -31.45 70.68 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.78 -0.835 . . . . 0.0 109.978 178.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.65 80.81 0.05 OUTLIER Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.72 -176.94 29.07 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.802 ' CD2' HG22 ' A' ' 46' ' ' ILE . 57.7 m-85 -113.17 130.96 56.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.438 -1.036 . . . . 0.0 109.58 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.409 ' HA ' ' O ' ' A' ' 4' ' ' SER . 36.8 t-20 -120.88 130.96 54.13 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.412 HG11 HG13 ' A' ' 73' ' ' ILE . 34.7 m -130.22 171.8 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.175 -0.953 . . . . 0.0 112.258 -177.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.2 m-20 -54.07 155.83 6.04 Favored Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.588 -0.695 . . . . 0.0 110.321 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.86 -18.12 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.409 1.215 . . . . 0.0 110.761 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.6 m -80.82 -39.76 26.09 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.965 -1.085 . . . . 0.0 109.208 178.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.37 -39.08 85.65 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . 0.478 ' CE1' ' HA ' ' A' ' 97' ' ' THR . 25.3 t80 -59.99 -50.0 75.44 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.634 -0.666 . . . . 0.0 110.762 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.773 HG23 ' HA ' ' A' ' 96' ' ' SER . 94.4 m -59.98 -38.95 84.02 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.58 -0.7 . . . . 0.0 111.103 -178.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -64.63 -40.02 94.74 Favored 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.962 -0.695 . . . . 0.0 111.562 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.423 HD11 ' O ' ' A' ' 69' ' ' ASN . 59.8 tp -69.03 -42.54 76.22 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.637 -0.665 . . . . 0.0 111.9 -178.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 49.0 t -100.25 -9.98 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.302 0 O-C-N 121.228 -0.92 . . . . 0.0 111.927 -178.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 99.5 -29.27 12.3 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 -178.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.773 ' HA ' HG23 ' A' ' 91' ' ' THR . 97.1 p -155.62 159.84 39.96 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.478 ' HA ' ' CE1' ' A' ' 90' ' ' PHE . 2.8 t -109.06 24.69 12.76 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.113 -0.992 . . . . 0.0 111.086 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -73.82 -22.83 59.66 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.555 -0.715 . . . . 0.0 111.067 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.95 -44.8 94.18 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.365 -0.834 . . . . 0.0 110.971 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.15 -68.07 0.53 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -140.25 135.52 32.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.946 . . . . 0.0 110.383 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 68.6 t -119.57 119.7 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -0.824 . . . . 0.0 110.155 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.9 p-10 -87.95 175.07 7.95 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-O 121.563 0.697 . . . . 0.0 111.181 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.3 t30 59.98 40.86 18.34 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.705 -0.622 . . . . 0.0 110.943 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.512 HG11 HG21 ' A' ' 3' ' ' ILE . 91.3 t -93.86 121.38 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.992 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -79.91 139.77 36.97 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 119.353 -0.939 . . . . 0.0 109.299 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.45 ' C ' HG13 ' A' ' 108' ' ' VAL . 41.1 p90 -136.67 142.22 43.17 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.864 -0.523 . . . . 0.0 110.517 -179.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.45 HG13 ' C ' ' A' ' 107' ' ' TYR . 34.8 m -148.33 150.35 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.616 -0.678 . . . . 0.0 110.581 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 61.2 tt0 -90.19 138.81 31.22 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.542 -0.724 . . . . 0.0 110.516 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.49 177.46 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.591 -0.693 . . . . 0.0 110.257 179.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.91 142.96 52.7 Favored 'General case' 0 N--CA 1.496 1.84 0 CA-C-O 121.582 0.706 . . . . 0.0 110.952 -178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.535 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.5 tt -60.11 -38.42 82.96 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.814 -0.554 . . . . 0.0 110.769 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 83.3 p -54.31 -37.01 64.33 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.561 -0.712 . . . . 0.0 111.359 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -70.07 -19.94 63.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.432 -0.793 . . . . 0.0 110.506 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 28.2 m -73.63 -52.17 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.483 HD11 HD21 ' A' ' 112' ' ' LEU . 86.5 mt -70.0 -39.99 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.523 -179.315 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -69.67 -40.0 76.69 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 120.025 -0.67 . . . . 0.0 110.108 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.27 -53.02 19.58 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -44.52 94.52 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.523 -0.987 . . . . 0.0 110.582 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.216 -179.901 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.089 0.471 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -113.28 140.48 47.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.742 -0.599 . . . . 0.0 109.958 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.774 HG23 HG21 ' A' ' 105' ' ' VAL . 38.5 pt -104.61 145.41 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.649 -0.657 . . . . 0.0 110.055 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 1.5 m -145.72 -171.6 3.72 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 51.7 p90 -146.16 150.0 35.04 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.41 179.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -129.01 146.17 59.62 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -81.07 -8.05 13.09 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.264 1.139 . . . . 0.0 112.449 -178.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.505 HG13 ' N ' ' A' ' 9' ' ' TYR . 37.5 pt -67.92 -40.09 82.83 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 120.889 -1.132 . . . . 0.0 110.789 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.66 ' HA ' HD22 ' A' ' 13' ' ' LEU . 52.3 m-85 -72.77 67.71 0.82 Allowed 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 122.9 1.333 . . . . 0.0 111.443 -178.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.1 171.1 7.49 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.065 176.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.94 -33.92 71.15 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -175.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -91.09 11.56 22.74 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.599 -1.313 . . . . 0.0 112.354 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.66 HD22 ' HA ' ' A' ' 9' ' ' TYR . 35.3 tp -70.02 123.37 21.38 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.289 -0.882 . . . . 0.0 109.844 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.26 136.12 49.59 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.642 0.734 . . . . 0.0 110.078 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.788 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -68.81 -16.68 63.85 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.979 -0.451 . . . . 0.0 111.869 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.77 -14.67 70.44 Favored Glycine 0 N--CA 1.495 2.586 0 O-C-N 120.917 -1.115 . . . . 0.0 111.309 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.2 t -91.05 -8.01 50.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.129 -1.218 . . . . 0.0 112.051 -178.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 15' ' ' MET . 8.6 p -96.01 167.82 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.107 -0.996 . . . . 0.0 110.26 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.784 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.39 -44.49 92.76 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.51 -0.744 . . . . 0.0 109.988 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.4 m -81.76 81.75 7.68 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.522 -0.736 . . . . 0.0 109.112 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -101.29 -79.57 0.51 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.619 -0.676 . . . . 0.0 112.594 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -131.6 10.18 4.73 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.282 -0.886 . . . . 0.0 112.723 -178.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.449 ' HA2' ' CH2' ' A' ' 52' ' ' TRP . . . -73.61 -148.27 1.17 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -64.7 -39.92 94.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 110.865 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.461 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 69.1 m-70 -101.16 15.87 27.31 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.331 -0.856 . . . . 0.0 111.231 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.69 131.32 51.99 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.592 HD22 HG21 ' A' ' 37' ' ' VAL . 83.2 mt -97.46 -4.83 37.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.903 -0.763 . . . . 0.0 110.466 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 38.3 tpp -60.87 -34.7 75.02 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.331 -0.855 . . . . 0.0 110.635 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.69 -76.75 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.48 -0.762 . . . . 0.0 111.96 -177.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . 0.415 ' NE2' ' CE2' ' A' ' 31' ' ' TYR . 12.7 tt0 -69.91 -39.99 75.86 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.433 -0.792 . . . . 0.0 110.367 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.522 ' CD2' HG23 ' A' ' 37' ' ' VAL . 58.0 m-85 -120.99 93.3 48.84 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.648 -0.658 . . . . 0.0 109.981 -179.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.07 -10.65 27.86 Favored 'Trans proline' 0 C--N 1.318 -1.069 0 O-C-N 123.413 1.217 . . . . 0.0 111.132 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.3 p -126.83 154.04 44.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.326 -0.859 . . . . 0.0 110.269 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 1.003 HD11 HG21 ' A' ' 43' ' ' VAL . 40.1 tp -78.09 116.03 18.25 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.51 34.0 0.03 OUTLIER Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.76 -48.04 0.07 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 110.613 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.592 HG21 HD22 ' A' ' 27' ' ' LEU . 2.2 t -61.33 -57.78 23.21 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 108.591 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.493 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.7 Cg_endo -78.8 -28.4 4.13 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 O-C-N 123.307 1.161 . . . . 0.0 109.485 178.179 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.83 -61.13 0.65 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 107.503 -2.239 . . . . 0.0 107.503 -178.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 163.24 -54.78 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.605 0 C-N-CA 123.414 0.685 . . . . 0.0 110.042 177.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.38 15.28 0.3 Allowed 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 121.563 1.509 . . . . 0.0 111.448 -178.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -125.37 39.9 3.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.358 -0.839 . . . . 0.0 109.244 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.003 HG21 HD11 ' A' ' 34' ' ' LEU . 9.4 p -123.66 147.52 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 CA-C-O 121.674 0.749 . . . . 0.0 110.264 -178.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.467 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -174.48 175.97 46.79 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.94 149.41 37.82 Favored Glycine 0 N--CA 1.484 1.839 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.466 HG13 HG12 ' A' ' 49' ' ' ILE . 1.1 pp -142.37 139.19 17.29 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.545 -0.974 . . . . 0.0 108.847 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -58.89 -10.51 9.91 Favored 'Trans proline' 0 N--CA 1.505 2.202 0 C-N-CA 122.046 1.831 . . . . 0.0 115.261 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.428 ' H ' HD12 ' A' ' 46' ' ' ILE . 84.3 m-20 -96.19 30.63 2.41 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 120.529 -1.357 . . . . 0.0 111.899 -178.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.571 HG23 ' HB2' ' A' ' 54' ' ' SER . 50.8 mm -119.99 125.99 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.82 -44.62 15.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.551 -0.718 . . . . 0.0 111.78 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.784 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 172.11 -130.6 1.96 Allowed Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.406 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.449 ' CH2' ' HA2' ' A' ' 23' ' ' GLY . 5.5 t90 -40.21 -30.04 0.09 Allowed 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 -177.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -158.97 72.98 0.59 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.689 -1.257 . . . . 0.0 110.83 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.571 ' HB2' HG23 ' A' ' 49' ' ' ILE . 4.0 t -54.53 140.32 57.19 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.671 -0.643 . . . . 0.0 111.317 -178.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.461 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -72.81 -20.42 22.61 Favored 'Trans proline' 0 C--N 1.319 -1.006 0 O-C-N 123.412 1.217 . . . . 0.0 110.558 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 59' ' ' THR . 18.9 m -103.93 14.85 29.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.347 -0.846 . . . . 0.0 111.294 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.412 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 5.0 t -67.74 144.68 55.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.117 -0.99 . . . . 0.0 110.383 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.13 8.31 82.06 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 56' ' ' SER . 25.8 p -80.6 159.71 25.33 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.536 ' SG ' HG23 ' A' ' 110' ' ' VAL . 41.9 t -110.79 137.54 48.32 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.789 -178.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 81.9 m95 -142.96 155.88 44.77 Favored 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.12 -0.988 . . . . 0.0 111.394 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 68.7 tttt -112.18 132.25 55.0 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 177.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.05 129.9 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.557 -0.715 . . . . 0.0 109.723 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.3 m -120.68 142.18 49.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.749 -0.595 . . . . 0.0 111.362 -178.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 48.0 pt -119.74 164.37 22.4 Favored Pre-proline 0 N--CA 1.499 2.022 0 O-C-N 121.496 -0.753 . . . . 0.0 110.209 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.35 -26.02 76.72 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.174 1.25 . . . . 0.0 112.891 -178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -64.76 -39.96 94.48 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.218 -0.926 . . . . 0.0 109.907 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.1 60.75 0.29 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -160.45 153.51 21.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.603 -0.939 . . . . 0.0 109.339 178.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.45 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 88.0 p -151.71 159.68 43.89 Favored 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 122.12 0.962 . . . . 0.0 112.149 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.462 HG12 HD13 ' A' ' 93' ' ' LEU . 43.8 pt -139.91 164.13 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.268 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -105.27 127.18 52.81 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 118.86 -1.136 . . . . 0.0 109.784 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -115.89 130.03 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.627 -0.671 . . . . 0.0 110.134 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.513 ' HD3' HG12 ' A' ' 37' ' ' VAL . 51.4 ttt180 -100.67 136.91 39.79 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.407 ' HA2' HG12 ' A' ' 46' ' ' ILE . . . -59.64 149.71 39.8 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.947 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.727 HG11 ' CG2' ' A' ' 43' ' ' VAL . 7.0 p -167.47 -35.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.809 -0.818 . . . . 0.0 110.635 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.57 ' OD2' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -129.89 174.48 9.7 Favored 'General case' 0 N--CA 1.508 2.435 0 O-C-N 120.748 -1.22 . . . . 0.0 108.948 179.465 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 36.9 t -98.59 143.14 29.31 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.357 -0.84 . . . . 0.0 110.535 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -107.89 140.29 15.38 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 -81.96 58.2 3.8 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.724 -0.868 . . . . 0.0 111.589 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.99 58.17 1.62 Allowed Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 151.15 5.42 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.791 -1.195 . . . . 0.0 110.386 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -73.68 145.18 45.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.866 -0.785 . . . . 0.0 110.963 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.455 ' HA ' ' O ' ' A' ' 4' ' ' SER . 19.7 t-20 -139.55 130.69 26.55 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.423 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.467 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.1 m -132.28 172.5 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.057 -1.027 . . . . 0.0 112.202 -178.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.7 m-20 -54.69 150.8 16.81 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.275 -0.891 . . . . 0.0 109.823 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.43 -18.3 63.96 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.321 1.169 . . . . 0.0 110.656 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 86.1 m -78.73 -40.01 34.7 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.934 -1.104 . . . . 0.0 109.376 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.34 -39.11 82.0 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.509 -0.744 . . . . 0.0 109.107 179.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -59.99 -49.93 75.75 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.767 -0.583 . . . . 0.0 110.704 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.8 m -60.05 -37.37 79.63 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.406 -0.809 . . . . 0.0 110.623 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -70.0 -39.96 75.58 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.043 -179.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.462 HD13 HG12 ' A' ' 71' ' ' ILE . 52.7 tp -70.01 -44.25 69.73 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.569 -0.707 . . . . 0.0 111.428 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 63.0 t -96.37 -39.92 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.304 -0.873 . . . . 0.0 111.561 -177.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.53 -29.43 4.99 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.7 p -152.66 160.65 43.16 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.461 -1.023 . . . . 0.0 110.457 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 72.7 p -94.62 8.17 43.25 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.532 -0.73 . . . . 0.0 110.857 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -69.15 -36.07 77.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.42 -0.8 . . . . 0.0 110.677 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.75 87.0 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.525 -0.735 . . . . 0.0 110.284 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.38 -63.54 3.64 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 21.3 ptt180 -150.8 157.59 43.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.673 -0.898 . . . . 0.0 110.745 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 105' ' ' VAL . 62.2 t -128.09 122.26 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.553 -0.717 . . . . 0.0 110.223 179.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -82.87 169.12 16.43 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.603 -0.686 . . . . 0.0 110.961 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t30 60.01 43.22 14.84 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.62 -0.675 . . . . 0.0 111.306 179.315 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.774 HG21 HG23 ' A' ' 3' ' ' ILE . 63.7 t -87.21 130.02 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 C-N-CA 120.06 -0.656 . . . . 0.0 109.966 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -87.19 139.43 30.57 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.804 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -139.9 144.32 37.1 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.914 -0.491 . . . . 0.0 111.173 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.95 143.2 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.529 -0.732 . . . . 0.0 110.734 179.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 66.1 tt0 -75.72 134.33 40.54 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.603 -0.685 . . . . 0.0 110.009 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.536 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.9 m -131.34 172.7 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.554 -0.716 . . . . 0.0 110.237 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -60.11 146.07 44.47 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.513 -0.742 . . . . 0.0 110.986 -179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.695 HD21 HD11 ' A' ' 116' ' ' ILE . 10.1 tt -60.96 -37.22 81.64 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.621 -0.674 . . . . 0.0 110.796 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.8 m -55.23 -40.07 70.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.51 -0.744 . . . . 0.0 110.221 -178.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -59.98 -37.41 79.55 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.731 -0.606 . . . . 0.0 110.317 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -63.32 -46.65 85.67 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.369 -0.832 . . . . 0.0 110.116 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.695 HD11 HD21 ' A' ' 112' ' ' LEU . 88.0 mt -70.02 -40.01 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.554 -0.717 . . . . 0.0 110.738 -178.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -66.88 -40.06 87.67 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.468 -0.77 . . . . 0.0 110.498 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.85 -48.08 51.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.97 94.34 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.598 -0.942 . . . . 0.0 110.603 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 118.047 -0.977 . . . . 0.0 110.265 -179.894 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.205 0.526 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t -111.18 137.72 48.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.628 -0.67 . . . . 0.0 109.3 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.642 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.1 pt -113.98 147.7 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.729 -0.607 . . . . 0.0 111.018 -179.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.06 -170.09 3.34 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -141.82 148.1 38.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.41 -0.806 . . . . 0.0 110.337 178.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -127.05 148.61 66.52 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.46 -0.775 . . . . 0.0 109.825 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -82.57 -7.43 11.63 Favored 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.391 1.206 . . . . 0.0 112.367 -179.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 27.4 pt -72.93 -42.29 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.139 0 O-C-N 120.933 -1.104 . . . . 0.0 110.885 -179.025 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 31.9 m-85 -72.29 67.18 0.68 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 122.651 1.215 . . . . 0.0 111.049 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.55 171.05 7.58 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.327 176.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -60.04 -34.16 73.02 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -175.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -90.05 10.62 23.51 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.416 -1.314 . . . . 0.0 112.136 -177.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.45 HD22 ' HA ' ' A' ' 9' ' ' TYR . 53.4 tp -71.02 126.05 28.53 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 178.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.1 t -69.95 136.02 50.07 Favored 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.791 0.805 . . . . 0.0 110.454 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.741 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -66.43 -19.07 65.7 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.436 -179.189 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.27 -14.06 63.48 Favored Glycine 0 N--CA 1.493 2.456 0 O-C-N 121.044 -1.035 . . . . 0.0 110.776 -179.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.9 m -93.16 -14.59 26.97 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -1.161 . . . . 0.0 111.796 -178.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.828 HG23 ' OD2' ' A' ' 77' ' ' ASP . 7.2 p -90.04 160.04 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 120.996 -1.065 . . . . 0.0 110.708 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.59 -42.63 83.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.699 -0.626 . . . . 0.0 110.565 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.0 m -81.64 72.89 8.7 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -101.78 -76.59 0.57 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.705 -0.622 . . . . 0.0 110.628 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -127.27 168.87 14.16 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.108 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.35 -154.81 16.49 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.52 -2.232 . . . . 0.0 107.52 -177.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -70.2 -39.92 74.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.292 -1.122 . . . . 0.0 110.271 179.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.433 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 58.8 m-70 -94.09 0.71 56.04 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.454 -0.779 . . . . 0.0 111.194 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.59 127.65 37.64 Favored Glycine 0 N--CA 1.495 2.611 0 O-C-N 120.964 -1.085 . . . . 0.0 110.423 -179.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.553 HD13 HG11 ' A' ' 37' ' ' VAL . 84.5 mt -100.04 -5.19 28.44 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 122.012 -0.699 . . . . 0.0 110.072 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.2 ttm -63.04 -37.72 88.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.28 -0.887 . . . . 0.0 109.764 179.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.92 -73.45 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.611 -0.681 . . . . 0.0 111.506 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -69.94 -40.05 75.72 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.157 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CG ' HG23 ' A' ' 37' ' ' VAL . 35.6 m-85 -120.36 89.89 44.44 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.864 -0.523 . . . . 0.0 109.801 -178.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.07 -10.01 25.38 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 O-C-N 123.196 1.103 . . . . 0.0 111.049 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 31.0 m -130.01 142.13 50.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.231 -0.918 . . . . 0.0 110.366 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.927 HD11 HG21 ' A' ' 43' ' ' VAL . 35.4 tp -69.94 119.25 13.87 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.642 -0.661 . . . . 0.0 110.405 -179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.76 32.6 0.04 OUTLIER Glycine 0 N--CA 1.497 2.746 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.985 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -156.95 -44.95 0.07 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -1.16 . . . . 0.0 110.096 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.553 HG11 HD13 ' A' ' 27' ' ' LEU . 2.7 t -63.62 -59.03 12.75 Favored Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.552 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.476 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.5 Cg_endo -76.82 -29.22 5.63 Favored 'Trans proline' 0 N--CA 1.487 1.109 0 O-C-N 123.271 1.143 . . . . 0.0 109.55 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 127.63 -61.92 0.64 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.635 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 164.69 -54.74 0.0 OUTLIER Pre-proline 0 N--CA 1.509 2.503 0 C-N-CA 123.368 0.667 . . . . 0.0 109.885 177.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.716 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -102.21 11.81 0.39 Allowed 'Trans proline' 0 C--N 1.325 -0.702 0 C-N-CA 121.473 1.448 . . . . 0.0 111.419 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -117.61 31.16 6.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.244 -0.91 . . . . 0.0 110.059 -178.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.963 ' CG2' HG11 ' A' ' 76' ' ' VAL . 15.0 p -110.46 139.92 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.561 0.696 . . . . 0.0 110.943 -179.306 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.504 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.5 173.79 42.59 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.488 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -94.32 163.72 25.38 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.787 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -154.27 162.53 26.7 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.806 -0.82 . . . . 0.0 109.888 179.015 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -67.33 -16.94 49.23 Favored 'Trans proline' 0 N--CA 1.5 1.902 0 C-N-CA 121.502 1.468 . . . . 0.0 113.95 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.546 ' H ' HD12 ' A' ' 46' ' ' ILE . 94.4 m-20 -89.39 15.83 8.53 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.541 -1.349 . . . . 0.0 113.025 -177.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.656 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.0 mm -108.02 122.63 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.72 -45.47 29.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.305 -0.872 . . . . 0.0 111.664 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.3 -127.81 1.66 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 118.983 -1.58 . . . . 0.0 110.95 -179.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.1 t90 -48.92 -26.03 2.25 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.897 -0.767 . . . . 0.0 112.841 -178.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -147.27 63.13 1.16 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.169 -0.957 . . . . 0.0 111.379 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.656 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.5 p -63.68 141.72 97.96 Favored Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.359 -0.838 . . . . 0.0 110.87 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.433 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -80.69 -21.74 6.98 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 O-C-N 123.41 1.216 . . . . 0.0 111.599 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.6 m -95.11 11.63 31.5 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.357 -0.84 . . . . 0.0 111.183 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -72.14 146.29 47.54 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.209 -0.932 . . . . 0.0 110.304 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.78 22.83 52.13 Favored Glycine 0 N--CA 1.495 2.568 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.098 178.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.1 m -109.29 170.65 7.92 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -1.11 . . . . 0.0 109.009 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 2.1 m -118.96 148.2 43.22 Favored 'General case' 0 N--CA 1.51 2.556 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -177.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.459 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 67.9 m95 -144.34 149.67 36.55 Favored 'General case' 0 N--CA 1.51 2.565 0 O-C-N 121.116 -0.99 . . . . 0.0 110.219 175.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.3 ttpt -101.46 131.2 47.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 176.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.444 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.8 t -108.61 124.47 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.64 -178.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 94.3 m -120.03 130.03 54.52 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-O 121.189 0.519 . . . . 0.0 111.42 -178.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.483 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.4 pt -106.85 166.15 11.63 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.789 -0.569 . . . . 0.0 110.492 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.7 Cg_endo -63.92 -27.56 66.77 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 O-C-N 123.347 1.183 . . . . 0.0 112.605 -178.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -64.3 -39.92 94.89 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.169 -0.957 . . . . 0.0 109.734 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.46 58.3 0.32 Allowed Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.468 ' HB2' HD11 ' A' ' 65' ' ' ILE . 85.1 m-20 -150.72 147.32 27.19 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 178.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 49.1 m -147.25 152.36 38.19 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.859 -1.136 . . . . 0.0 112.652 -179.467 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 93' ' ' LEU . 37.7 pt -140.13 161.66 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.31 129.76 47.34 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.093 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.0 mm -116.58 129.97 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 109.782 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.416 ' HD3' HG12 ' A' ' 37' ' ' VAL . 58.6 ttt180 -101.32 133.31 46.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.965 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -52.52 149.59 10.06 Favored Glycine 0 N--CA 1.498 2.795 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.963 HG11 ' CG2' ' A' ' 43' ' ' VAL . 14.9 p -174.48 -28.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.652 -0.91 . . . . 0.0 111.121 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.828 ' OD2' HG23 ' A' ' 18' ' ' VAL . 5.2 m-20 -129.75 167.47 18.02 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.717 -1.239 . . . . 0.0 109.422 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 77.7 p -97.84 155.89 16.84 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -0.835 . . . . 0.0 110.771 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.94 139.52 11.01 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -61.04 -39.9 91.56 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.837 -0.802 . . . . 0.0 110.209 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.61 73.53 0.08 OUTLIER Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 155.22 -163.34 31.45 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.89 -1.148 . . . . 0.0 110.298 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.787 ' CD2' HG22 ' A' ' 46' ' ' ILE . 39.8 m-85 -125.63 121.56 33.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.919 -0.753 . . . . 0.0 109.113 179.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -116.08 130.24 56.71 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.504 HG12 ' HA3' ' A' ' 44' ' ' GLY . 26.9 m -129.18 173.47 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -178.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.9 m-20 -56.53 158.2 8.55 Favored Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.544 -0.722 . . . . 0.0 110.021 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.83 -28.66 36.13 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.453 1.238 . . . . 0.0 111.06 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -70.03 -39.96 75.44 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.993 -1.067 . . . . 0.0 109.26 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.716 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.87 -41.31 87.47 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.645 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.64 -50.0 75.27 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.804 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -60.18 -40.04 88.58 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.515 -0.741 . . . . 0.0 110.839 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.27 -39.56 86.06 Favored 'General case' 0 N--CA 1.495 1.797 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.207 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.463 ' HB2' HD13 ' A' ' 71' ' ' ILE . 65.5 tp -69.95 -41.66 74.25 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.835 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -98.89 -36.65 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.255 -0.903 . . . . 0.0 111.722 -177.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.04 -27.43 6.75 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.8 p -153.07 160.46 42.95 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.552 -0.97 . . . . 0.0 109.81 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 60.9 p -90.87 6.82 42.92 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.366 -0.834 . . . . 0.0 110.793 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -69.98 -25.91 63.84 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.31 -0.868 . . . . 0.0 110.87 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.17 77.03 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.466 -0.771 . . . . 0.0 110.949 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.94 -80.46 1.76 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 19.1 ttm180 -137.07 139.94 41.66 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.677 -0.896 . . . . 0.0 110.119 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.24 119.93 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.523 -0.736 . . . . 0.0 110.231 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -90.43 169.7 10.84 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.754 0.787 . . . . 0.0 111.176 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 28.8 t30 59.95 40.05 19.4 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.695 -0.628 . . . . 0.0 111.497 179.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.512 HG21 HG12 ' A' ' 3' ' ' ILE . 81.5 t -84.41 126.98 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.709 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -92.58 152.26 19.7 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.13 -1.028 . . . . 0.0 108.87 179.179 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -146.82 150.0 34.43 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.631 -0.668 . . . . 0.0 112.074 -177.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -141.32 134.73 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.745 -0.597 . . . . 0.0 110.097 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.459 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 55.6 tt0 -72.46 141.61 48.6 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.524 0.678 . . . . 0.0 110.979 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.0 m -132.27 172.07 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -60.0 143.98 50.42 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.453 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.54 HD21 HD11 ' A' ' 116' ' ' ILE . 8.4 tt -60.03 -39.97 87.74 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.385 -0.822 . . . . 0.0 110.226 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.3 t -51.29 -33.98 31.08 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.615 -0.678 . . . . 0.0 111.28 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -65.38 -39.99 92.94 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.482 -0.761 . . . . 0.0 110.935 -179.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 86.8 m -60.42 -47.76 84.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.393 -0.817 . . . . 0.0 110.243 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 112' ' ' LEU . 88.1 mt -69.96 -40.02 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.955 -0.466 . . . . 0.0 110.772 -179.118 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -66.48 -39.99 89.08 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.498 -0.751 . . . . 0.0 110.866 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -78.68 -60.06 2.7 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.159 -178.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.13 93.59 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.418 -1.048 . . . . 0.0 110.738 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.402 -179.784 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.992 0.425 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.5 p -112.95 145.86 40.04 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.686 -0.634 . . . . 0.0 110.085 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 83' ' ' PHE . 45.1 pt -120.01 149.96 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.626 -0.671 . . . . 0.0 110.743 -179.529 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.415 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -145.62 -172.37 3.88 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.172 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -140.96 145.44 36.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.325 -0.859 . . . . 0.0 110.199 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.73 149.48 64.83 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.409 -0.807 . . . . 0.0 110.005 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.94 48.25 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.074 0 O-C-N 123.432 1.227 . . . . 0.0 110.602 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 9' ' ' TYR . 7.6 tp -118.79 -6.79 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.527 -0.733 . . . . 0.0 111.052 -179.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CD2' HG23 ' A' ' 8' ' ' ILE . 29.2 m-85 -122.69 70.94 1.01 Allowed 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 122.62 1.2 . . . . 0.0 110.182 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.54 171.45 7.56 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 114.597 -1.183 . . . . 0.0 107.921 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.646 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -56.56 -28.71 60.8 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -175.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.37 12.26 21.07 Favored 'General case' 0 N--CA 1.498 1.966 0 C-N-CA 118.323 -1.351 . . . . 0.0 112.236 -177.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 14' ' ' SER . 0.4 OUTLIER -69.55 116.62 10.17 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.205 -0.934 . . . . 0.0 109.817 179.779 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.424 ' N ' HD13 ' A' ' 13' ' ' LEU . 47.5 t -65.88 137.74 57.39 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.837 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.529 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.9 mmm -67.77 -16.37 64.08 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.87 -0.519 . . . . 0.0 111.715 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.14 -13.82 82.4 Favored Glycine 0 N--CA 1.495 2.607 0 O-C-N 120.849 -1.157 . . . . 0.0 110.626 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -94.98 -17.68 21.74 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.19 -1.183 . . . . 0.0 111.708 -178.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.635 HG21 HG22 ' A' ' 76' ' ' VAL . 8.2 p -87.21 159.16 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.186 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.517 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.44 -40.0 64.85 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.198 -0.939 . . . . 0.0 110.301 -179.556 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 62.8 m -78.88 82.61 5.06 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -90.45 -80.73 0.32 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.048 -1.032 . . . . 0.0 112.875 -177.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.461 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 24.5 p-10 -154.88 20.55 0.45 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.734 -1.229 . . . . 0.0 112.535 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.22 -144.91 0.04 OUTLIER Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -69.63 -39.93 76.84 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.821 -0.811 . . . . 0.0 109.808 178.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.529 ' CD2' ' HA ' ' A' ' 53' ' ' ASP . 2.3 p80 -95.57 4.57 53.02 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.468 -0.77 . . . . 0.0 110.098 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.76 140.75 43.55 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.183 -0.948 . . . . 0.0 111.174 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.574 HD13 HG11 ' A' ' 37' ' ' VAL . 91.2 mt -104.34 -0.04 28.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 122.049 -0.677 . . . . 0.0 110.389 178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.7 ttm -60.05 -35.06 74.32 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 110.521 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.51 -73.22 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.458 -0.776 . . . . 0.0 111.398 -177.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -70.36 -39.99 74.29 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.372 -0.83 . . . . 0.0 110.121 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.61 ' CG ' HG23 ' A' ' 37' ' ' VAL . 54.1 m-85 -116.97 86.47 19.8 Favored Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -178.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.31 -26.93 24.45 Favored 'Trans proline' 0 C--N 1.317 -1.101 0 O-C-N 123.39 1.205 . . . . 0.0 110.955 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 15.1 m -116.89 161.26 19.61 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.359 -0.838 . . . . 0.0 110.41 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 43' ' ' VAL . 42.3 tp -86.59 114.92 23.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.769 -0.582 . . . . 0.0 111.292 -178.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 156.49 37.09 0.02 OUTLIER Glycine 0 N--CA 1.497 2.734 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -162.2 -48.26 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.376 -1.073 . . . . 0.0 110.578 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.61 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.8 t -59.96 -59.36 14.11 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.494 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.3 Cg_endo -76.76 -31.98 3.77 Favored 'Trans proline' 0 C--N 1.317 -1.131 0 N-CA-C 109.007 -1.189 . . . . 0.0 109.007 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 133.68 -60.95 0.65 Allowed Glycine 0 N--CA 1.486 1.977 0 N-CA-C 107.498 -2.241 . . . . 0.0 107.498 -178.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.646 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 157.9 -51.06 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.665 0 C-N-CA 123.877 0.871 . . . . 0.0 109.936 177.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 52.9 Cg_endo -101.0 5.61 0.62 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.595 1.53 . . . . 0.0 112.039 -177.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -122.36 47.57 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.975 . . . . 0.0 109.961 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 34' ' ' LEU . 14.3 p -117.66 141.11 37.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.869 0.843 . . . . 0.0 110.181 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -169.79 176.19 43.7 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -92.22 165.06 28.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.776 HD11 ' CA ' ' A' ' 75' ' ' GLY . 0.9 OUTLIER -154.8 161.0 30.39 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.631 -0.923 . . . . 0.0 109.801 178.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -66.7 -35.01 29.95 Favored 'Trans proline' 0 N--CA 1.502 2.015 0 C-N-CA 121.777 1.651 . . . . 0.0 115.2 -175.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -68.95 -10.0 55.02 Favored 'General case' 0 N--CA 1.507 2.398 0 O-C-N 120.736 -1.227 . . . . 0.0 113.24 -177.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.1 mm -81.23 129.23 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 O-C-N 120.717 -1.24 . . . . 0.0 109.417 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.12 -49.64 7.17 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.325 -0.859 . . . . 0.0 112.108 -178.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.517 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.55 -139.35 4.85 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.995 -1.574 . . . . 0.0 111.608 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 70.7 t90 -49.01 -24.58 1.58 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.765 -0.844 . . . . 0.0 112.914 -178.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.529 ' HA ' ' CD2' ' A' ' 25' ' ' HIS . 14.7 t70 -142.27 71.93 1.36 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.191 -0.943 . . . . 0.0 109.583 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.47 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 9.8 p -82.65 136.91 44.72 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.937 -0.477 . . . . 0.0 110.318 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -78.6 -16.81 13.03 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 O-C-N 123.318 1.167 . . . . 0.0 111.167 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.3 m -97.39 4.19 50.74 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.316 -0.865 . . . . 0.0 112.543 -178.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.1 t -66.58 142.53 57.46 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.905 -1.122 . . . . 0.0 110.421 -179.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 94.13 -7.71 72.76 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.574 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 22.4 p -70.44 157.77 37.22 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 118.9 1.35 . . . . 0.0 110.743 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -107.21 130.8 54.68 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.939 -0.476 . . . . 0.0 110.553 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 92.9 m95 -135.17 147.62 49.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.279 -0.888 . . . . 0.0 110.561 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -106.42 135.55 47.73 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.0 t -108.2 123.88 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.65 -0.656 . . . . 0.0 109.382 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 41.3 m -119.59 137.31 53.93 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.111 0.481 . . . . 0.0 111.075 -178.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 35.1 pt -115.72 164.26 18.08 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.676 -0.64 . . . . 0.0 110.401 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.09 -25.18 80.77 Favored 'Trans proline' 0 N--CA 1.497 1.683 0 C-N-CA 121.268 1.312 . . . . 0.0 112.514 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -63.23 -40.0 96.21 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.256 -0.903 . . . . 0.0 109.706 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 114.61 60.72 0.38 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -159.95 151.99 20.49 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.717 -0.873 . . . . 0.0 108.854 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 61.3 p -155.48 161.07 41.02 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.115 -1.034 . . . . 0.0 112.428 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 73' ' ' ILE . 37.8 pt -137.36 166.48 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -105.52 127.04 52.79 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.665 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 71' ' ' ILE . 46.3 mm -120.04 129.95 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 121.463 -0.773 . . . . 0.0 110.547 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.536 ' HD3' HG12 ' A' ' 37' ' ' VAL . 59.9 ttt180 -100.42 140.04 35.24 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.443 -0.786 . . . . 0.0 109.016 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.776 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -60.02 149.45 41.5 Favored Glycine 0 N--CA 1.494 2.538 0 CA-C-O 122.019 0.788 . . . . 0.0 111.575 -178.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.635 HG22 HG21 ' A' ' 18' ' ' VAL . 4.0 p -159.0 -39.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 122.017 -0.696 . . . . 0.0 109.653 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.633 ' OD2' HG23 ' A' ' 18' ' ' VAL . 3.4 t70 -135.86 170.2 16.36 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 120.963 -1.086 . . . . 0.0 109.517 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.6 t -95.52 160.4 14.53 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.296 -0.877 . . . . 0.0 111.828 -178.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.85 149.14 18.71 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 63.6 mtt180 -60.07 -33.98 72.81 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.655 -0.909 . . . . 0.0 110.586 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.4 79.48 0.05 OUTLIER Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.44 169.0 13.4 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 3' ' ' ILE . 19.1 m-85 -91.24 120.13 31.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.953 . . . . 0.0 109.817 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.415 ' HA ' ' O ' ' A' ' 4' ' ' SER . 1.6 m120 -114.27 130.46 56.65 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 44' ' ' GLY . 34.9 m -134.86 176.59 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.029 -1.044 . . . . 0.0 111.869 -178.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -57.42 152.7 31.68 Favored Pre-proline 0 N--CA 1.496 1.855 0 C-N-CA 120.133 -0.627 . . . . 0.0 110.051 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.64 -22.69 64.34 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.353 1.186 . . . . 0.0 110.408 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -73.13 -41.03 64.41 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.015 -1.053 . . . . 0.0 108.745 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.85 -39.76 87.68 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -59.98 -49.98 75.55 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.127 179.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.464 ' CG2' HG23 ' A' ' 97' ' ' THR . 12.1 p -60.01 -35.53 75.25 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.44 -0.787 . . . . 0.0 110.77 -179.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 55.9 mttm -69.95 -40.03 75.71 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.342 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 67.1 tp -70.49 -46.08 64.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 0.0 111.41 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -101.76 -38.13 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.172 0 O-C-N 121.288 -0.883 . . . . 0.0 111.655 -177.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 -18.88 16.46 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 41.8 p -158.8 151.96 22.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.249 -1.148 . . . . 0.0 110.519 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.464 HG23 ' CG2' ' A' ' 91' ' ' THR . 75.1 p -93.89 8.51 41.0 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.632 -0.667 . . . . 0.0 110.917 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.44 -0.788 . . . . 0.0 110.552 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.0 85.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.608 -0.683 . . . . 0.0 110.92 -178.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -59.4 3.19 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 108.538 -1.825 . . . . 0.0 108.538 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 53.9 ptt85 -150.1 157.14 42.81 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.792 -0.828 . . . . 0.0 109.946 179.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.7 t -128.35 126.23 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.468 -0.77 . . . . 0.0 109.719 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -90.19 169.0 11.51 Favored 'General case' 0 N--CA 1.496 1.867 0 CA-C-O 121.771 0.796 . . . . 0.0 111.75 -178.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 53.2 t30 60.07 40.02 19.05 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 121.402 0.62 . . . . 0.0 111.002 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.519 HG21 HG12 ' A' ' 3' ' ' ILE . 79.9 t -85.17 129.68 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.506 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -88.27 138.83 31.09 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.234 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.1 p90 -132.99 140.85 47.98 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.34 0.59 . . . . 0.0 110.824 -178.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 18.8 m -143.83 139.94 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.755 -0.59 . . . . 0.0 110.987 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 54.9 tt0 -77.32 139.08 39.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.702 -0.624 . . . . 0.0 110.292 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 34.6 m -130.02 165.35 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.61 -0.681 . . . . 0.0 110.649 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -55.42 139.97 41.55 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.585 -0.697 . . . . 0.0 110.753 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.618 HD21 HD11 ' A' ' 116' ' ' ILE . 9.2 tt -60.83 -39.98 91.06 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.646 -0.659 . . . . 0.0 110.825 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.0 m -54.45 -37.87 65.69 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.577 -0.702 . . . . 0.0 111.112 -177.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -65.73 -36.9 84.91 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.558 -0.714 . . . . 0.0 111.12 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 81.0 m -63.05 -44.43 95.86 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.177 -0.952 . . . . 0.0 109.913 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.618 HD11 HD21 ' A' ' 112' ' ' LEU . 80.3 mt -69.64 -39.96 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.099 -179.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -66.4 -40.05 89.39 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.469 -0.769 . . . . 0.0 110.467 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -74.31 -56.52 5.12 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.26 93.94 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.445 -1.032 . . . . 0.0 110.256 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.7 t30 . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 117.832 -1.08 . . . . 0.0 111.054 179.611 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.2 m . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.438 0.637 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -114.09 142.35 46.31 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.381 0.61 . . . . 0.0 110.668 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.727 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.9 pt -114.25 149.96 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.353 0.596 . . . . 0.0 110.887 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 23.0 m -146.35 -172.82 4.03 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.166 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -140.06 149.32 42.98 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.82 179.106 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.38 148.9 71.75 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.457 -0.777 . . . . 0.0 109.435 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -84.0 -9.05 9.86 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.275 1.145 . . . . 0.0 112.636 -178.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.2 pt -70.01 -40.06 78.09 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.227 0 O-C-N 120.953 -1.092 . . . . 0.0 110.984 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.52 ' HA ' HD22 ' A' ' 13' ' ' LEU . 50.9 m-85 -73.3 67.3 0.97 Allowed 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 122.877 1.322 . . . . 0.0 111.324 -178.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.93 171.55 7.28 Favored 'General case' 0 N--CA 1.49 1.55 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.203 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.97 -34.45 71.81 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -175.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -89.95 10.94 22.03 Favored 'General case' 0 N--CA 1.501 2.11 0 C-N-CA 118.285 -1.366 . . . . 0.0 112.507 -177.538 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 9' ' ' TYR . 50.0 tp -70.61 124.45 24.28 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.245 -0.909 . . . . 0.0 109.666 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 61.5 p -70.76 137.66 49.81 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.672 0.748 . . . . 0.0 110.092 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.782 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.9 mmm -66.41 -19.1 65.71 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.938 -0.476 . . . . 0.0 112.025 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.78 -15.39 75.85 Favored Glycine 0 N--CA 1.495 2.626 0 O-C-N 120.95 -1.094 . . . . 0.0 111.296 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.9 p -89.04 -7.52 55.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.208 -1.172 . . . . 0.0 111.9 -178.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.782 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -99.86 169.47 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.098 -1.001 . . . . 0.0 110.638 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.782 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.89 -44.49 91.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.525 -0.734 . . . . 0.0 109.796 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.1 m -80.04 80.71 6.42 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -101.19 -81.56 0.48 Allowed 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.262 -0.899 . . . . 0.0 113.247 -177.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -131.12 11.14 5.02 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.139 -0.976 . . . . 0.0 113.025 -177.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.68 -153.49 3.43 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 179.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -65.93 -40.06 91.05 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.517 -0.99 . . . . 0.0 109.691 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 83.7 m-70 -91.0 6.31 45.3 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -0.797 . . . . 0.0 110.734 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -59.43 134.62 51.71 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.859 HD13 HG11 ' A' ' 37' ' ' VAL . 89.6 mt -101.16 -4.47 27.19 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 122.024 -0.692 . . . . 0.0 110.581 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 59.4 ttm -62.22 -37.03 83.79 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.273 -0.892 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.11 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.608 -0.683 . . . . 0.0 111.896 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -69.09 -39.99 78.67 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.367 -0.833 . . . . 0.0 109.743 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.557 ' CD2' HG23 ' A' ' 37' ' ' VAL . 48.7 m-85 -119.94 91.69 45.8 Favored Pre-proline 0 N--CA 1.491 1.608 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.92 -18.67 40.95 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.293 1.154 . . . . 0.0 111.241 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 90.6 m -123.75 141.27 52.18 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.229 -0.919 . . . . 0.0 110.026 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.897 HD11 HG21 ' A' ' 43' ' ' VAL . 41.7 tp -65.9 120.75 13.62 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.77 -0.581 . . . . 0.0 111.036 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.29 32.41 0.04 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.862 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.443 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 25.0 mt-10 -155.29 -49.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -1.128 . . . . 0.0 110.448 178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.859 HG11 HD13 ' A' ' 27' ' ' LEU . 3.1 t -60.27 -60.81 9.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.6 Cg_endo -74.79 -28.6 9.43 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 N-CA-C 108.979 -1.2 . . . . 0.0 108.979 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.43 -61.32 0.65 Allowed Glycine 0 N--CA 1.484 1.872 0 N-CA-C 107.017 -2.433 . . . . 0.0 107.017 -178.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.543 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.8 t80 165.48 -72.7 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.578 0 C-N-CA 123.377 0.671 . . . . 0.0 110.083 177.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.543 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -83.01 -8.58 10.94 Favored 'Trans proline' 0 N--CA 1.493 1.497 0 CA-C-N 118.995 0.677 . . . . 0.0 112.174 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -97.91 34.29 1.93 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.134 -0.979 . . . . 0.0 110.51 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.897 HG21 HD11 ' A' ' 34' ' ' LEU . 10.6 p -109.95 137.3 42.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.665 0.745 . . . . 0.0 109.498 179.277 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.701 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.62 172.89 43.22 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.044 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.54 156.34 29.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.74 HD12 ' HA2' ' A' ' 75' ' ' GLY . 81.3 mt -139.97 150.46 62.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.61 ' HD2' HG23 ' A' ' 46' ' ' ILE . 37.3 Cg_endo -59.36 -10.15 10.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.349 1.184 . . . . 0.0 113.626 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.601 ' H ' HG22 ' A' ' 46' ' ' ILE . 83.0 m-20 -94.58 -12.54 27.3 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.693 -1.254 . . . . 0.0 112.329 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.606 HG23 ' CB ' ' A' ' 54' ' ' SER . 51.3 mm -75.08 119.67 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 C-N-CA 118.601 -1.24 . . . . 0.0 108.397 178.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.74 -45.3 21.47 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.26 -0.9 . . . . 0.0 112.529 -178.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.782 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 169.9 -138.91 5.28 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.918 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 36.8 t90 -42.79 -28.81 0.27 Allowed 'General case' 0 N--CA 1.502 2.175 0 O-C-N 121.956 -0.731 . . . . 0.0 112.769 -179.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -142.62 65.34 1.35 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.339 -0.851 . . . . 0.0 110.112 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.606 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.0 p -66.39 134.51 94.58 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.643 -0.661 . . . . 0.0 110.899 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -74.93 -23.48 13.9 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 O-C-N 123.45 1.237 . . . . 0.0 111.05 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.62 15.19 14.89 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 111.385 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t -78.28 151.62 32.91 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 110.054 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 71.08 29.89 68.31 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.7 m -117.16 132.97 56.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.59 -0.947 . . . . 0.0 109.963 179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -81.07 145.5 31.07 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -177.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.47 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -149.34 150.09 31.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 110.471 178.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -108.45 132.03 54.2 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.3 t -108.9 127.36 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.49 -0.756 . . . . 0.0 109.597 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 88.0 m -120.06 136.66 54.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.942 -0.474 . . . . 0.0 110.939 -178.135 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.463 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 38.0 pt -115.95 164.82 16.36 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.541 -0.724 . . . . 0.0 110.568 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.8 -25.1 74.61 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 C-N-CA 121.236 1.29 . . . . 0.0 112.66 -178.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -64.89 -40.0 94.41 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.23 -0.919 . . . . 0.0 109.794 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.75 61.09 0.32 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.271 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -160.01 150.64 18.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.758 -0.848 . . . . 0.0 108.831 179.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.422 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 67.0 p -151.56 157.41 42.19 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.247 -0.981 . . . . 0.0 112.248 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 73' ' ' ILE . 44.3 pt -139.34 165.05 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -103.36 125.76 50.15 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.274 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 71' ' ' ILE . 49.5 mm -119.8 131.01 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.707 -0.621 . . . . 0.0 110.246 -178.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 -99.38 137.06 38.42 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.439 -0.788 . . . . 0.0 109.079 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.74 ' HA2' HD12 ' A' ' 46' ' ' ILE . . . -57.18 150.74 28.62 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 44' ' ' GLY . 11.9 p -169.54 -28.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.679 -0.895 . . . . 0.0 111.307 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.622 ' OD1' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -130.0 166.98 18.99 Favored 'General case' 0 N--CA 1.505 2.306 0 O-C-N 120.585 -1.322 . . . . 0.0 109.712 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.488 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 48.2 t -94.68 144.51 25.55 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.482 -0.761 . . . . 0.0 111.024 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -126.29 141.67 13.0 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -60.68 -28.38 68.57 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.759 -0.847 . . . . 0.0 109.814 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.04 79.92 0.05 OUTLIER Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.27 163.79 11.21 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.827 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.727 ' HB2' HG22 ' A' ' 3' ' ' ILE . 16.1 m-85 -92.16 115.33 27.99 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.666 -0.902 . . . . 0.0 109.915 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.415 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 57.7 t-20 -109.04 131.99 54.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.343 -0.848 . . . . 0.0 109.028 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.3 m -132.44 175.52 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.185 0 O-C-N 120.961 -1.087 . . . . 0.0 111.833 -178.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -55.73 156.69 8.83 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.41 -0.806 . . . . 0.0 109.953 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.07 -22.37 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.295 1.155 . . . . 0.0 110.65 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -76.28 -40.03 52.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.021 -1.049 . . . . 0.0 108.953 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.531 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.26 -39.87 89.76 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -60.04 -50.03 75.31 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.202 -0.599 . . . . 0.0 110.486 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 56.9 m -59.96 -39.5 85.82 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.546 -0.721 . . . . 0.0 110.709 -178.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.4 ' HE3' ' HA ' ' A' ' 89' ' ' ALA . 57.1 mtmt -70.03 -40.05 75.41 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.789 -178.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.422 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 65.4 tp -70.02 -43.4 71.42 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.65 -0.656 . . . . 0.0 111.492 -179.466 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.2 t -96.2 -39.82 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 O-C-N 121.262 -0.899 . . . . 0.0 111.258 -178.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.63 -38.96 2.55 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.8 m -139.98 152.2 46.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.686 -0.891 . . . . 0.0 110.182 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.6 p -90.71 6.33 44.51 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.403 -0.81 . . . . 0.0 111.169 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -70.04 -29.22 66.2 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.478 -0.764 . . . . 0.0 110.736 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.05 -40.09 84.02 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.538 -0.726 . . . . 0.0 110.625 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -74.48 1.68 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 12.1 ptt-85 -144.74 149.54 35.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.681 -0.894 . . . . 0.0 110.271 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.94 119.36 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.487 -0.758 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -83.84 173.49 11.21 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.723 -0.611 . . . . 0.0 110.604 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 60.01 45.75 11.72 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.636 -0.665 . . . . 0.0 110.998 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.405 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 73.7 t -95.53 128.06 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.493 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -85.4 136.1 33.6 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.092 -1.005 . . . . 0.0 109.639 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.8 p90 -132.87 140.98 48.18 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.134 0.492 . . . . 0.0 110.738 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.2 m -144.62 141.21 23.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.609 -0.682 . . . . 0.0 110.979 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.47 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 58.6 tt0 -70.93 140.73 51.05 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.536 -0.727 . . . . 0.0 110.334 178.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.23 167.44 26.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.105 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -61.28 148.26 41.76 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.414 -0.804 . . . . 0.0 110.325 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.73 -40.05 96.0 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.433 -0.792 . . . . 0.0 111.133 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 53.4 m -56.29 -38.18 70.88 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.583 -0.698 . . . . 0.0 110.587 -178.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.09 -35.71 75.81 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.432 -0.792 . . . . 0.0 110.287 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 80.5 m -70.04 -39.99 75.41 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.522 -0.736 . . . . 0.0 109.383 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 50.6 mm -66.77 -40.04 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 CA-C-O 121.473 0.654 . . . . 0.0 109.395 -178.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -69.98 -39.96 75.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.818 -0.551 . . . . 0.0 110.299 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.88 -57.73 5.67 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.96 -41.64 92.37 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.507 -0.996 . . . . 0.0 110.704 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.301 -179.889 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.456 HG23 ' HB ' ' A' ' 105' ' ' VAL . 34.8 m . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.464 0.65 . . . . 0.0 111.201 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.1 t -113.57 140.19 48.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.746 -0.596 . . . . 0.0 109.744 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.67 HG23 HG21 ' A' ' 105' ' ' VAL . 37.4 pt -109.16 148.14 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 111.042 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . 0.433 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -146.72 -170.82 3.61 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.321 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 50.3 p90 -144.71 150.01 36.58 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.967 179.276 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -130.29 148.58 70.39 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.566 -0.709 . . . . 0.0 109.554 178.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.79 -6.58 12.43 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 O-C-N 123.247 1.13 . . . . 0.0 112.46 -179.117 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 9' ' ' TYR . 30.1 pt -69.98 -40.0 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 120.865 -1.147 . . . . 0.0 110.925 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.528 ' HA ' HD22 ' A' ' 13' ' ' LEU . 40.5 m-85 -74.17 67.24 1.33 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-O 122.774 1.273 . . . . 0.0 111.132 -178.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.19 171.86 7.12 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 114.299 -1.319 . . . . 0.0 108.146 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.05 -33.93 72.72 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.98 10.22 24.84 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.428 -1.42 . . . . 0.0 112.316 -177.276 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.528 HD22 ' HA ' ' A' ' 9' ' ' TYR . 29.0 tp -70.33 123.33 21.46 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.263 -0.898 . . . . 0.0 109.703 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.1 m -69.14 136.63 52.46 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.783 -0.767 . . . . 0.0 109.961 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.802 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.6 mmm -67.21 -17.72 64.94 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 122.03 -0.419 . . . . 0.0 111.65 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -70.75 -14.7 73.01 Favored Glycine 0 N--CA 1.495 2.612 0 O-C-N 120.955 -1.091 . . . . 0.0 111.095 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -88.43 -9.44 52.55 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.203 -1.175 . . . . 0.0 111.787 -179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.802 HG12 ' O ' ' A' ' 15' ' ' MET . 8.4 p -95.54 168.49 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.072 -1.017 . . . . 0.0 110.092 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.8 -44.8 86.57 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.542 -0.724 . . . . 0.0 109.939 -179.658 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.5 m -81.28 84.05 6.71 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.4 m -99.95 -79.95 0.48 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.56 -0.712 . . . . 0.0 112.88 -178.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -131.09 9.93 4.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.24 -0.912 . . . . 0.0 112.77 -178.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.41 -153.2 1.83 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.755 -1.738 . . . . 0.0 108.755 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -70.01 -39.95 75.53 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.789 -0.83 . . . . 0.0 109.648 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 75.5 m-70 -90.03 0.21 57.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.625 -0.672 . . . . 0.0 110.866 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.71 137.89 49.06 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.67 HD13 HG11 ' A' ' 37' ' ' VAL . 75.0 mt -99.02 -5.22 30.8 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.916 -0.755 . . . . 0.0 110.251 178.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.401 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.1 ttm -60.01 -37.2 79.01 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.307 -0.871 . . . . 0.0 110.97 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.94 -74.84 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.497 -0.752 . . . . 0.0 111.798 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -70.0 -39.97 75.57 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.433 -0.792 . . . . 0.0 110.359 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.548 ' CD2' HG23 ' A' ' 37' ' ' VAL . 27.6 m-85 -120.02 93.27 47.73 Favored Pre-proline 0 N--CA 1.496 1.83 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -178.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -69.82 -21.87 32.62 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.423 1.223 . . . . 0.0 111.347 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.4 m -123.21 145.9 48.27 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 109.939 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 1.0 HD21 HG11 ' A' ' 43' ' ' VAL . 40.6 tp -68.68 121.15 15.86 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -0.756 . . . . 0.0 110.753 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.88 33.78 0.03 OUTLIER Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.774 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -160.31 -44.12 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.159 -1.201 . . . . 0.0 110.142 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.67 HG11 HD13 ' A' ' 27' ' ' LEU . 3.5 t -60.54 -61.28 8.28 Favored Pre-proline 0 N--CA 1.498 1.967 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -77.59 -26.11 7.4 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.108 1.057 . . . . 0.0 109.598 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.58 -62.0 0.63 Allowed Glycine 0 N--CA 1.486 1.988 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.572 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.0 t80 166.74 -72.45 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.449 0 C-N-CA 123.267 0.627 . . . . 0.0 109.632 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.572 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 60.2 Cg_endo -84.65 10.7 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 CA-C-N 118.912 0.647 . . . . 0.0 111.647 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -114.54 35.7 4.11 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.011 -1.056 . . . . 0.0 110.015 -178.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.0 HG11 HD21 ' A' ' 34' ' ' LEU . 13.1 p -117.54 143.36 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-O 121.455 0.645 . . . . 0.0 110.11 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.04 166.67 39.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.38 151.37 44.97 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 177.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.545 HD11 HG13 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -144.22 142.9 20.61 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.431 -1.04 . . . . 0.0 109.351 179.698 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -61.38 -13.02 26.55 Favored 'Trans proline' 0 N--CA 1.507 2.271 0 C-N-CA 122.193 1.929 . . . . 0.0 115.188 -177.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.434 ' HB2' HD12 ' A' ' 46' ' ' ILE . 94.9 m-20 -92.9 20.1 6.99 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.45 -1.406 . . . . 0.0 112.139 -178.121 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.816 HG23 ' CB ' ' A' ' 54' ' ' SER . 57.8 mt -118.57 127.67 75.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.301 -0.875 . . . . 0.0 109.038 177.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.0 -45.35 13.2 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 175.18 -141.17 5.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.403 -1.856 . . . . 0.0 112.194 -178.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.498 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 25.3 t90 -39.97 -29.87 0.08 Allowed 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 -178.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -146.15 64.14 1.22 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.985 -1.072 . . . . 0.0 111.325 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.816 ' CB ' HG23 ' A' ' 49' ' ' ILE . 6.5 t -66.27 139.39 96.34 Favored Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.45 -0.781 . . . . 0.0 110.866 -179.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.437 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -78.05 -20.66 11.37 Favored 'Trans proline' 0 C--N 1.32 -0.959 0 O-C-N 123.4 1.211 . . . . 0.0 110.65 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 17.8 m -92.97 11.54 27.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.484 -0.76 . . . . 0.0 111.231 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 6.6 t -69.66 145.16 52.61 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.093 -1.004 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.45 41.9 12.6 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.1 m -120.01 129.95 54.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.397 -1.06 . . . . 0.0 110.477 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.514 ' SG ' HG23 ' A' ' 110' ' ' VAL . 50.1 t -81.29 143.03 32.55 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.513 -178.444 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 71.9 m95 -146.4 155.62 42.72 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.526 178.231 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -114.11 130.19 56.59 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.6 129.59 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.405 -0.809 . . . . 0.0 109.706 -178.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.3 m -121.12 141.07 51.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.803 -0.561 . . . . 0.0 111.459 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.441 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.0 pt -117.62 163.58 23.35 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.521 -0.737 . . . . 0.0 110.036 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -62.32 -25.35 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 121.184 1.256 . . . . 0.0 112.507 -178.461 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -64.84 -39.01 92.88 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.384 -0.822 . . . . 0.0 109.715 179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.47 61.6 0.33 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -160.58 153.07 20.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.709 -0.877 . . . . 0.0 109.007 178.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.454 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -151.26 158.72 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.207 1.003 . . . . 0.0 112.352 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 pt -139.89 164.73 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.162 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.5 m-85 -106.58 127.0 52.98 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 118.879 -1.128 . . . . 0.0 109.928 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.37 131.89 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.622 -0.674 . . . . 0.0 110.582 -179.123 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.599 ' HD3' HG12 ' A' ' 37' ' ' VAL . 53.9 ttt180 -102.21 136.49 41.96 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.27 149.54 42.17 Favored Glycine 0 N--CA 1.494 2.557 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.318 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.593 HG22 HG21 ' A' ' 18' ' ' VAL . 5.7 p -156.91 -42.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.743 -0.857 . . . . 0.0 110.118 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.481 ' O ' HD12 ' A' ' 49' ' ' ILE . 12.3 t70 -128.34 169.99 13.6 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.109 -0.995 . . . . 0.0 110.06 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 41.8 t -87.67 156.85 19.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.426 -0.796 . . . . 0.0 111.081 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.43 137.34 10.92 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -63.08 -39.87 96.0 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.734 -0.862 . . . . 0.0 110.162 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -178.15 69.96 0.08 OUTLIER Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.74 172.09 18.19 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 3' ' ' ILE . 89.1 m-85 -98.63 122.53 41.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.652 -0.911 . . . . 0.0 110.334 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . 0.433 ' HA ' ' O ' ' A' ' 4' ' ' SER . 17.1 t-20 -115.05 130.31 56.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.391 -0.818 . . . . 0.0 109.048 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.423 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 35.6 m -132.97 174.47 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 120.933 -1.104 . . . . 0.0 111.741 -178.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -54.74 150.9 16.6 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.53 -0.731 . . . . 0.0 109.92 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.6 -21.01 59.97 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.404 1.213 . . . . 0.0 110.76 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 67.7 m -75.79 -39.95 56.02 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.065 -1.022 . . . . 0.0 109.23 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.77 -40.03 88.08 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.422 -0.798 . . . . 0.0 109.116 178.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -60.03 -49.68 76.72 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.807 -0.558 . . . . 0.0 110.632 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.6 m -60.04 -36.99 78.5 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.824 . . . . 0.0 110.787 -178.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -69.95 -40.07 75.67 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.412 -179.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.454 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 56.1 tp -70.39 -44.16 68.58 Favored 'General case' 0 N--CA 1.496 1.851 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.554 -178.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 91.1 t -95.39 -38.61 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.311 -0.868 . . . . 0.0 111.394 -177.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -27.35 6.07 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 43.7 t -156.04 161.19 40.46 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.466 -1.02 . . . . 0.0 110.292 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 68.3 p -97.81 13.24 31.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 111.151 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.99 -36.54 75.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.481 -0.762 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.02 -41.16 91.59 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.444 -0.785 . . . . 0.0 111.05 -178.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.28 -63.48 2.02 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 -179.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -149.37 153.45 37.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.59 -0.947 . . . . 0.0 110.57 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.1 118.94 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.456 -0.777 . . . . 0.0 110.149 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -81.87 169.44 16.84 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.577 -0.702 . . . . 0.0 111.181 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 63.7 t30 59.85 50.06 7.29 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.548 -0.72 . . . . 0.0 110.731 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.67 HG21 HG23 ' A' ' 3' ' ' ILE . 66.9 t -94.05 128.73 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -86.9 140.61 29.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.417 -0.913 . . . . 0.0 109.491 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -139.11 141.87 38.11 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.167 0.508 . . . . 0.0 110.736 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 m -141.14 139.89 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.695 -0.628 . . . . 0.0 110.161 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -77.4 136.86 38.44 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.964 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.514 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.3 m -134.22 -179.13 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.257 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.41 150.94 47.55 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.406 -0.809 . . . . 0.0 111.075 -179.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.455 HD11 ' NH1' ' A' ' 74' ' ' ARG . 7.7 tt -62.06 -40.0 94.29 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.559 -0.713 . . . . 0.0 111.389 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 55.8 m -54.28 -39.37 66.84 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.443 -0.785 . . . . 0.0 110.222 -178.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -59.99 -37.65 80.29 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.632 -0.668 . . . . 0.0 110.223 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -68.15 -42.43 80.09 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.49 -0.756 . . . . 0.0 109.481 178.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.0 mm -64.88 -40.52 89.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.023 -0.671 . . . . 0.0 109.853 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -70.05 -39.92 75.41 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.697 -0.627 . . . . 0.0 110.483 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.6 -53.14 37.07 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.05 -43.94 97.24 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.512 -0.993 . . . . 0.0 110.548 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 48.6 t30 . . . . . 0 N--CA 1.501 2.082 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.006 -179.824 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.418 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.4 m . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.25 0.548 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.8 t -114.63 141.18 48.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.536 -0.728 . . . . 0.0 110.39 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.755 HG22 ' HB2' ' A' ' 83' ' ' PHE . 39.3 pt -107.8 147.72 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.679 -0.638 . . . . 0.0 110.6 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.42 -171.89 3.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.8 p90 -142.87 147.32 35.18 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.35 -0.844 . . . . 0.0 110.802 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -137.7 155.22 75.17 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.488 178.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -88.28 48.06 1.37 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.275 1.145 . . . . 0.0 110.659 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.813 ' O ' HD22 ' A' ' 13' ' ' LEU . 8.7 tp -123.01 -8.65 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.48 -0.763 . . . . 0.0 111.276 -179.39 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 8' ' ' ILE . 35.3 m-85 -118.54 67.65 0.77 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 122.525 1.155 . . . . 0.0 110.947 178.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.02 170.37 7.9 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.679 177.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.82 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.6 -32.71 70.64 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 114.115 1.154 . . . . 0.0 114.115 -175.497 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -89.63 13.91 12.94 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 120.424 1.466 . . . . 0.0 112.5 -177.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.813 HD22 ' O ' ' A' ' 8' ' ' ILE . 64.0 tp -73.1 125.94 28.85 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.413 -0.804 . . . . 0.0 110.792 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.18 135.54 49.18 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.487 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.717 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -66.36 -15.86 63.61 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.777 -0.577 . . . . 0.0 112.048 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.62 -13.86 80.05 Favored Glycine 0 N--CA 1.497 2.701 0 O-C-N 120.977 -1.077 . . . . 0.0 111.337 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 -11.05 47.2 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.054 -1.262 . . . . 0.0 112.063 -178.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 15' ' ' MET . 8.5 p -93.72 168.25 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.068 -1.02 . . . . 0.0 110.041 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.24 -42.09 85.58 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.472 -0.768 . . . . 0.0 109.816 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.03 82.94 2.89 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.586 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.9 m -90.29 -79.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.989 -1.069 . . . . 0.0 112.894 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.488 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 17.9 p30 -143.56 14.21 1.77 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 120.631 -1.293 . . . . 0.0 112.428 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.64 -146.95 0.38 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -66.58 -40.51 88.97 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . 0.407 ' CD2' ' O ' ' A' ' 54' ' ' SER . 64.1 m-70 -90.02 0.56 57.05 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.798 -0.564 . . . . 0.0 110.265 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -55.05 130.4 47.08 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 84.3 mt -104.87 -5.98 20.62 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 122.146 -0.62 . . . . 0.0 111.203 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' MET . . . . . 0.404 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 44.4 ttm -59.96 -35.63 75.39 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.292 -0.88 . . . . 0.0 110.825 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.43 -63.1 1.26 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -67.26 -40.04 86.18 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.213 -0.93 . . . . 0.0 111.288 -177.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.69 ' CE1' HG21 ' A' ' 37' ' ' VAL . 5.5 p90 -143.64 113.72 5.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.879 . . . . 0.0 109.128 179.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.65 -1.62 10.1 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.443 1.233 . . . . 0.0 112.582 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' THR . . . . . 0.513 HG22 ' H ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -118.64 -172.1 2.21 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.995 -1.066 . . . . 0.0 109.71 179.786 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.764 HD11 HG21 ' A' ' 43' ' ' VAL . 61.5 tp -116.51 129.96 56.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.605 -0.685 . . . . 0.0 110.852 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.86 -40.82 1.27 Allowed Glycine 0 N--CA 1.489 2.172 0 C-N-CA 120.077 -1.059 . . . . 0.0 111.044 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -62.42 -39.94 94.93 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.182 -1.187 . . . . 0.0 111.483 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.747 HG12 ' HD3' ' A' ' 74' ' ' ARG . 3.2 t -87.62 -61.36 0.24 Allowed Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.336 -0.852 . . . . 0.0 112.699 -178.339 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PRO . . . . . 0.432 ' HG3' HD11 ' A' ' 34' ' ' LEU . 37.4 Cg_endo -64.54 -48.49 4.29 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 O-C-N 123.009 1.005 . . . . 0.0 113.063 -177.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . 0.431 ' O ' ' HD2' ' A' ' 41' ' ' PRO . . . 122.77 67.87 0.23 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 106.541 -2.624 . . . . 0.0 106.541 -177.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.82 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 8.8 t80 19.65 -78.99 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.343 0 N-CA-C 115.101 1.519 . . . . 0.0 115.101 -178.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.532 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.7 Cg_endo -81.91 17.8 1.48 Allowed 'Trans proline' 0 N--CA 1.499 1.804 0 CA-C-N 120.07 1.061 . . . . 0.0 112.588 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -123.79 47.33 2.06 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.836 -1.165 . . . . 0.0 110.201 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 34' ' ' LEU . 11.0 p -129.39 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 122.064 0.935 . . . . 0.0 110.334 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.519 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.08 175.31 42.3 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.32 161.75 31.6 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 49' ' ' ILE . 1.1 pt -147.46 152.1 41.35 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.64 -0.917 . . . . 0.0 110.063 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.69 -14.7 46.15 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.954 1.77 . . . . 0.0 113.763 -178.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -90.6 23.25 3.11 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 120.591 -1.318 . . . . 0.0 112.259 -178.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.558 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.8 mm -113.77 126.91 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.17 13.0 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.311 -0.868 . . . . 0.0 112.077 -178.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.856 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 173.23 -134.34 2.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 118.715 -1.707 . . . . 0.0 111.719 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.441 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 53.5 t90 -46.06 -28.48 1.2 Allowed 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -178.255 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -146.65 61.19 1.21 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.024 -1.048 . . . . 0.0 110.986 -179.173 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.558 ' CB ' HG23 ' A' ' 49' ' ' ILE . 35.1 p -61.95 140.07 95.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.49 -0.756 . . . . 0.0 110.444 -179.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.18 -21.8 19.89 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 123.328 1.172 . . . . 0.0 111.151 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.9 m -93.85 13.62 21.98 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.449 -0.782 . . . . 0.0 111.158 -179.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 2.2 t -73.17 145.43 46.32 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.259 -0.9 . . . . 0.0 110.561 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.58 22.79 71.81 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 86.8 m -104.22 139.11 39.71 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.358 -1.084 . . . . 0.0 110.751 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.439 ' SG ' HG23 ' A' ' 110' ' ' VAL . 46.5 t -80.12 132.96 36.03 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.545 -179.037 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' TRP . . . . . 0.405 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.7 m95 -134.36 147.32 50.51 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -0.76 . . . . 0.0 110.074 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -107.86 131.55 54.38 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.366 -0.834 . . . . 0.0 109.725 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.635 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.2 t -109.95 121.03 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.557 0.694 . . . . 0.0 110.252 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 97.8 m -119.99 146.03 46.23 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.859 -0.525 . . . . 0.0 110.575 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.469 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 17.2 pt -122.12 164.51 25.25 Favored Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.473 -0.767 . . . . 0.0 110.98 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -61.31 -25.94 81.09 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.561 1.507 . . . . 0.0 112.837 -178.611 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -66.08 -40.0 90.48 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.248 -0.907 . . . . 0.0 110.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.45 61.11 0.3 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -160.07 151.6 19.81 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.652 -0.911 . . . . 0.0 108.829 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.9 p -155.6 164.99 37.9 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 122.287 1.041 . . . . 0.0 112.193 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 40.0 pt -144.52 165.63 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -106.29 122.64 46.64 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.265 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.842 HD13 HG11 ' A' ' 85' ' ' VAL . 66.2 mt -120.02 131.41 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.857 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.747 ' HD3' HG12 ' A' ' 37' ' ' VAL . 24.8 ttt180 -95.25 136.5 35.53 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.663 -0.648 . . . . 0.0 109.407 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.39 149.72 31.43 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 110.336 -1.106 . . . . 0.0 110.336 -178.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.497 HG11 HG22 ' A' ' 43' ' ' VAL . 4.1 p -154.7 -44.08 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.723 -0.869 . . . . 0.0 109.513 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.556 ' HB2' HG23 ' A' ' 18' ' ' VAL . 11.9 t70 -131.87 169.02 16.84 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 178.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . 0.427 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 95.5 p -91.91 157.78 16.65 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.4 -0.813 . . . . 0.0 111.618 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -124.2 146.16 16.16 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -60.66 -31.04 70.29 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.649 -0.912 . . . . 0.0 110.174 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.09 76.45 0.04 OUTLIER Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.562 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.82 154.93 6.26 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.115 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.755 ' HB2' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -67.41 114.59 6.22 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.931 -0.746 . . . . 0.0 110.376 179.289 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -111.15 119.07 37.74 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 73' ' ' ILE . 26.8 m -131.1 176.95 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 120.89 -1.131 . . . . 0.0 112.474 -177.128 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.5 m-20 -55.7 150.9 24.41 Favored Pre-proline 0 N--CA 1.493 1.713 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.214 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.43 -17.27 57.26 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.395 1.208 . . . . 0.0 110.142 178.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 98.1 m -81.28 -40.66 23.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.916 -1.115 . . . . 0.0 109.182 178.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -39.84 91.12 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -60.06 -49.94 75.68 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.754 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.5 m -60.68 -40.0 90.53 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.429 -0.794 . . . . 0.0 111.108 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -68.48 -39.99 81.15 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.35 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 57.8 tp -73.31 -43.24 61.25 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.576 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 51.2 t -91.57 -42.36 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 121.344 -0.848 . . . . 0.0 111.52 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.27 -31.74 3.56 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 90.1 p -154.39 165.88 34.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.502 -0.999 . . . . 0.0 110.457 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.7 p -94.23 -0.05 55.37 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.451 -0.781 . . . . 0.0 111.756 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -70.95 -26.3 63.11 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.336 -0.853 . . . . 0.0 111.675 -179.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -39.98 87.86 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.322 -0.861 . . . . 0.0 110.898 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.68 -67.46 2.17 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -152.1 160.01 43.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.553 -0.969 . . . . 0.0 110.998 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 105' ' ' VAL . 60.7 t -131.11 112.73 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.952 179.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 36.1 p-10 -80.06 170.01 17.05 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.464 0.65 . . . . 0.0 111.113 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 59.98 40.02 19.36 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.627 -0.67 . . . . 0.0 111.597 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.636 HG21 HG23 ' A' ' 3' ' ' ILE . 94.5 t -85.15 129.94 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.417 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -86.72 139.49 30.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.002 -1.061 . . . . 0.0 109.545 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.437 ' C ' HG13 ' A' ' 108' ' ' VAL . 46.8 p90 -138.02 143.3 40.52 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 122.0 -0.438 . . . . 0.0 110.763 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.437 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.0 m -149.07 149.02 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.545 -0.722 . . . . 0.0 110.706 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' GLN . . . . . 0.405 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 58.9 tt0 -76.75 139.98 40.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.599 -0.688 . . . . 0.0 110.269 179.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.439 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.5 m -133.6 168.26 24.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -57.6 144.83 35.93 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.378 -0.826 . . . . 0.0 110.563 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.564 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.6 tt -59.91 -36.75 77.64 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.224 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 91.0 p -54.07 -36.14 62.82 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.491 -0.756 . . . . 0.0 110.502 -179.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -66.67 -39.58 88.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 111.179 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -59.97 -49.16 78.78 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.306 -0.871 . . . . 0.0 109.797 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ILE . . . . . 0.491 HD11 HD21 ' A' ' 112' ' ' LEU . 93.4 mt -69.81 -39.98 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.687 -0.633 . . . . 0.0 110.687 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -64.0 -39.94 95.25 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.35 -0.844 . . . . 0.0 111.052 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.14 -50.83 20.73 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.94 91.62 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.574 -0.957 . . . . 0.0 110.524 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.063 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 121.555 0.693 . . . . 0.0 111.691 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 79.9 p -111.33 139.9 46.35 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.456 0.646 . . . . 0.0 109.49 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.624 HG12 HG21 ' A' ' 105' ' ' VAL . 39.6 pt -118.13 149.98 20.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.837 -0.54 . . . . 0.0 111.273 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.1 OUTLIER -146.15 -169.55 3.28 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.757 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.412 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.5 p90 -141.58 148.07 38.67 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.417 -0.802 . . . . 0.0 110.178 178.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.49 143.48 43.32 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.406 -0.809 . . . . 0.0 109.777 179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -77.73 -9.86 17.05 Favored 'Trans proline' 0 C--N 1.318 -1.078 0 O-C-N 123.324 1.171 . . . . 0.0 112.331 -178.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 9' ' ' TYR . 44.5 pt -70.01 -39.95 77.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 120.968 -1.082 . . . . 0.0 111.434 -179.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.601 ' HA ' HD22 ' A' ' 13' ' ' LEU . 51.5 m-85 -72.14 67.5 0.67 Allowed 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 122.752 1.263 . . . . 0.0 111.72 -178.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.55 170.04 8.12 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.054 176.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.491 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.41 -34.38 68.85 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -175.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -90.92 12.12 20.56 Favored 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 118.431 -1.308 . . . . 0.0 112.265 -177.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.601 HD22 ' HA ' ' A' ' 9' ' ' TYR . 36.4 tp -72.53 123.71 23.73 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.246 -0.908 . . . . 0.0 110.2 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.5 t -70.54 137.35 50.06 Favored 'General case' 0 N--CA 1.49 1.573 0 C-N-CA 120.024 -0.67 . . . . 0.0 110.035 179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.806 ' O ' HG12 ' A' ' 18' ' ' VAL . 34.6 mtt -70.08 -15.39 62.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.802 -0.561 . . . . 0.0 111.915 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.63 -15.37 68.53 Favored Glycine 0 N--CA 1.494 2.559 0 O-C-N 120.793 -1.192 . . . . 0.0 110.878 -179.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 91.0 p -87.98 -4.45 58.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.192 -1.181 . . . . 0.0 112.157 -178.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.806 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -103.5 168.8 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.001 -1.062 . . . . 0.0 110.801 -179.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.72 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.04 -39.29 85.4 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.471 -0.768 . . . . 0.0 110.644 -179.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.76 67.72 3.7 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.291 -0.881 . . . . 0.0 110.088 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.6 m -108.71 110.13 21.46 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.155 -0.966 . . . . 0.0 110.565 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 36.3 m120 51.66 -140.98 0.84 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.714 -0.616 . . . . 0.0 111.11 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.43 -155.95 49.02 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -78.07 -41.82 34.2 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.428 -1.042 . . . . 0.0 111.066 179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.401 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 87.5 m-70 -89.94 2.14 55.42 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.181 -0.949 . . . . 0.0 111.748 -178.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.55 131.81 49.36 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.002 -1.061 . . . . 0.0 111.15 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.508 HD13 HG11 ' A' ' 37' ' ' VAL . 80.7 mt -96.28 -11.57 25.76 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 122.091 -0.652 . . . . 0.0 110.005 178.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.416 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 60.5 ttm -60.05 -34.42 73.38 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.267 -0.896 . . . . 0.0 110.836 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.21 -74.41 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.558 -0.714 . . . . 0.0 111.691 -178.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -70.04 -39.97 75.43 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.347 -0.846 . . . . 0.0 109.938 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.454 ' CD2' HG23 ' A' ' 37' ' ' VAL . 70.1 m-85 -120.67 89.69 45.19 Favored Pre-proline 0 N--CA 1.491 1.604 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.9 Cg_endo -70.82 -4.97 15.83 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.317 1.167 . . . . 0.0 112.298 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 4.7 m -135.13 149.1 49.94 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.019 -1.051 . . . . 0.0 110.406 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.943 HD11 HG21 ' A' ' 43' ' ' VAL . 28.9 tp -72.45 117.59 14.31 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.758 -0.589 . . . . 0.0 110.528 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.89 32.36 0.04 OUTLIER Glycine 0 N--CA 1.494 2.549 0 C-N-CA 119.992 -1.099 . . . . 0.0 110.924 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -158.81 -46.28 0.06 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.195 -1.18 . . . . 0.0 110.21 179.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 27' ' ' LEU . 3.0 t -61.05 -59.92 12.29 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.471 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 52.5 Cg_endo -76.63 -28.35 6.68 Favored 'Trans proline' 0 N--CA 1.487 1.146 0 O-C-N 123.182 1.096 . . . . 0.0 109.371 177.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.409 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.3 -62.35 0.63 Allowed Glycine 0 N--CA 1.488 2.146 0 N-CA-C 107.177 -2.369 . . . . 0.0 107.177 -178.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.675 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 165.27 -58.73 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.467 0 C-N-CA 123.248 0.619 . . . . 0.0 109.804 177.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.675 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -100.23 18.19 0.33 Allowed 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 121.076 1.184 . . . . 0.0 110.937 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -126.94 42.48 3.31 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.315 -0.866 . . . . 0.0 109.499 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.943 HG21 HD11 ' A' ' 34' ' ' LEU . 12.3 p -123.58 140.77 46.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-O 121.563 0.697 . . . . 0.0 109.73 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.554 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.59 169.09 40.46 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.456 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -80.08 157.53 41.19 Favored Glycine 0 N--CA 1.487 2.078 0 N-CA-C 108.624 -1.79 . . . . 0.0 108.624 178.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.57 HD12 ' H ' ' A' ' 48' ' ' ASP . 1.2 pp -146.23 145.21 23.39 Favored Pre-proline 0 N--CA 1.486 1.361 0 O-C-N 121.48 -1.012 . . . . 0.0 109.221 179.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.446 ' HD2' ' CE1' ' A' ' 83' ' ' PHE . 38.0 Cg_endo -61.73 -7.19 8.71 Favored 'Trans proline' 0 N--CA 1.506 2.249 0 C-N-CA 122.197 1.931 . . . . 0.0 115.075 -177.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.57 ' H ' HD12 ' A' ' 46' ' ' ILE . 91.4 m-20 -97.46 23.0 8.09 Favored 'General case' 0 N--CA 1.504 2.252 0 O-C-N 120.5 -1.375 . . . . 0.0 112.446 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.645 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.4 mm -110.13 130.1 63.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -85.17 -48.1 9.48 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.423 -0.798 . . . . 0.0 112.613 -177.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.72 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.67 -131.48 1.67 Allowed Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.609 -1.758 . . . . 0.0 111.926 -179.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 11.8 t90 -54.79 -22.9 15.77 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 -178.006 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.416 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 42.1 m-20 -147.94 62.51 1.12 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.008 -1.057 . . . . 0.0 110.754 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.645 ' CB ' HG23 ' A' ' 49' ' ' ILE . 50.0 p -58.6 141.97 83.57 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.476 -0.765 . . . . 0.0 110.967 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.401 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.9 Cg_endo -77.45 -21.4 11.64 Favored 'Trans proline' 0 C--N 1.319 -0.991 0 O-C-N 123.39 1.205 . . . . 0.0 110.752 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 50.8 m -97.89 13.81 29.34 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.507 -0.746 . . . . 0.0 111.073 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -68.05 141.34 56.2 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.152 -0.967 . . . . 0.0 109.628 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.8 42.38 11.32 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.2 m -120.03 130.05 54.53 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.395 -1.062 . . . . 0.0 110.198 179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 49.1 t -80.14 139.94 36.6 Favored 'General case' 0 N--CA 1.498 1.947 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.097 -177.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.435 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 64.3 m95 -145.27 150.88 37.44 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.543 -0.723 . . . . 0.0 110.376 178.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -109.63 133.02 53.59 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -110.03 128.89 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.443 -0.786 . . . . 0.0 109.727 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 29.5 m -119.98 142.67 48.57 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.831 -0.543 . . . . 0.0 111.662 -177.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.444 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 23.4 pt -119.67 163.55 26.84 Favored Pre-proline 0 N--CA 1.498 1.97 0 O-C-N 121.709 -0.619 . . . . 0.0 110.279 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.54 -23.56 74.88 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 121.3 1.334 . . . . 0.0 112.672 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -66.38 -40.01 89.42 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.274 -0.891 . . . . 0.0 109.83 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.89 60.42 0.29 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.896 -1.282 . . . . 0.0 109.896 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -160.02 150.6 18.81 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.629 -0.924 . . . . 0.0 109.088 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.1 m -151.06 156.91 42.06 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.037 0.923 . . . . 0.0 112.03 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.486 HG12 HD13 ' A' ' 93' ' ' LEU . 39.6 pt -138.0 165.71 25.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -106.92 127.5 53.49 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 118.964 -1.094 . . . . 0.0 110.145 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.6 mm -115.78 129.96 71.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.748 -0.595 . . . . 0.0 110.094 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.499 ' HD3' HG12 ' A' ' 37' ' ' VAL . 38.9 ttt180 -99.81 135.03 41.84 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.14 148.29 24.94 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -177.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 44' ' ' GLY . 4.8 p -159.9 -37.98 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.767 -0.843 . . . . 0.0 110.057 179.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.514 ' HB2' HG23 ' A' ' 18' ' ' VAL . 31.3 t70 -133.18 169.96 16.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.002 -1.061 . . . . 0.0 109.495 179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.422 ' CA ' ' HB ' ' A' ' 49' ' ' ILE . 86.9 p -97.26 160.05 14.56 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.409 -0.807 . . . . 0.0 110.899 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.94 141.74 12.94 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.5 mtp180 -60.73 -39.93 90.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.808 -0.819 . . . . 0.0 110.663 178.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.35 71.73 0.09 OUTLIER Glycine 0 N--CA 1.494 2.535 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.63 168.91 15.95 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.604 ' HB2' HG22 ' A' ' 3' ' ' ILE . 96.3 m-85 -98.49 128.57 44.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.755 -0.85 . . . . 0.0 109.948 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 47.6 t-20 -120.63 131.02 54.4 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.378 -0.826 . . . . 0.0 109.531 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.2 m -131.09 174.06 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.064 -1.023 . . . . 0.0 111.387 -178.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.1 m-20 -55.78 153.14 17.16 Favored Pre-proline 0 N--CA 1.498 1.934 0 O-C-N 121.355 -0.841 . . . . 0.0 109.996 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -65.76 -26.23 53.0 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 O-C-N 123.381 1.2 . . . . 0.0 110.019 179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 90.9 m -70.72 -39.98 73.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.092 -1.005 . . . . 0.0 108.982 178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.89 -40.73 79.04 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.9 t80 -60.08 -50.02 75.37 Favored 'General case' 0 N--CA 1.499 2.018 0 C-N-CA 120.141 -0.624 . . . . 0.0 110.689 179.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.8 m -60.04 -38.61 83.28 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.482 -0.761 . . . . 0.0 110.463 -178.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.07 -39.75 75.46 Favored 'General case' 0 N--CA 1.493 1.694 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.937 -179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.486 HD13 HG12 ' A' ' 71' ' ' ILE . 47.9 tp -70.07 -43.58 70.86 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.555 -0.715 . . . . 0.0 111.668 -179.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -95.01 -37.63 7.99 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.134 0 O-C-N 121.251 -0.906 . . . . 0.0 110.967 -178.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 123.71 -28.26 5.5 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 85.0 p -156.7 168.76 26.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -1.013 . . . . 0.0 110.121 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 55.1 p -96.77 8.41 44.35 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.534 -0.729 . . . . 0.0 110.801 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.04 -29.59 66.66 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.374 -0.829 . . . . 0.0 110.409 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.05 88.1 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.565 -0.709 . . . . 0.0 110.54 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 79.02 -83.67 1.28 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 29.2 ttt180 -130.03 133.13 46.53 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.627 -0.926 . . . . 0.0 110.133 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.68 120.13 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.489 -0.757 . . . . 0.0 110.304 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.406 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 43.7 p-10 -83.23 174.81 10.43 Favored 'General case' 0 N--CA 1.494 1.746 0 CA-C-O 121.718 0.77 . . . . 0.0 111.544 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 57.7 t30 59.99 40.66 18.56 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.704 -0.622 . . . . 0.0 112.013 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.624 HG21 HG12 ' A' ' 3' ' ' ILE . 59.3 t -88.91 127.34 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.937 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -85.14 138.32 32.46 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 119.328 -0.949 . . . . 0.0 109.871 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -134.57 140.48 46.15 Favored 'General case' 0 N--CA 1.494 1.743 0 CA-C-O 121.351 0.596 . . . . 0.0 110.746 -179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 28.4 m -142.67 145.25 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.668 -0.645 . . . . 0.0 109.916 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.435 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 55.4 tt0 -85.03 141.62 30.16 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.514 -0.741 . . . . 0.0 110.861 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -136.18 176.96 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.718 -0.614 . . . . 0.0 110.088 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -62.03 149.57 40.59 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.443 -0.786 . . . . 0.0 110.575 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.581 HD21 HD11 ' A' ' 116' ' ' ILE . 8.0 tt -60.08 -39.93 87.77 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.488 -0.757 . . . . 0.0 110.992 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 t -51.39 -38.94 55.99 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.424 -0.798 . . . . 0.0 110.822 -178.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -60.91 -39.99 91.45 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.49 -0.756 . . . . 0.0 111.274 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -61.53 -48.22 82.01 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.323 -0.861 . . . . 0.0 110.109 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.581 HD11 HD21 ' A' ' 112' ' ' LEU . 96.5 mt -67.84 -39.92 82.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.663 -0.648 . . . . 0.0 110.557 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -65.59 -40.0 92.23 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.463 -0.773 . . . . 0.0 110.571 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.96 -49.37 35.23 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.54 89.46 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.576 -0.955 . . . . 0.0 110.605 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.7 m120 . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 117.93 -1.034 . . . . 0.0 110.273 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 105' ' ' VAL . 27.6 m . . . . . 0 N--CA 1.499 1.994 0 CA-C-O 120.975 0.416 . . . . 0.0 110.415 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.426 ' HA ' ' HA ' ' A' ' 103' ' ' ASP . 50.5 m -113.3 143.01 45.15 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.537 -0.727 . . . . 0.0 110.795 -179.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.439 HG22 ' HB2' ' A' ' 83' ' ' PHE . 27.9 pt -114.36 149.93 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.81 -0.556 . . . . 0.0 110.861 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.5 p -147.07 -173.46 4.25 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.411 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.1 p90 -142.11 153.33 44.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.355 -0.841 . . . . 0.0 110.246 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.442 ' OD1' HD12 ' A' ' 8' ' ' ILE . 0.9 OUTLIER -132.78 145.94 59.24 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.404 -0.81 . . . . 0.0 110.359 -179.592 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 6' ' ' ASP . 53.2 Cg_endo -88.43 49.75 1.56 Allowed 'Trans proline' 0 N--CA 1.486 1.077 0 O-C-N 123.219 1.115 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.663 ' O ' HD22 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -134.05 5.88 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.562 0 O-C-N 120.751 -1.218 . . . . 0.0 110.936 178.196 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.558 ' CE2' HD11 ' A' ' 8' ' ' ILE . 31.5 m-85 -114.15 67.2 0.68 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 122.873 1.321 . . . . 0.0 109.442 178.386 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.31 170.83 7.83 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.858 177.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.98 -32.87 71.24 Favored 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -88.9 11.5 17.85 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.464 -1.397 . . . . 0.0 112.176 -177.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.663 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.5 tp -72.27 125.1 26.51 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.301 -0.874 . . . . 0.0 109.987 179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.4 m -70.38 136.19 49.42 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.276 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.715 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -65.26 -16.72 63.85 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.85 -0.531 . . . . 0.0 111.683 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.66 -11.49 80.54 Favored Glycine 0 N--CA 1.496 2.687 0 O-C-N 121.003 -1.061 . . . . 0.0 111.284 -179.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.4 m -89.96 -4.85 57.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.034 -1.274 . . . . 0.0 112.055 -178.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 15' ' ' MET . 9.4 p -100.7 169.02 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.966 -1.084 . . . . 0.0 110.434 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.754 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.06 87.58 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.415 -0.803 . . . . 0.0 110.267 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.15 69.0 4.3 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.499 -0.751 . . . . 0.0 109.884 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.3 m -108.58 110.81 22.36 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.181 -0.949 . . . . 0.0 110.783 -179.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.406 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 12.6 t-20 50.09 -141.47 0.71 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.747 -0.596 . . . . 0.0 111.406 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 64.64 -150.63 51.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -80.55 -46.26 16.06 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.977 . . . . 0.0 111.494 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 54' ' ' SER . 73.8 m-70 -89.99 1.99 55.65 Favored 'General case' 0 N--CA 1.504 2.262 0 O-C-N 121.209 -0.932 . . . . 0.0 111.84 -178.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.406 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -54.9 134.24 47.72 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 121.004 -1.06 . . . . 0.0 111.126 -179.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.812 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -100.03 -6.86 25.79 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 122.003 -0.704 . . . . 0.0 110.066 178.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.4 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.5 ttm -60.3 -35.47 75.67 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.258 -0.901 . . . . 0.0 110.088 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.75 -73.74 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.706 -0.622 . . . . 0.0 111.733 -177.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -69.93 -40.04 75.76 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.345 -0.847 . . . . 0.0 110.241 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.5 m-85 -119.81 91.25 44.93 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.53 -11.79 31.91 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.298 1.157 . . . . 0.0 111.579 -178.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.6 m -130.02 143.42 50.79 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.229 -0.92 . . . . 0.0 110.489 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.875 HD11 HG21 ' A' ' 43' ' ' VAL . 40.4 tp -67.91 119.99 13.46 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.781 -0.574 . . . . 0.0 110.117 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.8 32.53 0.05 OUTLIER Glycine 0 N--CA 1.495 2.623 0 C-N-CA 120.008 -1.092 . . . . 0.0 110.56 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 15.1 mt-10 -155.34 -46.42 0.08 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.312 -1.11 . . . . 0.0 110.14 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.812 HG11 HD13 ' A' ' 27' ' ' LEU . 2.9 t -61.84 -59.61 12.74 Favored Pre-proline 0 N--CA 1.496 1.844 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -76.23 -29.27 6.51 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 N-CA-C 109.184 -1.121 . . . . 0.0 109.184 177.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 128.5 -60.73 0.66 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 107.433 -2.267 . . . . 0.0 107.433 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.608 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 4.5 t80 162.41 -52.5 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.705 0 C-N-CA 123.595 0.758 . . . . 0.0 109.95 178.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.608 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.07 19.04 0.23 Allowed 'Trans proline' 0 C--N 1.322 -0.819 0 C-N-CA 121.392 1.395 . . . . 0.0 111.347 -178.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.8 m-20 -131.81 49.87 2.28 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.292 -0.88 . . . . 0.0 110.236 -178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.875 HG21 HD11 ' A' ' 34' ' ' LEU . 10.4 p -125.97 139.57 51.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-O 121.598 0.713 . . . . 0.0 109.961 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 84' ' ' ASN . . . -169.4 174.28 43.77 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.28 159.28 32.22 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.573 HG22 ' CE1' ' A' ' 83' ' ' PHE . 1.4 pt -149.98 158.09 37.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.662 -0.905 . . . . 0.0 110.634 179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.22 -13.22 35.65 Favored 'Trans proline' 0 N--CA 1.499 1.811 0 C-N-CA 121.419 1.413 . . . . 0.0 114.328 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -94.9 22.23 6.72 Favored 'General case' 0 N--CA 1.505 2.29 0 O-C-N 120.563 -1.336 . . . . 0.0 112.819 -177.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.616 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.5 mm -113.12 129.59 68.55 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.096 0 O-C-N 121.073 -1.017 . . . . 0.0 108.52 178.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.73 12.34 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.395 -0.816 . . . . 0.0 112.229 -178.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.754 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 170.64 -129.56 1.83 Allowed Glycine 0 N--CA 1.489 2.227 0 C-N-CA 118.813 -1.66 . . . . 0.0 111.139 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.501 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 44.7 t90 -52.1 -22.35 4.09 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.962 -0.728 . . . . 0.0 112.601 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -149.44 65.75 1.01 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.042 -1.036 . . . . 0.0 110.933 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.616 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.0 p -63.47 135.01 96.07 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.548 -0.72 . . . . 0.0 110.855 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -72.58 -20.76 23.03 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.333 1.175 . . . . 0.0 110.692 179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.493 ' O ' HG23 ' A' ' 59' ' ' THR . 13.7 m -98.1 11.53 37.39 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.489 -0.757 . . . . 0.0 111.116 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -65.98 145.29 56.07 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.176 -0.953 . . . . 0.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 83.24 29.21 34.26 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.493 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -101.6 147.69 26.12 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.532 -0.981 . . . . 0.0 110.548 179.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.688 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.6 t -97.73 126.96 43.35 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.655 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.491 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 97.5 m95 -131.04 147.67 52.65 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.344 -0.848 . . . . 0.0 110.709 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.7 tttp -109.06 130.7 55.48 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.5 t -110.78 122.56 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.561 -0.712 . . . . 0.0 110.298 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.474 ' O ' HG13 ' A' ' 105' ' ' VAL . 98.4 m -121.47 138.73 54.16 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.662 -0.649 . . . . 0.0 110.842 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.491 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 11.1 pt -113.59 165.54 13.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 O-C-N 121.631 -0.668 . . . . 0.0 110.777 -179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.491 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.43 -24.88 75.8 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 121.361 1.374 . . . . 0.0 112.825 -178.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -65.32 -39.87 93.01 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.223 -0.923 . . . . 0.0 109.99 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.19 60.07 0.28 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -160.33 152.18 20.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.669 -0.901 . . . . 0.0 108.887 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.418 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -153.75 158.9 41.65 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.047 -1.061 . . . . 0.0 112.373 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 31.0 pt -139.92 163.38 24.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -104.2 129.15 51.97 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 118.845 -1.142 . . . . 0.0 109.958 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.0 130.01 71.43 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.733 -0.604 . . . . 0.0 109.55 -179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.565 ' HD3' HG12 ' A' ' 37' ' ' VAL . 67.2 ttt180 -100.39 136.28 40.52 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.296 -0.878 . . . . 0.0 109.299 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -56.75 146.73 34.38 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -178.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.487 HG22 HG21 ' A' ' 18' ' ' VAL . 5.4 p -158.26 -42.51 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.816 -0.814 . . . . 0.0 109.461 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.527 ' HB2' HG23 ' A' ' 18' ' ' VAL . 16.9 t70 -130.43 168.94 16.17 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.225 -0.922 . . . . 0.0 109.522 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 58.6 p -97.44 160.66 14.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.515 -0.74 . . . . 0.0 111.637 -179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.03 149.37 19.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 65.0 mtt180 -61.88 -33.09 73.59 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.66 -0.906 . . . . 0.0 110.928 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.43 81.57 0.05 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.876 -1.154 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.3 149.99 5.39 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.897 -1.144 . . . . 0.0 110.351 179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.573 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.3 OUTLIER -65.78 136.37 56.12 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.968 -0.725 . . . . 0.0 110.388 179.503 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.428 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 56.9 t-20 -134.93 124.23 24.63 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.143 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.9 m -133.81 176.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.133 -177.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.9 m-20 -57.65 154.49 25.34 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.675 -0.64 . . . . 0.0 110.253 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.53 -26.86 46.66 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.468 1.246 . . . . 0.0 110.604 179.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -70.0 -40.54 75.23 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 120.919 -1.113 . . . . 0.0 108.632 178.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.88 -39.92 87.65 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.5 t80 -60.01 -50.06 75.21 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.85 -0.531 . . . . 0.0 110.474 179.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 90.5 m -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 121.424 -0.798 . . . . 0.0 110.538 -178.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -69.4 -40.08 77.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.79 -0.764 . . . . 0.0 111.493 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.418 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 40.6 tp -71.49 -43.02 67.32 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.525 -0.734 . . . . 0.0 111.504 -178.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.5 t -96.26 -39.63 9.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.309 -0.87 . . . . 0.0 111.492 -177.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.79 7.42 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.3 p -144.78 157.95 43.98 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.453 -1.027 . . . . 0.0 110.117 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.53 15.77 28.14 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.422 -0.799 . . . . 0.0 110.574 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -93.35 -15.0 26.2 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.452 -0.78 . . . . 0.0 110.761 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.93 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.231 -0.918 . . . . 0.0 110.405 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 86.82 -77.01 2.03 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.415 ' NE ' ' HB3' ' A' ' 2' ' ' SER . 61.6 ttt180 -137.82 135.62 36.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.595 -0.944 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 56.3 t -120.05 119.24 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.421 -0.799 . . . . 0.0 109.477 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 2' ' ' SER . 36.0 p-10 -85.18 177.05 8.01 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.792 0.806 . . . . 0.0 112.078 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 60.06 40.0 19.09 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.919 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.474 HG13 ' O ' ' A' ' 64' ' ' THR . 86.3 t -95.41 123.27 47.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 C-N-CA 119.497 -0.881 . . . . 0.0 109.231 179.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -84.5 146.72 27.44 Favored 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.762 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.428 ' C ' HG13 ' A' ' 108' ' ' VAL . 52.2 p90 -142.14 148.74 38.79 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.923 -0.486 . . . . 0.0 110.907 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.428 HG13 ' C ' ' A' ' 107' ' ' TYR . 24.4 m -149.93 144.91 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.17 0 O-C-N 121.348 -0.845 . . . . 0.0 111.782 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.491 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 55.1 tt0 -70.01 140.99 52.98 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.707 -0.62 . . . . 0.0 109.886 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.688 HG23 ' SG ' ' A' ' 60' ' ' CYS . 30.5 m -139.95 172.78 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.992 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.9 t0 -59.86 145.51 45.36 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.382 -0.824 . . . . 0.0 110.862 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.464 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.4 tt -59.99 -40.09 87.94 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.378 -0.826 . . . . 0.0 110.201 179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 70.6 m -54.92 -37.9 66.96 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.627 -0.671 . . . . 0.0 109.847 -179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -59.98 -39.99 87.56 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.56 -0.712 . . . . 0.0 110.059 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.8 m -64.04 -45.35 89.27 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.489 -0.757 . . . . 0.0 109.225 178.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.2 mm -62.89 -45.72 98.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 CA-C-O 121.259 0.552 . . . . 0.0 110.137 -178.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -66.53 -40.01 88.9 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.796 -0.565 . . . . 0.0 110.553 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.78 -42.93 99.81 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.56 -40.0 94.77 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.574 -0.957 . . . . 0.0 110.535 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 33.6 m120 . . . . . 0 N--CA 1.493 1.718 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.306 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 120.982 0.42 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.4 t -112.96 139.94 48.18 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.588 -0.695 . . . . 0.0 110.44 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.671 HG21 HG11 ' A' ' 105' ' ' VAL . 44.9 pt -107.71 145.68 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.688 -0.632 . . . . 0.0 110.693 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 3.9 m -144.33 -174.25 4.25 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.419 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 45.8 p90 -141.29 147.36 38.06 Favored 'General case' 0 N--CA 1.492 1.671 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.043 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -124.81 145.18 48.96 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.504 -0.747 . . . . 0.0 109.169 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -82.51 -10.08 11.03 Favored 'Trans proline' 0 C--N 1.316 -1.157 0 O-C-N 123.274 1.144 . . . . 0.0 112.733 -178.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.828 ' O ' HD23 ' A' ' 13' ' ' LEU . 48.9 pt -70.03 -40.04 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 O-C-N 120.947 -1.096 . . . . 0.0 111.37 -179.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.475 ' N ' HG13 ' A' ' 8' ' ' ILE . 42.6 m-85 -73.11 67.34 0.9 Allowed 'General case' 0 N--CA 1.495 1.776 0 CA-C-O 122.874 1.321 . . . . 0.0 111.698 -178.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.91 173.86 6.12 Favored 'General case' 0 N--CA 1.489 1.505 0 CA-C-N 114.401 -1.272 . . . . 0.0 108.107 176.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.5 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -56.71 -30.35 63.4 Favored 'General case' 0 N--CA 1.496 1.838 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -175.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.5 m-20 -89.99 11.55 20.23 Favored 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 118.237 -1.385 . . . . 0.0 112.262 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.828 HD23 ' O ' ' A' ' 8' ' ' ILE . 0.4 OUTLIER -67.51 119.78 12.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.295 -0.878 . . . . 0.0 109.878 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.454 ' N ' HD13 ' A' ' 13' ' ' LEU . 50.5 m -70.11 137.01 50.78 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 121.759 0.79 . . . . 0.0 110.007 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.776 ' O ' HG12 ' A' ' 18' ' ' VAL . 95.4 mmm -64.24 -21.87 66.74 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.885 -0.51 . . . . 0.0 111.634 -179.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.436 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.32 -16.07 77.13 Favored Glycine 0 N--CA 1.495 2.601 0 O-C-N 121.065 -1.022 . . . . 0.0 111.514 -178.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.4 m -90.0 -4.71 57.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.121 -1.223 . . . . 0.0 111.923 -178.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.776 HG12 ' O ' ' A' ' 15' ' ' MET . 9.9 p -101.04 168.64 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 120.959 -1.088 . . . . 0.0 110.618 -179.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.673 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.0 -42.73 94.87 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.476 -0.765 . . . . 0.0 110.005 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.5 m -80.47 71.98 7.33 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.85 -76.96 0.51 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.507 -0.746 . . . . 0.0 109.952 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -127.84 168.55 15.02 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.648 -0.658 . . . . 0.0 109.584 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.21 -154.95 16.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 -178.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -70.72 -42.77 70.15 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -1.109 . . . . 0.0 110.186 179.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.417 ' CD2' ' O ' ' A' ' 54' ' ' SER . 54.7 m-70 -92.61 3.35 55.73 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.412 -0.805 . . . . 0.0 110.836 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.05 129.74 48.07 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.407 HD13 HH21 ' A' ' 74' ' ' ARG . 85.8 mt -99.71 -3.12 33.64 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 122.039 -0.683 . . . . 0.0 110.21 179.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.436 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 58.8 tpp -60.01 -38.59 83.11 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.336 -0.853 . . . . 0.0 110.365 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.77 -75.05 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.68 -0.637 . . . . 0.0 112.195 -177.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -70.05 -41.17 74.56 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.325 -0.86 . . . . 0.0 111.446 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.641 ' CG ' HG23 ' A' ' 37' ' ' VAL . 97.6 m-85 -122.84 86.4 50.21 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.648 -0.657 . . . . 0.0 110.474 -178.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -71.06 -7.42 21.36 Favored 'Trans proline' 0 C--N 1.317 -1.099 0 O-C-N 123.387 1.203 . . . . 0.0 111.475 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 9.3 m -130.02 142.98 50.56 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.05 -1.031 . . . . 0.0 110.189 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.906 HD11 HG21 ' A' ' 43' ' ' VAL . 39.6 tp -75.4 117.83 17.62 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.78 -0.575 . . . . 0.0 110.644 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.05 30.29 0.05 OUTLIER Glycine 0 N--CA 1.496 2.676 0 C-N-CA 120.092 -1.052 . . . . 0.0 110.812 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.436 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 8.9 mt-10 -153.66 -52.79 0.1 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.218 -1.166 . . . . 0.0 110.336 179.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.641 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -60.65 -59.63 13.24 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 45.7 Cg_endo -73.36 -32.45 8.09 Favored 'Trans proline' 0 N--CA 1.486 1.068 0 N-CA-C 109.114 -1.148 . . . . 0.0 109.114 177.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.422 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.81 -64.35 0.61 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 107.739 -2.144 . . . . 0.0 107.739 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 162.75 -55.8 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.787 0 C-N-CA 123.477 0.711 . . . . 0.0 110.627 177.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.4 Cg_endo -101.07 13.09 0.44 Allowed 'Trans proline' 0 N--CA 1.48 0.715 0 C-N-CA 121.348 1.365 . . . . 0.0 111.522 -178.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -122.21 45.76 2.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.337 -0.852 . . . . 0.0 109.223 -179.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.906 HG21 HD11 ' A' ' 34' ' ' LEU . 12.6 p -126.78 141.06 47.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.832 0.825 . . . . 0.0 110.19 -179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.84 173.3 43.4 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.568 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.26 159.23 30.85 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.009 -1.636 . . . . 0.0 109.009 179.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.768 HD11 ' HA2' ' A' ' 75' ' ' GLY . 1.0 OUTLIER -153.38 160.18 31.25 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.581 -0.952 . . . . 0.0 109.493 179.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -65.14 -37.67 31.26 Favored 'Trans proline' 0 N--CA 1.505 2.184 0 C-N-CA 121.831 1.687 . . . . 0.0 116.125 -175.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -69.7 -9.95 56.4 Favored 'General case' 0 N--CA 1.509 2.493 0 O-C-N 120.561 -1.337 . . . . 0.0 112.974 -176.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 54' ' ' SER . 44.4 mm -77.04 125.04 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 O-C-N 120.713 -1.242 . . . . 0.0 108.527 178.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.18 -46.78 12.31 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.261 -0.899 . . . . 0.0 112.568 -178.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.673 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 171.94 -137.5 4.33 Favored Glycine 0 N--CA 1.491 2.351 0 C-N-CA 118.716 -1.707 . . . . 0.0 111.54 -179.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 58.2 t90 -42.88 -29.62 0.34 Allowed 'General case' 0 N--CA 1.5 2.07 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.401 ' HB2' ' CE3' ' A' ' 52' ' ' TRP . 25.4 t70 -144.98 62.27 1.31 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.247 -0.908 . . . . 0.0 110.508 -179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.579 ' CB ' HG23 ' A' ' 49' ' ' ILE . 12.5 p -61.82 139.31 95.55 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.651 -0.656 . . . . 0.0 110.651 -179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -76.17 -21.36 13.81 Favored 'Trans proline' 0 N--CA 1.484 0.951 0 O-C-N 123.373 1.196 . . . . 0.0 111.113 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.7 m -94.05 14.49 19.67 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.491 -0.755 . . . . 0.0 111.296 -179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.3 t -73.85 147.89 42.86 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.169 -0.957 . . . . 0.0 110.04 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.16 35.31 53.51 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.421 HG22 ' NE1' ' A' ' 61' ' ' TRP . 89.2 m -119.68 131.55 55.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.595 -0.944 . . . . 0.0 109.882 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.04 145.66 33.73 Favored 'General case' 0 N--CA 1.496 1.838 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.871 -177.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.445 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -149.83 149.34 30.35 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.684 -0.635 . . . . 0.0 110.124 178.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -112.16 135.55 52.67 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.6 t -108.77 126.77 65.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.8 m -119.22 140.39 50.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.964 -0.46 . . . . 0.0 110.834 -178.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.449 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 39.3 pt -119.16 164.2 22.58 Favored Pre-proline 0 N--CA 1.499 1.996 0 O-C-N 121.616 -0.677 . . . . 0.0 110.531 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.449 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.1 -24.41 79.28 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 121.273 1.315 . . . . 0.0 112.338 -178.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -63.89 -40.02 95.54 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.272 -0.892 . . . . 0.0 109.58 179.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.95 62.57 0.41 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 48.6 t-20 -162.01 153.45 18.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.708 -0.878 . . . . 0.0 108.975 179.229 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 83.4 p -154.64 160.96 41.75 Favored 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 119.261 -0.975 . . . . 0.0 112.329 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.527 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.0 pt -136.35 164.44 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -108.65 126.75 53.31 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.16 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.782 HD13 HG11 ' A' ' 85' ' ' VAL . 88.0 mt -129.99 140.0 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.254 -0.904 . . . . 0.0 111.454 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.466 ' CD ' HG12 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -100.87 144.35 29.94 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.868 -0.52 . . . . 0.0 109.654 179.742 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.768 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.54 151.06 46.93 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -179.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.559 HG11 HG22 ' A' ' 43' ' ' VAL . 2.7 p -155.73 -44.1 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 178.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.466 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.9 t70 -130.3 170.0 14.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.207 -0.933 . . . . 0.0 109.507 178.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 47.7 t -101.48 159.94 14.86 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.775 . . . . 0.0 111.318 -179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -130.13 154.32 20.5 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.1 mtt180 -59.97 -31.56 70.01 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.555 -0.967 . . . . 0.0 110.403 179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.17 81.73 0.05 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 119.979 -1.105 . . . . 0.0 110.571 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.06 163.9 11.01 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.161 -1.176 . . . . 0.0 110.161 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.577 ' CD2' HG22 ' A' ' 46' ' ' ILE . 28.0 m-85 -88.36 118.63 28.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.512 -0.993 . . . . 0.0 109.746 179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.406 ' HA ' ' O ' ' A' ' 4' ' ' SER . 54.6 t-20 -113.04 128.71 56.57 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.782 HG11 HD13 ' A' ' 73' ' ' ILE . 34.5 m -130.02 172.56 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.038 0 O-C-N 120.862 -1.149 . . . . 0.0 112.008 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 -56.52 156.22 12.26 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.504 -0.748 . . . . 0.0 109.594 179.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.44 -28.49 54.11 Favored 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.276 1.145 . . . . 0.0 110.663 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 89.9 m -70.28 -40.63 74.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.99 -1.069 . . . . 0.0 109.382 179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.39 -39.65 89.2 Favored 'General case' 0 N--CA 1.495 1.82 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -60.02 -49.84 76.08 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.826 -0.546 . . . . 0.0 110.311 179.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.9 m -60.11 -39.98 88.11 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.586 -0.696 . . . . 0.0 110.754 -178.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -68.67 -39.98 80.35 Favored 'General case' 0 N--CA 1.495 1.813 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.172 -178.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.402 HD13 HG23 ' A' ' 71' ' ' ILE . 63.1 tp -70.27 -42.9 71.52 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.627 -0.67 . . . . 0.0 111.749 -178.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 92.7 t -97.05 -39.93 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.312 -0.868 . . . . 0.0 111.829 -177.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.07 -25.75 7.36 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 80.9 p -149.93 161.03 43.1 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.351 -1.088 . . . . 0.0 110.317 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 77.4 p -99.1 1.87 45.54 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.477 -0.765 . . . . 0.0 111.298 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -69.96 -28.65 65.73 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.388 -0.82 . . . . 0.0 111.466 -179.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.82 -40.63 89.06 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.396 -0.815 . . . . 0.0 111.272 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 89.42 -66.26 2.98 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -151.23 155.99 39.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.486 -1.008 . . . . 0.0 110.581 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.97 117.65 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.551 -0.718 . . . . 0.0 109.785 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -80.62 169.51 17.55 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.474 -0.766 . . . . 0.0 110.427 -179.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 60.0 51.81 5.62 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.628 -0.67 . . . . 0.0 111.347 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.671 HG11 HG21 ' A' ' 3' ' ' ILE . 65.8 t -98.66 129.99 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 C-N-CA 119.934 -0.706 . . . . 0.0 110.434 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -89.04 138.68 31.19 Favored 'General case' 0 N--CA 1.492 1.649 0 C-N-CA 119.374 -0.93 . . . . 0.0 109.804 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.405 ' C ' HG13 ' A' ' 108' ' ' VAL . 38.3 p90 -133.3 140.98 47.75 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.907 -0.496 . . . . 0.0 110.557 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.405 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -146.03 143.0 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 O-C-N 121.589 -0.694 . . . . 0.0 111.242 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.445 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.2 tt0 -70.88 139.78 50.89 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.681 -0.637 . . . . 0.0 110.444 179.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.2 m -130.07 163.27 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.098 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -59.62 141.38 55.12 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.543 -0.723 . . . . 0.0 110.478 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.0 tt -60.0 -40.0 87.7 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.598 -0.689 . . . . 0.0 111.391 -179.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 78.6 p -55.72 -34.23 64.95 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.503 -0.748 . . . . 0.0 110.935 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.3 m-20 -69.92 -28.08 65.31 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.348 -0.845 . . . . 0.0 111.339 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 97.3 m -69.96 -46.45 65.22 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.23 -0.919 . . . . 0.0 109.179 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 89.2 mt -69.96 -40.01 78.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.143 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 -64.56 -40.0 94.78 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.459 -0.776 . . . . 0.0 110.618 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -83.81 -60.01 2.02 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 120.454 -0.879 . . . . 0.0 110.93 -178.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.04 -42.52 94.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.611 -0.934 . . . . 0.0 111.202 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.502 2.172 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.727 -179.711 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.573 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.694 0.759 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.9 p -111.81 138.94 47.73 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.712 HG23 HG21 ' A' ' 105' ' ' VAL . 29.9 pt -108.78 145.36 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.801 -0.562 . . . . 0.0 110.481 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.4 p -144.22 -173.32 3.98 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 39.4 p90 -140.02 141.24 36.32 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.456 -0.777 . . . . 0.0 110.696 179.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -120.14 150.07 50.55 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.483 -0.761 . . . . 0.0 109.284 179.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -82.83 -10.53 10.51 Favored 'Trans proline' 0 C--N 1.318 -1.067 0 O-C-N 123.105 1.055 . . . . 0.0 112.551 -178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.492 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.9 pt -70.06 -39.96 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 O-C-N 121.002 -1.061 . . . . 0.0 111.62 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.687 ' HA ' HD22 ' A' ' 13' ' ' LEU . 53.7 m-85 -73.2 67.51 0.95 Allowed 'General case' 0 N--CA 1.494 1.77 0 CA-C-O 122.875 1.321 . . . . 0.0 111.907 -178.32 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.8 169.65 8.36 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.854 176.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.521 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -57.87 -35.09 70.48 Favored 'General case' 0 N--CA 1.497 1.912 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 32.0 p-10 -90.23 10.39 24.86 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 120.497 -1.377 . . . . 0.0 112.295 -177.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.687 HD22 ' HA ' ' A' ' 9' ' ' TYR . 34.8 tp -68.49 123.45 20.85 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.315 -0.865 . . . . 0.0 109.829 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.3 m -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 119.806 -0.758 . . . . 0.0 109.775 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.811 ' O ' HG12 ' A' ' 18' ' ' VAL . 86.6 mtp -69.96 -15.28 63.02 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.91 -0.494 . . . . 0.0 111.864 -178.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.58 -15.95 73.59 Favored Glycine 0 N--CA 1.496 2.654 0 O-C-N 121.021 -1.049 . . . . 0.0 110.816 -179.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.5 m -90.05 -4.99 57.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.175 -1.191 . . . . 0.0 111.716 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.811 HG12 ' O ' ' A' ' 15' ' ' MET . 14.8 p -102.26 168.96 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.026 -1.046 . . . . 0.0 110.877 -179.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.92 -40.7 89.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.575 -0.703 . . . . 0.0 110.368 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 54.1 m -83.45 74.84 10.05 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.186 -0.946 . . . . 0.0 109.464 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.2 m -100.41 -77.04 0.54 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.385 -0.822 . . . . 0.0 110.388 -179.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -129.68 169.98 14.39 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 0.0 110.485 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 120.46 -154.4 16.45 Favored Glycine 0 N--CA 1.487 2.087 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 -178.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 55.0 t0 -70.2 -40.94 74.3 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.376 -1.073 . . . . 0.0 109.791 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.406 ' CD2' ' O ' ' A' ' 54' ' ' SER . 44.0 m-70 -91.82 0.59 57.48 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.519 -0.738 . . . . 0.0 110.982 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -52.42 126.07 30.33 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 110.224 -1.151 . . . . 0.0 110.224 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HB2' ' HE2' ' A' ' 15' ' ' MET . 87.2 mt -96.53 -9.42 29.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 122.032 -0.687 . . . . 0.0 110.128 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.5 tpp -59.95 -37.03 78.39 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.35 -0.844 . . . . 0.0 110.006 179.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.72 -74.37 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.513 -0.742 . . . . 0.0 111.983 -178.087 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -69.98 -39.99 75.6 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.237 -0.915 . . . . 0.0 110.455 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' CD2' HG23 ' A' ' 37' ' ' VAL . 87.3 m-85 -117.39 100.95 52.99 Favored Pre-proline 0 N--CA 1.491 1.584 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.04 -20.92 16.31 Favored 'Trans proline' 0 C--N 1.318 -1.046 0 O-C-N 123.307 1.161 . . . . 0.0 111.367 -178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 30.2 m -127.84 148.32 50.46 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.371 -0.831 . . . . 0.0 111.017 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.97 HD21 HG11 ' A' ' 43' ' ' VAL . 57.7 tp -67.13 120.44 13.72 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.784 -0.573 . . . . 0.0 110.374 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.46 30.02 0.05 OUTLIER Glycine 0 N--CA 1.495 2.603 0 C-N-CA 119.891 -1.147 . . . . 0.0 110.963 179.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.44 ' HB3' ' CE1' ' A' ' 31' ' ' TYR . 31.7 mt-10 -153.18 -48.67 0.1 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.226 -1.161 . . . . 0.0 110.325 179.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.551 HG23 ' CD2' ' A' ' 31' ' ' TYR . 3.2 t -60.55 -60.48 10.5 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.461 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.7 Cg_endo -75.67 -27.57 8.86 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.113 1.059 . . . . 0.0 109.466 177.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.406 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.27 -58.93 0.67 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.414 -2.274 . . . . 0.0 107.414 -178.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.565 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 165.89 -73.57 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.615 0 C-N-CA 123.666 0.786 . . . . 0.0 109.356 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.565 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -86.21 19.19 1.43 Allowed 'Trans proline' 0 N--CA 1.493 1.465 0 CA-C-N 119.306 0.788 . . . . 0.0 111.16 178.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -118.37 37.03 4.15 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.059 -1.026 . . . . 0.0 110.18 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.97 HG11 HD21 ' A' ' 34' ' ' LEU . 12.4 p -120.71 141.23 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 CA-C-O 121.757 0.789 . . . . 0.0 110.716 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.99 171.38 42.92 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -81.08 152.24 32.63 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.761 HG22 ' CE1' ' A' ' 83' ' ' PHE . 13.7 pt -141.88 156.81 65.41 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.665 -0.903 . . . . 0.0 109.742 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.3 -20.5 36.93 Favored 'Trans proline' 0 N--CA 1.499 1.841 0 C-N-CA 121.399 1.4 . . . . 0.0 113.966 -177.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 82.9 m-20 -88.92 20.68 3.44 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.805 -1.184 . . . . 0.0 112.541 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.835 HG23 ' CB ' ' A' ' 54' ' ' SER . 40.7 mt -120.02 120.0 61.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.074 -1.016 . . . . 0.0 108.398 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.48 -41.82 21.19 Favored 'General case' 0 N--CA 1.499 2.015 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -176.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.563 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.83 -138.96 4.6 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 118.323 -1.894 . . . . 0.0 112.171 -179.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.504 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 26.3 t90 -39.95 -30.06 0.08 Allowed 'General case' 0 N--CA 1.5 2.044 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -177.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -146.72 68.52 1.17 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.998 -1.064 . . . . 0.0 111.24 -178.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.835 ' CB ' HG23 ' A' ' 49' ' ' ILE . 2.1 t -64.51 136.87 96.94 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.622 -0.674 . . . . 0.0 110.586 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.29 -20.55 21.06 Favored 'Trans proline' 0 C--N 1.32 -0.968 0 O-C-N 123.303 1.159 . . . . 0.0 110.605 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.9 m -99.84 14.82 29.03 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.499 -0.751 . . . . 0.0 110.806 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 23.4 t -72.75 151.12 42.28 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.238 -0.913 . . . . 0.0 110.061 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.18 21.75 78.62 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 80.4 m -106.58 140.01 40.13 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.515 -0.991 . . . . 0.0 110.277 179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.703 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.3 t -78.59 136.21 37.46 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.687 -178.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.434 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -137.21 146.24 44.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.647 -0.658 . . . . 0.0 110.016 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -116.28 136.46 52.98 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.222 -0.924 . . . . 0.0 110.099 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -114.25 129.99 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.543 -0.723 . . . . 0.0 110.887 -179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 51.1 m -119.92 144.96 47.16 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.723 -0.611 . . . . 0.0 110.501 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.453 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.6 pt -123.44 164.33 28.85 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.307 -0.871 . . . . 0.0 111.11 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.28 -26.88 82.53 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.428 1.419 . . . . 0.0 112.574 -178.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -63.45 -39.71 95.2 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.317 -0.864 . . . . 0.0 109.741 179.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 115.26 61.65 0.37 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.5 t30 -160.6 153.29 20.99 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.832 -0.805 . . . . 0.0 109.077 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.402 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 84.0 p -150.65 158.49 44.21 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 122.18 0.99 . . . . 0.0 112.021 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.455 HG12 HD13 ' A' ' 93' ' ' LEU . 27.6 pt -138.7 162.77 28.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -107.27 123.83 48.89 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 118.859 -1.136 . . . . 0.0 109.794 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.403 HG13 HG11 ' A' ' 85' ' ' VAL . 48.5 mm -117.13 131.99 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.638 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.489 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.5 ttt180 -98.65 132.38 44.1 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.152 -0.968 . . . . 0.0 108.783 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.89 148.35 10.44 Favored Glycine 0 N--CA 1.498 2.769 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.555 HG11 HG22 ' A' ' 43' ' ' VAL . 5.6 p -159.96 -35.26 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.792 -0.828 . . . . 0.0 110.406 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.456 ' HB2' HG23 ' A' ' 18' ' ' VAL . 28.4 t70 -128.94 165.28 21.38 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.885 -1.134 . . . . 0.0 110.449 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.443 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 79.4 p -82.54 159.78 22.73 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.656 -0.653 . . . . 0.0 110.521 179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -127.49 135.4 8.73 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 78.0 mtt-85 -65.44 -39.95 92.67 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.923 -0.751 . . . . 0.0 109.608 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 176.29 70.28 0.05 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.46 -163.18 33.35 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.59 -1.29 . . . . 0.0 110.766 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.761 ' CE1' HG22 ' A' ' 46' ' ' ILE . 0.1 OUTLIER -123.34 136.61 54.75 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 122.025 -0.691 . . . . 0.0 109.415 -179.516 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 45.3 t-20 -137.97 126.89 24.02 Favored 'General case' 0 N--CA 1.495 1.814 0 C-N-CA 119.389 -0.925 . . . . 0.0 108.808 178.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 27.8 m -133.63 176.8 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.113 0 O-C-N 121.08 -1.012 . . . . 0.0 111.128 -178.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 19.3 m-20 -56.47 150.25 35.17 Favored Pre-proline 0 N--CA 1.497 1.919 0 O-C-N 121.227 -0.921 . . . . 0.0 109.537 179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.91 -25.68 67.11 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 O-C-N 123.367 1.193 . . . . 0.0 110.763 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.434 HG22 ' HE2' ' A' ' 92' ' ' LYS . 89.8 m -70.8 -40.03 72.77 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 120.976 -1.078 . . . . 0.0 109.308 178.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.79 -40.03 91.56 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.04 -49.93 75.74 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.868 -0.52 . . . . 0.0 110.586 178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.1 m -60.11 -39.94 87.98 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.439 -0.788 . . . . 0.0 110.606 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.434 ' HE2' HG22 ' A' ' 88' ' ' THR . 57.8 mtmt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.273 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.455 HD13 HG12 ' A' ' 71' ' ' ILE . 45.9 tp -71.6 -46.12 60.16 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 120.047 -0.661 . . . . 0.0 111.357 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.1 t -89.46 -41.39 13.78 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 O-C-N 121.4 -0.812 . . . . 0.0 111.334 -177.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 125.2 -27.25 5.37 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.7 p -158.85 162.32 36.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.551 -0.97 . . . . 0.0 110.024 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.9 p -91.97 1.57 57.1 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.478 -0.764 . . . . 0.0 111.372 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.66 -34.08 77.05 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.354 -0.841 . . . . 0.0 111.017 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.36 -41.5 80.25 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.45 -0.781 . . . . 0.0 111.456 -178.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.41 -80.47 1.82 Allowed Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.3 ttm180 -129.0 136.82 50.83 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.575 -0.956 . . . . 0.0 109.918 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.6 t -119.02 117.29 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.243 -0.91 . . . . 0.0 110.299 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -83.84 171.57 12.98 Favored 'General case' 0 N--CA 1.495 1.779 0 CA-C-O 121.525 0.679 . . . . 0.0 110.65 -179.339 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 64.52 52.0 1.87 Allowed 'General case' 0 N--CA 1.504 2.257 0 O-C-N 121.623 -0.673 . . . . 0.0 111.06 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.712 HG21 HG23 ' A' ' 3' ' ' ILE . 60.4 t -103.24 129.81 54.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 C-N-CA 119.279 -0.968 . . . . 0.0 110.607 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -90.64 137.92 31.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.309 -0.87 . . . . 0.0 109.6 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.469 ' C ' HG13 ' A' ' 108' ' ' VAL . 53.8 p90 -140.04 145.83 38.24 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.902 -0.499 . . . . 0.0 110.835 -178.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.469 HG13 ' C ' ' A' ' 107' ' ' TYR . 29.6 m -151.1 151.58 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.216 -0.928 . . . . 0.0 111.273 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.434 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 56.0 tt0 -72.37 141.05 48.75 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.682 -0.636 . . . . 0.0 110.47 179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.703 HG23 ' SG ' ' A' ' 60' ' ' CYS . 15.7 m -137.03 170.03 18.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -64.21 148.85 49.14 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.175 -0.953 . . . . 0.0 110.645 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.543 HD21 HD11 ' A' ' 116' ' ' ILE . 9.4 tt -60.08 -39.77 87.21 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.495 -0.753 . . . . 0.0 110.84 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 89.3 p -52.24 -37.41 55.13 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.413 -0.805 . . . . 0.0 110.614 -178.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.31 -39.27 93.57 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.583 -0.698 . . . . 0.0 111.089 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -59.97 -50.02 75.4 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.394 -0.816 . . . . 0.0 110.064 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.543 HD11 HD21 ' A' ' 112' ' ' LEU . 86.9 mt -69.84 -39.98 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.715 -0.616 . . . . 0.0 110.773 -179.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -39.98 96.24 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.39 -0.819 . . . . 0.0 110.521 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -72.66 -47.32 27.41 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.174 -1.171 . . . . 0.0 110.174 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.99 -40.78 90.33 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.502 -0.999 . . . . 0.0 110.707 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.5 t30 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.276 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.013 0.435 . . . . 0.0 110.243 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.2 t -113.68 139.19 49.27 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 121.672 0.749 . . . . 0.0 111.045 -179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.77 HG12 HG21 ' A' ' 105' ' ' VAL . 36.3 pt -111.02 147.65 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.83 -0.544 . . . . 0.0 109.797 179.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.1 m -146.09 -171.52 3.73 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.418 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 47.7 p90 -140.12 150.01 43.75 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.119 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -126.67 148.07 63.33 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.521 -0.737 . . . . 0.0 110.216 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -86.57 14.14 2.53 Favored 'Trans proline' 0 C--N 1.317 -1.09 0 O-C-N 123.399 1.21 . . . . 0.0 111.636 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 1.4 pt -100.1 10.06 7.56 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 121.029 -1.044 . . . . 0.0 111.666 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -123.46 66.64 1.0 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.701 1.239 . . . . 0.0 110.259 178.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.07 172.76 6.82 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.459 -1.246 . . . . 0.0 108.447 176.592 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.03 -31.97 67.51 Favored 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -175.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -89.76 11.98 18.44 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.332 -1.347 . . . . 0.0 111.9 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 14' ' ' SER . 0.6 OUTLIER -69.3 119.56 13.77 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.281 -0.887 . . . . 0.0 110.043 179.875 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.47 ' N ' HD13 ' A' ' 13' ' ' LEU . 52.6 m -69.18 135.85 51.24 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.757 -0.777 . . . . 0.0 108.958 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.726 ' O ' HG12 ' A' ' 18' ' ' VAL . 57.1 mtp -70.21 -14.59 62.69 Favored 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 120.211 -0.596 . . . . 0.0 111.926 -179.234 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.65 -18.61 74.08 Favored Glycine 0 N--CA 1.495 2.6 0 O-C-N 120.848 -1.157 . . . . 0.0 110.654 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 70.4 m -88.06 -9.64 52.72 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.289 -1.124 . . . . 0.0 111.615 -179.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 15' ' ' MET . 9.7 p -101.74 169.66 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.029 -1.044 . . . . 0.0 110.495 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.529 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.14 -39.76 83.39 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.568 -0.708 . . . . 0.0 110.594 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.31 82.84 3.08 Favored 'General case' 0 N--CA 1.5 2.025 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 -84.26 0.42 Allowed 'General case' 0 N--CA 1.503 2.186 0 O-C-N 120.794 -1.191 . . . . 0.0 113.395 -177.003 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -143.8 12.56 1.67 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.564 -1.335 . . . . 0.0 112.752 -177.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.89 -149.19 0.11 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -67.22 -39.89 86.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.891 -0.77 . . . . 0.0 110.456 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.603 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 11.8 p80 -97.86 6.2 48.08 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.31 138.79 35.53 Favored Glycine 0 N--CA 1.5 2.91 0 O-C-N 121.055 -1.028 . . . . 0.0 110.659 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.871 HD13 HG11 ' A' ' 37' ' ' VAL . 95.4 mt -102.31 -5.68 23.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.885 -0.774 . . . . 0.0 110.724 179.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.8 ttm -60.44 -33.1 72.05 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.23 -0.919 . . . . 0.0 110.486 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -51.79 -72.15 0.06 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.566 -0.709 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -70.0 -40.16 75.44 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.185 -0.947 . . . . 0.0 110.079 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.422 ' CD2' HG23 ' A' ' 37' ' ' VAL . 60.8 m-85 -122.86 95.16 46.66 Favored Pre-proline 0 N--CA 1.487 1.384 0 O-C-N 121.875 -0.516 . . . . 0.0 109.769 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -70.63 -19.32 32.13 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 O-C-N 123.398 1.209 . . . . 0.0 111.556 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 25.7 m -122.61 140.9 52.3 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.296 -0.878 . . . . 0.0 110.736 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.853 HD11 HG21 ' A' ' 43' ' ' VAL . 40.7 tp -61.65 119.91 9.59 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.912 -0.492 . . . . 0.0 110.317 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.77 33.36 0.04 OUTLIER Glycine 0 N--CA 1.496 2.679 0 C-N-CA 119.948 -1.12 . . . . 0.0 110.797 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.66 -45.98 0.06 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.195 -1.179 . . . . 0.0 110.013 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.871 HG11 HD13 ' A' ' 27' ' ' LEU . 3.2 t -62.69 -60.78 8.93 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 178.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.47 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.2 Cg_endo -75.97 -28.15 7.88 Favored 'Trans proline' 0 N--CA 1.485 1.028 0 N-CA-C 109.236 -1.102 . . . . 0.0 109.236 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.402 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 126.98 -60.93 0.65 Allowed Glycine 0 N--CA 1.486 2.019 0 N-CA-C 107.284 -2.326 . . . . 0.0 107.284 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.622 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.2 t80 164.04 -52.9 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.573 0 C-N-CA 123.381 0.672 . . . . 0.0 109.705 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.4 Cg_endo -101.78 13.94 0.37 Allowed 'Trans proline' 0 C--N 1.324 -0.742 0 C-N-CA 121.457 1.438 . . . . 0.0 111.486 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -123.46 40.73 3.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -0.928 . . . . 0.0 110.112 -178.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.853 HG21 HD11 ' A' ' 34' ' ' LEU . 12.2 p -115.44 135.74 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 CA-C-O 121.602 0.715 . . . . 0.0 110.681 -179.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.432 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -163.94 170.0 39.06 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.961 -1.255 . . . . 0.0 109.961 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.471 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -90.37 164.82 30.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.482 HG22 ' CD2' ' A' ' 83' ' ' PHE . 5.2 pt -150.92 163.47 23.64 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.74 -0.859 . . . . 0.0 110.12 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 55.6 Cg_endo -73.69 -15.05 24.41 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 121.43 1.42 . . . . 0.0 113.337 -177.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.412 ' HB2' HD12 ' A' ' 46' ' ' ILE . 79.5 m-20 -90.37 12.7 17.58 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.852 -1.155 . . . . 0.0 112.829 -177.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.784 HG23 ' CB ' ' A' ' 54' ' ' SER . 71.9 mt -110.8 129.92 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.068 -1.02 . . . . 0.0 110.18 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.41 -46.45 12.52 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.537 -0.727 . . . . 0.0 112.159 -178.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.76 -138.91 5.52 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.895 -1.621 . . . . 0.0 111.371 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.492 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.0 t90 -39.81 -28.78 0.05 Allowed 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -179.005 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.603 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 24.6 t70 -141.09 63.96 1.43 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.281 -0.887 . . . . 0.0 110.576 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.784 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.8 t -79.86 139.35 53.83 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.696 -0.627 . . . . 0.0 110.414 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -78.4 -16.63 13.45 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.331 1.174 . . . . 0.0 111.45 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 60.0 p -98.05 4.84 49.21 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.208 -0.932 . . . . 0.0 112.607 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.424 ' HB3' ' HD1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -61.59 140.36 58.14 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.738 -1.226 . . . . 0.0 109.73 -179.604 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.97 -7.93 80.75 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 120.332 -0.937 . . . . 0.0 110.871 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 55.4 m -69.42 149.84 47.91 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.117 -1.225 . . . . 0.0 109.514 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.6 130.58 45.14 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.987 -0.446 . . . . 0.0 111.341 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.4 m95 -128.15 140.27 52.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.483 -0.761 . . . . 0.0 109.2 178.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.452 ' HB2' HG11 ' A' ' 110' ' ' VAL . 86.8 tttt -103.16 132.68 49.24 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.418 HG13 HG11 ' A' ' 105' ' ' VAL . 64.9 t -110.02 124.56 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.621 -0.674 . . . . 0.0 110.499 -179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.5 m -118.66 135.79 54.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.913 -0.492 . . . . 0.0 110.633 -178.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.443 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.9 pt -115.66 163.58 20.31 Favored Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.461 -0.775 . . . . 0.0 110.723 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.65 -27.29 76.0 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 121.411 1.407 . . . . 0.0 113.15 -178.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -62.62 -40.0 95.59 Favored 'General case' 0 N--CA 1.501 2.109 0 O-C-N 121.132 -0.98 . . . . 0.0 109.582 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.9 60.06 0.29 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -155.05 151.11 27.99 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 89.6 p -149.83 153.34 36.6 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.029 0.919 . . . . 0.0 111.747 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.446 HG23 HD13 ' A' ' 93' ' ' LEU . 31.6 pt -139.14 163.09 27.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -105.51 129.42 53.8 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.008 -1.077 . . . . 0.0 109.871 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.568 ' CD1' HG11 ' A' ' 85' ' ' VAL . 48.9 mm -116.09 128.18 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.662 -0.649 . . . . 0.0 109.614 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.607 ' HD3' HG12 ' A' ' 37' ' ' VAL . 60.3 ttt180 -100.05 137.96 37.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.28 -0.888 . . . . 0.0 108.888 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -53.43 148.21 16.11 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.593 HG11 HG22 ' A' ' 43' ' ' VAL . 3.2 p -159.92 -43.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.837 -0.802 . . . . 0.0 109.164 178.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.534 ' HB2' HG23 ' A' ' 18' ' ' VAL . 22.8 t70 -132.39 165.48 24.17 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.475 -0.766 . . . . 0.0 109.844 179.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 79.4 p -107.62 161.59 14.72 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 110.158 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -145.01 173.57 25.41 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.1 mtm180 -60.28 -40.03 88.99 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.8 -0.824 . . . . 0.0 112.05 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.06 95.39 0.1 OUTLIER Glycine 0 N--CA 1.504 3.182 0 C-N-CA 119.373 -1.394 . . . . 0.0 111.816 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 150.64 -164.82 29.96 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 178.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.543 ' HB2' HG22 ' A' ' 3' ' ' ILE . 95.7 m-85 -123.31 120.24 32.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.625 -0.927 . . . . 0.0 109.241 178.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -119.09 130.06 55.4 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 ' CD1' ' A' ' 73' ' ' ILE . 27.5 m -130.02 174.68 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.036 0 O-C-N 121.088 -1.007 . . . . 0.0 111.725 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -57.9 156.8 17.52 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.554 -0.716 . . . . 0.0 109.935 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.36 -27.73 47.3 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.471 1.248 . . . . 0.0 110.705 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.03 -40.08 75.38 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.012 -1.055 . . . . 0.0 109.485 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.84 -40.13 87.85 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -60.03 -49.96 75.6 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.783 -0.573 . . . . 0.0 110.678 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 66.6 m -59.97 -38.7 83.29 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.532 -0.73 . . . . 0.0 110.601 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -68.25 -39.81 82.12 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.883 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.446 HD13 HG23 ' A' ' 71' ' ' ILE . 54.6 tp -70.0 -42.73 72.68 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.597 -0.689 . . . . 0.0 111.886 -179.098 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 40.6 t -98.66 -36.91 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.219 0 O-C-N 121.221 -0.925 . . . . 0.0 111.709 -177.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.47 -28.83 6.11 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 89.4 p -151.59 162.68 40.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.512 -0.993 . . . . 0.0 110.394 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.3 p -100.97 14.05 33.18 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.913 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -70.03 -36.68 75.23 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.421 -0.799 . . . . 0.0 111.012 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.87 -40.04 87.3 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.514 -0.742 . . . . 0.0 110.894 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.13 -65.75 2.52 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 50.5 ptt85 -143.19 151.65 40.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.579 -0.954 . . . . 0.0 110.313 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -121.86 121.41 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.548 -0.72 . . . . 0.0 109.979 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -90.13 172.19 8.99 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.342 -0.849 . . . . 0.0 110.635 -179.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 64.5 t30 60.05 47.93 9.1 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.546 -0.722 . . . . 0.0 110.441 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.77 HG21 HG12 ' A' ' 3' ' ' ILE . 96.6 t -96.68 124.49 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 119.832 -0.747 . . . . 0.0 110.38 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -82.68 139.92 33.41 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 119.253 -0.979 . . . . 0.0 108.741 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.418 ' C ' HG13 ' A' ' 108' ' ' VAL . 42.3 p90 -135.96 141.86 44.49 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.361 0.601 . . . . 0.0 111.505 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.418 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.9 m -147.52 145.8 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.769 -0.582 . . . . 0.0 110.847 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -72.08 138.2 47.64 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.635 -0.666 . . . . 0.0 110.069 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LYS . 35.1 m -129.91 162.06 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.738 -0.601 . . . . 0.0 110.3 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -59.65 144.85 46.7 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.483 -0.761 . . . . 0.0 110.301 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.5 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -60.02 -38.26 82.15 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.658 -0.651 . . . . 0.0 111.108 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.6 m -56.28 -39.11 72.14 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.531 -0.731 . . . . 0.0 110.384 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -59.98 -39.98 87.55 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.429 -0.794 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 76.6 m -61.86 -48.63 79.68 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.364 -0.835 . . . . 0.0 110.718 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.5 HD11 HD21 ' A' ' 112' ' ' LEU . 86.3 mt -70.05 -39.99 77.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.653 -0.654 . . . . 0.0 110.668 -178.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.12 -40.03 95.3 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.465 -0.772 . . . . 0.0 110.29 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.88 -47.08 49.44 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -40.26 88.64 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.999 . . . . 0.0 110.5 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 53.7 t30 . . . . . 0 N--CA 1.502 2.163 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.848 179.791 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.425 HG23 ' HB ' ' A' ' 105' ' ' VAL . 28.3 m . . . . . 0 N--CA 1.497 1.913 0 CA-C-O 120.876 0.37 . . . . 0.0 110.437 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -111.23 141.35 44.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.621 -0.674 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.555 HG22 ' HB3' ' A' ' 83' ' ' PHE . 42.7 pt -116.1 149.24 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.822 -0.549 . . . . 0.0 110.803 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 m -147.3 -172.1 3.94 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 52.7 p90 -142.83 147.28 35.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.158 -0.964 . . . . 0.0 110.852 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -135.73 152.96 76.98 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.417 -0.802 . . . . 0.0 110.079 179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -88.15 37.13 0.43 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.318 1.167 . . . . 0.0 111.031 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.598 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.0 tp -106.7 -3.46 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.438 -0.789 . . . . 0.0 111.077 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.494 ' CD2' HG23 ' A' ' 8' ' ' ILE . 42.9 m-85 -122.08 76.91 1.34 Allowed 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 122.769 1.271 . . . . 0.0 111.257 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -108.61 169.97 8.32 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 114.399 -1.273 . . . . 0.0 108.671 177.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.93 -32.69 71.02 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 -176.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -87.99 11.5 15.78 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 120.503 -1.373 . . . . 0.0 112.336 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.598 HD22 ' O ' ' A' ' 8' ' ' ILE . 40.1 tp -74.61 121.5 21.7 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.2 -0.937 . . . . 0.0 110.227 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.4 m -67.4 138.99 57.12 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.696 179.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.747 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -68.29 -13.7 62.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.73 -0.606 . . . . 0.0 111.797 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -72.32 -14.49 76.95 Favored Glycine 0 N--CA 1.497 2.703 0 O-C-N 120.98 -1.075 . . . . 0.0 111.312 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.3 t -92.84 -14.88 27.14 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.125 -1.22 . . . . 0.0 111.405 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.747 HG12 ' O ' ' A' ' 15' ' ' MET . 11.9 p -90.05 165.2 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.246 -0.909 . . . . 0.0 111.0 -178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -56.96 -45.38 82.9 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.573 -0.705 . . . . 0.0 110.347 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.8 m -80.89 80.08 7.44 Favored 'General case' 0 N--CA 1.502 2.171 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -96.32 -80.42 0.43 Allowed 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.116 -0.99 . . . . 0.0 113.216 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -138.86 10.08 2.62 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.102 -0.999 . . . . 0.0 112.605 -177.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.61 -150.46 0.45 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -65.65 -40.04 92.05 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.67 -0.9 . . . . 0.0 109.867 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.467 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . 22.5 m-70 -99.94 8.95 43.69 Favored 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.464 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.19 137.54 49.16 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.647 HD13 HG11 ' A' ' 37' ' ' VAL . 88.5 mt -98.65 -4.05 34.68 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.812 -0.817 . . . . 0.0 110.262 179.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.403 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 54.6 ttm -60.1 -39.55 86.56 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.324 -0.86 . . . . 0.0 110.763 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.83 -75.55 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.443 -0.785 . . . . 0.0 111.723 -177.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -70.06 -40.01 75.32 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.425 -0.797 . . . . 0.0 110.387 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 37' ' ' VAL . 94.4 m-85 -119.18 89.43 39.54 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.869 -0.519 . . . . 0.0 110.896 -178.081 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.07 -4.71 15.79 Favored 'Trans proline' 0 C--N 1.318 -1.045 0 O-C-N 123.251 1.132 . . . . 0.0 111.073 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 17.5 p -131.41 155.35 47.47 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.147 -0.971 . . . . 0.0 110.219 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.925 HD11 HG21 ' A' ' 43' ' ' VAL . 58.2 tp -85.1 113.11 21.25 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.326 -0.55 . . . . 0.0 109.769 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 155.24 33.4 0.03 OUTLIER Glycine 0 N--CA 1.492 2.425 0 C-N-CA 119.918 -1.134 . . . . 0.0 110.609 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.42 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 2.6 mt-10 -157.8 -47.77 0.06 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.248 -1.148 . . . . 0.0 109.954 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.647 HG11 HD13 ' A' ' 27' ' ' LEU . 2.4 t -62.25 -58.0 19.98 Favored Pre-proline 0 N--CA 1.497 1.877 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.661 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.517 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.3 Cg_endo -78.66 -31.62 2.46 Favored 'Trans proline' 0 C--N 1.319 -0.995 0 O-C-N 123.282 1.148 . . . . 0.0 109.29 177.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.456 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.26 -61.73 0.66 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.588 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 5.3 t80 161.21 -50.85 0.0 OUTLIER Pre-proline 0 N--CA 1.514 2.752 0 C-N-CA 123.664 0.785 . . . . 0.0 110.19 177.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.588 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 50.5 Cg_endo -101.87 18.41 0.25 Allowed 'Trans proline' 0 C--N 1.326 -0.652 0 C-N-CA 121.744 1.629 . . . . 0.0 111.62 -177.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.4 ' HB3' ' O ' ' A' ' 72' ' ' PHE . 74.9 m-20 -135.95 55.85 1.85 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.253 -0.904 . . . . 0.0 110.277 -178.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.926 HG23 HG11 ' A' ' 76' ' ' VAL . 12.6 p -130.32 141.8 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 CA-C-O 121.681 0.753 . . . . 0.0 110.524 -179.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -172.27 179.18 44.03 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.814 -1.315 . . . . 0.0 109.814 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.429 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -86.78 154.61 27.02 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 108.319 -1.912 . . . . 0.0 108.319 178.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.616 HG22 ' CE1' ' A' ' 83' ' ' PHE . 5.7 pt -143.44 160.05 52.74 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.512 -0.993 . . . . 0.0 109.998 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -69.07 -17.83 40.51 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 121.142 1.228 . . . . 0.0 114.033 -177.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -93.65 25.41 3.54 Favored 'General case' 0 N--CA 1.502 2.153 0 O-C-N 120.71 -1.244 . . . . 0.0 112.387 -178.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.509 HG12 HG13 ' A' ' 46' ' ' ILE . 37.1 mm -119.94 120.1 62.18 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.028 0 O-C-N 121.024 -1.047 . . . . 0.0 109.012 178.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.55 -44.12 29.62 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.195 -0.941 . . . . 0.0 111.977 -178.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.26 -141.55 6.87 Favored Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.078 -1.534 . . . . 0.0 111.424 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.488 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.3 t90 -41.49 -29.43 0.16 Allowed 'General case' 0 N--CA 1.5 2.071 0 N-CA-C 113.869 1.063 . . . . 0.0 113.869 -178.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -141.44 57.21 1.52 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.021 -1.049 . . . . 0.0 111.206 -178.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.41 ' HB3' ' HA ' ' A' ' 49' ' ' ILE . 18.2 m -69.05 144.34 95.39 Favored Pre-proline 0 N--CA 1.493 1.713 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.673 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.449 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.6 Cg_endo -74.15 -14.41 23.3 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.328 1.173 . . . . 0.0 111.619 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 70.3 m -103.43 18.4 21.9 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.385 -0.822 . . . . 0.0 111.735 -178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.467 ' HB2' ' HB3' ' A' ' 25' ' ' HIS . 3.5 m -69.97 139.94 52.89 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.987 -1.071 . . . . 0.0 109.112 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.33 27.66 57.22 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 97.7 m -106.52 138.15 43.22 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.507 -0.996 . . . . 0.0 110.164 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.634 ' SG ' HG23 ' A' ' 110' ' ' VAL . 53.2 t -80.04 131.59 35.81 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 121.389 0.614 . . . . 0.0 110.889 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.444 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.5 m95 -133.99 152.15 51.74 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.541 -0.724 . . . . 0.0 109.379 179.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 42.2 tttm -121.69 138.15 54.46 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 120.933 -1.105 . . . . 0.0 110.583 -179.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.444 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.7 t -113.7 126.79 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.615 -0.678 . . . . 0.0 111.344 -178.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.9 m -119.54 141.14 49.49 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.742 -0.599 . . . . 0.0 110.48 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 10.9 pt -119.95 163.93 25.16 Favored Pre-proline 0 N--CA 1.503 2.183 0 O-C-N 121.186 -0.947 . . . . 0.0 110.906 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.9 Cg_endo -62.1 -27.56 79.12 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 121.564 1.509 . . . . 0.0 113.201 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -62.51 -39.95 95.17 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.244 -0.91 . . . . 0.0 110.045 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.09 60.31 0.31 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -159.92 151.11 19.48 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 86.1 p -151.64 157.77 42.58 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.007 0.908 . . . . 0.0 111.664 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.491 HD12 HD11 ' A' ' 73' ' ' ILE . 41.8 pt -137.83 161.65 32.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.4 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 97.2 m-85 -102.12 121.29 41.93 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 118.581 -1.248 . . . . 0.0 109.187 179.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.491 HD11 HD12 ' A' ' 71' ' ' ILE . 48.3 mm -110.78 130.6 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.524 ' HD3' HG12 ' A' ' 37' ' ' VAL . 52.4 ttt180 -99.33 132.82 44.39 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.112 -0.993 . . . . 0.0 109.251 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -51.9 146.67 13.25 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.926 HG11 HG23 ' A' ' 43' ' ' VAL . 7.5 p -169.76 -33.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.863 -0.787 . . . . 0.0 110.323 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.521 ' CG ' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -130.0 171.89 12.3 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 120.925 -1.11 . . . . 0.0 108.711 179.737 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -98.09 142.43 29.79 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.669 -0.644 . . . . 0.0 109.791 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -114.5 144.79 18.45 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 77.6 mtt85 -89.22 103.4 16.02 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.578 -0.954 . . . . 0.0 110.526 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 50.12 56.98 10.73 Favored Glycine 0 N--CA 1.497 2.765 0 O-C-N 121.681 -0.637 . . . . 0.0 111.724 178.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.6 -163.5 33.59 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.045 -1.55 . . . . 0.0 111.915 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.616 ' CE1' HG22 ' A' ' 46' ' ' ILE 0.263 0.1 OUTLIER -123.25 122.5 38.52 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -178.908 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 -124.12 129.91 51.65 Favored 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 118.892 -1.123 . . . . 0.0 109.83 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.3 m -132.31 172.88 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 C-N-CA 119.649 -0.82 . . . . 0.0 111.376 -178.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.8 m-20 -54.15 156.79 5.12 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.551 -0.718 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -70.64 -18.72 32.7 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 O-C-N 123.477 1.251 . . . . 0.0 110.051 179.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -80.02 -40.97 26.71 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.088 -1.008 . . . . 0.0 108.991 178.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.59 89.24 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -59.99 -50.05 75.26 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.808 -0.557 . . . . 0.0 110.573 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 88.3 m -59.92 -40.05 87.57 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.929 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 91.8 mttt -69.0 -40.13 78.89 Favored 'General case' 0 N--CA 1.495 1.803 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.29 -178.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 49.7 tp -71.97 -43.36 65.27 Favored 'General case' 0 N--CA 1.496 1.871 0 C-N-CA 120.008 -0.677 . . . . 0.0 111.478 -179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -92.34 -40.51 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.06 0 O-C-N 121.462 -0.774 . . . . 0.0 111.54 -177.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 126.63 -34.96 3.03 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 95.2 p -152.69 164.63 37.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.664 -0.903 . . . . 0.0 110.262 179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 69.8 p -90.18 2.61 55.17 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.42 -0.8 . . . . 0.0 111.194 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -69.94 -27.75 65.01 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.327 -0.858 . . . . 0.0 110.738 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.01 -41.72 83.7 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.57 -0.706 . . . . 0.0 110.619 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.56 -80.7 1.63 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 59.9 ttp180 -130.86 138.88 50.04 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.565 -0.962 . . . . 0.0 111.042 -179.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.7 t -121.54 114.65 43.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.608 -0.682 . . . . 0.0 110.428 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 77.2 m-20 -82.46 171.02 14.6 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.665 -0.647 . . . . 0.0 110.588 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.7 t30 60.13 48.35 8.48 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.743 -0.598 . . . . 0.0 111.828 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.443 HG11 HG21 ' A' ' 3' ' ' ILE . 60.7 t -98.1 124.56 51.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.325 179.276 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t-20 -82.57 134.24 35.19 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.306 -0.958 . . . . 0.0 109.931 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.421 ' C ' HG13 ' A' ' 108' ' ' VAL . 54.4 p90 -135.75 140.85 44.67 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.8 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.421 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.1 m -150.01 154.67 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.237 -0.914 . . . . 0.0 111.001 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.444 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.4 tt0 -74.64 141.53 44.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.713 -0.617 . . . . 0.0 109.834 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.634 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.0 m -139.06 168.89 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 C-N-CA 120.047 -0.661 . . . . 0.0 109.553 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 94.2 m-20 -59.92 144.34 49.19 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.356 -0.84 . . . . 0.0 110.964 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.481 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.4 tt -59.9 -36.18 76.43 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.562 -0.711 . . . . 0.0 111.035 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.4 m -56.48 -39.16 72.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.502 -0.749 . . . . 0.0 109.836 -179.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -61.52 -38.57 87.87 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.562 -0.711 . . . . 0.0 110.859 179.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.22 -49.61 76.94 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.301 -0.874 . . . . 0.0 109.846 179.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.434 HD11 HD21 ' A' ' 112' ' ' LEU . 83.7 mt -69.83 -39.92 78.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.632 -0.668 . . . . 0.0 110.662 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -65.02 -40.49 94.95 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.463 -0.773 . . . . 0.0 110.643 -179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.12 -43.75 70.29 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.99 94.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.765 -0.844 . . . . 0.0 110.264 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.389 -179.86 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.486 HG11 ' CE1' ' A' ' 107' ' ' TYR . 35.1 m . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 p -112.47 141.95 45.6 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-O 122.15 0.976 . . . . 0.0 111.575 -178.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.782 HG12 HG21 ' A' ' 105' ' ' VAL . 35.2 pt -119.97 150.02 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.965 179.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 7.6 m -144.87 -173.0 3.95 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -140.44 147.5 39.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.477 -0.764 . . . . 0.0 109.489 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.658 ' HB3' HG22 ' A' ' 8' ' ' ILE . 8.5 m-20 -138.55 147.68 55.89 Favored Pre-proline 0 N--CA 1.491 1.593 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.823 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -74.39 -6.08 17.83 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 O-C-N 123.455 1.239 . . . . 0.0 110.532 178.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.67 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.3 tp -64.43 -15.86 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.36 -0.837 . . . . 0.0 111.095 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.532 ' CD2' HG23 ' A' ' 8' ' ' ILE . 43.2 m-85 -112.5 69.31 0.69 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 122.72 1.248 . . . . 0.0 110.786 178.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.28 170.03 8.16 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.523 -1.217 . . . . 0.0 108.309 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.9 -32.44 70.75 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 113.89 1.07 . . . . 0.0 113.89 -175.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -89.64 11.49 19.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 120.344 -1.473 . . . . 0.0 112.182 -177.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.67 HD22 ' O ' ' A' ' 8' ' ' ILE . 28.5 tp -71.6 126.32 29.38 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.317 -0.864 . . . . 0.0 109.974 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.5 p -70.7 136.9 49.33 Favored 'General case' 0 N--CA 1.488 1.473 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.247 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.611 ' O ' HG12 ' A' ' 18' ' ' VAL . 94.6 mmm -64.66 -15.1 60.78 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.802 -0.561 . . . . 0.0 111.823 -178.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -77.66 -12.49 84.43 Favored Glycine 0 N--CA 1.494 2.537 0 O-C-N 121.066 -1.021 . . . . 0.0 111.297 -179.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 18.1 t -85.88 -7.21 58.85 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.113 -1.228 . . . . 0.0 111.935 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.611 HG12 ' O ' ' A' ' 15' ' ' MET . 11.0 p -101.4 168.89 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.03 -1.044 . . . . 0.0 110.672 -179.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.03 -42.38 94.25 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.605 -0.685 . . . . 0.0 109.881 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.6 70.42 8.47 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.2 p -92.86 -74.89 0.51 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.782 -0.573 . . . . 0.0 109.691 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -130.01 169.93 14.63 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 121.17 -149.0 17.41 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -179.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -73.48 -44.16 58.58 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.641 -0.917 . . . . 0.0 111.05 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 44.8 m-70 -98.28 8.9 44.18 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.297 -0.877 . . . . 0.0 110.711 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.2 129.94 46.7 Favored Glycine 0 N--CA 1.496 2.657 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.8 mt -100.03 -4.21 30.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 122.041 -0.682 . . . . 0.0 110.245 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 57.2 ttm -61.67 -37.88 85.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.241 -0.912 . . . . 0.0 109.876 179.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.5 -74.11 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.671 -0.643 . . . . 0.0 112.059 -177.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -69.96 -40.38 75.44 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.273 -0.892 . . . . 0.0 110.659 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.555 ' CG ' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -120.25 86.3 37.91 Favored Pre-proline 0 N--CA 1.492 1.664 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -178.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.37 -11.18 30.75 Favored 'Trans proline' 0 C--N 1.316 -1.15 0 O-C-N 123.383 1.202 . . . . 0.0 111.145 -179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 21.7 m -130.04 141.19 50.76 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.177 -0.952 . . . . 0.0 110.105 179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.975 HD11 HG21 ' A' ' 43' ' ' VAL . 34.7 tp -69.68 117.46 11.32 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.684 -0.635 . . . . 0.0 110.491 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.43 33.59 0.03 OUTLIER Glycine 0 N--CA 1.499 2.843 0 C-N-CA 119.763 -1.208 . . . . 0.0 111.079 179.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -159.8 -46.07 0.05 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.176 -1.19 . . . . 0.0 110.64 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.555 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.6 t -63.0 -59.33 12.75 Favored Pre-proline 0 N--CA 1.499 1.984 0 O-C-N 121.359 -0.838 . . . . 0.0 108.83 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.44 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 47.2 Cg_endo -74.35 -31.77 7.08 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 O-C-N 123.222 1.117 . . . . 0.0 109.408 178.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.437 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 134.57 -63.39 0.61 Allowed Glycine 0 N--CA 1.486 1.979 0 N-CA-C 107.116 -2.393 . . . . 0.0 107.116 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.61 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 161.19 -55.12 0.0 OUTLIER Pre-proline 0 N--CA 1.513 2.7 0 C-N-CA 123.457 0.703 . . . . 0.0 110.484 177.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.813 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.4 Cg_endo -100.68 3.52 0.7 Allowed 'Trans proline' 0 C--N 1.322 -0.828 0 C-N-CA 121.068 1.178 . . . . 0.0 112.09 -178.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.471 HD22 HD11 ' A' ' 71' ' ' ILE . 19.3 m120 -120.19 42.13 3.03 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 0.0 109.415 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.975 HG21 HD11 ' A' ' 34' ' ' LEU . 7.6 p -109.89 142.64 21.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-O 121.742 0.782 . . . . 0.0 109.145 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' CA ' ' O ' ' A' ' 84' ' ' ASN . . . -167.36 172.99 42.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -89.91 161.54 29.43 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 HD12 ' A' ' 49' ' ' ILE . 18.0 pt -144.49 159.44 51.51 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.705 -0.879 . . . . 0.0 110.684 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.421 ' HD2' ' CE2' ' A' ' 83' ' ' PHE . 53.7 Cg_endo -71.25 -14.91 31.68 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 121.511 1.474 . . . . 0.0 113.115 -178.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -91.55 19.45 6.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.016 -1.053 . . . . 0.0 111.948 -177.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.507 ' HB ' ' HA ' ' A' ' 78' ' ' SER . 62.4 mt -119.97 120.22 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.275 -0.89 . . . . 0.0 108.938 177.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.69 -41.32 21.51 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -177.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 177.29 -126.32 1.09 Allowed Glycine 0 N--CA 1.492 2.38 0 C-N-CA 118.144 -1.979 . . . . 0.0 112.741 -178.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 4.7 t90 -40.01 -34.6 0.3 Allowed 'General case' 0 N--CA 1.504 2.257 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -177.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 39.9 p-10 -172.08 82.23 0.06 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.719 -1.238 . . . . 0.0 109.713 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.461 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 8.1 t -68.25 150.65 97.64 Favored Pre-proline 0 N--CA 1.495 1.793 0 O-C-N 121.69 -0.631 . . . . 0.0 110.678 -178.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.462 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 41.1 Cg_endo -66.96 -15.86 48.1 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 O-C-N 123.513 1.27 . . . . 0.0 111.194 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.594 ' O ' HG23 ' A' ' 59' ' ' THR . 57.7 m -106.84 9.73 30.86 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.327 -0.858 . . . . 0.0 111.446 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -60.84 141.86 56.7 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 120.846 -1.159 . . . . 0.0 109.947 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.8 17.13 58.69 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.594 HG23 ' O ' ' A' ' 56' ' ' SER . 16.8 p -91.49 167.31 12.34 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.282 -1.128 . . . . 0.0 110.055 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -110.13 136.09 49.9 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.943 -0.473 . . . . 0.0 110.64 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 98.6 m95 -132.02 137.63 47.91 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.497 -0.752 . . . . 0.0 109.096 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 77.4 tttt -100.88 133.31 45.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.298 -0.876 . . . . 0.0 109.598 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.9 t -109.98 120.49 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.616 -0.678 . . . . 0.0 109.71 -179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 44.7 m -116.98 141.89 47.65 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.742 -0.599 . . . . 0.0 111.312 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.446 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 36.8 pt -119.61 163.4 27.57 Favored Pre-proline 0 N--CA 1.5 2.059 0 O-C-N 121.539 -0.726 . . . . 0.0 110.508 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -61.95 -24.69 77.2 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 O-C-N 123.744 1.391 . . . . 0.0 112.675 -178.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -63.84 -40.08 95.73 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.226 -0.921 . . . . 0.0 109.723 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.67 62.02 0.3 Allowed Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 35.8 t-20 -160.06 153.16 21.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.661 -0.905 . . . . 0.0 109.214 178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.679 ' HA ' HD11 ' A' ' 93' ' ' LEU . 83.2 p -150.04 160.1 43.9 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.18 0.991 . . . . 0.0 112.246 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.471 HD11 HD22 ' A' ' 42' ' ' ASN . 12.6 tt -138.96 159.38 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.436 ' O ' ' HB3' ' A' ' 42' ' ' ASN . 93.1 m-85 -104.36 122.35 45.29 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 47.1 mm -114.85 130.01 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.469 -0.77 . . . . 0.0 110.314 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.686 HH12 HG23 ' A' ' 43' ' ' VAL . 5.2 ttp-105 -97.65 139.43 33.55 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.01 146.69 50.51 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' A' ' 77' ' ' ASP . 3.7 p -153.1 -43.55 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 122.072 -0.664 . . . . 0.0 109.369 179.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.419 ' N ' ' CG1' ' A' ' 76' ' ' VAL . 18.1 t70 -115.37 162.46 17.1 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.237 -0.915 . . . . 0.0 110.352 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.507 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 26.4 t -79.64 156.8 27.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.818 -0.551 . . . . 0.0 109.608 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -140.62 126.42 3.14 Favored Glycine 0 N--CA 1.482 1.721 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.401 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 67.2 mmt-85 -59.92 -40.0 87.38 Favored 'General case' 0 N--CA 1.497 1.899 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 176.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -167.77 169.13 41.1 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 107.875 -2.09 . . . . 0.0 107.875 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 64.52 -166.84 29.81 Favored Glycine 0 N--CA 1.5 2.928 0 O-C-N 121.186 -1.185 . . . . 0.0 112.571 177.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.546 ' HB2' HG22 ' A' ' 3' ' ' ILE . 80.1 m-85 -139.17 139.78 37.66 Favored 'General case' 0 N--CA 1.507 2.411 0 O-C-N 122.225 -0.573 . . . . 0.0 110.754 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.41 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 0.9 OUTLIER -123.58 130.24 52.38 Favored 'General case' 0 N--CA 1.51 2.573 0 O-C-N 121.019 -1.051 . . . . 0.0 110.14 178.495 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 33.4 m -129.02 166.53 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.873 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.8 m-20 -54.61 153.65 10.29 Favored Pre-proline 0 N--CA 1.499 1.978 0 O-C-N 121.53 -0.731 . . . . 0.0 110.19 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -66.24 -30.03 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.498 1.262 . . . . 0.0 110.241 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -69.92 -40.09 75.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.094 -1.004 . . . . 0.0 108.603 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.813 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -67.02 -38.28 85.66 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.11 -49.48 77.47 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.311 0.577 . . . . 0.0 110.099 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.8 m -59.96 -39.73 86.6 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.707 -0.621 . . . . 0.0 110.947 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -68.65 -39.99 80.44 Favored 'General case' 0 N--CA 1.496 1.858 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.707 -178.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.679 HD11 ' HA ' ' A' ' 70' ' ' SER . 52.7 tp -69.94 -40.62 75.37 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.475 -0.765 . . . . 0.0 112.047 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.6 t -96.65 -35.98 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.218 0 O-C-N 121.246 -0.909 . . . . 0.0 111.363 -177.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.77 -38.73 2.27 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 108.291 -1.924 . . . . 0.0 108.291 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 23.1 t -150.0 133.58 16.65 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.836 -0.802 . . . . 0.0 109.271 178.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.565 HG23 ' O ' ' A' ' 97' ' ' THR . 9.5 t -90.67 66.69 6.22 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.366 -0.834 . . . . 0.0 110.628 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -114.83 -27.18 7.51 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.624 -0.673 . . . . 0.0 110.637 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.08 -39.93 87.8 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.483 -0.76 . . . . 0.0 110.567 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 103.15 -50.94 0.87 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -157.84 160.02 37.29 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.709 -0.877 . . . . 0.0 110.237 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -128.52 129.97 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.543 -0.723 . . . . 0.0 109.83 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -98.14 169.9 9.28 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.845 -0.742 . . . . 0.0 110.206 -179.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 61.6 t30 59.91 41.34 17.93 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.564 -0.71 . . . . 0.0 110.219 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.782 HG21 HG12 ' A' ' 3' ' ' ILE . 61.3 t -89.26 122.04 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 C-N-CA 120.002 -0.679 . . . . 0.0 110.23 -179.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 -80.52 136.13 36.23 Favored 'General case' 0 N--CA 1.493 1.68 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.12 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.486 ' CE1' HG11 ' A' ' 1' ' ' VAL . 39.6 p90 -134.87 140.98 46.22 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-O 121.278 0.561 . . . . 0.0 111.532 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -146.36 144.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.714 -0.616 . . . . 0.0 110.61 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -73.21 144.43 46.79 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.612 -0.68 . . . . 0.0 110.318 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.92 168.89 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.618 -0.676 . . . . 0.0 110.509 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -59.96 144.15 49.86 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.547 -0.721 . . . . 0.0 110.448 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.448 HD21 ' CD1' ' A' ' 116' ' ' ILE . 9.4 tt -60.79 -40.03 91.07 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.567 -0.708 . . . . 0.0 110.998 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.9 m -54.61 -35.57 63.53 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.612 -0.68 . . . . 0.0 111.592 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -69.99 -22.13 63.16 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.169 -0.957 . . . . 0.0 111.457 -178.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 96.5 m -75.65 -48.64 21.23 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.2 -0.938 . . . . 0.0 109.35 178.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.448 ' CD1' HD21 ' A' ' 112' ' ' LEU . 94.8 mt -69.96 -40.03 78.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 CA-C-O 121.32 0.581 . . . . 0.0 109.773 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -67.18 -40.03 86.5 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.66 -0.65 . . . . 0.0 110.129 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.7 -49.96 39.64 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.68 -39.92 90.26 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.551 -0.97 . . . . 0.0 110.39 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 . . . . . 0 N--CA 1.492 1.672 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.316 -179.774 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.482 HG21 ' CD1' ' A' ' 107' ' ' TYR . 34.5 m . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 121.438 0.637 . . . . 0.0 110.383 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 54.5 m -113.14 145.19 41.37 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.034 0.921 . . . . 0.0 111.035 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.673 HG12 HG21 ' A' ' 105' ' ' VAL . 19.6 pt -115.19 146.36 19.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.25 -172.45 3.87 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.9 p90 -143.87 149.95 37.7 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.075 178.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -131.72 149.18 72.71 Favored Pre-proline 0 N--CA 1.492 1.667 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.547 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -85.12 9.26 4.21 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 O-C-N 123.39 1.205 . . . . 0.0 111.276 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.418 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.3 pt -90.05 -0.21 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.113 -0.992 . . . . 0.0 111.068 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 21.7 m-85 -117.35 66.8 0.73 Allowed 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 122.543 1.164 . . . . 0.0 109.569 178.148 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.7 170.64 8.04 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 114.834 -1.076 . . . . 0.0 108.231 176.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -56.68 -31.42 64.43 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -89.02 12.93 14.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 120.513 -1.367 . . . . 0.0 112.033 -177.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.458 ' HA ' HD22 ' A' ' 13' ' ' LEU . 0.4 OUTLIER -71.04 118.42 13.8 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.253 -0.904 . . . . 0.0 110.091 -179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.456 ' N ' HD13 ' A' ' 13' ' ' LEU . 40.6 m -68.22 137.63 54.94 Favored 'General case' 0 N--CA 1.488 1.436 0 CA-C-O 121.702 0.763 . . . . 0.0 110.43 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.575 ' O ' HG12 ' A' ' 18' ' ' VAL . 5.3 mmt -62.26 -20.02 63.83 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' N ' ' CE ' ' A' ' 28' ' ' MET . . . -73.85 -13.68 80.53 Favored Glycine 0 N--CA 1.498 2.79 0 O-C-N 121.037 -1.04 . . . . 0.0 112.079 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.5 -7.77 46.44 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.944 -1.327 . . . . 0.0 112.183 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.773 HG21 HG22 ' A' ' 76' ' ' VAL . 9.5 p -100.03 169.97 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.93 -1.106 . . . . 0.0 110.19 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.783 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.05 -43.5 82.08 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.279 -0.888 . . . . 0.0 109.711 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.18 83.41 6.06 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.4 m -94.12 -80.0 0.41 Allowed 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.254 -0.904 . . . . 0.0 112.557 -177.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.8 t30 -140.93 11.83 2.23 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.201 -0.937 . . . . 0.0 112.553 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.32 -146.12 0.31 Allowed Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -69.29 -39.99 77.99 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.812 -0.817 . . . . 0.0 109.268 178.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 80.7 m-70 -91.48 0.92 57.45 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.689 -0.632 . . . . 0.0 110.696 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.85 132.35 44.37 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.562 HD22 HG21 ' A' ' 37' ' ' VAL . 85.9 mt -98.82 -5.46 31.05 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 122.125 -0.633 . . . . 0.0 110.149 179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.428 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.6 ttm -63.24 -37.77 88.54 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.277 -0.889 . . . . 0.0 111.262 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.89 -74.05 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.522 -0.736 . . . . 0.0 111.667 -178.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -70.04 -39.9 75.44 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.254 -0.904 . . . . 0.0 109.687 179.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.45 ' CD2' HG23 ' A' ' 37' ' ' VAL . 44.2 m-85 -120.15 85.39 35.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 39.6 Cg_endo -66.53 -12.14 34.55 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 O-C-N 123.258 1.136 . . . . 0.0 111.228 -179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 12.9 m -129.18 146.98 50.99 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.228 -0.92 . . . . 0.0 110.349 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.74 HD11 HG21 ' A' ' 43' ' ' VAL . 45.1 tp -72.61 119.73 17.24 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.714 -0.616 . . . . 0.0 110.779 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.34 34.19 0.04 OUTLIER Glycine 0 N--CA 1.496 2.642 0 C-N-CA 120.067 -1.063 . . . . 0.0 110.485 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.448 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 21.7 tp10 -158.09 -49.18 0.06 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.298 -1.119 . . . . 0.0 110.485 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.562 HG21 HD22 ' A' ' 27' ' ' LEU . 2.7 t -60.63 -59.43 13.88 Favored Pre-proline 0 N--CA 1.499 2.001 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.456 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 51.2 Cg_endo -76.02 -29.78 6.36 Favored 'Trans proline' 0 N--CA 1.487 1.129 0 O-C-N 123.258 1.136 . . . . 0.0 109.335 177.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 128.85 -63.0 0.63 Allowed Glycine 0 N--CA 1.487 2.036 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 -178.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.522 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.9 t80 165.18 -72.22 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.571 0 C-N-CA 123.42 0.688 . . . . 0.0 110.017 177.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 57.4 Cg_endo -79.09 -18.99 10.99 Favored 'Trans proline' 0 N--CA 1.492 1.424 0 O-C-N 122.409 0.689 . . . . 0.0 111.579 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 36.0 m-20 -93.93 55.74 2.16 Favored 'General case' 0 N--CA 1.489 1.491 0 CA-C-O 121.8 0.809 . . . . 0.0 109.71 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.74 HG21 HD11 ' A' ' 34' ' ' LEU . 11.7 p -118.92 129.33 75.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-O 121.385 0.612 . . . . 0.0 109.655 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -161.68 167.59 36.51 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 119.991 -1.099 . . . . 0.0 111.279 -179.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.68 164.92 29.33 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 83' ' ' PHE . 10.8 pt -143.55 165.87 22.78 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.824 -0.81 . . . . 0.0 109.762 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 46' ' ' ILE . 56.9 Cg_endo -77.12 -10.57 17.86 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 120.972 1.115 . . . . 0.0 113.125 -177.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -95.41 16.65 16.35 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.071 -1.018 . . . . 0.0 111.916 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.802 HG23 ' CB ' ' A' ' 54' ' ' SER . 63.7 mt -109.34 121.31 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.048 -1.032 . . . . 0.0 109.256 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.52 -42.34 43.56 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.426 -0.796 . . . . 0.0 113.13 -178.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.783 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 165.97 -132.59 2.69 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 118.576 -1.773 . . . . 0.0 112.013 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.526 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 39.3 t90 -44.59 -30.68 0.95 Allowed 'General case' 0 N--CA 1.501 2.076 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -178.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -143.62 63.2 1.36 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.358 -0.839 . . . . 0.0 110.134 -179.227 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.802 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.8 p -66.24 136.32 95.21 Favored Pre-proline 0 N--CA 1.498 1.949 0 O-C-N 121.804 -0.56 . . . . 0.0 111.118 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -73.54 -21.34 19.54 Favored 'Trans proline' 0 C--N 1.32 -0.974 0 O-C-N 123.338 1.178 . . . . 0.0 111.104 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 15.4 m -96.48 12.01 32.96 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.388 -0.82 . . . . 0.0 111.089 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -66.56 143.75 56.85 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.124 -0.985 . . . . 0.0 109.713 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.04 25.27 58.08 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 25.8 m -106.28 137.35 44.39 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.487 -1.007 . . . . 0.0 109.857 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.67 131.13 35.44 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.911 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . . . . . . . . . 80.2 m95 -130.31 138.56 50.51 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -107.32 135.65 48.47 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.272 -0.893 . . . . 0.0 109.518 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.7 t -111.6 127.82 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.188 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 95.4 m -120.03 139.15 52.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.967 -0.458 . . . . 0.0 110.637 -178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.456 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 34.3 pt -117.74 163.73 22.88 Favored Pre-proline 0 N--CA 1.5 2.051 0 O-C-N 121.363 -0.836 . . . . 0.0 110.557 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -61.54 -23.04 75.94 Favored 'Trans proline' 0 N--CA 1.498 1.75 0 C-N-CA 121.371 1.381 . . . . 0.0 112.689 -178.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 96.8 m-20 -66.52 -40.02 88.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.375 -0.828 . . . . 0.0 109.697 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.29 57.4 0.32 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -150.78 148.62 28.73 Favored 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.3 p -151.09 156.23 40.61 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-O 121.93 0.871 . . . . 0.0 111.372 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.657 ' CD1' HD11 ' A' ' 73' ' ' ILE . 43.6 pt -139.46 164.23 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -109.09 126.59 53.35 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.097 -1.041 . . . . 0.0 108.785 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.784 HD13 ' CG1' ' A' ' 85' ' ' VAL . 87.6 mt -129.38 140.0 50.27 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.688 -178.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -98.04 139.5 33.77 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.547 -0.72 . . . . 0.0 109.872 -179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.71 150.28 39.06 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.773 HG22 HG21 ' A' ' 18' ' ' VAL . 11.9 p -149.45 -39.56 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.751 -0.852 . . . . 0.0 109.901 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.436 ' N ' HG13 ' A' ' 76' ' ' VAL . 15.7 t70 -129.32 168.02 16.85 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.224 -0.922 . . . . 0.0 110.5 179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.478 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 40.6 t -75.28 155.89 36.21 Favored 'General case' 0 N--CA 1.497 1.921 0 CA-C-O 121.618 0.723 . . . . 0.0 111.739 -178.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -137.66 132.26 5.84 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 179.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -60.02 -33.05 71.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 109.871 178.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.31 82.37 0.05 OUTLIER Glycine 0 N--CA 1.498 2.788 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.599 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.436 ' O ' ' HD3' ' A' ' 47' ' ' PRO . . . 151.97 -151.66 23.52 Favored Glycine 0 N--CA 1.499 2.866 0 C-N-CA 119.893 -1.146 . . . . 0.0 110.516 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 46' ' ' ILE . 87.0 m-85 -136.02 130.77 34.06 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.295 -1.121 . . . . 0.0 111.381 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.458 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 4.4 t-20 -115.61 127.52 55.28 Favored 'General case' 0 N--CA 1.502 2.152 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 178.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.784 ' CG1' HD13 ' A' ' 73' ' ' ILE . 33.2 m -129.95 164.62 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.363 -177.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-20 -54.54 157.1 5.41 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.328 -0.857 . . . . 0.0 109.897 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.37 -14.35 43.79 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.268 1.141 . . . . 0.0 110.657 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.7 m -82.71 -39.14 22.37 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.975 -1.078 . . . . 0.0 109.314 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.77 -39.82 84.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.448 -0.783 . . . . 0.0 109.037 179.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -59.99 -50.02 75.4 Favored 'General case' 0 N--CA 1.5 2.049 0 C-N-CA 120.081 -0.648 . . . . 0.0 110.762 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 73.2 m -60.14 -39.97 88.21 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.368 -0.832 . . . . 0.0 111.071 -178.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -69.68 -40.0 76.66 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.871 -0.732 . . . . 0.0 111.062 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 60.2 tp -70.62 -43.7 68.73 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.602 -0.686 . . . . 0.0 111.557 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.0 -42.61 12.34 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.402 -0.811 . . . . 0.0 111.579 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -20.22 7.93 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.3 t -156.21 159.52 39.02 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.213 -1.169 . . . . 0.0 110.944 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 65.7 p -98.42 6.89 46.86 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.543 -0.723 . . . . 0.0 110.812 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -69.17 -36.76 77.7 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.362 -0.836 . . . . 0.0 111.708 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.52 -40.12 86.09 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.379 -0.826 . . . . 0.0 110.696 -178.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 82.89 -75.03 2.44 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -127.78 133.17 49.46 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.631 -0.923 . . . . 0.0 109.857 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.14 120.14 63.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.467 -0.771 . . . . 0.0 110.116 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -86.16 178.43 7.2 Favored 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.359 0.599 . . . . 0.0 110.707 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.0 t-20 58.88 49.62 9.56 Favored 'General case' 0 N--CA 1.499 2.013 0 CA-C-O 121.28 0.562 . . . . 0.0 111.235 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.673 HG21 HG12 ' A' ' 3' ' ' ILE . 62.5 t -105.77 129.03 59.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.577 -179.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -86.61 137.07 32.78 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 118.936 -1.105 . . . . 0.0 109.477 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.482 ' CD1' HG21 ' A' ' 1' ' ' VAL . 38.0 p90 -135.45 141.52 45.41 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.93 -0.481 . . . . 0.0 110.536 -178.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.449 HG13 ' C ' ' A' ' 107' ' ' TYR . 35.0 m -148.09 148.17 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.527 -0.733 . . . . 0.0 111.037 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -76.18 143.52 41.05 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.595 -0.691 . . . . 0.0 110.236 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.3 m -137.79 167.83 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.578 -0.701 . . . . 0.0 110.561 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -61.52 148.26 42.66 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.403 -0.81 . . . . 0.0 110.749 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.509 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.6 tt -62.11 -40.07 94.63 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.517 -0.739 . . . . 0.0 112.075 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 82.1 p -53.12 -37.34 61.68 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.263 -0.898 . . . . 0.0 111.023 -178.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -61.12 -37.93 84.54 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.518 -0.739 . . . . 0.0 112.005 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 82.5 m -67.37 -46.29 73.77 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.119 -0.988 . . . . 0.0 110.415 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.509 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.2 mt -70.04 -39.94 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 120.109 -0.636 . . . . 0.0 110.518 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.69 -39.98 88.34 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.13 -46.19 44.92 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.989 -1.245 . . . . 0.0 109.989 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.03 -44.15 94.83 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.625 -0.926 . . . . 0.0 110.473 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 13.5 m120 . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.186 179.823 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.434 HG23 ' HB ' ' A' ' 105' ' ' VAL . 27.3 m . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.291 0.567 . . . . 0.0 111.401 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.2 p -111.78 139.85 46.91 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.738 -0.601 . . . . 0.0 109.764 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.726 HG23 HG21 ' A' ' 105' ' ' VAL . 27.9 pt -110.86 144.77 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.734 -0.604 . . . . 0.0 110.854 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.35 -176.02 4.57 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 179.118 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -140.09 141.62 36.15 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.453 179.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -135.71 151.66 74.67 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.441 -0.787 . . . . 0.0 110.433 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -77.12 0.07 10.09 Favored 'Trans proline' 0 N--CA 1.486 1.033 0 O-C-N 123.421 1.221 . . . . 0.0 111.506 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.74 ' O ' HD22 ' A' ' 13' ' ' LEU . 7.4 tp -69.54 -14.03 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.276 -0.89 . . . . 0.0 111.274 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.537 ' CD2' HG23 ' A' ' 8' ' ' ILE . 36.7 m-85 -116.72 69.01 0.74 Allowed 'General case' 0 N--CA 1.493 1.683 0 CA-C-O 122.507 1.146 . . . . 0.0 111.335 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.35 168.67 8.92 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.723 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.0 -32.02 70.47 Favored 'General case' 0 N--CA 1.498 1.953 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -88.13 12.08 14.57 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.44 -1.412 . . . . 0.0 112.199 -177.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 8' ' ' ILE . 41.6 tp -73.75 122.36 22.26 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.419 -0.801 . . . . 0.0 109.714 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.6 m -66.29 137.39 56.91 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.824 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.72 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -64.32 -18.99 65.14 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.902 -0.499 . . . . 0.0 111.247 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' N ' ' HE1' ' A' ' 28' ' ' MET . . . -72.2 -14.38 76.64 Favored Glycine 0 N--CA 1.493 2.499 0 O-C-N 121.073 -1.017 . . . . 0.0 110.752 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 76.7 p -91.63 -15.65 28.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.169 -1.194 . . . . 0.0 111.146 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.996 HG21 HG22 ' A' ' 76' ' ' VAL . 7.2 p -90.05 162.02 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.931 . . . . 0.0 109.63 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.818 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -54.93 -44.35 74.2 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.556 -0.715 . . . . 0.0 110.332 -179.379 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 83.89 5.83 Favored 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.52 -79.98 0.48 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.295 -0.878 . . . . 0.0 113.152 -177.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.1 t30 -136.72 10.11 3.12 Favored 'General case' 0 N--CA 1.499 1.991 0 O-C-N 121.108 -0.995 . . . . 0.0 113.098 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.43 -152.77 0.89 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 179.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -64.25 -39.95 95.01 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.571 -0.958 . . . . 0.0 108.586 177.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 72.8 m-70 -90.15 0.46 57.16 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.748 -0.595 . . . . 0.0 110.207 179.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.05 133.96 52.48 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.619 HD13 HG11 ' A' ' 37' ' ' VAL . 66.0 mt -102.47 1.13 34.78 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 122.06 -0.67 . . . . 0.0 110.226 179.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.425 ' HE1' ' N ' ' A' ' 16' ' ' GLY . 60.3 tpp -59.99 -38.48 82.71 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.315 -0.866 . . . . 0.0 111.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.22 -66.41 0.46 Allowed 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.469 -0.769 . . . . 0.0 112.203 -176.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -75.13 -41.4 58.48 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.423 ' CD2' HG23 ' A' ' 37' ' ' VAL . 46.2 m-85 -120.05 87.46 39.06 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.845 -0.534 . . . . 0.0 109.665 -178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.3 -8.08 22.66 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.4 1.211 . . . . 0.0 111.543 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -133.51 146.47 51.1 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.26 -0.9 . . . . 0.0 110.5 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.816 HD11 HG21 ' A' ' 43' ' ' VAL . 29.1 tp -71.04 119.17 14.79 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.695 -0.628 . . . . 0.0 110.664 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.19 32.89 0.04 OUTLIER Glycine 0 N--CA 1.498 2.774 0 C-N-CA 120.007 -1.092 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -157.39 -48.63 0.07 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.293 -1.122 . . . . 0.0 110.159 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.619 HG11 HD13 ' A' ' 27' ' ' LEU . 2.5 t -60.39 -58.61 18.06 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.489 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.2 Cg_endo -77.63 -30.8 3.67 Favored 'Trans proline' 0 C--N 1.318 -1.04 0 O-C-N 123.217 1.114 . . . . 0.0 109.537 177.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 129.97 -63.86 0.62 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 107.272 -2.331 . . . . 0.0 107.272 -178.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.723 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 164.53 -56.72 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.581 0 C-N-CA 123.37 0.668 . . . . 0.0 110.231 177.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.664 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 51.2 Cg_endo -101.03 15.55 0.37 Allowed 'Trans proline' 0 C--N 1.327 -0.594 0 C-N-CA 121.313 1.342 . . . . 0.0 111.246 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -125.32 47.52 2.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.252 -0.905 . . . . 0.0 109.296 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.816 HG21 HD11 ' A' ' 34' ' ' LEU . 14.6 p -125.47 140.04 49.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.914 0.864 . . . . 0.0 110.435 -179.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.87 175.35 42.76 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.107 -1.597 . . . . 0.0 109.107 -179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.441 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -88.62 159.47 29.43 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.689 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.1 pt -148.78 159.67 37.43 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.584 -0.95 . . . . 0.0 109.94 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -68.18 -15.9 43.49 Favored 'Trans proline' 0 N--CA 1.497 1.7 0 C-N-CA 121.245 1.297 . . . . 0.0 113.829 -177.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.568 ' H ' HD12 ' A' ' 46' ' ' ILE . 86.2 m-20 -91.7 21.26 4.87 Favored 'General case' 0 N--CA 1.501 2.118 0 O-C-N 120.706 -1.246 . . . . 0.0 113.129 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.596 HG23 ' CB ' ' A' ' 54' ' ' SER . 47.8 mm -112.28 122.59 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.079 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 177.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.63 -44.38 34.39 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.302 -0.874 . . . . 0.0 111.199 -179.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.818 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 164.83 -134.93 3.5 Favored Glycine 0 N--CA 1.484 1.886 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.425 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.472 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 64.4 t90 -43.83 -26.78 0.28 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -145.4 72.81 1.33 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.227 -0.921 . . . . 0.0 110.578 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.596 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.4 t -70.35 134.3 86.97 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.773 -0.58 . . . . 0.0 111.528 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.8 -23.98 16.01 Favored 'Trans proline' 0 C--N 1.32 -0.941 0 O-C-N 123.413 1.218 . . . . 0.0 110.545 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -97.42 12.44 33.23 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.445 -0.784 . . . . 0.0 111.058 -179.639 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 4.7 t -72.21 148.8 45.2 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.335 -0.853 . . . . 0.0 110.584 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.86 43.15 9.14 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.231 -1.148 . . . . 0.0 110.231 178.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.41 ' O ' ' HG3' ' A' ' 74' ' ' ARG . 8.5 m -130.62 168.74 16.62 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.707 -0.878 . . . . 0.0 108.684 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 16.8 t -113.38 148.6 35.49 Favored 'General case' 0 N--CA 1.511 2.596 0 O-C-N 121.118 -0.989 . . . . 0.0 113.143 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.481 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 31.5 m95 -139.82 145.35 38.03 Favored 'General case' 0 N--CA 1.505 2.289 0 O-C-N 121.027 -1.046 . . . . 0.0 110.36 177.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 83.4 tttt -105.53 129.84 53.72 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.1 t -110.63 129.95 64.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 O-C-N 121.316 -0.865 . . . . 0.0 109.95 -178.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 47.1 m -121.63 138.79 54.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.849 -0.532 . . . . 0.0 111.61 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.511 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 7.6 pt -114.35 166.09 12.32 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.534 -0.729 . . . . 0.0 109.809 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.44 -25.9 76.26 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 O-C-N 123.217 1.114 . . . . 0.0 112.928 -178.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 -64.81 -37.83 88.95 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.052 -1.03 . . . . 0.0 109.751 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 113.93 65.32 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -162.02 153.15 18.03 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.769 -0.842 . . . . 0.0 108.867 179.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 71.5 p -152.8 162.38 41.35 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 122.197 0.999 . . . . 0.0 112.456 -179.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.426 ' CD1' HD11 ' A' ' 73' ' ' ILE . 39.9 pt -139.39 162.3 27.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.128 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -107.48 127.15 53.35 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.019 -1.072 . . . . 0.0 109.246 179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.702 HD13 HG11 ' A' ' 85' ' ' VAL . 90.2 mt -125.9 134.93 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.491 -0.756 . . . . 0.0 110.493 -179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.546 ' HD3' HG12 ' A' ' 37' ' ' VAL . 65.9 ttt180 -95.49 133.92 38.93 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -63.59 144.17 48.8 Favored Glycine 0 N--CA 1.496 2.658 0 C-N-CA 120.296 -0.954 . . . . 0.0 110.76 -178.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.996 HG22 HG21 ' A' ' 18' ' ' VAL . 10.1 p -142.67 -41.62 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 122.104 -0.645 . . . . 0.0 109.906 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.579 ' HB2' HG23 ' A' ' 18' ' ' VAL . 6.3 t0 -133.67 171.57 13.95 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.114 -0.991 . . . . 0.0 109.496 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 43.9 t -83.75 146.66 28.05 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.443 -0.785 . . . . 0.0 110.635 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -108.12 148.71 16.73 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -89.07 101.67 14.32 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.487 -1.008 . . . . 0.0 110.601 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 52.79 53.46 32.99 Favored Glycine 0 N--CA 1.498 2.791 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.24 170.08 14.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.694 -1.241 . . . . 0.0 110.929 179.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.689 ' CD2' HG22 ' A' ' 46' ' ' ILE . 36.3 m-85 -93.13 128.94 39.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.749 -0.853 . . . . 0.0 109.996 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 22.7 t-20 -120.24 130.84 54.7 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.702 HG11 HD13 ' A' ' 73' ' ' ILE . 34.2 m -129.99 174.35 12.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.694 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -55.51 156.8 7.99 Favored Pre-proline 0 N--CA 1.495 1.816 0 O-C-N 121.658 -0.651 . . . . 0.0 109.966 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.7 -27.43 38.26 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.387 1.204 . . . . 0.0 109.706 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.417 HG22 ' HE3' ' A' ' 92' ' ' LYS . 94.3 m -71.28 -40.19 71.07 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.24 -39.56 86.21 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.3 t80 -59.99 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.737 -0.602 . . . . 0.0 110.514 179.302 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 58.0 m -59.82 -36.92 77.78 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.534 -0.729 . . . . 0.0 110.631 -178.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.417 ' HE3' HG22 ' A' ' 88' ' ' THR . 98.3 mttt -69.72 -40.02 76.5 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 119.805 -0.758 . . . . 0.0 111.258 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.508 ' HG ' HG21 ' A' ' 65' ' ' ILE . 52.6 tp -69.95 -41.81 74.06 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.472 -0.768 . . . . 0.0 111.688 -178.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 94.9 t -100.2 -36.12 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.117 0 O-C-N 121.164 -0.96 . . . . 0.0 111.413 -178.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 117.84 -30.62 6.05 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 69.0 m -143.03 155.12 44.57 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.48 -1.012 . . . . 0.0 110.897 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.0 p -90.23 1.53 56.39 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.521 -0.737 . . . . 0.0 110.989 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.95 -22.18 63.2 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.381 -0.824 . . . . 0.0 110.702 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.29 -45.27 88.25 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.382 -0.824 . . . . 0.0 110.717 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.68 -77.45 2.11 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 43.0 ttm180 -135.44 132.1 37.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.641 -0.917 . . . . 0.0 110.682 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 57.5 t -116.19 115.97 50.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.523 -0.736 . . . . 0.0 109.739 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -84.37 172.53 11.69 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.766 0.794 . . . . 0.0 111.375 -178.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 59.6 t30 60.07 40.02 19.03 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.807 -0.558 . . . . 0.0 111.591 179.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.726 HG21 HG23 ' A' ' 3' ' ' ILE . 62.8 t -81.65 127.43 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.126 179.124 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.5 t30 -91.88 139.98 30.13 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 119.064 -1.054 . . . . 0.0 108.989 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.7 p90 -140.81 147.22 38.69 Favored 'General case' 0 N--CA 1.493 1.684 0 CA-C-O 121.502 0.668 . . . . 0.0 112.129 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -141.9 142.57 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.747 -0.595 . . . . 0.0 109.813 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.481 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 62.3 tt0 -84.93 140.44 31.1 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.459 -0.775 . . . . 0.0 110.843 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 27.1 m -129.93 175.32 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -62.62 150.75 39.9 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.391 -0.818 . . . . 0.0 111.004 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.506 HD21 ' CD1' ' A' ' 116' ' ' ILE . 8.1 tt -60.06 -39.94 87.76 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.74 -0.6 . . . . 0.0 110.795 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 61.9 m -52.55 -35.66 54.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.59 -0.694 . . . . 0.0 111.186 -178.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -65.1 -40.01 93.95 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.426 -0.796 . . . . 0.0 110.967 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -61.06 -49.34 77.77 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.293 -0.879 . . . . 0.0 110.14 179.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.506 ' CD1' HD21 ' A' ' 112' ' ' LEU . 96.7 mt -70.03 -39.94 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.611 -0.681 . . . . 0.0 110.834 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -66.19 -40.07 90.14 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.453 -0.78 . . . . 0.0 110.829 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -79.99 -57.48 3.02 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 -178.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.83 -43.2 94.68 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.518 -0.989 . . . . 0.0 110.469 -179.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 60.0 t30 . . . . . 0 N--CA 1.501 2.075 0 CA-C-O 117.796 -1.097 . . . . 0.0 110.916 179.83 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.496 1.838 0 CA-C-O 121.187 0.517 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 p -112.67 147.01 37.66 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.707 -0.62 . . . . 0.0 111.019 -179.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.726 HG21 HG11 ' A' ' 105' ' ' VAL . 24.7 pt -113.8 147.9 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.796 -0.565 . . . . 0.0 110.161 179.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -145.84 -172.34 3.89 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.373 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -142.22 149.34 39.52 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.519 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -139.09 152.99 71.08 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.377 -0.827 . . . . 0.0 110.078 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -83.55 2.36 8.38 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 O-C-N 123.407 1.214 . . . . 0.0 111.39 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.421 ' O ' HG22 ' A' ' 8' ' ' ILE . 26.2 mm -76.5 -2.79 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 121.16 -0.962 . . . . 0.0 111.165 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.8 m-85 -127.34 64.64 1.33 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 122.347 1.07 . . . . 0.0 110.765 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.15 173.97 6.21 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.602 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -60.04 -32.17 70.66 Favored 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -175.239 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -89.41 12.28 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 120.446 1.475 . . . . 0.0 112.084 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 8' ' ' ILE . 0.1 OUTLIER -69.71 114.55 8.02 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.303 -0.873 . . . . 0.0 109.301 179.426 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m -62.76 139.4 58.68 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.801 0.81 . . . . 0.0 110.631 -179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.68 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.1 mmm -62.56 -26.38 68.55 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.985 -179.415 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -19.44 76.44 Favored Glycine 0 N--CA 1.494 2.507 0 O-C-N 121.126 -0.984 . . . . 0.0 110.896 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 75.4 m -86.46 -17.77 33.38 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.228 -1.16 . . . . 0.0 111.375 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.927 HG21 HG22 ' A' ' 76' ' ' VAL . 7.3 p -89.98 160.02 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.328 -0.858 . . . . 0.0 109.676 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.17 -41.82 65.57 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.58 -0.7 . . . . 0.0 111.164 -178.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 82.92 4.83 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.294 -0.879 . . . . 0.0 108.835 179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 m -91.42 -79.34 0.37 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.26 -0.9 . . . . 0.0 113.014 -177.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.4 t30 -144.09 14.82 1.69 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.772 -1.205 . . . . 0.0 112.474 -178.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.49 -147.19 0.37 Allowed Glycine 0 N--CA 1.493 2.435 0 N-CA-C 108.671 -1.772 . . . . 0.0 108.671 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -69.58 -39.97 76.99 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.622 -0.928 . . . . 0.0 108.85 178.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.431 ' CD2' ' O ' ' A' ' 54' ' ' SER . 56.0 m-70 -89.93 0.04 57.3 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.698 -0.626 . . . . 0.0 110.208 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -56.74 133.05 52.3 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.567 HD13 HH21 ' A' ' 74' ' ' ARG . 65.0 mt -103.73 -0.07 29.86 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 122.139 -0.624 . . . . 0.0 110.47 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.5 ttm -64.0 -35.46 80.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.274 -0.891 . . . . 0.0 111.068 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.69 -66.16 0.47 Allowed 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.41 -0.806 . . . . 0.0 111.883 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.436 ' HG3' ' N ' ' A' ' 31' ' ' TYR . 28.1 pt20 -72.71 -40.5 66.13 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.126 -0.984 . . . . 0.0 110.775 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.683 ' CD2' HG23 ' A' ' 37' ' ' VAL . 53.9 m-85 -126.73 91.04 48.22 Favored Pre-proline 0 N--CA 1.497 1.877 0 O-C-N 121.429 -0.794 . . . . 0.0 109.428 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.54 -9.89 27.41 Favored 'Trans proline' 0 N--CA 1.488 1.161 0 O-C-N 123.554 1.292 . . . . 0.0 112.04 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 18.9 m -129.03 143.95 51.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.098 -1.001 . . . . 0.0 110.575 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.996 HD11 HG21 ' A' ' 43' ' ' VAL . 21.2 tp -69.93 120.02 15.02 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.878 -0.514 . . . . 0.0 110.546 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 147.36 30.32 0.07 OUTLIER Glycine 0 N--CA 1.496 2.697 0 C-N-CA 119.927 -1.13 . . . . 0.0 110.822 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -154.13 -50.9 0.09 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.26 -1.141 . . . . 0.0 110.286 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.683 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.7 t -61.66 -59.47 13.29 Favored Pre-proline 0 N--CA 1.497 1.904 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.439 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.0 Cg_endo -74.08 -32.08 7.25 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 O-C-N 123.258 1.136 . . . . 0.0 109.24 177.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.429 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 131.21 -65.05 0.6 Allowed Glycine 0 N--CA 1.484 1.856 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.602 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 1.7 t80 163.94 -69.66 0.0 OUTLIER Pre-proline 0 N--CA 1.515 2.793 0 C-N-CA 123.522 0.729 . . . . 0.0 110.393 177.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.547 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.9 Cg_endo -80.61 -0.22 10.47 Favored 'Trans proline' 0 N--CA 1.497 1.724 0 C-N-CA 120.387 0.725 . . . . 0.0 112.714 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.6 m-20 -111.24 53.66 0.7 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.872 -1.143 . . . . 0.0 110.425 -178.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.996 HG21 HD11 ' A' ' 34' ' ' LEU . 14.4 p -132.44 141.09 46.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 121.859 0.838 . . . . 0.0 110.054 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -168.69 175.39 43.24 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.652 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -87.51 157.67 29.13 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 179.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.739 HD11 ' CA ' ' A' ' 75' ' ' GLY . 1.7 pt -156.01 160.06 31.07 Favored Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.592 -0.946 . . . . 0.0 109.771 179.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -67.02 -23.49 46.45 Favored 'Trans proline' 0 N--CA 1.502 1.983 0 C-N-CA 121.643 1.562 . . . . 0.0 115.291 -176.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -77.03 -5.02 47.13 Favored 'General case' 0 N--CA 1.506 2.374 0 O-C-N 120.381 -1.45 . . . . 0.0 112.497 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.587 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.1 mm -89.71 121.34 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.992 -1.067 . . . . 0.0 108.45 178.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.65 -43.55 47.07 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.243 -0.91 . . . . 0.0 111.537 -179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.98 -131.73 2.43 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.004 -1.569 . . . . 0.0 110.771 -179.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.478 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 61.9 t90 -48.71 -26.02 2.11 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.886 -0.773 . . . . 0.0 112.749 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.8 64.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.184 -0.948 . . . . 0.0 110.713 -179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.587 ' CB ' HG23 ' A' ' 49' ' ' ILE . 7.9 p -63.5 133.64 95.57 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.648 -0.658 . . . . 0.0 110.986 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.64 -19.47 27.9 Favored 'Trans proline' 0 N--CA 1.485 1.011 0 O-C-N 123.212 1.112 . . . . 0.0 110.911 179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 59' ' ' THR . 54.0 p -99.04 10.8 40.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.378 -0.827 . . . . 0.0 111.025 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -65.13 143.1 58.11 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.135 -0.978 . . . . 0.0 110.056 -179.757 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.41 26.01 48.92 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.431 HG23 ' O ' ' A' ' 56' ' ' SER . 17.1 p -100.01 134.99 42.12 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.453 -1.027 . . . . 0.0 110.615 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.472 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.0 t -81.49 131.11 35.27 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.795 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.474 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 85.6 m95 -133.6 143.58 48.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.387 -0.82 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 tttm -110.67 130.98 55.43 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -111.02 129.73 65.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.945 -0.702 . . . . 0.0 110.349 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 69.0 m -120.04 135.55 54.89 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.868 -0.52 . . . . 0.0 110.604 -178.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.479 ' CG2' HD21 ' A' ' 93' ' ' LEU . 8.7 pt -113.8 164.83 14.92 Favored Pre-proline 0 N--CA 1.502 2.135 0 O-C-N 121.425 -0.797 . . . . 0.0 110.849 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -62.96 -27.93 74.79 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.241 1.294 . . . . 0.0 112.937 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.401 ' HB3' ' CD1' ' A' ' 65' ' ' ILE . 22.5 t-20 -64.58 -40.0 94.76 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.239 -0.913 . . . . 0.0 109.701 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.18 60.01 0.28 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 179.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -153.7 148.7 26.71 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.699 -0.883 . . . . 0.0 108.745 178.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 47.1 m -149.37 155.49 40.56 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 119.3 -0.96 . . . . 0.0 112.233 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 43.3 pt -140.76 166.9 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -110.71 125.45 53.51 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.134 -1.026 . . . . 0.0 109.404 179.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.624 HD13 HG11 ' A' ' 85' ' ' VAL . 96.9 mt -124.1 138.63 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.466 -0.771 . . . . 0.0 110.518 -179.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.567 HH21 HD13 ' A' ' 27' ' ' LEU . 1.9 ttp-105 -100.85 146.47 27.27 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.586 -0.696 . . . . 0.0 109.745 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.739 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -68.11 151.33 51.81 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.927 HG22 HG21 ' A' ' 18' ' ' VAL . 9.6 p -154.81 -44.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.826 -0.808 . . . . 0.0 109.522 179.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.571 ' HB2' HG23 ' A' ' 18' ' ' VAL . 5.2 t0 -129.62 169.82 14.56 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.059 -1.025 . . . . 0.0 109.622 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' ILE . 92.6 p -101.57 160.07 14.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.577 -0.702 . . . . 0.0 111.055 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.96 155.06 21.62 Favored Glycine 0 N--CA 1.486 1.989 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 75.4 mtp85 -59.97 -31.41 69.87 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.484 -1.01 . . . . 0.0 109.679 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -176.69 -179.8 47.3 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 50.83 -178.88 0.04 OUTLIER Glycine 0 N--CA 1.496 2.675 0 O-C-N 121.434 -1.039 . . . . 0.0 111.87 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.612 ' CD2' HG22 ' A' ' 46' ' ' ILE . 42.7 m-85 -107.74 127.46 53.71 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.891 -0.77 . . . . 0.0 109.008 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.403 ' HA ' ' O ' ' A' ' 4' ' ' SER . 41.7 t-20 -117.83 127.73 54.16 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.511 -0.875 . . . . 0.0 108.64 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.624 HG11 HD13 ' A' ' 73' ' ' ILE . 34.4 m -130.79 172.37 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.697 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 -55.58 152.79 16.96 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.534 -0.729 . . . . 0.0 109.528 179.338 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.21 -26.33 57.0 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 O-C-N 123.35 1.184 . . . . 0.0 110.186 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.773 HG22 ' HE2' ' A' ' 92' ' ' LYS . 94.3 m -70.08 -40.24 75.13 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.076 -1.015 . . . . 0.0 109.346 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.03 -40.57 87.24 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -60.71 -50.08 74.9 Favored 'General case' 0 N--CA 1.498 1.956 0 C-N-CA 120.214 -0.595 . . . . 0.0 110.719 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 87.1 m -61.14 -39.96 92.01 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.403 -0.811 . . . . 0.0 111.273 -178.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.773 ' HE2' HG22 ' A' ' 88' ' ' THR . 56.3 mtmt -69.99 -40.05 75.55 Favored 'General case' 0 N--CA 1.494 1.771 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.999 -179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.479 HD21 ' CG2' ' A' ' 65' ' ' ILE . 48.0 tp -69.91 -42.93 72.69 Favored 'General case' 0 N--CA 1.496 1.846 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.365 -179.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.22 -41.6 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 O-C-N 121.45 -0.781 . . . . 0.0 111.83 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.72 -34.5 4.05 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 4.3 m -142.44 153.67 43.91 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.524 -0.986 . . . . 0.0 110.14 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.6 p -90.28 3.49 53.46 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.477 -0.765 . . . . 0.0 110.976 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.98 -26.22 63.99 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.423 -0.798 . . . . 0.0 111.158 -179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.94 -39.92 87.19 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.413 -0.804 . . . . 0.0 110.513 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.75 -79.49 1.84 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 50.5 ttp180 -131.8 138.87 48.71 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.694 -0.886 . . . . 0.0 110.47 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 105' ' ' VAL . 63.0 t -120.32 116.97 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 C-N-CA 119.722 -0.791 . . . . 0.0 109.804 178.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -80.55 170.14 16.74 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.656 0.741 . . . . 0.0 111.346 -178.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 60.0 39.93 19.37 Favored 'General case' 0 N--CA 1.501 2.122 0 CA-C-O 121.007 0.432 . . . . 0.0 111.816 179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.726 HG11 HG21 ' A' ' 3' ' ' ILE . 78.5 t -85.48 127.52 39.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.134 178.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.5 m120 -87.36 140.05 29.93 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.14 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -139.22 144.5 38.5 Favored 'General case' 0 N--CA 1.491 1.616 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.579 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.8 m -144.69 141.68 23.53 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.932 0 O-C-N 121.498 -0.751 . . . . 0.0 111.231 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.474 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 52.2 tt0 -73.45 135.01 44.09 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.561 -0.712 . . . . 0.0 109.755 178.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.472 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.5 m -132.27 173.09 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.437 179.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -60.34 149.71 32.88 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.357 -0.839 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.463 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.4 tt -59.93 -39.08 84.29 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.505 -0.747 . . . . 0.0 110.58 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.9 m -53.5 -38.01 63.28 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.557 -0.714 . . . . 0.0 110.57 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -60.22 -39.93 88.35 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.496 -0.753 . . . . 0.0 111.126 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -60.07 -49.83 76.11 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.257 -0.902 . . . . 0.0 110.246 179.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.432 HD11 HD21 ' A' ' 112' ' ' LEU . 90.4 mt -69.25 -39.99 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.704 -0.622 . . . . 0.0 110.253 -179.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.63 -39.93 95.37 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.401 -0.812 . . . . 0.0 110.281 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.81 -41.82 81.41 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.35 -39.97 94.86 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.75 -0.853 . . . . 0.0 110.305 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.9 p30 . . . . . 0 N--CA 1.495 1.815 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.551 -179.864 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 121.51 0.671 . . . . 0.0 111.046 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.9 p -114.61 153.99 29.15 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.874 -0.516 . . . . 0.0 110.545 -179.519 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.495 HG21 HG11 ' A' ' 105' ' ' VAL . 39.5 pt -119.99 150.05 22.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.476 -0.765 . . . . 0.0 110.534 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.6 p -147.84 -171.76 3.89 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.422 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.4 p90 -141.5 142.47 33.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 110.465 178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.73 ' HB3' HG22 ' A' ' 8' ' ' ILE . 4.5 m-20 -133.78 150.01 73.47 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.476 -0.765 . . . . 0.0 110.208 179.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -78.87 -0.93 11.18 Favored 'Trans proline' 0 C--N 1.317 -1.08 0 O-C-N 123.377 1.199 . . . . 0.0 111.114 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.792 ' O ' HD22 ' A' ' 13' ' ' LEU . 6.4 tp -71.67 -15.22 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.244 -0.91 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CD2' HG23 ' A' ' 8' ' ' ILE . 34.3 m-85 -114.88 68.53 0.7 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 122.613 1.197 . . . . 0.0 110.553 178.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.24 170.06 8.09 Favored 'General case' 0 N--CA 1.492 1.67 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.599 177.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.716 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.91 -34.42 73.19 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 -175.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -88.22 13.53 11.27 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.417 -1.427 . . . . 0.0 112.422 -176.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.792 HD22 ' O ' ' A' ' 8' ' ' ILE . 43.9 tp -75.56 122.82 24.47 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.355 -0.841 . . . . 0.0 110.091 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.8 m -65.73 137.62 57.4 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.801 -0.76 . . . . 0.0 109.627 179.533 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.8 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.4 mmm -64.22 -19.08 65.11 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.823 -0.548 . . . . 0.0 111.313 -179.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.5 -16.55 78.93 Favored Glycine 0 N--CA 1.495 2.59 0 O-C-N 120.95 -1.094 . . . . 0.0 110.986 -179.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 54.1 m -88.18 -13.78 40.28 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.165 -1.197 . . . . 0.0 111.599 -179.148 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 15' ' ' MET . 13.0 p -90.04 159.54 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.149 -0.97 . . . . 0.0 108.869 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.769 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -49.07 -41.36 35.04 Favored 'General case' 0 N--CA 1.507 2.418 0 O-C-N 121.266 -0.896 . . . . 0.0 110.562 -179.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -78.23 87.14 4.31 Favored 'General case' 0 N--CA 1.498 1.954 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 70.8 m -99.4 -82.31 0.44 Allowed 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.117 -0.989 . . . . 0.0 112.954 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -137.91 9.58 2.82 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.087 -1.008 . . . . 0.0 112.922 -178.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.08 -148.0 0.5 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.801 -1.72 . . . . 0.0 108.801 179.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -63.03 -40.01 96.47 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.625 -0.927 . . . . 0.0 109.526 178.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.414 ' CD2' ' O ' ' A' ' 54' ' ' SER . 89.6 m-70 -94.6 8.56 41.89 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.567 -0.708 . . . . 0.0 111.151 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.15 127.42 35.89 Favored Glycine 0 N--CA 1.502 3.064 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.508 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 91.2 mt -102.47 -11.46 18.55 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 122.03 -0.688 . . . . 0.0 111.532 -178.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 ttp -60.03 -27.32 66.81 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.261 -0.899 . . . . 0.0 110.81 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -57.52 -61.75 2.27 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.425 -0.797 . . . . 0.0 112.898 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -69.96 -40.01 75.69 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 120.88 -1.137 . . . . 0.0 111.36 -178.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.615 ' CE1' HG21 ' A' ' 37' ' ' VAL . 3.8 p90 -136.21 104.76 9.49 Favored Pre-proline 0 C--N 1.302 -1.491 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.42 -11.15 29.01 Favored 'Trans proline' 0 N--CA 1.485 0.98 0 O-C-N 123.482 1.254 . . . . 0.0 111.647 -178.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 20.2 m -126.85 135.76 51.42 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.245 -0.91 . . . . 0.0 109.761 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.949 HD21 HG11 ' A' ' 43' ' ' VAL . 39.4 tp -61.46 126.05 25.95 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.522 -0.736 . . . . 0.0 109.858 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.413 ' HA2' ' HA ' ' A' ' 40' ' ' PHE . . . 148.79 27.77 0.06 OUTLIER Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.538 -1.315 . . . . 0.0 111.787 179.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -144.99 -47.91 0.24 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.074 -1.25 . . . . 0.0 110.917 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.615 HG21 ' CE1' ' A' ' 31' ' ' TYR . 1.7 t -67.42 -55.45 15.02 Favored Pre-proline 0 N--CA 1.496 1.844 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.389 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.426 ' HD2' ' N ' ' A' ' 37' ' ' VAL . 42.5 Cg_endo -76.19 -31.44 4.77 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.396 1.208 . . . . 0.0 108.988 178.079 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.424 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 129.77 -64.6 0.6 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.716 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 2.1 t80 164.38 -56.74 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.595 0 C-N-CA 123.33 0.652 . . . . 0.0 110.844 177.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.638 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 55.7 Cg_endo -97.42 16.84 0.61 Allowed 'Trans proline' 0 N--CA 1.481 0.773 0 C-N-CA 120.982 1.121 . . . . 0.0 112.044 -177.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 38.6 m-20 -126.12 47.49 2.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.2 -0.937 . . . . 0.0 109.758 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.949 HG11 HD21 ' A' ' 34' ' ' LEU . 10.2 p -128.09 142.43 43.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.596 0.712 . . . . 0.0 109.78 -179.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.418 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -166.56 170.43 41.09 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.453 ' C ' HG23 ' A' ' 46' ' ' ILE . . . -83.79 158.58 35.36 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 178.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.698 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.5 pt -147.81 156.2 44.52 Favored Pre-proline 0 N--CA 1.493 1.698 0 O-C-N 121.439 -1.036 . . . . 0.0 110.188 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.66 -12.22 34.79 Favored 'Trans proline' 0 N--CA 1.504 2.119 0 C-N-CA 121.934 1.756 . . . . 0.0 114.668 -177.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -96.72 21.31 9.61 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 120.491 -1.381 . . . . 0.0 112.796 -177.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 54' ' ' SER . 48.9 mm -110.7 129.98 64.9 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.37 -0.831 . . . . 0.0 108.807 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.15 -48.26 11.54 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.443 -0.786 . . . . 0.0 112.256 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.769 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 168.53 -129.04 1.8 Allowed Glycine 0 N--CA 1.488 2.119 0 C-N-CA 118.806 -1.664 . . . . 0.0 111.384 -179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.454 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 20.1 t90 -50.2 -24.99 3.18 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.89 -0.771 . . . . 0.0 112.881 -178.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -146.93 71.3 1.22 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.402 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.634 ' CB ' HG23 ' A' ' 49' ' ' ILE . 11.2 t -70.04 130.37 89.87 Favored Pre-proline 0 N--CA 1.496 1.853 0 O-C-N 121.865 -0.522 . . . . 0.0 111.075 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -70.36 -21.47 30.65 Favored 'Trans proline' 0 N--CA 1.486 1.053 0 O-C-N 123.246 1.13 . . . . 0.0 110.566 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -98.52 13.48 31.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.445 -0.785 . . . . 0.0 110.983 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -70.98 147.18 48.91 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.182 -0.949 . . . . 0.0 110.271 179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.1 35.37 44.02 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 95.6 m -119.59 135.17 54.91 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.503 -0.998 . . . . 0.0 110.484 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -78.96 145.64 33.88 Favored 'General case' 0 N--CA 1.498 1.963 0 CA-C-N 115.835 -0.621 . . . . 0.0 112.053 -178.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.449 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 96.0 m95 -148.38 143.98 27.19 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.801 -0.562 . . . . 0.0 109.537 178.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -107.36 134.89 49.76 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.305 -0.872 . . . . 0.0 109.134 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 123.34 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.496 -0.752 . . . . 0.0 110.216 -179.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.2 m -118.42 139.71 50.98 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.893 -0.505 . . . . 0.0 110.378 -179.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.472 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 21.0 pt -119.58 164.29 22.62 Favored Pre-proline 0 N--CA 1.5 2.044 0 O-C-N 121.471 -0.768 . . . . 0.0 110.881 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 36.6 Cg_endo -60.58 -24.11 77.42 Favored 'Trans proline' 0 N--CA 1.496 1.632 0 C-N-CA 121.445 1.43 . . . . 0.0 112.794 -178.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -65.55 -36.61 84.28 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.217 -0.927 . . . . 0.0 109.712 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.11 63.41 0.47 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -163.82 153.99 15.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.755 -0.85 . . . . 0.0 108.988 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 95.6 p -155.43 158.38 38.51 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.583 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 44.6 pt -140.02 166.72 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -104.96 125.78 51.32 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.612 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -117.98 130.06 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.75 -0.594 . . . . 0.0 109.621 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.484 ' CD ' HG12 ' A' ' 37' ' ' VAL . 1.3 ttp-105 -99.23 139.52 34.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.524 -0.735 . . . . 0.0 109.517 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -59.59 148.04 42.16 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 -179.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.636 HG22 HG21 ' A' ' 18' ' ' VAL . 3.8 p -155.66 -41.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.807 -0.819 . . . . 0.0 109.798 179.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.647 ' OD2' HG23 ' A' ' 18' ' ' VAL . 1.9 t0 -134.58 175.18 9.77 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.145 -0.972 . . . . 0.0 109.767 179.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 28.8 t -103.81 154.81 19.17 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.471 -0.768 . . . . 0.0 111.521 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.77 147.75 16.66 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 81.9 mtt180 -60.0 -39.99 87.68 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.648 -0.913 . . . . 0.0 110.742 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -177.39 73.65 0.07 OUTLIER Glycine 0 N--CA 1.495 2.585 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.638 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 146.65 147.33 4.54 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.467 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.698 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.5 m-85 -73.02 135.16 44.89 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 122.031 -0.688 . . . . 0.0 110.506 179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.3 131.01 46.87 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 178.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.4 m -131.72 173.73 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.269 -0.972 . . . . 0.0 111.636 -178.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 -55.17 152.16 15.77 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 109.927 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -65.27 -27.55 55.89 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 O-C-N 123.422 1.222 . . . . 0.0 110.11 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.5 m -70.02 -40.02 75.46 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.952 -1.092 . . . . 0.0 109.048 178.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.92 -40.16 87.59 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.432 -0.793 . . . . 0.0 108.977 178.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.47 -49.95 75.51 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.799 179.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 38.9 m -60.02 -39.56 86.25 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.657 -0.652 . . . . 0.0 111.28 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 49.9 mttm -68.89 -40.02 79.41 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.499 -179.074 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.4 HD21 ' CG2' ' A' ' 65' ' ' ILE . 41.4 tp -70.78 -42.74 69.95 Favored 'General case' 0 N--CA 1.496 1.847 0 C-N-CA 119.8 -0.76 . . . . 0.0 111.627 -178.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 61.1 t -97.74 -40.39 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.145 0 O-C-N 121.201 -0.937 . . . . 0.0 111.733 -177.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 118.17 -37.7 3.17 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 70.9 m -134.69 149.62 50.52 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.608 -0.937 . . . . 0.0 110.199 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 70.8 p -94.02 3.98 54.56 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.421 -0.799 . . . . 0.0 111.053 179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 -69.93 -27.64 64.93 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.43 -0.794 . . . . 0.0 111.164 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.97 87.75 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.495 -0.753 . . . . 0.0 110.67 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.28 -60.45 3.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 16.2 ptt180 -153.61 156.91 38.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.616 -0.932 . . . . 0.0 110.546 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -125.44 117.24 49.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.45 -0.781 . . . . 0.0 109.672 179.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -81.09 169.99 16.74 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.49 -0.756 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 56.4 t30 61.64 47.92 6.05 Favored 'General case' 0 N--CA 1.501 2.12 0 O-C-N 121.573 -0.704 . . . . 0.0 111.646 179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.495 HG11 HG21 ' A' ' 3' ' ' ILE . 81.1 t -96.17 124.75 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.031 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -84.92 145.76 27.61 Favored 'General case' 0 N--CA 1.493 1.675 0 C-N-CA 119.779 -0.768 . . . . 0.0 109.281 179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.02 147.2 40.04 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.833 -0.542 . . . . 0.0 111.598 -178.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.8 m -147.27 148.66 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.653 -0.654 . . . . 0.0 110.829 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.449 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 16.9 tt0 -82.98 140.93 32.48 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.656 -0.652 . . . . 0.0 110.314 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 35.4 m -132.54 168.8 23.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 C-N-CA 120.211 -0.595 . . . . 0.0 109.742 179.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -59.97 149.05 33.12 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.296 -0.878 . . . . 0.0 109.925 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.0 tt -60.08 -40.0 88.03 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.408 -0.807 . . . . 0.0 110.94 -179.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 54.0 p -55.45 -35.54 65.57 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.556 -0.715 . . . . 0.0 110.665 -178.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -60.0 -38.39 82.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.435 -0.79 . . . . 0.0 110.075 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 85.8 m -69.63 -39.93 76.86 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 178.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 49.8 mm -64.09 -43.94 97.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 C-N-CA 120.274 -0.571 . . . . 0.0 109.845 -178.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -70.0 -40.02 75.53 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.76 -0.588 . . . . 0.0 110.547 179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.44 -51.63 46.86 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -64.57 -40.04 94.83 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.588 -0.948 . . . . 0.0 110.249 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.087 -179.87 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.351 0.596 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.9 m -111.36 137.26 49.36 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.441 HG21 HG11 ' A' ' 105' ' ' VAL . 37.8 pt -109.75 146.69 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.6 -0.688 . . . . 0.0 110.354 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.9 m -143.29 -174.59 4.25 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -142.73 150.0 39.51 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.985 179.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.55 152.7 77.03 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.504 -0.748 . . . . 0.0 109.755 179.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -84.52 -12.0 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 O-C-N 123.348 1.183 . . . . 0.0 112.659 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.479 HG13 ' N ' ' A' ' 9' ' ' TYR . 35.9 pt -70.05 -39.91 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 120.871 -1.143 . . . . 0.0 111.333 -178.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.605 ' HA ' HD22 ' A' ' 13' ' ' LEU . 46.3 m-85 -72.94 65.22 0.73 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-O 122.652 1.215 . . . . 0.0 111.712 -178.653 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.89 170.46 7.86 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.55 -34.84 73.18 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 113.179 0.807 . . . . 0.0 113.179 -175.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -87.83 8.99 23.35 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.016 -1.474 . . . . 0.0 111.542 -177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.605 HD22 ' HA ' ' A' ' 9' ' ' TYR . 45.3 tp -70.01 122.13 18.76 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.303 -0.873 . . . . 0.0 109.424 179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 54.1 m -68.31 135.59 52.12 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.413 179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.851 ' O ' HG12 ' A' ' 18' ' ' VAL . 87.0 mtp -70.07 -15.23 62.96 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.16 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -15.87 72.74 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 120.805 -1.184 . . . . 0.0 110.168 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 t -88.55 -6.67 57.42 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.259 -1.142 . . . . 0.0 111.735 -179.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.851 HG12 ' O ' ' A' ' 15' ' ' MET . 10.8 p -96.74 165.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.997 -1.064 . . . . 0.0 110.603 -179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.633 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -60.01 -42.33 94.07 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.783 -0.573 . . . . 0.0 110.907 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 48.1 m -76.98 71.72 3.5 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.383 -0.823 . . . . 0.0 110.186 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 4.2 p -108.36 111.9 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.467 -0.771 . . . . 0.0 110.405 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.41 ' CA ' ' HA3' ' A' ' 26' ' ' GLY . 13.1 t-20 51.99 -139.71 0.96 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.592 -0.692 . . . . 0.0 110.561 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.458 ' CA ' ' CH2' ' A' ' 52' ' ' TRP . . . 66.02 -156.12 50.1 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -74.25 -41.03 61.94 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.684 -0.892 . . . . 0.0 112.025 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.403 ' CD2' ' O ' ' A' ' 54' ' ' SER . 79.5 m-70 -99.69 10.04 42.04 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.074 -1.016 . . . . 0.0 111.51 -178.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.41 ' HA3' ' CA ' ' A' ' 22' ' ' ASN . . . -56.78 130.85 51.17 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 120.073 -1.06 . . . . 0.0 110.523 -179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 1.005 HD13 HG11 ' A' ' 37' ' ' VAL . 95.0 mt -100.6 -5.93 26.02 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.071 -0.664 . . . . 0.0 110.12 178.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 34.3 tpp -59.95 -36.08 76.31 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.281 -0.887 . . . . 0.0 109.599 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.24 -72.46 0.05 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.723 -0.611 . . . . 0.0 111.784 -178.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -69.95 -39.99 75.72 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.349 -0.845 . . . . 0.0 110.223 -179.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.644 ' CD2' HG23 ' A' ' 37' ' ' VAL . 75.8 m-85 -120.38 102.31 45.65 Favored Pre-proline 0 N--CA 1.491 1.596 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 -178.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.97 -22.39 19.75 Favored 'Trans proline' 0 C--N 1.316 -1.154 0 O-C-N 123.322 1.17 . . . . 0.0 111.381 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.1 m -122.69 144.23 49.28 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.327 -0.858 . . . . 0.0 110.711 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.663 HD21 HG11 ' A' ' 43' ' ' VAL . 52.9 tp -64.94 120.82 13.29 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.855 -0.528 . . . . 0.0 110.088 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.29 32.17 0.04 OUTLIER Glycine 0 N--CA 1.496 2.698 0 C-N-CA 119.906 -1.14 . . . . 0.0 110.993 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.446 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 19.1 mt-10 -156.09 -48.17 0.08 Allowed 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.335 -1.097 . . . . 0.0 109.979 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 1.005 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -62.95 -59.48 12.38 Favored Pre-proline 0 N--CA 1.493 1.711 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.436 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 46.9 Cg_endo -73.73 -32.29 7.65 Favored 'Trans proline' 0 C--N 1.318 -1.066 0 N-CA-C 108.733 -1.295 . . . . 0.0 108.733 177.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' A' ' 40' ' ' PHE . . . 130.1 -63.46 0.63 Allowed Glycine 0 N--CA 1.487 2.049 0 N-CA-C 107.197 -2.361 . . . . 0.0 107.197 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.644 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.5 t80 163.32 -53.58 0.0 OUTLIER Pre-proline 0 N--CA 1.51 2.556 0 C-N-CA 123.601 0.76 . . . . 0.0 109.91 177.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.666 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -100.55 12.95 0.49 Allowed 'Trans proline' 0 C--N 1.324 -0.728 0 C-N-CA 121.29 1.327 . . . . 0.0 111.198 -179.029 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 46.6 m-20 -125.15 52.19 1.61 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.216 -0.928 . . . . 0.0 109.765 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.663 HG11 HD21 ' A' ' 34' ' ' LEU . 13.4 p -126.21 136.71 60.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 CA-C-O 121.538 0.685 . . . . 0.0 110.283 -179.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.573 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -165.8 171.26 40.91 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.81 160.14 29.74 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.899 -1.681 . . . . 0.0 108.899 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.646 HG22 ' CE1' ' A' ' 83' ' ' PHE . 8.8 pt -146.65 158.63 45.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.806 -0.82 . . . . 0.0 110.414 179.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -70.14 -16.41 35.94 Favored 'Trans proline' 0 N--CA 1.497 1.73 0 C-N-CA 121.713 1.609 . . . . 0.0 113.63 -178.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -89.94 18.69 5.47 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.816 -1.177 . . . . 0.0 112.577 -177.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.437 ' HA ' ' CB ' ' A' ' 54' ' ' SER . 56.0 mt -119.99 123.17 70.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.146 -0.971 . . . . 0.0 109.05 177.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.58 -43.64 16.8 Favored 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 113.388 0.885 . . . . 0.0 113.388 -177.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.633 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 179.54 -125.33 0.96 Allowed Glycine 0 N--CA 1.493 2.452 0 C-N-CA 118.119 -1.991 . . . . 0.0 112.909 -178.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.469 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 6.8 t90 -40.32 -32.8 0.2 Allowed 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 114.56 1.319 . . . . 0.0 114.56 -176.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 40.9 p-10 -174.15 76.83 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.084 0 O-C-N 120.493 -1.38 . . . . 0.0 109.975 178.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 49' ' ' ILE . 25.4 p -62.74 155.11 72.01 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.636 -0.665 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 -14.36 40.05 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.566 1.298 . . . . 0.0 110.813 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 59' ' ' THR . 6.2 m -102.36 7.79 40.4 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.315 -0.865 . . . . 0.0 111.841 -179.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 41.5 t -65.4 143.65 57.59 Favored 'General case' 0 N--CA 1.5 2.048 0 O-C-N 120.755 -1.216 . . . . 0.0 110.109 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.26 6.45 81.35 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.556 HG23 ' O ' ' A' ' 56' ' ' SER . 20.9 p -77.67 158.12 29.85 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.149 -1.207 . . . . 0.0 110.998 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 48.8 t -103.41 120.02 40.01 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.19 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.431 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 98.0 m95 -121.36 139.97 52.73 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.39 -0.819 . . . . 0.0 110.934 179.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -105.92 134.14 49.52 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.651 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.8 t -111.69 125.62 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.587 -0.696 . . . . 0.0 110.47 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.509 ' O ' HG13 ' A' ' 105' ' ' VAL . 58.8 m -116.41 134.8 54.46 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.692 -0.63 . . . . 0.0 110.552 -178.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 12.8 pt -116.29 164.04 19.56 Favored Pre-proline 0 N--CA 1.503 2.179 0 O-C-N 121.407 -0.808 . . . . 0.0 111.331 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.3 Cg_endo -63.38 -27.36 71.12 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 121.679 1.586 . . . . 0.0 113.296 -178.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -64.67 -40.03 94.71 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.064 -1.023 . . . . 0.0 109.917 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 119.92 58.53 0.25 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 178.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 81.2 m-20 -154.7 148.43 25.43 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.72 -0.871 . . . . 0.0 108.666 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 74.9 m -146.44 143.74 29.22 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.738 -179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.553 HG23 HD13 ' A' ' 93' ' ' LEU . 33.9 pt -134.3 164.35 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -107.13 127.92 53.93 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 118.948 -1.101 . . . . 0.0 109.829 179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -112.79 130.01 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.666 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.5 ttt180 -98.6 134.89 40.91 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.179 -0.95 . . . . 0.0 109.244 -179.299 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -55.96 147.04 30.76 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -178.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.455 HG22 HG21 ' A' ' 18' ' ' VAL . 3.7 p -155.4 -44.46 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.55 ' HB2' HG23 ' A' ' 18' ' ' VAL . 14.4 t70 -128.73 166.38 19.08 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.2 -0.937 . . . . 0.0 109.563 178.75 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 83.5 p -88.88 161.16 16.84 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.579 -0.701 . . . . 0.0 110.338 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.56 142.97 14.13 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 88.4 mtt-85 -60.08 -34.01 72.86 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.601 -0.941 . . . . 0.0 110.009 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.24 75.65 0.04 OUTLIER Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.62 149.93 5.1 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.99 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.651 ' CE2' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -66.53 140.07 57.97 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.855 -0.791 . . . . 0.0 110.491 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.414 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 52.3 t-20 -136.77 119.0 15.56 Favored 'General case' 0 N--CA 1.493 1.68 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.573 HG12 ' HA3' ' A' ' 44' ' ' GLY . 27.3 m -130.24 176.11 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 C-N-CA 119.102 -1.039 . . . . 0.0 112.449 -177.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 20.2 m-20 -56.18 157.58 8.67 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.578 -0.701 . . . . 0.0 109.937 179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -70.35 -28.17 22.76 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.407 1.214 . . . . 0.0 110.166 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.0 m -70.36 -41.41 73.18 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.033 -1.042 . . . . 0.0 109.549 178.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.666 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.0 -40.09 90.86 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 t80 -60.05 -49.93 75.74 Favored 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 120.401 -0.52 . . . . 0.0 110.708 178.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.7 m -60.01 -39.71 86.73 Favored 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.44 -0.788 . . . . 0.0 111.416 -178.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -69.61 -39.99 76.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.563 -0.711 . . . . 0.0 111.274 -178.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.553 HD13 HG23 ' A' ' 71' ' ' ILE . 61.0 tp -71.31 -43.46 67.04 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.587 -0.696 . . . . 0.0 111.296 -179.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.6 t -93.32 -40.55 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.473 -0.767 . . . . 0.0 111.293 -178.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.29 -38.78 2.47 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.911 -1.676 . . . . 0.0 108.911 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 74.5 m -142.28 156.93 45.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.674 -0.897 . . . . 0.0 110.416 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 67.2 p -89.95 4.17 50.87 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.458 -0.776 . . . . 0.0 110.776 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.98 -26.65 64.19 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.452 -0.78 . . . . 0.0 110.445 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.01 93.21 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.57 -0.706 . . . . 0.0 110.385 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.33 -75.35 2.39 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -133.42 136.63 45.34 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.558 -0.966 . . . . 0.0 110.572 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.8 t -116.8 113.76 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.438 -0.788 . . . . 0.0 109.76 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -86.84 170.58 11.56 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-O 121.848 0.832 . . . . 0.0 111.608 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.2 t30 60.07 40.01 19.04 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.505 0.669 . . . . 0.0 110.333 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.509 HG13 ' O ' ' A' ' 64' ' ' THR . 93.8 t -90.73 122.01 41.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -80.0 140.4 36.59 Favored 'General case' 0 N--CA 1.493 1.707 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.651 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 107' ' ' TYR . 42.2 p90 -139.27 143.88 38.14 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.882 -0.512 . . . . 0.0 111.231 -178.49 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 35.5 m -145.54 139.99 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.539 -0.726 . . . . 0.0 111.17 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.431 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 57.3 tt0 -72.66 140.01 47.66 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.618 -0.676 . . . . 0.0 109.364 178.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.8 m -138.48 177.7 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 C-N-CA 119.716 -0.794 . . . . 0.0 110.836 179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 47.4 t0 -59.89 146.19 43.07 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.665 -0.647 . . . . 0.0 109.976 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 116' ' ' ILE . 9.3 tt -60.0 -37.95 81.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.456 -0.777 . . . . 0.0 110.514 -179.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 72.7 p -52.71 -35.14 55.22 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.517 -0.739 . . . . 0.0 110.595 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -66.45 -36.3 82.45 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.511 -0.743 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.3 m -62.96 -50.18 71.79 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.264 -0.898 . . . . 0.0 110.038 179.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.47 HD11 HD21 ' A' ' 112' ' ' LEU . 90.0 mt -69.3 -40.03 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.748 -0.595 . . . . 0.0 110.457 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -65.44 -40.02 92.75 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.44 -0.787 . . . . 0.0 110.158 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.58 -42.18 97.51 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.05 91.1 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.675 -0.897 . . . . 0.0 109.945 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 66.5 t30 . . . . . 0 N--CA 1.5 2.058 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.645 179.898 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 31.8 m . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 121.375 0.607 . . . . 0.0 111.904 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.0 m -111.77 140.7 46.19 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.661 0.744 . . . . 0.0 110.241 179.429 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.636 HG21 HG11 ' A' ' 105' ' ' VAL . 35.6 pt -112.18 147.36 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.755 -0.591 . . . . 0.0 110.487 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.419 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 4.0 p -145.78 -173.24 4.09 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.441 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 53.1 p90 -142.5 148.88 38.4 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.656 178.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -124.95 150.38 66.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.468 -0.77 . . . . 0.0 109.608 179.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -84.55 -7.77 9.64 Favored 'Trans proline' 0 C--N 1.317 -1.088 0 O-C-N 123.303 1.159 . . . . 0.0 112.854 -178.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 41.0 pt -70.02 -40.09 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.201 0 O-C-N 120.887 -1.133 . . . . 0.0 111.102 -179.356 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 38.0 m-85 -72.13 66.86 0.64 Allowed 'General case' 0 N--CA 1.496 1.827 0 CA-C-O 122.684 1.23 . . . . 0.0 111.756 -178.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.69 172.2 6.95 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.126 176.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.97 -33.17 71.57 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -90.3 11.33 21.62 Favored 'General case' 0 N--CA 1.501 2.09 0 C-N-CA 118.078 -1.449 . . . . 0.0 112.424 -177.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.456 HD22 ' HA ' ' A' ' 9' ' ' TYR . 28.2 tp -72.63 123.87 24.11 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.214 -0.928 . . . . 0.0 109.956 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 48.4 t -69.54 136.31 51.2 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.027 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.779 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.1 mmm -69.98 -15.95 63.11 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.856 -0.527 . . . . 0.0 111.717 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.418 ' CA ' ' HE1' ' A' ' 28' ' ' MET . . . -69.93 -11.18 66.12 Favored Glycine 0 N--CA 1.495 2.632 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.8 m -93.15 -11.97 31.51 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.254 -1.144 . . . . 0.0 111.708 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.779 HG12 ' O ' ' A' ' 15' ' ' MET . 7.1 p -92.45 165.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.17 -0.956 . . . . 0.0 110.46 -179.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.819 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.98 -45.3 86.98 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.642 -0.661 . . . . 0.0 110.093 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -80.23 80.32 6.68 Favored 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.97 -80.02 0.4 Allowed 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.485 -0.76 . . . . 0.0 112.903 -177.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.7 t30 -139.91 9.43 2.36 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.217 -0.927 . . . . 0.0 112.917 -178.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.47 -143.97 0.24 Allowed Glycine 0 N--CA 1.493 2.493 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -69.97 -40.02 75.64 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.647 -0.914 . . . . 0.0 109.71 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 92.9 m-70 -90.38 2.37 55.65 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.457 -0.777 . . . . 0.0 110.815 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.03 126.42 33.21 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.423 -1.071 . . . . 0.0 110.423 -179.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.842 HD13 HG11 ' A' ' 37' ' ' VAL . 96.1 mt -100.09 0.93 41.71 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 122.132 -0.628 . . . . 0.0 110.21 178.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.418 ' HE1' ' CA ' ' A' ' 16' ' ' GLY . 56.6 ttm -68.13 -30.65 69.84 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.364 -0.835 . . . . 0.0 110.339 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.0 -71.8 0.06 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.553 -0.717 . . . . 0.0 111.53 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 37.2 mt-30 -69.97 -40.1 75.6 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.285 -0.884 . . . . 0.0 109.99 179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.623 ' CD2' HG23 ' A' ' 37' ' ' VAL . 66.5 m-85 -123.16 95.07 46.29 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.843 -0.536 . . . . 0.0 110.049 -179.168 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.02 -18.75 27.32 Favored 'Trans proline' 0 C--N 1.318 -1.054 0 O-C-N 123.411 1.216 . . . . 0.0 111.483 -179.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 3.5 m -121.39 149.32 43.16 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.257 -0.902 . . . . 0.0 110.435 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 1.096 HD11 HG21 ' A' ' 43' ' ' VAL . 34.1 tp -70.64 119.89 15.46 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.793 -0.567 . . . . 0.0 110.422 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 149.29 33.46 0.05 OUTLIER Glycine 0 N--CA 1.495 2.609 0 C-N-CA 120.104 -1.046 . . . . 0.0 110.593 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.455 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 1.6 mt-10 -157.71 -49.91 0.07 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.206 -1.173 . . . . 0.0 110.422 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 27' ' ' LEU . 2.6 t -60.1 -58.61 18.11 Favored Pre-proline 0 N--CA 1.502 2.125 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -78.54 -29.23 3.84 Favored 'Trans proline' 0 N--CA 1.486 1.079 0 N-CA-C 109.008 -1.189 . . . . 0.0 109.008 176.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 125.4 -64.88 0.56 Allowed Glycine 0 N--CA 1.486 1.982 0 N-CA-C 106.676 -2.57 . . . . 0.0 106.676 -178.151 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.559 ' CB ' ' HD3' ' A' ' 41' ' ' PRO . 0.1 OUTLIER 167.98 -58.88 0.0 OUTLIER Pre-proline 0 N--CA 1.507 2.377 0 O-C-N 122.277 -0.543 . . . . 0.0 109.962 177.091 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.719 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 53.4 Cg_endo -95.57 16.87 0.83 Allowed 'Trans proline' 0 C--N 1.325 -0.68 0 O-C-N 123.071 1.037 . . . . 0.0 109.806 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.4 m120 -123.32 38.8 4.11 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.469 -0.769 . . . . 0.0 109.526 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.096 HG21 HD11 ' A' ' 34' ' ' LEU . 14.8 p -127.89 140.87 47.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.527 0.679 . . . . 0.0 110.915 -178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -167.68 175.18 42.69 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -89.46 161.76 30.13 Favored Glycine 0 N--CA 1.498 2.807 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.732 HG23 ' O ' ' A' ' 45' ' ' GLY . 0.5 OUTLIER -161.26 164.79 18.01 Favored Pre-proline 0 N--CA 1.503 2.21 0 CA-C-N 118.457 1.128 . . . . 0.0 111.422 -179.097 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.24 -22.27 25.79 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 121.439 1.426 . . . . 0.0 114.593 -177.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -83.94 3.25 34.95 Favored 'General case' 0 N--CA 1.506 2.367 0 O-C-N 120.382 -1.449 . . . . 0.0 112.762 -177.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.61 HG23 ' CB ' ' A' ' 54' ' ' SER . 45.6 mm -97.38 128.94 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.064 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 177.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.37 -51.01 7.29 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.409 -0.807 . . . . 0.0 111.961 -178.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.819 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.68 -135.94 3.3 Favored Glycine 0 N--CA 1.487 2.098 0 C-N-CA 118.882 -1.628 . . . . 0.0 111.241 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.458 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 9.4 t90 -42.74 -27.22 0.16 Allowed 'General case' 0 N--CA 1.5 2.054 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.411 ' OD2' ' CE3' ' A' ' 52' ' ' TRP . 47.2 m-20 -147.0 62.84 1.18 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.208 -0.932 . . . . 0.0 110.901 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.61 ' CB ' HG23 ' A' ' 49' ' ' ILE . 5.1 p -56.96 132.9 79.91 Favored Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.436 -0.79 . . . . 0.0 110.461 -179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.63 -21.16 22.38 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 O-C-N 123.252 1.133 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 38.8 m -96.15 9.47 40.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.456 -0.777 . . . . 0.0 111.043 -179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -64.0 141.65 58.69 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.327 -0.858 . . . . 0.0 110.265 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 95.33 -24.97 26.64 Favored Glycine 0 N--CA 1.5 2.933 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 178.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 71.1 m -56.93 161.32 3.02 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.257 -1.143 . . . . 0.0 110.622 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.431 ' SG ' HG23 ' A' ' 110' ' ' VAL . 42.5 t -113.46 152.32 30.28 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.969 -0.457 . . . . 0.0 111.307 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.432 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 52.6 m95 -142.53 149.04 38.58 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.241 -0.912 . . . . 0.0 110.75 178.029 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 107' ' ' TYR . 36.3 tttp -110.71 129.56 55.8 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 178.019 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.2 t -110.9 129.75 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.316 -0.865 . . . . 0.0 110.383 -178.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.5 m -121.12 140.18 52.33 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.842 -0.536 . . . . 0.0 111.381 -178.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.473 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 13.2 pt -119.27 164.65 20.3 Favored Pre-proline 0 N--CA 1.5 2.057 0 O-C-N 121.499 -0.751 . . . . 0.0 110.311 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.1 Cg_endo -63.5 -24.07 70.61 Favored 'Trans proline' 0 N--CA 1.495 1.613 0 O-C-N 123.404 1.213 . . . . 0.0 112.593 -178.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 58.3 t-20 -64.47 -39.99 94.86 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.237 -0.915 . . . . 0.0 109.61 179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.65 60.56 0.32 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.1 t30 -159.99 150.78 19.03 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.704 -0.88 . . . . 0.0 109.145 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.446 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 14.8 m -149.4 157.38 43.26 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 121.992 0.901 . . . . 0.0 112.029 -179.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.863 HG12 HD13 ' A' ' 93' ' ' LEU . 36.8 pt -140.06 165.84 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.8 m-85 -107.61 130.25 54.91 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.128 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.4 mm -116.11 130.04 71.51 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.994 0 O-C-N 121.691 -0.631 . . . . 0.0 110.726 -178.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.521 ' HD3' HG12 ' A' ' 37' ' ' VAL . 66.4 ttt180 -101.24 135.33 42.88 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.176 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.711 ' HA2' HD11 ' A' ' 46' ' ' ILE . . . -62.24 149.34 47.92 Favored Glycine 0 N--CA 1.496 2.664 0 C-N-CA 120.124 -1.036 . . . . 0.0 111.386 -177.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.48 HG11 HG22 ' A' ' 43' ' ' VAL . 2.6 p -152.63 -45.75 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.577 ' HB2' HG23 ' A' ' 18' ' ' VAL . 10.3 t70 -129.49 169.04 15.46 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.34 -0.85 . . . . 0.0 109.517 179.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 82.9 p -103.9 159.94 15.23 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.604 -0.685 . . . . 0.0 110.111 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.52 156.64 21.96 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -60.03 -35.78 75.84 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.674 -0.898 . . . . 0.0 109.109 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -171.32 177.55 44.15 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 51.54 -168.32 0.56 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 121.355 -1.085 . . . . 0.0 111.567 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.706 ' CD2' HG22 ' A' ' 46' ' ' ILE . 32.4 m-85 -120.0 139.06 53.06 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.965 -0.727 . . . . 0.0 109.15 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.419 ' HA ' ' O ' ' A' ' 4' ' ' SER . 33.4 t-20 -129.29 128.48 43.28 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.052 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 33.3 m -130.72 172.07 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.005 0 O-C-N 121.088 -1.008 . . . . 0.0 112.025 -178.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 12.3 m-20 -55.84 152.77 18.8 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.29 -0.881 . . . . 0.0 109.663 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.36 -21.35 61.22 Favored 'Trans proline' 0 C--N 1.314 -1.288 0 O-C-N 123.386 1.203 . . . . 0.0 110.732 -179.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.2 m -78.76 -40.04 34.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.928 -1.107 . . . . 0.0 109.33 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.719 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.68 -40.03 88.38 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 178.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -60.01 -49.87 75.99 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.794 -0.566 . . . . 0.0 110.447 179.088 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -59.99 -38.74 83.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.583 -0.698 . . . . 0.0 110.661 -178.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -69.87 -39.87 76.06 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.141 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.863 HD13 HG12 ' A' ' 71' ' ' ILE . 61.2 tp -70.14 -43.97 69.82 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.507 -0.746 . . . . 0.0 111.283 -179.133 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.51 -39.88 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.055 0 O-C-N 121.298 -0.876 . . . . 0.0 111.461 -178.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 119.89 -35.19 3.91 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 64.2 m -140.03 150.83 44.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.525 -0.985 . . . . 0.0 110.889 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 75.8 p -89.57 3.74 51.56 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.516 -0.74 . . . . 0.0 110.627 179.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -70.08 -28.32 65.33 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.441 -0.787 . . . . 0.0 110.951 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.17 -40.03 84.37 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.456 -0.777 . . . . 0.0 110.417 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 80.57 -79.6 1.74 Allowed Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 3' ' ' ILE . 37.0 ttm180 -129.85 132.69 46.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.659 -0.906 . . . . 0.0 110.219 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.5 t -119.34 120.06 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.396 -0.815 . . . . 0.0 110.276 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.4 ' O ' ' HB2' ' A' ' 104' ' ' ASN . 9.3 t70 -85.05 173.11 10.75 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.42 0.629 . . . . 0.0 110.876 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 103' ' ' ASP . 94.9 m-20 60.04 39.97 19.19 Favored 'General case' 0 N--CA 1.499 2.018 0 CA-C-O 121.091 0.472 . . . . 0.0 111.569 179.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.636 HG11 HG21 ' A' ' 3' ' ' ILE . 63.0 t -86.95 122.58 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -82.25 134.58 35.29 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 119.173 -1.011 . . . . 0.0 109.425 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 62' ' ' LYS . 47.8 p90 -136.28 142.72 43.97 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.325 0.583 . . . . 0.0 111.323 -178.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.8 m -144.07 140.05 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.731 -0.606 . . . . 0.0 110.184 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.9 tt0 -71.43 140.75 50.2 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.698 . . . . 0.0 110.422 179.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.431 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.2 m -136.57 173.26 13.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.829 178.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -61.12 149.67 36.54 Favored 'General case' 0 N--CA 1.501 2.091 0 O-C-N 121.386 -0.822 . . . . 0.0 110.833 -179.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.571 HD21 HD11 ' A' ' 116' ' ' ILE . 9.5 tt -59.98 -39.3 85.21 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.456 -0.778 . . . . 0.0 110.794 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 62.8 m -53.85 -39.44 65.63 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.447 -0.783 . . . . 0.0 110.226 -178.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -60.25 -39.3 86.24 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.606 -0.684 . . . . 0.0 110.988 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -59.97 -49.37 77.94 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.238 -0.914 . . . . 0.0 110.059 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.571 HD11 HD21 ' A' ' 112' ' ' LEU . 85.7 mt -69.84 -40.03 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.704 -0.622 . . . . 0.0 110.57 -179.163 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.18 -40.0 95.18 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.342 -0.849 . . . . 0.0 110.316 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.45 -39.97 79.65 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.26 -39.96 88.62 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.604 -0.939 . . . . 0.0 110.276 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 . . . . . 0 N--CA 1.493 1.709 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.194 179.911 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.863 0.363 . . . . 0.0 110.66 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.3 m -110.95 141.73 44.0 Favored 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.832 0.825 . . . . 0.0 111.332 -179.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.512 HG21 HG11 ' A' ' 105' ' ' VAL . 45.8 pt -119.93 149.94 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.89 -0.507 . . . . 0.0 110.407 179.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.409 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 67.6 m -143.97 -174.08 4.17 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -141.5 150.0 41.63 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.362 -0.836 . . . . 0.0 110.538 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -132.88 144.73 54.07 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.609 -0.682 . . . . 0.0 109.543 179.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.6 -4.46 14.13 Favored 'Trans proline' 0 C--N 1.317 -1.11 0 O-C-N 123.381 1.201 . . . . 0.0 112.405 -178.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.661 HD11 ' CZ ' ' A' ' 9' ' ' TYR . 33.9 pt -69.99 -40.03 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 120.899 -1.126 . . . . 0.0 110.439 -179.478 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.661 ' CZ ' HD11 ' A' ' 8' ' ' ILE . 30.8 m-85 -74.52 66.66 1.42 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 122.815 1.293 . . . . 0.0 110.611 -178.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.72 171.62 7.26 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 114.307 -1.315 . . . . 0.0 108.458 177.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.83 -34.47 73.13 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 -175.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 84.9 m-20 -89.1 10.1 23.03 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.45 -1.406 . . . . 0.0 111.966 -177.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.478 HD22 ' O ' ' A' ' 8' ' ' ILE . 58.7 tp -71.16 122.87 20.93 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.359 -0.838 . . . . 0.0 109.431 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.3 m -68.89 136.84 53.25 Favored 'General case' 0 N--CA 1.489 1.52 0 CA-C-O 121.705 0.764 . . . . 0.0 110.199 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.617 ' O ' HG12 ' A' ' 18' ' ' VAL . 89.4 mmm -65.58 -16.98 64.23 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.471 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.57 -16.59 77.65 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.012 -1.055 . . . . 0.0 111.069 -179.208 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 79.6 p -90.33 -17.65 26.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.138 -1.213 . . . . 0.0 111.256 -179.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.896 HG23 ' OD1' ' A' ' 77' ' ' ASP . 7.6 p -89.97 155.16 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.333 -0.854 . . . . 0.0 109.598 -179.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.619 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -48.41 -40.02 24.53 Favored 'General case' 0 N--CA 1.505 2.298 0 O-C-N 121.513 -0.742 . . . . 0.0 110.406 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.29 82.59 4.58 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.9 m -92.51 -83.41 0.3 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 120.895 -1.128 . . . . 0.0 112.596 -177.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.424 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 60.3 t30 -154.5 18.02 0.47 Allowed 'General case' 0 N--CA 1.499 2.015 0 O-C-N 120.802 -1.186 . . . . 0.0 112.339 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -66.06 -141.33 0.04 OUTLIER Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.3 t0 -70.13 -42.56 72.45 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.692 -0.887 . . . . 0.0 109.634 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.664 ' NE2' ' HA ' ' A' ' 53' ' ' ASP . 8.2 p80 -97.31 4.48 50.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.477 -0.765 . . . . 0.0 110.861 -179.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.56 144.43 37.42 Favored Glycine 0 N--CA 1.494 2.541 0 O-C-N 121.14 -0.975 . . . . 0.0 110.734 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 94.5 mt -99.58 -3.05 34.16 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.825 -0.809 . . . . 0.0 110.539 179.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.407 ' HA ' ' HA ' ' A' ' 32' ' ' PRO . 55.3 tpp -60.12 -36.39 77.38 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.328 -0.858 . . . . 0.0 110.562 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -50.89 -77.79 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.423 -0.798 . . . . 0.0 111.977 -177.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -69.98 -39.99 75.63 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.38 -0.825 . . . . 0.0 111.053 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.506 ' CD2' HG23 ' A' ' 37' ' ' VAL . 68.1 m-85 -119.99 88.44 40.65 Favored Pre-proline 0 N--CA 1.493 1.698 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 28' ' ' MET . 42.7 Cg_endo -68.59 -16.51 42.65 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.353 1.186 . . . . 0.0 111.51 -178.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 22.5 m -125.6 140.21 52.93 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.214 -0.929 . . . . 0.0 110.308 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.658 HD21 HG21 ' A' ' 43' ' ' VAL . 51.2 tp -68.55 119.74 13.47 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.68 -0.637 . . . . 0.0 110.65 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.31 32.78 0.04 OUTLIER Glycine 0 N--CA 1.497 2.713 0 C-N-CA 119.96 -1.114 . . . . 0.0 110.782 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 -156.14 -49.55 0.08 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.161 -1.199 . . . . 0.0 110.603 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.506 HG23 ' CD2' ' A' ' 31' ' ' TYR . 2.4 t -61.18 -59.64 13.1 Favored Pre-proline 0 N--CA 1.499 2.008 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.179 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.453 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 48.5 Cg_endo -75.38 -31.76 5.5 Favored 'Trans proline' 0 C--N 1.318 -1.075 0 N-CA-C 108.872 -1.241 . . . . 0.0 108.872 177.64 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.438 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 130.69 -64.22 0.62 Allowed Glycine 0 N--CA 1.486 1.972 0 N-CA-C 107.316 -2.314 . . . . 0.0 107.316 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.539 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.3 t80 163.54 -68.32 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.645 0 C-N-CA 123.533 0.733 . . . . 0.0 109.555 177.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.539 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.4 Cg_endo -80.41 -0.54 10.71 Favored 'Trans proline' 0 N--CA 1.493 1.452 0 O-C-N 122.734 0.86 . . . . 0.0 111.423 179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -109.95 57.18 0.61 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.195 -0.94 . . . . 0.0 109.449 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.658 HG21 HD21 ' A' ' 34' ' ' LEU . 11.4 p -129.62 135.66 60.93 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-O 121.551 0.691 . . . . 0.0 110.557 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.698 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -165.12 173.01 40.91 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.94 163.79 28.34 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.802 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -143.73 157.02 59.2 Favored Pre-proline 0 N--CA 1.495 1.81 0 O-C-N 121.698 -0.884 . . . . 0.0 110.19 179.336 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.48 -9.26 25.48 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 121.567 1.511 . . . . 0.0 113.044 -178.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -99.01 28.16 4.58 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.918 -1.114 . . . . 0.0 112.239 -178.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.576 HD11 HD11 ' A' ' 46' ' ' ILE . 48.6 mm -119.58 121.57 66.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.085 -1.01 . . . . 0.0 109.36 179.185 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.5 -43.01 57.94 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.323 -0.86 . . . . 0.0 111.487 -179.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.619 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 163.96 -133.33 2.99 Favored Glycine 0 N--CA 1.489 2.185 0 C-N-CA 119.296 -1.43 . . . . 0.0 111.141 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.483 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 71.4 t90 -51.11 -23.69 3.39 Favored 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -178.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.664 ' HA ' ' NE2' ' A' ' 25' ' ' HIS . 21.5 t70 -143.99 64.4 1.32 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.362 -0.836 . . . . 0.0 110.427 -178.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.601 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 44.0 m -79.37 142.36 58.34 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.431 -0.793 . . . . 0.0 111.03 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.47 -19.27 15.02 Favored 'Trans proline' 0 C--N 1.317 -1.119 0 O-C-N 123.421 1.222 . . . . 0.0 111.031 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.44 9.86 42.17 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.228 -0.92 . . . . 0.0 112.109 -178.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.465 ' HB3' ' ND1' ' A' ' 25' ' ' HIS . 0.5 OUTLIER -72.06 154.09 41.33 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.912 -1.117 . . . . 0.0 108.776 178.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.403 ' HA2' ' CZ ' ' A' ' 74' ' ' ARG . . . 78.61 10.02 86.55 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 96.3 m -99.88 139.96 34.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.306 -1.114 . . . . 0.0 109.706 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.4 m -80.12 143.59 33.78 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 121.299 0.571 . . . . 0.0 111.063 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 70.1 m95 -145.39 133.64 21.68 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.443 -0.785 . . . . 0.0 109.871 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -108.53 141.55 40.26 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.181 -0.949 . . . . 0.0 110.571 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.433 HG13 HG11 ' A' ' 105' ' ' VAL . 62.4 t -112.95 127.89 69.97 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 CA-C-O 121.385 0.612 . . . . 0.0 110.977 -179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 m -120.03 143.5 48.05 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.702 -0.624 . . . . 0.0 110.254 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.468 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 9.5 pt -120.74 164.15 24.97 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.171 -0.955 . . . . 0.0 111.218 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.468 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.2 Cg_endo -61.49 -26.24 80.71 Favored 'Trans proline' 0 N--CA 1.498 1.794 0 C-N-CA 121.682 1.588 . . . . 0.0 113.067 -178.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -63.42 -35.67 81.18 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.227 -0.921 . . . . 0.0 109.761 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 112.59 63.17 0.46 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.423 ' O ' HD11 ' A' ' 93' ' ' LEU . 40.4 t-20 -164.42 157.23 17.15 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.774 -0.839 . . . . 0.0 109.209 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 73.9 p -154.74 159.74 40.88 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 122.025 0.917 . . . . 0.0 111.515 -179.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.482 HD12 HD11 ' A' ' 73' ' ' ILE . 21.7 pt -133.61 164.27 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -103.61 125.0 49.86 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 118.319 -1.353 . . . . 0.0 109.895 -178.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.482 HD11 HD12 ' A' ' 71' ' ' ILE . 48.4 mm -119.78 123.54 71.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 O-C-N 121.621 -0.674 . . . . 0.0 109.911 -178.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.403 ' CZ ' ' HA2' ' A' ' 58' ' ' GLY . 0.0 OUTLIER -93.69 133.66 36.81 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.406 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -54.8 144.77 30.28 Favored Glycine 0 N--CA 1.496 2.648 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 -178.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.698 HG12 ' O ' ' A' ' 44' ' ' GLY . 13.4 p -168.35 -28.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.802 -0.822 . . . . 0.0 111.138 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.896 ' OD1' HG23 ' A' ' 18' ' ' VAL . 5.4 m-20 -126.07 170.0 12.2 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.721 -1.237 . . . . 0.0 110.258 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.406 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 47.5 t -101.4 151.92 21.34 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.7 -0.625 . . . . 0.0 110.686 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -133.73 144.32 16.24 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.084 -1.207 . . . . 0.0 110.084 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 -60.66 -31.45 70.68 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.78 -0.835 . . . . 0.0 109.978 178.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 171.65 80.81 0.05 OUTLIER Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.564 -1.414 . . . . 0.0 109.564 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.72 -176.94 29.07 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.802 ' CD2' HG22 ' A' ' 46' ' ' ILE . 57.7 m-85 -113.17 130.96 56.05 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.438 -1.036 . . . . 0.0 109.58 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.409 ' HA ' ' O ' ' A' ' 4' ' ' SER . 36.8 t-20 -120.88 130.96 54.13 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.412 HG11 HG13 ' A' ' 73' ' ' ILE . 34.7 m -130.22 171.8 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 O-C-N 121.175 -0.953 . . . . 0.0 112.258 -177.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 21.2 m-20 -54.07 155.83 6.04 Favored Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.588 -0.695 . . . . 0.0 110.321 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.86 -18.12 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.286 0 O-C-N 123.409 1.215 . . . . 0.0 110.761 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.6 m -80.82 -39.76 26.09 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.965 -1.085 . . . . 0.0 109.208 178.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -67.37 -39.08 85.65 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.478 ' CE1' ' HA ' ' A' ' 97' ' ' THR . 25.3 t80 -59.99 -50.0 75.44 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.634 -0.666 . . . . 0.0 110.762 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.773 HG23 ' HA ' ' A' ' 96' ' ' SER . 94.4 m -59.98 -38.95 84.02 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.58 -0.7 . . . . 0.0 111.103 -178.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -64.63 -40.02 94.74 Favored 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.962 -0.695 . . . . 0.0 111.562 -179.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.423 HD11 ' O ' ' A' ' 69' ' ' ASN . 59.8 tp -69.03 -42.54 76.22 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.637 -0.665 . . . . 0.0 111.9 -178.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 49.0 t -100.25 -9.98 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.302 0 O-C-N 121.228 -0.92 . . . . 0.0 111.927 -178.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 99.5 -29.27 12.3 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.448 -1.861 . . . . 0.0 108.448 -178.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.773 ' HA ' HG23 ' A' ' 91' ' ' THR . 97.1 p -155.62 159.84 39.96 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.478 ' HA ' ' CE1' ' A' ' 90' ' ' PHE . 2.8 t -109.06 24.69 12.76 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.113 -0.992 . . . . 0.0 111.086 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -73.82 -22.83 59.66 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.555 -0.715 . . . . 0.0 111.067 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.95 -44.8 94.18 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.365 -0.834 . . . . 0.0 110.971 -178.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.15 -68.07 0.53 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 37.7 ttm180 -140.25 135.52 32.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.946 . . . . 0.0 110.383 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 68.6 t -119.57 119.7 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -0.824 . . . . 0.0 110.155 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 27.9 p-10 -87.95 175.07 7.95 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-O 121.563 0.697 . . . . 0.0 111.181 -179.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.3 t30 59.98 40.86 18.34 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.705 -0.622 . . . . 0.0 110.943 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.512 HG11 HG21 ' A' ' 3' ' ' ILE . 91.3 t -93.86 121.38 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.992 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -79.91 139.77 36.97 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 119.353 -0.939 . . . . 0.0 109.299 179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.45 ' C ' HG13 ' A' ' 108' ' ' VAL . 41.1 p90 -136.67 142.22 43.17 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.864 -0.523 . . . . 0.0 110.517 -179.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.45 HG13 ' C ' ' A' ' 107' ' ' TYR . 34.8 m -148.33 150.35 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.616 -0.678 . . . . 0.0 110.581 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 61.2 tt0 -90.19 138.81 31.22 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.542 -0.724 . . . . 0.0 110.516 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.49 177.46 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.591 -0.693 . . . . 0.0 110.257 179.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.91 142.96 52.7 Favored 'General case' 0 N--CA 1.496 1.84 0 CA-C-O 121.582 0.706 . . . . 0.0 110.952 -178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.535 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.5 tt -60.11 -38.42 82.96 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.814 -0.554 . . . . 0.0 110.769 179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 83.3 p -54.31 -37.01 64.33 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.561 -0.712 . . . . 0.0 111.359 -177.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -70.07 -19.94 63.25 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.432 -0.793 . . . . 0.0 110.506 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 28.2 m -73.63 -52.17 14.29 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.483 HD11 HD21 ' A' ' 112' ' ' LEU . 86.5 mt -70.0 -39.99 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.523 -179.315 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -69.67 -40.0 76.69 Favored 'General case' 0 N--CA 1.495 1.798 0 C-N-CA 120.025 -0.67 . . . . 0.0 110.108 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -69.27 -53.02 19.58 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -44.52 94.52 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.523 -0.987 . . . . 0.0 110.582 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.216 -179.901 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.089 0.471 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.2 m -113.28 140.48 47.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.742 -0.599 . . . . 0.0 109.958 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.774 HG23 HG21 ' A' ' 105' ' ' VAL . 38.5 pt -104.61 145.41 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.649 -0.657 . . . . 0.0 110.055 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 1.5 m -145.72 -171.6 3.72 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.448 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 51.7 p90 -146.16 150.0 35.04 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 119.047 -1.061 . . . . 0.0 111.41 179.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -129.01 146.17 59.62 Favored Pre-proline 0 N--CA 1.493 1.7 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -81.07 -8.05 13.09 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.264 1.139 . . . . 0.0 112.449 -178.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.505 HG13 ' N ' ' A' ' 9' ' ' TYR . 37.5 pt -67.92 -40.09 82.83 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 120.889 -1.132 . . . . 0.0 110.789 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.66 ' HA ' HD22 ' A' ' 13' ' ' LEU . 52.3 m-85 -72.77 67.71 0.82 Allowed 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 122.9 1.333 . . . . 0.0 111.443 -178.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.1 171.1 7.49 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.065 176.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.94 -33.92 71.15 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 113.62 0.97 . . . . 0.0 113.62 -175.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -91.09 11.56 22.74 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.599 -1.313 . . . . 0.0 112.354 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.66 HD22 ' HA ' ' A' ' 9' ' ' TYR . 35.3 tp -70.02 123.37 21.38 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.289 -0.882 . . . . 0.0 109.844 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.26 136.12 49.59 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.642 0.734 . . . . 0.0 110.078 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.788 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.8 mmm -68.81 -16.68 63.85 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.979 -0.451 . . . . 0.0 111.869 -178.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.77 -14.67 70.44 Favored Glycine 0 N--CA 1.495 2.586 0 O-C-N 120.917 -1.115 . . . . 0.0 111.309 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 10.2 t -91.05 -8.01 50.22 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.129 -1.218 . . . . 0.0 112.051 -178.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 15' ' ' MET . 8.6 p -96.01 167.82 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.107 -0.996 . . . . 0.0 110.26 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.784 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -59.39 -44.49 92.76 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.51 -0.744 . . . . 0.0 109.988 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.4 m -81.76 81.75 7.68 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.522 -0.736 . . . . 0.0 109.112 178.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.5 m -101.29 -79.57 0.51 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.619 -0.676 . . . . 0.0 112.594 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -131.6 10.18 4.73 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.282 -0.886 . . . . 0.0 112.723 -178.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.449 ' HA2' ' CH2' ' A' ' 52' ' ' TRP . . . -73.61 -148.27 1.17 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -64.7 -39.92 94.48 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.764 -0.845 . . . . 0.0 110.865 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.461 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 69.1 m-70 -101.16 15.87 27.31 Favored 'General case' 0 N--CA 1.5 2.057 0 O-C-N 121.331 -0.856 . . . . 0.0 111.231 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.69 131.32 51.99 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.592 HD22 HG21 ' A' ' 37' ' ' VAL . 83.2 mt -97.46 -4.83 37.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.903 -0.763 . . . . 0.0 110.466 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 38.3 tpp -60.87 -34.7 75.02 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.331 -0.855 . . . . 0.0 110.635 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.69 -76.75 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.48 -0.762 . . . . 0.0 111.96 -177.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . 0.415 ' NE2' ' CE2' ' A' ' 31' ' ' TYR . 12.7 tt0 -69.91 -39.99 75.86 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.433 -0.792 . . . . 0.0 110.367 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.522 ' CD2' HG23 ' A' ' 37' ' ' VAL . 58.0 m-85 -120.99 93.3 48.84 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.648 -0.658 . . . . 0.0 109.981 -179.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.07 -10.65 27.86 Favored 'Trans proline' 0 C--N 1.318 -1.069 0 O-C-N 123.413 1.217 . . . . 0.0 111.132 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 23.3 p -126.83 154.04 44.86 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.326 -0.859 . . . . 0.0 110.269 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 1.003 HD11 HG21 ' A' ' 43' ' ' VAL . 40.1 tp -78.09 116.03 18.25 Favored 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 154.51 34.0 0.03 OUTLIER Glycine 0 N--CA 1.491 2.331 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.76 -48.04 0.07 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.281 -1.129 . . . . 0.0 110.613 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.592 HG21 HD22 ' A' ' 27' ' ' LEU . 2.2 t -61.33 -57.78 23.21 Favored Pre-proline 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 108.591 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.493 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 54.7 Cg_endo -78.8 -28.4 4.13 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 O-C-N 123.307 1.161 . . . . 0.0 109.485 178.179 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.411 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.83 -61.13 0.65 Allowed Glycine 0 N--CA 1.487 2.054 0 N-CA-C 107.503 -2.239 . . . . 0.0 107.503 -178.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.629 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.4 t80 163.24 -54.78 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.605 0 C-N-CA 123.414 0.685 . . . . 0.0 110.042 177.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 54.2 Cg_endo -102.38 15.28 0.3 Allowed 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 121.563 1.509 . . . . 0.0 111.448 -178.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 34.8 m120 -125.37 39.9 3.86 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.358 -0.839 . . . . 0.0 109.244 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.003 HG21 HD11 ' A' ' 34' ' ' LEU . 9.4 p -123.66 147.52 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 CA-C-O 121.674 0.749 . . . . 0.0 110.264 -178.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.467 ' HA3' ' HA ' ' A' ' 85' ' ' VAL . . . -174.48 175.97 46.79 Favored Glycine 0 N--CA 1.485 1.953 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.94 149.41 37.82 Favored Glycine 0 N--CA 1.484 1.839 0 N-CA-C 107.172 -2.371 . . . . 0.0 107.172 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.466 HG13 HG12 ' A' ' 49' ' ' ILE . 1.1 pp -142.37 139.19 17.29 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.545 -0.974 . . . . 0.0 108.847 -179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -58.89 -10.51 9.91 Favored 'Trans proline' 0 N--CA 1.505 2.202 0 C-N-CA 122.046 1.831 . . . . 0.0 115.261 -177.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.428 ' H ' HD12 ' A' ' 46' ' ' ILE . 84.3 m-20 -96.19 30.63 2.41 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 120.529 -1.357 . . . . 0.0 111.899 -178.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.571 HG23 ' HB2' ' A' ' 54' ' ' SER . 50.8 mm -119.99 125.99 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.82 -44.62 15.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.551 -0.718 . . . . 0.0 111.78 -178.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.784 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 172.11 -130.6 1.96 Allowed Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.406 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.449 ' CH2' ' HA2' ' A' ' 23' ' ' GLY . 5.5 t90 -40.21 -30.04 0.09 Allowed 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 -177.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -158.97 72.98 0.59 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 120.689 -1.257 . . . . 0.0 110.83 179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.571 ' HB2' HG23 ' A' ' 49' ' ' ILE . 4.0 t -54.53 140.32 57.19 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.671 -0.643 . . . . 0.0 111.317 -178.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.461 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -72.81 -20.42 22.61 Favored 'Trans proline' 0 C--N 1.319 -1.006 0 O-C-N 123.412 1.217 . . . . 0.0 110.558 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 59' ' ' THR . 18.9 m -103.93 14.85 29.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.347 -0.846 . . . . 0.0 111.294 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.412 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 5.0 t -67.74 144.68 55.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.117 -0.99 . . . . 0.0 110.383 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.13 8.31 82.06 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . 0.477 HG23 ' O ' ' A' ' 56' ' ' SER . 25.8 p -80.6 159.71 25.33 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.536 ' SG ' HG23 ' A' ' 110' ' ' VAL . 41.9 t -110.79 137.54 48.32 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.789 -178.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 81.9 m95 -142.96 155.88 44.77 Favored 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.12 -0.988 . . . . 0.0 111.394 179.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 68.7 tttt -112.18 132.25 55.0 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 177.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.05 129.9 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.557 -0.715 . . . . 0.0 109.723 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.3 m -120.68 142.18 49.71 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.749 -0.595 . . . . 0.0 111.362 -178.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.46 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 48.0 pt -119.74 164.37 22.4 Favored Pre-proline 0 N--CA 1.499 2.022 0 O-C-N 121.496 -0.753 . . . . 0.0 110.209 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -62.35 -26.02 76.72 Favored 'Trans proline' 0 N--CA 1.496 1.664 0 C-N-CA 121.174 1.25 . . . . 0.0 112.891 -178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.4 t-20 -64.76 -39.96 94.48 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.218 -0.926 . . . . 0.0 109.907 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 118.1 60.75 0.29 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -160.45 153.51 21.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.603 -0.939 . . . . 0.0 109.339 178.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.45 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 88.0 p -151.71 159.68 43.89 Favored 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 122.12 0.962 . . . . 0.0 112.149 -179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.462 HG12 HD13 ' A' ' 93' ' ' LEU . 43.8 pt -139.91 164.13 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 179.268 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -105.27 127.18 52.81 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 118.86 -1.136 . . . . 0.0 109.784 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -115.89 130.03 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.627 -0.671 . . . . 0.0 110.134 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.513 ' HD3' HG12 ' A' ' 37' ' ' VAL . 51.4 ttt180 -100.67 136.91 39.79 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.407 ' HA2' HG12 ' A' ' 46' ' ' ILE . . . -59.64 149.71 39.8 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.947 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.727 HG11 ' CG2' ' A' ' 43' ' ' VAL . 7.0 p -167.47 -35.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.809 -0.818 . . . . 0.0 110.635 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.57 ' OD2' HG13 ' A' ' 76' ' ' VAL . 0.0 OUTLIER -129.89 174.48 9.7 Favored 'General case' 0 N--CA 1.508 2.435 0 O-C-N 120.748 -1.22 . . . . 0.0 108.948 179.465 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 36.9 t -98.59 143.14 29.31 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.357 -0.84 . . . . 0.0 110.535 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -107.89 140.29 15.38 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 7.0 ptm180 -81.96 58.2 3.8 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.724 -0.868 . . . . 0.0 111.589 -179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.99 58.17 1.62 Allowed Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.21 151.15 5.42 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.791 -1.195 . . . . 0.0 110.386 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -73.68 145.18 45.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.866 -0.785 . . . . 0.0 110.963 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.455 ' HA ' ' O ' ' A' ' 4' ' ' SER . 19.7 t-20 -139.55 130.69 26.55 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.423 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.467 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 34.1 m -132.28 172.5 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.057 -1.027 . . . . 0.0 112.202 -178.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.7 m-20 -54.69 150.8 16.81 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.275 -0.891 . . . . 0.0 109.823 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -63.43 -18.3 63.96 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 123.321 1.169 . . . . 0.0 110.656 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 86.1 m -78.73 -40.01 34.7 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.934 -1.104 . . . . 0.0 109.376 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -68.34 -39.11 82.0 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.509 -0.744 . . . . 0.0 109.107 179.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -59.99 -49.93 75.75 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.767 -0.583 . . . . 0.0 110.704 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 91.8 m -60.05 -37.37 79.63 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.406 -0.809 . . . . 0.0 110.623 -178.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -70.0 -39.96 75.58 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.043 -179.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.462 HD13 HG12 ' A' ' 71' ' ' ILE . 52.7 tp -70.01 -44.25 69.73 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.569 -0.707 . . . . 0.0 111.428 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 63.0 t -96.37 -39.92 9.93 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.132 0 O-C-N 121.304 -0.873 . . . . 0.0 111.561 -177.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 124.53 -29.43 4.99 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 82.7 p -152.66 160.65 43.16 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.461 -1.023 . . . . 0.0 110.457 179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 72.7 p -94.62 8.17 43.25 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.532 -0.73 . . . . 0.0 110.857 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -69.15 -36.07 77.02 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.42 -0.8 . . . . 0.0 110.677 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.04 -39.75 87.0 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.525 -0.735 . . . . 0.0 110.284 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.38 -63.54 3.64 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 21.3 ptt180 -150.8 157.59 43.12 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.673 -0.898 . . . . 0.0 110.745 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 105' ' ' VAL . 62.2 t -128.09 122.26 57.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.553 -0.717 . . . . 0.0 110.223 179.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -82.87 169.12 16.43 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.603 -0.686 . . . . 0.0 110.961 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t30 60.01 43.22 14.84 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.62 -0.675 . . . . 0.0 111.306 179.315 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.774 HG21 HG23 ' A' ' 3' ' ' ILE . 63.7 t -87.21 130.02 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 C-N-CA 120.06 -0.656 . . . . 0.0 109.966 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -87.19 139.43 30.57 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.804 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -139.9 144.32 37.1 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.914 -0.491 . . . . 0.0 111.173 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.6 m -144.95 143.2 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.019 0 O-C-N 121.529 -0.732 . . . . 0.0 110.734 179.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 66.1 tt0 -75.72 134.33 40.54 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.603 -0.685 . . . . 0.0 110.009 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.536 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.9 m -131.34 172.7 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.554 -0.716 . . . . 0.0 110.237 179.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -60.11 146.07 44.47 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.513 -0.742 . . . . 0.0 110.986 -179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.695 HD21 HD11 ' A' ' 116' ' ' ILE . 10.1 tt -60.96 -37.22 81.64 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.621 -0.674 . . . . 0.0 110.796 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.8 m -55.23 -40.07 70.44 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.51 -0.744 . . . . 0.0 110.221 -178.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -59.98 -37.41 79.55 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.731 -0.606 . . . . 0.0 110.317 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -63.32 -46.65 85.67 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.369 -0.832 . . . . 0.0 110.116 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.695 HD11 HD21 ' A' ' 112' ' ' LEU . 88.0 mt -70.02 -40.01 78.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.554 -0.717 . . . . 0.0 110.738 -178.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -66.88 -40.06 87.67 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.468 -0.77 . . . . 0.0 110.498 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -68.85 -48.08 51.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -62.13 -39.97 94.34 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.598 -0.942 . . . . 0.0 110.603 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 . . . . . 0 N--CA 1.493 1.688 0 CA-C-O 118.047 -0.977 . . . . 0.0 110.265 -179.894 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.7 m . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.205 0.526 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t -111.18 137.72 48.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.628 -0.67 . . . . 0.0 109.3 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.642 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.1 pt -113.98 147.7 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.729 -0.607 . . . . 0.0 111.018 -179.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.06 -170.09 3.34 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -141.82 148.1 38.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.41 -0.806 . . . . 0.0 110.337 178.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -127.05 148.61 66.52 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.46 -0.775 . . . . 0.0 109.825 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -82.57 -7.43 11.63 Favored 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.391 1.206 . . . . 0.0 112.367 -179.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.482 HG13 ' N ' ' A' ' 9' ' ' TYR . 27.4 pt -72.93 -42.29 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.139 0 O-C-N 120.933 -1.104 . . . . 0.0 110.885 -179.025 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.482 ' N ' HG13 ' A' ' 8' ' ' ILE . 31.9 m-85 -72.29 67.18 0.68 Allowed 'General case' 0 N--CA 1.496 1.852 0 CA-C-O 122.651 1.215 . . . . 0.0 111.049 -178.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.55 171.05 7.58 Favored 'General case' 0 N--CA 1.491 1.584 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.327 176.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.486 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -60.04 -34.16 73.02 Favored 'General case' 0 N--CA 1.497 1.894 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -175.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -90.05 10.62 23.51 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.416 -1.314 . . . . 0.0 112.136 -177.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.45 HD22 ' HA ' ' A' ' 9' ' ' TYR . 53.4 tp -71.02 126.05 28.53 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 178.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.1 t -69.95 136.02 50.07 Favored 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.791 0.805 . . . . 0.0 110.454 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.741 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.2 mmm -66.43 -19.07 65.7 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.436 -179.189 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.27 -14.06 63.48 Favored Glycine 0 N--CA 1.493 2.456 0 O-C-N 121.044 -1.035 . . . . 0.0 110.776 -179.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 50.9 m -93.16 -14.59 26.97 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.226 -1.161 . . . . 0.0 111.796 -178.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.828 HG23 ' OD2' ' A' ' 77' ' ' ASP . 7.2 p -90.04 160.04 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 120.996 -1.065 . . . . 0.0 110.708 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.725 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.59 -42.63 83.56 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.699 -0.626 . . . . 0.0 110.565 -179.335 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.0 m -81.64 72.89 8.7 Favored 'General case' 0 N--CA 1.494 1.771 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.1 p -101.78 -76.59 0.57 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.705 -0.622 . . . . 0.0 110.628 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 -127.27 168.87 14.16 Favored 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.108 -179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.35 -154.81 16.49 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.52 -2.232 . . . . 0.0 107.52 -177.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -70.2 -39.92 74.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.292 -1.122 . . . . 0.0 110.271 179.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.433 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 58.8 m-70 -94.09 0.71 56.04 Favored 'General case' 0 N--CA 1.502 2.169 0 O-C-N 121.454 -0.779 . . . . 0.0 111.194 -179.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -53.59 127.65 37.64 Favored Glycine 0 N--CA 1.495 2.611 0 O-C-N 120.964 -1.085 . . . . 0.0 110.423 -179.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.553 HD13 HG11 ' A' ' 37' ' ' VAL . 84.5 mt -100.04 -5.19 28.44 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 122.012 -0.699 . . . . 0.0 110.072 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 58.2 ttm -63.04 -37.72 88.31 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.28 -0.887 . . . . 0.0 109.764 179.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.92 -73.45 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.611 -0.681 . . . . 0.0 111.506 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -69.94 -40.05 75.72 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.157 179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CG ' HG23 ' A' ' 37' ' ' VAL . 35.6 m-85 -120.36 89.89 44.44 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.864 -0.523 . . . . 0.0 109.801 -178.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.07 -10.01 25.38 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 O-C-N 123.196 1.103 . . . . 0.0 111.049 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 31.0 m -130.01 142.13 50.66 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.231 -0.918 . . . . 0.0 110.366 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.927 HD11 HG21 ' A' ' 43' ' ' VAL . 35.4 tp -69.94 119.25 13.87 Favored 'General case' 0 N--CA 1.498 1.925 0 O-C-N 121.642 -0.661 . . . . 0.0 110.405 -179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 150.76 32.6 0.04 OUTLIER Glycine 0 N--CA 1.497 2.746 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.985 179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -156.95 -44.95 0.07 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.228 -1.16 . . . . 0.0 110.096 179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.553 HG11 HD13 ' A' ' 27' ' ' LEU . 2.7 t -63.62 -59.03 12.75 Favored Pre-proline 0 N--CA 1.496 1.875 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 178.552 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.476 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 53.5 Cg_endo -76.82 -29.22 5.63 Favored 'Trans proline' 0 N--CA 1.487 1.109 0 O-C-N 123.271 1.143 . . . . 0.0 109.55 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 127.63 -61.92 0.64 Allowed Glycine 0 N--CA 1.488 2.129 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 -178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.635 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 2.9 t80 164.69 -54.74 0.0 OUTLIER Pre-proline 0 N--CA 1.509 2.503 0 C-N-CA 123.368 0.667 . . . . 0.0 109.885 177.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.716 ' O ' ' HB2' ' A' ' 89' ' ' ALA . 55.2 Cg_endo -102.21 11.81 0.39 Allowed 'Trans proline' 0 C--N 1.325 -0.702 0 C-N-CA 121.473 1.448 . . . . 0.0 111.419 -178.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 29.3 m120 -117.61 31.16 6.87 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.244 -0.91 . . . . 0.0 110.059 -178.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.963 ' CG2' HG11 ' A' ' 76' ' ' VAL . 15.0 p -110.46 139.92 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.561 0.696 . . . . 0.0 110.943 -179.306 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.504 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.5 173.79 42.59 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.488 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -94.32 163.72 25.38 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.787 HG22 ' CD2' ' A' ' 83' ' ' PHE . 1.0 OUTLIER -154.27 162.53 26.7 Favored Pre-proline 0 N--CA 1.498 1.946 0 O-C-N 121.806 -0.82 . . . . 0.0 109.888 179.015 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -67.33 -16.94 49.23 Favored 'Trans proline' 0 N--CA 1.5 1.902 0 C-N-CA 121.502 1.468 . . . . 0.0 113.95 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.546 ' H ' HD12 ' A' ' 46' ' ' ILE . 94.4 m-20 -89.39 15.83 8.53 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.541 -1.349 . . . . 0.0 113.025 -177.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.656 HG23 ' CB ' ' A' ' 54' ' ' SER . 43.0 mm -108.02 122.63 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.177 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.72 -45.47 29.25 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.305 -0.872 . . . . 0.0 111.664 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.725 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 166.3 -127.81 1.66 Allowed Glycine 0 N--CA 1.486 2.009 0 C-N-CA 118.983 -1.58 . . . . 0.0 110.95 -179.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 49.1 t90 -48.92 -26.03 2.25 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.897 -0.767 . . . . 0.0 112.841 -178.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -147.27 63.13 1.16 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.169 -0.957 . . . . 0.0 111.379 -179.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.656 ' CB ' HG23 ' A' ' 49' ' ' ILE . 4.5 p -63.68 141.72 97.96 Favored Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.359 -0.838 . . . . 0.0 110.87 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.433 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 50.5 Cg_endo -80.69 -21.74 6.98 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 O-C-N 123.41 1.216 . . . . 0.0 111.599 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 16.6 m -95.11 11.63 31.5 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.357 -0.84 . . . . 0.0 111.183 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 5.1 t -72.14 146.29 47.54 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.209 -0.932 . . . . 0.0 110.304 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.78 22.83 52.13 Favored Glycine 0 N--CA 1.495 2.568 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.098 178.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 27.1 m -109.29 170.65 7.92 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.313 -1.11 . . . . 0.0 109.009 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 2.1 m -118.96 148.2 43.22 Favored 'General case' 0 N--CA 1.51 2.556 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -177.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.459 ' CZ3' ' N ' ' A' ' 109' ' ' GLN . 67.9 m95 -144.34 149.67 36.55 Favored 'General case' 0 N--CA 1.51 2.565 0 O-C-N 121.116 -0.99 . . . . 0.0 110.219 175.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 26.3 ttpt -101.46 131.2 47.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 176.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.444 ' O ' ' HA ' ' A' ' 70' ' ' SER . 62.8 t -108.61 124.47 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.64 -178.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 94.3 m -120.03 130.03 54.52 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-O 121.189 0.519 . . . . 0.0 111.42 -178.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.483 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.4 pt -106.85 166.15 11.63 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 121.789 -0.569 . . . . 0.0 110.492 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 38.7 Cg_endo -63.92 -27.56 66.77 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 O-C-N 123.347 1.183 . . . . 0.0 112.605 -178.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -64.3 -39.92 94.89 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.169 -0.957 . . . . 0.0 109.734 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.46 58.3 0.32 Allowed Glycine 0 N--CA 1.491 2.361 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 179.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.468 ' HB2' HD11 ' A' ' 65' ' ' ILE . 85.1 m-20 -150.72 147.32 27.19 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 178.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.444 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 49.1 m -147.25 152.36 38.19 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.859 -1.136 . . . . 0.0 112.652 -179.467 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HB2' ' A' ' 93' ' ' LEU . 37.7 pt -140.13 161.66 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.29 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -101.31 129.76 47.34 Favored 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.093 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.0 mm -116.58 129.97 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 109.782 -179.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.416 ' HD3' HG12 ' A' ' 37' ' ' VAL . 58.6 ttt180 -101.32 133.31 46.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.965 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -52.52 149.59 10.06 Favored Glycine 0 N--CA 1.498 2.795 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 -178.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.963 HG11 ' CG2' ' A' ' 43' ' ' VAL . 14.9 p -174.48 -28.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.652 -0.91 . . . . 0.0 111.121 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.828 ' OD2' HG23 ' A' ' 18' ' ' VAL . 5.2 m-20 -129.75 167.47 18.02 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.717 -1.239 . . . . 0.0 109.422 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 77.7 p -97.84 155.89 16.84 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.364 -0.835 . . . . 0.0 110.771 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -131.94 139.52 11.01 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 80.3 mtt85 -61.04 -39.9 91.56 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.837 -0.802 . . . . 0.0 110.209 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -175.61 73.53 0.08 OUTLIER Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 155.22 -163.34 31.45 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.89 -1.148 . . . . 0.0 110.298 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.787 ' CD2' HG22 ' A' ' 46' ' ' ILE . 39.8 m-85 -125.63 121.56 33.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.919 -0.753 . . . . 0.0 109.113 179.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -116.08 130.24 56.71 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.504 HG12 ' HA3' ' A' ' 44' ' ' GLY . 26.9 m -129.18 173.47 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.275 -0.891 . . . . 0.0 111.279 -178.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.9 m-20 -56.53 158.2 8.55 Favored Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.544 -0.722 . . . . 0.0 110.021 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -67.83 -28.66 36.13 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.453 1.238 . . . . 0.0 111.06 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.2 m -70.03 -39.96 75.44 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.993 -1.067 . . . . 0.0 109.26 179.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.716 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.87 -41.31 87.47 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.645 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 56.4 t80 -60.64 -50.0 75.27 Favored 'General case' 0 N--CA 1.498 1.959 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.804 179.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 94.4 m -60.18 -40.04 88.58 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.515 -0.741 . . . . 0.0 110.839 -178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.27 -39.56 86.06 Favored 'General case' 0 N--CA 1.495 1.797 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.207 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.463 ' HB2' HD13 ' A' ' 71' ' ' ILE . 65.5 tp -69.95 -41.66 74.25 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.835 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -98.89 -36.65 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 O-C-N 121.255 -0.903 . . . . 0.0 111.722 -177.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.04 -27.43 6.75 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 79.8 p -153.07 160.46 42.95 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.552 -0.97 . . . . 0.0 109.81 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 60.9 p -90.87 6.82 42.92 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.366 -0.834 . . . . 0.0 110.793 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 99.7 mt-10 -69.98 -25.91 63.84 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.31 -0.868 . . . . 0.0 110.87 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.17 77.03 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.466 -0.771 . . . . 0.0 110.949 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 81.94 -80.46 1.76 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 19.1 ttm180 -137.07 139.94 41.66 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.677 -0.896 . . . . 0.0 110.119 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.24 119.93 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.523 -0.736 . . . . 0.0 110.231 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -90.43 169.7 10.84 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-O 121.754 0.787 . . . . 0.0 111.176 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 28.8 t30 59.95 40.05 19.4 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.695 -0.628 . . . . 0.0 111.497 179.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.512 HG21 HG12 ' A' ' 3' ' ' ILE . 81.5 t -84.41 126.98 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.709 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.6 p-10 -92.58 152.26 19.7 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.13 -1.028 . . . . 0.0 108.87 179.179 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -146.82 150.0 34.43 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.631 -0.668 . . . . 0.0 112.074 -177.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.0 m -141.32 134.73 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.745 -0.597 . . . . 0.0 110.097 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.459 ' N ' ' CZ3' ' A' ' 61' ' ' TRP . 55.6 tt0 -72.46 141.61 48.6 Favored 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.524 0.678 . . . . 0.0 110.979 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 30.0 m -132.27 172.07 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -60.0 143.98 50.42 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.299 -0.876 . . . . 0.0 110.453 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.54 HD21 HD11 ' A' ' 116' ' ' ILE . 8.4 tt -60.03 -39.97 87.74 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.385 -0.822 . . . . 0.0 110.226 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.3 t -51.29 -33.98 31.08 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.615 -0.678 . . . . 0.0 111.28 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -65.38 -39.99 92.94 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.482 -0.761 . . . . 0.0 110.935 -179.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 86.8 m -60.42 -47.76 84.71 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.393 -0.817 . . . . 0.0 110.243 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 112' ' ' LEU . 88.1 mt -69.96 -40.02 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.955 -0.466 . . . . 0.0 110.772 -179.118 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -66.48 -39.99 89.08 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.498 -0.751 . . . . 0.0 110.866 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -78.68 -60.06 2.7 Favored Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.159 -178.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.0 -42.13 93.59 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.418 -1.048 . . . . 0.0 110.738 -178.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.402 -179.784 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 N--CA 1.492 1.649 0 CA-C-O 120.992 0.425 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.5 p -112.95 145.86 40.04 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.686 -0.634 . . . . 0.0 110.085 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 83' ' ' PHE . 45.1 pt -120.01 149.96 22.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 O-C-N 121.626 -0.671 . . . . 0.0 110.743 -179.529 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.415 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.7 OUTLIER -145.62 -172.37 3.88 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.172 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -140.96 145.44 36.01 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.325 -0.859 . . . . 0.0 110.199 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -137.73 149.48 64.83 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.409 -0.807 . . . . 0.0 110.005 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.94 48.25 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.074 0 O-C-N 123.432 1.227 . . . . 0.0 110.602 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 9' ' ' TYR . 7.6 tp -118.79 -6.79 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.527 -0.733 . . . . 0.0 111.052 -179.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CD2' HG23 ' A' ' 8' ' ' ILE . 29.2 m-85 -122.69 70.94 1.01 Allowed 'General case' 0 N--CA 1.493 1.689 0 CA-C-O 122.62 1.2 . . . . 0.0 110.182 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -101.54 171.45 7.56 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 114.597 -1.183 . . . . 0.0 107.921 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.646 ' HB2' ' HE1' ' A' ' 40' ' ' PHE . . . -56.56 -28.71 60.8 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -175.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -91.37 12.26 21.07 Favored 'General case' 0 N--CA 1.498 1.966 0 C-N-CA 118.323 -1.351 . . . . 0.0 112.236 -177.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 14' ' ' SER . 0.4 OUTLIER -69.55 116.62 10.17 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.205 -0.934 . . . . 0.0 109.817 179.779 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.424 ' N ' HD13 ' A' ' 13' ' ' LEU . 47.5 t -65.88 137.74 57.39 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.777 -0.769 . . . . 0.0 109.837 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.529 ' O ' HG12 ' A' ' 18' ' ' VAL . 93.9 mmm -67.77 -16.37 64.08 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.87 -0.519 . . . . 0.0 111.715 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.14 -13.82 82.4 Favored Glycine 0 N--CA 1.495 2.607 0 O-C-N 120.849 -1.157 . . . . 0.0 110.626 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.4 p -94.98 -17.68 21.74 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.19 -1.183 . . . . 0.0 111.708 -178.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.635 HG21 HG22 ' A' ' 76' ' ' VAL . 8.2 p -87.21 159.16 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.264 -0.897 . . . . 0.0 109.186 -179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.517 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -53.44 -40.0 64.85 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.198 -0.939 . . . . 0.0 110.301 -179.556 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 62.8 m -78.88 82.61 5.06 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.8 m -90.45 -80.73 0.32 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.048 -1.032 . . . . 0.0 112.875 -177.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.461 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 24.5 p-10 -154.88 20.55 0.45 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.734 -1.229 . . . . 0.0 112.535 -179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -65.22 -144.91 0.04 OUTLIER Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -69.63 -39.93 76.84 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.821 -0.811 . . . . 0.0 109.808 178.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.529 ' CD2' ' HA ' ' A' ' 53' ' ' ASP . 2.3 p80 -95.57 4.57 53.02 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.468 -0.77 . . . . 0.0 110.098 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -56.76 140.75 43.55 Favored Glycine 0 N--CA 1.493 2.467 0 O-C-N 121.183 -0.948 . . . . 0.0 111.174 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.574 HD13 HG11 ' A' ' 37' ' ' VAL . 91.2 mt -104.34 -0.04 28.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 122.049 -0.677 . . . . 0.0 110.389 178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 60.7 ttm -60.05 -35.06 74.32 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 110.521 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -52.51 -73.22 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.458 -0.776 . . . . 0.0 111.398 -177.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -70.36 -39.99 74.29 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.372 -0.83 . . . . 0.0 110.121 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.61 ' CG ' HG23 ' A' ' 37' ' ' VAL . 54.1 m-85 -116.97 86.47 19.8 Favored Pre-proline 0 N--CA 1.492 1.67 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -178.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -70.31 -26.93 24.45 Favored 'Trans proline' 0 C--N 1.317 -1.101 0 O-C-N 123.39 1.205 . . . . 0.0 110.955 -179.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 15.1 m -116.89 161.26 19.61 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.359 -0.838 . . . . 0.0 110.41 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 43' ' ' VAL . 42.3 tp -86.59 114.92 23.71 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.769 -0.582 . . . . 0.0 111.292 -178.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 156.49 37.09 0.02 OUTLIER Glycine 0 N--CA 1.497 2.734 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -162.2 -48.26 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.376 -1.073 . . . . 0.0 110.578 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.61 HG23 ' CG ' ' A' ' 31' ' ' TYR . 2.8 t -59.96 -59.36 14.11 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.494 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.3 Cg_endo -76.76 -31.98 3.77 Favored 'Trans proline' 0 C--N 1.317 -1.131 0 N-CA-C 109.007 -1.189 . . . . 0.0 109.007 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.44 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 133.68 -60.95 0.65 Allowed Glycine 0 N--CA 1.486 1.977 0 N-CA-C 107.498 -2.241 . . . . 0.0 107.498 -178.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.646 ' HE1' ' HB2' ' A' ' 11' ' ' ALA . 3.1 t80 157.9 -51.06 0.0 OUTLIER Pre-proline 0 N--CA 1.512 2.665 0 C-N-CA 123.877 0.871 . . . . 0.0 109.936 177.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.587 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 52.9 Cg_endo -101.0 5.61 0.62 Allowed 'Trans proline' 0 C--N 1.325 -0.707 0 C-N-CA 121.595 1.53 . . . . 0.0 112.039 -177.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -122.36 47.57 1.9 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.139 -0.975 . . . . 0.0 109.961 -179.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 34' ' ' LEU . 14.3 p -117.66 141.11 37.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-O 121.869 0.843 . . . . 0.0 110.181 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.472 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -169.79 176.19 43.7 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 46' ' ' ILE . . . -92.22 165.06 28.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.776 HD11 ' CA ' ' A' ' 75' ' ' GLY . 0.9 OUTLIER -154.8 161.0 30.39 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.631 -0.923 . . . . 0.0 109.801 178.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -66.7 -35.01 29.95 Favored 'Trans proline' 0 N--CA 1.502 2.015 0 C-N-CA 121.777 1.651 . . . . 0.0 115.2 -175.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -68.95 -10.0 55.02 Favored 'General case' 0 N--CA 1.507 2.398 0 O-C-N 120.736 -1.227 . . . . 0.0 113.24 -177.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.1 mm -81.23 129.23 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.379 0 O-C-N 120.717 -1.24 . . . . 0.0 109.417 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.12 -49.64 7.17 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.325 -0.859 . . . . 0.0 112.108 -178.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.517 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 174.55 -139.35 4.85 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.995 -1.574 . . . . 0.0 111.608 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.48 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 70.7 t90 -49.01 -24.58 1.58 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.765 -0.844 . . . . 0.0 112.914 -178.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.529 ' HA ' ' CD2' ' A' ' 25' ' ' HIS . 14.7 t70 -142.27 71.93 1.36 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.191 -0.943 . . . . 0.0 109.583 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.47 ' N ' ' NE2' ' A' ' 25' ' ' HIS . 9.8 p -82.65 136.91 44.72 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.937 -0.477 . . . . 0.0 110.318 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -78.6 -16.81 13.03 Favored 'Trans proline' 0 C--N 1.317 -1.094 0 O-C-N 123.318 1.167 . . . . 0.0 111.167 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.3 m -97.39 4.19 50.74 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.316 -0.865 . . . . 0.0 112.543 -178.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 21.1 t -66.58 142.53 57.46 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.905 -1.122 . . . . 0.0 110.421 -179.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 94.13 -7.71 72.76 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.642 -0.79 . . . . 0.0 111.574 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 22.4 p -70.44 157.77 37.22 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 118.9 1.35 . . . . 0.0 110.743 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -107.21 130.8 54.68 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.939 -0.476 . . . . 0.0 110.553 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.457 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 92.9 m95 -135.17 147.62 49.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.279 -0.888 . . . . 0.0 110.561 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 82.6 tttt -106.42 135.55 47.73 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 72.0 t -108.2 123.88 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.65 -0.656 . . . . 0.0 109.382 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 41.3 m -119.59 137.31 53.93 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.111 0.481 . . . . 0.0 111.075 -178.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.454 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 35.1 pt -115.72 164.26 18.08 Favored Pre-proline 0 N--CA 1.497 1.908 0 O-C-N 121.676 -0.64 . . . . 0.0 110.401 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.3 Cg_endo -61.09 -25.18 80.77 Favored 'Trans proline' 0 N--CA 1.497 1.683 0 C-N-CA 121.268 1.312 . . . . 0.0 112.514 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -63.23 -40.0 96.21 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.256 -0.903 . . . . 0.0 109.706 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 114.61 60.72 0.38 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -159.95 151.99 20.49 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.717 -0.873 . . . . 0.0 108.854 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 61.3 p -155.48 161.07 41.02 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.115 -1.034 . . . . 0.0 112.428 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 73' ' ' ILE . 37.8 pt -137.36 166.48 25.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 179.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -105.52 127.04 52.79 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 119.233 -0.987 . . . . 0.0 109.665 179.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 71' ' ' ILE . 46.3 mm -120.04 129.95 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 121.463 -0.773 . . . . 0.0 110.547 -179.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.536 ' HD3' HG12 ' A' ' 37' ' ' VAL . 59.9 ttt180 -100.42 140.04 35.24 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.443 -0.786 . . . . 0.0 109.016 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.776 ' CA ' HD11 ' A' ' 46' ' ' ILE . . . -60.02 149.45 41.5 Favored Glycine 0 N--CA 1.494 2.538 0 CA-C-O 122.019 0.788 . . . . 0.0 111.575 -178.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.635 HG22 HG21 ' A' ' 18' ' ' VAL . 4.0 p -159.0 -39.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 122.017 -0.696 . . . . 0.0 109.653 178.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.633 ' OD2' HG23 ' A' ' 18' ' ' VAL . 3.4 t70 -135.86 170.2 16.36 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 120.963 -1.086 . . . . 0.0 109.517 179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 5.6 t -95.52 160.4 14.53 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.296 -0.877 . . . . 0.0 111.828 -178.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -129.85 149.14 18.71 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 63.6 mtt180 -60.07 -33.98 72.81 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.655 -0.909 . . . . 0.0 110.586 179.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 172.4 79.48 0.05 OUTLIER Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.44 169.0 13.4 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.606 ' HB2' HG22 ' A' ' 3' ' ' ILE . 19.1 m-85 -91.24 120.13 31.89 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.953 . . . . 0.0 109.817 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.415 ' HA ' ' O ' ' A' ' 4' ' ' SER . 1.6 m120 -114.27 130.46 56.65 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 178.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 44' ' ' GLY . 34.9 m -134.86 176.59 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.029 -1.044 . . . . 0.0 111.869 -178.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -57.42 152.7 31.68 Favored Pre-proline 0 N--CA 1.496 1.855 0 C-N-CA 120.133 -0.627 . . . . 0.0 110.051 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.64 -22.69 64.34 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.353 1.186 . . . . 0.0 110.408 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 94.3 m -73.13 -41.03 64.41 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.015 -1.053 . . . . 0.0 108.745 178.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -66.85 -39.76 87.68 Favored 'General case' 0 N--CA 1.494 1.731 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -59.98 -49.98 75.55 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.127 179.188 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.464 ' CG2' HG23 ' A' ' 97' ' ' THR . 12.1 p -60.01 -35.53 75.25 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.44 -0.787 . . . . 0.0 110.77 -179.114 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 55.9 mttm -69.95 -40.03 75.71 Favored 'General case' 0 N--CA 1.494 1.742 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.342 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 67.1 tp -70.49 -46.08 64.42 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.767 -0.583 . . . . 0.0 111.41 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -101.76 -38.13 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.172 0 O-C-N 121.288 -0.883 . . . . 0.0 111.655 -177.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 -18.88 16.46 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 41.8 p -158.8 151.96 22.54 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.249 -1.148 . . . . 0.0 110.519 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.464 HG23 ' CG2' ' A' ' 91' ' ' THR . 75.1 p -93.89 8.51 41.0 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.632 -0.667 . . . . 0.0 110.917 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.44 -0.788 . . . . 0.0 110.552 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.0 85.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.608 -0.683 . . . . 0.0 110.92 -178.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -59.4 3.19 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 108.538 -1.825 . . . . 0.0 108.538 -179.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 53.9 ptt85 -150.1 157.14 42.81 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.792 -0.828 . . . . 0.0 109.946 179.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.7 t -128.35 126.23 65.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.468 -0.77 . . . . 0.0 109.719 179.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -90.19 169.0 11.51 Favored 'General case' 0 N--CA 1.496 1.867 0 CA-C-O 121.771 0.796 . . . . 0.0 111.75 -178.562 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 53.2 t30 60.07 40.02 19.05 Favored 'General case' 0 N--CA 1.5 2.056 0 CA-C-O 121.402 0.62 . . . . 0.0 111.002 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.519 HG21 HG12 ' A' ' 3' ' ' ILE . 79.9 t -85.17 129.68 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.506 179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -88.27 138.83 31.09 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.234 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.1 p90 -132.99 140.85 47.98 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.34 0.59 . . . . 0.0 110.824 -178.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 18.8 m -143.83 139.94 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.944 0 O-C-N 121.755 -0.59 . . . . 0.0 110.987 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.457 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 54.9 tt0 -77.32 139.08 39.7 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.702 -0.624 . . . . 0.0 110.292 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 34.6 m -130.02 165.35 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.61 -0.681 . . . . 0.0 110.649 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -55.42 139.97 41.55 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.585 -0.697 . . . . 0.0 110.753 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.618 HD21 HD11 ' A' ' 116' ' ' ILE . 9.2 tt -60.83 -39.98 91.06 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.646 -0.659 . . . . 0.0 110.825 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 68.0 m -54.45 -37.87 65.69 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.577 -0.702 . . . . 0.0 111.112 -177.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -65.73 -36.9 84.91 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.558 -0.714 . . . . 0.0 111.12 -179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 81.0 m -63.05 -44.43 95.86 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.177 -0.952 . . . . 0.0 109.913 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.618 HD11 HD21 ' A' ' 112' ' ' LEU . 80.3 mt -69.64 -39.96 78.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 C-N-CA 120.273 -0.571 . . . . 0.0 110.099 -179.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -66.4 -40.05 89.39 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.469 -0.769 . . . . 0.0 110.467 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -74.31 -56.52 5.12 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -60.01 -42.26 93.94 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.445 -1.032 . . . . 0.0 110.256 -179.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 50.7 t30 . . . . . 0 N--CA 1.499 1.987 0 CA-C-O 117.832 -1.08 . . . . 0.0 111.054 179.611 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 105' ' ' VAL . 34.2 m . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.438 0.637 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -114.09 142.35 46.31 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.381 0.61 . . . . 0.0 110.668 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.727 HG22 ' HB2' ' A' ' 83' ' ' PHE . 42.9 pt -114.25 149.96 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 CA-C-O 121.353 0.596 . . . . 0.0 110.887 -179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 23.0 m -146.35 -172.82 4.03 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.166 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 52.3 p90 -140.06 149.32 42.98 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.82 179.106 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -130.38 148.9 71.75 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.457 -0.777 . . . . 0.0 109.435 179.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -84.0 -9.05 9.86 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.275 1.145 . . . . 0.0 112.636 -178.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 9' ' ' TYR . 33.2 pt -70.01 -40.06 78.09 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.227 0 O-C-N 120.953 -1.092 . . . . 0.0 110.984 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.52 ' HA ' HD22 ' A' ' 13' ' ' LEU . 50.9 m-85 -73.3 67.3 0.97 Allowed 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 122.877 1.322 . . . . 0.0 111.324 -178.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.93 171.55 7.28 Favored 'General case' 0 N--CA 1.49 1.55 0 CA-C-N 114.214 -1.357 . . . . 0.0 108.203 176.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -58.97 -34.45 71.81 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -175.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -89.95 10.94 22.03 Favored 'General case' 0 N--CA 1.501 2.11 0 C-N-CA 118.285 -1.366 . . . . 0.0 112.507 -177.538 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 9' ' ' TYR . 50.0 tp -70.61 124.45 24.28 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.245 -0.909 . . . . 0.0 109.666 179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 61.5 p -70.76 137.66 49.81 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.672 0.748 . . . . 0.0 110.092 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.782 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.9 mmm -66.41 -19.1 65.71 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.938 -0.476 . . . . 0.0 112.025 -178.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.78 -15.39 75.85 Favored Glycine 0 N--CA 1.495 2.626 0 O-C-N 120.95 -1.094 . . . . 0.0 111.296 -178.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.9 p -89.04 -7.52 55.74 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.208 -1.172 . . . . 0.0 111.9 -178.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.782 HG12 ' O ' ' A' ' 15' ' ' MET . 9.8 p -99.86 169.47 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.098 -1.001 . . . . 0.0 110.638 -179.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.782 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.89 -44.49 91.19 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.525 -0.734 . . . . 0.0 109.796 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.1 m -80.04 80.71 6.42 Favored 'General case' 0 N--CA 1.499 2.02 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -101.19 -81.56 0.48 Allowed 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.262 -0.899 . . . . 0.0 113.247 -177.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -131.12 11.14 5.02 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.139 -0.976 . . . . 0.0 113.025 -177.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -74.68 -153.49 3.43 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 179.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -65.93 -40.06 91.05 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.517 -0.99 . . . . 0.0 109.691 178.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.426 ' CD2' ' O ' ' A' ' 54' ' ' SER . 83.7 m-70 -91.0 6.31 45.3 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -0.797 . . . . 0.0 110.734 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -59.43 134.62 51.71 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.859 HD13 HG11 ' A' ' 37' ' ' VAL . 89.6 mt -101.16 -4.47 27.19 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 122.024 -0.692 . . . . 0.0 110.581 179.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 59.4 ttm -62.22 -37.03 83.79 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.273 -0.892 . . . . 0.0 110.948 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -48.11 -75.43 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.608 -0.683 . . . . 0.0 111.896 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -69.09 -39.99 78.67 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.367 -0.833 . . . . 0.0 109.743 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.557 ' CD2' HG23 ' A' ' 37' ' ' VAL . 48.7 m-85 -119.94 91.69 45.8 Favored Pre-proline 0 N--CA 1.491 1.608 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.92 -18.67 40.95 Favored 'Trans proline' 0 C--N 1.317 -1.125 0 O-C-N 123.293 1.154 . . . . 0.0 111.241 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 90.6 m -123.75 141.27 52.18 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.229 -0.919 . . . . 0.0 110.026 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.897 HD11 HG21 ' A' ' 43' ' ' VAL . 41.7 tp -65.9 120.75 13.62 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.77 -0.581 . . . . 0.0 111.036 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 151.29 32.41 0.04 OUTLIER Glycine 0 N--CA 1.497 2.712 0 C-N-CA 120.122 -1.037 . . . . 0.0 110.862 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.443 ' HB3' ' CD1' ' A' ' 31' ' ' TYR . 25.0 mt-10 -155.29 -49.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.283 -1.128 . . . . 0.0 110.448 178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.859 HG11 HD13 ' A' ' 27' ' ' LEU . 3.1 t -60.27 -60.81 9.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 50.6 Cg_endo -74.79 -28.6 9.43 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 N-CA-C 108.979 -1.2 . . . . 0.0 108.979 177.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.42 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.43 -61.32 0.65 Allowed Glycine 0 N--CA 1.484 1.872 0 N-CA-C 107.017 -2.433 . . . . 0.0 107.017 -178.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.543 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 1.8 t80 165.48 -72.7 0.0 OUTLIER Pre-proline 0 N--CA 1.511 2.578 0 C-N-CA 123.377 0.671 . . . . 0.0 110.083 177.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.543 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 59.6 Cg_endo -83.01 -8.58 10.94 Favored 'Trans proline' 0 N--CA 1.493 1.497 0 CA-C-N 118.995 0.677 . . . . 0.0 112.174 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -97.91 34.29 1.93 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.134 -0.979 . . . . 0.0 110.51 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.897 HG21 HD11 ' A' ' 34' ' ' LEU . 10.6 p -109.95 137.3 42.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-O 121.665 0.745 . . . . 0.0 109.498 179.277 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.701 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.62 172.89 43.22 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -179.044 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -86.54 156.34 29.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 179.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.74 HD12 ' HA2' ' A' ' 75' ' ' GLY . 81.3 mt -139.97 150.46 62.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.61 ' HD2' HG23 ' A' ' 46' ' ' ILE . 37.3 Cg_endo -59.36 -10.15 10.23 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.349 1.184 . . . . 0.0 113.626 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.601 ' H ' HG22 ' A' ' 46' ' ' ILE . 83.0 m-20 -94.58 -12.54 27.3 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 120.693 -1.254 . . . . 0.0 112.329 -179.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.606 HG23 ' CB ' ' A' ' 54' ' ' SER . 51.3 mm -75.08 119.67 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.226 0 C-N-CA 118.601 -1.24 . . . . 0.0 108.397 178.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.74 -45.3 21.47 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.26 -0.9 . . . . 0.0 112.529 -178.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.782 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 169.9 -138.91 5.28 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.918 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.466 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 36.8 t90 -42.79 -28.81 0.27 Allowed 'General case' 0 N--CA 1.502 2.175 0 O-C-N 121.956 -0.731 . . . . 0.0 112.769 -179.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -142.62 65.34 1.35 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.339 -0.851 . . . . 0.0 110.112 -179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.606 ' CB ' HG23 ' A' ' 49' ' ' ILE . 3.0 p -66.39 134.51 94.58 Favored Pre-proline 0 N--CA 1.497 1.905 0 O-C-N 121.643 -0.661 . . . . 0.0 110.899 -179.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -74.93 -23.48 13.9 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 O-C-N 123.45 1.237 . . . . 0.0 111.05 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.62 15.19 14.89 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 111.385 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 6.9 t -78.28 151.62 32.91 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 110.054 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 71.08 29.89 68.31 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 23.7 m -117.16 132.97 56.53 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.59 -0.947 . . . . 0.0 109.963 179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.2 m -81.07 145.5 31.07 Favored 'General case' 0 N--CA 1.497 1.898 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -177.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.47 ' CH2' ' HB2' ' A' ' 109' ' ' GLN . 94.2 m95 -149.34 150.09 31.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 110.471 178.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -108.45 132.03 54.2 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.3 t -108.9 127.36 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.49 -0.756 . . . . 0.0 109.597 -179.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 88.0 m -120.06 136.66 54.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.942 -0.474 . . . . 0.0 110.939 -178.135 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.463 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 38.0 pt -115.95 164.82 16.36 Favored Pre-proline 0 N--CA 1.499 2.025 0 O-C-N 121.541 -0.724 . . . . 0.0 110.568 -179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.463 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.8 Cg_endo -62.8 -25.1 74.61 Favored 'Trans proline' 0 N--CA 1.497 1.699 0 C-N-CA 121.236 1.29 . . . . 0.0 112.66 -178.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -64.89 -40.0 94.41 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.23 -0.919 . . . . 0.0 109.794 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.75 61.09 0.32 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.271 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 46.5 t-20 -160.01 150.64 18.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.758 -0.848 . . . . 0.0 108.831 179.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.422 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 67.0 p -151.56 157.41 42.19 Favored 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.247 -0.981 . . . . 0.0 112.248 -179.317 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 73' ' ' ILE . 44.3 pt -139.34 165.05 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.163 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -103.36 125.76 50.15 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 118.858 -1.137 . . . . 0.0 109.274 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 71' ' ' ILE . 49.5 mm -119.8 131.01 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.707 -0.621 . . . . 0.0 110.246 -178.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 -99.38 137.06 38.42 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.439 -0.788 . . . . 0.0 109.079 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.74 ' HA2' HD12 ' A' ' 46' ' ' ILE . . . -57.18 150.74 28.62 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 44' ' ' GLY . 11.9 p -169.54 -28.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.679 -0.895 . . . . 0.0 111.307 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.622 ' OD1' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -130.0 166.98 18.99 Favored 'General case' 0 N--CA 1.505 2.306 0 O-C-N 120.585 -1.322 . . . . 0.0 109.712 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.488 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 48.2 t -94.68 144.51 25.55 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.482 -0.761 . . . . 0.0 111.024 179.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -126.29 141.67 13.0 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 179.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -60.68 -28.38 68.57 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.759 -0.847 . . . . 0.0 109.814 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.04 79.92 0.05 OUTLIER Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 149.27 163.79 11.21 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.827 179.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.727 ' HB2' HG22 ' A' ' 3' ' ' ILE . 16.1 m-85 -92.16 115.33 27.99 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.666 -0.902 . . . . 0.0 109.915 179.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.415 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 57.7 t-20 -109.04 131.99 54.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.343 -0.848 . . . . 0.0 109.028 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 5' ' ' TYR . 34.3 m -132.44 175.52 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.185 0 O-C-N 120.961 -1.087 . . . . 0.0 111.833 -178.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -55.73 156.69 8.83 Favored Pre-proline 0 N--CA 1.498 1.969 0 O-C-N 121.41 -0.806 . . . . 0.0 109.953 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.07 -22.37 41.48 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.295 1.155 . . . . 0.0 110.65 -179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 18.4 m -76.28 -40.03 52.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.021 -1.049 . . . . 0.0 108.953 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.531 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.26 -39.87 89.76 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 178.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -60.04 -50.03 75.31 Favored 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 120.202 -0.599 . . . . 0.0 110.486 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 56.9 m -59.96 -39.5 85.82 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.546 -0.721 . . . . 0.0 110.709 -178.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.4 ' HE3' ' HA ' ' A' ' 89' ' ' ALA . 57.1 mtmt -70.03 -40.05 75.41 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.789 -178.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.422 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 65.4 tp -70.02 -43.4 71.42 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.65 -0.656 . . . . 0.0 111.492 -179.466 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.2 t -96.2 -39.82 9.89 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 O-C-N 121.262 -0.899 . . . . 0.0 111.258 -178.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 120.63 -38.96 2.55 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.892 -1.683 . . . . 0.0 108.892 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 52.8 m -139.98 152.2 46.11 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.686 -0.891 . . . . 0.0 110.182 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 74.6 p -90.71 6.33 44.51 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.403 -0.81 . . . . 0.0 111.169 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 59.0 tt0 -70.04 -29.22 66.2 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.478 -0.764 . . . . 0.0 110.736 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -59.05 -40.09 84.02 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.538 -0.726 . . . . 0.0 110.625 -179.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.94 -74.48 1.68 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 12.1 ptt-85 -144.74 149.54 35.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.681 -0.894 . . . . 0.0 110.271 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 62.5 t -122.94 119.36 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.487 -0.758 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -83.84 173.49 11.21 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.723 -0.611 . . . . 0.0 110.604 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 60.01 45.75 11.72 Favored 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.636 -0.665 . . . . 0.0 110.998 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.405 ' O ' ' CG2' ' A' ' 1' ' ' VAL . 73.7 t -95.53 128.06 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.493 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -85.4 136.1 33.6 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.092 -1.005 . . . . 0.0 109.639 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 38.8 p90 -132.87 140.98 48.18 Favored 'General case' 0 N--CA 1.496 1.833 0 CA-C-O 121.134 0.492 . . . . 0.0 110.738 -179.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 34.2 m -144.62 141.21 23.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.609 -0.682 . . . . 0.0 110.979 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.47 ' HB2' ' CH2' ' A' ' 61' ' ' TRP . 58.6 tt0 -70.93 140.73 51.05 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.536 -0.727 . . . . 0.0 110.334 178.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.23 167.44 26.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.105 179.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -61.28 148.26 41.76 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.414 -0.804 . . . . 0.0 110.325 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.73 -40.05 96.0 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.433 -0.792 . . . . 0.0 111.133 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 53.4 m -56.29 -38.18 70.88 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.583 -0.698 . . . . 0.0 110.587 -178.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.09 -35.71 75.81 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.432 -0.792 . . . . 0.0 110.287 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 80.5 m -70.04 -39.99 75.41 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.522 -0.736 . . . . 0.0 109.383 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 50.6 mm -66.77 -40.04 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 CA-C-O 121.473 0.654 . . . . 0.0 109.395 -178.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -69.98 -39.96 75.64 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.818 -0.551 . . . . 0.0 110.299 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.88 -57.73 5.67 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -59.96 -41.64 92.37 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.507 -0.996 . . . . 0.0 110.704 -179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 117.955 -1.022 . . . . 0.0 110.301 -179.889 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.456 HG23 ' HB ' ' A' ' 105' ' ' VAL . 34.8 m . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.464 0.65 . . . . 0.0 111.201 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.1 t -113.57 140.19 48.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.746 -0.596 . . . . 0.0 109.744 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.67 HG23 HG21 ' A' ' 105' ' ' VAL . 37.4 pt -109.16 148.14 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.601 -0.687 . . . . 0.0 111.042 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.433 ' O ' ' HA ' ' A' ' 84' ' ' ASN . 0.4 OUTLIER -146.72 -170.82 3.61 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.321 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 50.3 p90 -144.71 150.01 36.58 Favored 'General case' 0 N--CA 1.495 1.78 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.967 179.276 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -130.29 148.58 70.39 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.566 -0.709 . . . . 0.0 109.554 178.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -81.79 -6.58 12.43 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 O-C-N 123.247 1.13 . . . . 0.0 112.46 -179.117 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 9' ' ' TYR . 30.1 pt -69.98 -40.0 78.08 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.118 0 O-C-N 120.865 -1.147 . . . . 0.0 110.925 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.528 ' HA ' HD22 ' A' ' 13' ' ' LEU . 40.5 m-85 -74.17 67.24 1.33 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-O 122.774 1.273 . . . . 0.0 111.132 -178.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.19 171.86 7.12 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-N 114.299 -1.319 . . . . 0.0 108.146 176.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.05 -33.93 72.72 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -175.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -89.98 10.22 24.84 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.428 -1.42 . . . . 0.0 112.316 -177.276 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.528 HD22 ' HA ' ' A' ' 9' ' ' TYR . 29.0 tp -70.33 123.33 21.46 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.263 -0.898 . . . . 0.0 109.703 179.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.1 m -69.14 136.63 52.46 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.783 -0.767 . . . . 0.0 109.961 -179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.802 ' O ' HG12 ' A' ' 18' ' ' VAL . 96.6 mmm -67.21 -17.72 64.94 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 122.03 -0.419 . . . . 0.0 111.65 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -70.75 -14.7 73.01 Favored Glycine 0 N--CA 1.495 2.612 0 O-C-N 120.955 -1.091 . . . . 0.0 111.095 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -88.43 -9.44 52.55 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.203 -1.175 . . . . 0.0 111.787 -179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.802 HG12 ' O ' ' A' ' 15' ' ' MET . 8.4 p -95.54 168.49 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.072 -1.017 . . . . 0.0 110.092 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.825 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -57.8 -44.8 86.57 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.542 -0.724 . . . . 0.0 109.939 -179.658 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 74.5 m -81.28 84.05 6.71 Favored 'General case' 0 N--CA 1.498 1.955 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.4 m -99.95 -79.95 0.48 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.56 -0.712 . . . . 0.0 112.88 -178.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -131.09 9.93 4.9 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.24 -0.912 . . . . 0.0 112.77 -178.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -72.41 -153.2 1.83 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 108.755 -1.738 . . . . 0.0 108.755 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -70.01 -39.95 75.53 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.789 -0.83 . . . . 0.0 109.648 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.437 ' CE1' ' HA ' ' A' ' 55' ' ' PRO . 75.5 m-70 -90.03 0.21 57.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.625 -0.672 . . . . 0.0 110.866 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -57.71 137.89 49.06 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -179.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.67 HD13 HG11 ' A' ' 37' ' ' VAL . 75.0 mt -99.02 -5.22 30.8 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.916 -0.755 . . . . 0.0 110.251 178.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.401 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 59.1 ttm -60.01 -37.2 79.01 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.307 -0.871 . . . . 0.0 110.97 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -49.94 -74.84 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.497 -0.752 . . . . 0.0 111.798 -177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -70.0 -39.97 75.57 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.433 -0.792 . . . . 0.0 110.359 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.548 ' CD2' HG23 ' A' ' 37' ' ' VAL . 27.6 m-85 -120.02 93.27 47.73 Favored Pre-proline 0 N--CA 1.496 1.83 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -178.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -69.82 -21.87 32.62 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 O-C-N 123.423 1.223 . . . . 0.0 111.347 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . . . . . . . . . 33.4 m -123.21 145.9 48.27 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.307 -0.871 . . . . 0.0 109.939 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 1.0 HD21 HG11 ' A' ' 43' ' ' VAL . 40.6 tp -68.68 121.15 15.86 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.491 -0.756 . . . . 0.0 110.753 -179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 153.88 33.78 0.03 OUTLIER Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.774 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 64.5 tt0 -160.31 -44.12 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.159 -1.201 . . . . 0.0 110.142 179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.67 HG11 HD13 ' A' ' 27' ' ' LEU . 3.5 t -60.54 -61.28 8.28 Favored Pre-proline 0 N--CA 1.498 1.967 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 37' ' ' VAL . 55.5 Cg_endo -77.59 -26.11 7.4 Favored 'Trans proline' 0 N--CA 1.488 1.199 0 O-C-N 123.108 1.057 . . . . 0.0 109.598 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.403 ' O ' ' CB ' ' A' ' 40' ' ' PHE . . . 127.58 -62.0 0.63 Allowed Glycine 0 N--CA 1.486 1.988 0 N-CA-C 106.715 -2.554 . . . . 0.0 106.715 -178.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.572 ' HB3' ' HD3' ' A' ' 41' ' ' PRO . 3.0 t80 166.74 -72.45 0.0 OUTLIER Pre-proline 0 N--CA 1.508 2.449 0 C-N-CA 123.267 0.627 . . . . 0.0 109.632 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.572 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 60.2 Cg_endo -84.65 10.7 3.62 Favored 'Trans proline' 0 N--CA 1.492 1.422 0 CA-C-N 118.912 0.647 . . . . 0.0 111.647 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -114.54 35.7 4.11 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.011 -1.056 . . . . 0.0 110.015 -178.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.0 HG11 HD21 ' A' ' 34' ' ' LEU . 13.1 p -117.54 143.36 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 CA-C-O 121.455 0.645 . . . . 0.0 110.11 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 76' ' ' VAL . . . -168.04 166.67 39.61 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.38 151.37 44.97 Favored Glycine 0 N--CA 1.484 1.894 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 177.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.545 HD11 HG13 ' A' ' 49' ' ' ILE . 1.0 OUTLIER -144.22 142.9 20.61 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.431 -1.04 . . . . 0.0 109.351 179.698 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -61.38 -13.02 26.55 Favored 'Trans proline' 0 N--CA 1.507 2.271 0 C-N-CA 122.193 1.929 . . . . 0.0 115.188 -177.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.434 ' HB2' HD12 ' A' ' 46' ' ' ILE . 94.9 m-20 -92.9 20.1 6.99 Favored 'General case' 0 N--CA 1.503 2.18 0 O-C-N 120.45 -1.406 . . . . 0.0 112.139 -178.121 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.816 HG23 ' CB ' ' A' ' 54' ' ' SER . 57.8 mt -118.57 127.67 75.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.301 -0.875 . . . . 0.0 109.038 177.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.0 -45.35 13.2 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.825 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 175.18 -141.17 5.62 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.403 -1.856 . . . . 0.0 112.194 -178.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.498 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 25.3 t90 -39.97 -29.87 0.08 Allowed 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 114.319 1.229 . . . . 0.0 114.319 -178.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -146.15 64.14 1.22 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.985 -1.072 . . . . 0.0 111.325 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.816 ' CB ' HG23 ' A' ' 49' ' ' ILE . 6.5 t -66.27 139.39 96.34 Favored Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.45 -0.781 . . . . 0.0 110.866 -179.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.437 ' HA ' ' CE1' ' A' ' 25' ' ' HIS . 47.0 Cg_endo -78.05 -20.66 11.37 Favored 'Trans proline' 0 C--N 1.32 -0.959 0 O-C-N 123.4 1.211 . . . . 0.0 110.65 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 17.8 m -92.97 11.54 27.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.484 -0.76 . . . . 0.0 111.231 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.4 ' HB3' ' HB3' ' A' ' 25' ' ' HIS . 6.6 t -69.66 145.16 52.61 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.093 -1.004 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.45 41.9 12.6 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 94.1 m -120.01 129.95 54.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.397 -1.06 . . . . 0.0 110.477 179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.514 ' SG ' HG23 ' A' ' 110' ' ' VAL . 50.1 t -81.29 143.03 32.55 Favored 'General case' 0 N--CA 1.496 1.871 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.513 -178.444 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.4 ' O ' ' HA ' ' A' ' 72' ' ' PHE . 71.9 m95 -146.4 155.62 42.72 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.602 -0.686 . . . . 0.0 110.526 178.231 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -114.11 130.19 56.59 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 177.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.6 129.59 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.405 -0.809 . . . . 0.0 109.706 -178.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.3 m -121.12 141.07 51.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.803 -0.561 . . . . 0.0 111.459 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.441 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 14.0 pt -117.62 163.58 23.35 Favored Pre-proline 0 N--CA 1.497 1.895 0 O-C-N 121.521 -0.737 . . . . 0.0 110.036 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.441 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.4 Cg_endo -62.32 -25.35 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.633 0 C-N-CA 121.184 1.256 . . . . 0.0 112.507 -178.461 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -64.84 -39.01 92.88 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.384 -0.822 . . . . 0.0 109.715 179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 116.47 61.6 0.33 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -160.58 153.07 20.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.709 -0.877 . . . . 0.0 109.007 178.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.454 ' HA ' ' CD1' ' A' ' 93' ' ' LEU . 97.0 p -151.26 158.72 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.207 1.003 . . . . 0.0 112.352 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 pt -139.89 164.73 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.162 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' A' ' 61' ' ' TRP . 95.5 m-85 -106.58 127.0 52.98 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 118.879 -1.128 . . . . 0.0 109.928 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -117.37 131.89 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.622 -0.674 . . . . 0.0 110.582 -179.123 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.599 ' HD3' HG12 ' A' ' 37' ' ' VAL . 53.9 ttt180 -102.21 136.49 41.96 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -60.27 149.54 42.17 Favored Glycine 0 N--CA 1.494 2.557 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.318 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.593 HG22 HG21 ' A' ' 18' ' ' VAL . 5.7 p -156.91 -42.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.743 -0.857 . . . . 0.0 110.118 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.481 ' O ' HD12 ' A' ' 49' ' ' ILE . 12.3 t70 -128.34 169.99 13.6 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.109 -0.995 . . . . 0.0 110.06 179.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 41.8 t -87.67 156.85 19.27 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.426 -0.796 . . . . 0.0 111.081 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -123.43 137.34 10.92 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -63.08 -39.87 96.0 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.734 -0.862 . . . . 0.0 110.162 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . -178.15 69.96 0.08 OUTLIER Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.74 172.09 18.19 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.601 ' HB2' HG22 ' A' ' 3' ' ' ILE . 89.1 m-85 -98.63 122.53 41.95 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.652 -0.911 . . . . 0.0 110.334 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.433 ' HA ' ' O ' ' A' ' 4' ' ' SER . 17.1 t-20 -115.05 130.31 56.9 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.391 -0.818 . . . . 0.0 109.048 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.423 ' HA ' ' HA3' ' A' ' 44' ' ' GLY . 35.6 m -132.97 174.47 13.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 120.933 -1.104 . . . . 0.0 111.741 -178.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m-20 -54.74 150.9 16.6 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.53 -0.731 . . . . 0.0 109.92 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -65.6 -21.01 59.97 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.404 1.213 . . . . 0.0 110.76 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 67.7 m -75.79 -39.95 56.02 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.065 -1.022 . . . . 0.0 109.23 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 41' ' ' PRO . . . -66.77 -40.03 88.08 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.422 -0.798 . . . . 0.0 109.116 178.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -60.03 -49.68 76.72 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.807 -0.558 . . . . 0.0 110.632 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.6 m -60.04 -36.99 78.5 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.824 . . . . 0.0 110.787 -178.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -69.95 -40.07 75.67 Favored 'General case' 0 N--CA 1.494 1.758 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.412 -179.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.454 ' CD1' ' HA ' ' A' ' 70' ' ' SER . 56.1 tp -70.39 -44.16 68.58 Favored 'General case' 0 N--CA 1.496 1.851 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.554 -178.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 91.1 t -95.39 -38.61 8.91 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.311 -0.868 . . . . 0.0 111.394 -177.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 122.43 -27.35 6.07 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 43.7 t -156.04 161.19 40.46 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.466 -1.02 . . . . 0.0 110.292 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 68.3 p -97.81 13.24 31.19 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.503 -0.748 . . . . 0.0 111.151 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.99 -36.54 75.25 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.481 -0.762 . . . . 0.0 111.112 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.02 -41.16 91.59 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.444 -0.785 . . . . 0.0 111.05 -178.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.28 -63.48 2.02 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.168 -1.573 . . . . 0.0 109.168 -179.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -149.37 153.45 37.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.59 -0.947 . . . . 0.0 110.57 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -125.1 118.94 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.456 -0.777 . . . . 0.0 110.149 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -81.87 169.44 16.84 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.577 -0.702 . . . . 0.0 111.181 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 63.7 t30 59.85 50.06 7.29 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.548 -0.72 . . . . 0.0 110.731 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.67 HG21 HG23 ' A' ' 3' ' ' ILE . 66.9 t -94.05 128.73 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 C-N-CA 119.919 -0.712 . . . . 0.0 109.902 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -86.9 140.61 29.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 119.417 -0.913 . . . . 0.0 109.491 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -139.11 141.87 38.11 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.167 0.508 . . . . 0.0 110.736 -178.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 26.9 m -141.14 139.89 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.695 -0.628 . . . . 0.0 110.161 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -77.4 136.86 38.44 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.964 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.514 HG23 ' SG ' ' A' ' 60' ' ' CYS . 35.3 m -134.22 -179.13 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.257 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.41 150.94 47.55 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.406 -0.809 . . . . 0.0 111.075 -179.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.455 HD11 ' NH1' ' A' ' 74' ' ' ARG . 7.7 tt -62.06 -40.0 94.29 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.559 -0.713 . . . . 0.0 111.389 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 55.8 m -54.28 -39.37 66.84 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.443 -0.785 . . . . 0.0 110.222 -178.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -59.99 -37.65 80.29 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.632 -0.668 . . . . 0.0 110.223 179.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.2 m -68.15 -42.43 80.09 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.49 -0.756 . . . . 0.0 109.481 178.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.0 mm -64.88 -40.52 89.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 120.023 -0.671 . . . . 0.0 109.853 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -70.05 -39.92 75.41 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.697 -0.627 . . . . 0.0 110.483 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -64.6 -53.14 37.07 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 -179.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.05 -43.94 97.24 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.512 -0.993 . . . . 0.0 110.548 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 48.6 t30 . . . . . 0 N--CA 1.501 2.082 0 CA-C-O 118.023 -0.989 . . . . 0.0 111.006 -179.824 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.418 HG23 ' HB ' ' A' ' 105' ' ' VAL . 35.4 m . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 121.25 0.548 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.8 t -114.63 141.18 48.11 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.536 -0.728 . . . . 0.0 110.39 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.755 HG22 ' HB2' ' A' ' 83' ' ' PHE . 39.3 pt -107.8 147.72 12.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.679 -0.638 . . . . 0.0 110.6 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -147.42 -171.89 3.9 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 51.8 p90 -142.87 147.32 35.18 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.35 -0.844 . . . . 0.0 110.802 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -137.7 155.22 75.17 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.383 -0.823 . . . . 0.0 109.488 178.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -88.28 48.06 1.37 Allowed 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.275 1.145 . . . . 0.0 110.659 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.813 ' O ' HD22 ' A' ' 13' ' ' LEU . 8.7 tp -123.01 -8.65 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.48 -0.763 . . . . 0.0 111.276 -179.39 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.497 ' CD2' HG23 ' A' ' 8' ' ' ILE . 35.3 m-85 -118.54 67.65 0.77 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 122.525 1.155 . . . . 0.0 110.947 178.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -105.02 170.37 7.9 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.679 177.082 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.82 ' HB2' ' CE1' ' A' ' 40' ' ' PHE . . . -59.6 -32.71 70.64 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 114.115 1.154 . . . . 0.0 114.115 -175.497 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -89.63 13.91 12.94 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 120.424 1.466 . . . . 0.0 112.5 -177.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.813 HD22 ' O ' ' A' ' 8' ' ' ILE . 64.0 tp -73.1 125.94 28.85 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.413 -0.804 . . . . 0.0 110.792 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.6 t -70.18 135.54 49.18 Favored 'General case' 0 N--CA 1.486 1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.487 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.717 ' O ' HG12 ' A' ' 18' ' ' VAL . 97.6 mmm -66.36 -15.86 63.61 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.777 -0.577 . . . . 0.0 112.048 -178.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.404 ' CA ' ' CE ' ' A' ' 28' ' ' MET . . . -73.62 -13.86 80.05 Favored Glycine 0 N--CA 1.497 2.701 0 O-C-N 120.977 -1.077 . . . . 0.0 111.337 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.41 -11.05 47.2 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.054 -1.262 . . . . 0.0 112.063 -178.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 15' ' ' MET . 8.5 p -93.72 168.25 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.068 -1.02 . . . . 0.0 110.041 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.856 ' HB1' ' O ' ' A' ' 51' ' ' GLY . . . -58.24 -42.09 85.58 Favored 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.472 -0.768 . . . . 0.0 109.816 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.03 82.94 2.89 Favored 'General case' 0 N--CA 1.499 2.001 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.586 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.9 m -90.29 -79.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.989 -1.069 . . . . 0.0 112.894 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.488 ' HA ' ' HA3' ' A' ' 26' ' ' GLY . 17.9 p30 -143.56 14.21 1.77 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 120.631 -1.293 . . . . 0.0 112.428 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -70.64 -146.95 0.38 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -66.58 -40.51 88.97 Favored 'General case' 0 N--CA 1.495 1.816 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . 0.407 ' CD2' ' O ' ' A' ' 54' ' ' SER . 64.1 m-70 -90.02 0.56 57.05 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.798 -0.564 . . . . 0.0 110.265 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -55.05 130.4 47.08 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 31' ' ' TYR . 84.3 mt -104.87 -5.98 20.62 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 122.146 -0.62 . . . . 0.0 111.203 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . 0.404 ' CE ' ' CA ' ' A' ' 16' ' ' GLY . 44.4 ttm -59.96 -35.63 75.39 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.292 -0.88 . . . . 0.0 110.825 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -53.43 -63.1 1.26 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -67.26 -40.04 86.18 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.213 -0.93 . . . . 0.0 111.288 -177.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.69 ' CE1' HG21 ' A' ' 37' ' ' VAL . 5.5 p90 -143.64 113.72 5.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.879 . . . . 0.0 109.128 179.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.65 -1.62 10.1 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.443 1.233 . . . . 0.0 112.582 -178.229 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' THR . . . . . 0.513 HG22 ' H ' ' A' ' 34' ' ' LEU . 0.2 OUTLIER -118.64 -172.1 2.21 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.995 -1.066 . . . . 0.0 109.71 179.786 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.764 HD11 HG21 ' A' ' 43' ' ' VAL . 61.5 tp -116.51 129.96 56.49 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.605 -0.685 . . . . 0.0 110.852 -178.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 141.86 -40.82 1.27 Allowed Glycine 0 N--CA 1.489 2.172 0 C-N-CA 120.077 -1.059 . . . . 0.0 111.044 178.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -62.42 -39.94 94.93 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.182 -1.187 . . . . 0.0 111.483 -179.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.747 HG12 ' HD3' ' A' ' 74' ' ' ARG . 3.2 t -87.62 -61.36 0.24 Allowed Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.336 -0.852 . . . . 0.0 112.699 -178.339 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.432 ' HG3' HD11 ' A' ' 34' ' ' LEU . 37.4 Cg_endo -64.54 -48.49 4.29 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 O-C-N 123.009 1.005 . . . . 0.0 113.063 -177.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.431 ' O ' ' HD2' ' A' ' 41' ' ' PRO . . . 122.77 67.87 0.23 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 106.541 -2.624 . . . . 0.0 106.541 -177.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.82 ' CE1' ' HB2' ' A' ' 11' ' ' ALA . 8.8 t80 19.65 -78.99 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.343 0 N-CA-C 115.101 1.519 . . . . 0.0 115.101 -178.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.532 ' HD3' ' HB3' ' A' ' 40' ' ' PHE . 58.7 Cg_endo -81.91 17.8 1.48 Allowed 'Trans proline' 0 N--CA 1.499 1.804 0 CA-C-N 120.07 1.061 . . . . 0.0 112.588 -179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -123.79 47.33 2.06 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.836 -1.165 . . . . 0.0 110.201 -179.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.764 HG21 HD11 ' A' ' 34' ' ' LEU . 11.0 p -129.39 141.64 46.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-O 122.064 0.935 . . . . 0.0 110.334 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.519 ' HA3' HG12 ' A' ' 85' ' ' VAL . . . -167.08 175.31 42.3 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -88.32 161.75 31.6 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 49' ' ' ILE . 1.1 pt -147.46 152.1 41.35 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.64 -0.917 . . . . 0.0 110.063 179.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.69 -14.7 46.15 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 C-N-CA 121.954 1.77 . . . . 0.0 113.763 -178.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -90.6 23.25 3.11 Favored 'General case' 0 N--CA 1.503 2.219 0 O-C-N 120.591 -1.318 . . . . 0.0 112.259 -178.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.558 HG23 ' CB ' ' A' ' 54' ' ' SER . 49.8 mm -113.77 126.91 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -83.22 -46.17 13.0 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.311 -0.868 . . . . 0.0 112.077 -178.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.856 ' O ' ' HB1' ' A' ' 19' ' ' ALA . . . 173.23 -134.34 2.9 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 118.715 -1.707 . . . . 0.0 111.719 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.441 ' HA ' ' O ' ' A' ' 19' ' ' ALA . 53.5 t90 -46.06 -28.48 1.2 Allowed 'General case' 0 N--CA 1.499 2.004 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -178.255 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -146.65 61.19 1.21 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.024 -1.048 . . . . 0.0 110.986 -179.173 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.558 ' CB ' HG23 ' A' ' 49' ' ' ILE . 35.1 p -61.95 140.07 95.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 O-C-N 121.49 -0.756 . . . . 0.0 110.444 -179.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.18 -21.8 19.89 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 O-C-N 123.328 1.172 . . . . 0.0 111.151 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.9 m -93.85 13.62 21.98 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.449 -0.782 . . . . 0.0 111.158 -179.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . . . . . . . . . 2.2 t -73.17 145.43 46.32 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.259 -0.9 . . . . 0.0 110.561 -179.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.58 22.79 71.81 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' THR . . . . . . . . . . . . . 86.8 m -104.22 139.11 39.71 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.358 -1.084 . . . . 0.0 110.751 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.439 ' SG ' HG23 ' A' ' 110' ' ' VAL . 46.5 t -80.12 132.96 36.03 Favored 'General case' 0 N--CA 1.498 1.936 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.545 -179.037 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TRP . . . . . 0.405 ' CZ3' ' HB2' ' A' ' 109' ' ' GLN . 95.7 m95 -134.36 147.32 50.51 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -0.76 . . . . 0.0 110.074 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -107.86 131.55 54.38 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.366 -0.834 . . . . 0.0 109.725 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.635 HG22 ' CE2' ' A' ' 83' ' ' PHE . 62.2 t -109.95 121.03 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 121.557 0.694 . . . . 0.0 110.252 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 97.8 m -119.99 146.03 46.23 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.859 -0.525 . . . . 0.0 110.575 -178.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.469 ' HB ' ' HD2' ' A' ' 66' ' ' PRO . 17.2 pt -122.12 164.51 25.25 Favored Pre-proline 0 N--CA 1.5 2.07 0 O-C-N 121.473 -0.767 . . . . 0.0 110.98 -179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' A' ' 65' ' ' ILE . 37.6 Cg_endo -61.31 -25.94 81.09 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 121.561 1.507 . . . . 0.0 112.837 -178.611 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -66.08 -40.0 90.48 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.248 -0.907 . . . . 0.0 110.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 117.45 61.11 0.3 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 54.3 t30 -160.07 151.6 19.81 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.652 -0.911 . . . . 0.0 108.829 179.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.9 p -155.6 164.99 37.9 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 122.287 1.041 . . . . 0.0 112.193 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.439 HD11 HD11 ' A' ' 73' ' ' ILE . 40.0 pt -144.52 165.63 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -106.29 122.64 46.64 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 118.908 -1.117 . . . . 0.0 109.265 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.842 HD13 HG11 ' A' ' 85' ' ' VAL . 66.2 mt -120.02 131.41 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.857 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.747 ' HD3' HG12 ' A' ' 37' ' ' VAL . 24.8 ttt180 -95.25 136.5 35.53 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.663 -0.648 . . . . 0.0 109.407 -179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -57.39 149.72 31.43 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 110.336 -1.106 . . . . 0.0 110.336 -178.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.497 HG11 HG22 ' A' ' 43' ' ' VAL . 4.1 p -154.7 -44.08 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.723 -0.869 . . . . 0.0 109.513 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.556 ' HB2' HG23 ' A' ' 18' ' ' VAL . 11.9 t70 -131.87 169.02 16.84 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.187 -0.946 . . . . 0.0 109.178 178.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . 0.427 ' HA ' ' HB ' ' A' ' 49' ' ' ILE . 95.5 p -91.91 157.78 16.65 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.4 -0.813 . . . . 0.0 111.618 -179.374 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -124.2 146.16 16.16 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ARG . . . . . . . . . . . . . 94.0 mtt-85 -60.66 -31.04 70.29 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.649 -0.912 . . . . 0.0 110.174 179.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 170.09 76.45 0.04 OUTLIER Glycine 0 N--CA 1.494 2.558 0 C-N-CA 119.973 -1.108 . . . . 0.0 110.562 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.82 154.93 6.26 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 119.575 -1.298 . . . . 0.0 111.115 178.565 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.755 ' HB2' HG22 ' A' ' 3' ' ' ILE . 0.2 OUTLIER -67.41 114.59 6.22 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.931 -0.746 . . . . 0.0 110.376 179.289 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -111.15 119.07 37.74 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.842 HG11 HD13 ' A' ' 73' ' ' ILE . 26.8 m -131.1 176.95 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 120.89 -1.131 . . . . 0.0 112.474 -177.128 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 15.5 m-20 -55.7 150.9 24.41 Favored Pre-proline 0 N--CA 1.493 1.713 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.214 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.43 -17.27 57.26 Favored 'Trans proline' 0 C--N 1.311 -1.44 0 O-C-N 123.395 1.208 . . . . 0.0 110.142 178.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 98.1 m -81.28 -40.66 23.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.916 -1.115 . . . . 0.0 109.182 178.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -65.86 -39.84 91.12 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -60.06 -49.94 75.68 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.754 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.5 m -60.68 -40.0 90.53 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.429 -0.794 . . . . 0.0 111.108 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -68.48 -39.99 81.15 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 119.911 -0.716 . . . . 0.0 111.35 -177.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 57.8 tp -73.31 -43.24 61.25 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.823 -0.751 . . . . 0.0 111.576 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 51.2 t -91.57 -42.36 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 121.344 -0.848 . . . . 0.0 111.52 -177.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.27 -31.74 3.56 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 90.1 p -154.39 165.88 34.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.502 -0.999 . . . . 0.0 110.457 179.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 48.7 p -94.23 -0.05 55.37 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.451 -0.781 . . . . 0.0 111.756 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -70.95 -26.3 63.11 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.336 -0.853 . . . . 0.0 111.675 -179.065 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -60.05 -39.98 87.86 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.322 -0.861 . . . . 0.0 110.898 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 91.68 -67.46 2.17 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 31.3 ptt180 -152.1 160.01 43.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.553 -0.969 . . . . 0.0 110.998 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 105' ' ' VAL . 60.7 t -131.11 112.73 22.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.952 179.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 36.1 p-10 -80.06 170.01 17.05 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.464 0.65 . . . . 0.0 111.113 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 59.98 40.02 19.36 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.627 -0.67 . . . . 0.0 111.597 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.636 HG21 HG23 ' A' ' 3' ' ' ILE . 94.5 t -85.15 129.94 36.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.417 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 34.7 m120 -86.72 139.49 30.69 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.002 -1.061 . . . . 0.0 109.545 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.437 ' C ' HG13 ' A' ' 108' ' ' VAL . 46.8 p90 -138.02 143.3 40.52 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 122.0 -0.438 . . . . 0.0 110.763 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.437 HG13 ' C ' ' A' ' 107' ' ' TYR . 27.0 m -149.07 149.02 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.545 -0.722 . . . . 0.0 110.706 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.405 ' HB2' ' CZ3' ' A' ' 61' ' ' TRP . 58.9 tt0 -76.75 139.98 40.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.599 -0.688 . . . . 0.0 110.269 179.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.439 HG23 ' SG ' ' A' ' 60' ' ' CYS . 33.5 m -133.6 168.26 24.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -57.6 144.83 35.93 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.378 -0.826 . . . . 0.0 110.563 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.564 HD23 ' C ' ' A' ' 112' ' ' LEU . 9.6 tt -59.91 -36.75 77.64 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.502 -0.749 . . . . 0.0 110.224 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 91.0 p -54.07 -36.14 62.82 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.491 -0.756 . . . . 0.0 110.502 -179.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -66.67 -39.58 88.21 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 111.179 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -59.97 -49.16 78.78 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 121.306 -0.871 . . . . 0.0 109.797 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.491 HD11 HD21 ' A' ' 112' ' ' LEU . 93.4 mt -69.81 -39.98 78.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.687 -0.633 . . . . 0.0 110.687 -179.749 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -64.0 -39.94 95.25 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.35 -0.844 . . . . 0.0 111.052 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -71.14 -50.83 20.73 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -61.0 -39.94 91.62 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.574 -0.957 . . . . 0.0 110.524 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 118.022 -0.989 . . . . 0.0 110.063 -179.776 . . . . . . . . 1 1 . 1 stop_ save_